Clustering O 0 0.001687153009697795
of O 0 6.299388769548386e-05
missense O 0 0.007061744574457407
mutations O 0 0.0005958913243375719
in O 0 6.316809049167205e-06
the O 0 1.3342400052351877e-05
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999781847000122
telangiectasia I-Disease 1 0.9999997615814209
gene O 0 4.937619814882055e-05
in O 0 5.949775072622288e-07
a O 0 1.460083581150684e-06
sporadic B-Disease 0 0.00017961050616577268
T I-Disease 1 0.9857433438301086
- I-Disease 1 0.9556301832199097
cell I-Disease 1 0.5652725100517273
leukaemia I-Disease 1 0.9980226755142212
. O 0 5.68603900319431e-05

Ataxia B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999891519546509
telangiectasia I-Disease 1 0.9999992847442627
( O 0 0.0004137310024816543
A B-Disease 0 0.0016637967200949788
- I-Disease 1 0.9994895458221436
T I-Disease 1 0.9999967813491821
) O 0 5.352398147806525e-06
is O 0 3.768176952689828e-07
a O 0 1.44768512200244e-06
recessive B-Disease 0 0.0003937770670745522
multi I-Disease 0 0.013882155530154705
- I-Disease 1 0.9965544939041138
system I-Disease 0 0.049290888011455536
disorder I-Disease 1 0.9197975397109985
caused O 0 2.375740405113902e-05
by O 0 9.718766023070202e-07
mutations O 0 6.452451088989619e-06
in O 0 1.2525107706551353e-07
the O 0 1.484361007442203e-07
ATM O 0 1.968585820577573e-05
gene O 0 1.512396465841448e-06
at O 0 3.046445158361166e-07
11q22 O 0 2.1296740669640712e-05
- O 0 0.00012880319263786077
q23 O 0 9.216880425810814e-05
( O 0 1.3016804132348625e-06
ref O 0 8.413103205384687e-05
. O 0 5.578719992627157e-07
3 O 0 3.821801328740548e-06
) O 0 4.044139586767415e-06
. O 0 8.991304639494047e-06

The O 0 9.80474942480214e-05
risk O 0 0.000534387188963592
of O 0 2.5701279810164124e-05
cancer B-Disease 1 0.5802649259567261
, O 0 5.799342034151778e-06
especially O 0 1.0421331353427377e-05
lymphoid B-Disease 0 0.02509310096502304
neoplasias I-Disease 0 0.11898388713598251
, O 0 1.6846081507537747e-06
is O 0 3.190087625171145e-07
substantially O 0 6.222347110451665e-06
elevated O 0 1.8002530850935727e-05
in O 0 1.3981380106997676e-06
A B-Disease 0 0.003964971750974655
- I-Disease 1 0.9999982118606567
T I-Disease 1 1.0
patients O 0 0.10598725825548172
and O 0 1.1408292266423814e-06
has O 0 9.123128847932094e-07
long O 0 6.1506407291744836e-06
been O 0 1.4810296988798655e-06
associated O 0 1.0538945389271248e-05
with O 0 3.1366656912723556e-05
chromosomal O 1 0.9997507929801941
instability O 1 0.9502288699150085
. O 0 9.609884000383317e-05

By O 0 0.0001904167584143579
analysing O 0 0.03741411492228508
tumour B-Disease 1 0.9999963045120239
DNA O 0 0.0017689376836642623
from O 0 1.3534310710383579e-05
patients O 0 0.0002282908681081608
with O 0 3.1790918910701293e-06
sporadic B-Disease 0 0.0005218573496676981
T I-Disease 1 0.9855522513389587
- I-Disease 0 0.4531230032444
cell I-Disease 0 0.015993036329746246
prolymphocytic I-Disease 1 0.8565094470977783
leukaemia I-Disease 1 0.9998169541358948
( O 0 3.436968836467713e-05
T B-Disease 1 0.5624598264694214
- I-Disease 0 0.017865773290395737
PLL I-Disease 0 0.007035610266029835
) O 0 8.89299542450317e-07
, O 0 1.7666890528289514e-07
a O 0 5.382185577218479e-07
rare O 0 1.4730971997778397e-05
clonal B-Disease 0 0.02109682187438011
malignancy I-Disease 0 0.3375244438648224
with O 0 1.2622047051991103e-06
similarities O 0 2.784458729365724e-06
to O 0 3.2517812087462517e-07
a O 0 1.8482716086509754e-06
mature B-Disease 0 0.0026297220028936863
T I-Disease 1 0.9364839196205139
- I-Disease 1 0.7512513399124146
cell I-Disease 0 0.027790265157818794
leukaemia I-Disease 1 0.9810576438903809
seen O 0 3.860723609250272e-06
in O 0 4.6110142193356296e-07
A B-Disease 0 0.00011464571434771642
- I-Disease 1 0.987999439239502
T I-Disease 1 0.9999779462814331
, O 0 1.371713096887106e-06
we O 0 1.6494733756644564e-07
demonstrate O 0 6.311374249889923e-07
a O 0 2.116923241146651e-07
high O 0 7.939597139738908e-07
frequency O 0 1.2652428722503828e-06
of O 0 3.614556476350117e-07
ATM O 0 0.00039489322807639837
mutations O 0 2.4594721253379248e-05
in O 0 1.3695760117116151e-06
T B-Disease 0 0.09622252732515335
- I-Disease 0 0.040369078516960144
PLL I-Disease 0 0.027056967839598656
. O 0 4.16862458223477e-05

In O 0 3.683242903207429e-05
marked O 0 2.0968192984582856e-05
contrast O 0 1.1735152838809881e-05
to O 0 5.153415258973837e-07
the O 0 4.61793206341099e-07
ATM O 0 0.00018414802616462111
mutation O 0 8.880556379153859e-06
pattern O 0 4.366088887763908e-06
in O 0 5.978772605885752e-07
A B-Disease 0 0.00011628977517830208
- I-Disease 1 0.9807547330856323
T I-Disease 1 0.9999624490737915
, O 0 6.513519679174351e-07
the O 0 7.255194134359044e-08
most O 0 1.356276300157333e-07
frequent O 0 1.4561495618181652e-06
nucleotide O 0 7.809010639903136e-06
changes O 0 6.864089527880424e-07
in O 0 4.278206517938088e-07
this O 0 1.4169398809826816e-06
leukaemia B-Disease 1 0.9915822148323059
were O 0 1.122917456086725e-05
missense O 0 0.002471205312758684
mutations O 0 0.0003054933622479439
. O 0 2.688835229491815e-05

These O 0 2.3354652512352914e-05
clustered O 0 5.93686563661322e-05
in O 0 1.6979340671241516e-06
the O 0 4.575611001200741e-07
region O 0 2.7363687422621297e-06
corresponding O 0 5.951176831331395e-07
to O 0 1.0167169506303253e-07
the O 0 1.575389063646071e-07
kinase O 0 2.4543855033698492e-05
domain O 0 9.091306196751248e-07
, O 0 1.536921132583302e-07
which O 0 9.302856085469102e-08
is O 0 9.796076483326033e-08
highly O 0 4.168772989032732e-07
conserved O 0 4.989576609659707e-07
in O 0 1.7516990169497149e-07
ATM O 0 2.1631451090797782e-05
- O 0 7.146505959099159e-05
related O 0 2.4093401407299098e-06
proteins O 0 4.707737559783709e-07
in O 0 1.8113014732534793e-07
mouse O 0 3.24490883940598e-06
, O 0 9.052028531186807e-07
yeast O 0 7.89431287557818e-05
and O 0 4.167081897321623e-06
Drosophila O 0 6.487667269539088e-05
. O 0 1.922698356793262e-05

The O 0 4.183463170193136e-05
resulting O 0 6.425836181733757e-05
amino O 0 2.1666919565177523e-05
- O 0 0.00012790216715075076
acid O 0 3.8655318348901346e-05
substitutions O 0 2.581729631856433e-06
are O 0 2.0482207219174597e-07
predicted O 0 2.4472765289829113e-06
to O 0 2.3076711386238458e-07
interfere O 0 1.3529848956750357e-06
with O 0 5.305736863192578e-07
ATP O 0 0.0015543292975053191
binding O 0 1.1610974070208613e-05
or O 0 3.1244758247339632e-06
substrate O 0 0.00014339544577524066
recognition O 0 3.0407491067308e-05
. O 0 1.9935501768486574e-05

Two O 0 1.8244219972984865e-05
of O 0 5.023762696509948e-06
seventeen O 0 2.7563961339183152e-05
mutated O 0 0.0001568291336297989
T B-Disease 0 0.027705024927854538
- I-Disease 0 0.0011232272954657674
PLL I-Disease 0 0.0016683919820934534
samples O 0 5.967908236925723e-06
had O 0 6.022999059496215e-07
a O 0 5.807505658594891e-07
previously O 0 7.0768069235782605e-06
reported O 0 1.436478032701416e-05
A B-Disease 0 0.00013340398436412215
- I-Disease 1 0.9638365507125854
T I-Disease 1 0.99991774559021
allele O 0 0.0003725783317349851
. O 0 1.923314448504243e-05

In O 0 7.312845264095813e-05
contrast O 0 0.0001715715479804203
, O 0 6.874387509014923e-06
no O 0 2.5750880467967363e-06
mutations O 0 1.517751570645487e-05
were O 0 2.7020038828595716e-07
detected O 0 1.9195447293895995e-06
in O 0 1.336567834187008e-07
the O 0 1.5037170442155912e-07
p53 O 0 3.529442437866237e-06
gene O 0 2.468878392392071e-06
, O 0 3.9637080817556125e-07
suggesting O 0 2.1263367671053857e-06
that O 0 2.2395744281311636e-07
this O 0 1.789077714420273e-06
tumour B-Disease 1 0.9999555349349976
suppressor O 0 0.016842592507600784
is O 0 7.877540042500186e-07
not O 0 3.174857567955769e-07
frequently O 0 1.5008072296041064e-06
altered O 0 1.5012687981652562e-05
in O 0 1.4747746490684221e-06
this O 0 5.370161034079501e-06
leukaemia B-Disease 1 0.9957067370414734
. O 0 6.229191058082506e-05

Occasional O 0 0.0021336397621780634
missense O 0 0.19489319622516632
mutations O 0 0.001193907461129129
in O 0 5.162385605217423e-06
ATM O 0 0.0001059730420820415
were O 0 7.325079423026182e-07
also O 0 6.39959807813284e-07
found O 0 9.883578968583606e-07
in O 0 5.920477633480914e-06
tumour B-Disease 1 0.9998942613601685
DNA O 0 0.0002332378935534507
from O 0 3.179319492119248e-06
patients O 0 2.3272681573871523e-05
with O 0 4.7112229140111594e-07
B B-Disease 0 0.00012749813322443515
- I-Disease 0 0.012199945747852325
cell I-Disease 0 0.0016145871486514807
non I-Disease 0 0.00019512340077199042
- I-Disease 1 0.9927991628646851
Hodgkins I-Disease 1 0.9999996423721313
lymphomas I-Disease 1 0.9998106360435486
( O 0 3.2789214401418576e-06
B B-Disease 0 9.747570402396377e-06
- I-Disease 0 3.668824501801282e-05
NHL I-Disease 0 5.595361926680198e-06
) O 0 3.1336378469859483e-07
and O 0 8.41845277932407e-08
a O 0 3.649745963230089e-07
B B-Disease 0 1.56239875650499e-05
- I-Disease 0 9.047887579072267e-05
NHL I-Disease 0 2.268264870508574e-05
cell O 0 2.9866499971831217e-05
line O 0 1.2048353710270021e-05
. O 0 1.1495561921037734e-05

The O 0 1.7023838154273108e-05
evidence O 0 7.966804332681932e-06
of O 0 6.590612997570133e-07
a O 0 9.079305414161354e-07
significant O 0 1.28515182495903e-06
proportion O 0 2.2020467440597713e-06
of O 0 3.4859348829741066e-07
loss O 0 2.291531018272508e-05
- O 0 6.305686110863462e-05
of O 0 4.896028826806287e-07
- O 0 0.002323821419849992
function O 0 3.440880846028449e-06
mutations O 0 3.5891248444386292e-06
and O 0 9.602756989579575e-08
a O 0 1.908670981265459e-07
complete O 0 1.5814025573490653e-06
absence O 0 6.428432470784173e-07
of O 0 6.38393160556916e-08
the O 0 1.034766725638292e-07
normal O 0 3.989705419371603e-07
copy O 0 6.418508746719453e-07
of O 0 5.2921127036142934e-08
ATM O 0 1.4111443306319416e-05
in O 0 8.954732066968063e-08
the O 0 9.09233150991895e-08
majority O 0 4.985818691238819e-07
of O 0 6.00808277795295e-07
mutated O 0 0.0005369338905438781
tumours B-Disease 1 0.9998914003372192
establishes O 0 0.0006155844894237816
somatic O 0 0.0006866264156997204
inactivation O 0 0.0008212738903239369
of O 0 1.9644510018679284e-07
this O 0 1.4376139745309047e-07
gene O 0 1.1256590823904844e-06
in O 0 1.4088470834394684e-07
the O 0 2.800838103667047e-07
pathogenesis O 0 9.799936378840357e-05
of O 0 5.345917770682718e-07
sporadic B-Disease 0 8.931415504775941e-05
T I-Disease 1 0.7676444053649902
- I-Disease 0 0.0036061154678463936
PLL I-Disease 0 0.000991049688309431
and O 0 7.391216172436543e-07
suggests O 0 1.2262723885214655e-06
that O 0 1.7356919101985113e-07
ATM O 0 1.8618318790686317e-05
acts O 0 1.3543003660743125e-06
as O 0 6.684447839688801e-07
a O 0 1.3790076991426758e-05
tumour B-Disease 1 0.9999469518661499
suppressor O 0 0.03985809162259102
. O 0 5.083264841232449e-05

As O 0 2.9227019695099443e-05
constitutional O 0 2.5318955522379838e-05
DNA O 0 3.3109139621956274e-05
was O 0 1.5019040802144445e-06
not O 0 2.950563100512227e-07
available O 0 2.6358000582149543e-07
, O 0 2.555562730321981e-07
a O 0 1.4154448990666424e-06
putative O 0 0.006039103958755732
hereditary O 1 0.6548653244972229
predisposition O 0 0.0006560676265507936
to O 0 3.1431216029886855e-06
T B-Disease 1 0.5989283323287964
- I-Disease 0 0.010409679263830185
PLL I-Disease 0 0.003963892348110676
will O 0 1.0509160119909211e-06
require O 0 1.8676346371648833e-06
further O 0 1.176651380774274e-06
investigation O 0 8.712911039765459e-06
. O 0 2.9508912575693103e-06
. O 0 1.820247598516289e-05

Myotonic B-Disease 1 0.9999946355819702
dystrophy I-Disease 1 0.9999978542327881
protein O 0 0.03448287397623062
kinase O 0 0.01670432649552822
is O 0 5.918134775129147e-06
involved O 0 2.1871910576010123e-06
in O 0 5.23769585925038e-07
the O 0 2.607003182220069e-07
modulation O 0 3.581896180548938e-06
of O 0 2.1896505586482817e-07
the O 0 6.362573685692041e-07
Ca2 O 0 0.00015547615475952625
+ O 0 0.00034715564106591046
homeostasis O 0 0.00026415998581796885
in O 0 6.423256763810059e-06
skeletal O 0 0.00693616084754467
muscle O 0 0.0026687101926654577
cells O 0 0.0006254113395698369
. O 0 3.147963070659898e-05

Myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 1.0
( O 1 0.9842441082000732
DM B-Disease 1 1.0
) O 0 0.0003825326857622713
, O 0 1.7971663055504905e-06
the O 0 4.649537004297599e-07
most O 0 2.248104919999605e-06
prevalent O 0 0.010234653018414974
muscular B-Disease 1 0.9999685287475586
disorder I-Disease 1 0.9997546076774597
in O 0 3.5452576412353665e-05
adults O 0 0.0001012374268611893
, O 0 1.321935542364372e-06
is O 0 5.41705276191351e-07
caused O 0 5.279130618873751e-06
by O 0 3.939100849947863e-07
( O 0 2.1429975731734885e-06
CTG O 0 0.0005050142062827945
) O 0 8.483701208206185e-07
n O 0 9.09033406060189e-06
- O 0 1.6330510334228165e-05
repeat O 0 4.6084210225671995e-06
expansion O 0 7.221066198326298e-07
in O 0 1.2653971737108805e-07
a O 0 2.4769175865912985e-07
gene O 0 1.0947450164167094e-06
encoding O 0 7.834954089958046e-07
a O 0 3.343498633512354e-07
protein O 0 3.958158231398556e-06
kinase O 0 8.231908577727154e-05
( O 0 4.367158908280544e-06
DM B-Disease 1 0.9998760223388672
protein O 0 1.08762633317383e-05
kinase O 0 2.3858301574364305e-05
; O 0 1.8413910538583877e-06
DMPK O 0 9.383148426422849e-05
) O 0 4.349845141859987e-07
and O 0 1.8431603621138493e-07
involves O 0 1.0645550219123834e-06
changes O 0 8.971688316705695e-07
in O 0 6.917529162819847e-07
cytoarchitecture O 0 0.0004920779610984027
and O 0 8.588603122916538e-06
ion O 0 0.0006282107788138092
homeostasis O 0 0.0010001079645007849
. O 0 3.2406656828243285e-05

To O 0 3.177178223268129e-05
obtain O 0 2.689969005587045e-05
clues O 0 2.1605454094242305e-05
to O 0 8.049590292102948e-07
the O 0 5.572350119109615e-07
normal O 0 2.7229934858041815e-06
biological O 0 1.72531917996821e-06
role O 0 5.421099444902211e-07
of O 0 2.641895378019399e-07
DMPK O 0 0.0007434257422573864
in O 0 1.5423522654600674e-06
cellular O 0 3.933936022804119e-05
ion O 0 8.779812924331054e-05
homeostasis O 0 9.013639646582305e-05
, O 0 3.603319100875524e-07
we O 0 5.365330935092061e-08
have O 0 6.083288894842553e-08
compared O 0 3.189737753928057e-07
the O 0 1.3009093891014345e-07
resting O 0 1.0021106390922796e-05
[ O 0 1.3689759725821204e-05
Ca2 O 0 5.2833795052720234e-05
+ O 0 4.4507436541607603e-05
] O 0 2.268140860905987e-06
i O 0 1.298413110362162e-07
, O 0 8.633901416033041e-08
the O 0 7.963653558817896e-08
amplitude O 0 7.155795742619375e-07
and O 0 1.8468219309397682e-07
shape O 0 1.990015562114422e-06
of O 0 4.6750591309319134e-07
depolarization O 0 0.00010972096788464114
- O 0 0.0037228967994451523
induced O 0 0.0011365229729562998
Ca2 O 0 0.00011183423339389265
+ O 0 8.0743724538479e-05
transients O 0 3.8662325096083805e-05
, O 0 1.249721179874541e-07
and O 0 5.737875952149807e-08
the O 0 5.652927725918744e-08
content O 0 2.590361702914379e-07
of O 0 8.604934720324309e-08
ATP O 0 0.00013008590030949563
- O 0 2.1215395463514142e-05
driven O 0 3.7623310618073447e-06
ion O 0 7.797849320922978e-06
pumps O 0 6.770057552785147e-06
in O 0 5.213237272982951e-07
cultured O 0 9.619602496968582e-05
skeletal O 0 0.0018594719003885984
muscle O 0 0.00025017675943672657
cells O 0 1.079199410014553e-05
of O 0 1.3038008717103367e-07
wild O 0 2.700499180718907e-06
- O 0 6.260491500142962e-05
type O 0 3.232890094295726e-06
and O 0 8.814101306597877e-07
DMPK O 0 0.004488097038120031
[ O 0 2.0249392036930658e-05
- O 0 0.0002486894081812352
/ O 0 0.0004126273561269045
- O 0 0.0008258785819634795
] O 0 0.00011889981396961957
knockout O 0 0.0006837307591922581
mice O 0 0.0003933707776013762
. O 0 2.7427087843534537e-05

In O 0 0.00010366196511313319
vitro O 0 0.0010950842406600714
- O 0 0.001781528815627098
differentiated O 0 0.0006135879666544497
DMPK O 0 0.0053905644454061985
[ O 0 3.851710425806232e-05
- O 0 0.0003359241527505219
/ O 0 0.0002591834345366806
- O 0 9.642194345360622e-05
] O 0 9.463833521294873e-06
myotubes O 0 3.105138603132218e-05
exhibit O 0 1.5117749398996239e-06
a O 0 3.126247065665666e-07
higher O 0 1.5509012882830575e-06
resting O 0 8.98616144695552e-06
[ O 0 9.11387542146258e-06
Ca2 O 0 4.4469295971794054e-05
+ O 0 7.029374683042988e-05
] O 0 4.066943347424967e-06
i O 0 2.0254879018466454e-07
than O 0 9.165444225800456e-08
do O 0 2.0857022775544465e-07
wild O 0 1.7082672911783447e-06
- O 0 0.000297605583909899
type O 0 9.274601325159892e-06
myotubes O 0 0.00015593209536746144
because O 0 2.0687292590082507e-07
of O 0 7.48951194395886e-08
an O 0 2.3609996446793957e-07
altered O 0 3.2176949389395304e-06
open O 0 2.101099425999564e-06
probability O 0 5.335542709872243e-07
of O 0 9.955392243909955e-08
voltage O 0 4.206353878544178e-06
- O 0 4.765682388097048e-05
dependent O 0 1.7740951079758815e-05
l O 0 0.0005289239343255758
- O 0 3.8907837733859196e-05
type O 0 2.5943320451915497e-06
Ca2 O 0 2.0059727830812335e-05
+ O 0 1.7436219422961585e-05
and O 0 7.671251864849182e-07
Na O 0 0.00013512915757019073
+ O 0 4.216832167003304e-05
channels O 0 1.423843150405446e-05
. O 0 1.3590224625659175e-05

The O 0 5.415414852905087e-05
mutant O 0 0.00019221357069909573
myotubes O 0 0.0008006758289411664
exhibit O 0 1.7453256077715196e-05
smaller O 0 3.217992798454361e-06
and O 0 8.751082418712031e-07
slower O 0 1.1191658813913818e-05
Ca2 O 0 7.628608727827668e-05
+ O 0 7.746204937575385e-05
responses O 0 1.5843507981117e-06
upon O 0 3.804354093972506e-07
triggering O 0 4.84918791698874e-06
by O 0 6.636434477513831e-07
acetylcholine O 0 5.411315942183137e-05
or O 0 8.261420134658692e-07
high O 0 3.228188461434911e-06
external O 0 4.878645631833933e-05
K O 0 0.00026579381665214896
+ O 0 0.00040347539470531046
. O 0 2.2461619664682075e-05

In O 0 4.5673961722059175e-05
addition O 0 1.0886454219871666e-05
, O 0 2.0692987163783982e-06
we O 0 6.291386398515897e-07
observed O 0 1.0514243058423745e-06
that O 0 2.1051538112715207e-07
these O 0 3.084208231030061e-07
Ca2 O 0 5.140416033100337e-05
+ O 0 0.0001613530475879088
transients O 0 0.00020296817820053548
partially O 0 1.7023920008796267e-05
result O 0 7.011925617916859e-07
from O 0 9.486610252906758e-08
an O 0 6.717192491123569e-08
influx O 0 5.930124302722106e-07
of O 0 1.2167592444711772e-07
extracellular O 0 2.4222601950896205e-06
Ca2 O 0 1.0429464964545332e-05
+ O 0 5.9485605561349075e-06
through O 0 2.1788000026390364e-07
the O 0 2.454856939948513e-07
l O 0 0.0002076097298413515
- O 0 8.031453035073355e-05
type O 0 1.1163431736349594e-05
Ca2 O 0 8.456489740638062e-05
+ O 0 7.628579623997211e-05
channel O 0 3.451136944931932e-05
. O 0 1.3097634109726641e-05

Neither O 0 0.00015299122605938464
the O 0 5.178163974051131e-06
content O 0 4.194257144263247e-06
nor O 0 2.748698079813039e-06
the O 0 2.785000674521143e-07
activity O 0 5.490355192705465e-07
of O 0 2.769147329217958e-07
Na O 0 0.0002828173746820539
+ O 0 0.00012456212425604463
/ O 0 2.303733526787255e-05
K O 0 8.755141607252881e-06
+ O 0 1.811041329347063e-05
ATPase O 0 3.5089615266770124e-05
and O 0 1.6366633417419507e-06
sarcoplasmic O 0 0.0004632654890883714
reticulum O 0 0.0005506163579411805
Ca2 O 0 8.850751328282058e-05
+ O 0 5.175170736038126e-05
- O 0 5.1149592763977125e-05
ATPase O 0 0.00010133072646567598
are O 0 3.655497096133331e-07
affected O 0 1.1631137795120594e-06
by O 0 1.1802624158008257e-06
DMPK O 0 0.0008385180844925344
absence O 0 4.592045661411248e-05
. O 0 2.4102357201627456e-05

In O 0 7.53791318857111e-05
conclusion O 0 3.9491820643888786e-05
, O 0 2.3344778128375765e-06
our O 0 1.1106959618700785e-06
data O 0 1.623985440346587e-06
suggest O 0 1.3603091701952508e-06
that O 0 2.262398055563608e-07
DMPK O 0 0.00030354701448231936
is O 0 4.850414256907243e-07
involved O 0 5.003957994631492e-07
in O 0 3.3644207064753573e-07
modulating O 0 2.6127725504920818e-05
the O 0 2.52349281026909e-07
initial O 0 1.935313775902614e-06
events O 0 2.065198714262806e-07
of O 0 2.2146058142880065e-07
excitation O 0 1.9908749891328625e-05
- O 0 0.0002676034637261182
contraction O 0 0.00013212108751758933
coupling O 0 8.976980097941123e-06
in O 0 2.6898121632257244e-06
skeletal O 0 0.002396888332441449
muscle O 0 0.0006710270536132157
. O 0 6.5212288973270915e-06
. O 0 2.0218421923345886e-05

Constitutional O 0 0.0011680863099172711
RB1 O 1 0.9847106337547302
- O 1 0.8584256172180176
gene O 0 0.0009667676058597863
mutations O 0 0.0003080639289692044
in O 0 6.623050921916729e-06
patients O 0 0.0002186083875130862
with O 0 8.809858627500944e-06
isolated O 0 0.001056074514053762
unilateral B-Disease 0 0.10540378838777542
retinoblastoma I-Disease 1 0.9622787237167358
. O 0 0.00012014392268611118

In O 0 0.00010042868962045759
most O 0 2.7351994503987953e-05
patients O 0 0.00044038199121132493
with O 0 5.392134880821686e-06
isolated O 0 0.0002508871257305145
unilateral B-Disease 0 0.0257085170596838
retinoblastoma I-Disease 1 0.9877417087554932
, O 0 6.553828279720619e-05
tumor B-Disease 0 0.001843497040681541
development O 0 2.9746197469648905e-06
is O 0 4.430210083228303e-07
initiated O 0 4.191945663478691e-06
by O 0 8.12794155535812e-07
somatic O 0 0.00018967474170494825
inactivation O 0 0.0002922662242781371
of O 0 2.0222317687057512e-07
both O 0 4.239447832787846e-07
alleles O 0 3.4987986055057263e-06
of O 0 4.872385375165322e-07
the O 0 3.388863206055248e-06
RB1 O 0 0.29436609148979187
gene O 0 7.988640572875738e-05
. O 0 2.1767324142274447e-05

However O 0 5.31761470483616e-05
, O 0 3.0020212307135807e-06
some O 0 4.830255875276634e-07
of O 0 5.701264171875664e-07
these O 0 1.53076132392016e-06
patients O 0 0.00014444762200582772
can O 0 2.6305469873477705e-06
transmit O 0 0.0001663849106989801
retinoblastoma B-Disease 0 0.22333058714866638
predisposition O 0 0.0002609772200230509
to O 0 1.5419847159137134e-06
their O 0 7.012566584307933e-06
offspring O 0 0.0002758394693955779
. O 0 3.282806574134156e-05

To O 0 4.3477506551425904e-05
determine O 0 2.6823301595868543e-05
the O 0 2.5180647753586527e-06
frequency O 0 4.276638264855137e-06
and O 0 7.100130119397363e-07
nature O 0 1.4181687220116146e-06
of O 0 6.108065235821414e-07
constitutional O 0 9.417231012776028e-06
RB1 O 1 0.8478097915649414
- O 1 0.6100608706474304
gene O 0 8.888229058356956e-05
mutations O 0 3.843894592137076e-05
in O 0 1.0975509212585166e-06
patients O 0 5.1608098146971315e-05
with O 0 2.1582527551800013e-06
isolated O 0 0.00015493285900447518
unilateral B-Disease 0 0.002946990542113781
retinoblastoma I-Disease 1 0.515676736831665
, O 0 1.6783077398940804e-06
we O 0 2.528382765376591e-07
analyzed O 0 2.4211424261011416e-06
DNA O 0 3.085610615016776e-06
from O 0 6.051660079720023e-07
peripheral O 0 0.0001192105482914485
blood O 0 3.7261677789501846e-05
and O 0 4.522891231317772e-06
from O 0 2.591039265098516e-05
tumor B-Disease 1 0.5022134780883789
tissue O 0 0.0025760086718946695
. O 0 2.9397086109383963e-05

The O 0 3.895223926519975e-05
analysis O 0 3.585797821870074e-05
of O 0 8.293949576909654e-06
tumors B-Disease 1 0.9987081289291382
from O 0 2.9438808724080445e-06
54 O 0 3.699485750985332e-05
( O 0 1.6612183344477671e-06
71 O 0 6.471215328929247e-06
% O 0 6.392132263499661e-07
) O 0 2.6263754193678324e-07
of O 0 1.6294109173031757e-07
76 O 0 4.611538315657526e-05
informative O 0 4.715016621048562e-05
patients O 0 0.00029038055799901485
showed O 0 1.0274598935211543e-05
loss O 0 8.86500311025884e-06
of O 0 9.814261829887982e-07
constitutional O 0 1.8728245777310804e-05
heterozygosity O 0 0.30401718616485596
( O 0 8.164652535924688e-05
LOH O 1 0.9999837875366211
) O 0 7.94445259089116e-06
at O 0 3.3064413855754538e-06
intragenic O 0 0.0012462087906897068
loci O 0 0.00017327131354250014
. O 0 2.688465974642895e-05

Three O 0 3.0731251172255725e-05
of O 0 1.3215209946793038e-05
13 O 0 0.00011984207958448678
uninformative O 1 0.8966447114944458
patients O 0 0.054595913738012314
had O 0 1.3877546734875068e-05
constitutional O 0 4.102120874449611e-05
deletions O 0 0.00037592669832520187
. O 0 4.6260473027359694e-05

For O 0 4.7906069085001945e-05
39 O 0 6.622874934691936e-05
randomly O 0 3.0481349313049577e-05
selected O 0 1.9194445485481992e-05
tumors B-Disease 1 0.9839667677879333
, O 0 3.304928213765379e-06
SSCP O 0 0.0015611376147717237
, O 0 4.025177986477502e-06
hetero O 0 0.005832576658576727
- O 0 0.00038205270539037883
duplex O 0 0.0008552960935048759
analysis O 0 2.8853999083366944e-06
, O 0 3.4029272910629516e-07
sequencing O 0 1.1291814416836132e-06
, O 0 1.9066932566147443e-07
and O 0 2.8243590577403666e-07
Southern O 0 1.8248217656946508e-06
blot O 0 0.0001265972969122231
analysis O 0 1.694498223514529e-06
were O 0 1.4132528747268225e-07
used O 0 3.653419753391063e-07
to O 0 1.3409577377387905e-06
identify O 0 7.266498869284987e-05
mutations O 0 0.000128785046399571
. O 0 1.9464012439129874e-05

Mutations O 0 0.004027219023555517
were O 0 1.6350317309843376e-05
detected O 0 3.294247289886698e-05
in O 0 1.795429284356942e-06
21 O 0 4.475034984352533e-06
( O 0 1.5570113873764058e-06
91 O 0 6.381670118571492e-06
% O 0 8.804112212601467e-07
) O 0 5.714110216104018e-07
of O 0 7.609934868924029e-07
23 O 0 0.0004887300310656428
tumors B-Disease 1 0.9998623132705688
with O 0 0.0001407931122230366
LOH O 1 0.9999960660934448
. O 0 0.0001377783337375149

In O 0 4.328278373577632e-05
6 O 0 4.976638228981756e-05
( O 0 2.9288153200468514e-06
38 O 0 2.713862386372057e-06
% O 0 1.1577960776776308e-06
) O 0 5.156522320248769e-07
of O 0 3.575349865059252e-07
16 O 0 9.308572771260515e-05
tumors B-Disease 1 0.9996765851974487
without O 0 1.1518145583977457e-05
LOH O 1 0.9999909400939941
, O 0 1.926269305840833e-06
one O 0 3.1730809268992743e-07
mutation O 0 2.50088851316832e-06
was O 0 4.2407376099617977e-07
detected O 0 1.8322748474020045e-06
, O 0 1.0809115025267602e-07
and O 0 1.6109268585751124e-07
in O 0 3.416636786823801e-07
9 O 0 6.401626706065144e-06
( O 0 5.86809392189025e-07
56 O 0 2.5198160074069165e-06
% O 0 9.368191626890621e-07
) O 0 2.3423535822075792e-07
of O 0 1.4390857927537581e-07
the O 0 4.013808393210638e-06
tumors B-Disease 1 0.9999157190322876
without O 0 3.047109021281358e-05
LOH O 1 0.9999873638153076
, O 0 2.7763212528952863e-06
both O 0 1.3588141882792115e-06
mutations O 0 2.0952860722900368e-05
were O 0 1.0324104096071096e-06
found O 0 4.023508154205047e-06
. O 0 1.2735908057948109e-05

Thus O 0 5.883913763682358e-05
, O 0 3.8530620258825365e-06
a O 0 1.3250670463094139e-06
total O 0 9.701115004645544e-07
of O 0 5.141241103956418e-07
45 O 0 7.106523298716638e-06
mutations O 0 1.7610398572287522e-05
were O 0 4.162575635291432e-07
identified O 0 7.244274002005113e-06
in O 0 8.898340638552327e-06
tumors B-Disease 1 0.9985257983207703
of O 0 4.820288268092554e-06
36 O 0 0.0005931504420004785
patients O 0 0.0012635134626179934
. O 0 2.8088730687159114e-05

Thirty O 0 0.00013621182006318122
- O 0 0.0001020329145831056
nine O 0 3.161164158882457e-06
of O 0 4.4011866862092575e-07
the O 0 5.051908260611526e-07
mutations O 0 6.528111043735407e-06
- O 0 1.4604409443563782e-05
including O 0 3.2080910727927403e-07
34 O 0 1.1927304512937553e-06
small O 0 7.603015319546103e-07
mutations O 0 4.860874469159171e-06
, O 0 1.7643353089624725e-07
2 O 0 7.132297810130694e-07
large O 0 1.0853112826225697e-06
structural O 0 0.00014018667570780963
alterations O 0 2.7674266675603576e-05
, O 0 7.121993803593796e-07
and O 0 1.411473590451351e-06
hypermethylation O 0 0.010713550262153149
in O 0 4.372230705484981e-06
3 O 0 0.0027213706634938717
tumors O 1 0.9997971653938293
- O 0 0.0004664348089136183
were O 0 2.9578066573776596e-07
not O 0 1.3434211609819613e-07
detected O 0 9.222345624948503e-07
in O 0 8.763495173980118e-08
the O 0 2.2212877581750945e-07
corresponding O 0 5.647265425068326e-06
peripheral O 0 0.00033980191801674664
blood O 0 0.00018338246445637196
DNA O 0 0.00019289767078589648
. O 0 2.0594119632733054e-05

In O 0 7.139912486309186e-05
6 O 0 8.139628334902227e-05
( O 0 7.868839020375162e-06
17 O 0 4.109313977096463e-06
% O 0 9.900003306029248e-07
) O 0 2.6012986609202926e-07
of O 0 1.1612955574946682e-07
the O 0 4.222528957598115e-07
36 O 0 9.513935219729319e-05
patients O 0 0.00013842240150552243
, O 0 4.4457937065089936e-07
a O 0 8.765348411543528e-07
mutation O 0 9.999330359278247e-06
was O 0 5.950626587036822e-07
detected O 0 2.679637418623315e-06
in O 0 1.801640081566802e-07
constitutional O 0 7.599636546729016e-07
DNA O 0 6.088447207730496e-06
, O 0 2.4765205353105557e-07
and O 0 1.4743822873697354e-07
1 O 0 6.271965276027913e-07
of O 0 9.941160783455416e-08
these O 0 3.3136154797830386e-07
mutations O 0 5.35098979526083e-06
is O 0 1.0529279137472258e-07
known O 0 4.615946522790182e-07
to O 0 2.0623113528017711e-07
be O 0 2.4545900600969617e-07
associated O 0 1.6976637198240496e-06
with O 0 2.5576161988283275e-06
reduced O 0 0.00016970644355751574
expressivity O 0 0.05910967290401459
. O 0 5.276501542539336e-05

The O 0 1.8983875634148717e-05
presence O 0 7.550464943051338e-06
of O 0 6.748320515725936e-07
a O 0 1.2233779216330731e-06
constitutional O 0 4.930726390739437e-06
mutation O 0 1.2825882549805101e-05
was O 0 5.171049792807025e-07
not O 0 1.8271849455686606e-07
associated O 0 7.295824957509467e-07
with O 0 1.9123623928862798e-07
an O 0 5.387274768509087e-07
early O 0 1.071621500159381e-05
age O 0 5.327617145667318e-06
at O 0 7.28572695152252e-06
treatment O 0 0.00048812644672580063
. O 0 4.07363913836889e-05

In O 0 0.00011119694681838155
1 O 0 0.00014661249588243663
patient O 0 0.00024701020447537303
, O 0 4.920692390442127e-06
somatic O 0 0.0003645645047072321
mosaicism O 0 0.01992553286254406
was O 0 3.30970988215995e-06
demonstrated O 0 3.750448740902357e-06
by O 0 5.940347023170034e-07
molecular O 0 9.179103471979033e-06
analysis O 0 1.3167140195946558e-06
of O 0 2.9231628673187515e-07
DNA O 0 4.73537602374563e-06
and O 0 6.203518410075048e-07
RNA O 0 6.935589681233978e-06
from O 0 1.4343630709845456e-06
peripheral O 0 0.00033279837225563824
blood O 0 0.00023366970708593726
. O 0 2.7069198040408082e-05

In O 0 0.00020662331371568143
2 O 0 0.0010439790785312653
patients O 0 0.0009857823606580496
without O 0 2.191531848438899e-06
a O 0 3.248816256018472e-06
detectable O 0 0.00010350601223763078
mutation O 0 1.8229784473078325e-05
in O 0 1.4827567156316945e-06
peripheral O 0 0.000438518327428028
blood O 0 7.827887748135254e-05
, O 0 5.0261492106074e-06
mosaicism O 0 0.007294931914657354
was O 0 9.878000355456606e-07
suggested O 0 1.5727185882496997e-06
because O 0 1.5273943176907778e-07
1 O 0 5.402369538387575e-07
of O 0 1.95862583041162e-07
the O 0 3.4081538160535274e-06
patients O 0 0.0041996487416327
showed O 0 0.00021734267647843808
multifocal O 1 0.9999707937240601
tumors B-Disease 1 0.999995231628418
and O 0 8.854051429807441e-07
the O 0 1.8458639772234164e-07
other O 0 3.192927238160337e-07
later O 0 1.8964866512760636e-06
developed O 0 1.1338655895087868e-05
bilateral B-Disease 0 0.00013340194709599018
retinoblastoma I-Disease 0 0.4214043915271759
. O 0 4.839001121581532e-05

In O 0 5.759077248512767e-05
conclusion O 0 2.5102934159804136e-05
, O 0 2.4902835775719723e-06
our O 0 1.6068883041953086e-06
results O 0 5.157268333277898e-06
emphasize O 0 5.59111049369676e-06
that O 0 2.0762496433235356e-07
the O 0 1.788141474889926e-07
manifestation O 0 4.166966391494498e-06
and O 0 7.546179858763935e-07
transmissibility O 0 8.204433106584474e-05
of O 0 5.469926236401079e-07
retinoblastoma B-Disease 0 0.014850744977593422
depend O 0 4.841655936616007e-06
on O 0 2.8000235374747717e-07
the O 0 1.3211032978688309e-07
nature O 0 3.342915420034842e-07
of O 0 6.748012282287164e-08
the O 0 1.1516957698631813e-07
first O 0 8.127755108944257e-07
mutation O 0 2.093259354296606e-06
, O 0 7.948509050947905e-08
its O 0 8.666636119869509e-08
time O 0 6.661767315563338e-08
in O 0 7.145806080188777e-08
development O 0 3.592620601011731e-07
, O 0 1.7725417933434073e-07
and O 0 1.010148693580959e-07
the O 0 7.898289311469853e-08
number O 0 9.77949952130075e-08
and O 0 1.757929481982501e-07
types O 0 8.946560683398275e-07
of O 0 3.586113166420546e-07
cells O 0 2.9890834412071854e-05
that O 0 3.0370031822712917e-07
are O 0 4.543689158253983e-07
affected O 0 3.635371740529081e-06
. O 0 2.8302390546741663e-06
. O 0 1.191657611343544e-05

Hereditary B-Disease 1 0.9999845027923584
deficiency I-Disease 1 0.9996092915534973
of I-Disease 0 5.435970251710387e-06
the I-Disease 0 1.6586363926762715e-06
fifth I-Disease 0 5.056919690105133e-06
component I-Disease 0 2.4431190013274318e-06
of I-Disease 0 5.63937987863028e-07
complement I-Disease 0 3.4529282402218087e-06
in O 0 1.8943534314530552e-06
man O 0 2.4784967536106706e-05
. O 0 2.2598525902139954e-05

I O 0 0.0017456423956900835
. O 0 0.0006876141997054219

Clinical O 0 0.3600097596645355
, O 0 5.071392661193386e-05
immunochemical O 0 0.005867362953722477
, O 0 9.345266335003544e-06
and O 0 5.6916874200396705e-06
family O 0 3.6491899663815275e-05
studies O 0 5.2043298637727275e-05
. O 0 4.922509106108919e-05

The O 0 3.8246289477683604e-05
first O 0 1.3753777238889597e-05
recognized O 0 1.291931766900234e-05
human O 0 1.153594257630175e-05
kindred O 0 0.06470430642366409
with O 0 0.0006488090148195624
hereditary B-Disease 1 0.9999823570251465
deficiency I-Disease 1 0.9947637319564819
of I-Disease 0 4.614533395397302e-07
the I-Disease 0 3.430935180404049e-07
fifth I-Disease 0 2.6948396225634497e-06
component I-Disease 0 9.887435226119123e-07
of I-Disease 0 1.8779152810566302e-07
complement I-Disease 0 3.5711486816580873e-06
( O 0 2.9207653824414592e-06
C5 O 0 0.0009339040261693299
) O 0 3.235588792449562e-06
is O 0 1.4831456383035402e-06
described O 0 3.4312015486648306e-05
. O 0 2.3161686840467155e-05

The O 0 2.5437131625949405e-05
proband O 0 0.0008063640561886132
, O 0 2.085575715682353e-06
a O 0 8.56895667311619e-07
20 O 0 1.2447819699445972e-06
- O 0 9.587678505340591e-05
year O 0 3.031339701919933e-06
- O 0 4.604828427545726e-05
old O 0 4.955899839842459e-06
black O 0 6.350092735374346e-05
female O 0 6.74955008435063e-05
with O 0 0.042594198137521744
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.00010469063272466883
age O 0 4.411916961544193e-06
11 O 0 2.368541572650429e-06
, O 0 9.103313232117216e-07
lacked O 0 3.896821363014169e-05
serum O 0 0.00028116151224821806
hemolytic O 1 0.8962820172309875
complement O 0 1.381463971483754e-05
activity O 0 2.505646534700645e-06
, O 0 7.309558895940427e-07
even O 0 1.99939950107364e-06
during O 0 1.7582662621862255e-05
remission O 0 0.00249687023460865
. O 0 4.114913099328987e-05

C5 O 0 0.1318768709897995
was O 0 8.593613165430725e-05
undetectable O 0 0.0005097754765301943
in O 0 7.358669790846761e-06
her O 0 7.78260437073186e-06
serum O 0 2.6222407541354187e-05
by O 0 9.567359029460931e-07
both O 0 1.8725569361777161e-06
immunodiffusion O 0 0.011626169085502625
and O 0 0.00011980871204286814
hemolytic O 1 0.9998660087585449
assays O 0 0.00357221276499331
. O 0 5.9472586144693196e-05

Other O 0 2.9390357667580247e-05
complement O 0 3.193457087036222e-05
components O 0 1.4800082681176718e-05
were O 0 1.305721184508002e-06
normal O 0 3.3995156627497636e-06
during O 0 6.07492165727308e-06
remission O 0 0.0011527691967785358
of O 0 1.3263743312563747e-05
lupus O 1 0.9999922513961792
, O 0 3.3281505693594227e-06
but O 0 7.597100761813635e-07
C1 O 0 0.00015729641017969698
, O 0 9.739688948684488e-07
C4 O 0 0.00046808330807834864
, O 0 1.060475483427581e-06
C2 O 0 0.00011108715261798352
, O 0 4.5169758777774405e-07
and O 0 3.6555459814735514e-07
C3 O 0 0.0012346868170425296
levels O 0 6.813031632191269e-06
fell O 0 1.989246447919868e-05
during O 0 2.6511394025874324e-05
exacerbations O 1 0.6877532601356506
. O 0 6.533323175972328e-05

A O 0 0.0001322482421528548
younger O 0 0.0001208156390930526
half O 0 1.2586487173393834e-05
- O 0 0.001164066488854587
sister O 0 6.611907156184316e-05
, O 0 1.744050791785412e-06
who O 0 1.0024231187344412e-06
had O 0 1.0740510560935945e-06
no O 0 6.721077170368517e-06
underlying O 0 0.44013962149620056
disease O 0 0.01978672668337822
, O 0 1.3845984767613118e-06
was O 0 6.278751811805705e-07
also O 0 3.7762495708193455e-07
found O 0 3.832835488992714e-07
to O 0 5.830913778481772e-07
lack O 0 8.399169928452466e-06
immunochemically O 0 0.0421450175344944
detectable O 0 0.00030158687150105834
C5 O 0 0.002305476227775216
. O 0 4.8218884330708534e-05

By O 0 0.00048748060362413526
hemolytic O 1 0.9999339580535889
assay O 0 0.07082699239253998
, O 0 2.2363468815456145e-05
she O 0 4.873026227869559e-06
exhibited O 0 6.54610312267323e-06
1 O 0 1.647482918087917e-06
- O 0 2.696420779102482e-05
2 O 0 2.0024983768962556e-06
% O 0 2.983808542467159e-07
of O 0 8.667446138588275e-08
the O 0 1.9860499378410168e-07
normal O 0 1.3685706790056429e-06
serum O 0 9.092389518627897e-06
C5 O 0 0.00010039297922048718
level O 0 7.225530112009437e-07
and O 0 2.9406297130663006e-07
normal O 0 1.1254861647103098e-06
concentrations O 0 2.2931139938009437e-06
of O 0 1.5949962062222767e-07
other O 0 2.9666881573575665e-07
complement O 0 6.552830200234894e-06
components O 0 3.849243148579262e-05
. O 0 2.121367651852779e-05

C5 O 0 0.17741990089416504
levels O 0 6.876228144392371e-05
of O 0 2.2273745798884192e-06
other O 0 7.918379196780734e-07
family O 0 1.581263859407045e-06
members O 0 5.506001912181091e-07
were O 0 1.3921319919063535e-07
either O 0 2.0995319971461868e-07
normal O 0 5.316079523254302e-07
or O 0 2.1593841381672974e-07
approximately O 0 1.9379463367386052e-07
half O 0 2.4959587108241976e-07
- O 0 6.234118336578831e-05
normal O 0 1.7756290162651567e-06
, O 0 3.7026350696578447e-07
consistent O 0 2.72377246801625e-06
with O 0 2.8597285108844517e-06
autosomal O 0 0.016516663134098053
codominant O 0 0.016030553728342056
inheritance O 0 1.1858566722366959e-05
of O 0 3.560371624189429e-07
the O 0 1.9144968064210843e-06
gene O 0 9.335828508483246e-05
determining O 0 0.00032682158052921295
C5 B-Disease 1 0.9999978542327881
deficiency I-Disease 1 0.9999874830245972
. O 0 0.00012002494622720405

Normal O 0 0.014027019031345844
hemolytic O 1 0.9998825788497925
titers O 0 0.08242332190275192
were O 0 9.891821719065774e-06
restored O 0 8.12931375548942e-06
to O 0 9.815440762395156e-07
both O 0 1.4581006553271436e-06
homozygous O 0 5.515713564818725e-05
C5 B-Disease 1 0.9991713762283325
- I-Disease 1 0.997462272644043
deficient I-Disease 1 0.9999462366104126
( O 0 3.0227367460611276e-05
C5D B-Disease 1 0.9984751343727112
) O 0 5.503311513166409e-06
sera O 0 1.711679396976251e-05
by O 0 1.8749214802937786e-07
addition O 0 4.621862217391026e-07
of O 0 3.7771536653963267e-07
highly O 0 7.391389317490393e-06
purified O 0 0.00014937222294975072
human O 0 1.8553957488620654e-05
C5 O 0 0.0028157439082860947
. O 0 4.33298664574977e-05

In O 0 0.00010971805022563785
specific O 0 3.5499226214597e-05
C5 O 0 0.011783644556999207
titrations O 0 0.09711329638957977
, O 0 6.4881410253292415e-06
however O 0 1.4363835134645342e-06
, O 0 5.891960199733148e-07
it O 0 1.7491731796326349e-07
was O 0 3.292510086794209e-07
noted O 0 5.199661927690613e-07
that O 0 6.808166830296614e-08
when O 0 1.3861850334251358e-07
limited O 0 3.366940575233457e-07
amounts O 0 2.8674412533291616e-07
of O 0 1.1240344832685878e-07
C5 O 0 6.17712430539541e-05
were O 0 2.676555084235588e-07
assayed O 0 1.3269386727188248e-06
in O 0 9.89747590551815e-08
the O 0 6.404775376722682e-08
presence O 0 2.6290041432730504e-07
of O 0 1.6964808935426845e-07
low O 0 4.975325282430276e-06
dilutions O 0 0.0001779095910023898
of O 0 4.227577505844238e-07
either O 0 1.9527094536897494e-06
C5D B-Disease 1 0.9952670335769653
serum O 0 7.361359166679904e-05
, O 0 5.576624175773759e-07
curving O 0 4.535473635769449e-06
rather O 0 5.476957198879973e-07
than O 0 2.587882761417859e-07
linear O 0 8.6605050455546e-06
dose O 0 3.967576412833296e-05
- O 0 4.2619612941052765e-05
response O 0 1.4462348190136254e-06
plots O 0 1.2255732144694775e-06
were O 0 2.1121076088093105e-07
consistently O 0 1.3706959407500108e-06
obtained O 0 1.3256308193376753e-06
, O 0 5.916595569033234e-07
suggesting O 0 3.8045459405111615e-06
some O 0 8.373355626645207e-07
inhibitory O 0 7.755748083582148e-05
effect O 0 2.1996240320731886e-05
. O 0 1.5215383427857887e-05

Further O 0 0.00019731497741304338
studies O 0 7.660173287149519e-05
suggested O 0 1.8038896087091416e-05
that O 0 1.1095980880782008e-06
low O 0 7.269035904755583e-06
dilutions O 0 0.0004999347147531807
of O 0 2.194608214267646e-06
C5D B-Disease 1 0.9998217225074768
serum O 0 0.00011968561739195138
contain O 0 1.225437813445751e-06
a O 0 5.775503950644634e-07
factor O 0 1.4372399164130911e-06
( O 0 4.904150614493119e-07
or O 0 4.19005658613969e-07
factors O 0 7.511041530960938e-07
) O 0 4.0323908478967496e-07
interfering O 0 1.6139528042913298e-06
at O 0 1.9794714489762555e-07
some O 0 9.764811892409853e-08
step O 0 1.298652477998985e-06
in O 0 4.1773250814003404e-07
the O 0 1.6195127727769432e-06
hemolytic O 1 0.9823889136314392
assay O 0 0.0003197411715518683
of O 0 9.049939535543672e-07
C5 O 0 0.0025317783001810312
, O 0 5.568323899751704e-07
rather O 0 2.507436533960572e-07
than O 0 1.1741332173187402e-07
a O 0 5.311807740326913e-07
true O 0 4.936914137942949e-06
C5 O 0 0.0043881782330572605
inhibitor O 0 6.73283648211509e-05
or O 0 5.697769665857777e-06
inactivator O 0 0.0011706036748364568
. O 0 2.2264093786361627e-05

Of O 0 8.436127245659009e-05
clinical O 0 0.0027212505228817463
interest O 0 7.65100139688002e-06
are O 0 1.1161314432683866e-06
( O 0 1.09143525151012e-06
a O 0 6.568550929841876e-07
) O 0 9.510911240795394e-07
the O 0 2.810349712945026e-07
documentation O 0 5.637429694616003e-06
of O 0 1.985391918424284e-06
membranous O 1 0.9849861264228821
glomerulonephritis B-Disease 1 0.9999998807907104
, O 0 0.015514139086008072
vasculitis B-Disease 1 0.9999997615814209
, O 0 0.0001450220006518066
and O 0 0.010420326143503189
arthritis B-Disease 1 1.0
in O 0 7.3524129220459145e-06
an O 0 5.938709364272654e-07
individual O 0 1.6243695881712483e-06
lacking O 0 2.2490639821626246e-05
C5 O 0 0.02248484082520008
( O 0 6.58062106140278e-07
and O 0 1.677891958706823e-07
its O 0 4.972508804712561e-07
biologic O 0 7.364707562373951e-05
functions O 0 4.738772929613333e-07
) O 0 3.9165433918242343e-07
, O 0 2.1644684977673023e-07
and O 0 3.9326894807345525e-07
( O 0 1.7742934232956031e-06
b O 0 6.213487722561695e-06
) O 0 3.7245035855448805e-07
a O 0 3.2885625955714204e-07
remarkable O 0 6.219464012247045e-06
propensity O 0 0.0018752756295725703
to O 0 0.00012841029092669487
bacterial B-Disease 1 0.999972939491272
infections I-Disease 1 0.9994660019874573
in O 0 5.870249424333451e-07
the O 0 2.7025376425626746e-07
proband O 0 0.0009057731367647648
, O 0 3.70719646980433e-07
even O 0 1.8920430022717483e-07
during O 0 2.409982755580131e-07
periods O 0 5.247745207270782e-07
of O 0 1.3181107760829036e-07
low O 0 4.777110461873235e-06
- O 0 0.00033195610740222037
dose O 0 1.991197859751992e-05
or O 0 5.25837606346613e-07
alternate O 0 3.757242893698276e-06
- O 0 0.0002741672215051949
day O 0 5.461953332996927e-05
corticosteroid O 1 0.5182671546936035
therapy O 0 0.0008742043864913285
. O 0 3.301297692814842e-05

Other O 0 4.9037447752198204e-05
observations O 0 9.05559427337721e-05
indicate O 0 1.587090446264483e-05
that O 0 7.12139581082738e-07
the O 0 4.6738466608076124e-07
C5D B-Disease 1 0.9693310260772705
state O 0 8.780977509559307e-07
is O 0 2.141713366654585e-07
compatible O 0 1.9916253677365603e-06
with O 0 6.260336249397369e-07
normal O 0 2.9763280053884955e-06
coagulation O 0 2.8412670872057788e-05
function O 0 3.7736216995654104e-07
and O 0 1.395451079133636e-07
the O 0 8.972460818768013e-08
capacity O 0 4.1845297005238535e-07
to O 0 2.484815126990725e-07
mount O 0 6.422466867661569e-06
a O 0 7.624538739037234e-06
neutrophilic O 1 0.9766162037849426
leukocytosis O 1 0.9779427647590637
during O 0 0.00029938193620182574
pyogenic B-Disease 1 0.9995121955871582
infection I-Disease 0 0.030035365372896194
. O 0 7.956675290188286e-06
. O 0 2.1381745682447217e-05

Susceptibility O 1 0.7731963396072388
to O 0 0.0021414572838693857
ankylosing B-Disease 1 0.9999998807907104
spondylitis I-Disease 1 1.0
in O 0 0.004319213330745697
twins O 0 0.14329957962036133
: O 0 3.581609462344204e-06
the O 0 2.3096525580967864e-07
role O 0 4.599459373366699e-07
of O 0 2.66369028167901e-07
genes O 0 2.4226228561019525e-06
, O 0 9.331055252914666e-07
HLA O 0 0.017590457573533058
, O 0 6.901530014147284e-07
and O 0 4.664775872242899e-07
the O 0 1.3644017826663912e-06
environment O 0 6.228158599697053e-05
. O 0 2.2218409867491573e-05

OBJECTIVE O 0 0.0002745517704170197
To O 0 1.1137327419419307e-05
determine O 0 6.413707524188794e-06
the O 0 6.786320341234386e-07
relative O 0 5.390355909185018e-06
effects O 0 2.6708032237365842e-05
of O 0 8.942704994296946e-07
genetic O 0 7.857976743252948e-05
and O 0 5.453105131891789e-06
environmental O 0 0.0002307714894413948
factors O 0 7.781038220855407e-06
in O 0 6.645536814176012e-06
susceptibility O 0 0.15469378232955933
to O 0 0.0036120037548244
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0002879100211430341
AS B-Disease 0 0.0001772265968611464
) O 0 1.7503893104731105e-05
. O 0 2.130645043507684e-05

METHODS O 0 0.001671479782089591
Twins O 0 0.011913174763321877
with O 0 6.743393441865919e-06
AS B-Disease 0 4.8525042075198144e-05
were O 0 7.631884386682941e-07
identified O 0 2.3162579054769594e-06
from O 0 1.813181995657942e-07
the O 0 3.43600078167583e-07
Royal O 0 2.516712629585527e-05
National O 0 1.6731135474401526e-05
Hospital O 0 0.01397941168397665
for O 0 0.0005642372998408973
Rheumatic B-Disease 1 0.9999997615814209
Diseases I-Disease 1 0.985332190990448
database O 0 0.000209180245292373
. O 0 3.2621963327983394e-05

Clinical O 1 0.6184285879135132
and O 0 4.277886910131201e-05
radiographic O 0 0.1767398566007614
examinations O 0 0.00013674930960405618
were O 0 1.6589464166827383e-06
performed O 0 3.21125162372482e-06
to O 0 5.433298611023929e-07
establish O 0 3.855025352095254e-05
diagnoses O 1 0.8139413595199585
, O 0 1.5057911696203519e-05
and O 0 0.0003504519409034401
disease O 0 0.44558995962142944
severity O 0 0.0410822369158268
was O 0 3.4450015391485067e-06
assessed O 0 5.763702120020753e-06
using O 0 7.602731670885987e-07
a O 0 9.498783697381441e-07
combination O 0 9.62471585808089e-06
of O 0 1.1253295042479294e-06
validated O 0 3.072896652156487e-05
scoring O 0 7.000472578511108e-06
systems O 0 0.00010146512067876756
. O 0 2.6792724383994937e-05

HLA O 1 0.554484486579895
typing O 0 0.0006958366138860583
for O 0 2.6379017072031274e-05
HLA O 0 0.17458555102348328
- O 0 0.001068182522431016
B27 O 0 0.0002676208096090704
, O 0 3.6394196740729967e-06
HLA O 0 0.0014883348485454917
- O 0 8.139767305692658e-05
B60 O 0 3.595755697460845e-05
, O 0 5.91343621181295e-07
and O 0 9.71375243352668e-07
HLA O 0 0.19134438037872314
- O 0 0.0014266306534409523
DR1 O 0 0.004451438318938017
was O 0 4.879816515312996e-07
performed O 0 4.1339811218676914e-07
by O 0 1.3398783949014614e-07
polymerase O 0 6.881307854200713e-06
chain O 0 2.512394303266774e-06
reaction O 0 6.380809054462588e-07
with O 0 1.2768721546763118e-07
sequence O 0 4.160448554557661e-07
- O 0 7.68726476962911e-06
specific O 0 4.118052459034516e-07
primers O 0 6.147327439975925e-06
, O 0 2.482065326603333e-07
and O 0 3.05695749602819e-07
zygosity O 0 0.0001956468913704157
was O 0 1.7169825241580838e-06
assessed O 0 6.726322226313641e-06
using O 0 6.5218259805988055e-06
microsatellite O 0 0.00039392823236994445
markers O 0 0.0001297916314797476
. O 0 2.96409798465902e-05

Genetic O 0 0.005021545570343733
and O 0 2.7621454137261026e-05
environmental O 0 7.903201185399666e-05
variance O 0 8.010313649720047e-06
components O 0 9.91864908428397e-06
were O 0 5.614405722553784e-07
assessed O 0 2.4960090740933083e-06
with O 0 2.389983251305239e-07
the O 0 2.0851990711889812e-07
program O 0 1.3846341744283563e-06
Mx O 0 3.3801497920649126e-05
, O 0 1.3654752706315776e-07
using O 0 1.4705345563470473e-07
data O 0 2.121551432310298e-07
from O 0 5.699612160015022e-08
this O 0 5.3066880667529404e-08
and O 0 2.3448032493433857e-07
previous O 0 5.222032541496446e-06
studies O 0 1.3024180134380003e-06
of O 0 3.555550165401655e-07
twins O 0 0.0001622512936592102
with O 0 4.522766630543629e-06
AS B-Disease 0 0.00042625152855180204
. O 0 3.6410176107892767e-05

RESULTS O 0 0.0007845127256587148
Six O 0 1.5612265997333452e-05
of O 0 3.5524965369404526e-06
8 O 0 4.531404556473717e-05
monozygotic O 0 0.011326386593282223
( O 0 2.8782253139070235e-05
MZ O 1 0.986017644405365
) O 0 9.780423170013819e-06
twin O 0 0.00010370319796493277
pairs O 0 7.114714662748156e-06
were O 0 3.435729468037607e-06
disease O 0 0.00013593015319202095
concordant O 0 0.00045867677545174956
, O 0 1.2032103313686093e-06
compared O 0 8.157372803907492e-07
with O 0 1.6544342429369863e-07
4 O 0 9.467599397794402e-07
of O 0 1.3310942392763536e-07
15 O 0 1.017383851831255e-06
B27 O 0 5.126180622028187e-05
- O 0 0.0001330031082034111
positive O 0 3.4384238460916094e-06
dizygotic O 0 7.270526111824438e-05
( O 0 2.0615536868717754e-06
DZ O 0 0.026632795110344887
) O 0 1.972925247173407e-06
twin O 0 2.3272503312909976e-05
pairs O 0 1.9339227037562523e-06
( O 0 5.529001896320551e-07
27 O 0 1.243264478034689e-06
% O 0 4.0100331943904166e-07
) O 0 1.7591638368230633e-07
and O 0 7.376591071306393e-08
4 O 0 4.5705735374212964e-07
of O 0 1.465317041038361e-07
32 O 0 3.936005668947473e-06
DZ O 0 0.27404600381851196
twin O 0 0.0001401983026880771
pairs O 0 2.5887070478347596e-06
overall O 0 4.924960194330197e-06
( O 0 3.087881168539752e-07
12 O 0 4.807686195817951e-07
. O 0 2.1637130487306422e-07
5 O 0 1.6733821439629537e-06
% O 0 3.084589707214036e-06
) O 0 3.7138174775463995e-06
. O 0 8.021910616662353e-06

Nonsignificant O 0 0.37391752004623413
increases O 0 0.00022599501244258136
in O 0 4.19504885940114e-06
similarity O 0 9.725656127557158e-06
with O 0 1.4706245110573946e-06
regard O 0 3.996703071607044e-06
to O 0 1.3019511015954777e-06
age O 0 8.406340384681243e-06
at O 0 6.196770846145228e-05
disease O 0 0.3841928541660309
onset O 0 0.3267728388309479
and O 0 7.461002269337769e-07
all O 0 7.428847226265134e-08
of O 0 2.5794017233238264e-07
the O 0 1.501572387496708e-05
disease O 0 0.33630600571632385
severity O 0 0.06388162821531296
scores O 0 4.0570350392954424e-05
assessed O 0 2.5272636776207946e-05
were O 0 5.726461154154094e-07
noted O 0 5.893432899028994e-06
in O 0 1.1895229363290127e-05
disease O 0 0.003877149196341634
- O 0 0.13256359100341797
concordant O 1 0.7651848196983337
MZ O 1 0.9996055960655212
twins O 0 0.0031726781744509935
compared O 0 1.750285991874989e-05
with O 0 9.861775652098004e-06
concordant O 0 0.32328593730926514
DZ O 1 0.9996726512908936
twins O 0 0.015269637107849121
. O 0 8.045826689340174e-05

HLA O 1 0.9489095211029053
- O 0 0.015377935022115707
B27 O 0 0.0008279544999822974
and O 0 5.764026354881935e-06
B60 O 0 8.948831964517012e-05
were O 0 7.079352144501172e-07
associated O 0 1.041086306940997e-06
with O 0 4.891086859970528e-07
the O 0 5.9796902860398404e-06
disease O 0 0.000806208117865026
in O 0 1.6635599422443192e-06
probands O 0 0.040101371705532074
, O 0 5.676795353792841e-07
and O 0 1.4719671526108868e-07
the O 0 1.2036150565108983e-07
rate O 0 1.1153355217174976e-06
of O 0 8.434265623691317e-07
disease O 0 0.00012229254934936762
concordance O 0 4.5292999857338145e-05
was O 0 1.432591375305492e-06
significantly O 0 4.5860792852181476e-06
increased O 0 7.979638780852838e-07
among O 0 6.660616804765596e-07
DZ O 0 0.21040473878383636
twin O 0 0.00013985781697556376
pairs O 0 1.0693026979424758e-06
in O 0 1.3483075633757835e-07
which O 0 8.005351048723242e-08
the O 0 1.418046906564996e-07
co O 0 3.479282167972997e-05
- O 0 0.00015344646817538887
twin O 0 0.0001243828737642616
was O 0 4.051030941809586e-07
positive O 0 3.569394380065205e-07
for O 0 2.046713234449271e-07
both O 0 8.627134207017662e-07
B27 O 0 0.00020430500444490463
and O 0 1.7957965610548854e-05
DR1 O 0 0.1108149066567421
. O 0 4.0679715311853215e-05

Additive O 0 0.005416069645434618
genetic O 0 0.002746572019532323
effects O 0 0.00014869576261844486
were O 0 1.7174509139294969e-06
estimated O 0 1.7296864598392858e-06
to O 0 4.075420179106004e-07
contribute O 0 1.2919879281980684e-06
97 O 0 2.293599436598015e-06
% O 0 6.487544510491716e-07
of O 0 1.6538457714432298e-07
the O 0 5.029362455388764e-07
population O 0 2.8452261631173315e-06
variance O 0 1.3599611520476174e-05
. O 0 1.8927441487903707e-05

CONCLUSION O 0 0.001294889603741467
Susceptibility O 0 0.002540576970204711
to O 0 7.452479167113779e-06
AS B-Disease 0 2.1177573216846213e-05
is O 0 1.4902190059729037e-06
largely O 0 5.066260200692341e-06
genetically O 0 4.6375003876164556e-05
determined O 0 3.803454092121683e-06
, O 0 3.4643633739506186e-07
and O 0 2.3815195504539588e-07
the O 0 4.853371251556382e-07
environmental O 0 6.341711559798568e-05
trigger O 0 6.605788075830787e-05
for O 0 1.526274445495801e-06
the O 0 1.3330736692296341e-05
disease O 0 0.0024305612314492464
is O 0 1.6793020449767937e-06
probably O 0 8.052845259953756e-06
ubiquitous O 0 7.960200309753418e-05
. O 0 2.0767494788742624e-05

HLA O 1 0.8719233274459839
- O 0 0.0027093938551843166
B27 O 0 0.0005122066359035671
accounts O 0 7.366990757873282e-06
for O 0 6.370600544869376e-07
a O 0 5.20907235568302e-07
minority O 0 2.261855115648359e-06
of O 0 2.9606286489070044e-07
the O 0 7.025452646303165e-07
overall O 0 0.0001740271836752072
genetic O 0 0.0002941362909041345
susceptibility O 0 0.00046283958363346756
to O 0 3.287108938820893e-06
AS B-Disease 0 0.0001318364083999768
. O 0 3.9313479646807536e-05

Cell O 0 0.0038737806025892496
cycle O 0 0.0003664876858238131
- O 0 0.00038244371535256505
dependent O 0 2.7771797249442898e-05
colocalization O 0 6.78281212458387e-05
of O 0 7.661711265427584e-07
BARD1 O 0 0.00026448312564752996
and O 0 2.0796967419300927e-06
BRCA1 O 0 8.221208554459736e-05
proteins O 0 1.4106016124060261e-06
in O 0 6.638808258685458e-07
discrete O 0 2.5688101231935434e-05
nuclear O 0 0.0002572493685875088
domains O 0 0.00010336298146285117
. O 0 3.43771607731469e-05

Germ O 0 0.13130860030651093
- O 0 0.0015516866696998477
line O 0 6.377341196639463e-05
mutations O 0 3.101182301179506e-05
of O 0 6.959062943678873e-07
the O 0 1.1891518170159543e-06
BRCA1 O 0 0.00025198436924256384
gene O 0 1.4375016689882614e-05
predispose O 0 7.019474287517369e-05
women O 0 1.678978492236638e-06
to O 0 4.370986346202699e-07
early O 0 1.495163633080665e-05
- O 1 0.9981643557548523
onset O 1 0.9999651908874512
breast B-Disease 1 0.9999257326126099
and I-Disease 1 0.9509734511375427
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999969482421875
by O 0 1.4830764030193677e-06
compromising O 0 3.420727080083452e-05
the O 0 8.391934329665673e-07
genes O 0 6.081692390580429e-06
presumptive O 0 0.00018394131620880216
function O 0 1.4899902680554078e-06
as O 0 9.010497024064534e-07
a O 0 1.6541011063964106e-05
tumor B-Disease 0 0.035022489726543427
suppressor O 0 0.004140978679060936
. O 0 4.4298172724666074e-05

Although O 0 6.713090260745957e-05
the O 0 7.858954631956294e-06
biochemical O 0 5.751190838054754e-05
properties O 0 1.1056769835704472e-05
of O 0 1.400526912220812e-06
BRCA1 O 0 0.00043723394628614187
polypeptides O 0 6.645054963883013e-05
are O 0 3.0775535719840263e-07
not O 0 1.92643312857399e-07
understood O 0 6.417027407223941e-07
, O 0 1.5693684929374285e-07
their O 0 1.8454609573836933e-07
expression O 0 9.652895869294298e-07
pattern O 0 2.8884121547889663e-06
and O 0 6.519592261611251e-07
subcellular O 0 2.002698602154851e-05
localization O 0 2.7655429221340455e-05
suggest O 0 2.2377498680725694e-06
a O 0 3.420627479044924e-07
role O 0 1.0630342330841813e-06
in O 0 1.2918252423332888e-06
cell O 0 0.00011020415695384145
- O 0 0.0010898109758272767
cycle O 0 0.00017691965331323445
regulation O 0 6.610261334571987e-05
. O 0 2.6568946850602515e-05

When O 0 0.00010861089685931802
resting O 0 0.0004449216357897967
cells O 0 0.00023940410756040365
are O 0 1.9038310483665555e-06
induced O 0 6.497790309367701e-05
to O 0 9.941585403794306e-07
proliferate O 0 3.1566327379550785e-05
, O 0 2.512750825189869e-07
the O 0 1.2293492090975633e-07
steady O 0 2.4015425879042596e-06
- O 0 2.0089551981072873e-05
state O 0 3.1527446253676317e-07
levels O 0 4.0340677287531435e-07
of O 0 1.9297962694508897e-07
BRCA1 O 0 4.081101360497996e-05
increase O 0 1.4012764495419106e-06
in O 0 2.715701157285366e-07
late O 0 2.879561407098663e-06
G1 O 0 8.815239561954513e-05
and O 0 2.1599566935037728e-07
reach O 0 5.447099056254956e-07
a O 0 3.539716431077977e-07
maximum O 0 2.606801899673883e-06
during O 0 5.372230134526035e-06
S O 0 0.0015231798170134425
phase O 0 0.00015064235776662827
. O 0 2.626565401442349e-05

Moreover O 0 0.0003234044124837965
, O 0 8.857498869474512e-06
in O 0 3.100968342550914e-06
S O 0 0.009204946458339691
phase O 0 0.00027000688714906573
cells O 0 9.512738324701786e-05
, O 0 1.7776690128812334e-06
BRCA1 O 0 4.3714226194424555e-05
polypeptides O 0 1.2136909390392248e-05
are O 0 4.5120549430066603e-07
hyperphosphorylated O 0 5.259401223156601e-05
and O 0 8.260316803898604e-07
accumulate O 0 8.225913916248828e-06
into O 0 9.120371373683156e-07
discrete O 0 1.0405401553725824e-05
subnuclear O 0 0.0005076983361504972
foci O 0 0.0003789412439800799
termed O 0 0.00012931687524542212
" O 0 1.51662452481105e-05
BRCA1 O 0 0.0003362782299518585
nuclear O 0 0.0002558015112299472
dots O 0 0.000646508764475584
. O 0 3.031547566934023e-05

" O 0 0.0014635147526860237
BRCA1 O 0 0.18180277943611145
associates O 1 0.7116203904151917
in O 0 2.7176773073733784e-05
vivo O 0 0.010295921936631203
with O 0 2.506215423636604e-06
a O 0 7.062149961711839e-06
structurally O 0 0.007132759317755699
related O 0 6.19476122665219e-05
protein O 0 7.239186379592866e-05
termed O 0 0.0007075944449752569
BARD1 O 0 0.09364745765924454
. O 0 4.350778544903733e-05

Here O 0 3.3797019568737596e-05
we O 0 3.013107061633491e-06
show O 0 1.495607875767746e-06
that O 0 1.545920440548798e-07
the O 0 2.010917796724243e-07
steady O 0 6.368155936797848e-06
- O 0 3.4120053896913305e-05
state O 0 4.1818927343229007e-07
levels O 0 4.054594739955064e-07
of O 0 1.300364829148748e-07
BARD1 O 0 0.00019661108672153205
, O 0 3.5506062090462365e-07
unlike O 0 3.335775318191736e-07
those O 0 9.929525646157344e-08
of O 0 2.582608829015953e-07
BRCA1 O 0 0.00025975715834647417
, O 0 1.2777080655723694e-06
remain O 0 1.5437517504324205e-06
relatively O 0 1.3563335414801259e-06
constant O 0 2.9701238872803515e-06
during O 0 5.9825420066772494e-06
cell O 0 0.0002803050447255373
cycle O 0 0.0004523757379502058
progression O 0 0.0005029895110055804
. O 0 2.7159931050846353e-05

However O 0 0.00015626579988747835
, O 0 2.741845673881471e-05
immunostaining O 0 0.0018124767811968923
revealed O 0 7.750410441076383e-05
that O 0 2.071812332360423e-06
BARD1 O 0 0.0008292889106087387
resides O 0 2.669270361366216e-05
within O 0 2.3599534415552625e-06
BRCA1 O 0 0.0001760790473781526
nuclear O 0 9.443065209779888e-05
dots O 0 9.916028648149222e-05
during O 0 3.813500370597467e-06
S O 0 0.0012447222834452987
phase O 0 4.658401394408429e-06
of O 0 1.4439440576552443e-07
the O 0 2.494168995781365e-07
cell O 0 3.2711126550566405e-05
cycle O 0 1.556674214953091e-05
, O 0 3.423616874442814e-07
but O 0 1.853816939956232e-07
not O 0 1.8162000969823566e-07
during O 0 5.965393938822672e-07
the O 0 1.3497617601387901e-06
G1 O 0 0.0013881940394639969
phase O 0 9.588473767507821e-05
. O 0 1.573540248500649e-05

Nevertheless O 0 0.0006332300836220384
, O 0 2.1562183974310756e-05
BARD1 O 0 0.0009826687164604664
polypeptides O 0 8.185731712728739e-05
are O 0 4.4833510060016124e-07
found O 0 4.128827413296676e-07
exclusively O 0 4.406348352858913e-07
in O 0 1.22058978035966e-07
the O 0 1.1599496474445914e-07
nuclear O 0 3.3475041618657997e-06
fractions O 0 8.715219337318558e-07
of O 0 1.0544835049586254e-07
both O 0 2.2764201901281922e-07
G1 O 0 0.00020111729099880904
- O 0 3.3288528356933966e-05
and O 0 1.0955503739751293e-06
S O 0 0.001970408484339714
- O 0 0.001130244811065495
phase O 0 0.00018285465193912387
cells O 0 0.0001367847726214677
. O 0 2.0377559849293903e-05

Therefore O 0 8.498752140440047e-05
, O 0 7.229235961858649e-06
progression O 0 2.3305081413127482e-05
to O 0 1.3614616136692348e-06
S O 0 0.008179589174687862
phase O 0 2.233103441540152e-05
is O 0 1.9743961843232682e-07
accompanied O 0 6.044047040631995e-07
by O 0 7.641280319603538e-08
the O 0 9.839539671929742e-08
aggregation O 0 1.6626686374365818e-06
of O 0 4.0389184619016305e-07
nuclear O 0 2.8323229344096035e-05
BARD1 O 0 0.00038130496977828443
polypeptides O 0 2.604386827442795e-05
into O 0 3.231832806704915e-06
BRCA1 O 0 0.00024197199672926217
nuclear O 0 0.00013262902211863548
dots O 0 0.00032444079988636076
. O 0 3.8222620787564665e-05

This O 0 5.178824358154088e-05
cell O 0 0.00022608920698985457
cycle O 0 6.513130938401446e-05
- O 0 0.00021711339650209993
dependent O 0 2.0202272935421206e-05
colocalization O 0 5.5721498938510194e-05
of O 0 5.740699862144538e-07
BARD1 O 0 0.0015758435474708676
and O 0 3.817291599261807e-06
BRCA1 O 0 0.00016149188741110265
indicates O 0 2.8334798116702586e-06
a O 0 3.821903646894498e-07
role O 0 7.68772281389829e-07
for O 0 9.79730657491018e-07
BARD1 O 0 0.02840443141758442
in O 0 7.738508429611102e-06
BRCA1 O 0 0.0015229261480271816
- O 0 0.46192294359207153
mediated O 1 0.7636711001396179
tumor B-Disease 0 0.2239517718553543
suppression O 0 0.0002519149275030941
. O 0 2.350352588109672e-05

Ethnic O 0 0.000247166637564078
differences O 0 0.00011023579281754792
in O 0 7.215474397526123e-06
the O 0 5.7348729569639545e-06
HFE O 0 0.0016455731820315123
codon O 0 0.00010450569970998913
282 O 0 0.0001955685584107414
( O 0 2.987983316415921e-05
Cys O 1 0.92391037940979
/ O 0 0.004061703570187092
Tyr O 0 0.0215316005051136
) O 0 2.2806303604738787e-05
polymorphism O 0 0.00013789201329927891
. O 0 2.255585241073277e-05

Recent O 0 0.0006016154075041413
studies O 0 0.00011638553405646235
have O 0 3.225948148610769e-06
shown O 0 5.791090643469943e-06
that O 0 1.646483906370122e-05
hereditary B-Disease 1 0.9999995231628418
hemochromatosis I-Disease 1 1.0
( O 0 0.11979619413614273
HH B-Disease 1 0.9999781847000122
) O 0 1.296160917263478e-05
is O 0 2.135073344788907e-07
likely O 0 4.479461779283156e-07
to O 0 1.159434219744071e-07
be O 0 1.4687391569623287e-07
caused O 0 1.2481472140279948e-06
by O 0 2.0941088507697714e-07
homozygosity O 0 8.375720062758774e-05
for O 0 3.079917121340259e-07
a O 0 1.0375231340731261e-06
Cys282Tyr O 0 0.004605382680892944
mutation O 0 7.08176230546087e-06
in O 0 3.08204420207403e-07
the O 0 6.832491976638266e-07
HFE O 0 0.0008971623610705137
gene O 0 1.009637981042033e-05
located O 0 2.84832390207157e-06
4 O 0 1.3311782822711393e-05
. O 0 1.761246494424995e-05

5 O 0 0.00030157281435094774
Mb O 0 0.0033098559360951185
telomeric O 0 0.00462042773142457
to O 0 2.2888401872478426e-05
HLA O 0 0.1473066508769989
- O 0 0.0005235793069005013
A O 0 3.175097663188353e-05
. O 0 3.7620437069563195e-05

Population O 0 0.00012386671733111143
studies O 0 2.4325559934368357e-05
of O 0 9.355915722153441e-07
this O 0 6.249681518966099e-07
polymorphism O 0 1.0915468010352924e-05
are O 0 2.943163224244927e-07
facilitated O 0 3.452375494816806e-06
by O 0 1.9624026492692792e-07
the O 0 1.5745705184144754e-07
fact O 0 2.7205484798287216e-07
that O 0 1.0854650156488788e-07
the O 0 3.210523971119983e-07
Cys282Tyr O 0 0.0007513379096053541
mutation O 0 1.2537764632725157e-05
creates O 0 2.53034181696421e-06
a O 0 1.5889930864432245e-06
Rsal O 0 0.00023569741460960358
restriction O 0 7.830570211808663e-06
site O 0 1.3178007066017017e-05
. O 0 1.515739677415695e-05

We O 0 3.33790885633789e-05
have O 0 5.9573203543550335e-06
studied O 0 5.553243227041094e-06
the O 0 1.8462369553162716e-06
codon O 0 2.266225783387199e-05
282 O 0 7.407411612803116e-05
( O 0 1.35048758238554e-05
Cys O 1 0.9579395055770874
/ O 0 0.018022943288087845
Tyr O 0 0.012261263094842434
) O 0 1.7991985714616021e-06
polymorphism O 0 4.192121650703484e-06
in O 0 3.473937795206439e-07
different O 0 6.183402092574397e-07
ethnic O 0 3.413957074371865e-06
groups O 0 5.449663149192929e-06
. O 0 1.4345341696753167e-05

In O 0 4.358880687505007e-05
agreement O 0 1.4464112609857693e-05
with O 0 2.150853788407403e-06
previous O 0 7.748041753075086e-06
observations O 0 5.295230039337184e-06
the O 0 7.514279900533438e-07
Tyr O 0 0.0011301327031105757
allele O 0 1.1775857274187729e-05
appeared O 0 9.89033992482291e-07
to O 0 1.1722904247335464e-07
be O 0 1.1948885969559342e-07
rare O 0 1.0703698762881686e-06
or O 0 1.0405185548734153e-06
absent O 0 1.2601512025867123e-05
in O 0 9.516137424725457e-07
Asiatic O 0 0.00010430072143208236
( O 0 8.620323797003948e-07
Indian O 0 1.0415203632874181e-06
, O 0 4.3410969396973087e-07
Chinese O 0 7.302118092411547e-07
) O 0 3.2538116556679597e-06
populations O 0 1.4459864360105712e-05
. O 0 1.1462501788628288e-05

The O 0 4.0951123082777485e-05
highest O 0 6.05769528192468e-05
allele O 0 8.934055222198367e-05
frequency O 0 1.2949896699865349e-05
( O 0 1.5241943174260086e-06
7 O 0 2.0813320134038804e-06
. O 0 2.6401471586723346e-07
5 O 0 1.0680714694899507e-06
% O 0 9.981599760067184e-07
) O 0 5.014315433982119e-07
was O 0 3.5521168229024624e-07
found O 0 8.20049876892881e-07
in O 0 1.4801712495682295e-06
Swedes O 0 0.00034914223942905664
. O 0 2.6296478608855978e-05

Saamis O 0 0.05846388265490532
( O 0 7.205466681625694e-05
2 O 0 1.3628564374812413e-05
% O 0 3.65495725418441e-06
) O 0 1.094011281566054e-06
and O 0 4.686567081080284e-07
Mordvinians O 0 0.00013623845006804913
( O 0 8.482787166030903e-07
1 O 0 5.220744583311898e-07
. O 0 1.6861514495758456e-07
8 O 0 9.133941034633608e-07
% O 0 7.52082542021526e-07
) O 0 3.403459629680583e-07
had O 0 2.7978853722743224e-07
significantly O 0 2.1239575289655477e-06
lower O 0 1.2222280929563567e-06
frequencies O 0 1.0509631920285756e-06
of O 0 3.244000481572584e-07
the O 0 1.7445631783630233e-06
Tyr O 0 0.012889955192804337
allele O 0 0.00017646391643211246
. O 0 1.3778168977296446e-05

Comparisons O 0 0.00017139117699116468
with O 0 1.266345952899428e-05
allele O 0 5.4788964916951954e-05
frequencies O 0 1.017451813822845e-05
based O 0 5.980728474241914e-06
on O 0 3.2310374535882147e-06
prevalence O 0 0.00014716980513185263
estimates O 0 2.2307536710286513e-05
of O 0 1.3430335457087494e-06
HH B-Disease 1 0.9678966999053955
showed O 0 7.2866373557189945e-06
some O 0 1.413785355453001e-07
disagreements O 0 3.01453519568895e-06
with O 0 2.980924591611256e-07
the O 0 4.5389990077637776e-07
RFLP O 0 0.00026026758132502437
data O 0 2.95730865218502e-06
, O 0 4.7139957359831897e-07
particularly O 0 1.0922786941591767e-06
in O 0 1.347102397630806e-06
Finns O 0 0.0003092637052759528
. O 0 3.4313092328375205e-05

The O 0 4.7355923015857115e-05
newly O 0 7.330165681196377e-05
described O 0 5.1767012337222695e-05
HFE O 0 0.001793924137018621
marker O 0 1.4750483387615532e-05
provides O 0 1.8343257579545025e-06
a O 0 4.3967565943603404e-07
new O 0 4.990804427507101e-07
approach O 0 5.038786525801697e-07
to O 0 1.2383318903630425e-07
the O 0 1.3727991188261512e-07
screening O 0 1.034972456182004e-06
of O 0 2.3096239942788088e-07
HH B-Disease 1 0.6824132800102234
as O 0 3.615166690451588e-07
well O 0 1.9638721937553782e-07
as O 0 1.3853404823294113e-07
studies O 0 2.486042660621024e-07
of O 0 5.324897855985e-08
the O 0 1.2840770580169192e-07
relationship O 0 8.145835863615503e-07
between O 0 4.417498473685555e-07
the O 0 1.2418259984769975e-06
HFE O 0 0.046721260994672775
Tyr O 0 0.06599420309066772
allele O 0 2.5913208446581848e-05
and O 0 2.6811610496224603e-06
different O 0 1.047998284775531e-05
disorders O 1 0.890334963798523
including O 0 0.0006123894709162414
cancer B-Disease 1 0.9502615928649902

Autosomal B-Disease 1 0.9998032450675964
dominant I-Disease 1 0.952400803565979
neurohypophyseal I-Disease 1 0.9999935626983643
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.999982476234436
associated O 0 0.0003788796893786639
with O 0 3.259386403442477e-06
a O 0 9.040139957505744e-06
missense O 0 0.000587749935220927
mutation O 0 2.0149418560322374e-05
encoding O 0 1.2586955563165247e-05
Gly23 O 0 0.00034131211577914655
- O 0 0.000622738094534725
- O 0 0.004099058918654919
> O 0 0.00036924571031704545
Val O 0 0.00031565138488076627
in O 0 4.808135599887464e-06
neurophysin O 0 0.0008774197776801884
II O 0 0.000325981731293723
. O 0 3.669422949315049e-05

Autosomal B-Disease 1 0.9996622800827026
dominant I-Disease 1 0.896009624004364
neurohypophyseal I-Disease 1 0.9999936819076538
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.999994158744812
( O 0 0.0006864137831144035
ADNDI B-Disease 1 0.7901126146316528
) O 0 4.8904912546277046e-05
is O 0 3.2315858788933838e-06
an O 0 7.696430839132518e-05
inherited B-Disease 1 0.9999996423721313
disease I-Disease 1 0.9999985694885254
caused O 0 0.001068540965206921
by O 0 5.1554634410422295e-06
progressive O 0 0.012451429851353168
degeneration O 0 0.3508446216583252
of O 0 5.367121502786176e-07
the O 0 7.522497185163957e-07
magnocellular O 0 0.010634389705955982
neurons O 0 3.312392072984949e-05
of O 0 1.1481208161967515e-07
the O 0 2.507701992726652e-07
hypothalamus O 0 9.260239494324196e-06
leading O 0 1.2659163530770456e-06
to O 0 2.865268129426113e-07
decreased O 0 3.1868751193542266e-06
ability O 0 6.433885459955491e-07
to O 0 2.614694665226125e-07
produce O 0 1.4861374211250222e-06
the O 0 9.450180868952884e-07
hormone O 0 2.256553307233844e-05
arginine O 0 9.561739716446027e-05
vasopressin O 0 0.0002673022972885519
( O 0 3.6859637475572526e-06
AVP O 0 0.00025768461637198925
) O 0 8.230999810621142e-06
. O 0 8.62212800711859e-06

Affected O 0 0.0010913017904385924
individuals O 0 2.459493225615006e-05
are O 0 1.872853431450494e-06
not O 0 1.374827434119652e-06
symptomatic O 0 0.0004906316753476858
at O 0 6.5058607106038835e-06
birth O 0 5.403148315963335e-05
, O 0 2.2389431251212955e-06
but O 0 1.3087155821267515e-06
usually O 0 1.5125887330214027e-05
develop O 0 0.31504324078559875
diabetes B-Disease 1 0.9998433589935303
insipidus I-Disease 1 0.943283200263977
at O 0 1.5332714156102156e-06
1 O 0 4.96348229717114e-06
- O 0 0.00044145758147351444
6 O 0 3.959566674893722e-05
yr O 0 0.03448805958032608
of O 0 1.29803947856999e-06
age O 0 1.2080407941539306e-05
. O 0 2.271132507303264e-05

The O 0 5.030421743867919e-05
genetic O 0 0.00015129029634408653
locus O 0 5.6998178479261696e-05
of O 0 2.257504320368753e-06
the O 0 8.492965207551606e-06
disease O 0 0.0003873638343065977
is O 0 4.4828379941463936e-07
the O 0 5.58395811367518e-07
AVP O 0 0.026971062645316124
- O 0 0.012667234055697918
neurophysin O 0 0.04953116178512573
II O 0 0.00014577747788280249
( O 0 2.561507017162512e-06
NPII O 0 0.0004278298292774707
) O 0 9.902005331241526e-07
gene O 0 8.498406600665476e-07
, O 0 2.612829916870396e-07
and O 0 1.1618753887887578e-06
mutations O 0 2.0428382413228974e-05
that O 0 4.229376315834088e-07
cause O 0 8.639931365905795e-06
ADNDI B-Disease 0 0.021961616352200508
have O 0 3.792714835526567e-07
been O 0 1.3762281980689295e-07
found O 0 1.1739653160702801e-07
in O 0 8.226796666122027e-08
both O 0 7.283938430191483e-08
the O 0 1.0582533604974742e-07
signal O 0 9.369809959025588e-07
peptide O 0 9.483459280090756e-07
of O 0 1.2721100972612476e-07
the O 0 3.1247031984094065e-07
prepro O 0 0.00010895528248511255
- O 0 0.00010450489207869396
AVP O 0 0.0004373308620415628
- O 0 0.00011477281077532098
NPII O 0 0.0002579655556473881
precursor O 0 7.382146577583626e-06
and O 0 6.914191885698528e-07
within O 0 1.3868794894733583e-06
NPII O 0 0.0005593845271505415
itself O 0 4.497849295148626e-05
. O 0 1.5650115528842434e-05

An O 0 6.0152240621391684e-05
affected O 0 8.136275573633611e-05
girl O 0 0.00011370569700375199
who O 0 5.4352549341274425e-06
presented O 0 6.393579042196507e-06
at O 0 1.0935023055935744e-06
9 O 0 6.647083409916377e-06
months O 0 1.9429996882536216e-06
of O 0 2.396830893758306e-07
age O 0 8.138815701386193e-07
and O 0 5.778721288152155e-07
her O 0 4.131870355195133e-06
similarly O 0 3.952165207010694e-05
affected O 0 6.345294877974084e-06
younger O 0 1.1710110811691266e-05
brother O 0 9.824143489822745e-06
and O 0 1.1470934850876802e-06
father O 0 2.0593251974787563e-06
were O 0 1.008941410418629e-07
all O 0 3.8957338688305754e-08
found O 0 1.4934899184027017e-07
to O 0 9.011084500798461e-08
have O 0 1.419812889480454e-07
a O 0 5.611044002762355e-07
novel O 0 8.28226711746538e-06
missense O 0 0.00023905445414129645
mutation O 0 1.2659764252020977e-05
( O 0 8.398876616411144e-07
G1758 O 0 2.7387670343159698e-05
- O 0 0.00018149663810618222
- O 0 0.0025394908152520657
> O 0 0.0001727353665046394
T O 0 0.00025518640177324414
) O 0 1.898466734928661e-07
encoding O 0 3.5957569366473763e-07
the O 0 7.089737863452683e-08
amino O 0 7.230603387142764e-07
acid O 0 2.892723614422721e-06
substitution O 0 1.1525257832545321e-06
Gly23 O 0 4.363821790320799e-05
- O 0 0.00010715749522205442
- O 0 0.0004753809771500528
> O 0 0.00013325066538527608
Val O 0 0.00011503699352033436
within O 0 5.036724814999616e-06
NPII O 0 0.0006710747256875038
. O 0 2.209003832831513e-05

The O 0 6.821205170126632e-05
mutation O 0 0.00019266056187916547
was O 0 8.027099283935968e-06
confirmed O 0 1.0792334251163993e-05
by O 0 1.8436243180985912e-06
restriction O 0 1.1206376257177908e-05
endonuclease O 0 0.0002563850430306047
analysis O 0 6.960641621844843e-05
. O 0 3.054094486287795e-05

A O 0 0.0001297601847909391
T1 O 0 0.017541546374559402
- O 0 0.00031731935450807214
weighted O 0 2.27657328650821e-05
magnetic O 0 1.91000071936287e-05
resonance O 0 1.8719942090683617e-05
imaging O 0 7.654404907952994e-05
of O 0 4.99393706832052e-07
the O 0 1.3349720120459097e-06
fathers O 0 0.00020002909877803177
pituitary O 0 0.318502813577652
gland O 0 0.008310031145811081
demonstrates O 0 1.1698356502165552e-05
an O 0 9.813709311856655e-07
attenuated O 0 0.0002741599455475807
posterior O 0 0.0022171945311129093
pituitary O 0 0.04407287761569023
bright O 0 0.00042355028563179076
spot O 0 6.21591170784086e-05
. O 0 2.6560004698694684e-05

This O 0 6.898815627209842e-05
mutation O 0 0.0002669862296897918
may O 0 9.387506906932686e-06
be O 0 4.1086062196882267e-07
valuable O 0 1.0164227433051565e-06
for O 0 4.529675550202228e-07
developing O 0 1.0145207852474414e-05
models O 0 9.274999683839269e-06
of O 0 1.1210460115762544e-06
dominantly B-Disease 0 0.21824868023395538
inherited I-Disease 1 0.9835350513458252
neurodegeneration I-Disease 1 1.0
, O 0 5.21046149515314e-06
as O 0 1.4197721043274214e-07
the O 0 1.51686123217587e-07
early O 0 1.2652453733608127e-06
age O 0 6.437199431275076e-07
of O 0 7.831623065612803e-07
onset O 0 0.3303276300430298
of O 0 1.553271067677997e-05
symptoms O 1 0.71907639503479
suggests O 0 1.3204979950387497e-05
that O 0 2.1247284109904285e-07
this O 0 3.6936381775376503e-07
mutation O 0 8.91515810508281e-06
may O 0 1.9917792997148354e-06
be O 0 1.1547928835398125e-07
particularly O 0 6.47555282284884e-07
deleterious O 0 1.0822656804521102e-05
to O 0 3.13503988991215e-07
the O 0 9.197393069371174e-07
magnocellular O 0 0.005712300539016724
neuron O 0 0.0004092642047908157
. O 0 5.469093594001606e-06
. O 0 1.4453507901635021e-05

Frequent O 0 0.0025767465122044086
inactivation O 0 0.09017314016819
of O 0 6.030587974237278e-05
PTEN O 1 0.952255129814148
/ O 0 0.17976927757263184
MMAC1 O 0 0.47730427980422974
in O 0 0.00029959206585772336
primary O 1 0.8875529170036316
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999959468841553
. O 0 0.00020544990547932684

Sporadic B-Disease 1 0.9998568296432495
prostate I-Disease 1 0.9999997615814209
carcinoma I-Disease 1 1.0
is O 0 2.8596316042239778e-05
the O 0 1.3429515774987522e-06
most O 0 7.439027172040369e-07
common O 0 3.635913526522927e-05
male B-Disease 0 0.0064629907719790936
cancer I-Disease 0 0.09419842064380646
in O 0 2.147104254390797e-07
the O 0 9.307842674388667e-08
Western O 0 1.1213625157324714e-06
world O 0 5.916194254496077e-07
, O 0 1.8314818817088963e-07
yet O 0 1.0711811881947142e-07
many O 0 2.8241402105777524e-08
of O 0 3.938153625426821e-08
the O 0 2.0370974596062297e-07
major O 0 2.54572387348162e-06
genetic O 0 9.115770808421075e-06
events O 0 3.740500460480689e-07
involved O 0 4.250118479376397e-07
in O 0 1.377735685537118e-07
the O 0 3.1067560257724836e-07
progression O 0 2.2480091502075084e-05
of O 0 2.4055924541244167e-07
this O 0 5.941950007581909e-07
often O 0 4.9334023060509935e-05
fatal O 1 0.997826874256134
cancer B-Disease 0 0.4814774990081787
remain O 0 4.7283365347539075e-06
to O 0 7.120906957425177e-07
be O 0 1.2892395488961483e-06
elucidated O 0 0.00021188129903748631
. O 0 1.8570261090644635e-05

Numerous O 0 0.00043534801807254553
cytogenetic O 0 0.14460992813110352
and O 0 7.563936378573999e-05
allelotype O 1 0.5127277374267578
studies O 0 6.245328404475003e-05
have O 0 2.370589072597795e-06
reported O 0 8.925716429075692e-06
frequent O 0 8.642510692880023e-06
loss O 0 2.3588381736772135e-05
of O 0 6.743829885635932e-07
heterozygosity O 0 0.0038781086914241314
on O 0 9.501115528109949e-06
chromosomal O 0 0.001786944572813809
arm O 0 0.0009568954119458795
10q O 0 0.012353443540632725
in O 0 0.00013105280231684446
sporadic B-Disease 1 0.9971296191215515
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999938011169434
. O 0 0.000162379743414931

Deletion O 0 0.010597443208098412
mapping O 0 0.001489733112975955
studies O 0 7.066365651553497e-05
have O 0 3.0338007945829304e-06
unambiguously O 0 6.885204493300989e-05
identified O 0 4.16883494835929e-06
a O 0 8.979957328847377e-07
region O 0 8.346746653842274e-06
of O 0 9.060820502782008e-07
chromosome O 0 2.8797407139791176e-05
10q23 O 0 2.531313475628849e-05
to O 0 2.567050501056656e-07
be O 0 8.691665698279394e-08
the O 0 1.4102745637956104e-07
minimal O 0 2.2125886971480213e-06
area O 0 1.2969716181032709e-06
of O 0 1.4378130117620458e-06
loss O 0 0.00024449144257232547
. O 0 3.140334956697188e-05

A O 0 0.00013259613479021937
new O 0 0.00017413539171684533
tumor B-Disease 0 0.015953797847032547
suppressor O 0 0.0023553979117423296
gene O 0 5.6663364375708625e-05
, O 0 7.036394890747033e-06
PTEN O 0 0.17205825448036194
/ O 0 0.001799467601813376
MMAC1 O 0 0.004010993987321854
, O 0 1.1609273542489973e-06
was O 0 4.6114143970044097e-07
isolated O 0 2.600790139695164e-06
recently O 0 1.6834358120831894e-06
at O 0 1.6823382509301155e-07
this O 0 7.787726730157374e-08
region O 0 2.004992211368517e-06
of O 0 4.420321886300371e-07
chromosome O 0 2.2898291717865504e-05
10q23 O 0 2.8875618227175437e-05
and O 0 3.723573058778129e-07
found O 0 2.012529307648947e-07
to O 0 1.1900294083488916e-07
be O 0 1.272954648356972e-07
inactivated O 0 2.0741690605063923e-06
by O 0 2.477682983226259e-07
mutation O 0 3.7960835470585153e-06
in O 0 1.9258725387771847e-06
three O 0 0.0035759536549448967
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999951124191284
cell O 0 0.024752305820584297
lines O 0 0.0001438475155737251
. O 0 2.8622400350286625e-05

We O 0 8.378684287890792e-05
screened O 0 0.0002575873804744333
80 O 0 0.0009392026695422828
prostate B-Disease 1 0.9999328851699829
tumors I-Disease 1 0.9998669624328613
by O 0 6.1694099713349715e-06
microsatellite O 0 0.0004910698626190424
analysis O 0 1.1021661521226633e-05
and O 0 1.251978574146051e-06
found O 0 2.056348193946178e-06
chromosome O 0 1.4489762179437093e-05
10q23 O 0 2.4955234039225616e-05
to O 0 4.80615085507452e-07
be O 0 2.1204370170835318e-07
deleted O 0 3.0991441235528328e-06
in O 0 8.284758337140374e-07
23 O 0 1.7115780792664737e-05
cases O 0 8.362618245882913e-06
. O 0 1.345489545201417e-05

We O 0 2.121788202202879e-05
then O 0 3.721858774952125e-06
proceeded O 0 5.533698640647344e-06
with O 0 6.146643727333867e-07
sequence O 0 9.9739395409415e-07
analysis O 0 8.102526294351264e-07
of O 0 1.3674913645900233e-07
the O 0 3.580331338071119e-07
entire O 0 3.292069095550687e-06
PTEN O 0 0.005676111206412315
/ O 0 0.00015952829562593251
MMAC1 O 0 0.0007836650474928319
coding O 0 0.00012356930528767407
region O 0 7.328668289119378e-06
and O 0 7.206797363323858e-07
tested O 0 2.3362906631518854e-06
for O 0 3.2217897683040064e-07
homozygous O 0 5.93420827499358e-06
deletion O 0 8.572565093345474e-06
with O 0 3.8736175156373065e-07
new O 0 3.0025767046026886e-06
intragenic O 0 0.00048213894478976727
markers O 0 6.019478405505652e-06
in O 0 2.7753284825848823e-07
these O 0 1.3637158247092884e-07
23 O 0 3.304064875919721e-06
cases O 0 5.82554434913618e-07
with O 0 6.054506229702383e-07
10q23 O 0 0.0007074211607687175
loss O 0 7.717908010818064e-05
of O 0 4.47106322098989e-06
heterozygosity O 0 0.011819802224636078
. O 0 3.73625589418225e-05

The O 0 1.999227242777124e-05
identification O 0 1.4645343981101178e-05
of O 0 1.0354424375691451e-06
the O 0 6.412341235773056e-07
second O 0 2.322818772881874e-06
mutational O 0 0.0002389079163549468
event O 0 2.2289809749054257e-06
in O 0 2.776072278720676e-07
10 O 0 5.100657745060744e-07
( O 0 5.105076184008794e-07
43 O 0 2.670466074050637e-06
% O 0 4.201398496661568e-06
) O 0 1.7521597328595817e-05
tumors B-Disease 1 0.994207501411438
establishes O 0 0.0006448780768550932
PTEN O 1 0.5892066955566406
/ O 0 0.00019019430328626186
MMAC1 O 0 0.00010284720337949693
as O 0 2.0257506605503295e-07
a O 0 2.3569275242607546e-07
main O 0 1.3353196663956624e-06
inactivation O 0 0.00017895408382173628
target O 0 1.6434576082247077e-06
of O 0 4.832015747524565e-07
10q O 0 0.0002535385137889534
loss O 0 0.0002069350448437035
in O 0 0.00011110462219221517
sporadic B-Disease 1 0.9996641874313354
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
. O 0 2.6081446776515804e-05
. O 0 3.78670338250231e-05

Risk O 0 0.037583667784929276
reversals O 0 0.0034983016084879637
in O 0 4.16221737395972e-05
predictive O 0 0.0011549813207238913
testing O 0 0.0006550193065777421
for O 0 0.0012246811529621482
Huntington B-Disease 1 0.9999992847442627
disease I-Disease 1 0.9999498128890991
. O 0 0.00010221442062174901

The O 0 3.4241053072037175e-05
first O 0 1.630401129659731e-05
predictive O 0 0.0002364634128753096
testing O 0 0.0001789438392734155
for O 0 0.0004444343503564596
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999924898147583
( O 0 3.207857662346214e-05
HD B-Disease 0 0.0005778303602710366
) O 0 7.352360285040049e-07
was O 0 1.9481210244975955e-07
based O 0 3.590407970932574e-07
on O 0 2.709037687509408e-07
analysis O 0 5.785272492175864e-07
of O 0 2.1821479379013908e-07
linked O 0 1.9887116650352255e-05
polymorphic O 0 0.00019174533372279257
DNA O 0 1.5869496564846486e-05
markers O 0 2.0292050066927914e-06
to O 0 2.2583085979022144e-07
estimate O 0 2.3985189727682155e-06
the O 0 1.7862207357666193e-07
likelihood O 0 1.1391853149689268e-06
of O 0 1.3747879279435438e-07
inheriting O 0 2.475834480719641e-05
the O 0 1.1524707588250749e-06
mutation O 0 1.1996345165243838e-05
for O 0 1.4370220924320165e-06
HD B-Disease 0 0.000422847515437752
. O 0 1.8566684957477264e-05

Limits O 0 7.513943273806944e-05
to O 0 7.411344085994642e-06
accuracy O 0 1.1129225640615914e-05
included O 0 1.9018821149074938e-06
recombination O 0 4.008995347248856e-06
between O 0 3.928712430933956e-07
the O 0 3.752477084617567e-07
DNA O 0 7.4326553658465855e-06
markers O 0 3.146696826661355e-06
and O 0 4.741232260130346e-07
the O 0 4.717157366940228e-07
mutation O 0 9.984322787204292e-06
, O 0 5.886293479306914e-07
pedigree O 0 2.535643034207169e-05
structure O 0 3.181867441526265e-06
, O 0 3.446416769747884e-07
and O 0 2.870568778234883e-07
whether O 0 5.162052616469737e-07
DNA O 0 4.886325768893585e-06
samples O 0 1.131016801991791e-06
were O 0 9.738548811810688e-08
available O 0 2.559436040883156e-07
from O 0 2.9728792583227914e-07
family O 0 3.404963308639708e-06
members O 0 8.742358659219462e-06
. O 0 2.1109019144205377e-05

With O 0 4.564182381727733e-05
direct O 0 2.2187388822203502e-05
tests O 0 8.9211034719483e-06
for O 0 7.015423193479364e-07
the O 0 6.55099711366347e-07
HD B-Disease 0 0.0003332736960146576
mutation O 0 6.61032436255482e-06
, O 0 2.7226639076616266e-07
we O 0 9.419285618150752e-08
have O 0 1.2167302543275582e-07
assessed O 0 1.0151294418392354e-06
the O 0 1.3814565136271995e-07
accuracy O 0 1.5666230410715798e-06
of O 0 1.9820348029497836e-07
results O 0 5.454222900880268e-06
obtained O 0 1.1590135500227916e-06
by O 0 2.4983114599308465e-07
linkage O 0 7.1979834501689766e-06
approaches O 0 4.0441241253574844e-06
when O 0 4.3352261513973644e-07
requested O 0 9.406895173924568e-07
to O 0 1.461236678323985e-07
do O 0 1.864758729652749e-07
so O 0 1.1990552195584314e-07
by O 0 1.38899707735618e-07
the O 0 3.9766607073943305e-07
test O 0 5.474385034176521e-06
individuals O 0 3.6513824852590915e-06
. O 0 1.1094457477156539e-05

For O 0 1.9011216863873415e-05
six O 0 8.801393960311543e-06
such O 0 1.4161469152895734e-06
individuals O 0 1.3787612260784954e-06
, O 0 7.476779728676775e-07
there O 0 1.311277628701646e-07
was O 0 5.965712261968292e-07
significant O 0 1.595003823240404e-06
disparity O 0 1.3667896382685285e-05
between O 0 9.452948006583028e-07
the O 0 1.933815838128794e-06
tests O 0 2.3691067326581106e-05
. O 0 1.5846946553210728e-05

Three O 0 2.3245862394105643e-05
went O 0 9.892236448649783e-06
from O 0 1.6919098015932832e-06
a O 0 2.337596470169956e-06
decreased O 0 0.00010957209451589733
risk O 0 1.577896546223201e-05
to O 0 3.830189996278932e-07
an O 0 3.277769735632319e-07
increased O 0 4.220357368467376e-06
risk O 0 1.4513329006149434e-05
, O 0 3.8846565075800754e-07
while O 0 1.7789024298053846e-07
in O 0 9.324599403726097e-08
another O 0 1.2749423206059873e-07
three O 0 2.8251321282368735e-07
the O 0 1.1440280331953545e-06
risk O 0 3.812462091445923e-05
was O 0 2.749589611994452e-06
decreased O 0 4.98455083288718e-05
. O 0 1.7040503735188395e-05

Knowledge O 0 5.901446274947375e-05
of O 0 3.3139610877697123e-06
the O 0 2.1485209344973555e-06
potential O 0 5.095337201055372e-06
reasons O 0 1.4832093029326643e-06
for O 0 2.525358695493196e-07
these O 0 1.693837816674204e-07
changes O 0 8.98429277640389e-07
in O 0 7.524957936766441e-07
results O 0 9.032884008775e-06
and O 0 7.542812454630621e-07
impact O 0 1.7264484313272987e-06
of O 0 3.3643723895693256e-07
these O 0 1.203511033054383e-06
risk O 0 2.920840597653296e-05
reversals O 0 3.390312849660404e-05
on O 0 1.2774851256835973e-06
both O 0 1.8224460518467822e-06
patients O 0 5.228940426604822e-05
and O 0 3.705443418766663e-07
the O 0 2.9980648719174496e-07
counseling O 0 6.073913482396165e-06
team O 0 4.271308569059329e-07
can O 0 8.002893281400247e-08
assist O 0 2.3512812674653105e-07
in O 0 6.659276863274499e-08
the O 0 7.077846930769738e-08
development O 0 3.410783619983704e-07
of O 0 1.4885371513173595e-07
strategies O 0 7.650125553482212e-06
for O 0 2.9049988370388746e-07
the O 0 8.853342592374247e-07
prevention O 0 3.6073237424716353e-05
and O 0 1.0004386012951727e-06
, O 0 3.204082474894676e-07
where O 0 2.0442728043690295e-07
necessary O 0 4.75447649250782e-07
, O 0 5.046014166509849e-07
management O 0 5.831564521940891e-06
of O 0 1.8769912912830478e-07
a O 0 5.041265922045568e-06
risk O 0 9.801403939491138e-05
reversal O 0 5.796975165139884e-05
in O 0 4.740418262372259e-07
any O 0 5.040714086135267e-07
predictive O 0 2.5694980649859644e-05
testing O 0 1.073439034371404e-05
program O 0 4.861134584643878e-06
. O 0 2.6296313535567606e-06
. O 0 8.868960321706254e-06

A O 0 0.00021100594312883914
novel O 0 0.00016944159870035946
common O 0 7.381364412140101e-05
missense O 0 0.002132662571966648
mutation O 0 0.0001038964037434198
G301C O 0 0.0001039575508912094
in O 0 1.1335586123095709e-06
the O 0 4.44983612624128e-07
N O 0 5.152263111085631e-05
- O 0 7.039099727990106e-05
acetylgalactosamine O 0 0.0001671112113399431
- O 0 8.096393139567226e-05
6 O 0 1.0722522347350605e-05
- O 0 0.00046732157352380455
sulfate O 0 0.0004844150389544666
sulfatase O 0 0.0010209929896518588
gene O 0 1.0422305422252975e-05
in O 0 3.1364861570182256e-06
mucopolysaccharidosis B-Disease 0 0.0017098415410146117
IVA I-Disease 0 0.14893709123134613
. O 0 5.661291288561188e-05

Mucopolysaccharidosis B-Disease 1 0.8528578877449036
IVA I-Disease 1 0.999619722366333
( O 0 0.0010558863868936896
MPS B-Disease 1 0.9932060241699219
IVA I-Disease 1 0.9999970197677612
) O 0 6.836117245256901e-05
is O 0 2.100526444337447e-06
an O 0 1.1139133675897028e-05
autosomal B-Disease 1 0.9577616453170776
recessive I-Disease 1 0.9572014212608337
lysosomal I-Disease 1 0.9998195767402649
storage I-Disease 1 0.9971126317977905
disorder I-Disease 1 0.9997100234031677
caused O 0 7.887697574915364e-05
by O 0 1.0393512184236897e-06
a O 0 1.8024280507233925e-05
genetic B-Disease 1 0.8641735911369324
defect I-Disease 1 0.899802029132843
in O 0 1.4179415757098468e-06
N O 0 0.0001929200952872634
- O 0 0.00022025432554073632
acetylgalactosamine O 0 0.0009763275738805532
- O 0 0.00018462692969478667
6 O 0 1.785111271601636e-05
- O 0 0.013273012824356556
sulfate O 0 0.014355195686221123
sulfatase O 0 0.014870235696434975
( O 0 4.236268978274893e-06
GALNS O 0 0.0003947356599383056
) O 0 8.803677701507695e-06
. O 0 8.578125743952114e-06

In O 0 4.924377935822122e-05
previous O 0 8.676101424498484e-05
studies O 0 1.5596297089359723e-05
, O 0 9.774628324521473e-07
we O 0 1.9068497181251587e-07
have O 0 1.0372564673843954e-07
found O 0 1.4633019418397453e-07
two O 0 1.8377490107468475e-07
common O 0 1.5560179235762917e-05
mutations O 0 2.923332249338273e-05
in O 0 4.066851602146926e-07
Caucasians O 0 3.223033490939997e-05
and O 0 5.118550916449749e-07
Japanese O 0 4.728940439235885e-06
, O 0 2.633950998642831e-06
respectively O 0 1.954947401827667e-05
. O 0 1.8878210539696738e-05

To O 0 4.6318389649968594e-05
characterize O 0 0.00022299923875834793
the O 0 5.887332463316852e-06
mutational O 0 0.0010763966711238027
spectrum O 0 2.4363960619666614e-05
in O 0 8.646968581160763e-07
various O 0 3.537242605489155e-07
ethnic O 0 1.2650184544327203e-06
groups O 0 6.33999889032566e-07
, O 0 7.052391310935491e-07
mutations O 0 3.0687863272760296e-06
in O 0 1.6067336616742978e-07
the O 0 2.2121530207641626e-07
GALNS O 0 0.00044215837260708213
gene O 0 2.9070931759633822e-06
in O 0 4.769258339365479e-07
Colombian O 0 2.4850927729858086e-05
MPS B-Disease 1 0.9770578145980835
IVA I-Disease 1 0.9999998807907104
patients O 0 0.0362883098423481
were O 0 6.015341114107287e-07
investigated O 0 1.2206230167066678e-05
, O 0 5.575465138463187e-07
and O 0 9.357182761959848e-07
genetic O 0 1.0620912689773832e-05
backgrounds O 0 7.85465363151161e-06
were O 0 3.539024362453347e-07
extensively O 0 2.116324822054594e-06
analyzed O 0 2.448737859594985e-06
to O 0 3.0104246206974494e-07
identify O 0 1.9395488379814196e-06
racial O 0 9.502534226157877e-07
origin O 0 5.413096459960798e-07
, O 0 2.8041466748618404e-07
based O 0 1.033708940667566e-06
on O 0 6.810763579778722e-07
mitochondrial O 0 4.872164208791219e-05
DNA O 0 8.44058595248498e-05
( O 0 3.678052507893881e-06
mtDNA O 0 2.5068295144592412e-05
) O 0 7.339214789681137e-06
lineages O 0 4.3372529034968466e-05
. O 0 2.00282629521098e-05

Three O 0 5.27303091075737e-05
novel O 0 0.00011883895058417693
missense O 0 0.003501662751659751
mutations O 0 0.0007755454280413687
never O 0 1.0449115507071838e-05
identified O 0 8.818860806059092e-06
previously O 0 2.407334932286176e-06
in O 0 3.527258058966254e-07
other O 0 3.323803525745461e-07
populations O 0 2.2023114070179872e-06
and O 0 5.642069709210773e-07
found O 0 3.316878292025649e-07
in O 0 1.4182700169840246e-07
16 O 0 3.618129369442613e-07
out O 0 1.601150358965242e-07
of O 0 2.0265949274289596e-07
19 O 0 5.338878509064671e-06
Colombian O 0 2.6483168767299503e-05
MPS B-Disease 0 0.41368725895881653
IVA I-Disease 1 0.9998877048492432
unrelated O 0 0.00018306921992916614
alleles O 0 1.9034761862712912e-05
account O 0 4.197073394607287e-06
for O 0 2.132012241418124e-06
84 O 0 8.30330463941209e-05
. O 0 3.194337114109658e-05

2 O 0 0.0001876529713626951
% O 0 1.3806894457957242e-05
of O 0 7.621737836416287e-07
the O 0 1.0145932947125402e-06
alleles O 0 8.502090167894494e-06
in O 0 1.0317342002963414e-06
this O 0 1.3214125829108525e-06
study O 0 1.4405648471438326e-05
. O 0 1.9781420633080415e-05

The O 0 7.780897431075573e-05
G301C O 0 0.0005755805177614093
and O 0 1.7112583009293303e-05
S162F O 0 0.0012170514091849327
mutations O 0 9.358342504128814e-05
account O 0 6.232799933059141e-06
for O 0 2.7596379368333146e-06
68 O 0 8.006722782738507e-05
. O 0 3.563412246876396e-05

4 O 0 0.0002675761643331498
% O 0 3.168116745655425e-05
and O 0 7.602016921737231e-06
10 O 0 1.937908928084653e-05
. O 0 1.9364719264558516e-05

5 O 0 0.00017168709018733352
% O 0 2.288630639668554e-05
of O 0 3.1657345971325412e-06
mutations O 0 5.043607598054223e-05
, O 0 7.858076855882246e-07
respectively O 0 3.637435156633728e-06
, O 0 2.946154040728288e-07
whereas O 0 6.233871658878343e-07
the O 0 1.268747951144178e-07
remaining O 0 8.850320227793418e-07
F69V O 0 0.0006536211003549397
is O 0 2.878592795241275e-07
limited O 0 4.4039452973265725e-07
to O 0 1.639123752283922e-07
a O 0 7.090061444614548e-07
single O 0 6.230303824850125e-06
allele O 0 6.85334816807881e-05
. O 0 1.115723807743052e-05

The O 0 6.47311971988529e-05
skewed O 0 0.0005247133667580783
prevalence O 0 0.000353394279954955
of O 0 3.111695150437299e-06
G301C O 0 0.00015296803030651063
in O 0 1.0004138175645494e-06
only O 0 2.787689936667448e-07
Colombian O 0 3.785216176765971e-05
patients O 0 7.246383029269055e-05
and O 0 1.7058221146726282e-06
haplotype O 0 0.0009544575004838407
analysis O 0 2.2203632852324517e-06
by O 0 2.976794633013924e-07
restriction O 0 8.902822514755826e-07
fragment O 0 2.785058768495219e-06
length O 0 1.5757332221255638e-06
polymorphisms O 0 1.4829230167379137e-05
in O 0 1.4354588984133443e-07
the O 0 2.4315590962942224e-07
GALNS O 0 0.0007693835650570691
gene O 0 2.3471932308893884e-06
suggest O 0 9.295528116126661e-07
that O 0 1.7879746394555696e-07
G301C O 0 2.115585630235728e-05
originated O 0 1.4164224921842106e-06
from O 0 2.563473913141934e-07
a O 0 8.947438914219674e-07
common O 0 1.2566230907395948e-05
ancestor O 0 4.976500349584967e-05
. O 0 2.448732266202569e-05

Investigation O 0 0.0002084652369376272
of O 0 4.70940858576796e-06
the O 0 3.160081860187347e-06
genetic O 0 1.4838269635220058e-05
background O 0 5.000254986953223e-06
by O 0 4.7451766249650973e-07
means O 0 7.14720954420045e-07
of O 0 2.799812364173704e-07
mtDNA O 0 1.3241562555776909e-05
lineages O 0 5.009873802919174e-06
indicate O 0 1.3443700481730048e-06
that O 0 7.716915462196994e-08
all O 0 8.905355031174622e-08
our O 0 1.951350441231625e-06
patients O 0 7.193713099695742e-05
are O 0 2.439565491840767e-07
probably O 0 7.38664368782338e-07
of O 0 4.871437795372913e-07
native O 0 1.1700811228365637e-05
American O 0 2.660964491951745e-05
descent O 0 0.0004939264617860317

Low O 0 0.0002541183785069734
frequency O 0 6.850748468423262e-05
of O 0 1.1771355275413953e-05
BRCA1 O 0 0.0033886171877384186
germline O 1 0.5452685952186584
mutations O 0 0.00024636954185552895
in O 0 3.6157327940600226e-06
45 O 0 4.1855026211123914e-05
German O 1 0.9502190351486206
breast B-Disease 1 0.9999921321868896
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999946355819702
families O 0 0.0001435960439266637
. O 0 5.523535583051853e-05

In O 0 3.9001493860268965e-05
this O 0 4.759266630571801e-06
study O 0 5.865274943062104e-06
we O 0 1.3998833310324699e-06
investigated O 0 2.2137275664135814e-05
45 O 0 5.493461503647268e-05
German O 1 0.9838312864303589
breast B-Disease 1 0.9999955892562866
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999908208847046
families O 0 1.8351363905821927e-05
for O 0 1.0548256796028e-05
germline O 1 0.9311267137527466
mutations O 0 0.0001267353363800794
in O 0 7.754959483463608e-07
the O 0 2.644113692440442e-06
BRCA1 O 0 0.002021069172769785
gene O 0 7.690503844060004e-05
. O 0 2.1195717636146583e-05

We O 0 6.048944123904221e-05
identified O 0 4.821993934456259e-05
four O 0 1.2646743925870396e-05
germline O 0 0.3536856770515442
mutations O 0 0.00030989086371846497
in O 0 3.6654917039413704e-06
three O 0 7.807029760442674e-05
breast B-Disease 1 0.9999635219573975
cancer I-Disease 1 0.9427728652954102
families O 0 4.368720965430839e-06
and O 0 8.810285407889751e-07
in O 0 2.133102270818199e-06
one O 0 4.49256767751649e-05
breast B-Disease 1 0.9999653100967407
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
family O 0 2.1133753762114793e-05
. O 0 3.548176152889937e-07
among O 0 1.447441917434844e-07
these O 0 6.175881139824924e-08
were O 0 1.158026350367436e-07
one O 0 3.7894534443694283e-07
frameshift O 0 0.0020491397008299828
mutation O 0 8.663578228151891e-06
, O 0 2.86409317595826e-07
one O 0 2.0797652666715294e-07
nonsense O 0 1.7639107682043687e-05
mutation O 0 4.0072868614515755e-06
, O 0 1.594929273096568e-07
one O 0 1.605038164598227e-07
novel O 0 9.441497468287707e-07
splice O 0 9.379471885040402e-05
site O 0 4.5517099351854995e-06
mutation O 0 6.129333087301347e-06
, O 0 4.1963426156144124e-07
and O 0 6.392643854269409e-07
one O 0 3.254159082644037e-06
missense O 0 0.0009948167717084289
mutation O 0 0.00016435053839813918
. O 0 2.964833220175933e-05

The O 0 0.00010043615475296974
missense O 0 0.004954908974468708
mutation O 0 0.00013526696420740336
was O 0 4.789751528733177e-06
also O 0 2.0951965780113824e-06
found O 0 1.7424913494323846e-06
in O 0 1.6732896028770483e-06
2 O 0 3.348305472172797e-05
. O 0 2.6441626687301323e-05

8 O 0 0.000182946037966758
% O 0 1.1015703421435319e-05
of O 0 7.153531100811961e-07
the O 0 5.07217464473797e-07
general O 0 1.4138865935819922e-06
population O 0 4.766961865243502e-07
, O 0 3.4613645993886166e-07
suggesting O 0 1.2884540865343297e-06
that O 0 1.2337652322003123e-07
it O 0 2.2681660993839614e-07
is O 0 1.2323829423621646e-06
not O 0 8.140655154420529e-06
disease O 0 0.002477269386872649
associated O 0 6.072357064113021e-05
. O 0 2.5827301215031184e-05

The O 0 2.3166523533291183e-05
average O 0 3.535105861374177e-05
age O 0 1.7510104953544214e-05
of O 0 1.468993923481321e-05
disease O 0 0.4189609885215759
onset O 0 0.350535124540329
in O 0 4.532261300482787e-06
those O 0 1.2961555739821051e-06
families O 0 8.609204087406397e-06
harbouring O 1 0.6198358535766602
causative O 0 0.05450473725795746
mutations O 0 6.560407200595364e-05
was O 0 1.066240542968444e-06
between O 0 1.362422835882171e-06
32 O 0 1.75301047420362e-05
. O 0 2.1201478375587612e-05

3 O 0 0.0003999391046818346
and O 0 6.558017048519105e-05
37 O 0 0.0002347747067688033
. O 0 0.00011163391900481656

4 O 0 0.0004005234513897449
years O 0 2.6346961021772586e-05
, O 0 2.7287724151392467e-06
whereas O 0 2.8683678010565927e-06
the O 0 4.5204666321296827e-07
family O 0 4.686666216002777e-06
harbouring O 0 0.0034295355435460806
the O 0 2.205257942478056e-06
missense O 0 0.00046643990208394825
mutation O 0 1.0002067938330583e-05
had O 0 3.021662564606231e-07
an O 0 1.804814644401631e-07
average O 0 1.8787441149470396e-06
age O 0 9.070018904822064e-07
of O 0 9.345803277938103e-07
onset O 0 0.0046630436554551125
of O 0 3.2761963666416705e-06
51 O 0 0.0001114592669182457
. O 0 3.1456522265216336e-05

2 O 0 0.0012821448035538197
years O 0 0.0005259083118289709
. O 0 0.00021089031361043453

These O 0 6.124498759163544e-05
findings O 0 8.418929792242125e-05
show O 0 7.172349341999507e-06
that O 0 1.829720190471562e-06
BRCA1 O 0 0.00027427211171016097
is O 0 1.1914117976630223e-06
implicated O 0 3.1587678677169606e-05
in O 0 2.471450386565266e-07
a O 0 4.073461923326249e-07
small O 0 7.681185820729297e-07
fraction O 0 5.42150564797339e-06
of O 0 2.3507695004809648e-05
breast B-Disease 1 0.999987006187439
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999828338623047
families O 0 8.158172931871377e-06
suggesting O 0 4.436146809894126e-06
the O 0 2.5251560487049574e-07
involvement O 0 3.531940592438332e-06
of O 0 3.1294089808397985e-07
another O 0 5.577913270826684e-06
susceptibility O 0 0.008478843607008457
gene O 0 7.236549572553486e-05
( O 0 1.4790235582040623e-05
s O 0 0.00435602618381381
) O 0 6.583570211660117e-05

Paternal O 0 0.122000552713871
transmission O 0 0.04322992265224457
of O 0 0.004818514455109835
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.004859533626586199

We O 0 6.0324175137793645e-05
report O 0 3.660646689240821e-05
a O 0 5.8405253184901085e-06
rare O 0 3.278057920397259e-05
case O 0 1.2590568985615391e-05
of O 0 2.0234047042322345e-05
paternally O 1 0.9993452429771423
transmitted O 1 0.9993922710418701
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.5768022537231445
DM B-Disease 1 0.9999998807907104
) O 0 0.00020443224639166147
. O 0 3.7081885238876566e-05

The O 0 3.2351079426007345e-05
proband O 0 0.0012327113654464483
is O 0 2.373301185798482e-06
a O 0 1.570296717545716e-06
23 O 0 5.717845397157362e-06
year O 0 2.63300648839504e-06
old O 0 2.797882552840747e-05
, O 0 7.581910904264078e-05
mentally B-Disease 1 0.999921441078186
retarded I-Disease 1 0.9995983242988586
male O 0 0.028759680688381195
who O 0 0.03024851530790329
suffers O 1 0.9999949932098389
severe O 1 0.999784529209137
muscular B-Disease 1 0.9997938275337219
weakness I-Disease 1 0.9569739699363708
. O 0 0.0001209005931741558

He O 0 8.870066812960431e-05
presented O 0 0.00011307500244583935
with O 0 9.16689241421409e-05
respiratory O 1 0.9956570863723755
and O 0 4.004791480838321e-05
feeding O 0 0.0001931291917571798
difficulties O 0 0.0006441427976824343
at O 0 1.9175984562025405e-05
birth O 0 0.0003298702067695558
. O 0 5.691279875463806e-05

His O 0 0.0001975378836505115
two O 0 0.00013106428377795964
sibs O 1 0.9997342228889465
suffer O 1 0.9322842359542847
from O 0 9.638673509471118e-05
childhood O 0 0.1513160765171051
onset O 1 0.9998376369476318
DM B-Disease 1 0.9999997615814209
. O 0 0.0012442434672266245

Their O 0 3.543631828506477e-05
late O 0 4.3515545257832855e-05
father O 0 1.0783034667838365e-05
had O 0 1.2266244766578893e-06
the O 0 3.2823461992848024e-07
adult O 0 1.6880255770956865e-06
type O 0 2.1343762455217075e-06
of O 0 1.5291096815417404e-06
DM B-Disease 1 0.9999998807907104
, O 0 9.017649972520303e-06
with O 0 2.0284621768951183e-06
onset O 0 0.001545959385111928
around O 0 7.487490165658528e-07
30 O 0 4.937699941365281e-06
years O 0 8.447463187621906e-06
. O 0 1.3003283129364718e-05

Only O 0 1.4379582353285514e-05
six O 0 8.105825145321433e-06
other O 0 1.371281427964277e-06
cases O 0 1.4749223282706225e-06
of O 0 8.235798532041372e-07
paternal O 0 0.00014370026474352926
transmission O 0 0.000654552539344877
of O 0 0.0006721247336827219
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 5.382371455198154e-05
been O 0 5.766187314293347e-06
reported O 0 3.872575325658545e-05
recently O 0 3.703431866597384e-05
. O 0 2.351154944335576e-05

We O 0 3.6834397178608924e-05
review O 0 2.1185996956774034e-05
the O 0 1.5163795978878625e-06
sex O 0 7.188921244960511e-06
related O 0 1.448666716896696e-05
effects O 0 3.9708316762698814e-05
on O 0 1.0560566806816496e-05
transmission O 0 0.0010047360556200147
of O 0 0.00030472365324385464
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.001117643085308373

Decreased O 0 0.005855742376297712
fertility O 0 0.003331610932946205
of O 0 9.40373502089642e-06
males O 0 2.4856426534825005e-05
with O 0 6.968434263399104e-06
adult O 0 0.00042881976696662605
onset O 1 0.9979898929595947
DM B-Disease 1 1.0
and O 0 3.302154073026031e-05
contraction O 0 7.164910493884236e-05
of O 0 1.8947821445181035e-07
the O 0 2.666742773271835e-07
repeat O 0 1.2464587598515209e-05
upon O 0 9.895067023535375e-07
male O 0 3.5368416320125107e-06
transmission O 0 4.487380920181749e-06
contribute O 0 7.060937718961213e-07
to O 0 1.0683918105769408e-07
the O 0 1.1330405413900735e-07
almost O 0 3.8899503351785825e-07
absent O 0 6.539339665323496e-06
occurrence O 0 3.6902968076901743e-06
of O 0 5.733002126362408e-07
paternal O 0 0.00010429533722344786
transmission O 0 0.00036984513280913234
of O 0 0.00025640707463026047
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.0010243644937872887

Also O 0 1.7936796211870387e-05
the O 0 2.1997168460075045e-06
fathers O 0 5.647798843710916e-06
of O 0 4.345015156559384e-07
the O 0 8.434515166300116e-07
reported O 0 8.033061749301851e-05
congenitally O 0 0.23721793293952942
affected O 0 2.3835264073568396e-05
children O 0 2.187261770814075e-06
showed O 0 2.7645928639685735e-06
, O 0 2.3805975502000365e-07
on O 0 3.080322130699642e-07
average O 0 1.5144257758947788e-06
, O 0 5.932811291131657e-07
shorter O 0 2.1150046450202353e-05
CTG O 0 0.0007333674002438784
repeat O 0 3.837291296804324e-05
lengths O 0 4.342972897575237e-05
and O 0 1.69679947248369e-06
hence O 0 2.6590898414724506e-05
less O 0 0.0001241959835169837
severe O 1 0.998985230922699
clinical O 1 0.992597222328186
symptoms O 0 0.3353064954280853
than O 0 4.2019814827654045e-07
the O 0 8.524625059180835e-07
mothers O 0 2.8143509553046897e-05
of O 0 1.5661106544939685e-06
children O 0 5.264970604912378e-05
with O 0 0.004635773599147797
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 1.0
. O 0 0.001442760811187327

We O 0 8.24210510472767e-05
conclude O 0 0.00016557554772589356
that O 0 4.138156327826437e-06
paternal O 0 8.782726217759773e-05
transmission O 0 0.00029517203802242875
of O 0 0.00016538903582841158
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 9.422915172763169e-05
rare O 0 6.070666131563485e-05
and O 0 3.834747531072935e-06
preferentially O 0 0.0001168422240880318
occurs O 0 3.7992560919519747e-06
with O 0 1.1338299827912124e-06
onset O 0 0.008328426629304886
of O 0 1.6485467995153158e-06
DM B-Disease 1 0.9999996423721313
past O 0 5.4280135373119265e-06
30 O 0 1.552991193420894e-06
years O 0 4.529870238911826e-07
in O 0 1.8889294040036475e-07
the O 0 3.836975395188347e-07
father O 0 7.169470336521044e-06
. O 0 3.3382334549969528e-06
. O 0 1.2754115232382901e-05

The O 0 0.00014099491818342358
RB1 O 1 0.7794983983039856
gene O 0 0.0005421281093731523
mutation O 0 7.61660048738122e-05
in O 0 2.950406951640616e-06
a O 0 4.2204701458103955e-06
child O 0 0.00012239217176102102
with O 0 0.00032780985930003226
ectopic B-Disease 1 0.9999884366989136
intracranial I-Disease 1 0.999977707862854
retinoblastoma I-Disease 1 0.9978650212287903
. O 0 0.0001399522734573111

The O 0 0.00017078545351978391
RB1 O 1 0.7548993229866028
gene O 0 0.00052236596820876
mutation O 0 0.00011803721281467006
was O 0 3.545047547959257e-06
investigated O 0 1.7489261153968982e-05
in O 0 6.409620709746378e-07
a O 0 2.080440708596143e-06
child O 0 3.365740121807903e-05
with O 0 5.743253859691322e-05
ectopic B-Disease 1 0.9999697208404541
intracranial I-Disease 1 0.9978339076042175
retinoblastoma I-Disease 0 0.34393104910850525
using O 0 6.343213954096427e-06
DNA O 0 2.04354746529134e-05
obtained O 0 1.3512402574633597e-06
from O 0 1.3901075135436258e-07
both O 0 1.781632477104722e-07
the O 0 6.131351142357744e-07
pineal B-Disease 0 0.08699988573789597
and I-Disease 0 6.753387424396351e-05
retinal I-Disease 1 0.9978508949279785
tumours I-Disease 1 0.9999850988388062
of O 0 2.4089081307465676e-06
the O 0 7.955089131428394e-06
patient O 0 0.0007375975837931037
. O 0 3.734844722202979e-05

A O 0 0.00014487275620922446
nonsense O 0 0.000659709214232862
mutation O 0 7.063845987431705e-05
in O 0 2.7706500986823812e-06
exon O 0 3.0286346373031847e-05
17 O 0 4.568260465021012e-06
( O 0 7.25385859823291e-07
codon O 0 3.021001930392231e-06
556 O 0 2.9045243081782246e-06
) O 0 2.2177401604039915e-07
of O 0 9.457901484211106e-08
the O 0 4.2110920617233205e-07
RB1 O 0 0.04762038588523865
gene O 0 2.897892500186572e-06
was O 0 1.436924463860123e-07
found O 0 1.2134299254284997e-07
to O 0 7.140057078913742e-08
be O 0 6.894045156968787e-08
present O 0 2.769384934708796e-07
homozygously O 0 0.000113804402644746
in O 0 2.4394608999500633e-07
both O 0 1.4687657312606461e-07
the O 0 6.020943033036019e-07
retinal B-Disease 0 0.007949876599013805
and I-Disease 0 2.9768189051537775e-06
the I-Disease 0 1.2492625501181465e-05
pineal I-Disease 1 0.997473418712616
tumours I-Disease 1 0.9999872446060181
. O 0 7.26201687939465e-05

The O 0 2.465203942847438e-05
same O 0 8.83591656020144e-06
mutation O 0 2.0678251530625857e-05
was O 0 1.3844399973095278e-06
present O 0 1.3774048284176388e-06
heterozygously O 0 0.00016430213872808963
in O 0 3.9132652318585315e-07
the O 0 2.2514510078508465e-07
DNA O 0 2.4248440695373574e-06
from O 0 1.8212057284472394e-07
the O 0 1.2157454420957947e-07
constitutional O 0 9.257910278392956e-07
cells O 0 2.936545797638246e-06
of O 0 8.927361960786584e-08
the O 0 4.898653855889279e-07
patient O 0 7.10210224497132e-05
, O 0 1.1055780078095268e-06
proving O 0 9.689413673186209e-06
it O 0 1.1142027744881489e-07
to O 0 1.9946618579069764e-07
be O 0 2.513196761810832e-07
of O 0 1.379300442749809e-06
germline O 0 0.008056320250034332
origin O 0 4.081771112396382e-05
. O 0 2.662091537786182e-05

The O 0 6.0083562857471406e-05
initial O 0 0.00021828245371580124
mutation O 0 5.9068621339974925e-05
was O 0 1.6230922028626082e-06
shown O 0 9.626556902730954e-07
to O 0 2.5617509891162626e-07
have O 0 2.9272609936015215e-07
occurred O 0 1.0211085736955283e-06
in O 0 3.572595801415446e-07
the O 0 9.377139917887689e-07
paternally O 0 0.00045745898387394845
derived O 0 7.265909516718239e-05
RB1 O 0 0.024239709600806236
allele O 0 0.00013688030594494194
. O 0 2.515090636734385e-05

The O 0 4.521200753515586e-05
mutation O 0 5.922237687627785e-05
is O 0 9.352347092317359e-07
in O 0 3.2931384907897154e-07
an O 0 1.4425374672555336e-07
area O 0 2.0179722071134165e-07
of O 0 5.8807167135910277e-08
the O 0 1.5745959558444156e-07
gene O 0 8.264839834737359e-07
that O 0 5.551748571974713e-08
encodes O 0 4.212469377762318e-07
the O 0 7.710838900720773e-08
protein O 0 8.542740488337586e-07
- O 0 1.310454354097601e-05
binding O 0 2.9222644570836565e-06
region O 0 1.7221777852682862e-06
known O 0 3.165126258863893e-07
as O 0 6.863776036425406e-08
the O 0 1.1664523924537207e-07
pocket O 0 6.982394552323967e-05
region O 0 8.042270565056242e-06
and O 0 5.418426667347376e-07
has O 0 3.7357662563408667e-07
been O 0 3.0874718959239544e-07
detected O 0 3.2572859254287323e-06
in O 0 2.2144601530271757e-07
other O 0 2.2288101320100395e-07
cases O 0 8.910195106182073e-07
of O 0 8.514095384271059e-07
retinoblastoma B-Disease 0 0.20652644336223602
. O 0 1.2928290743730031e-05
. O 0 2.1701744117308408e-05

Low O 0 0.00025352061493322253
levels O 0 2.2641152099822648e-05
of O 0 1.347085685665661e-06
beta O 0 1.4413893040909898e-05
hexosaminidase O 0 6.540392496390268e-05
A O 0 1.4482181995845167e-06
in O 0 1.3362775916903047e-06
healthy O 0 1.1636980161711108e-05
individuals O 0 1.1859738151542842e-06
with O 0 6.260554073378444e-06
apparent O 0 0.38833919167518616
deficiency O 1 0.9209226369857788
of O 0 1.2892076028947486e-06
this O 0 3.0828252874925965e-06
enzyme O 0 0.00012783290003426373
. O 0 1.9960803911089897e-05

Appreciable O 0 0.0025045587681233883
beta O 0 0.000665584288071841
hexosaminidase O 0 0.0012641865760087967
A O 0 1.1936877854168415e-05
( O 0 3.5517750802682713e-06
hex O 0 2.4043218218139373e-05
A O 0 1.8447182128511486e-06
) O 0 1.0408817843199358e-06
activity O 0 5.867081540600338e-07
has O 0 2.3659808334741683e-07
been O 0 2.9813764967911993e-07
detected O 0 4.484519195102621e-06
in O 0 1.0587312999632559e-06
cultured O 0 0.015638070181012154
skin O 1 0.9962239265441895
fibroblasts O 1 0.668419599533081
and O 0 0.007256173063069582
melanoma B-Disease 1 0.9999979734420776
tissue O 0 0.007154492195695639
from O 0 2.2434574020735454e-06
healthy O 0 2.094127376039978e-05
individuals O 0 8.678212566337606e-07
previously O 0 7.227870810311288e-06
reported O 0 1.0055166967504192e-05
as O 0 4.6200995029721525e-07
having O 0 6.459685209847521e-06
deficiency B-Disease 0 0.015566129237413406
of I-Disease 0 1.8488414355033456e-07
hex I-Disease 0 7.719761197222397e-05
A I-Disease 0 8.281771783913427e-07
activity O 0 7.306952625185659e-07
indistinguishable O 0 1.8290817251909175e-06
from O 0 1.0431987362835571e-07
that O 0 8.858226152597126e-08
of O 0 6.099432994233212e-07
patients O 0 0.0005092525971122086
with O 0 0.0003053390537388623
Tay B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Sachs I-Disease 1 1.0
disease I-Disease 1 0.89724200963974
( O 0 2.798165223794058e-05
TSD B-Disease 0 0.13580769300460815
) O 0 1.3626380678033456e-05
. O 0 1.4991369425843004e-05

Identification O 0 0.00022968731354922056
and O 0 1.586960206623189e-05
quantitation O 0 0.0006591681158170104
of O 0 2.5154006380034843e-06
hex O 0 9.887947089737281e-05
A O 0 4.02676732846885e-06
, O 0 1.4217736179489293e-06
amounting O 0 5.6462313295924105e-06
to O 0 1.3351234429137548e-06
3 O 0 1.7357315300614573e-05
. O 0 1.9613298718468286e-05

5 O 0 0.00037325226003304124
% O 0 8.953390351962298e-05
- O 0 0.0009333177586086094
6 O 0 0.00012008882913505659
. O 0 5.059905015514232e-05

9 O 0 0.00016245871665887535
% O 0 1.0618827218422666e-05
of O 0 8.098214721030672e-07
total O 0 1.7519842003821395e-06
beta O 0 9.403842341271229e-06
hexosaminidase O 0 8.790912397671491e-05
activity O 0 1.2091896905985777e-06
, O 0 2.1254133741877013e-07
has O 0 1.7225771387074928e-07
been O 0 1.2238056967817101e-07
obtained O 0 3.525923091274308e-07
by O 0 3.2939078664639965e-07
cellulose O 0 0.0002316647587576881
acetate O 0 0.0002210196398664266
gel O 0 0.00022212874318938702
electrophoresis O 0 1.4177187040331773e-05
, O 0 3.2805749583530996e-07
DEAE O 0 3.741871478268877e-05
- O 0 2.49304484896129e-05
cellulose O 0 4.831891055800952e-05
ion O 0 8.325521775987e-06
- O 0 7.161597750382498e-06
exchange O 0 1.3520807442546356e-06
chromatography O 0 1.2275476365175564e-05
, O 0 6.96945733125176e-07
radial O 0 4.827068551094271e-05
immunodiffusion O 0 0.00018946631462313235
, O 0 1.8640898815647233e-06
and O 0 2.9296591037564212e-06
radioimmunoassay O 0 0.0013603831175714731
. O 0 2.585228685347829e-05

Previous O 0 0.0006530507234856486
family O 0 0.0002033451310126111
studies O 0 3.675285552162677e-05
suggested O 0 9.28889676288236e-06
that O 0 4.004629374776414e-07
these O 0 3.987677814620838e-07
individuals O 0 5.284779831526976e-07
may O 0 1.6214413562920527e-06
be O 0 1.868673535909693e-07
compound O 0 1.2277994756004773e-05
heterozygotes O 0 4.536502092378214e-05
for O 0 1.974386663050609e-07
the O 0 2.437577109049016e-07
common O 0 2.463161081323051e-06
mutant O 0 3.8221383874770254e-05
TSD B-Disease 0 0.28910791873931885
gene O 0 6.832701728853863e-06
and O 0 4.366740711247985e-07
a O 0 1.3633325579576194e-06
rare O 0 4.0454640839016065e-05
( O 0 7.059617928462103e-06
allelic O 0 0.00012786765000782907
) O 0 6.109129571996164e-06
mutant O 0 4.3913158151553944e-05
gene O 0 5.2003419114043936e-05
. O 0 3.1404997571371496e-05

Thus O 0 6.90882807248272e-05
, O 0 5.4938409448368475e-06
the O 0 1.577424654897186e-06
postulated O 0 1.467320544179529e-05
rate O 0 3.1078516258276068e-06
mutant O 0 8.325807357323356e-06
gene O 0 3.1127101465244778e-06
appears O 0 8.378547704523953e-07
to O 0 9.393629341047927e-08
code O 0 1.564293938827177e-07
for O 0 7.356737086183784e-08
the O 0 8.40364506871083e-08
expression O 0 2.926923059476394e-07
of O 0 1.1560953083744607e-07
low O 0 2.2324359179037856e-06
amounts O 0 1.3671395890924032e-06
of O 0 4.876253001384612e-07
hex O 0 0.0001316472189500928
A O 0 1.0834894965228159e-05
. O 0 2.3105054424377158e-05

Heterozygotes O 0 0.0074859256856143475
for O 0 1.940418587764725e-05
the O 0 3.995937277068151e-06
rare O 0 3.639004353317432e-05
mutant O 0 0.00011274973076069728
may O 0 6.321582077362109e-06
be O 0 2.5439129558435525e-07
indistinguishable O 0 3.936550001526484e-06
from O 0 5.340633038031228e-07
heterozygotes O 0 3.671750528155826e-05
for O 0 5.529028044293227e-07
the O 0 1.4147268529995927e-06
common O 0 3.7346988392528147e-05
TSD B-Disease 1 0.7270856499671936
mutant O 0 0.0003896135021932423
. O 0 4.232758146827109e-05

However O 0 3.7597634218400344e-05
, O 0 3.56709483639861e-06
direct O 0 2.4482710614393e-06
visualization O 0 3.2660565921105444e-05
and O 0 1.269711674467544e-06
quantitation O 0 0.00018090936646331102
of O 0 5.116818329042871e-07
hex O 0 3.7384543247753754e-05
A O 0 6.292299303822801e-07
by O 0 2.2680276856590353e-07
the O 0 2.2115604281225387e-07
methods O 0 5.1496358537406195e-06
described O 0 3.484931221464649e-05
may O 0 6.748443411197513e-06
prevent O 0 4.442074441612931e-06
false O 0 3.222759914933704e-05
- O 0 0.09056068956851959
positive O 0 5.307669562171213e-05
prenatal O 0 0.4492947459220886
diagnosis O 0 0.14169086515903473
of O 0 2.2174258447194006e-06
TSD B-Disease 1 0.9179720878601074
in O 0 5.775262252427638e-06
fetuses O 0 8.301009074784815e-05
having O 0 3.654081979220791e-07
the O 0 2.2845389935355342e-07
incomplete O 0 4.531137619778747e-06
hex B-Disease 0 0.0004772663814947009
A I-Disease 0 9.150245023192838e-05
deficiency I-Disease 0 0.12138208001852036
of O 0 1.6663847191011882e-07
the O 0 4.690475350344059e-07
type O 0 9.76767114480026e-06
described O 0 8.527343197783921e-06
in O 0 2.1852257248156093e-07
the O 0 4.0035754977907345e-07
four O 0 4.488455488171894e-06
healthy O 0 7.744477625237778e-05
individuals O 0 3.2778763852547854e-05

The O 0 0.00021450675558298826
tumor B-Disease 0 0.015462464652955532
suppressor O 0 0.0022740988060832024
gene O 0 0.00010449693218106404
Smad4 O 0 0.004652861505746841
/ O 0 0.0017730093095451593
Dpc4 O 0 0.0003361848066560924
is O 0 5.081688527752704e-07
required O 0 4.352737335011625e-07
for O 0 5.03359501635714e-07
gastrulation O 0 0.0007374584092758596
and O 0 6.713503353239503e-07
later O 0 8.179777069017291e-07
for O 0 5.520166155292827e-07
anterior O 0 0.00017953568021766841
development O 0 1.7584504803380696e-06
of O 0 4.892686433777271e-07
the O 0 1.638820322114043e-06
mouse O 0 0.0001101018424378708
embryo O 0 0.00025119134807027876
. O 0 3.3006901503540576e-05

Mutations O 0 0.002159364055842161
in O 0 1.3893965842726175e-05
the O 0 6.5941176217165776e-06
SMAD4 O 0 0.059917137026786804
/ O 0 0.10453363507986069
DPC4 O 1 0.9179741740226746
tumor B-Disease 0 0.0465540885925293
suppressor O 0 0.0002639827725943178
gene O 0 4.8711490308051e-06
, O 0 3.142037883208104e-07
a O 0 2.576583995050896e-07
key O 0 1.5812607898624265e-06
signal O 0 4.404623268783325e-06
transducer O 0 6.456750998040661e-05
in O 0 4.6772754558332963e-07
most O 0 4.3470336663631315e-07
TGFbeta O 0 0.0006720433593727648
- O 0 0.008465475402772427
related O 0 1.9510602214722894e-05
pathways O 0 6.062559350539232e-06
, O 0 3.000049844104069e-07
are O 0 8.399847217788192e-08
involved O 0 2.2948105993236823e-07
in O 0 2.164148469319116e-07
50 O 0 1.073401904250204e-06
% O 0 6.74904185871128e-06
of O 0 3.0579816666431725e-05
pancreatic B-Disease 1 0.9999949932098389
cancers I-Disease 1 0.9951267242431641
. O 0 8.509773761034012e-05

Homozygous O 0 0.010420677252113819
Smad4 O 0 0.22169069945812225
mutant O 0 0.0413171611726284
mice O 1 0.5768751502037048
die O 0 0.05846412852406502
before O 0 8.241563591582235e-06
day O 0 6.853036666143453e-06
7 O 0 2.1720959921367466e-05
. O 0 1.6375708582927473e-05

5 O 0 0.0005661281174980104
of O 0 9.497175778960809e-05
embryogenesis O 0 0.005984651856124401
. O 0 0.00019546305702533573

Mutant O 0 0.0024020050186663866
embryos O 0 0.0007530861184932292
have O 0 5.018054707761621e-06
reduced O 0 6.424880211852724e-06
size O 0 2.7166697691427544e-06
, O 0 1.3814646990795154e-06
fail O 0 1.4361329704115633e-05
to O 0 4.498679686548712e-07
gastrulate O 0 0.00010431653936393559
or O 0 4.999083671464177e-07
express O 0 3.102627943007974e-06
a O 0 6.290259193519887e-07
mesodermal O 0 0.00018663621449377388
marker O 0 6.89842454448808e-06
, O 0 5.973347469989676e-07
and O 0 7.433339987983345e-07
show O 0 9.411046448803972e-06
abnormal O 0 0.00017097854288294911
visceral O 0 0.0001883477671071887
endoderm O 0 0.08044619113206863
development O 0 6.37224584352225e-05
. O 0 5.0878134061349556e-05

Growth B-Disease 1 0.9983494281768799
retardation I-Disease 1 0.9998899698257446
of O 0 9.95641494228039e-06
the O 0 5.0024204938381445e-06
Smad4 O 0 0.033872418105602264
- O 1 0.7335543632507324
deficient O 0 0.2672484219074249
embryos O 0 9.21251266845502e-05
results O 0 4.450512278708629e-06
from O 0 4.736884591238777e-07
reduced O 0 1.3757896340393927e-05
cell O 0 0.00014313874999061227
proliferation O 0 1.907212208607234e-05
rather O 0 1.0846636087080697e-06
than O 0 8.457132594230643e-07
increased O 0 7.786249625496566e-06
apoptosis O 0 0.00018097562133334577
. O 0 2.858265543181915e-05

Aggregation O 0 0.00039354836917482316
of O 0 1.335004981228849e-05
mutant O 0 0.00013071043940726668
Smad4 O 0 0.003621262265369296
ES O 0 0.10916265845298767
cells O 0 5.0866099627455696e-05
with O 0 7.13174017619167e-07
wild O 0 6.475555437646108e-06
- O 0 0.00035896513145416975
type O 0 1.3477445463649929e-05
tetraploid O 0 0.0003970296820625663
morulae O 0 0.0006021635490469635
rescues O 0 0.00015964030171744525
the O 0 8.067004273470957e-06
gastrulation B-Disease 0 0.07067843526601791
defect I-Disease 0 0.0016916379099711776
. O 0 2.159900395781733e-05

These O 0 2.8856620701844804e-05
results O 0 3.32622803398408e-05
indicate O 0 6.20760647507268e-06
that O 0 3.393532210793637e-07
Smad4 O 0 6.372087955242023e-05
is O 0 3.094877172316046e-07
initially O 0 7.049271175674221e-07
required O 0 1.641700180243788e-07
for O 0 5.5360040107643727e-08
the O 0 7.919151556734505e-08
differentiation O 0 7.427515242852678e-07
of O 0 5.986862561258022e-08
the O 0 2.4732540282457194e-07
visceral O 0 1.9304812667542137e-05
endoderm O 0 0.00532608013600111
and O 0 3.603776121963165e-07
that O 0 1.0019895313462257e-07
the O 0 3.61232338264017e-07
gastrulation B-Disease 0 0.03972724452614784
defect I-Disease 0 0.00010997340723406523
in O 0 2.3111708458145586e-07
the O 0 3.8369245203284663e-07
epiblast O 0 0.015994325280189514
is O 0 5.562866931541066e-07
secondary O 0 9.343486340185336e-07
and O 0 5.976560828457878e-07
non O 0 1.522275670140516e-05
- O 0 0.0002746096288319677
cell O 0 0.00017971653142012656
autonomous O 0 6.533323175972328e-05
. O 0 2.4955710614449345e-05

Rescued O 0 0.021999789401888847
embryos O 0 0.005299305077642202
show O 0 0.0005690876278094947
severe O 1 0.5953904390335083
anterior O 0 0.3294552266597748
truncations O 1 0.7114812731742859
, O 0 9.722985851112753e-06
indicating O 0 5.1304346015967894e-06
a O 0 4.0379939036938595e-07
second O 0 8.585283239881392e-07
important O 0 3.269455817189737e-07
role O 0 6.653315836047113e-07
for O 0 8.113412945931486e-07
Smad4 O 0 0.0008917998056858778
in O 0 5.5031014198902994e-06
anterior O 0 0.008814815431833267
patterning O 0 0.11201860755681992
during O 0 6.78670039633289e-05
embryogenesis O 0 0.0031920811161398888
. O 0 6.351643241941929e-05

Prevalence O 0 0.00935303047299385
of O 0 3.1422638130607083e-05
p16 O 0 0.0006291121826507151
and O 0 2.0427525669219904e-05
CDK4 O 1 0.654397189617157
germline O 1 0.9332244396209717
mutations O 0 0.000334010022925213
in O 0 3.4435595352988457e-06
48 O 0 0.0004029367119073868
melanoma B-Disease 1 0.999976396560669
- O 1 0.7631464600563049
prone O 0 0.0020734379068017006
families O 0 1.0281793947797269e-05
in O 0 4.921504569210811e-06
France O 0 7.638377428520471e-05
. O 0 3.773577918764204e-05

The O 0 0.00022224083659239113
French O 0 0.00608564680442214
Familial B-Disease 1 0.9997010231018066
Melanoma I-Disease 1 0.9999992847442627
Study O 0 0.0009900294244289398
Group O 0 0.0008813798194751143
. O 0 0.00011136790999444202

Germline O 1 0.9909725189208984
mutations O 0 0.004485434852540493
in O 0 9.542643056192901e-06
the O 0 2.5904480480676284e-06
p16 O 0 4.516770059126429e-05
and O 0 2.8802096494473517e-06
CDK4 O 0 0.027715666219592094
genes O 0 9.352113920613192e-06
have O 0 2.9841444870726264e-07
been O 0 2.564432577401021e-07
reported O 0 1.3728176782024093e-06
in O 0 1.019141961933201e-07
a O 0 2.894874171488482e-07
subset O 0 1.0787231076392345e-05
of O 0 5.64240417588735e-06
melanoma B-Disease 1 0.9998887777328491
pedigrees O 0 0.001189210801385343
, O 0 9.461137437938305e-07
but O 0 2.60200835100477e-07
their O 0 1.3597554016087088e-06
prevalence O 0 0.00010936310718534514
is O 0 4.1308442177978577e-07
not O 0 3.033532323115651e-07
well O 0 1.4773761449760059e-06
known O 0 1.4260606803873088e-05
. O 0 1.8867158360080793e-05

We O 0 3.4217548090964556e-05
searched O 0 5.095179221825674e-05
for O 0 5.0132425712945405e-06
such O 0 5.204779881751165e-06
germline O 0 0.11632979661226273
mutations O 0 0.00012975858408026397
in O 0 1.4919082786946092e-06
48 O 0 2.908471469709184e-05
French O 0 0.0007267568144015968
melanoma B-Disease 1 0.9999785423278809
- O 0 0.47497937083244324
prone O 0 0.0005507392343133688
families O 0 1.2410635008563986e-06
selected O 0 2.9839480930604623e-07
according O 0 1.9094592573765112e-07
to O 0 6.411900699276885e-08
two O 0 9.075456119944647e-08
major O 0 5.583356141869444e-07
criteria O 0 2.777465169856441e-06
families O 0 3.83235317258368e-07
with O 0 1.8399515511191566e-07
at O 0 2.591661427686631e-07
least O 0 1.7436238408663485e-07
three O 0 2.71061935563921e-07
affected O 0 5.801803695248964e-07
members O 0 2.3582316543979687e-07
( O 0 3.9604054791197996e-07
n O 0 2.5609311705920845e-05
= O 0 3.615337845985778e-05
20 O 0 4.3216658696110244e-07
) O 0 2.1448960296766018e-07
or O 0 9.924526978011272e-08
families O 0 1.4367573442086723e-07
with O 0 1.259339228454337e-07
two O 0 4.7171616301966424e-07
affected O 0 1.3111916814523283e-06
members O 0 2.9316780114641006e-07
, O 0 7.410280034036987e-08
one O 0 3.734568920776837e-08
of O 0 4.109914542027582e-08
them O 0 1.2735168297695054e-07
affected O 0 6.652243769167399e-07
before O 0 1.3750631921993772e-07
the O 0 8.323946332211563e-08
age O 0 1.1231471575001706e-07
of O 0 4.954100774057224e-08
50 O 0 3.951200824303669e-07
( O 0 4.61671703533284e-07
n O 0 3.193052179994993e-05
= O 0 5.177204729989171e-05
28 O 0 3.4447648431523703e-06
) O 0 3.296535169283743e-07
, O 0 1.2904115465062205e-07
and O 0 1.2733700316402974e-07
one O 0 2.473161941907165e-07
additional O 0 3.6274618651077617e-06
minor O 0 2.840952765836846e-05
criterion O 0 0.00017782971553970128
. O 0 2.4968803700176068e-05

Sixteen O 0 0.0002900164690800011
different O 0 4.542454189504497e-05
p16 O 0 0.0007016640156507492
germline O 0 0.1995593160390854
mutations O 0 0.00040791070205159485
were O 0 1.9121905552310636e-06
found O 0 1.0783328434627037e-06
in O 0 6.140018058431451e-07
21 O 0 4.677414381148992e-06
families O 0 8.518301797266759e-07
, O 0 3.4849111330004234e-07
while O 0 3.433353867876576e-07
one O 0 7.663106771360617e-07
germline O 0 0.022491518408060074
mutation O 0 1.927916491695214e-05
, O 0 5.457019938148733e-07
Arg24His O 0 8.201631862903014e-05
, O 0 7.05153013313975e-07
was O 0 4.812755491911958e-07
detected O 0 2.593112412796472e-06
in O 0 3.750981534267339e-07
the O 0 1.225477490152116e-06
CDK4 O 0 0.05374164879322052
gene O 0 7.261878636199981e-05
. O 0 1.6030822735046968e-05

The O 0 1.8945482224808075e-05
frequency O 0 1.3954958376416471e-05
of O 0 1.5987013739504619e-06
p16 O 0 6.932488759048283e-05
gene O 0 1.4944137546990532e-05
mutation O 0 5.109380253998097e-06
in O 0 2.517351163078274e-07
our O 0 3.0920421068003634e-07
sample O 0 6.723716978740413e-07
( O 0 3.715988725616626e-07
44 O 0 5.860114242750569e-07
% O 0 8.330774221576576e-07
) O 0 2.8359784209897043e-07
is O 0 6.166417421127335e-08
among O 0 6.293343091101633e-08
the O 0 9.053913174739137e-08
highest O 0 1.797742356757226e-06
rates O 0 2.1719383767049294e-06
yet O 0 8.937010989029659e-07
reported O 0 1.0616239478622447e-06
and O 0 1.2093056511730538e-07
the O 0 2.445183611143875e-07
CDK4 O 0 0.027960127219557762
mutation O 0 5.435887032945175e-06
is O 0 1.0866332900150155e-07
the O 0 1.408311049999611e-07
second O 0 2.6878301468968857e-06
mutation O 0 2.1149360691197217e-05
detected O 0 4.792676008946728e-06
in O 0 1.922666967857367e-07
this O 0 3.766344889299944e-07
gene O 0 9.92909826891264e-06
worldwide O 0 1.5669840649934486e-05
. O 0 1.2434740710887127e-05

In O 0 4.970614463672973e-05
summary O 0 7.401756010949612e-05
, O 0 3.0941414479457308e-06
our O 0 1.941525169968372e-06
results O 0 5.130150839249836e-06
show O 0 8.446476726930996e-07
frequent O 0 2.142482799172285e-06
involvement O 0 2.8942356493644184e-06
of O 0 3.015047695953399e-07
the O 0 1.050303922056628e-06
p16 O 0 6.709147419314831e-05
gene O 0 1.4897819710313343e-05
in O 0 4.5328447413339745e-06
familial B-Disease 1 0.9110201597213745
melanoma I-Disease 1 0.9999971389770508
and O 0 1.2175653864687774e-05
confirm O 0 8.513385182595812e-06
the O 0 1.197229266836075e-07
role O 0 2.3868261678217095e-07
of O 0 9.730695182952331e-08
the O 0 2.7952822279075917e-07
CDK4 O 0 0.001859387499280274
gene O 0 2.9806396923959255e-06
as O 0 3.604380935939844e-07
a O 0 7.774377991154324e-06
melanoma B-Disease 1 0.9997345805168152
- O 0 0.21747568249702454
predisposing O 0 0.0008399102953262627
gene O 0 1.651412276260089e-05
. O 0 3.11509165840107e-06
. O 0 1.2151942428317852e-05

Progression O 0 0.0039375945925712585
of O 0 4.4624906877288595e-05
somatic O 0 0.0021835807710886
CTG O 0 0.03608493506908417
repeat O 0 0.0008117096731439233
length O 0 2.492804742360022e-05
heterogeneity O 0 0.0001799584861146286
in O 0 1.8093850258082966e-06
the O 0 2.9896527848904952e-06
blood O 0 0.00019725310266949236
cells O 0 0.0009356782538816333
of O 0 0.0001543889957247302
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9880651831626892
. O 0 0.00012029673234792426

The O 0 7.959463982842863e-05
genetic O 0 0.00017664606275502592
basis O 0 1.8082126189256087e-05
of O 0 8.59054853208363e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.3937869668006897
DM B-Disease 1 1.0
) O 0 8.326379429490771e-06
is O 0 1.7389639594966866e-07
the O 0 9.227186126281595e-08
expansion O 0 7.723577368778933e-07
of O 0 1.0034468544972697e-07
an O 0 6.320034913187556e-07
unstable O 0 0.0011631199158728123
CTG O 0 0.020216885954141617
repeat O 0 3.4473221603548154e-05
in O 0 1.9953733954025665e-07
the O 0 1.2466954046885803e-07
34 O 0 8.167772307388077e-07
UTR O 0 0.0001341563620371744
of O 0 1.8565732773367927e-07
the O 0 6.571602284566325e-07
DM B-Disease 1 0.9999862909317017
protein O 0 3.1124585802899674e-05
kinase O 0 6.641076470259577e-05
gene O 0 4.515831278695259e-06
on O 0 2.0749662326124962e-06
chromosome O 0 4.635736331692897e-05
19 O 0 2.555734863562975e-05
. O 0 1.7814245438785292e-05

One O 0 1.2836297173635103e-05
of O 0 1.966435775102582e-06
the O 0 7.603239282616414e-07
principal O 0 2.2858755528432084e-06
features O 0 8.22078732198861e-07
of O 0 4.030191860238119e-07
the O 0 3.532055188770755e-06
DM B-Disease 1 1.0
mutation O 0 8.521540439687669e-05
is O 0 2.3875068677625677e-07
an O 0 1.7815457908909593e-07
extraordinarily O 0 9.622311154089402e-06
high O 0 1.0672050620996743e-06
level O 0 4.6956492383287696e-07
of O 0 3.4018597716567456e-07
somatic O 0 0.00016850036627147347
mosaicism O 0 0.009860786609351635
, O 0 9.218265404342674e-07
due O 0 9.512372685094306e-07
to O 0 1.557176290134521e-07
an O 0 2.703478401144821e-07
extremely O 0 4.672572686104104e-06
high O 0 4.405673280416522e-06
degree O 0 8.292129678011406e-06
of O 0 7.912476007732039e-07
somatic O 0 0.0022438757587224245
instability O 0 4.8336241889046505e-05
both O 0 2.417851021618844e-07
within O 0 2.0456360516618588e-07
and O 0 4.348990501057415e-07
between O 0 1.113739017455373e-06
different O 0 3.1386196042149095e-06
tissues O 0 0.0001947956916410476
. O 0 2.9273713153088465e-05

This O 0 4.71622624900192e-05
instability O 0 0.0002451774780638516
appears O 0 1.2108792361686938e-05
to O 0 8.019477490961435e-07
be O 0 2.269297709744933e-07
biased O 0 1.7576054460732848e-06
towards O 0 4.1381187543265696e-07
further O 0 3.603879292768397e-07
expansion O 0 1.330534814769635e-06
and O 0 2.075265825851602e-07
continuous O 0 1.0296710115653696e-06
throughout O 0 1.8792589173699525e-07
the O 0 7.443115634941933e-08
life O 0 1.4151571292586596e-07
of O 0 5.29891046596731e-08
an O 0 1.3345807303721813e-07
individual O 0 3.491298059543624e-07
, O 0 1.643924889549453e-07
features O 0 3.802928461027477e-07
that O 0 8.502819071054546e-08
could O 0 1.4714744622779108e-07
be O 0 7.18771673291485e-08
associated O 0 3.4979535712409415e-07
with O 0 1.321151188449221e-07
the O 0 3.977127391863178e-07
progressive O 0 9.947888611350209e-05
nature O 0 2.4108180696202908e-06
of O 0 1.1259973007327062e-06
the O 0 2.1500893126358278e-05
disease O 0 0.004202676936984062
. O 0 2.1053670934634283e-05

Although O 0 9.102398325921968e-05
increasing O 0 3.908642247552052e-05
measured O 0 2.2490166884381324e-05
allele O 0 2.6142881324631162e-05
size O 0 4.6095024117676076e-06
between O 0 3.9811720853322186e-06
patients O 0 0.0003533016424626112
clearly O 0 4.682198778027669e-06
correlates O 0 1.1631011147983372e-05
with O 0 6.022045795361919e-07
an O 0 1.1469819582998753e-06
increased O 0 1.6415719073847868e-05
severity O 0 0.012544697150588036
of O 0 9.076969035959337e-06
symptoms O 0 0.1538468301296234
and O 0 1.9123017409583554e-06
an O 0 5.914327516620688e-07
earlier O 0 7.328758783842204e-06
age O 0 7.944459525788261e-07
of O 0 5.325004508449638e-07
onset O 0 0.05309641733765602
, O 0 1.1556735444173682e-06
this O 0 1.430570506499862e-07
correlation O 0 8.066727446021105e-07
is O 0 1.5832753774702724e-07
not O 0 1.0594307298106287e-07
precise O 0 1.4408286688194494e-06
and O 0 6.478078944383014e-07
measured O 0 4.5017277443548664e-06
allele O 0 2.8754120648954995e-06
length O 0 7.677605253775255e-07
cannot O 0 4.244213300808042e-07
be O 0 4.346933835108757e-08
used O 0 9.011943546965995e-08
as O 0 9.553431112863109e-08
an O 0 1.98410376128777e-07
accurate O 0 1.1730799997167196e-05
predictor O 0 0.00020713954290840775
of O 0 9.211498763761483e-07
age O 0 4.802109742740868e-06
of O 0 5.6110407058440614e-06
onset O 0 0.0675293430685997
. O 0 7.823343912605196e-05

In O 0 4.3015646951971576e-05
order O 0 6.633582870563259e-06
to O 0 1.5367144214906148e-06
further O 0 1.7252353927688091e-06
characterize O 0 1.6843136108946055e-05
the O 0 1.0707843784985016e-06
dynamics O 0 9.816050442168489e-05
of O 0 2.985532773891464e-06
DM B-Disease 1 0.9999997615814209
CTG O 1 0.5299293398857117
repeat O 0 0.0004190612235106528
somatic O 0 0.0003063295444007963
instability O 0 2.24356754188193e-05
, O 0 3.8132134250190575e-07
we O 0 1.4108208290508628e-07
have O 0 2.121142870237236e-07
studied O 0 1.4369809377967613e-06
repeat O 0 1.4982852917455602e-05
length O 0 1.5715821746198344e-06
changes O 0 4.775010893354192e-07
over O 0 1.9208067669751472e-07
time O 0 7.548626967945893e-07
in O 0 3.417742391320644e-06
111 O 0 0.32651251554489136
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.8315730690956116
with O 0 1.1512533092172816e-05
varying O 0 0.0039514112286269665
clinical O 0 0.21796129643917084
severity O 0 0.03009314090013504
and O 0 7.262916824402055e-06
CTG O 0 0.012883209623396397
repeat O 0 3.9443300920538604e-05
size O 0 7.078994599396538e-07
over O 0 1.601388674998816e-07
time O 0 1.7627492354677088e-07
intervals O 0 4.659933665607241e-07
of O 0 1.0032803743342811e-07
1 O 0 1.573201529936341e-06
- O 0 8.332845027325675e-05
7 O 0 1.6024157957872376e-05
years O 0 8.274689207610209e-06
. O 0 1.1655416528810747e-05

We O 0 2.3852431695559062e-05
have O 0 2.5961339815694373e-06
found O 0 5.673174428011407e-07
a O 0 3.723502004504553e-07
direct O 0 1.0867220225918572e-06
progression O 0 1.3991362720844336e-05
of O 0 1.7382195949267043e-07
the O 0 2.22077304101731e-07
size O 0 1.510960601081024e-06
heterogeneity O 0 1.777353281795513e-05
over O 0 3.800963384037459e-07
time O 0 2.918068560120446e-07
related O 0 7.641169759153854e-07
to O 0 2.0238388742654934e-07
initial O 0 6.424494131351821e-06
CTG O 0 0.00027965212939307094
repeat O 0 1.0573859071882907e-05
size O 0 4.711968699666613e-07
and O 0 8.738408752151372e-08
the O 0 7.555772185696696e-08
time O 0 1.547622758835132e-07
interval O 0 8.843916816658748e-07
and O 0 3.19882502708424e-07
always O 0 6.836950774413708e-07
biased O 0 7.173053290898679e-06
towards O 0 2.427822209938313e-06
further O 0 4.260749392415164e-06
expansion O 0 4.4646523747360334e-05
. O 0 2.577715349616483e-05

Attempts O 0 0.0002464602002874017
to O 0 1.9850775061058812e-05
mathematically O 0 6.915677658980712e-05
model O 0 9.296146345150191e-06
the O 0 1.490818817728723e-06
dynamics O 0 8.637756400275975e-05
have O 0 4.46649806917776e-07
proved O 0 1.436345201000222e-06
only O 0 1.4229630096451729e-07
partially O 0 9.214906640409026e-06
successful O 0 3.3236842682526913e-06
suggesting O 0 3.4622337352629984e-06
that O 0 1.1921954978788563e-07
individual O 0 2.89373957684802e-07
specific O 0 6.388097517628921e-07
genetic O 0 9.004680578073021e-06
and O 0 2.4573660084570292e-06
/ O 0 0.012683913111686707
or O 0 3.370549393366673e-06
environmental O 0 2.7887217584066093e-05
factors O 0 1.037176843965426e-06
also O 0 1.3826821998463856e-07
play O 0 1.3546448940360278e-07
a O 0 3.1698206726105127e-07
role O 0 1.4988935390647384e-06
in O 0 2.6487268769415095e-06
somatic O 0 0.0015231710858643055
mosaicism O 0 0.0598904974758625
. O 0 6.0140673667774536e-06
. O 0 1.1003524377883878e-05

Aspartylglucosaminuria B-Disease 1 0.9950268864631653
among O 0 0.0002614776021800935
Palestinian O 0 0.0015700572403147817
Arabs O 0 0.001054649823345244
. O 0 0.00010409682727186009

Aspartylglucosaminuria B-Disease 1 0.9999468326568604
( O 0 0.061045583337545395
AGU B-Disease 1 0.9999942779541016
) O 0 7.846340304240584e-05
is O 0 1.5868579339439748e-06
a O 0 4.357602847449016e-06
rare O 0 0.004578744992613792
disorder B-Disease 1 0.6668351888656616
of I-Disease 0 2.8566130367835285e-06
glycoprotein I-Disease 0 0.13525643944740295
metabolism I-Disease 0 0.002449609339237213
caused O 0 1.8817059753928334e-05
by O 0 6.000581720400078e-07
the O 0 2.178854856538237e-06
deficiency B-Disease 0 0.018735937774181366
of I-Disease 0 2.0316474547144026e-07
the I-Disease 0 1.1689016901073046e-06
lysosomal I-Disease 0 0.011187822557985783
enzyme I-Disease 0 0.00023531210899818689
aspartylglucosaminidase I-Disease 0 0.008070530369877815
( O 0 6.924658009666018e-06
AGA O 0 0.0007738434942439198
) O 0 1.5404091755044647e-05
. O 0 1.4930775250832085e-05

AGU B-Disease 1 0.9999839067459106
is O 0 0.0003143112116958946
inherited O 0 0.007620150223374367
as O 0 8.406869710597675e-06
an O 0 3.924295015167445e-05
autosomal O 1 0.9939642548561096
recessive O 1 0.9708122611045837
trait O 0 0.0008343521039932966
and O 0 1.2911275007354561e-05
occurs O 0 2.5366091449541273e-06
with O 0 2.3319735475979542e-07
a O 0 6.500519589280884e-07
high O 0 4.295382950658677e-06
frequency O 0 2.8978702175663784e-06
in O 0 2.950338000573538e-07
Finland O 0 1.109548429667484e-05
because O 0 2.9176456450841215e-07
of O 0 2.4591611236246536e-07
a O 0 1.6902889683478861e-06
founder O 0 0.0004820185713469982
effect O 0 4.3530068069230765e-05
. O 0 1.4325559277494904e-05

While O 0 8.092611096799374e-05
very O 0 1.2822018106817268e-05
few O 0 1.0471630957908928e-05
patients O 0 0.00032220908906310797
with O 0 2.0935323846060783e-05
AGU B-Disease 1 0.9999990463256836
have O 0 2.4179305455618305e-06
been O 0 4.575890386604442e-07
reported O 0 1.4929502185623278e-06
from O 0 1.4085864563639916e-07
non O 0 3.0299841000669403e-06
- O 0 0.00010299294808646664
Finnish O 0 0.00017818683409132063
origin O 0 2.1566645500570303e-06
, O 0 6.914389700796164e-07
we O 0 1.3894133417124976e-06
diagnosed O 0 0.060598839074373245
the O 0 6.318381110759219e-06
disorder O 0 0.224129319190979
in O 0 3.278996473454754e-06
8 O 0 0.00010880058107431978
patients O 0 4.5199332816991955e-05
originating O 0 9.962237754734815e-07
from O 0 1.9810673279607727e-07
3 O 0 7.0375426730606705e-06
unrelated O 0 1.170101222669473e-05
families O 0 9.128960414273024e-07
, O 0 1.7287915454744507e-07
all O 0 6.694183696254186e-08
Palestinian O 0 3.907368409272749e-06
Arabs O 0 3.78394611288968e-06
from O 0 1.7048058964519441e-07
the O 0 2.0740628769999603e-07
region O 0 4.938505753671052e-06
of O 0 1.586160351507715e-06
Jerusalem O 0 0.0001995787170017138
. O 0 2.752794353000354e-05

The O 0 0.0004971291637048125
clinical O 1 0.8594725131988525
diagnosis O 1 0.9872608184814453
of O 0 7.889066910138354e-05
AGU B-Disease 1 0.9999994039535522
is O 0 1.4822371667833067e-05
often O 0 1.947916416611406e-06
difficult O 0 5.086898909212323e-06
, O 0 8.749955782150209e-07
in O 0 2.46634812128832e-07
particular O 0 3.1758781915414147e-07
early O 0 5.293384788274125e-07
in O 0 9.452112692542869e-08
the O 0 9.491713370834987e-08
course O 0 1.3604648074760917e-06
of O 0 3.216239576886437e-07
the O 0 1.0805320926010609e-05
disease O 0 0.003972754813730717
, O 0 6.308209208327753e-07
and O 0 1.9544162910278828e-07
most O 0 1.045555322320979e-07
of O 0 1.6594134422120987e-07
the O 0 4.412636826600647e-06
patients O 0 0.00836954452097416
are O 0 4.775251909450162e-06
diagnosed O 0 0.18144318461418152
after O 0 1.4144058013698668e-06
the O 0 2.3469328880310059e-07
age O 0 4.652136453842104e-07
of O 0 2.7125847168463224e-07
5 O 0 9.468003554502502e-06
years O 0 1.106681338569615e-05
. O 0 1.2840202543884516e-05

However O 0 0.00012040679575875401
, O 0 9.117422450799495e-06
since O 0 4.759380317409523e-06
these O 0 2.099374796671327e-06
patients O 0 8.273334242403507e-05
excrete O 0 6.817744724685326e-05
early O 0 1.766592617968854e-06
large O 0 6.580118565580051e-07
amounts O 0 6.426557206395955e-07
of O 0 2.1141489980891492e-07
aspartylglucosamine O 0 0.00022357873967848718
in O 0 1.145375108535518e-06
urine O 0 1.4307085621112492e-05
, O 0 1.0763499176391633e-06
biochemical O 0 8.498888746544253e-06
screening O 0 2.829402319548535e-06
is O 0 2.7804307478618284e-07
easy O 0 2.213525704064523e-06
by O 0 1.712371044959582e-06
urine O 0 6.766486330889165e-05
chromatography O 0 0.0008992600487545133
. O 0 6.081912943045609e-06
. O 0 1.706319017102942e-05

Detection O 0 0.0006398099358193576
of O 0 2.456525544403121e-05
heterozygous O 0 8.075581718003377e-05
carriers O 0 2.102604412357323e-05
of O 0 2.0544252947729547e-06
the O 0 1.2404349035932682e-05
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9998748302459717
telangiectasia I-Disease 1 0.9999994039535522
( O 0 1.362180682917824e-05
ATM O 0 9.068124927580357e-05
) O 0 1.7317860283583286e-06
gene O 0 2.136304829036817e-06
by O 0 9.830766884988407e-07
G2 O 0 0.03127026930451393
phase O 0 0.00016113842139020562
chromosomal O 0 0.00023799216432962567
radiosensitivity O 0 0.00045999750727787614
of O 0 4.3166096475033555e-06
peripheral O 0 0.006763392128050327
blood O 0 0.00854420941323042
lymphocytes O 0 0.1226578950881958
. O 0 4.839416578761302e-05

In O 0 0.003001763252541423
ataxia B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999842643737793
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.00016838697774801403
A B-Disease 0 0.001661286223679781
- I-Disease 1 0.9999117851257324
T I-Disease 1 0.9999998807907104
) O 0 0.00018412747886031866
patients O 0 0.0002393801260041073
, O 0 1.305777118432161e-06
mutations O 0 5.312229404808022e-06
in O 0 1.1072496874930948e-07
a O 0 2.0177971293833252e-07
single O 0 1.9304125089547597e-06
gene O 0 2.1501809897017665e-06
, O 0 3.599664921694057e-07
ATM O 0 6.061803287593648e-05
, O 0 9.181959512716276e-07
result O 0 2.124070988429594e-06
in O 0 4.010968950751703e-06
an O 0 0.002547754906117916
autosomal B-Disease 1 1.0
recessive I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
that O 0 2.33431296692288e-06
embraces O 0 3.275220296927728e-05
a O 0 7.895576459304721e-07
variety O 0 1.2020817621305468e-06
of O 0 8.081905207291129e-07
clinical O 0 8.17244072095491e-05
features O 0 6.469321306212805e-06
and O 0 4.767721293319482e-06
manifests O 0 0.00016876583686098456
extreme O 0 4.371005707071163e-05
radiosensitivity O 0 0.0004230431222822517
and O 0 2.5581817908459925e-07
a O 0 4.906705157736724e-07
strong O 0 2.418830035821884e-06
pre O 0 9.06503846636042e-05
- O 0 0.0017425407422706485
disposition O 0 0.0001703097950667143
to O 0 1.3917942851549014e-05
malignancy B-Disease 0 0.10895571112632751
. O 0 3.6972422094549984e-05

Heterozygotes O 0 0.004574485123157501
for O 0 2.1005922462791204e-05
the O 0 4.1232810872315895e-06
ATM O 0 0.00015643812366761267
gene O 0 1.082824201148469e-05
have O 0 7.465337148460094e-07
no O 0 1.0411399671284016e-06
clinical O 0 2.9668273782590404e-05
expression O 0 8.220065979003266e-07
of O 0 3.1129752642300446e-07
A B-Disease 0 0.00048279057955369353
- I-Disease 1 0.9997835755348206
T I-Disease 1 0.9999992847442627
but O 0 1.0917518920905422e-05
may O 0 2.050674993370194e-05
be O 0 2.151623220925103e-06
cancer B-Disease 0 0.014642930589616299
prone O 0 2.275841688970104e-05
with O 0 4.890615628028172e-07
a O 0 1.9257072381151374e-06
moderate O 0 0.00016136706108227372
increase O 0 6.946432222321164e-06
in O 0 1.993847035919316e-06
in O 0 5.5667373999312986e-06
vitro O 0 0.001185484230518341
radiosensitivity O 0 0.027427537366747856
. O 0 3.695613850140944e-05

We O 0 3.961447873734869e-05
performed O 0 1.5188433280854952e-05
a O 0 4.868757059739437e-06
blind O 0 0.00013779160508420318
chromosomal O 0 0.0006994957802817225
analysis O 0 9.286311069445219e-06
on O 0 3.903026026819134e-06
G2 O 1 0.883812665939331
- O 0 0.030427800491452217
phase O 0 0.0001853207650128752
lymphocytes O 0 0.0005624530604109168
from O 0 4.2210271544718125e-07
7 O 0 4.217134573991643e-06
unrelated O 0 9.28744520933833e-06
A B-Disease 0 0.0003574025759007782
- I-Disease 1 0.9999586343765259
T I-Disease 1 1.0
patients O 0 0.006329662166535854
, O 0 6.538327284033585e-07
13 O 0 1.9674369013955584e-06
obligate O 0 5.8735931816045195e-06
A B-Disease 0 9.84355210675858e-05
- I-Disease 1 0.9962551593780518
T I-Disease 1 0.9999982118606567
heterozygotes O 0 0.007461307570338249
( O 0 1.1932754659937927e-06
parents O 0 3.335364908707561e-07
of O 0 1.158184375071869e-07
the O 0 1.6428245999122737e-06
patients O 0 0.000281053245998919
) O 0 1.382112941428204e-06
, O 0 2.2392349308120174e-07
and O 0 1.664161430880995e-07
14 O 0 6.234864713405841e-07
normal O 0 5.49787955606007e-07
controls O 0 8.489496394759044e-07
following O 0 6.644014547418919e-07
X O 0 5.299561962601729e-05
- O 0 5.506532033905387e-05
irradiation O 0 3.5666964777192334e-06
with O 0 2.13274944371733e-07
1 O 0 1.5520613487751689e-06
Gy O 0 0.021783387288451195
in O 0 2.870070261451474e-07
order O 0 2.3126325743305642e-07
to O 0 2.156025971089548e-07
evaluate O 0 5.775686076958664e-06
this O 0 1.5173358747233578e-07
cytogenetic O 0 7.530555740231648e-05
method O 0 5.929971393925371e-07
as O 0 8.27187491836412e-08
a O 0 1.3898146278279455e-07
tool O 0 1.5699254163337173e-06
for O 0 3.1584110615767713e-07
detection O 0 8.727356544113718e-06
of O 0 6.334184945444576e-07
ATM O 0 0.0004758467839565128
carriers O 0 3.689254299388267e-05
. O 0 1.1767348041757941e-05

Both O 0 6.884987669764087e-05
A B-Disease 0 0.00047377820010297
- I-Disease 1 0.9853774905204773
T I-Disease 1 0.9999909400939941
homozygotes O 0 0.07957042008638382
and O 0 5.8194254961563274e-06
heterozygotes O 0 0.00019183001131750643
showed O 0 5.736754701501923e-06
significantly O 0 3.566611667338293e-06
increased O 0 9.085949272957805e-07
levels O 0 1.353374727841583e-06
of O 0 5.430356395663694e-07
radiation O 0 0.0003689075820147991
- O 0 0.09465207904577255
induced O 0 0.044277433305978775
chromatid O 1 0.7761479616165161
damage O 0 9.229132410837337e-05
relative O 0 1.4066066569284885e-06
to O 0 3.028710580110783e-07
that O 0 1.7695016651941842e-07
of O 0 4.093213306077814e-07
normal O 0 7.267087767104385e-06
controls O 0 5.3877796744927764e-05
. O 0 2.2966698452364653e-05

These O 0 4.3698677473003045e-05
results O 0 4.1661136492621154e-05
show O 0 3.5311929877934745e-06
that O 0 4.2029432734125294e-07
the O 0 5.855823701494955e-07
G2 O 0 0.026351535692811012
- O 0 0.0007018964388407767
phase O 0 6.332979683065787e-05
chromosomal O 0 0.00010479610500624403
radiosensitivity O 0 0.0003143780049867928
assay O 0 2.105236671923194e-05
can O 0 1.272762943926864e-07
be O 0 3.6946310899566015e-08
used O 0 6.552809139748206e-08
for O 0 7.702769266870746e-08
the O 0 1.4180184848555655e-07
detection O 0 7.96356107457541e-06
of O 0 4.623043423634954e-07
A B-Disease 0 0.000352090981323272
- I-Disease 1 0.9989588260650635
T I-Disease 1 0.999992847442627
heterozygotes O 0 0.006200293079018593
. O 0 1.9040735423914157e-05

In O 0 5.501666237250902e-05
combination O 0 0.00010721942817326635
with O 0 1.1221583918086253e-05
molecular O 0 0.0005986227770335972
genetic O 0 0.0003088164667133242
analyses O 0 6.627727270824835e-05
, O 0 1.553094875816896e-06
this O 0 2.4870956849554204e-07
test O 0 1.8611536916068872e-06
may O 0 1.2904254163004225e-06
be O 0 2.958454281554168e-08
of O 0 3.9006707197586366e-08
value O 0 2.2961503987062315e-07
in O 0 5.928066002525156e-07
studies O 0 1.0853444791791844e-06
of O 0 3.533180290560267e-07
familial B-Disease 0 0.01220390573143959
and I-Disease 0 2.4041797587415203e-05
sporadic I-Disease 0 0.019372260197997093
cancers I-Disease 0 0.10590844601392746
aimed O 0 6.586148174392292e-06
at O 0 6.225916422408773e-07
determination O 0 3.95292227040045e-06
of O 0 1.2953260863923788e-07
the O 0 1.6028707250370644e-07
potential O 0 1.1297910305074765e-06
involvement O 0 2.6585460091155255e-06
of O 0 4.1273077044934325e-07
ATM O 0 0.08133950084447861
mutations O 0 0.00016690994380041957
in O 0 9.218387276632711e-06
tumor B-Disease 0 0.28221073746681213
risk O 0 7.212024502223358e-05
or O 0 2.82550854535657e-06
development O 0 7.808891496097203e-06
. O 0 4.564028586173663e-06
. O 0 1.4873487998556811e-05

Ataxia B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999535083770752
telangiectasia I-Disease 1 0.9999979734420776
: O 0 9.2459908046294e-05
identification O 0 7.886418643465731e-06
and O 0 6.511581887025386e-07
detection O 0 5.353669621399604e-06
of O 0 5.730460088670952e-07
founder O 0 9.212090662913397e-05
- O 0 0.0028297684621065855
effect O 0 1.0972004929499235e-05
mutations O 0 3.963903964177007e-06
in O 0 1.2558633954995457e-07
the O 0 1.670795910513334e-07
ATM O 0 5.54198632016778e-05
gene O 0 3.714036893143202e-06
in O 0 6.812510946474504e-07
ethnic O 0 9.29596080823103e-06
populations O 0 4.571627141558565e-05
. O 0 2.15918571484508e-05

To O 0 1.4950069271435495e-05
facilitate O 0 2.0934567146468908e-05
the O 0 2.5699976049509132e-06
evaluation O 0 7.395619377348339e-06
of O 0 7.382150215562433e-07
ATM O 0 0.000199685717234388
heterozygotes O 0 0.0001485316752223298
for O 0 9.882128324534278e-07
susceptibility O 0 0.00012160008191131055
to O 0 1.4608801848225994e-06
other O 0 7.260493475769181e-06
diseases O 0 0.01233508437871933
, O 0 1.175641841655306e-06
such O 0 6.755905701538722e-07
as O 0 0.00017024323460645974
breast B-Disease 1 0.9998884201049805
cancer I-Disease 1 0.8197565674781799
, O 0 1.38720224640565e-06
we O 0 1.194090089029487e-07
have O 0 9.834436554001513e-08
attempted O 0 1.1262786756560672e-06
to O 0 1.790014749758484e-07
define O 0 1.784721916919807e-06
the O 0 1.3969916778933111e-07
most O 0 2.786546815514157e-07
common O 0 4.703152171714464e-06
mutations O 0 8.15861585579114e-06
and O 0 1.535283189468828e-07
their O 0 3.5713898682843137e-07
frequencies O 0 3.9857422962086275e-06
in O 0 7.1788022069085855e-06
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999098777770996
telangiectasia I-Disease 1 0.9999997615814209
( O 0 1.0353226571169216e-05
A B-Disease 0 5.974366649752483e-05
- I-Disease 1 0.9594596028327942
T I-Disease 1 0.9999169111251831
) O 0 4.65727316623088e-06
homozygotes O 0 3.499717786326073e-05
from O 0 4.639854296328849e-07
10 O 0 7.66475125146826e-07
ethnic O 0 5.6088574638124555e-06
populations O 0 2.3277607397176325e-05
. O 0 1.5567082300549373e-05

Both O 0 0.00010104799730470404
genomic O 0 0.0008431848837062716
mutations O 0 0.00017320936603937298
and O 0 1.4902929024174227e-06
their O 0 1.6747535482863896e-06
effects O 0 1.2862336916441564e-05
on O 0 1.4232008425096865e-06
cDNA O 0 1.5034752323117573e-05
were O 0 2.648418785611284e-06
characterized O 0 0.00012269342551007867
. O 0 2.711606794036925e-05

Protein O 0 0.0003265341219957918
- O 0 0.0003706988354679197
truncation O 0 0.00012780902034137398
testing O 0 8.128165973175783e-06
of O 0 4.078849826782971e-07
the O 0 3.3957562095565663e-07
entire O 0 1.324197910435032e-06
ATM O 0 1.2403354958223645e-05
cDNA O 0 7.758023457427043e-06
detected O 0 4.52631729785935e-06
92 O 0 2.806613110806211e-06
( O 0 4.148107279888791e-07
66 O 0 2.7820801733469125e-06
% O 0 1.3922569905844284e-06
) O 0 8.963111213233788e-07
truncating O 0 6.0509570175781846e-05
mutations O 0 8.195595000870526e-06
in O 0 3.5570050727073976e-07
140 O 0 4.322281711210962e-06
mutant O 0 3.4325403248658404e-05
alleles O 0 4.417393574840389e-05
screened O 0 6.583727372344583e-05
. O 0 2.689553366508335e-05

The O 0 3.3074524253606796e-05
haplotyping O 0 0.0018309889128431678
of O 0 9.05210617929697e-06
patients O 0 0.00030267430702224374
with O 0 3.3611122489674017e-06
identical O 0 0.0006794115179218352
mutations O 0 0.00022764335153624415
indicates O 0 7.273245046235388e-06
that O 0 8.701419318413173e-08
almost O 0 7.301269278059408e-08
all O 0 2.3435326568232995e-08
of O 0 4.1511651005521344e-08
these O 0 9.92581448144847e-08
represent O 0 3.324396118387085e-07
common O 0 2.790673988783965e-06
ancestry O 0 1.3694696463062428e-05
and O 0 5.570075813920994e-07
that O 0 2.880608178656985e-07
very O 0 6.58969554478972e-07
few O 0 2.0966356260032626e-06
spontaneously O 0 9.748858428793028e-05
recurring O 0 7.321719749597833e-05
ATM O 0 0.003450151067227125
mutations O 0 0.00030792647157795727
exist O 0 2.061042505374644e-05
. O 0 1.4702117368869949e-05

Assays O 0 0.0018184268847107887
requiring O 0 0.0002020670217461884
minimal O 0 5.835054980707355e-05
amounts O 0 8.749715561862104e-06
of O 0 1.24880909879721e-06
genomic O 0 2.030634459515568e-05
DNA O 0 9.397745998285245e-06
were O 0 2.7574151317821816e-07
designed O 0 1.452230435461388e-06
to O 0 3.4278639304829994e-07
allow O 0 1.1277178373347851e-06
rapid O 0 1.0261017450829968e-05
screening O 0 3.765622523133061e-06
for O 0 7.822986276551092e-07
common O 0 1.0673082215362228e-05
ethnic O 0 5.7682664191816e-05
mutations O 0 0.00027059600688517094
. O 0 2.6418036213726737e-05

These O 0 5.653706466546282e-05
rapid O 0 0.00039217970333993435
assays O 0 0.0005668327794410288
detected O 0 0.00017344158550258726
mutations O 0 2.9619002816616558e-05
in O 0 4.958439490110322e-07
76 O 0 1.0633733836584724e-05
% O 0 8.679139682499226e-07
of O 0 2.554873219651199e-07
Costa O 0 4.049721246701665e-05
Rican O 0 0.00011539449042174965
patients O 0 8.87697096914053e-05
( O 0 7.271777349160402e-07
3 O 0 1.5938679780447274e-06
) O 0 3.458919479726319e-07
, O 0 1.0218845858389614e-07
50 O 0 1.6773512356849096e-07
% O 0 2.9919866051386634e-07
of O 0 1.8603536489081307e-07
Norwegian O 0 0.022040577605366707
patients O 0 0.0020531865302473307
( O 0 8.137124041240895e-07
1 O 0 1.3553728877013782e-06
) O 0 4.516024034728616e-07
, O 0 1.5917838425139053e-07
25 O 0 1.9895720981821796e-07
% O 0 2.653421802278899e-07
of O 0 2.0368720754504466e-07
Polish O 0 0.16974224150180817
patients O 0 0.003715614089742303
( O 0 1.4358206499309745e-06
4 O 0 4.139430984650971e-06
) O 0 6.546956115016656e-07
, O 0 1.544434979905418e-07
and O 0 1.4846540352664306e-07
14 O 0 8.290005553135416e-07
% O 0 3.831344486115995e-07
of O 0 1.7816901731748658e-07
Italian O 0 0.014254175126552582
patients O 0 0.000760106195230037
( O 0 1.1143998790430487e-06
1 O 0 2.124148068105569e-06
) O 0 3.9572157106704253e-07
, O 0 6.277302588841849e-08
as O 0 5.326766938651417e-08
well O 0 1.0710279951808843e-07
as O 0 1.882904143712949e-07
in O 0 7.41158771688788e-07
patients O 0 1.6071540812845342e-05
of O 0 3.1957574719854165e-07
Amish O 0 0.00024232616124209017
/ O 0 0.002082505729049444
Mennonite O 0 0.00024020504497457296
and O 0 1.7814146531236474e-06
Irish O 0 7.054247362248134e-06
English O 0 6.174937880132347e-06
backgrounds O 0 7.568416913272813e-05
. O 0 2.795143700495828e-05

Additional O 0 0.0002618153521325439
mutations O 0 0.00033495292882435024
were O 0 1.7444300510760513e-06
observed O 0 2.153797368009691e-06
in O 0 3.480072336969897e-07
Japanese O 0 2.3586371753481217e-06
, O 0 8.377317612939805e-07
Utah O 0 3.14032308779133e-06
Mormon O 0 3.421737574171857e-06
, O 0 4.094364953743934e-07
and O 0 4.423016548571468e-07
African O 0 4.274183993402403e-06
American O 0 3.144821312162094e-05
patients O 0 0.00019216648070141673
. O 0 2.0973173377569765e-05

These O 0 3.549367465893738e-05
assays O 0 6.406354805221781e-05
should O 0 2.0385230072861305e-06
facilitate O 0 2.292016233695904e-06
screening O 0 3.148284577036975e-06
for O 0 5.375542855290405e-07
A B-Disease 0 0.00010362629109295085
- I-Disease 1 0.9937765598297119
T I-Disease 1 0.9999927282333374
heterozygotes O 0 0.0006632849690504372
in O 0 4.908282562610111e-07
the O 0 5.445951387628156e-07
populations O 0 6.0939660215808544e-06
studied O 0 5.626623078569537e-06
. O 0 3.0674900699523278e-06
. O 0 1.4360508430399932e-05

The O 0 0.0001688353659119457
von B-Disease 1 0.9595353007316589
Hippel I-Disease 1 0.9984808564186096
- I-Disease 1 0.9802529811859131
Lindau I-Disease 1 0.999482274055481
tumor I-Disease 0 0.36220240592956543
suppressor O 0 0.0010096055921167135
gene O 0 1.2211283319629729e-05
is O 0 5.274769705465587e-07
required O 0 6.55621647638327e-07
for O 0 4.7381266199408856e-07
cell O 0 3.938267764169723e-05
cycle O 0 2.0439314539544284e-05
exit O 0 3.078076770179905e-05
upon O 0 4.4321550376480445e-06
serum O 0 0.00010503640805836767
withdrawal O 0 0.00016197907098103315
. O 0 2.4022247089305893e-05

The O 0 5.5531061661895365e-05
inactivation O 0 0.0017525661969557405
of O 0 6.139944616734283e-06
the O 0 6.545703399751801e-06
von B-Disease 1 0.8891147971153259
Hippel I-Disease 1 0.9993671774864197
- I-Disease 1 0.9226271510124207
Lindau I-Disease 1 0.9796826243400574
( I-Disease 0 1.7734964785631746e-05
VHL I-Disease 0 0.021858643740415573
) I-Disease 0 2.1842039132025093e-05
tumor I-Disease 0 0.000444231292931363
suppressor O 0 0.00037083562347106636
gene O 0 1.415500355506083e-05
predisposes O 0 0.00016886128287296742
affected O 0 5.042828433943214e-06
individuals O 0 3.934700600893848e-07
to O 0 2.647635994890152e-07
the O 0 2.1956384443910792e-06
human O 0 0.0009926657658070326
VHL B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999978542327881
and O 0 7.40930136089446e-06
is O 0 2.853454361684271e-06
associated O 0 9.526203029963654e-06
with O 0 1.596875154064037e-05
sporadic B-Disease 1 0.9642896056175232
renal I-Disease 1 0.9999998807907104
cell I-Disease 1 0.999914288520813
carcinomas I-Disease 1 1.0
( O 0 0.0002373431925661862
RCC B-Disease 1 0.9662598371505737
) O 0 1.8852086213883013e-05
and O 0 1.7076099538826384e-05
brain B-Disease 0 0.002894741715863347
hemangioblastomas I-Disease 0 0.04892546311020851
. O 0 5.0966609705938026e-05

VHL O 1 0.9694569110870361
- O 0 0.016500236466526985
negative O 0 0.0001456767349736765
786 O 0 0.0009081113967113197
- O 0 0.0011845924891531467
0 O 0 0.0002037892263615504
RCC B-Disease 0 0.24203713238239288
cells O 0 4.247489050612785e-05
are O 0 7.168603133322904e-07
tumorigenic O 0 0.00012150840484537184
in O 0 1.4247461876948364e-06
nude O 0 8.090349729172885e-05
mice O 0 6.758412200724706e-05
which O 0 4.17673930996898e-07
is O 0 3.7304758393474913e-07
suppressed O 0 1.677499767538393e-06
by O 0 2.0835749126035807e-07
the O 0 5.186627163311641e-07
reintroduction O 0 0.00010250364721287042
of O 0 8.353611519851256e-06
VHL B-Disease 0 0.03927116468548775
. O 0 3.604469748097472e-05

Remarkably O 0 0.0030762178357690573
, O 0 1.6089574273792095e-05
this O 0 1.9328531379869673e-06
occurs O 0 3.3972148685279535e-06
without O 0 8.719709398974373e-07
affecting O 0 1.7270873513552942e-06
the O 0 3.311429281893652e-07
growth O 0 4.3821569306601305e-06
rate O 0 7.813159186298435e-07
and O 0 4.994799382984638e-07
cell O 0 2.171402047679294e-05
cycle O 0 1.1272800293227192e-05
profile O 0 3.91679259337252e-06
of O 0 1.8475512320037524e-07
these O 0 5.123498567627394e-07
cells O 0 1.4433384421863593e-05
in O 0 1.2830503237637458e-06
culture O 0 1.191648425447056e-05
. O 0 1.4538624782289844e-05

The O 0 4.583317422657274e-05
786 O 0 0.001728030969388783
- O 0 0.002082869643345475
0 O 0 5.936163870501332e-05
cell O 0 2.3722539481241256e-05
line O 0 1.6654854562148103e-06
, O 0 4.6289727606563247e-07
like O 0 6.172973030516005e-07
many O 0 2.3649483864573995e-06
cancer B-Disease 0 0.019641263410449028
cells O 0 5.404148032539524e-05
, O 0 1.0112029258380062e-06
fails O 0 1.5134703971853014e-05
to O 0 1.8239762766825152e-07
exit O 0 2.800015181492199e-06
the O 0 5.174794068807387e-07
cell O 0 3.635233952081762e-05
cycle O 0 2.5407020075363107e-05
upon O 0 4.4824541873822454e-06
serum O 0 0.00011824324610643089
withdrawal O 0 0.0001743030152283609
. O 0 2.328670962015167e-05

Here O 0 8.338543557329103e-05
, O 0 5.0383441703161225e-06
it O 0 6.647525196967763e-07
is O 0 3.6062931485503213e-07
shown O 0 4.220829623591271e-07
that O 0 1.3687477462553943e-07
reintroduction O 0 5.272866019367939e-06
of O 0 9.14803166551792e-08
the O 0 1.4455285679559893e-07
wild O 0 3.7567126582871424e-06
- O 0 0.00017871345335152
type O 0 1.3055109775450546e-05
VHL B-Disease 0 0.005368383601307869
gene O 0 3.0880510166753083e-06
restores O 0 7.845341315260157e-06
the O 0 2.3938042659210623e-07
ability O 0 6.075015903661551e-07
of O 0 4.600454985848046e-07
VHL O 0 0.0906909704208374
- O 0 0.14495651423931122
negative O 0 0.00016927624528761953
RCC B-Disease 1 0.9992541670799255
cancer I-Disease 0 0.29349440336227417
cells O 0 8.916706065065227e-06
to O 0 2.409431090200087e-07
exit O 0 3.3001192605297547e-06
the O 0 3.8453276829386596e-07
cell O 0 1.582073309691623e-05
cycle O 0 8.08306776889367e-06
and O 0 9.335158779322228e-07
enter O 0 8.045592039707117e-06
G0 O 0 0.01864560693502426
/ O 0 0.00035404376103542745
quiescence O 0 0.0004404563514981419
in O 0 4.087964498467045e-06
low O 0 5.3184921853244305e-05
serum O 0 0.00032294963602907956
. O 0 3.1382096494780853e-05

Both O 0 0.00013564954861067235
VHL O 0 0.3321855962276459
- O 0 0.0016292064683511853
positive O 0 2.1857311367057264e-05
and O 0 5.606349532172317e-06
VHL O 0 0.03878610208630562
- O 0 0.0018680832581594586
negative O 0 1.6889009202714078e-05
RCC B-Disease 0 0.03299539163708687
cells O 0 1.872815664683003e-05
exit O 0 4.7933749556250405e-06
the O 0 3.9168156718005775e-07
cell O 0 2.096163370879367e-05
cycle O 0 1.0855228538275696e-05
by O 0 1.4471191889242618e-06
contact O 0 1.5821742636035196e-05
inhibition O 0 7.032364374026656e-05
. O 0 1.931985934788827e-05

The O 0 8.472130866721272e-05
cyclin O 0 0.0030507557094097137
- O 0 0.0009650771389715374
dependent O 0 8.798217459116131e-05
kinase O 0 0.0002331378636881709
inhibitor O 0 3.5466273402562365e-05
, O 0 1.910575292640715e-06
p27 O 0 4.178646486252546e-05
, O 0 8.925452448238502e-07
accumulates O 0 3.7403472106234403e-06
upon O 0 1.136080300057074e-06
serum O 0 1.9971539586549625e-05
withdrawal O 0 1.4472280781774316e-05
, O 0 2.0736177930302802e-07
only O 0 5.1871218431642774e-08
in O 0 7.093227338828001e-08
the O 0 8.108217031121967e-08
presence O 0 3.8713423577974027e-07
of O 0 3.1295462576963473e-07
VHL B-Disease 0 0.015401843935251236
, O 0 4.767198333865963e-07
as O 0 8.855489852521714e-08
a O 0 1.7455371903452033e-07
result O 0 3.948322842006746e-07
of O 0 7.875559759895623e-08
the O 0 1.5934271857531712e-07
stabilization O 0 5.337351467460394e-06
of O 0 3.458447679349774e-07
the O 0 1.0377527814853238e-06
protein O 0 2.2136558982310817e-05
. O 0 1.2631929166673217e-05

We O 0 3.5688193747773767e-05
propose O 0 0.00010149067384190857
that O 0 1.6552185115870088e-06
the O 0 7.520245048908691e-07
loss O 0 9.265408152714372e-06
of O 0 4.7477024622821773e-07
wild O 0 1.9091703507001512e-05
- O 0 0.03737804666161537
type O 0 7.110032311175019e-05
VHL B-Disease 0 0.3199942111968994
gene O 0 1.7988149920711294e-05
results O 0 2.246645408376935e-06
in O 0 1.9431038822403934e-07
a O 0 5.135145215717785e-07
specific O 0 1.8256554312756634e-06
cellular O 0 8.205771882785484e-05
defect O 0 0.00015559999155811965
in O 0 7.61881665312103e-07
serum O 0 2.3208845959743485e-05
- O 0 0.000428917002864182
dependent O 0 2.1813790226588026e-05
growth O 0 6.764152203686535e-06
control O 0 1.3985461464471882e-06
, O 0 5.160629825695651e-07
which O 0 6.938440151316172e-07
may O 0 1.3505507922673132e-05
initiate O 0 0.0002916938392445445
tumor B-Disease 0 0.0058321342803537846
formation O 0 0.00018432229990139604
. O 0 4.361520768725313e-05

This O 0 3.2341024052584544e-05
is O 0 8.057938430283684e-06
corrected O 0 6.423459126381204e-05
by O 0 8.810453664409579e-07
the O 0 4.124093209156854e-07
reintroduction O 0 2.2358224669005722e-05
of O 0 4.183005444247101e-07
wild O 0 1.1495945727801882e-05
- O 0 0.011574198491871357
type O 0 3.632364678196609e-05
VHL B-Disease 0 0.015632806345820427
, O 0 2.6717375476437155e-06
implicating O 0 0.0003562478523235768
VHL B-Disease 0 0.010625683702528477
as O 0 4.1114600435321336e-07
the O 0 2.6934932861877314e-07
first O 0 3.6955514133296674e-06
tumor B-Disease 0 0.0005612639361061156
suppressor O 0 0.00015450829232577235
involved O 0 8.827526585264422e-07
in O 0 1.440324268742188e-07
the O 0 1.1139923827840903e-07
regulation O 0 1.1593871249715448e-06
of O 0 1.8401165391424001e-07
cell O 0 1.8865630408981815e-05
cycle O 0 1.0788906365633011e-05
exit O 0 2.3286553187062964e-05
, O 0 3.1029185265651904e-07
which O 0 1.0655427473693635e-07
is O 0 7.118490685797951e-08
consistent O 0 4.6437097012130835e-07
with O 0 1.2229121182372182e-07
its O 0 1.1862599649248295e-06
gatekeeper O 0 8.351873111678287e-05
function O 0 9.292017466577818e-07
in O 0 4.917263822790119e-07
the O 0 2.476058170941542e-06
kidney O 0 0.33017489314079285
. O 0 1.1068935236835387e-05
. O 0 2.416163988527842e-05

Piebaldism B-Disease 1 0.999729573726654
with O 0 0.06887011229991913
deafness B-Disease 1 0.9999997615814209
: O 0 0.0007575394120067358
molecular O 0 0.00036236681626178324
evidence O 0 6.137990567367524e-06
for O 0 1.5458822417713236e-06
an O 0 6.148447027953807e-06
expanded O 0 0.0008169626817107201
syndrome O 1 0.9995819926261902
. O 0 7.87679964560084e-05

In O 0 3.766448935493827e-05
a O 0 6.185458005347755e-06
South O 0 6.3370885072799865e-06
African O 0 5.283547579892911e-06
girl O 0 1.6732859876356088e-05
of O 0 8.252065981650958e-07
Xhosa O 0 0.044534310698509216
stock O 0 0.00011142100265715271
with O 0 1.1891769645444583e-05
severe O 0 0.32489949464797974
piebaldism B-Disease 1 0.9799454212188721
and O 0 0.0008671600371599197
profound O 1 0.9570850133895874
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 6.04750239290297e-05
identified O 0 1.0188800843025092e-05
a O 0 7.409806244140782e-07
novel O 0 3.872106390190311e-06
missense O 0 1.5588742826366797e-05
substitution O 0 1.1639815511443885e-06
at O 0 1.7104112259858084e-07
a O 0 2.535097394229524e-07
highly O 0 9.99999883788405e-07
conserved O 0 9.209689437739144e-07
residue O 0 1.754363211148302e-06
in O 0 1.544547103549121e-07
the O 0 1.8726591122231184e-07
intracellular O 0 2.970854666273226e-06
kinase O 0 1.1069261745433323e-05
domain O 0 9.803635521166143e-07
of O 0 1.888819554096699e-07
the O 0 4.317068942327751e-07
KIT O 0 0.0003253002359997481
proto O 0 0.010026900097727776
- O 0 0.006561793386936188
oncogene O 0 0.0014349928824231029
, O 0 5.403011527960189e-06
R796G O 0 0.0001512711023679003
. O 0 2.9396747777354904e-05

Though O 0 0.0003269029257353395
auditory B-Disease 0 0.03645315021276474
anomalies I-Disease 1 0.504665732383728
have O 0 5.195872745389352e-06
been O 0 1.1670036883515422e-06
observed O 0 3.5829793887387495e-06
in O 0 1.1407964848331176e-06
mice O 0 5.062211857875809e-05
with O 0 1.8858221437767497e-06
dominant O 0 5.3944779210723937e-05
white O 0 0.0007172391633503139
spotting O 0 0.05199464038014412
( O 0 3.185986133757979e-05
W O 0 0.40872400999069214
) O 0 1.429198960067879e-06
due O 0 1.5350666444646777e-06
to O 0 1.0034112847279175e-06
KIT O 1 0.9119612574577332
mutations O 0 0.003617290174588561
, O 0 2.4985234631458297e-05
deafness B-Disease 1 0.999998927116394
is O 0 2.885576122935163e-06
not O 0 3.0367394288077776e-07
typical O 0 6.2799049374007154e-06
in O 0 2.9796192393405363e-06
human O 0 9.021691766974982e-06
piebaldism B-Disease 0 0.005718180909752846
. O 0 3.6536745028570294e-05

Thus O 0 0.00013602129183709621
, O 0 7.808563168509863e-06
the O 0 2.2502842966787284e-06
occurrence O 0 2.5853791157715023e-05
of O 0 9.402076102560386e-06
sensorineural B-Disease 1 0.9999995231628418
deafness I-Disease 1 1.0
in O 0 4.763092510984279e-05
this O 0 1.6862910570125678e-06
patient O 0 3.9482667489210144e-05
extends O 0 2.0077452063560486e-05
considerably O 0 1.0018756256613415e-05
the O 0 3.428838510899368e-07
phenotypic O 0 2.120148792528198e-06
range O 0 6.418520683837414e-07
of O 0 2.2297264479220757e-07
piebaldism B-Disease 0 0.00022023142082616687
due O 0 3.0548230824933853e-06
to O 0 3.316786489904189e-07
KIT O 0 0.004191759508103132
gene O 0 1.6187103028642014e-05
mutation O 0 3.7780976072099293e-06
in O 0 1.9046396459998505e-07
humans O 0 3.4128427728319366e-07
and O 0 5.219689569457842e-07
tightens O 0 0.020501937717199326
the O 0 3.3296298624918563e-06
clinical O 0 4.698042175732553e-05
similarity O 0 2.3461166165361647e-06
between O 0 4.3134349425599794e-07
piebaldism B-Disease 0 0.0004238196706864983
and O 0 3.799231080847676e-07
the O 0 2.0470548633966246e-07
various O 0 3.2335327659893665e-07
forms O 0 6.507970283564646e-06
of O 0 8.108013571472839e-05
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999991655349731
. O 0 1.1326486855978146e-05
. O 0 1.7672060494078323e-05

Cycloheximide O 0 0.009921577759087086
facilitates O 0 0.0003603730001486838
the O 0 6.683053925371496e-06
identification O 0 6.983388630033005e-06
of O 0 1.1201098004676169e-06
aberrant O 0 7.198419916676357e-05
transcripts O 0 2.9839115086360835e-05
resulting O 0 3.641026978584705e-06
from O 0 2.2317665582249901e-07
a O 0 6.018623821546498e-07
novel O 0 2.053845264526899e-06
splice O 0 0.0002050438488367945
- O 0 0.0003096120781265199
site O 0 4.024479039799189e-06
mutation O 0 2.9034804356342647e-06
in O 0 3.27958645129911e-07
COL17A1 O 0 0.0010204993886873126
in O 0 7.856473303036182e-07
a O 0 4.871130386163713e-06
patient O 0 0.0003043688484467566
with O 0 6.83702965034172e-05
generalized O 1 0.7300499677658081
atrophic B-Disease 1 0.9999959468841553
benign I-Disease 1 0.999915599822998
epidermolysis I-Disease 1 0.9999873638153076
bullosa I-Disease 1 0.9998898506164551
. O 0 0.0002786291006486863

Patients O 1 0.9214653968811035
with O 0 0.00040742859710007906
generalized O 1 0.785983145236969
atrophic B-Disease 1 0.9999954700469971
benign I-Disease 1 0.9999818801879883
epidermolysis I-Disease 1 0.9999946355819702
bullosa I-Disease 1 0.999968409538269
often O 0 0.0001067804842023179
show O 0 1.817392694647424e-05
decreased O 0 2.0297884475439787e-05
expression O 0 3.6015264868183294e-06
of O 0 7.602782829962962e-07
type O 0 2.493163810868282e-05
XVII O 0 0.4865761399269104
collagen O 0 0.0002613462565932423
, O 0 6.172190296638291e-07
a O 0 7.171570928221627e-07
transmembrane O 0 2.0069659512955695e-05
hemidesmosomal O 0 7.558831566711888e-05
protein O 0 3.752316160898772e-06
encoded O 0 2.5840747639449546e-06
by O 0 2.0697229956567753e-06
COL17A1 O 0 0.0006656406912952662
. O 0 3.360550545039587e-05

This O 0 5.423322363640182e-05
report O 0 3.434760219533928e-05
documents O 0 8.460508070129436e-06
a O 0 1.9737476577574853e-06
novel O 0 5.141582732903771e-06
splice O 0 0.00030474370578303933
- O 0 0.0004397644952405244
site O 0 7.6170240390638355e-06
mutation O 0 4.8138481361093e-06
in O 0 4.082433804342145e-07
COL17A1 O 0 0.0009595434530638158
in O 0 1.088864109988208e-06
a O 0 2.929820993813337e-06
patient O 0 0.00011920008546439931
with O 0 2.1182622731430456e-05
generalized O 1 0.7477719187736511
atrophic B-Disease 1 0.9999984502792358
benign I-Disease 1 0.9995077848434448
epidermolysis I-Disease 1 0.999995231628418
bullosa I-Disease 1 0.9997273087501526
, O 0 5.092208994028624e-06
and O 0 5.265250706543156e-07
applies O 0 1.107200773731165e-06
a O 0 3.310993577088084e-07
new O 0 1.2661084838327952e-06
methodology O 0 4.85656983073568e-06
to O 0 2.8691809461633966e-07
define O 0 2.908410351665225e-06
and O 0 6.043130724719958e-07
characterize O 0 1.7087682863348164e-05
the O 0 4.612694510797155e-07
resulting O 0 4.729703050543321e-06
mRNA O 0 2.0358329493319616e-05
splice O 0 0.00038277730345726013
variants O 0 6.788718746975064e-05
. O 0 2.019424209720455e-05

Mutational O 0 0.032804328948259354
analysis O 0 0.00018097647989634424
of O 0 1.4692614058731124e-05
COL17A1 O 0 0.010233740322291851
identified O 0 2.378973294980824e-05
a O 0 5.926742232986726e-06
maternally O 0 0.001108724856749177
inherited O 0 0.0013586118584498763
G O 0 0.059872619807720184
- O 0 0.00017036779900081456
to O 0 9.00945735793357e-07
- O 0 0.00036166104837320745
T O 0 0.005993308965116739
transversion O 0 2.932037205027882e-05
at O 0 1.9102279225080565e-07
the O 0 7.733446949487188e-08
- O 0 3.1151898838288616e-06
1 O 0 6.579234081982577e-07
position O 0 8.817380034997768e-07
of O 0 6.281704258981335e-07
exon O 0 3.8893929740879685e-05
32 O 0 1.8975424609379843e-05
. O 0 2.0376530301291496e-05

This O 0 2.383838000241667e-05
acceptor O 0 0.00011547275062184781
splice O 0 0.0003302326949778944
- O 0 0.00036156573332846165
site O 0 5.855410563526675e-06
mutation O 0 3.364402800798416e-06
led O 0 3.988176047187153e-07
to O 0 8.977801968512722e-08
the O 0 1.1818826806120342e-07
formation O 0 1.4440365703194402e-06
of O 0 3.233196537166805e-07
aberrant O 0 3.043066681129858e-05
transcripts O 0 7.28429586160928e-06
present O 0 1.067714038072154e-06
at O 0 7.638736292392423e-07
extremely O 0 8.02279100753367e-06
low O 0 3.144071524729952e-05
levels O 0 2.495066473784391e-05
. O 0 2.9612672733492218e-05

Based O 0 5.910101754125208e-05
on O 0 5.028392934036674e-06
our O 0 2.486579205651651e-06
recent O 0 3.142369223496644e-06
finding O 0 2.7142921226186445e-06
that O 0 8.139359124470502e-07
cycloheximide O 0 0.0003950509999413043
stabilized O 0 0.00023699042503722012
mutant O 0 3.457257480476983e-05
COL17A1 O 0 0.0003909475344698876
transcripts O 0 2.722196040849667e-05
in O 0 1.96305177269096e-06
keratinocytes O 0 0.0022661942057311535
homozygous O 0 1.2896852240373846e-05
for O 0 5.601847306024865e-07
a O 0 4.1710459299793e-06
frameshift O 0 0.07789791375398636
mutation O 0 2.783184936561156e-05
, O 0 3.903045637798641e-07
the O 0 2.4396516096203413e-07
effects O 0 1.3868663018001826e-06
of O 0 7.551896885615861e-08
the O 0 1.5876510417456302e-07
splice O 0 0.0001476654433645308
- O 0 6.059457882656716e-05
site O 0 1.3986248177388916e-06
mutation O 0 1.133832142841129e-06
on O 0 1.7343879221698444e-07
splicing O 0 4.852352503803559e-06
of O 0 2.1272931860494282e-07
COL17A1 O 0 0.00010993106116075069
transcripts O 0 4.975941919838078e-06
were O 0 2.0996040461795928e-07
determined O 0 4.680885297148052e-07
using O 0 4.946056151311495e-07
reverse O 0 1.1405645636841655e-05
transcriptase O 0 7.556423952337354e-05
polymerase O 0 1.2305975360504817e-05
chain O 0 2.552484602347249e-06
reaction O 0 8.57419649946678e-07
of O 0 8.630214409777182e-08
total O 0 3.19519045888228e-07
RNA O 0 2.0987743027944816e-06
from O 0 9.224298196386371e-07
keratinocytes O 0 0.0001659485715208575
incubated O 0 1.3892959032091312e-05
for O 0 1.3922211792305461e-06
2 O 0 1.5432249711011536e-05
. O 0 2.4059045244939625e-05

5 O 0 0.00026814875309355557
h O 0 0.0008974974625743926
in O 0 2.8087927148590097e-06
the O 0 6.107191552473523e-07
presence O 0 9.58090936364897e-07
or O 0 4.5608945242747723e-07
absence O 0 1.0181582865698147e-06
of O 0 2.824283740210376e-07
10 O 0 1.6426491811216692e-06
microg O 0 0.00035816282615996897
cycloheximide O 0 0.0004173605120740831
per O 0 6.933129498065682e-06
ml O 0 0.0007013581343926489
. O 0 1.912486732180696e-05

Using O 0 5.173991303308867e-05
this O 0 3.847950665658573e-06
approach O 0 7.983628165675327e-06
, O 0 1.4544633586410782e-06
an O 0 1.1022774515367928e-06
abnormally O 0 0.00040878422441892326
spliced O 0 0.00044492544839158654
transcript O 0 8.529018668923527e-05
was O 0 9.79788637778256e-07
identified O 0 1.109234176510654e-06
that O 0 7.494685405617929e-08
contains O 0 1.3259958109301806e-07
an O 0 8.343322122073005e-08
extra O 0 3.272516266861203e-07
264 O 0 1.5818671954548336e-06
bases O 0 4.5157784711591376e-07
upstream O 0 8.061329026531894e-07
from O 0 2.3134906257382681e-07
exon O 0 3.3091450859501492e-06
32 O 0 9.75573357209214e-07
, O 0 2.927420155174332e-07
resulting O 0 8.897848147171317e-07
in O 0 2.14101305573422e-07
a O 0 1.9553463062038645e-06
premature O 0 0.00035269721411168575
termination O 0 3.788000321947038e-05
codon O 0 6.247302735573612e-06
27 O 0 3.140955413982738e-06
bp O 0 5.4250602261163294e-05
downstream O 0 4.079844075022265e-06
from O 0 5.50298864254728e-07
the O 0 1.313369352828886e-06
cryptic O 0 9.949824743671343e-05
splice O 0 0.0008879968663677573
site O 0 4.2944207962136716e-05
. O 0 2.792660779959988e-05

Three O 0 2.4732007659622468e-05
other O 0 3.0869205147610046e-06
splice O 0 0.000145748708746396
variants O 0 1.1071690096287057e-05
, O 0 5.316936153576535e-07
including O 0 2.720011309520487e-07
one O 0 1.0748651391168096e-07
derived O 0 4.530496369170578e-07
from O 0 9.13373483513169e-08
the O 0 1.0182228749044953e-07
skipping O 0 1.1498854064484476e-06
of O 0 1.7240152772046713e-07
exon O 0 8.227239959524013e-06
32 O 0 1.4054132861929247e-06
, O 0 3.573406672785495e-07
were O 0 3.171284106429084e-07
also O 0 1.7897807538247434e-06
identified O 0 1.7766451492207125e-05
. O 0 1.4223054677131586e-05

These O 0 4.0369741327594966e-05
results O 0 4.23427190980874e-05
indicate O 0 4.789610102307051e-06
the O 0 6.353114940793603e-07
usefulness O 0 4.956613338436e-06
of O 0 7.887373385528917e-07
cycloheximide O 0 0.14702823758125305
treatment O 0 0.00024904057499952614
in O 0 1.4400758345800568e-06
evaluating O 0 1.612222877156455e-05
the O 0 4.99808209042385e-07
abnormal O 0 1.4289944374468178e-05
processing O 0 1.1344822041792213e-06
of O 0 1.330137280319832e-07
mRNA O 0 1.3367631481742137e-06
due O 0 4.930778345624276e-07
to O 0 1.4230798228709318e-07
splice O 0 5.5934826377779245e-05
- O 0 0.00013406018842943013
site O 0 4.992597951058997e-06
mutations O 0 7.52849973650882e-06
, O 0 2.757044512691209e-07
because O 0 3.0419974450524023e-07
( O 0 5.246384375823254e-07
i O 0 3.3957431355702283e-07
) O 0 6.926216542524344e-07
aberrant O 0 6.2682970565219875e-06
splicing O 0 1.2062770110787824e-05
often O 0 3.891345556894521e-07
generates O 0 1.6096134913823335e-06
a O 0 1.367674258290208e-06
premature O 0 0.0002659704477991909
termination O 0 3.770013790926896e-05
codon O 0 6.680575097561814e-06
, O 0 5.222791514825076e-07
( O 0 4.139452869367233e-07
ii O 0 5.723361027776264e-06
) O 0 9.036295978148701e-07
transcripts O 0 3.8406656130973715e-06
with O 0 1.2283137493795948e-06
premature O 0 0.0017700140597298741
termination O 0 0.00011790289863711223
codons O 0 2.1919307982898317e-05
can O 0 4.0159000036510406e-07
occur O 0 5.720642661799502e-07
at O 0 1.970895056047084e-07
low O 0 2.8050744731444865e-06
or O 0 1.3184242106945021e-06
undetectable O 0 3.897605711244978e-05
levels O 0 8.588862669967057e-07
due O 0 4.0829942804521124e-07
to O 0 1.4033919626399438e-07
nonsense O 0 3.91140611100127e-06
- O 0 1.4473576811724342e-05
mediated O 0 1.7630380170885473e-05
mRNA O 0 3.0690700896229828e-06
decay O 0 1.7018411426761304e-06
, O 0 2.3830439488392585e-07
and O 0 2.731425468027737e-07
( O 0 1.6441348407170153e-06
iii O 0 5.848653381690383e-05
) O 0 4.437520999545086e-07
the O 0 8.319089062069907e-08
levels O 0 2.0993137184177613e-07
of O 0 5.326401009142501e-08
these O 0 1.0382818516063708e-07
transcripts O 0 2.1967609882267425e-06
can O 0 1.0698009589305002e-07
be O 0 7.74632056277369e-08
increased O 0 4.5228728140500607e-07
by O 0 1.3247650940684252e-06
cycloheximide O 0 0.001343674142844975
. O 0 2.1883381123188883e-05

A O 0 0.0002569052448961884
deletion O 0 0.02804981917142868
mutation O 0 0.00019051721028517932
in O 0 2.1780967927043093e-06
COL17A1 O 0 0.006901765242218971
in O 0 1.7859869103631354e-06
five O 0 1.9898295704479096e-06
Austrian O 0 0.0003491565294098109
families O 0 5.7418342294113245e-06
with O 0 1.3435571418085601e-05
generalized O 0 0.2185678482055664
atrophic B-Disease 1 0.9999982118606567
benign I-Disease 1 0.9997819066047668
epidermolysis I-Disease 1 0.9999901056289673
bullosa I-Disease 1 0.9997530579566956
represents O 0 3.776101584662683e-05
propagation O 0 1.3860748367733322e-05
of O 0 9.757343377714278e-07
an O 0 2.182134267059155e-06
ancestral O 0 0.00017018690414261073
allele O 0 0.00033959155553020537
. O 0 3.0815124773653224e-05

Patients O 1 0.9742140173912048
with O 0 0.0005553439259529114
generalized O 1 0.9806883335113525
atrophic B-Disease 1 0.9999991655349731
benign I-Disease 1 0.999976396560669
epidermolysis I-Disease 1 0.9999951124191284
bullosa I-Disease 1 0.9999814033508301
, O 0 3.9173140976345167e-05
a O 0 5.255711130303098e-06
usually O 0 5.758593033533543e-06
nonlethal O 0 0.00011409149010432884
form O 0 6.451613899116637e-06
of O 0 5.43364285476855e-06
junctional B-Disease 1 0.9972010850906372
epidermolysis I-Disease 1 0.999984622001648
bullosa I-Disease 1 0.9997960925102234
, O 0 7.0068176682980265e-06
have O 0 1.0884914445341565e-06
generalized O 0 4.3196479964535683e-05
blistering B-Disease 0 0.029138658195734024
, O 0 6.724405102431774e-05
nail B-Disease 1 0.9999908208847046
dystrophy I-Disease 1 0.9999936819076538
, O 0 0.0002095937088597566
patchy B-Disease 1 0.9999113082885742
alopecia I-Disease 1 0.9999998807907104
, O 0 0.000158524009748362
and O 0 0.0003037904971279204
dental B-Disease 1 0.9998377561569214
abnormalities I-Disease 1 0.9984690546989441
. O 0 0.00011775334132835269

Skin B-Disease 1 0.9999346733093262
fragility I-Disease 1 0.9961296319961548
in O 0 4.9205656978301704e-05
most O 0 4.527319106273353e-06
cases O 0 4.92238677907153e-06
is O 0 7.157809704949614e-07
due O 0 5.048646471550455e-06
to O 0 1.241250402017613e-06
mutations O 0 9.721762580738869e-06
in O 0 1.7618785363993084e-07
the O 0 2.314485954002521e-07
gene O 0 2.679167437236174e-06
encoding O 0 6.007079718983732e-06
type O 0 2.382212915108539e-05
XVII O 0 0.31163936853408813
collagen O 0 0.003644857555627823
( O 0 8.029150194488466e-06
COL17A1 O 0 0.003185136476531625
) O 0 9.447438969800714e-06
. O 0 1.0456571544636972e-05

Recently O 0 0.0005140246357768774
, O 0 8.861173228069674e-06
we O 0 1.4500285487883957e-06
reported O 0 4.642333806259558e-06
five O 0 1.1647688324956107e-06
Austrian O 0 0.00019239142420701683
families O 0 7.1527515501657035e-06
with O 0 2.1831272533745505e-05
generalized O 0 0.3496411144733429
atrophic B-Disease 1 0.9999978542327881
benign I-Disease 1 0.9995736479759216
epidermolysis I-Disease 1 0.9999779462814331
bullosa I-Disease 1 0.9996392726898193
who O 0 1.9381530364626087e-05
share O 0 7.047334747767309e-06
the O 0 1.6383107777073747e-06
same O 0 4.952158178639365e-06
COL17A1 O 0 0.07339411228895187
mutation O 0 0.0003534636925905943
. O 0 3.535645373631269e-05

Affected O 0 0.001046862336806953
individuals O 0 1.488839006924536e-05
in O 0 1.872198026831029e-06
three O 0 1.0338370657336782e-06
families O 0 2.2102603907114826e-06
are O 0 5.5800501286285e-07
homozygous O 0 4.4830267142970115e-06
for O 0 4.38113204381807e-07
4003delTC O 0 0.00019464807701297104
, O 0 1.2166807437097305e-06
whereas O 0 1.6760477592470124e-06
those O 0 1.0336817268807863e-07
in O 0 9.495697383954393e-08
two O 0 1.7845385968939809e-07
others O 0 1.4355755411088467e-06
are O 0 6.043753160156484e-07
compound O 0 0.00012706605775747448
heterozygotes O 0 0.0007933113374747336
. O 0 1.6620928363408893e-05

To O 0 4.5181746827438474e-05
determine O 0 2.2671443730359897e-05
if O 0 1.246818214895029e-06
the O 0 3.134265682547266e-07
occurrence O 0 2.1586274669971317e-06
of O 0 3.63088446420079e-07
4003delTC O 0 0.00016856529691722244
in O 0 8.101289381556853e-07
these O 0 2.278727038174111e-07
unrelated O 0 3.564010285117547e-06
families O 0 1.0581356946204323e-06
signifies O 0 1.1991542123723775e-05
propagation O 0 2.634805014167796e-06
of O 0 1.163670262371852e-07
an O 0 1.6253630974460975e-07
ancestral O 0 1.1871000424434897e-05
allele O 0 1.2222513760207221e-05
or O 0 4.72757847091998e-07
a O 0 6.570831487806572e-07
mutational O 0 0.00020844714890699834
hot O 0 2.08148831006838e-05
spot O 0 6.159333679534029e-06
, O 0 1.2039954526699148e-06
haplotypes O 0 5.3078420023666695e-05
were O 0 2.414910795778269e-07
determined O 0 7.15211854185327e-07
for O 0 2.964075065392535e-07
polymorphisms O 0 2.8850430680904537e-05
both O 0 3.9268132923098165e-07
within O 0 5.871200983165181e-07
and O 0 2.4740661501709837e-06
flanking O 0 0.0002694347349461168
COL17A1 O 0 0.10921336710453033
. O 0 3.808276233030483e-05

Five O 0 0.0001467944821342826
intragenic O 0 0.006718425080180168
polymorphisms O 0 0.000799452536739409
were O 0 2.6637842438503867e-06
chosen O 0 2.271905486850301e-06
based O 0 1.8984896996698808e-06
on O 0 1.0862349881790578e-06
their O 0 6.8037925302633084e-06
informativeness O 0 0.011161873117089272
. O 0 4.403758066473529e-05

One O 0 1.278164654650027e-05
of O 0 2.390066129009938e-06
these O 0 5.761096417700173e-07
, O 0 6.079194463382009e-07
not O 0 3.035149802599335e-07
previously O 0 4.484515102376463e-06
reported O 0 3.944870513805654e-06
, O 0 2.858883760836761e-07
was O 0 4.0995573158397747e-07
2988 O 0 1.9130759028485045e-05
A O 0 6.239105800887046e-07
or O 0 4.914188593829749e-07
C O 0 6.907713668624638e-06
that O 0 6.98592117487351e-08
introduces O 0 1.229932536261913e-06
a O 0 2.1107221925831254e-07
new O 0 7.031015911707073e-07
restriction O 0 5.222672143645468e-07
site O 0 8.092609959930996e-07
for O 0 7.799706622790836e-07
Eco0109 O 0 0.0001300240255659446
I O 0 1.2909120414406061e-05
. O 0 2.15667714655865e-05

All O 0 1.6062253052950837e-05
the O 0 1.020228592096828e-05
4003delTC O 0 0.0003188428236171603
alleles O 0 3.711563840624876e-05
showed O 0 4.654178610508097e-06
the O 0 4.244257638674753e-07
same O 0 6.728052994731115e-07
haplotype O 0 0.00010841749462997541
for O 0 3.861305799546244e-07
these O 0 3.2865872867660073e-07
five O 0 1.6458606069136295e-06
polymorphic O 0 0.0005747845862060785
markers O 0 8.91040253918618e-05
. O 0 2.4243392545031384e-05

Fourteen O 0 0.0004946199478581548
microsatellite O 0 0.004139881115406752
polymorphisms O 0 0.0011073800269514322
were O 0 2.8963784188817954e-06
selected O 0 1.9816936855932e-06
based O 0 1.3285048225952778e-06
on O 0 3.474524135071988e-07
their O 0 5.716879059036728e-07
high O 0 2.993604311996023e-06
heterozygosity O 0 9.067104110727087e-05
and O 0 3.110135651240853e-07
their O 0 2.4274163479276467e-07
location O 0 7.47901140130125e-07
within O 0 4.2148965917476744e-07
10q23 O 0 2.7796466383733787e-05
- O 0 9.68620806816034e-05
q25 O 0 0.00010335451224818826
near O 0 1.6351517842849717e-05
COL17A1 O 0 0.0022911853156983852
. O 0 4.0203158278018236e-05

Three O 0 3.934378764824942e-05
families O 0 2.695464536373038e-05
shared O 0 2.462567681504879e-05
microsatellite O 0 0.0014895314816385508
polymorphisms O 0 0.0010762802558019757
covering O 0 2.1302388631738722e-05
at O 0 1.740593006616109e-06
most O 0 4.906452204522793e-07
19 O 0 6.7187311287852935e-06
cM O 0 0.00021667809050995857
, O 0 5.821584636578336e-07
whereas O 0 6.325980734800396e-07
the O 0 1.3193671577482746e-07
others O 0 3.5898978012482985e-07
shared O 0 3.6214228771314083e-07
smaller O 0 8.8812828380469e-07
regions O 0 2.474457687640097e-06
consistent O 0 1.142826363320637e-06
with O 0 2.1460705568188132e-07
cross O 0 1.193778530250711e-06
- O 0 3.3954707760130987e-05
over O 0 4.416201022650057e-07
events O 0 2.752743455403106e-07
during O 0 2.496444153621269e-07
passage O 0 4.5445776208907773e-07
of O 0 1.0993310439744164e-07
this O 0 1.8627733311404882e-07
mutation O 0 2.399221557425335e-06
through O 0 5.072599833511049e-07
several O 0 1.7702387822282617e-06
generations O 0 3.302478580735624e-05
. O 0 2.015499194385484e-05

These O 0 7.146017014747486e-05
results O 0 7.172916230047122e-05
indicate O 0 1.1668039405776653e-05
that O 0 6.922835495970503e-07
4003delTC O 0 9.50266548898071e-05
occurs O 0 1.0635908438416664e-06
on O 0 2.12519239539688e-07
a O 0 4.3403105109973694e-07
single O 0 3.2302702948072692e-06
ancestral O 0 4.8545967729296535e-05
allele O 0 7.046938844723627e-05
. O 0 4.3286177060508635e-06
. O 0 1.3270589079183992e-05

The O 0 9.569327812641859e-05
haptoglobin O 0 0.0055472333915531635
- O 0 0.012407000176608562
gene O 0 0.000159122355398722
deletion O 0 0.00022110689315013587
responsible O 0 2.9760565666947514e-05
for O 0 1.0362048669776414e-05
anhaptoglobinemia B-Disease 0 0.019180694594979286
. O 0 6.70034351060167e-05

We O 0 1.858798168541398e-05
have O 0 3.6791363982047187e-06
found O 0 2.2378458197636064e-06
an O 0 8.590844799982733e-07
allelic O 0 5.9389953094068915e-05
deletion O 0 1.970760968106333e-05
of O 0 2.798357741085056e-07
the O 0 7.247855933201208e-07
haptoglobin O 0 0.0006204361561685801
( O 0 2.203933263444924e-06
Hp O 0 6.018626663717441e-05
) O 0 8.207641712942859e-07
gene O 0 6.805237831031263e-07
from O 0 1.308838761815423e-07
an O 0 1.4539790527123841e-07
individual O 0 7.248927431646734e-07
with O 0 3.3331912163703237e-06
anhaptoglobinemia B-Disease 0 0.010230903513729572
. O 0 2.188359030697029e-05

The O 0 5.9551181038841605e-05
Hp O 0 0.0009463734459131956
gene O 0 4.99446687172167e-05
cluster O 0 2.3090031390893273e-05
consists O 0 2.1087878394610016e-06
of O 0 3.398299384116399e-07
coding O 0 1.781784521881491e-05
regions O 0 8.870439387465012e-07
of O 0 9.83361090334256e-08
the O 0 1.1823267698218842e-07
alpha O 0 2.229963456557016e-06
chain O 0 7.233458632072143e-07
and O 0 1.338730015731926e-07
beta O 0 1.3027162140133441e-06
chain O 0 6.073585154808825e-07
of O 0 1.0136112393865915e-07
the O 0 2.745989320374065e-07
haptoglobin O 0 0.00013536476762965322
gene O 0 3.7268700907588936e-06
( O 0 7.253906915138941e-07
Hp O 0 2.1406778614618815e-05
) O 0 1.9609097989814472e-07
and O 0 5.5232003859373435e-08
of O 0 4.80343764763802e-08
the O 0 1.2058140441695286e-07
alpha O 0 4.093145435035694e-06
chain O 0 9.755017345014494e-07
and O 0 1.4490980504433537e-07
beta O 0 1.0457213193149073e-06
chain O 0 3.820751999228378e-07
of O 0 7.07338045913275e-08
the O 0 3.1883510587249475e-07
haptoglobin O 0 0.00035201432183384895
- O 0 0.0006678196368739009
related O 0 1.399407301505562e-05
gene O 0 5.786602741864044e-06
( O 0 1.9830076780635864e-06
Hpr O 0 0.00027054466772824526
) O 0 7.384953164546459e-07
, O 0 1.9662803651954164e-07
in O 0 1.608834310218299e-07
tandem O 0 2.0981258330721175e-06
from O 0 2.1700033414617792e-07
the O 0 3.1031316893859184e-07
5 O 0 5.566408162849257e-06
side O 0 8.70800249685999e-06
. O 0 2.224664785899222e-05

Southern O 0 0.0003923474287148565
blot O 0 0.0030870758928358555
and O 0 1.7668284272076562e-05
PCR O 0 0.00043652683962136507
analyses O 0 3.052434476558119e-05
have O 0 1.1484344213386066e-06
indicated O 0 3.6623050618800335e-06
that O 0 1.1241502306802431e-07
the O 0 9.051581884023108e-08
individual O 0 2.064336115381593e-07
with O 0 4.750696405153576e-07
anhaptoglobinemia B-Disease 0 0.0036658586468547583
was O 0 9.66032757787616e-07
homozygous O 0 1.7417072513126186e-06
for O 0 1.6786297862836363e-07
the O 0 2.747655400980875e-07
gene O 0 3.0819167022855254e-06
deletion O 0 5.822239472763613e-06
and O 0 2.305673660885077e-07
that O 0 1.0943999484425149e-07
the O 0 2.1098789204643253e-07
gene O 0 2.5802185064094374e-06
deletion O 0 6.407276032405207e-06
was O 0 2.1792092752548342e-07
included O 0 1.9774394388605288e-07
at O 0 1.8240650945244852e-07
least O 0 1.4523520519560407e-07
from O 0 9.359613528658883e-08
the O 0 1.4141588167149166e-07
promoter O 0 1.0201099030382466e-05
region O 0 2.1046530491730664e-06
of O 0 2.939805483492819e-07
Hp O 0 3.196662510163151e-05
to O 0 4.2419227952450456e-07
Hpr O 0 0.00011991706560365856
alpha O 0 3.121014970020042e-06
but O 0 1.5114333962173987e-07
not O 0 1.2928418868796143e-07
to O 0 3.737212921350874e-07
Hpr O 0 0.0004502983938436955
beta O 0 3.794602525886148e-05
( O 0 3.307586439404986e-06
Hpdel O 0 0.00020914035849273205
) O 0 7.058042228891281e-06
. O 0 1.2696760677499697e-05

In O 0 4.3116433516843244e-05
addition O 0 1.0664364708645735e-05
, O 0 1.2652780014832388e-06
we O 0 3.0004559903318295e-07
found O 0 3.20336425829737e-07
seven O 0 4.3603779431578005e-07
individuals O 0 2.0478456974615256e-07
with O 0 2.53736146760275e-07
hypohaptoglobinemia B-Disease 0 0.021965457126498222
in O 0 5.946473606854852e-07
three O 0 3.353321460508596e-07
families O 0 8.514047067365027e-07
, O 0 2.632669975355384e-07
and O 0 1.2395666715292464e-07
the O 0 2.2817150124865293e-07
genotypes O 0 2.682115518837236e-05
of O 0 7.764559484257916e-08
six O 0 1.1701335722591466e-07
of O 0 6.838242683215867e-08
the O 0 1.1018311596444619e-07
seven O 0 7.232176244542643e-07
individuals O 0 2.0073539985787647e-07
were O 0 8.621263702934812e-08
found O 0 1.622945262624853e-07
to O 0 2.4373585461034963e-07
be O 0 5.713440032195649e-07
Hp2 O 0 0.0004310383810661733
/ O 0 0.000741562049370259
Hpdel O 0 0.0010753343813121319
. O 0 2.7068010240327567e-05

The O 0 3.61167112714611e-05
phenotypes O 0 0.0012443471932783723
and O 0 1.1094372894149274e-05
genotypes O 0 0.0004358677251730114
in O 0 7.434913413817412e-07
one O 0 1.4240599455206393e-07
of O 0 9.703986592057845e-08
these O 0 1.0533859295946968e-07
three O 0 1.8680356106415275e-07
families O 0 7.193970645857917e-07
showed O 0 7.506129691137176e-07
the O 0 1.0074837319962171e-07
father O 0 8.149767722898105e-07
to O 0 1.9591675481933635e-07
be O 0 1.5698938682362495e-07
hypohaptoglobinemic B-Disease 0 0.00019374889961909503
( O 0 1.180638378173171e-06
Hp2 O 0 4.887702743872069e-05
) O 0 4.403806599384552e-07
and O 0 2.642406684572052e-07
Hp2 O 0 0.00043877027928829193
/ O 0 0.0002332312287762761
Hpdel O 0 8.023231930565089e-05
, O 0 1.8821411629232898e-07
the O 0 9.726964833589591e-08
mother O 0 6.962900442886166e-07
to O 0 1.0209883782863471e-07
be O 0 1.0855602283754706e-07
Hp2 O 0 2.7243928343523294e-05
- O 0 2.9644937967532314e-05
1 O 0 1.2507472320066881e-06
and O 0 3.4405977089591033e-07
Hp1 O 0 0.0002364340762142092
/ O 0 9.193592268275097e-05
Hp2 O 0 4.099129364476539e-05
, O 0 1.0451126541966005e-07
one O 0 3.701091344510132e-08
of O 0 3.1998158789292575e-08
the O 0 6.18750704006743e-08
two O 0 1.813424006513742e-07
children O 0 4.0724944483372383e-07
to O 0 1.3450083713451022e-07
be O 0 1.96465151702796e-07
hypohaptoglobinemic B-Disease 0 0.00036649065441451967
( O 0 1.5905759482848225e-06
Hp2 O 0 7.323696627281606e-05
) O 0 4.206427774988697e-07
and O 0 3.0998663191894593e-07
Hp2 O 0 0.0002310801501153037
/ O 0 0.00017258241132367402
Hpdel O 0 7.429483957821503e-05
, O 0 2.01352762019269e-07
and O 0 8.389567796029951e-08
the O 0 7.005001378956877e-08
other O 0 1.1502293517651196e-07
child O 0 8.090912615443813e-07
to O 0 1.4448808371980704e-07
be O 0 1.3620092431665398e-07
Hp1 O 0 5.206553760217503e-05
and O 0 1.0869966899917927e-06
Hp1 O 0 0.0010965894907712936
/ O 0 0.0002773494925349951
Hpdel O 0 0.00011579912825254723
, O 0 4.0334023765353777e-07
showing O 0 1.0271562587149674e-06
an O 0 3.124852128166822e-07
anomalous O 0 6.4948653744068e-05
inheritance O 0 1.1770714991143905e-05
of O 0 6.318047098829993e-07
Hp O 0 0.04696791246533394
phenotypes O 0 9.758307714946568e-05
in O 0 4.556920600862213e-07
the O 0 6.965769330236071e-07
child O 0 5.136525032867212e-06
with O 0 8.889748642104678e-06
Hp1 O 0 0.02978525310754776
. O 0 6.158296309877187e-05

The O 0 7.141574315028265e-05
Hp2 O 0 0.018813464790582657
/ O 0 0.049107447266578674
Hpdel O 0 0.00549329211935401
individuals O 0 4.867239113082178e-06
had O 0 8.941775604398572e-07
an O 0 3.575561322577414e-07
extremely O 0 1.7643936871536425e-06
low O 0 2.5931299205694813e-06
level O 0 5.86382611800218e-07
of O 0 3.0608458700953634e-07
Hp O 0 8.115593664115295e-05
( O 0 5.791393959952984e-07
mean O 0 6.565457510987471e-07
+ O 0 2.188365215261001e-05
/ O 0 1.9312343283672817e-05
- O 0 3.0598806915804744e-05
SD O 0 9.038151620188728e-05
= O 0 1.2749665074807126e-05
0 O 0 1.5054230289024417e-06
. O 0 3.430634194501181e-07
049 O 0 6.693127943435684e-05
+ O 0 6.77416319376789e-05
/ O 0 3.532093614921905e-05
- O 0 2.0345247321529314e-05
0 O 0 3.275896460763761e-06
. O 0 7.175128189373936e-07
043 O 0 0.0001158800077973865
mg O 0 0.00035889772698283195
/ O 0 9.223693632520735e-05
ml O 0 0.00027380313258618116
; O 0 1.7655247575021349e-06
n O 0 2.1315272533684038e-05
= O 0 3.135355655103922e-05
6 O 0 4.897027338301996e-06
) O 0 3.6272328429731715e-07
, O 0 1.076956195333878e-07
compared O 0 1.8013756175605522e-07
with O 0 6.308894739959214e-08
the O 0 8.20415380076156e-08
level O 0 2.777759391392465e-07
( O 0 1.750089353436124e-07
1 O 0 2.16427849863976e-07
. O 0 9.362327091366751e-08
64 O 0 4.935294555252767e-07
+ O 0 2.377667260589078e-05
/ O 0 1.0091335752804298e-05
- O 0 5.7343804655829445e-06
1 O 0 9.113372243518825e-07
. O 0 2.009669799463154e-07
07 O 0 1.5609912225045264e-05
mg O 0 0.00018546750652603805
/ O 0 6.058556027710438e-05
ml O 0 0.00012954173143953085
) O 0 3.6318263596513134e-07
obtained O 0 3.7190659440966556e-07
from O 0 1.8398533541130746e-07
52 O 0 5.776666966994526e-06
healthy O 0 5.3586090871249326e-06
volunteers O 0 3.364999429322779e-06
having O 0 2.0224740637786454e-06
phenotype O 0 0.0002728222752921283
Hp2 O 0 0.00016818255244288594
, O 0 7.771847663207154e-07
whereas O 0 8.573509830966941e-07
the O 0 2.0778759335371433e-07
serum O 0 7.4076338023587596e-06
Hp O 0 2.3592428988195024e-05
level O 0 3.4631872836143884e-07
of O 0 7.00370534900685e-08
an O 0 1.1916033315628738e-07
individual O 0 3.0843816034575866e-07
with O 0 9.807984042708995e-07
Hp1 O 0 0.010566594079136848
/ O 0 0.00037444455665536225
Hpdel O 0 0.00018793802883010358
was O 0 2.651628165040165e-06
0 O 0 2.0992943973396905e-05
. O 0 1.73078260559123e-05

50 O 0 0.0002620661398395896
mg O 0 0.06920793652534485
/ O 0 0.013916741125285625
ml O 0 0.0069664837792515755
, O 0 9.853227993517066e-07
which O 0 1.9404632212172146e-07
was O 0 1.3158813771951827e-07
approximately O 0 1.0241421222190183e-07
half O 0 8.916946825365812e-08
the O 0 4.8656797702051335e-08
level O 0 1.7021010023654526e-07
of O 0 1.009382160077621e-07
Hp O 0 2.6560410333331674e-05
in O 0 4.145074115058378e-07
control O 0 1.4096898439674987e-06
sera O 0 2.846131792466622e-05
from O 0 2.5857463015199755e-07
the O 0 2.910861383043084e-07
Hp1 O 0 0.002114685019478202
phenotype O 0 0.0008395355544053018
( O 0 5.20474770837609e-07
1 O 0 4.3908318048124784e-07
. O 0 1.8560972137038334e-07
26 O 0 1.409821607012418e-06
+ O 0 6.0366357502061874e-05
/ O 0 3.0289813366835006e-05
- O 0 2.1256688341964036e-05
0 O 0 2.280734634041437e-06
. O 0 1.7962771892143792e-07
33 O 0 1.444517351956165e-06
mg O 0 0.00010809716332005337
/ O 0 4.886235183221288e-05
ml O 0 0.00011261068721069023
; O 0 7.706118481110025e-07
n O 0 1.1175830877618864e-05
= O 0 1.8184553482569754e-05
9 O 0 1.3714553688259912e-06
) O 0 2.3258370163148356e-07
, O 0 1.1062196136890634e-07
showing O 0 5.501677264874161e-07
a O 0 8.839616612021928e-07
gene O 0 2.1750414816779085e-05
- O 0 0.0013245377922430634
dosage O 0 0.0005157317500561476
effect O 0 4.073313175467774e-05
. O 0 1.6310728824464604e-05

The O 0 2.481668343534693e-05
other O 0 8.895201972336508e-06
allele O 0 4.123126927879639e-05
( O 0 5.0326725613558665e-06
Hp2 O 0 0.0001893398875836283
) O 0 8.211744670916232e-07
of O 0 1.9271148232746782e-07
individuals O 0 3.263011194576393e-07
with O 0 6.233437943592435e-07
Hp2 O 0 0.02952921763062477
/ O 0 0.0022765472531318665
Hpdel O 0 0.00022569912835024297
was O 0 5.004674221709138e-07
found O 0 2.1985916021094454e-07
to O 0 9.643282794513652e-08
have O 0 6.430136778590168e-08
, O 0 1.0246032644545267e-07
in O 0 8.376616733585251e-08
all O 0 7.442917393518655e-08
exons O 0 1.975510167540051e-05
, O 0 4.755601139549981e-07
no O 0 5.042849124947679e-07
mutation O 0 2.281739625686896e-06
, O 0 2.2664103482838982e-07
by O 0 6.512165668937087e-07
DNA O 0 1.964220246009063e-05
sequencing O 0 3.296195063740015e-05
. O 0 1.2110235729778651e-05

On O 0 1.9449131286819465e-05
the O 0 2.414391246929881e-06
basis O 0 1.1139057960463106e-06
of O 0 2.2108706332346628e-07
the O 0 3.4518146208029066e-07
present O 0 9.12627911020536e-07
study O 0 1.0895591913140379e-06
, O 0 1.9057971201164037e-07
the O 0 1.011235966075219e-07
mechanism O 0 3.1824666280044767e-07
of O 0 1.3439633050893462e-07
anhaptoglobinemia B-Disease 0 0.0001507078850409016
and O 0 1.974109977709304e-07
the O 0 8.06070801218084e-08
mechanism O 0 7.195699254225474e-07
of O 0 3.6800798852709704e-07
anomalous O 0 0.00016706054157111794
inheritance O 0 1.6159325241460465e-05
of O 0 1.1102671351181925e-06
Hp O 0 0.015295276418328285
phenotypes O 0 0.00019733623776119202
were O 0 5.842168775416212e-07
well O 0 1.3451317499857396e-06
explained O 0 1.8520850062486716e-05
. O 0 1.408036314387573e-05

However O 0 7.931634900160134e-05
, O 0 5.7991983339888975e-06
the O 0 1.8146434968002723e-06
mechanism O 0 7.378979262284702e-06
of O 0 3.7977779356879182e-06
hypohaptoglobinemia B-Disease 0 0.01692171022295952
remains O 0 0.00014098227256909013
unknown O 0 0.000127556748338975

ATM O 0 0.12389584630727768
mutations O 0 0.008862252347171307
and O 0 7.108167483238503e-05
phenotypes O 0 0.03159826993942261
in O 0 0.00025516425375826657
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999920129776001
telangiectasia I-Disease 1 0.9999998807907104
families O 0 4.060022547491826e-05
in O 0 6.352878472171142e-07
the O 0 4.2527011601123377e-07
British O 0 3.7109355162101565e-06
Isles O 0 3.5779961763182655e-05
: O 0 9.15377142973739e-07
expression O 0 8.483377200718678e-07
of O 0 1.8936893297905044e-07
mutant O 0 3.9737183215038385e-06
ATM O 0 4.5939552364870906e-05
and O 0 5.084703502689081e-07
the O 0 8.117390279949177e-07
risk O 0 4.851694393437356e-05
of O 0 2.571106051618699e-05
leukemia B-Disease 1 0.9999996423721313
, O 1 0.5001401901245117
lymphoma B-Disease 1 1.0
, O 0 0.0012696424964815378
and O 0 0.03875308856368065
breast B-Disease 1 0.9999475479125977
cancer I-Disease 1 0.8574508428573608
. O 0 4.4123295083409175e-05

We O 0 2.9097091100993566e-05
report O 0 1.0320410183339845e-05
the O 0 1.0158345276067848e-06
spectrum O 0 4.670060206990456e-06
of O 0 5.740207029703015e-07
59 O 0 3.459447543718852e-05
ATM O 0 0.006285546347498894
mutations O 0 0.0001926781696965918
observed O 0 9.637850780563895e-06
in O 0 1.8069387806463055e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999904632568359
telangiectasia I-Disease 1 0.9999998807907104
( O 0 3.584690057323314e-05
A B-Disease 0 0.0007726214826107025
- I-Disease 1 0.999667763710022
T I-Disease 1 0.9999996423721313
) O 0 9.335997310699895e-05
patients O 0 5.19994500791654e-05
in O 0 4.546203058453102e-07
the O 0 8.277673941847752e-07
British O 0 2.770563878584653e-05
Isles O 0 0.0007227151072584093
. O 0 4.4065516703994945e-05

Of O 0 2.805660551530309e-05
51 O 0 0.00012365655857138336
ATM O 0 0.002845684764906764
mutations O 0 0.00012733291077893227
identified O 0 3.6486117096501403e-06
in O 0 2.635463260958204e-07
families O 0 5.390224373513774e-07
native O 0 9.45155079534743e-07
to O 0 1.8412524127597862e-07
the O 0 1.8443928695432987e-07
British O 0 3.043781362066511e-06
Isles O 0 4.341316525824368e-05
, O 0 7.465180260624038e-07
11 O 0 7.631083462911192e-07
were O 0 1.6374674771668651e-07
founder O 0 4.278841879568063e-05
mutations O 0 7.72293788031675e-06
, O 0 1.0101217640112736e-07
and O 0 1.1539859201548097e-07
2 O 0 6.893833983667719e-07
of O 0 7.869463303222801e-08
these O 0 1.4222818833786732e-07
11 O 0 2.3797492758603767e-06
conferred O 0 1.8922963135992177e-05
a O 0 7.578679287689738e-06
milder O 1 0.9844142198562622
clinical O 0 0.18836930394172668
phenotype O 0 0.008776561357080936
with O 0 4.6818141186122375e-07
respect O 0 5.727706025027146e-07
to O 0 4.909896915705758e-07
both O 0 3.794794793066103e-06
cerebellar B-Disease 1 0.9752563238143921
degeneration I-Disease 1 0.9959303736686707
and O 0 1.4299638678494375e-05
cellular O 0 0.0001846413651946932
features O 0 2.2345713659888133e-05
. O 0 2.682458216440864e-05

We O 0 5.9996589698130265e-05
report O 0 1.90236751222983e-05
, O 0 7.207732437564118e-07
in O 0 2.820222277932771e-07
two O 0 4.352762630333018e-07
A B-Disease 0 0.0007926970138214529
- I-Disease 1 0.9996100068092346
T I-Disease 1 0.9999974966049194
families O 0 8.366368092538323e-06
, O 0 4.1451176002738066e-07
an O 0 3.102101970853255e-07
ATM O 0 0.0001245507155545056
mutation O 0 7.779494808346499e-06
( O 0 6.140913342278509e-07
7271T O 0 1.63186778081581e-05
- O 0 0.00018106019706465304
- O 0 0.012543154880404472
> O 0 0.0011644745245575905
G O 0 0.012652505189180374
) O 0 8.242115541179373e-07
that O 0 1.0626971658211914e-07
may O 0 5.609653044302831e-07
be O 0 6.033691590801027e-08
associated O 0 2.496105935279047e-07
with O 0 1.4630285249950248e-07
an O 0 7.059443305479363e-07
increased O 0 1.9606080968515016e-05
risk O 0 5.791399235022254e-05
of O 0 1.96351593331201e-05
breast B-Disease 1 0.9997692704200745
cancer I-Disease 1 0.6331793069839478
in O 0 1.292892648052657e-06
both O 0 1.0044615237347898e-06
homozygotes O 0 0.004015618469566107
and O 0 3.5385421597311506e-06
heterozygotes O 0 0.0002611743984743953
( O 0 1.5551653405054822e-06
relative O 0 4.676580374507466e-06
risk O 0 1.007026276056422e-05
12 O 0 1.2881727116109687e-06
. O 0 3.6167807593301404e-07
7 O 0 4.056055331602693e-06
; O 0 3.485982460915693e-06
P O 0 0.023910120129585266
= O 0 0.0005175193073228002
. O 0 1.6597914509475231e-06
0025 O 0 0.0002497982350178063
) O 0 6.771205676159298e-07
, O 0 1.5327582048030308e-07
although O 0 1.5913437323433755e-07
there O 0 4.424247990186814e-08
is O 0 1.3498321038696304e-07
a O 0 1.0508999821468024e-06
less O 0 2.6664234610507265e-05
severe O 0 0.16617652773857117
A B-Disease 0 0.12436357140541077
- I-Disease 1 0.9999926090240479
T I-Disease 1 0.9999998807907104
phenotype O 0 0.17480121552944183
in O 0 3.3742981031537056e-07
terms O 0 3.4464599707462185e-07
of O 0 1.214145299854863e-07
the O 0 6.153893536975374e-07
degree O 0 2.1805593860335648e-05
of O 0 1.935631917149294e-05
cerebellar B-Disease 1 0.9997304081916809
degeneration I-Disease 1 0.9998741149902344
. O 0 0.0001460150961065665

This O 0 4.587007424561307e-05
mutation O 0 0.00010880058107431978
( O 0 7.626262686244445e-06
7271T O 0 0.00010906526586040854
- O 0 0.0004982235841453075
- O 0 0.002117722062394023
> O 0 0.00015825712762307376
G O 0 0.00030260710627771914
) O 0 4.031137450510869e-07
also O 0 8.572450127530828e-08
allows O 0 1.4105383172591246e-07
expression O 0 1.3199448289924476e-07
of O 0 3.3643335228816795e-08
full O 0 2.693292913136247e-07
- O 0 4.138977146794787e-06
length O 0 6.10934080214065e-07
ATM O 0 7.3364717536605895e-06
protein O 0 3.649805080385704e-07
at O 0 5.5087230776962315e-08
a O 0 9.446381454836228e-08
level O 0 2.916287940024631e-07
comparable O 0 1.2341234878476826e-06
with O 0 3.85719090445491e-07
that O 0 5.610006041933957e-07
in O 0 3.6416624880075688e-06
unaffected O 0 0.00040217131027020514
individuals O 0 1.3331919944903348e-05
. O 0 2.2815895135863684e-05

In O 0 3.6368361179484054e-05
addition O 0 8.484683348797262e-06
, O 0 1.179207060886256e-06
we O 0 2.616829988255631e-07
have O 0 1.3073568538857216e-07
studied O 0 1.0037642823590431e-06
18 O 0 3.7388495002232958e-06
A B-Disease 0 0.01675291731953621
- I-Disease 1 0.9999978542327881
T I-Disease 1 1.0
patients O 0 0.13456562161445618
, O 0 7.700123774156964e-07
in O 0 3.032618280940369e-07
15 O 0 1.122064304581727e-06
families O 0 1.1109439128631493e-06
, O 0 1.5134656905502197e-06
who O 0 1.1613642527663615e-05
developed O 0 0.032248105853796005
leukemia B-Disease 1 0.9999985694885254
, O 0 0.10159792751073837
lymphoma B-Disease 1 1.0
, O 0 4.675302261603065e-05
preleukemic O 1 0.5649687647819519
T O 1 0.9720478653907776
- O 0 0.23211689293384552
cell O 0 0.006420584861189127
proliferation O 0 0.00011329658445902169
, O 0 4.1595494622015394e-06
or O 0 0.0012951029930263758
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 5.542324288398959e-05
mostly O 0 5.687270913767861e-06
in O 0 5.072003204986686e-06
childhood O 0 0.0001698933047009632
. O 0 3.771617411985062e-05

A O 0 8.078393148025498e-05
wide O 0 2.877396582334768e-05
variety O 0 6.438362561311806e-06
of O 0 2.2911988253326854e-06
ATM O 0 0.0011835909681394696
mutation O 0 3.4160231734858826e-05
types O 0 1.8851659433494206e-06
, O 0 5.011742700844479e-07
including O 0 1.180235358333448e-06
missense O 0 0.0005154346581548452
mutations O 0 2.2860629542265087e-05
and O 0 2.6672515218706394e-07
in O 0 2.2809665267686796e-07
- O 0 7.391084363916889e-05
frame O 0 4.13488014601171e-05
deletions O 0 1.3541218322643545e-05
, O 0 2.778246823709196e-07
were O 0 1.0056118782131307e-07
seen O 0 8.218560765271832e-07
in O 0 6.306019599833235e-07
these O 0 2.4250800834124675e-06
patients O 0 0.00022003853518981487
. O 0 2.1980264136800542e-05

We O 0 2.5308694603154436e-05
also O 0 4.648944013752043e-06
show O 0 1.6037253089962178e-06
that O 0 2.4639007278892677e-07
25 O 0 4.3198073740313703e-07
% O 0 2.5545929815962154e-07
of O 0 8.806038209741018e-08
all O 0 1.5962409349867812e-07
A B-Disease 0 0.00041193090146407485
- I-Disease 1 0.9999817609786987
T I-Disease 1 1.0
patients O 0 0.0027767254505306482
carried O 0 6.892295232319157e-07
in O 0 2.8815287578254356e-07
- O 0 2.613348260638304e-05
frame O 0 1.8215985619463027e-05
deletions O 0 2.005483111133799e-05
or O 0 2.081621687466395e-06
missense O 0 0.0004131441528443247
mutations O 0 2.7327640054863878e-05
, O 0 1.4475800469426758e-07
many O 0 4.5208370380578344e-08
of O 0 7.621645181643544e-08
which O 0 1.7382329531301366e-07
were O 0 1.0950180495683526e-07
also O 0 4.207418839996535e-07
associated O 0 6.711276228088536e-07
with O 0 2.314395430857985e-07
expression O 0 1.3078284837320098e-06
of O 0 5.440059567263233e-07
mutant O 0 2.0076493456144817e-05
ATM O 0 0.00018026659381575882
protein O 0 4.122041355003603e-05
. O 0 2.0575784219545312e-05

The O 0 6.119210593169555e-05
DMPK O 0 0.00612421240657568
gene O 0 8.206859638448805e-05
of O 0 1.3603709703602362e-05
severely O 0 0.4582551121711731
affected O 0 0.40625226497650146
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9894995093345642
is O 0 5.377212346502347e-06
hypermethylated O 0 0.0024034029338508844
proximal O 0 0.0003683576360344887
to O 0 9.24618404951616e-07
the O 0 9.811229801925947e-07
largely O 0 8.463518497592304e-06
expanded O 0 2.8348200430627912e-05
CTG O 0 0.002542294329032302
repeat O 0 0.00045947189209982753
. O 0 3.5903151001548395e-05

Using O 0 6.852146179880947e-05
methylation O 0 0.00014854923938401043
- O 0 0.00024202343774959445
sensitive O 0 1.5221001376630738e-05
restriction O 0 3.1158347155724186e-06
enzymes O 0 7.004238796071149e-06
, O 0 5.078786102785671e-07
we O 0 2.2833866353266785e-07
characterized O 0 3.529533159962739e-06
the O 0 3.025434125447646e-07
methylation O 0 7.658046342839953e-06
pattern O 0 5.240311566012679e-06
on O 0 2.5689459448585694e-07
the O 0 1.057159906281413e-07
5 O 0 5.37958385393722e-07
side O 0 2.3165196694208134e-07
of O 0 9.080061857957844e-08
the O 0 3.162066946060804e-07
CTG O 0 0.0008225897327065468
repeat O 0 2.3987293388927355e-05
in O 0 2.455901153552986e-07
the O 0 2.1281779538639967e-07
DMPK O 0 0.00024751469027251005
gene O 0 1.1892856264239526e-06
of O 0 9.969263459197464e-08
normal O 0 1.2986326964892214e-06
individuals O 0 2.39558772818782e-07
and O 0 2.991353369452554e-07
of O 0 1.792613034012902e-06
patients O 0 0.004612358286976814
affected O 0 3.3812593756010756e-05
with O 0 0.00029540230752900243
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
, O 0 1.086170959752053e-05
showing O 0 5.579876415140461e-06
expansions O 0 7.521818133682245e-06
of O 0 3.442104059558915e-07
the O 0 1.2018341521979892e-06
repetitive O 0 0.000252246594754979
sequence O 0 2.3687023713137023e-05
. O 0 1.9174065528204665e-05

The O 0 5.897569644730538e-05
gene O 0 5.418142245616764e-05
segment O 0 2.2252164853853174e-05
analyzed O 0 1.3204538845457137e-05
corresponds O 0 4.638771315512713e-06
to O 0 4.5490656930269324e-07
the O 0 5.821723334520357e-07
genomic O 0 1.0356417078583036e-05
SacI O 0 0.00012077027349732816
- O 0 4.9856538680614904e-05
HindIII O 0 5.70606098335702e-05
fragment O 0 3.850527718896046e-06
carrying O 0 1.2724901807814604e-06
exons O 0 1.4022232790011913e-05
11 O 0 3.3351850561302854e-06
- O 0 5.157945633982308e-05
15 O 0 8.964616426965222e-06
. O 0 1.7164820746984333e-05

There O 0 2.215252425230574e-05
is O 0 4.121669007872697e-06
constitutive O 0 5.7840425142785534e-05
methylation O 0 2.4479595595039427e-05
in O 0 1.2289171991142211e-06
intron O 0 8.564619201933965e-05
12 O 0 1.7374816252413439e-06
at O 0 2.5020835892064497e-07
restriction O 0 2.4102953943838656e-07
sites O 0 1.3839316181929462e-07
of O 0 6.25596712211518e-08
SacII O 0 2.6879075448960066e-05
and O 0 7.736788347756374e-07
HhaI O 0 0.00011294935393380001
, O 0 4.693661139754113e-07
localized O 0 3.8359912650776096e-06
1 O 0 7.238696184685978e-07
, O 0 1.9318237320931075e-07
159 O 0 2.8538381684484193e-06
- O 0 2.451063846820034e-05
1 O 0 1.3890476111555472e-06
, O 0 2.7872857799593476e-07
232 O 0 3.1279223549063317e-06
bp O 0 6.0039281379431486e-05
upstream O 0 1.3563375205194461e-06
of O 0 1.1313473891050307e-07
the O 0 2.780446948236204e-07
CTG O 0 0.0009449499193578959
repeat O 0 3.9078073314158246e-05
, O 0 3.477962309261784e-07
whereas O 0 6.553859748237301e-07
most O 0 9.217001917249945e-08
, O 0 1.3144502020168147e-07
if O 0 7.298498871932679e-08
not O 0 3.6776867773369304e-08
all O 0 2.1642078351646887e-08
, O 0 4.0214835905771906e-08
of O 0 2.9019298963817164e-08
the O 0 5.282410953100225e-08
other O 0 6.384650674817749e-08
sites O 0 1.8807720891800273e-07
of O 0 8.577225685257872e-08
SacII O 0 0.00011034338240278885
, O 0 6.191438615132938e-07
HhaI O 0 6.4318192016799e-05
, O 0 2.3003477167549136e-07
and O 0 2.1119645055023284e-07
HpaII O 0 7.563481631223112e-05
in O 0 2.3214825262130034e-07
this O 0 1.2601344678841997e-07
region O 0 3.7886836707912153e-06
are O 0 2.1943685624137288e-07
unmethylated O 0 7.836746226530522e-05
, O 0 4.4991773506808386e-07
in O 0 2.4661787279001146e-07
normal O 0 1.3596502412838163e-06
individuals O 0 2.985866842664109e-07
and O 0 2.3089523892849684e-07
most O 0 2.7692581738847366e-07
of O 0 5.359153760764457e-07
the O 0 9.198943189403508e-06
patients O 0 0.0009086676291190088
. O 0 3.528720117174089e-05

In O 0 2.579323700047098e-05
a O 0 5.018744104745565e-06
number O 0 1.0168153039558092e-06
of O 0 4.7614142317797814e-07
young O 0 1.1615581570367794e-05
and O 0 1.3315452633833047e-05
severely O 0 0.31448689103126526
affected O 0 0.001031400403007865
patients O 0 0.0007260202546603978
, O 0 7.716899403931166e-07
however O 0 2.770848652744462e-07
, O 0 1.517373533488353e-07
complete O 0 1.155878635472618e-06
methylation O 0 2.6715081276051933e-06
of O 0 8.753221436563763e-08
these O 0 9.24986451877885e-08
restriction O 0 3.62047671842447e-07
sites O 0 3.009219256000506e-07
was O 0 1.9078611046552396e-07
found O 0 1.9940131323892274e-07
in O 0 3.063263704916608e-07
the O 0 1.3071289686195087e-06
mutated O 0 8.797412010608241e-05
allele O 0 7.744425238342956e-05
. O 0 2.2718602849636227e-05

In O 0 2.623336149554234e-05
most O 0 3.5950752135249786e-06
of O 0 1.4865386219753418e-06
these O 0 2.7272762963548303e-06
patients O 0 0.00023989856708794832
, O 0 7.355207571890787e-07
the O 0 8.566595397496712e-07
onset O 0 0.0025330574717372656
of O 0 1.5433087128258194e-06
the O 0 5.044151112088002e-05
disease O 1 0.5480160713195801
was O 0 0.00043118445319123566
congenital O 1 0.9999916553497314
. O 0 0.0001656192762311548

Preliminary O 0 0.0009769282769411802
in O 0 7.907731924206018e-05
vivo O 0 0.14248208701610565
footprinting O 0 0.4487179219722748
data O 0 1.4141294741421007e-05
gave O 0 3.3229555356228957e-06
evidence O 0 9.109843972510134e-07
for O 0 3.262180428009742e-07
protein O 0 2.437210468997364e-06
- O 0 9.106982179218903e-05
DNA O 0 9.778324056242127e-06
contact O 0 6.77474531585176e-07
in O 0 1.6915309686282853e-07
normal O 0 6.06300602612464e-07
genes O 0 5.799811901852081e-07
at O 0 1.217137537423696e-07
an O 0 1.4370519352269184e-07
Sp1 O 0 4.073635136592202e-05
consensus O 0 8.961752087088826e-07
binding O 0 7.943050377434702e-07
site O 0 3.5886412774743803e-07
upstream O 0 4.289470041385357e-07
of O 0 9.046248550248492e-08
the O 0 3.4135493365283764e-07
CTG O 0 0.00029049519798718393
repeat O 0 1.7591850337339565e-05
and O 0 1.813596952615626e-07
for O 0 1.2043706476561056e-07
a O 0 3.488542290597252e-07
significant O 0 6.7078849497193e-07
reduction O 0 7.712456863373518e-06
of O 0 1.2523042869361234e-07
this O 0 9.430629432927162e-08
interaction O 0 4.319890081205813e-07
in O 0 3.46031157505422e-07
cells O 0 4.960207206750056e-06
with O 0 3.1642602493775485e-07
a O 0 2.0074260191904614e-06
hypermethylated O 0 0.02975025214254856
DMPK O 0 0.09568285942077637
gene O 0 1.6240681361523457e-05
. O 0 1.949155830516247e-06
. O 0 1.0441316590004135e-05

The O 0 0.00023630291980225593
hemochromatosis B-Disease 1 0.9999651908874512
gene O 0 0.00021094377734698355
product O 0 1.545684426673688e-05
complexes O 0 6.036424565536436e-06
with O 0 5.002322041036678e-07
the O 0 5.542966050597897e-07
transferrin O 0 5.533985313377343e-05
receptor O 0 7.281170837813988e-06
and O 0 5.853919446963118e-07
lowers O 0 3.88119624403771e-05
its O 0 5.305473678163253e-07
affinity O 0 2.2638469090452418e-06
for O 0 6.606042575185711e-07
ligand O 0 4.103306127944961e-05
binding O 0 4.84599731862545e-05
. O 0 2.0128905816818587e-05

We O 0 5.916926238569431e-05
recently O 0 4.3736454244935885e-05
reported O 0 1.1441456081229262e-05
the O 0 7.926138323455234e-07
positional O 0 9.186966963170562e-06
cloning O 0 4.960756086802576e-06
of O 0 2.853956004855718e-07
a O 0 1.816601752580027e-06
candidate O 0 2.0791416318388656e-05
gene O 0 5.231738032307476e-05
for O 0 6.430188659578562e-05
hereditary B-Disease 1 0.9999986886978149
hemochromatosis I-Disease 1 1.0
called O 0 0.10931827872991562
HFE O 1 0.9170677661895752
. O 0 0.0001243473234353587

The O 0 4.663173240260221e-05
gene O 0 5.939901893725619e-05
product O 0 1.0091787771671079e-05
, O 0 8.355368095180893e-07
a O 0 4.5689657213188184e-07
member O 0 7.850990186852869e-07
of O 0 1.237237654549972e-07
the O 0 2.7637756261356117e-07
major O 0 1.8822340734914178e-06
histocompatibility O 0 0.0003324771241750568
complex O 0 3.143982212350238e-06
class O 0 1.6655569652357372e-06
I O 0 8.246817628787539e-07
- O 0 2.3962003979249857e-05
like O 0 3.762248752536834e-07
family O 0 9.678677770352806e-07
, O 0 2.444584197291988e-07
was O 0 1.1914521991229776e-07
found O 0 9.423706615052652e-08
to O 0 6.786735440300617e-08
have O 0 8.18332139829181e-08
a O 0 2.9687146252399543e-07
mutation O 0 2.9689572329516523e-06
, O 0 5.385096528698341e-07
Cys O 0 0.03642359748482704
- O 0 8.023102418519557e-05
282 O 0 2.9306143915164284e-05
- O 0 0.0002674703428056091
- O 0 0.0015152546111494303
> O 0 0.00013451835548039526
Tyr O 0 0.0006002239533700049
( O 0 7.964767974044662e-07
C282Y O 0 1.7226477211806923e-05
) O 0 5.15224598984787e-07
, O 0 1.3722467429033713e-07
in O 0 1.2543553395971685e-07
85 O 0 2.2585531951335724e-06
% O 0 1.8593672166389297e-06
of O 0 2.104673285430181e-06
patient O 0 0.0002523861185181886
chromosomes O 0 0.00016872094420250505
. O 0 4.4129523303126916e-05

This O 0 5.5808712204452604e-05
mutation O 0 8.35717873997055e-05
eliminates O 0 4.180559699307196e-05
the O 0 1.0354453934269259e-06
ability O 0 1.9616857116488973e-06
of O 0 4.423134498665604e-07
HFE O 0 0.0004298300191294402
to O 0 7.186783932411345e-07
associate O 0 4.31732996730716e-06
with O 0 8.570019645048887e-07
beta2 O 0 0.01828763820230961
- O 0 0.028726588934659958
microglobulin O 0 0.011926625855267048
( O 0 1.3829278486809926e-06
beta2m O 0 4.346071364125237e-05
) O 0 5.080937057755364e-07
and O 0 5.094717039355601e-07
prevents O 0 6.0137231230328325e-06
cell O 0 5.6156735809054226e-05
- O 0 0.0003197695186827332
surface O 0 7.681013084948063e-05
expression O 0 2.8671765903709456e-05
. O 0 1.6469221009174362e-05

A O 0 8.4317522123456e-05
second O 0 4.3959869799437e-05
mutation O 0 4.0360271668760106e-05
that O 0 6.902793643348559e-07
has O 0 5.247890726423066e-07
no O 0 3.838995894511754e-07
effect O 0 1.0049664069811115e-06
on O 0 8.788601348896918e-07
beta2m O 0 0.009947451762855053
association O 0 4.888106559519656e-06
, O 0 5.234330160419631e-07
H63D O 0 0.00035807699896395206
, O 0 4.939381597068859e-07
was O 0 1.8634716525411932e-07
found O 0 1.1158339674466333e-07
in O 0 6.125821983005153e-08
eight O 0 1.3508687857211044e-07
out O 0 1.1716667813743697e-07
of O 0 3.33377471406493e-07
nine O 0 2.5906734663294628e-05
patients O 0 7.917827315395698e-05
heterozygous O 0 2.3908662569738226e-06
for O 0 3.513875412863854e-07
the O 0 1.3792766822007252e-06
C282Y O 0 0.000293757941108197
mutant O 0 0.00013329666398931295
. O 0 2.743221375567373e-05

In O 0 4.8898848035605624e-05
this O 0 4.5655001486011315e-06
report O 0 6.885082257213071e-06
, O 0 7.252170348692744e-07
we O 0 3.4332688869653794e-07
demonstrate O 0 1.7173346122945077e-06
in O 0 9.437104040443955e-07
cultured O 0 0.0001914152380777523
293 O 0 0.0002537592954467982
cells O 0 0.0001823452184908092
overexpressing O 0 0.0006201665964908898
wild O 0 5.421097284852294e-06
- O 0 8.326171519001946e-05
type O 0 2.9474035727616865e-06
or O 0 5.662547550855379e-07
mutant O 0 5.502944077306893e-06
HFE O 0 0.0002434899506624788
proteins O 0 7.895018825365696e-07
that O 0 8.356158787137247e-08
both O 0 6.40747543911857e-08
the O 0 1.0674813211153378e-07
wild O 0 2.6463080757821444e-06
- O 0 0.0001380689936922863
type O 0 3.3811797948146705e-06
and O 0 1.152697336692654e-06
H63D O 0 0.0015472957165911794
HFE O 0 0.0010551830055192113
proteins O 0 1.5130817700992338e-06
form O 0 5.677563876815839e-07
stable O 0 4.472649834497133e-06
complexes O 0 2.6670227271097247e-06
with O 0 2.4886045935090806e-07
the O 0 6.246511929930421e-07
transferrin O 0 0.0004448514664545655
receptor O 0 4.425806400831789e-05
( O 0 6.643857432209188e-06
TfR O 0 0.0001553012989461422
) O 0 8.95753146323841e-06
. O 0 1.522506499895826e-05

The O 0 6.148855027277023e-05
C282Y O 0 0.001283210120163858
mutation O 0 0.00010645901056705043
nearly O 0 5.173001682123868e-06
completely O 0 7.191692020569462e-06
prevents O 0 4.923138021695195e-06
the O 0 3.1261100730262115e-07
association O 0 6.466302124863432e-07
of O 0 1.3278877020184154e-07
the O 0 3.586492880458536e-07
mutant O 0 1.8236305550090037e-05
HFE O 0 0.0008184110629372299
protein O 0 4.539156179816928e-06
with O 0 1.0643987025105162e-06
the O 0 5.190454430703539e-06
TfR O 0 0.0008582129958085716
. O 0 2.2906111553311348e-05

Studies O 0 0.0003471850941423327
on O 0 1.8247927073389292e-05
cell O 0 0.0003187459078617394
- O 0 0.0008059703977778554
associated O 0 1.4731099327036645e-05
transferrin O 0 7.11490138201043e-05
at O 0 1.149872218775272e-06
37 O 0 4.1443449845246505e-06
degrees O 0 2.2304473532130942e-05
C O 0 8.012008765945211e-05
suggest O 0 2.4217567897721892e-06
that O 0 1.383110799224596e-07
the O 0 3.582131000712252e-07
overexpressed O 0 6.953921547392383e-05
wild O 0 5.052046617493033e-06
- O 0 0.0001248001353815198
type O 0 9.41863254411146e-06
HFE O 0 0.00038084015250205994
protein O 0 4.605222784448415e-06
decreases O 0 1.6674258631610428e-06
the O 0 1.6565482496844197e-07
affinity O 0 9.631993407310802e-07
of O 0 2.5745407583599444e-07
the O 0 6.280943694036978e-07
TfR O 0 0.0001357529399683699
for O 0 3.706906682054978e-06
transferrin O 0 0.000717342016287148
. O 0 2.4592727640992962e-05

The O 0 8.680289465701208e-05
overexpressed O 0 0.002338818274438381
H63D O 0 0.008326685056090355
protein O 0 5.6060853239614516e-05
does O 0 2.268188382004155e-06
not O 0 3.1293194524550927e-07
have O 0 1.1434690350142773e-07
this O 0 1.0329604549497162e-07
effect O 0 6.312746450021223e-07
, O 0 1.3417133004622883e-07
providing O 0 2.4397911602136446e-07
the O 0 7.238676857923565e-08
first O 0 1.863818255287697e-07
direct O 0 3.6036664141647634e-07
evidence O 0 4.4169379975755874e-07
for O 0 1.1783330222669974e-07
a O 0 4.4785005570702197e-07
functional O 0 5.938176855124766e-06
consequence O 0 2.826980335157714e-06
of O 0 3.4228366985189496e-07
the O 0 2.1784435375593603e-06
H63D O 0 0.21094602346420288
mutation O 0 0.00018922871095128357
. O 0 1.855847040133085e-05

Addition O 0 6.860999565105885e-05
of O 0 1.0450230547576211e-05
soluble O 0 0.0006683442043140531
wild O 0 4.7018518671393394e-05
- O 0 0.000728533836081624
type O 0 3.740543979802169e-05
HFE O 0 0.0036833719350397587
/ O 0 0.000333071977365762
beta2m O 0 0.00020634278189390898
heterodimers O 0 0.0001564476842759177
to O 0 1.206312504109519e-06
cultured O 0 0.0002878170053008944
cells O 0 5.209345181356184e-05
also O 0 6.014176960889017e-07
decreased O 0 2.1639968963427236e-06
the O 0 1.6598121987954073e-07
apparent O 0 2.9589591576950625e-06
affinity O 0 1.03222726011154e-06
of O 0 1.2054321985033312e-07
the O 0 2.2060919491195818e-07
TfR O 0 1.9437151422607712e-05
for O 0 1.2213828881613153e-07
its O 0 3.014409344359592e-07
ligand O 0 3.727588364199619e-06
under O 0 3.008163105278072e-07
steady O 0 5.93480854149675e-06
- O 0 8.030044409679249e-05
state O 0 7.081580406520516e-07
conditions O 0 8.419354344368912e-06
, O 0 3.311094758373656e-07
both O 0 2.0651178544994764e-07
in O 0 5.666215656674467e-07
293 O 0 4.952257586410269e-05
cells O 0 3.676021515275352e-05
and O 0 9.621785466151778e-07
in O 0 6.811199909861898e-06
HeLa O 0 0.09285611659288406
cells O 0 0.0006640655337832868
. O 0 2.8384691177052446e-05

Furthermore O 0 0.0002856932987924665
, O 0 1.1016774806194007e-05
at O 0 2.2533315586770186e-06
4 O 0 4.029114279546775e-06
degrees O 0 2.167688035115134e-05
C O 0 4.9208145355805755e-05
, O 0 4.910140773972671e-07
the O 0 2.2527912335590372e-07
added O 0 9.822417723626131e-07
soluble O 0 2.4182316337828524e-05
complex O 0 1.9108413198409835e-06
of O 0 5.780937613053538e-07
HFE O 0 0.008019527420401573
/ O 0 0.00038021025829948485
beta2m O 0 0.0003054834669455886
inhibited O 0 1.1928365893254522e-05
binding O 0 1.7085149011109024e-06
of O 0 2.990782945744286e-07
transferrin O 0 2.125206810887903e-05
to O 0 8.954438612818194e-07
HeLa O 0 0.0007608580635860562
cell O 0 5.597025665338151e-05
TfR O 0 3.421457586227916e-05
in O 0 4.914554097013024e-07
a O 0 1.0857171446332359e-06
concentration O 0 3.9372273022308946e-05
- O 0 0.000542264839168638
dependent O 0 6.692241004202515e-05
manner O 0 3.192891017533839e-05
. O 0 2.7707250410458073e-05

Scatchard O 0 0.002068971050903201
plots O 0 0.00016225715808104724
of O 0 4.785934379469836e-06
these O 0 1.2802170203940477e-06
data O 0 2.0484601463977015e-06
indicate O 0 1.2674953495661612e-06
that O 0 1.1648627662452782e-07
the O 0 1.4348225363391975e-07
added O 0 8.065219958552916e-07
heterodimer O 0 4.018498657387681e-05
substantially O 0 3.94703829442733e-06
reduced O 0 9.67802293416753e-07
the O 0 1.7447032973905152e-07
affinity O 0 1.8298231907465379e-06
of O 0 8.958231774158776e-07
TfR O 0 0.00011580443242564797
for O 0 4.6044278860790655e-06
transferrin O 0 0.0006815106607973576
. O 0 3.533474955474958e-05

These O 0 5.05142415931914e-05
results O 0 3.076221764786169e-05
establish O 0 6.436152489186497e-06
a O 0 2.3215832243295154e-06
molecular O 0 2.536300780775491e-05
link O 0 6.8302915678941645e-06
between O 0 1.109943127630686e-06
HFE O 0 0.001224403502419591
and O 0 4.1281501239609497e-07
a O 0 2.7313163286635245e-07
key O 0 1.7762640709406696e-06
protein O 0 2.314319090146455e-06
involved O 0 3.3689124734337383e-07
in O 0 3.2439137953588215e-07
iron O 0 7.751068187644705e-05
transport O 0 1.8820774130290374e-05
, O 0 3.44457674827936e-07
the O 0 1.897948891382839e-07
TfR O 0 4.0499686292605475e-05
, O 0 2.9169194704081747e-07
and O 0 2.1142398054507794e-07
raise O 0 8.076373205767595e-07
the O 0 1.7704468291412923e-07
possibility O 0 7.904029644123511e-07
that O 0 1.6600290564383613e-07
alterations O 0 4.776472906087292e-06
in O 0 3.622866699970473e-07
this O 0 2.7568523819354596e-07
regulatory O 0 1.735205114528071e-05
mechanism O 0 4.76453942610533e-06
may O 0 1.0208525509369792e-06
play O 0 1.40045315788484e-07
a O 0 2.23400050458622e-07
role O 0 6.245916210900759e-07
in O 0 4.631834258361778e-07
the O 0 1.599103939042834e-06
pathogenesis O 0 0.025618722662329674
of O 0 4.3144151277374476e-05
hereditary B-Disease 1 0.9999996423721313
hemochromatosis I-Disease 1 1.0
. O 0 8.523726864950731e-05
. O 0 3.251307862228714e-05

Genomic O 0 0.0012290867744013667
organization O 0 5.0492370064603165e-05
of O 0 4.19889101976878e-06
the O 0 3.074266714975238e-06
UBE3A O 0 0.008313891477882862
/ O 0 0.0016086846590042114
E6 O 0 0.049539610743522644
- O 0 0.027681082487106323
AP O 0 0.0005560554563999176
gene O 0 7.795313649694435e-06
and O 0 1.8936760852739098e-06
related O 0 2.8289356123423204e-05
pseudogenes O 0 0.0003305331338196993
. O 0 2.3302327463170514e-05

The O 0 8.313193393405527e-05
UBE3A O 0 0.0027368925511837006
gene O 0 5.591440276475623e-05
encodes O 0 1.5665673345210962e-05
the O 0 1.3712094641959993e-06
E6 O 0 0.00033726022229529917
- O 0 0.00020901874813716859
AP O 0 5.0848837418016046e-05
ubiquitin O 0 7.923115845187567e-06
- O 0 1.7262987967114896e-05
protein O 0 1.5359452163465903e-06
ligase O 0 1.6348600411220104e-06
and O 0 1.0206379386090703e-07
has O 0 1.4467988762589812e-07
recently O 0 6.144609869807027e-07
been O 0 1.3633061257678492e-07
shown O 0 2.1206957967478957e-07
to O 0 2.1273216077588586e-07
be O 0 7.538195632150746e-07
mutated O 0 0.0006765974685549736
in O 0 0.07234223186969757
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9501277804374695
who O 0 9.739672350406181e-06
lack O 0 7.529368758696364e-06
15q11 O 0 0.0001879247574834153
- O 0 0.0004388641391415149
q13 O 0 0.00014104398724157363
deletions O 0 2.3409620553138666e-05
or O 0 1.7044009155142703e-06
chromosome O 0 2.6393612643005326e-05
15 O 0 8.822041309031192e-06
paternal O 0 0.00011135367094539106
uniparental B-Disease 0 0.11868082731962204
disomy I-Disease 0 0.062529057264328
. O 0 7.745969196548685e-05

Previous O 0 0.0003380427078809589
UBE3A O 0 0.0032326430082321167
cDNA O 0 0.0002876110083889216
analysis O 0 3.093590203206986e-05
has O 0 1.987000132430694e-06
shown O 0 1.1410293154767714e-06
a O 0 1.049739125846827e-06
coding O 0 8.785943646216765e-05
region O 0 5.150956894794945e-06
of O 0 6.02819966388779e-07
approximately O 0 2.189866563639953e-06
2 O 0 1.4812480003456585e-05
. O 0 1.61299485625932e-05

6 O 0 0.00039592431858181953
kb O 0 0.0016324501484632492
and O 0 3.79352104573627e-06
a O 0 1.6580432884438778e-06
3 O 0 1.1264482964179479e-05
- O 0 0.0018730286974459887
untranslated O 0 0.29020121693611145
region O 0 2.6966807126882486e-05
( O 0 1.6635314068480511e-06
UTR O 0 0.0006193836452439427
) O 0 5.404626790550537e-07
of O 0 1.3804687171159458e-07
< O 0 1.3782359019387513e-05
50 O 0 1.1229699339310173e-06
bp O 0 0.00019568775314837694
, O 0 4.315339765526005e-07
whereas O 0 8.589174171902414e-07
Northern O 0 4.327815474880481e-07
analysis O 0 6.875266080896836e-07
has O 0 1.8329200202060747e-07
indicated O 0 6.834277428424684e-07
mRNA O 0 7.582378316328686e-07
sizes O 0 6.264230023589334e-07
of O 0 1.804448146458526e-07
5 O 0 1.8896496385423234e-06
- O 0 7.769212970742956e-05
8 O 0 1.8151702533941716e-05
kb O 0 0.00045481420238502324
. O 0 1.908904596348293e-05

We O 0 2.9944674679427408e-05
have O 0 4.052737949677976e-06
analyzed O 0 8.61106764205033e-06
additional O 0 2.0774728000105824e-06
cDNA O 0 1.1024510058632586e-05
clones O 0 1.4305790500657167e-05
and O 0 6.360553470585728e-07
provide O 0 1.1244960660405923e-06
evidence O 0 9.160984859590826e-07
for O 0 2.648820611739211e-07
an O 0 4.287580566142424e-07
additional O 0 3.6577744140231516e-06
0 O 0 4.365215863799676e-05
. O 0 2.2835378331365064e-05

5 O 0 0.00010210609616478905
kb O 0 0.00034524925285950303
of O 0 3.362394863870577e-06
5 O 0 6.281797595875105e-06
- O 0 0.0001294362882617861
UTR O 0 0.0031309504993259907
and O 0 9.390635113959434e-07
> O 0 9.221288564731367e-06
2 O 0 1.3114943158143433e-06
kb O 0 2.746032623690553e-05
of O 0 3.6462287766880763e-07
3 O 0 1.0337480489397421e-05
- O 0 0.002294778823852539
UTR O 0 0.22759371995925903
. O 0 2.985158425872214e-05

We O 0 1.93079231394222e-05
have O 0 2.3936747766128974e-06
established O 0 1.5982532204361632e-06
the O 0 4.939706741424743e-07
genomic O 0 6.753568413842004e-06
organization O 0 1.2379840654830332e-06
of O 0 4.893321374765947e-07
UBE3A O 0 0.00018149751122109592
and O 0 2.919953203672776e-07
the O 0 1.7298188481618126e-07
sequence O 0 7.996352451300481e-07
of O 0 5.861019189978833e-07
intron O 0 0.00014594648382626474
- O 0 0.00022332307707984
exon O 0 0.00012623854854609817
borders O 0 4.2424810089869425e-05
. O 0 2.3482578399125487e-05

We O 0 2.676825715752784e-05
have O 0 2.2007386633049464e-06
also O 0 1.006719003271428e-06
mapped O 0 4.197509952064138e-06
two O 0 6.01213002937584e-07
highly O 0 1.7243355614482425e-06
homologous O 0 7.306211045943201e-06
processed O 0 4.9581976782064885e-06
pseudogenes O 0 1.4510726941807661e-05
, O 0 5.204911417422409e-07
UBE3AP1 O 0 0.0001047098048729822
and O 0 5.581455297942739e-07
UBE3AP2 O 0 0.00022757741680834442
, O 0 3.3403244970031665e-07
to O 0 1.4719236673954583e-07
chromosomes O 0 9.504392437520437e-07
2 O 0 6.026181722518231e-07
and O 0 1.7519846551294904e-07
21 O 0 9.47400337736326e-07
, O 0 2.598861215119541e-07
respectively O 0 1.1774540098485886e-06
, O 0 1.6085029130863404e-07
and O 0 3.3503485497021757e-07
determined O 0 1.4363698710440076e-06
their O 0 1.2116554444219219e-06
genomic O 0 5.772696385974996e-05
organization O 0 1.607570993655827e-05
. O 0 1.727655944705475e-05

These O 0 3.4416192647768185e-05
results O 0 3.252632086514495e-05
will O 0 8.018903372430941e-07
form O 0 5.359389092518541e-07
the O 0 1.4748505350326013e-07
basis O 0 2.3250719038969692e-07
for O 0 2.3492931688906538e-07
studies O 0 1.1744909897970501e-06
of O 0 4.627975442872412e-07
mutation O 0 1.515003987151431e-05
and O 0 2.993886937474599e-06
imprinting O 0 0.00025066954549402
of O 0 1.0677134014258627e-05
UBE3A O 0 0.02568923309445381
. O 0 5.826175038237125e-05

Mutation O 0 0.003315994516015053
spectrum O 0 0.00038991952897049487
and O 0 4.499535498325713e-05
genotype O 0 0.23677809536457062
- O 1 0.979444682598114
phenotype O 1 0.7814643979072571
analyses O 0 0.00023439469805452973
in O 0 3.189877679687925e-05
Cowden B-Disease 1 0.9998444318771362
disease I-Disease 0 0.37267136573791504
and O 0 2.8391026717144996e-05
Bannayan B-Disease 1 0.9952996969223022
- I-Disease 1 0.9999943971633911
Zonana I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999830722808838
, O 0 4.679110134020448e-06
two O 0 1.7042877516360022e-05
hamartoma B-Disease 1 0.999901533126831
syndromes I-Disease 1 0.9996857643127441
with O 0 0.00017367854889016598
germline O 1 0.997654914855957
PTEN O 1 0.9983812570571899
mutation O 0 0.0007687071338295937
. O 0 4.0903352783061564e-05

The O 0 0.00041151492041535676
tumour B-Disease 1 0.9998834133148193
suppressor O 0 0.0688447654247284
gene O 0 0.0003068872611038387
PTEN O 0 0.004045894369482994
, O 0 3.967765678680735e-06
which O 0 1.2989361266591004e-06
maps O 0 7.033583642623853e-06
to O 0 3.01341447084269e-06
10q23 O 0 0.0003186073445249349
. O 0 2.799225148919504e-05

3 O 0 7.107733108568937e-05
and O 0 5.784207587566925e-06
encodes O 0 1.1882315448019654e-05
a O 0 1.9579886156861903e-06
403 O 0 5.362980118661653e-06
amino O 0 4.403270395414438e-06
acid O 0 8.277940651169047e-06
dual O 0 4.91913942823885e-06
specificity O 0 7.891030691098422e-06
phosphatase O 0 0.027587739750742912
( O 0 1.0536125500948401e-06
protein O 0 2.6414572857902385e-06
tyrosine O 0 4.4607419113162905e-05
phosphatase O 0 0.037092991173267365
; O 0 3.968605597037822e-06
PTPase O 0 6.772205961169675e-05
) O 0 6.68611846776912e-07
, O 0 9.916012544408659e-08
was O 0 1.3855769509518723e-07
shown O 0 3.2981986919367046e-07
recently O 0 4.632612160548888e-07
to O 0 1.1459166415761501e-07
play O 0 1.5097205618985754e-07
a O 0 2.508792817934591e-07
broad O 0 8.225655619753525e-06
role O 0 4.604406058206223e-06
in O 0 6.6828438320953865e-06
human O 0 5.268150198389776e-05
malignancy B-Disease 1 0.6547657251358032
. O 0 4.84777228848543e-05

Somatic O 0 0.06730026751756668
PTEN O 1 0.9092972278594971
deletions O 0 0.002865449758246541
and O 0 6.606739043490961e-05
mutations O 0 0.00015512017125729471
were O 0 1.3502071851689834e-06
observed O 0 3.4969436910614604e-06
in O 0 3.2394391382695176e-06
sporadic B-Disease 0 0.032592691481113434
breast I-Disease 1 0.9947245717048645
, I-Disease 0 0.000815394741948694
brain I-Disease 1 0.5956274271011353
, I-Disease 0 0.000453506363555789
prostate I-Disease 1 0.9999836683273315
and I-Disease 0 0.293891042470932
kidney I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9976576566696167
cell O 0 0.001494161318987608
lines O 0 5.564051662076963e-06
and O 0 6.33387742254854e-07
in O 0 3.0601833600485406e-07
several O 0 8.107735993689857e-07
primary O 0 8.05100062279962e-05
tumours B-Disease 1 0.9999241828918457
such O 0 2.7181363293493632e-06
as O 0 6.64637191221118e-05
endometrial B-Disease 1 0.9999372959136963
carcinomas I-Disease 1 1.0
, O 1 0.9944685697555542
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.983799934387207
thyroid B-Disease 1 0.9999998807907104
tumours I-Disease 1 0.9999997615814209
. O 0 0.00018304130935575813

In O 0 4.40767798863817e-05
addition O 0 1.2695986697508488e-05
, O 0 6.10278220847249e-06
PTEN O 0 0.015429527498781681
was O 0 2.2606302536587464e-06
identified O 0 1.8071414160658605e-06
as O 0 2.9916500920990075e-07
the O 0 5.85651605433668e-07
susceptibility O 0 0.00011946077574975789
gene O 0 5.00808664583019e-06
for O 0 1.3809337815473555e-06
two O 0 9.101807518163696e-05
hamartoma B-Disease 1 0.9999994039535522
syndromes I-Disease 1 0.9999996423721313
Cowden B-Disease 1 0.9999992847442627
disease I-Disease 1 0.9480992555618286
( O 0 4.9989680519502144e-06
CD B-Disease 0 0.00010588577424641699
; O 0 8.030437129491474e-06
MIM O 0 0.011964152567088604
158350 O 0 0.00022125389659777284
) O 0 9.300475767304306e-07
and O 0 6.325329309220251e-07
Bannayan B-Disease 0 0.0004753621469717473
- I-Disease 0 0.05061115697026253
Zonana I-Disease 0 0.22273187339305878
( I-Disease 0 2.4822954856063006e-06
BZS I-Disease 0 0.0002217969304183498
) I-Disease 0 9.940608833858278e-07
or I-Disease 0 1.384149527439149e-06
Ruvalcaba I-Disease 0 0.0015324032865464687
- I-Disease 0 0.025024911388754845
Riley I-Disease 0 0.0008178361458703876
- I-Disease 1 0.9379410743713379
Smith I-Disease 1 0.5188071131706238
syndrome I-Disease 1 0.9999481439590454
( O 0 2.5539098714943975e-05
MIM O 0 0.10680016875267029
153480 O 0 0.001169330207630992
) O 0 1.0832900443347171e-05
. O 0 1.617937050468754e-05

Constitutive O 0 0.0035159343387931585
DNA O 0 0.0002490576880518347
from O 0 9.405958735442255e-06
37 O 0 9.13750318431994e-06
CD B-Disease 0 2.213315929111559e-05
families O 0 1.644064354877628e-06
and O 0 5.447639637168322e-07
seven O 0 2.5903270852722926e-06
BZS B-Disease 0 0.0011436059139668941
families O 0 2.5818874291871907e-06
was O 0 1.0530037570788409e-06
screened O 0 6.895043497934239e-06
for O 0 6.987399046920473e-06
germline O 1 0.6308535933494568
PTEN O 1 0.9870328903198242
mutations O 0 0.0012234685709699988
. O 0 2.9585067750304006e-05

PTEN O 1 0.9985629916191101
mutations O 0 0.008233348838984966
were O 0 1.0510139873076696e-05
identified O 0 5.452985078591155e-06
in O 0 7.574427627332625e-07
30 O 0 8.32253135740757e-07
of O 0 2.2942592181607324e-07
37 O 0 3.2287828162225196e-06
( O 0 8.919955121200474e-07
81 O 0 4.268204065738246e-06
% O 0 9.114606314142293e-07
) O 0 4.5373715806817927e-07
CD B-Disease 0 5.468613835546421e-06
families O 0 5.510251526175125e-07
, O 0 2.1199841171437583e-07
including O 0 4.340182044870744e-07
missense O 0 3.058827496715821e-05
and O 0 7.752852297926438e-07
nonsense O 0 2.9157699827919714e-05
point O 0 3.4538700219854945e-06
mutations O 0 1.5435738532687537e-05
, O 0 5.349911020857689e-07
deletions O 0 5.486453574121697e-06
, O 0 4.738393215575343e-07
insertions O 0 8.073422577581368e-06
, O 0 4.032240781270957e-07
a O 0 8.680364658175677e-07
deletion O 0 0.00010660804400686175
/ O 0 9.808031609281898e-05
insertion O 0 1.0597885193419643e-05
and O 0 2.0933709947712487e-06
splice O 0 0.0008974582306109369
site O 0 4.780822200700641e-05
mutations O 0 0.0001905816898215562
. O 0 3.0148316000122577e-05

These O 0 5.506032903213054e-05
mutations O 0 9.570806287229061e-05
were O 0 9.08212882677617e-07
scattered O 0 1.064376306203485e-06
over O 0 2.3559522333016503e-07
the O 0 1.3098402007472032e-07
entire O 0 5.202400075177138e-07
length O 0 1.1405267059672042e-06
of O 0 3.613563706039713e-07
PTEN O 0 0.020769992843270302
, O 0 2.0245472853730462e-07
with O 0 8.824449082567298e-08
the O 0 6.771955440854072e-08
exception O 0 1.8949647540011938e-07
of O 0 4.0893809227782185e-08
the O 0 6.293007004387619e-08
first O 0 1.9052900768201653e-07
, O 0 2.482259446878743e-07
fourth O 0 2.15706972994667e-06
and O 0 1.0293744026057539e-06
last O 0 1.3925483472121414e-05
exons O 0 0.00038054262404330075
. O 0 2.3245263946591876e-05

A O 0 4.525755502982065e-05
hot O 0 6.347115413518623e-05
spot O 0 2.5646535505075008e-05
for O 0 4.361594164947746e-06
PTEN O 0 0.2151772528886795
mutation O 0 1.445179896109039e-05
in O 0 3.955211980155582e-07
CD B-Disease 0 1.8097136489814147e-05
was O 0 9.447009006180451e-07
identified O 0 8.458672482447582e-07
in O 0 1.8685274483232206e-07
exon O 0 3.7554086702584755e-06
5 O 0 5.165726406630711e-07
that O 0 4.969431799395352e-08
contains O 0 1.0039522635452158e-07
the O 0 9.318821270198896e-08
PTPase O 0 1.0862373528652824e-05
core O 0 4.101816102775047e-06
motif O 0 2.0188781491015106e-06
, O 0 1.4903028500157234e-07
with O 0 1.0148337281634667e-07
13 O 0 3.522283122947556e-07
of O 0 9.72117817354956e-08
30 O 0 1.0058073485197383e-06
( O 0 4.7139732828327396e-07
43 O 0 1.3599601516034454e-06
% O 0 1.0260851013299543e-06
) O 0 7.917533366708085e-07
CD B-Disease 0 7.368557999143377e-05
mutations O 0 1.946082011272665e-05
identified O 0 1.2283511523492052e-06
in O 0 3.72808926840662e-07
this O 0 1.1553033800737467e-06
exon O 0 0.00011101970449090004
. O 0 1.4848856153548695e-05

Seven O 0 3.303133780718781e-05
of O 0 3.881674274452962e-06
30 O 0 5.6265371313202195e-06
( O 0 2.032270913332468e-06
23 O 0 2.7207352104596794e-06
% O 0 1.0769537084343028e-06
) O 0 2.088454778004234e-07
were O 0 5.861143037577676e-08
within O 0 6.117146966744258e-08
the O 0 7.780258926004535e-08
core O 0 2.235887450297014e-06
motif O 0 3.6515461943054106e-06
, O 0 1.5261042562997318e-07
the O 0 7.00834235090042e-08
majority O 0 5.228991426520224e-07
( O 0 1.619533094299186e-07
five O 0 5.733740593427683e-08
of O 0 4.5949036575620994e-08
seven O 0 4.0794409983391233e-07
) O 0 2.776291978534573e-07
of O 0 6.289107545853767e-08
which O 0 1.5539926323526743e-07
were O 0 5.062721584181418e-07
missense O 0 0.00019550965225789696
mutations O 0 1.7032998584909365e-05
, O 0 3.0623846214439254e-07
possibly O 0 7.130733479243645e-07
pointing O 0 9.512009455647785e-07
to O 0 9.681340173983699e-08
the O 0 1.3854779012945073e-07
functional O 0 1.4772267604712397e-06
significance O 0 7.964030714902037e-07
of O 0 3.40070840820772e-07
this O 0 1.3705846413358813e-06
region O 0 6.615300662815571e-05
. O 0 2.4010843844735064e-05

Germline O 1 0.9968771934509277
PTEN O 1 0.9994705319404602
mutations O 0 0.007665671873837709
were O 0 8.138481462083291e-06
identified O 0 5.1943070502602495e-06
in O 0 3.192467374901753e-07
four O 0 2.386926496455999e-07
of O 0 1.460935692421117e-07
seven O 0 1.7298531247433857e-06
( O 0 1.3439046142593725e-06
57 O 0 7.598240244988119e-06
% O 0 2.3535410491604125e-06
) O 0 2.227841832791455e-06
BZS B-Disease 0 0.00038148643216118217
families O 0 5.617454917228315e-06
studied O 0 1.2925997907586861e-05
. O 0 1.714073914627079e-05

Interestingly O 0 0.002008075127378106
, O 0 2.2297201212495565e-05
none O 0 7.083092441462213e-06
of O 0 1.0078977084049257e-06
these O 0 1.3010114798817085e-06
mutations O 0 2.7495123504195362e-05
was O 0 6.257446898416674e-07
observed O 0 1.0801587677633506e-06
in O 0 2.9912678201071685e-07
the O 0 6.923039563844213e-07
PTPase O 0 0.00020792589930351824
core O 0 5.957367466180585e-05
motif O 0 9.274265903513879e-05
. O 0 2.230432437499985e-05

It O 0 1.583406083227601e-05
is O 0 2.2935862489248393e-06
also O 0 9.264623486160417e-07
worthy O 0 1.2744333162117982e-06
of O 0 2.1669364969056915e-07
note O 0 2.825858928190428e-06
that O 0 9.563823510916336e-08
a O 0 2.1698792807001155e-07
single O 0 1.0441258382343221e-06
nonsense O 0 1.223458366439445e-05
point O 0 6.997682930887095e-07
mutation O 0 2.272544861625647e-06
, O 0 3.035349607216631e-07
R233X O 0 1.72700183611596e-05
, O 0 3.213320951545029e-07
was O 0 2.076192089361939e-07
observed O 0 4.843475949201093e-07
in O 0 1.2968625640041864e-07
the O 0 3.0707400355822756e-07
germline O 0 0.0008166509214788675
DNA O 0 4.47415141024976e-06
from O 0 1.2189741482870886e-07
two O 0 1.879380846503409e-07
unrelated O 0 5.6555877563368995e-06
CD B-Disease 0 1.9293785953777842e-05
families O 0 9.732603984957677e-07
and O 0 7.248720521602081e-07
one O 0 2.0705679162347224e-06
BZS B-Disease 0 0.0016406148206442595
family O 0 2.2173979232320562e-05
. O 0 2.2691689082421362e-05

Genotype O 1 0.9927733540534973
- O 1 0.9955403208732605
phenotype O 1 0.9656809568405151
studies O 0 3.502512845443562e-05
were O 0 5.491769456966722e-07
not O 0 2.8443153610169247e-07
performed O 0 8.081133842097188e-07
on O 0 2.1673541539257712e-07
this O 0 1.1798397991924503e-07
small O 0 5.882544655833044e-07
group O 0 7.698516128584743e-06
of O 0 1.8681653273233678e-06
BZS B-Disease 0 0.002844198141247034
families O 0 2.060323276964482e-05
. O 0 1.926844743138645e-05

However O 0 0.00012800660624634475
, O 0 3.434091922827065e-05
genotype O 0 0.004166661761701107
- O 0 0.09617617726325989
phenotype O 0 0.030495161190629005
analysis O 0 1.4784481209062506e-05
inthe O 0 0.00025494006695225835
group O 0 6.510565526696155e-06
of O 0 1.875057336064856e-07
CD B-Disease 0 3.178763290634379e-05
families O 0 2.129616404999979e-06
revealed O 0 3.964399184042122e-06
two O 0 1.7965648169138149e-07
possible O 0 4.4236406893105595e-07
associations O 0 4.869189638156968e-07
worthy O 0 7.08094546553184e-07
of O 0 1.07193535825445e-07
follow O 0 8.343607191818592e-07
- O 0 1.68537262652535e-05
up O 0 7.183961088230717e-07
in O 0 1.3052381291345228e-06
independent O 0 1.0515724170545582e-05
analyses O 0 5.267693268251605e-05
. O 0 2.410576053080149e-05

The O 0 1.7315023796982132e-05
first O 0 6.6735833570419345e-06
was O 0 1.2710056580544915e-06
an O 0 5.182968152439571e-07
association O 0 4.505825472733704e-06
noted O 0 1.0724645562731894e-06
in O 0 1.7710395638914633e-07
the O 0 1.4909198853274575e-07
group O 0 1.6897055274966988e-06
of O 0 2.1970782881908235e-07
CD B-Disease 0 8.37971456348896e-05
families O 0 1.5329818779719062e-05
with O 0 0.00026565269217826426
breast B-Disease 1 0.999796450138092
disease I-Disease 0 0.333980530500412
. O 0 6.959665915928781e-05

A O 0 8.731894195079803e-05
correlation O 0 5.258478631731123e-05
was O 0 4.87869010612485e-06
observed O 0 3.1360407319880323e-06
between O 0 4.263873165655241e-07
the O 0 3.8137227420520503e-07
presence O 0 1.7823815596784698e-06
/ O 0 7.310069486266002e-05
absence O 0 1.0957425047308789e-06
of O 0 1.9150652974531113e-07
a O 0 2.255653498650645e-06
PTEN O 1 0.9284375905990601
mutation O 0 1.3406953257799614e-05
and O 0 3.2465385402247193e-07
the O 0 4.0367461906498647e-07
type O 0 7.379077942459844e-06
of O 0 5.136500476510264e-06
breast O 1 0.7624938488006592
involvement O 0 0.0007515196921303868
( O 0 3.0074486858211458e-05
unaffected O 0 0.0003890864609275013
versus O 0 0.0007753223180770874
benign O 0 0.3340129852294922
versus O 0 0.040252845734357834
malignant O 1 0.9958916902542114
) O 0 3.825256135314703e-05
. O 0 2.5681951228762046e-05

Specifically O 0 8.87460118974559e-05
and O 0 4.9436180233897176e-06
more O 0 8.098755870378227e-07
directly O 0 8.95041750936798e-07
, O 0 3.8597704588028137e-07
an O 0 2.020621963083613e-07
association O 0 2.1546538846450858e-06
was O 0 3.934280243811372e-07
also O 0 3.8941558955229993e-07
observed O 0 3.9209382407534576e-07
between O 0 8.653569949501616e-08
the O 0 1.2269164528788679e-07
presence O 0 3.391839982214151e-07
of O 0 2.1203378253176197e-07
a O 0 9.923683137458283e-06
PTEN O 1 0.9982509016990662
mutation O 0 0.003791039576753974
and O 0 0.0077924467623233795
malignant B-Disease 1 0.9999997615814209
breast I-Disease 1 0.9999966621398926
disease I-Disease 1 0.9582421779632568
. O 0 7.43675627745688e-05

Secondly O 0 0.004142862744629383
, O 0 2.3359663828159682e-05
there O 0 1.5748994428577134e-06
appeared O 0 2.156649998141802e-06
to O 0 2.8371525218062743e-07
be O 0 1.2939518967414188e-07
an O 0 2.5947034032469674e-07
interdependent O 0 0.0002396420604782179
association O 0 5.414529823610792e-06
between O 0 4.990795332560083e-07
mutations O 0 4.122809059481369e-06
upstream O 0 7.450372550010798e-07
and O 0 9.15876867679799e-08
within O 0 6.58666721164991e-08
the O 0 9.122087618607111e-08
PTPase O 0 2.123780177498702e-05
core O 0 2.9770887977065286e-06
motif O 0 2.205062401117175e-06
, O 0 8.846676990970082e-08
the O 0 4.364812866697321e-08
core O 0 1.1564586657186737e-06
motif O 0 1.0471753739693668e-06
containing O 0 2.767035596207279e-07
the O 0 1.1179579217923674e-07
majority O 0 4.96663687954424e-07
of O 0 4.308620304982469e-07
missense O 0 0.0005484531284309924
mutations O 0 2.845480412361212e-05
, O 0 2.1697033503187413e-07
and O 0 1.528093633851313e-07
the O 0 1.4881410947964469e-07
involvement O 0 1.932985924213426e-06
of O 0 1.0537797834331286e-07
all O 0 1.4202488785031164e-07
major O 0 2.278147576362244e-06
organ O 0 0.00013491658319253474
systems O 0 0.0001083675742847845
( O 0 1.9382857772143325e-06
central O 0 2.627941739774542e-06
nervous O 0 3.786793604376726e-05
system O 0 5.716078703699168e-06
, O 0 2.4142338588717394e-05
thyroid O 1 0.9965448975563049
, O 0 6.701155507471412e-05
breast O 1 0.8300095796585083
, O 0 0.0001861936179921031
skin O 1 0.9998169541358948
and O 1 0.5749613642692566
gastrointestinal O 1 0.9999885559082031
tract O 1 0.5129367709159851
) O 0 6.082615436753258e-05
. O 0 3.4885018976638094e-05

However O 0 5.266829248284921e-05
, O 0 4.912678832624806e-06
these O 0 5.922533432567434e-07
observations O 0 2.474292614351725e-06
would O 0 3.221673239295342e-07
need O 0 2.4420560862381535e-07
to O 0 1.557201443347367e-07
be O 0 1.2680959571298445e-07
confirmed O 0 1.029303689392691e-06
by O 0 1.310236257268116e-07
studying O 0 3.538312398632115e-07
a O 0 1.773810112126739e-07
larger O 0 5.031253067500074e-07
number O 0 2.276661206224162e-07
of O 0 2.7033470928472525e-07
CD B-Disease 0 5.2254363254178315e-05
families O 0 1.2015226275252644e-05
. O 0 1.0769993423309643e-05

Molecular O 1 0.7800256013870239
defects O 1 0.9826299548149109
leading O 0 5.351286017685197e-05
to O 0 3.425168870307971e-06
human O 0 3.2467287383042276e-06
complement B-Disease 0 2.0580335331032984e-05
component I-Disease 0 0.0024257772602140903
C6 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999947547912598
in O 0 8.7495470779686e-07
an O 0 3.7392166518657177e-07
African O 0 1.854941046985914e-06
- O 0 0.00013005081564188004
American O 0 4.601912223733962e-06
family O 0 9.328678061137907e-06
. O 0 1.5384508515126072e-05

Complement B-Disease 0 0.0017706475919112563
component I-Disease 0 0.05086410418152809
C6 I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999996423721313
( O 0 0.00021291982557158917
C6D B-Disease 0 0.4157559275627136
) O 0 1.9228120436309837e-05
was O 0 7.808213922544383e-06
diagnosed O 0 0.002769836224615574
in O 0 2.5538525960655534e-07
a O 0 4.337451287028671e-07
16 O 0 2.184566483265371e-06
- O 0 6.697436765534803e-05
year O 0 2.3817153760319343e-06
- O 0 1.4881972674629651e-05
old O 0 1.433325223842985e-06
African O 0 1.0490065278645488e-06
- O 0 2.4903811208787374e-05
American O 0 1.719578108350106e-06
male O 0 7.344942332565552e-06
with O 0 6.78865471854806e-05
meningococcal B-Disease 1 0.9999794960021973
meningitis I-Disease 1 0.9996980428695679
. O 0 7.340882439166307e-05

The O 0 0.00015989242820069194
patients O 0 0.019918402656912804
father O 0 2.4505940018570982e-05
and O 0 2.0298477920732694e-06
two O 0 1.2456238209779258e-06
brothers O 0 0.00012671746662817895
also O 0 1.5585563915010425e-06
had O 0 9.841302244240069e-07
C6D B-Disease 0 0.0013286391040310264
, O 0 9.127097655436955e-07
but O 0 2.685048059447581e-07
gave O 0 7.17733200872317e-07
no O 0 3.6856786778116657e-07
history O 0 6.238177547857049e-07
of O 0 3.349410690134391e-06
meningitis B-Disease 1 0.9596189856529236
or O 0 9.432907972950488e-06
other O 0 1.5564395653200336e-05
neisserial B-Disease 1 0.9873595833778381
infection I-Disease 0 0.01937853917479515
. O 0 2.5406316126463935e-05

By O 0 3.8995203794911504e-05
using O 0 1.1997352885373402e-05
exon O 0 5.1638420700328425e-05
- O 0 4.8096870159497485e-05
specific O 0 2.996383500430966e-06
polymerase O 0 1.5614261428709142e-05
chain O 0 8.276961125375237e-06
reaction O 0 3.0433604933932656e-06
( O 0 8.715518902135955e-07
PCR O 0 1.3255651538202073e-05
) O 0 6.065724278414564e-07
/ O 0 3.4393683563394006e-06
single O 0 4.734549463591975e-07
- O 0 2.0224362742737867e-05
strand O 0 1.764309490681626e-05
conformation O 0 3.5222535643697483e-06
polymorphism O 0 2.205871851401753e-06
as O 0 7.807790325387032e-08
a O 0 1.2718625441721088e-07
screening O 0 7.603572953485127e-07
step O 0 6.917819632690225e-07
and O 0 1.3344941862669657e-07
nucleotide O 0 1.411336370438221e-06
sequencing O 0 6.374970098477206e-07
of O 0 7.011510660959175e-08
target O 0 8.228113301811391e-07
exons O 0 8.541048373444937e-06
, O 0 2.580548255082249e-07
we O 0 8.299753773144403e-08
determined O 0 3.0223023372855096e-07
that O 0 6.599557167419334e-08
the O 0 1.6261662949546007e-07
proband O 0 7.057261245790869e-05
was O 0 3.047590269034117e-07
a O 0 2.6218958737445064e-07
compound O 0 7.192473731265636e-06
heterozygote O 0 3.925833516404964e-05
for O 0 5.153228244125785e-07
two O 0 2.2388001070794417e-06
C6 O 1 0.9191867113113403
gene O 0 0.0001879362389445305
mutations O 0 0.00014351389836519957
. O 0 1.924017306009773e-05

The O 0 1.46860866152565e-05
first O 0 5.48032994629466e-06
, O 0 1.5244968381011859e-06
1195delC O 0 2.419325028313324e-05
located O 0 8.633348329567525e-07
in O 0 3.9009989905025577e-07
exon O 0 8.798892849881668e-06
7 O 0 3.4880606563092442e-06
, O 0 2.0614579909761233e-07
is O 0 1.0774575542882303e-07
a O 0 2.94206330408997e-07
novel O 0 5.285271072352771e-06
mutation O 0 5.756868631578982e-06
, O 0 1.7284699538322457e-07
while O 0 9.403722600609399e-08
the O 0 5.502202427010161e-08
second O 0 3.9621170344616985e-07
, O 0 3.379695954208728e-07
1936delG O 0 1.4825539437879343e-05
in O 0 3.137049588985974e-07
exon O 0 5.637779395328835e-06
12 O 0 8.16922920421348e-07
, O 0 1.8981896232617146e-07
has O 0 1.4079631682761828e-07
been O 0 1.701398417708333e-07
described O 0 2.038713546426152e-06
before O 0 3.024257182460133e-07
to O 0 4.613226565197692e-07
cause O 0 6.831887731095776e-06
C6D B-Disease 0 0.005623701494187117
in O 0 6.830146617176069e-07
an O 0 3.5581314250521245e-07
unrelated O 0 7.377937890851172e-06
African O 0 1.483432811255625e-06
- O 0 7.060640928102657e-05
American O 0 5.527833309315611e-06
individual O 0 5.897075880056946e-06
. O 0 1.3487860996974632e-05

Both O 0 0.0003339584800414741
mutations O 0 0.0026279143057763577
result O 0 3.092803308391012e-05
in O 0 1.2134975804656278e-05
premature O 0 0.012956134043633938
termination O 0 0.0008861434180289507
codons O 0 0.00010393821867182851
and O 0 7.519659448007587e-06
C6 O 0 0.25982484221458435
null O 0 0.0007570789894089103
alleles O 0 0.00014662885223515332
. O 0 3.842091973638162e-05

Allele O 0 0.0016083912923932076
- O 0 0.000977549352683127
specific O 0 9.942619726643898e-06
PCR O 0 9.169690019916743e-05
indicated O 0 7.522521173086716e-06
that O 0 1.2573339347454748e-07
the O 0 1.720280380368422e-07
probands O 0 3.6917670513503253e-05
two O 0 5.106020921630261e-07
brothers O 0 5.7281846238765866e-05
also O 0 1.7193715393659659e-06
inherited O 0 2.138727177225519e-05
the O 0 5.632467718896805e-07
1195delC O 0 0.00026546683511696756
mutation O 0 3.7201909890427487e-06
from O 0 1.308544312905724e-07
their O 0 3.1443940429198847e-07
heterozygous O 0 4.26447695645038e-06
mother O 0 1.8700709460972575e-06
and O 0 1.517819328000769e-07
the O 0 2.736833835115249e-07
1936delG O 0 0.0001415001170244068
mutation O 0 4.610557425621664e-06
from O 0 2.5255729951823014e-07
their O 0 8.917752438719617e-07
homozygous O 0 2.5100755010498688e-05
father O 0 7.658965841983445e-06
. O 0 3.4985084766958607e-06
. O 0 1.255741335626226e-05

PAX6 O 1 0.9973950386047363
mutations O 1 0.8160604238510132
reviewed O 0 0.003919921815395355
. O 0 0.0006031607044860721

Mutations O 0 0.01070807408541441
in O 0 4.979552613804117e-05
PAX6 O 0 0.10294883698225021
are O 0 2.638969590407214e-06
responsible O 0 8.133826668199617e-06
for O 0 1.3047005040789372e-06
human O 0 5.928461177973077e-06
aniridia B-Disease 1 0.9955000281333923
and O 0 3.4033400879707187e-06
have O 0 2.4857962444002624e-07
also O 0 3.988096466400748e-07
been O 0 2.811491981447034e-07
found O 0 7.165602369241242e-07
in O 0 4.431030902196653e-06
patients O 0 0.0003358229878358543
with O 0 2.2255306248553097e-05
Peters B-Disease 1 0.9999785423278809
anomaly I-Disease 1 0.9991297125816345
, O 0 2.4350114472326823e-05
with O 0 0.0022790138609707355
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999997615814209
, O 0 0.0001881112257251516
with O 0 0.00017275627760682255
autosomal B-Disease 1 0.984820544719696
dominant I-Disease 0 0.21127963066101074
keratitis I-Disease 1 0.9997902512550354
, O 0 1.946605152625125e-06
and O 0 1.6116825918288669e-06
with O 0 1.651163438509684e-05
isolated B-Disease 0 0.02150854654610157
foveal I-Disease 1 0.999994158744812
hypoplasia I-Disease 1 0.9999951124191284
. O 0 0.00015415142115671188

No O 0 5.914703069720417e-05
locus O 0 6.461629527620971e-05
other O 0 2.579008196335053e-06
than O 0 1.8516218460717937e-06
chromosome O 0 3.7628618883900344e-05
11p13 O 0 0.00010441295307828113
has O 0 1.3441047030937625e-06
been O 0 6.422182536880428e-07
implicated O 0 2.6215029720333405e-05
in O 0 2.1950290829408914e-06
aniridia B-Disease 1 0.9980098605155945
, O 0 3.5632153867481975e-06
and O 0 1.695836886028701e-06
PAX6 O 0 0.006380120292305946
is O 0 5.9570595567493e-07
clearly O 0 5.848858108947752e-07
the O 0 1.2570473018058692e-07
major O 0 4.774869353241229e-07
, O 0 4.12469518096259e-07
if O 0 1.8557147996034473e-07
not O 0 1.1889336093418024e-07
only O 0 1.152799029568996e-07
, O 0 1.342310042673489e-06
gene O 0 1.6285006495309062e-05
responsible O 0 3.5881923395209014e-05
. O 0 2.2807935238233767e-05

Twenty O 0 0.00017963413847610354
- O 0 0.00023808360856492072
eight O 0 7.4684026003524195e-06
percent O 0 1.2179763871245086e-05
of O 0 1.2300462230996345e-06
identified O 0 2.392140777374152e-05
PAX6 O 0 0.13743478059768677
mutations O 0 6.0615609982050955e-05
are O 0 3.12786056611003e-07
C O 0 3.805611777352169e-05
- O 0 0.0014404309913516045
T O 0 0.013140332885086536
changes O 0 8.68766107942065e-07
at O 0 4.028412661227776e-07
CpG O 0 2.2581853045267053e-05
dinucleotides O 0 8.555380190955475e-05
, O 0 3.3218864814443805e-07
20 O 0 2.2794203857756656e-07
% O 0 2.525910076656146e-07
are O 0 7.427317427755042e-08
splicing O 0 1.7678903532214463e-05
errors O 0 5.1325687309145e-06
, O 0 1.4637959111496457e-07
and O 0 7.127402312789854e-08
more O 0 6.967291454884617e-08
than O 0 8.683612406912289e-08
30 O 0 5.167170229469775e-07
% O 0 5.281806920720555e-07
are O 0 2.1357250545861461e-07
deletion O 0 9.374919500260148e-06
or O 0 1.1952116665270296e-06
insertion O 0 2.6200958018307574e-05
events O 0 4.175885351287434e-06
. O 0 1.0938852028630208e-05

There O 0 3.0134029657347128e-05
is O 0 4.353448730398668e-06
a O 0 2.471872676323983e-06
noticeably O 0 4.0972099668579176e-05
elevated O 0 1.952143429662101e-05
level O 0 8.262609867415449e-07
of O 0 1.9761800729156676e-07
mutation O 0 1.7987815681408392e-06
in O 0 1.459974612316728e-07
the O 0 1.2633978485609987e-07
paired O 0 4.093371899216436e-06
domain O 0 8.771737043389294e-07
compared O 0 3.8971313642832683e-07
with O 0 6.612837921693426e-08
the O 0 1.3868222481505654e-07
rest O 0 3.515370394779893e-07
of O 0 2.5433672590224887e-07
the O 0 1.5167802303039934e-06
gene O 0 2.738082730502356e-05
. O 0 1.7560727428644896e-05

Increased O 0 0.00024062037118710577
mutation O 0 0.00011789648851845413
in O 0 2.8682554784609238e-06
the O 0 1.2942409739480354e-06
homeodomain O 0 0.000178131100255996
is O 0 8.055242233240278e-07
accounted O 0 1.295097945330781e-06
for O 0 1.5953051502037852e-07
by O 0 2.837837200786453e-07
the O 0 6.774066605430562e-07
hypermutable O 0 0.0007139745284803212
CpG O 0 0.0001787988585419953
dinucleotide O 0 0.0002717488387133926
in O 0 2.3018428692012094e-06
codon O 0 3.158608160447329e-05
240 O 0 1.6377176507376134e-05
. O 0 1.420948319719173e-05

Very O 0 3.748057133634575e-05
nearly O 0 9.866704203886911e-06
all O 0 1.7055455145964515e-06
mutations O 0 1.840004370023962e-05
appear O 0 3.2367925086873583e-06
to O 0 9.542592351863277e-07
cause O 0 1.6974929167190567e-05
loss O 0 8.19219621917e-06
of O 0 1.1308955549793609e-07
function O 0 2.0680978707332542e-07
of O 0 7.963623005480258e-08
the O 0 2.5962899030673725e-07
mutant O 0 1.138091738539515e-05
allele O 0 3.825881776720053e-06
, O 0 1.8420796266127581e-07
and O 0 7.309908767183515e-08
more O 0 5.113818346558219e-08
than O 0 9.811578394192111e-08
80 O 0 5.038157269154908e-07
% O 0 3.647512016868859e-07
of O 0 2.067478703793313e-07
exonic O 0 0.0001769559021340683
substitutions O 0 1.0870757250813767e-05
result O 0 2.429390406177845e-06
in O 0 2.1162297798582586e-06
nonsense O 0 0.00018807391461450607
codons O 0 0.00024626243975944817
. O 0 2.6541241822997108e-05

In O 0 3.5288008803036064e-05
a O 0 9.651905202190392e-06
gene O 0 1.0244308214168996e-05
with O 0 8.692824167155777e-07
such O 0 7.581293743896822e-07
extraordinarily O 0 3.840025601675734e-05
high O 0 3.9867836676421575e-06
sequence O 0 1.429412918696471e-06
conservation O 0 1.9219260138925165e-06
throughout O 0 3.7455944834619004e-07
evolution O 0 7.719858672317059e-07
, O 0 1.7681099961919244e-07
there O 0 8.304076715148767e-08
are O 0 1.6425474314019084e-07
presumed O 0 3.4491535188863054e-05
undiscovered O 0 0.004063604399561882
missense O 0 0.0008670568349771202
mutations O 0 2.638304249558132e-05
, O 0 2.3112744429454324e-07
these O 0 9.255512622985407e-08
are O 0 9.451391491666072e-08
hypothesized O 0 2.741138132478227e-06
to O 0 1.7360294179979974e-07
exist O 0 2.886509946620208e-07
in O 0 1.0645128867281528e-07
as O 0 2.635480882418051e-07
- O 0 0.00016836817667353898
yet O 0 8.729120963835157e-06
unidentified O 0 0.00010110612493008375
phenotypes O 0 0.0002641298051457852
. O 0 4.4505036385089625e-06
. O 0 1.2352678822935559e-05

Genetic O 0 0.007045274134725332
heterogeneity O 0 0.005987601820379496
and O 0 3.364450458320789e-05
penetrance O 0 0.009253793396055698
analysis O 0 1.2277338100830093e-05
of O 0 7.418736913678003e-07
the O 0 1.5839427760511171e-06
BRCA1 O 0 0.0005002724356018007
and O 0 1.5317225916078314e-05
BRCA2 O 0 0.02396322786808014
genes O 0 6.797866808483377e-05
in O 0 0.00016239492106251419
breast B-Disease 1 0.9996682405471802
cancer I-Disease 1 0.967500627040863
families O 0 6.28191337455064e-05
. O 0 4.5145992771722376e-05

The O 0 0.08041312545537949
Breast B-Disease 1 0.9999988079071045
Cancer I-Disease 1 0.9999902248382568
Linkage O 0 0.011783760972321033
Consortium O 0 0.0037375695537775755
. O 0 0.00016082100046332926

The O 0 2.3722539481241256e-05
contribution O 0 2.812054481182713e-05
of O 0 4.1805874388956e-06
BRCA1 O 0 0.0009795280639082193
and O 0 3.6946763430023566e-05
BRCA2 O 0 0.4556175768375397
to O 0 0.0022632568143308163
inherited B-Disease 1 0.9999998807907104
breast I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
was O 0 1.586246071383357e-05
assessed O 0 3.326573641970754e-05
by O 0 6.632264444306202e-07
linkage O 0 3.222993836971e-05
and O 0 4.441142664290965e-06
mutation O 0 7.823449777788483e-06
analysis O 0 1.1935394468309823e-06
in O 0 3.0784894988755696e-07
237 O 0 1.2266571502550505e-05
families O 0 7.706793780926091e-07
, O 0 1.1372983266255687e-07
each O 0 4.036961342990253e-08
with O 0 1.3867865789052303e-07
at O 0 2.3997196763048123e-07
least O 0 1.3244134322576429e-07
four O 0 5.886473104510515e-07
cases O 0 1.6878678934517666e-06
of O 0 9.25194126466522e-06
breast B-Disease 1 0.9999300241470337
cancer I-Disease 1 0.7890877723693848
, O 0 1.0827144478753326e-06
collected O 0 5.903744408897182e-07
by O 0 1.0697433481254848e-06
the O 0 9.189726551994681e-05
Breast B-Disease 1 0.9999994039535522
Cancer I-Disease 1 0.9998328685760498
Linkage O 0 0.0010075099999085069
Consortium O 0 0.0004763221659231931
. O 0 3.7524630897678435e-05

Families O 0 0.0001465613313484937
were O 0 4.877457286056597e-06
included O 0 2.268895968882134e-06
without O 0 8.272260743069637e-07
regard O 0 1.3342464626475703e-06
to O 0 3.338286092002818e-07
the O 0 5.35415779268078e-07
occurrence O 0 1.7376592950313352e-05
of O 0 5.215482815401629e-06
ovarian B-Disease 1 0.9973734617233276
or I-Disease 0 1.650100966799073e-05
other I-Disease 0 4.0041079046204686e-05
cancers I-Disease 0 0.39802125096321106
. O 0 3.294322596048005e-05

Overall O 0 0.034851498901844025
, O 0 0.001100869383662939
disease O 0 0.01630142331123352
was O 0 3.953947725676699e-06
linked O 0 2.2670581529382616e-05
to O 0 1.955637344508432e-06
BRCA1 O 0 0.0002927612222265452
in O 0 5.516029659702326e-07
an O 0 2.0357087748834601e-07
estimated O 0 1.3407147889665794e-06
52 O 0 3.2227562769548967e-06
% O 0 3.6693145943900163e-07
of O 0 7.921311606651216e-08
families O 0 4.852121264775633e-07
, O 0 2.623246473376639e-07
to O 0 5.24576933003118e-07
BRCA2 O 0 0.00010389758972451091
in O 0 1.881932973901712e-07
32 O 0 5.935623903496889e-07
% O 0 2.357628972049497e-07
of O 0 8.446180288501637e-08
families O 0 5.144871124684869e-07
, O 0 1.8294377923666616e-07
and O 0 1.310900046291863e-07
to O 0 1.6408284864155576e-07
neither O 0 1.2269742910575587e-06
gene O 0 9.673888143879594e-07
in O 0 1.4255505220717168e-07
16 O 0 6.21346600837569e-07
% O 0 5.659707653649093e-07
( O 0 1.6970228955415223e-07
95 O 0 5.042671205046645e-07
% O 0 5.226509074418573e-07
confidence O 0 1.797941195036401e-06
interval O 0 2.132410827471176e-06
[ O 0 6.485246103693498e-06
CI O 0 0.02562449499964714
] O 0 5.824511390528642e-06
6 O 0 9.331037631454819e-07
% O 0 5.52167193745845e-07
- O 0 2.8132319130236283e-05
28 O 0 4.383954546938185e-06
% O 0 1.2627693877220736e-06
) O 0 4.48559603682952e-07
, O 0 5.190937599763856e-07
suggesting O 0 4.193313088762807e-06
other O 0 2.1202904463279992e-06
predisposition O 0 0.00045200748718343675
genes O 0 5.896377842873335e-05
. O 0 2.5977637051255442e-05

The O 0 2.6488572984817438e-05
majority O 0 3.028186984010972e-05
( O 0 6.394390311470488e-06
81 O 0 1.096381492970977e-05
% O 0 1.2895505960841547e-06
) O 0 3.641311536739522e-07
of O 0 2.394779130554525e-07
the O 0 1.4078294952923898e-05
breast B-Disease 1 0.9999246597290039
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999957084655762
families O 0 4.255563453625655e-06
were O 0 1.5034703437777353e-07
due O 0 1.5423642025780282e-06
to O 0 6.697452477055776e-07
BRCA1 O 0 0.00017956289229914546
, O 0 2.7560270154936006e-07
with O 0 2.2181103531693225e-07
most O 0 4.0405055301562243e-07
others O 0 2.4965422653622227e-06
( O 0 6.526608444801241e-07
14 O 0 1.3826033864461351e-06
% O 0 1.3418019761957112e-06
) O 0 1.1441348988228128e-06
due O 0 3.4307197438465664e-06
to O 0 5.029726253269473e-06
BRCA2 O 0 0.002282867208123207
. O 0 3.167270915582776e-05

Conversely O 0 0.0010077087208628654
, O 0 7.80900245445082e-06
the O 0 6.845190796411771e-07
majority O 0 1.0444266536069335e-06
of O 0 1.8388290357052028e-07
families O 0 9.272188776776602e-07
with O 0 7.73941565057612e-07
male B-Disease 0 1.7712551198201254e-05
and I-Disease 0 1.7783504517865367e-05
female I-Disease 0 0.14424653351306915
breast I-Disease 1 0.9998494386672974
cancer I-Disease 1 0.5017834901809692
were O 0 5.337521997716976e-07
due O 0 4.3925292629865e-06
to O 0 2.2473611807072302e-06
BRCA2 O 0 0.0026641071308404207
( O 0 2.5389520033058943e-06
76 O 0 2.287314782734029e-05
% O 0 5.43660280527547e-06
) O 0 7.0658079494023696e-06
. O 0 1.0183555787079968e-05

The O 0 2.1680105419363827e-05
largest O 0 3.5008892155019566e-05
proportion O 0 1.631866325624287e-05
( O 0 2.3272266389540164e-06
67 O 0 1.320756200584583e-05
% O 0 1.2133760947108385e-06
) O 0 3.0251339921960607e-07
of O 0 8.489303837677653e-08
families O 0 6.961592475818179e-07
due O 0 1.4170263966661878e-06
to O 0 1.754074361315361e-07
other O 0 1.8035689208772965e-07
genes O 0 9.414173405275506e-07
was O 0 1.98532276840524e-07
found O 0 1.4093362210587657e-07
in O 0 1.2422009376678034e-07
families O 0 2.3994152797968127e-07
with O 0 1.3581751545643783e-07
four O 0 4.3091216639368213e-07
or O 0 6.50837876037258e-07
five O 0 1.1221488875889918e-06
cases O 0 9.374224987368507e-07
of O 0 1.3695721463591326e-06
female O 0 0.0566621832549572
breast B-Disease 1 0.9995573163032532
cancer I-Disease 0 0.15022438764572144
only O 0 3.6778312733076746e-06
. O 0 2.8554322852869518e-05

These O 0 5.03713745274581e-05
estimates O 0 7.179279782576486e-05
were O 0 1.8937555523734773e-06
not O 0 8.171122658495733e-07
substantially O 0 5.631894964608364e-06
affected O 0 1.061060288520821e-06
either O 0 3.076285679526336e-07
by O 0 2.3679920957420109e-07
changing O 0 1.2335998462731368e-06
the O 0 2.7761598175857216e-07
assumed O 0 5.219627382757608e-06
penetrance O 0 0.00016443517233710736
model O 0 2.6391833216621308e-06
for O 0 5.422433559942874e-07
BRCA1 O 0 5.305483500706032e-05
or O 0 3.8564368765037216e-07
by O 0 2.4468701553814753e-07
including O 0 4.5900819145572314e-07
or O 0 2.3385061922454042e-06
excluding O 0 0.00016565404075663537
BRCA1 O 0 0.0038711277302354574
mutation O 0 9.820348350331187e-05
data O 0 1.7841157387010753e-05
. O 0 1.7113559806603007e-05

Among O 0 6.700720405206084e-05
those O 0 8.406806045968551e-06
families O 0 1.3720409697270952e-05
with O 0 7.263942825375125e-05
disease O 0 0.1206686943769455
due O 0 3.0679075280204415e-05
to O 0 3.2692767035769066e-06
BRCA1 O 0 0.00030367090948857367
that O 0 1.7457469425607997e-07
were O 0 1.403966223278985e-07
tested O 0 8.667807378515135e-07
by O 0 7.058797990566745e-08
one O 0 4.8168690369720935e-08
of O 0 5.4788383607728974e-08
the O 0 1.0572021835741907e-07
standard O 0 1.81879113370087e-06
screening O 0 2.4388939436903456e-06
methods O 0 1.6505007351952372e-06
, O 0 8.76243973380042e-07
mutations O 0 3.5558625768317143e-06
were O 0 1.6421356008322618e-07
detected O 0 1.2313244042161386e-06
in O 0 5.872623987102088e-08
the O 0 7.732562323781167e-08
coding O 0 6.0109996411483735e-06
sequence O 0 5.654016490552749e-07
or O 0 1.6195531316043343e-07
splice O 0 1.248443095391849e-05
sites O 0 3.5988682611787226e-07
in O 0 8.91626683596769e-08
an O 0 1.32002654140706e-07
estimated O 0 7.109330795174174e-07
63 O 0 3.721454049809836e-06
% O 0 6.610838454434997e-07
( O 0 1.711285761984982e-07
95 O 0 6.510265961878758e-07
% O 0 8.473513162243762e-07
CI O 0 0.0015352163463830948
51 O 0 6.451072749769082e-06
% O 0 1.3303014156917925e-06
- O 0 3.6453220673138276e-05
77 O 0 1.2603411960299127e-05
% O 0 4.222374172968557e-06
) O 0 4.2606152419466525e-06
. O 0 1.245451312570367e-05

The O 0 4.501375951804221e-05
estimated O 0 3.336938243592158e-05
sensitivity O 0 2.024080094997771e-05
was O 0 1.8066554048346006e-06
identical O 0 2.8820420538977487e-06
for O 0 3.686184584239527e-07
direct O 0 1.2394619943734142e-06
sequencing O 0 6.6877782955998555e-06
and O 0 5.276626211525581e-07
other O 0 7.24552762676467e-07
techniques O 0 3.879938958561979e-05
. O 0 2.077704448311124e-05

The O 0 0.00010361948079662398
penetrance O 0 0.004896150436252356
of O 0 2.3918284568935633e-05
BRCA2 O 0 0.004920050036162138
was O 0 4.077382072864566e-06
estimated O 0 2.174601604565396e-06
by O 0 6.115980681897781e-07
maximizing O 0 7.111675586202182e-06
the O 0 6.088506552259787e-07
LOD O 0 0.0021069671493023634
score O 0 1.9467204310785746e-06
in O 0 2.1736041162512265e-06
BRCA2 O 0 0.005014990922063589
- O 0 0.12740594148635864
mutation O 0 2.1635740267811343e-05
families O 0 6.738083015989105e-07
, O 0 2.038825215322504e-07
over O 0 1.89956054441609e-07
all O 0 3.3341819971610676e-07
possible O 0 3.7487106965272687e-06
penetrance O 0 0.0007706154719926417
functions O 0 9.428824341739528e-06
. O 0 1.557991527079139e-05

The O 0 5.3551248129224405e-05
estimated O 0 7.26845973986201e-05
cumulative O 0 0.00020236933778505772
risk O 0 0.00011864318366860971
of O 0 1.9493993022479117e-05
breast B-Disease 1 0.9997920393943787
cancer I-Disease 1 0.85676109790802
reached O 0 7.052323326206533e-06
28 O 0 4.277576408640016e-06
% O 0 6.641201366619498e-07
( O 0 2.1070015066015912e-07
95 O 0 6.801352014917939e-07
% O 0 1.0832442285391153e-06
CI O 0 0.002171107567846775
9 O 0 1.7606251958568464e-06
% O 0 3.496452904983016e-07
- O 0 7.747170457150787e-06
44 O 0 8.407097880080983e-07
% O 0 4.305437357743358e-07
) O 0 1.8338100460368878e-07
by O 0 9.255953870024314e-08
age O 0 2.432560961551644e-07
50 O 0 1.6113493472857954e-07
years O 0 2.473279892001301e-07
and O 0 1.579931279138691e-07
84 O 0 2.39026212511817e-06
% O 0 4.3225026047366555e-07
( O 0 1.3146409116870927e-07
95 O 0 5.342589588508417e-07
% O 0 8.072599371189426e-07
CI O 0 0.0007390222745016217
43 O 0 1.7056904653145466e-06
% O 0 3.167714055507531e-07
- O 0 5.7535098676453345e-06
95 O 0 1.749606440171192e-06
% O 0 7.064743385853944e-07
) O 0 2.944842378838075e-07
by O 0 2.060241541812502e-07
age O 0 1.0066537470265757e-06
70 O 0 4.482920303416904e-06
years O 0 5.808346941194031e-06
. O 0 1.572172186570242e-05

The O 0 0.0005093936342746019
corresponding O 1 0.9785349369049072
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
risks O 0 0.14048223197460175
were O 0 1.533579961687792e-05
0 O 0 0.00013025694352108985
. O 0 5.027007500757463e-05

4 O 0 0.00014873263717163354
% O 0 1.9971463188994676e-05
( O 0 2.4477619717799826e-06
95 O 0 2.5104109226958826e-06
% O 0 2.231529151686118e-06
CI O 0 0.00367468548938632
0 O 0 4.698337306763278e-06
% O 0 7.377553856713348e-07
- O 0 1.831062945711892e-05
1 O 0 1.2185572586531634e-06
% O 0 4.943095177623036e-07
) O 0 1.5858094570830872e-07
by O 0 6.548236086700854e-08
age O 0 1.4205089371444046e-07
50 O 0 1.727224230307911e-07
years O 0 1.9679876572809007e-07
and O 0 1.4981574736339098e-07
27 O 0 1.4768013443244854e-06
% O 0 5.450351636682171e-07
( O 0 1.8731913087322027e-07
95 O 0 5.882185973860032e-07
% O 0 5.720287390431622e-07
CI O 0 0.000380037963623181
0 O 0 2.6446127776580397e-06
% O 0 6.878951808175771e-07
- O 0 1.508878904132871e-05
47 O 0 4.9609452617005445e-06
% O 0 5.855940798937809e-07
) O 0 2.5568962769284553e-07
by O 0 2.095762994258621e-07
age O 0 6.792277531530999e-07
70 O 0 3.0064477414271096e-06
years O 0 4.542577244137647e-06
. O 0 1.2530857020465191e-05

The O 0 0.00013944062811788172
lifetime O 0 0.0017837280174717307
risk O 0 0.0009049148065969348
of O 0 0.00012781756231561303
breast B-Disease 1 0.9999897480010986
cancer I-Disease 1 0.991215705871582
appears O 0 1.388404689350864e-05
similar O 0 8.817044090392301e-07
to O 0 3.626576017268235e-07
the O 0 6.115467385825468e-07
risk O 0 1.7641328668105416e-05
in O 0 1.6704817653589998e-06
BRCA1 O 0 0.00044965132838115096
carriers O 0 1.0354441656090785e-05
, O 0 3.130450920707517e-07
but O 0 8.16891230215333e-08
there O 0 4.327963409878066e-08
was O 0 9.732235639603459e-08
some O 0 7.990630024323764e-08
suggestion O 0 8.026279942896508e-07
of O 0 1.1195710669653636e-07
a O 0 7.73148485677666e-07
lower O 0 0.00014843285316601396
risk O 0 3.156984894303605e-05
in O 0 1.5458909956578282e-06
BRCA2 O 0 0.0004240969428792596
carriers O 0 5.6980638873938005e-06
< O 0 1.965111914614681e-05
50 O 0 8.461674383397622e-07
years O 0 7.144783467083471e-07
of O 0 7.370036883003195e-07
age O 0 7.439534329023445e-06
. O 0 1.3763854440185241e-05

Eye B-Disease 1 0.9946526288986206
movement I-Disease 0 0.07686300575733185
abnormalities I-Disease 1 0.9937724471092224
correlate O 0 0.0010577283101156354
with O 0 5.296647213981487e-05
genotype O 1 0.7900335788726807
in O 0 0.00023108214372768998
autosomal O 1 0.9850580096244812
dominant O 1 0.6182215213775635
cerebellar B-Disease 1 0.999990701675415
ataxia I-Disease 1 0.9999980926513672
type I-Disease 0 0.002078667748719454
I I-Disease 0 9.789083560463041e-05
. O 0 5.888427040190436e-05

We O 0 5.5352833442157134e-05
compared O 0 4.991847890778445e-05
horizontal O 0 0.00017636331904213876
eye O 0 0.02017064578831196
movements O 0 3.975314029958099e-05
( O 0 3.9568558349856175e-06
visually O 0 1.1315160918456968e-05
guided O 0 1.4645023838966154e-05
saccades O 0 0.026408594101667404
, O 0 2.1282803572830744e-06
antisaccades O 0 0.00013370859960559756
, O 0 4.6857806523803447e-07
and O 0 2.8154738629382337e-07
smooth O 0 2.4100243535940535e-05
pursuit O 0 9.863050217973068e-05
) O 0 1.402418092766311e-06
in O 0 2.752578041054221e-07
control O 0 1.1324425486236578e-06
subjects O 0 1.8702421584748663e-06
( O 0 1.3936970617578481e-06
n O 0 0.00015948449436109513
= O 0 0.00020879127259831876
14 O 0 4.852556230616756e-06
) O 0 1.4482872074950137e-06
and O 0 2.294691057613818e-06
patients O 0 2.2951964638195932e-05
with O 0 2.6090825144819974e-07
three O 0 9.163562708636164e-07
forms O 0 8.83318716660142e-06
of O 0 3.580936436264892e-06
autosomal O 0 0.12335047125816345
dominant O 0 0.00042247967212460935
cerebellar B-Disease 1 0.5929639935493469
ataxias I-Disease 0 0.06795680522918701
type I-Disease 0 2.261234294564929e-05
I I-Disease 0 4.8944129957817495e-06
spinocerebellar B-Disease 0 0.09188346564769745
ataxias I-Disease 0 0.0023927208967506886
1 I-Disease 0 2.723019406403182e-06
and I-Disease 0 2.762974702363863e-07
2 I-Disease 0 2.9966122383484617e-06
( O 0 7.767979468553676e-07
SCA1 B-Disease 0 8.35462924442254e-05
, O 0 3.7383787798717094e-07
n O 0 2.1704847313230857e-05
= O 0 3.2081821700558066e-05
11 O 0 1.537111643301614e-06
; O 0 1.071195015356352e-06
SCA2 B-Disease 0 7.222031126730144e-05
, O 0 4.2515537757026323e-07
n O 0 3.055455090361647e-05
= O 0 2.2532720322487876e-05
10 O 0 4.425674546837399e-07
) O 0 3.988229480000882e-07
and O 0 5.458300051941478e-07
SCA3 B-Disease 1 0.9945425987243652
/ O 0 0.014493557624518871
Machado B-Disease 0 0.00015908866771496832
- I-Disease 0 0.18166352808475494
Joseph I-Disease 0 0.0061355940997600555
disease I-Disease 0 0.0015918260905891657
( O 0 6.811823823227314e-06
MJD B-Disease 1 0.998121440410614
) O 0 5.298963060340611e-06
( O 0 1.3117120261085802e-06
n O 0 3.722033943631686e-05
= O 0 7.66422162996605e-05
16 O 0 3.954354724555742e-06
) O 0 3.685478532133857e-06
. O 0 7.886057574069127e-06

In O 0 8.842956594889984e-05
SCA1 B-Disease 0 0.0030395237263292074
, O 0 1.0414406460768078e-05
saccade O 0 0.00026472582248970866
amplitude O 0 1.533756949356757e-05
was O 0 1.901243763313687e-06
significantly O 0 4.90025104227243e-06
increased O 0 1.4388458566827467e-06
, O 0 1.275272211387346e-06
resulting O 0 6.169739663164364e-06
in O 0 3.6466358324105386e-06
hypermetria B-Disease 0 0.003372859675437212
. O 0 3.0087139748502523e-05

The O 0 6.20212740614079e-05
smooth O 0 0.00025822396855801344
pursuit O 0 0.00031007552752271295
gain O 0 0.00019275849626865238
was O 0 2.724221303651575e-05
decreased O 0 0.00011619667202467099
. O 0 4.2249146645190194e-05

In O 0 0.0001117544888984412
SCA2 B-Disease 0 0.004853332880884409
, O 0 2.6337213057558984e-05
saccade O 0 0.0005524670123122633
velocity O 0 4.464626908884384e-05
was O 0 8.472619811072946e-06
markedly O 0 0.0001260040298802778
decreased O 0 9.30450769374147e-05
. O 0 3.465271947789006e-05

The O 0 2.0064971977262758e-05
percentage O 0 2.5758159608813003e-05
of O 0 1.8634997331901104e-06
errors O 0 1.9565513866837136e-05
in O 0 1.35100572151714e-06
antisaccades O 0 0.0018810994224622846
was O 0 1.583367406965408e-06
greatly O 0 1.245638031832641e-06
increased O 0 4.4404802679309796e-07
and O 0 2.4661292741257057e-07
was O 0 7.09711741819774e-07
significantly O 0 1.1052257832488976e-05
correlated O 0 1.576547401782591e-05
with O 0 1.908695821839501e-06
age O 0 2.508919897081796e-05
at O 0 0.00011831565643660724
disease O 1 0.5602198243141174
onset O 1 0.5792192816734314
. O 0 9.21453392948024e-05

In O 0 2.8959120754734613e-05
addition O 0 6.634601049881894e-06
, O 0 1.2986574802198447e-06
a O 0 7.264249575200665e-07
correlation O 0 1.6325432170560816e-06
between O 0 4.0499108422409336e-07
smooth O 0 2.9384640583884902e-05
pursuit O 0 4.1110262827714905e-05
gain O 0 1.1008467481588013e-05
and O 0 2.2213681916127825e-07
the O 0 1.6827169702082756e-07
number O 0 2.8181088396195264e-07
of O 0 8.519276661900221e-07
trinucleotide O 0 0.0023048040457069874
repeats O 0 8.405357220908627e-05
was O 0 2.5019644454005174e-06
found O 0 6.0375991779437754e-06
. O 0 1.6473039067932405e-05

In O 0 0.000165570032550022
SCA3 B-Disease 1 0.9961399435997009
, O 0 3.2613970688544214e-05
gaze B-Disease 0 0.0005171470111235976
- I-Disease 0 0.01650550402700901
evoked I-Disease 0 0.0006445873877964914
nystagmus I-Disease 0 0.16241997480392456
was O 0 1.3921772961111856e-06
often O 0 4.497521501889423e-07
present O 0 2.9315995675460726e-07
as O 0 2.099423710433257e-07
was O 0 7.473030336768716e-07
saccade O 0 0.00012909363431390375
hypometria O 0 0.0001844520156737417
and O 0 6.611701905967493e-07
smooth O 0 1.7444817785872146e-05
pursuit O 0 2.8838301659561694e-05
gain O 0 2.4654791559441946e-05
was O 0 4.506358436628943e-06
markedly O 0 0.00018442425061948597
decreased O 0 0.00010605594434309751
. O 0 2.528322147554718e-05

Three O 0 4.010788325103931e-05
major O 0 1.9528788470779546e-05
criteria O 0 1.8752838514046744e-05
, O 0 2.4674448013684014e-06
saccade O 0 0.00011431189341237769
amplitude O 0 6.967637091293e-06
, O 0 9.269130032407702e-07
saccade O 0 4.2061848944285884e-05
velocity O 0 3.311945420136908e-06
, O 0 2.3418911609951465e-07
and O 0 1.1901269658665115e-07
presence O 0 1.9579236720801418e-07
of O 0 1.4343588361498405e-07
gaze B-Disease 0 2.7215159207116812e-05
- I-Disease 0 0.0011806772090494633
evoked I-Disease 0 0.00013742053124587983
nystagmus I-Disease 0 0.018343722447752953
, O 0 2.424734759642888e-07
permitted O 0 1.5461431246421853e-07
the O 0 1.0374424874726174e-07
correct O 0 2.5063156954274746e-06
assignment O 0 4.964870186086046e-07
of O 0 6.837916544100153e-08
90 O 0 3.038842919522722e-07
% O 0 1.9003542206519342e-07
of O 0 4.4146467814698553e-08
the O 0 2.3164335516412393e-07
SCA1 B-Disease 0 0.00038875185418874025
, O 0 3.6896383903695096e-07
90 O 0 3.286236278654542e-07
% O 0 1.6102679012419685e-07
of O 0 3.265267167762431e-08
the O 0 1.5301191069738707e-07
SCA2 B-Disease 0 0.0019105359679087996
, O 0 4.912267286272254e-07
and O 0 2.542687980167102e-07
93 O 0 2.5968347472371534e-06
% O 0 2.8112398808843864e-07
of O 0 8.214927049721155e-08
the O 0 8.773912441029097e-07
patients O 0 2.3456970666302368e-05
with O 0 8.205646508940845e-07
SCA3 B-Disease 1 0.996562659740448
to O 0 7.613884349666478e-07
their O 0 2.0436698378034635e-06
genetically O 0 0.0011216257698833942
confirmed O 0 8.328824333148077e-05
patient O 0 2.2188447474036366e-05
group O 0 7.4500144364719745e-06
and O 0 6.463620252361579e-07
, O 0 7.648022801731713e-07
therefore O 0 3.3055135872928076e-07
, O 0 4.282460110971442e-07
may O 0 1.0953486935250112e-06
help O 0 1.716589622446918e-06
orient O 0 0.022523347288370132
diagnoses O 0 0.004277089145034552
of O 0 4.961050876772788e-07
SCA1 B-Disease 0 0.031601570546627045
, O 0 2.2239232748688664e-06
SCA2 B-Disease 0 0.0003436434781178832
, O 0 5.773873681391706e-07
and O 0 6.710059778924915e-07
SCA3 B-Disease 1 0.9942947030067444
at O 0 3.0392943699553143e-06
early O 0 2.2128411728772335e-05
clinical O 0 5.1149156206520274e-05
stages O 0 1.5859632185311057e-05
of O 0 8.842997658575769e-07
the O 0 2.2987338525126688e-05
diseases O 0 0.1719180792570114
. O 0 9.347048944619019e-06
. O 0 2.8452850528992712e-05

Genetic O 0 0.001445477595552802
basis O 0 4.1333423723699525e-05
and O 0 1.668889308348298e-05
molecular O 0 0.0004604766145348549
mechanism O 0 0.00020914831839036196
for O 0 0.002043880056589842
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999994039535522
fibrillation I-Disease 1 0.9999997615814209
. O 0 0.0008947591995820403

Ventricular B-Disease 1 0.9999768733978271
fibrillation I-Disease 1 0.9999964237213135
causes O 0 0.005125146824866533
more O 0 4.310607437219005e-06
than O 0 1.0830490282387473e-06
300 O 0 1.8791007505569723e-06
, O 0 1.4739647440364934e-06
000 O 0 3.142698551528156e-05
sudden O 0 0.00018127699149772525
deaths O 0 6.64143180983956e-06
each O 0 1.398059197299517e-07
year O 0 5.625365702144336e-07
in O 0 3.101918650827429e-07
the O 0 8.303805429932254e-07
USA O 0 6.559211760759354e-05
alone O 0 1.1278617421339732e-05
. O 0 8.747196261538193e-06

In O 0 3.038348768313881e-05
approximately O 0 7.672074389120098e-06
5 O 0 4.410827386891469e-06
- O 0 4.883728252025321e-05
12 O 0 2.594623992990819e-06
% O 0 7.442589549100376e-07
of O 0 1.1130430266348412e-07
these O 0 2.1187491938690073e-07
cases O 0 1.3361858464122633e-06
, O 0 3.038245779407589e-07
there O 0 1.0212103518369986e-07
are O 0 1.4453659957780474e-07
no O 0 1.6774278037701151e-06
demonstrable O 0 0.23570550978183746
cardiac O 1 0.9641045331954956
or O 0 1.9497525499900803e-05
non O 0 0.011143529787659645
- O 1 0.9987800717353821
cardiac O 1 0.9993982315063477
causes O 0 1.1270478353253566e-05
to O 0 2.21596636151844e-07
account O 0 3.916625530564488e-07
for O 0 9.659335375999945e-08
the O 0 1.3041514534961607e-07
episode O 0 1.34674144192104e-06
, O 0 2.5257872948714066e-07
which O 0 1.5671444941744994e-07
is O 0 2.622653596517921e-07
therefore O 0 1.713128995106672e-06
classified O 0 0.00010722495062509552
as O 0 0.0001775330601958558
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999997615814209
fibrillation I-Disease 1 1.0
( O 0 0.09678096324205399
IVF B-Disease 1 0.9999939203262329
) O 0 7.442091009579599e-05
. O 0 2.5653460397734307e-05

A O 0 0.00010737372213043272
distinct O 0 0.00011517473467392847
group O 0 0.00025481663760729134
of O 0 3.316817310405895e-05
IVF B-Disease 1 0.9999998807907104
patients O 1 0.6940058469772339
has O 0 2.146863835150725e-06
been O 0 4.319890081205813e-07
found O 0 2.3161683770922536e-07
to O 0 1.3054143721547007e-07
present O 0 2.7656321321956057e-07
with O 0 3.200396463398647e-07
a O 0 3.299949185020523e-06
characteristic O 0 0.0003021849843207747
electrocardiographic O 0 0.45048651099205017
pattern O 0 0.0003989016986452043
. O 0 2.770400169538334e-05

Because O 0 2.2868718588142656e-05
of O 0 1.3523463167075533e-06
the O 0 5.051474545325618e-07
small O 0 5.238405265117763e-07
size O 0 5.650448429150856e-07
of O 0 1.5102301631486625e-07
most O 0 2.8684777930720884e-07
pedigrees O 0 1.531862471892964e-05
and O 0 5.477751301441458e-07
the O 0 3.4446884455974214e-07
high O 0 1.5558251106995158e-05
incidence O 0 0.0002310951385879889
of O 0 2.165691967093153e-06
sudden B-Disease 0 0.05007827281951904
death I-Disease 0 2.136389048246201e-05
, O 0 9.27348025925312e-07
however O 0 5.206778155297798e-07
, O 0 1.1637628176686121e-06
molecular O 0 5.953370055067353e-05
genetic O 0 3.501497121760622e-05
studies O 0 3.6475678371061804e-06
of O 0 1.5608277408318827e-06
IVF B-Disease 1 0.9999724626541138
have O 0 1.776337057890487e-06
not O 0 5.102857016936468e-07
yet O 0 1.122134904107952e-06
been O 0 8.375448032893473e-07
done O 0 5.093850631965324e-06
. O 0 1.2645899914787151e-05

Because O 0 0.005267458967864513
IVF B-Disease 1 0.9999983310699463
causes O 1 0.994299054145813
cardiac O 1 0.9999737739562988
rhythm O 1 0.8764857053756714
disturbance O 0 0.4199640452861786
, O 0 6.1078362705302425e-06
we O 0 8.04870751380804e-07
investigated O 0 1.0572124665486626e-05
whether O 0 8.417086405643204e-07
malfunction O 0 4.2364816181361675e-05
of O 0 2.334171966822396e-07
ion O 0 1.719388455967419e-05
channels O 0 1.9497229004628025e-06
could O 0 8.391166375076864e-07
cause O 0 2.682577814994147e-06
the O 0 1.1870646403622231e-06
disorder O 0 0.0070452881045639515
by O 0 9.599402801541146e-07
studying O 0 7.787237336742692e-06
mutations O 0 2.1117335563758388e-05
in O 0 4.4576597701961873e-07
the O 0 1.9817298380075954e-06
cardiac O 0 0.36145684123039246
sodium O 0 0.0002783468517009169
channel O 0 3.771153569687158e-05
gene O 0 2.9261602321639657e-05
SCN5A O 0 0.0007322080782614648
. O 0 3.212373485439457e-05

We O 0 2.9155862648622133e-05
have O 0 4.031312982988311e-06
now O 0 2.188613962061936e-06
identified O 0 2.649815769473207e-06
a O 0 1.5152810419749585e-06
missense O 0 0.0003642049850896001
mutation O 0 1.3404946912487503e-05
, O 0 3.129149490632699e-07
a O 0 5.108475988890859e-07
splice O 0 0.0009999250760301948
- O 0 0.07855416089296341
donor O 0 0.004194203764200211
mutation O 0 1.5024920685391407e-05
, O 0 3.2118134640768403e-07
and O 0 3.157113042107085e-07
a O 0 2.1597436443698825e-06
frameshift O 0 0.0628790557384491
mutation O 0 1.1590318536036648e-05
in O 0 1.5162220279307803e-07
the O 0 1.4942848736154701e-07
coding O 0 1.8953702237922698e-05
region O 0 2.596480499050813e-06
of O 0 3.045922198907647e-07
SCN5A O 0 0.0029608162585645914
in O 0 1.2062066616636002e-06
three O 0 5.210729796090163e-06
IVF B-Disease 1 0.9972832202911377
families O 0 5.474212593981065e-05
. O 0 1.8534012269810773e-05

We O 0 2.5133904273388907e-05
show O 0 9.306188076152466e-06
that O 0 8.265573114840663e-07
sodium O 0 4.697069471149007e-06
channels O 0 9.602991895008017e-07
with O 0 2.3515886482528003e-07
the O 0 4.469702332698944e-07
missense O 0 8.537075336789712e-05
mutation O 0 1.682432230154518e-05
recover O 0 4.7909223212627694e-05
from O 0 5.636336481984472e-07
inactivation O 0 0.0014739737380295992
more O 0 1.8965558012951078e-07
rapidly O 0 9.65852223089314e-07
than O 0 8.743710111502878e-08
normal O 0 2.8516487304841576e-07
and O 0 1.252242185501018e-07
that O 0 1.4250625213207968e-07
the O 0 5.323634013620904e-07
frameshift O 0 0.02586558647453785
mutation O 0 2.3286842406378128e-05
causes O 0 1.5818234260223107e-06
the O 0 1.3894964467908721e-07
sodium O 0 3.9024675970722456e-06
channel O 0 8.47892920319282e-07
to O 0 1.601205497081537e-07
be O 0 1.60466328225084e-07
non O 0 3.67023153557966e-06
- O 0 0.00010128608846571296
functional O 0 3.4547399991424754e-05
. O 0 1.326594519923674e-05

Our O 0 0.00011191103112651035
results O 0 0.00010730422945925966
indicate O 0 1.9124994651065208e-05
that O 0 1.8303416027265484e-06
mutations O 0 2.3700333258602768e-05
in O 0 2.361063252465101e-06
cardiac O 0 0.075456902384758
ion O 0 0.00014448288129642606
- O 0 0.00011135091335745528
channel O 0 2.953715238618315e-06
genes O 0 6.942689765310206e-07
contribute O 0 3.053408477171615e-07
to O 0 1.6416126413787424e-07
the O 0 3.1834593983148807e-07
risk O 0 6.065601610316662e-06
of O 0 1.0233831062578247e-06
developing O 0 0.0007446272647939622
IVF B-Disease 1 0.9995543360710144
. O 0 1.774748307070695e-05
. O 0 2.4665137971169315e-05

Molecular O 0 0.004122092854231596
heterogeneity O 0 0.0033338062930852175
in O 0 2.984261664096266e-05
mucopolysaccharidosis B-Disease 0 0.07831625640392303
IVA I-Disease 1 0.9278924465179443
in O 0 3.946111974073574e-06
Australia O 0 1.5801980453034048e-06
and O 0 4.4489661377156153e-07
Northern O 0 8.746810635784641e-07
Ireland O 0 2.2479871404357255e-06
: O 0 8.711887176104938e-07
nine O 0 8.76155354490038e-07
novel O 0 4.407026153785409e-06
mutations O 0 7.678728252358269e-06
including O 0 3.325081081584358e-07
T312S O 0 6.799643597332761e-05
, O 0 6.392278351086134e-07
a O 0 6.399359335773624e-07
common O 0 5.697498181689298e-06
allele O 0 2.1321473468560725e-05
that O 0 7.904481549303455e-07
confers O 0 9.535633580526337e-05
a O 0 4.559458466246724e-05
mild O 1 0.9692626595497131
phenotype O 1 0.7881293296813965
. O 0 8.385350520256907e-05

Mucopolysaccharidosis B-Disease 1 0.9467757940292358
IVA I-Disease 1 0.9998247027397156
( O 0 0.0014333430444821715
MPS B-Disease 1 0.9983032941818237
IVA I-Disease 1 0.9999984502792358
) O 0 4.396225995151326e-05
is O 0 1.8486065300749033e-06
an O 0 1.1836906196549535e-05
autosomal B-Disease 1 0.9885204434394836
recessive I-Disease 1 0.9978092312812805
lysosomal I-Disease 1 0.9999631643295288
storage I-Disease 1 0.9996805191040039
disorder I-Disease 1 0.9997232556343079
caused O 0 9.138386667473242e-05
by O 0 1.348577939097595e-06
a O 0 1.885384881461505e-05
genetic B-Disease 1 0.947310209274292
defect I-Disease 1 0.9613221883773804
in O 0 2.0222232706146315e-06
N O 0 0.00045142893213778734
- O 0 0.0005109923658892512
acetylgalactosamine O 0 0.0008286568918265402
- O 0 0.00013407399819698185
6 O 0 1.6084357412182726e-05
- O 0 0.0016394297126680613
sulfate O 0 0.0024884191807359457
sulfatase O 0 0.004204339813441038
( O 0 4.501096555031836e-06
GALNS O 0 0.0003101447655353695
) O 0 9.431252692593262e-06
. O 0 1.3311694601725321e-05

Previous O 0 0.0006017624982632697
studies O 0 9.249942377209663e-05
of O 0 5.7090182963293046e-06
patients O 0 0.00021804115385748446
from O 0 5.318883609106706e-07
a O 0 1.3912138001614949e-06
British O 0 2.22146791202249e-05
- O 0 0.040126074105501175
Irish O 0 2.5769262720132247e-05
population O 0 6.504704970211606e-07
showed O 0 5.381046435104508e-07
that O 0 5.645945222454429e-08
the O 0 1.7961623655082803e-07
I113F O 0 0.00013016880257055163
mutation O 0 6.463086720032152e-06
is O 0 8.784498106706451e-08
the O 0 6.344698988414166e-08
most O 0 1.3661214381954778e-07
common O 0 6.968633101678279e-07
single O 0 6.373642008838942e-06
mutation O 0 1.7203414245159365e-05
among O 0 2.965829935419606e-06
MPS B-Disease 1 0.9932644367218018
IVA I-Disease 1 0.9999998807907104
patients O 0 0.13307474553585052
and O 0 3.386523985682288e-06
produces O 0 0.00021124571503605694
a O 0 0.00023171381326392293
severe O 1 0.9988918900489807
clinical O 1 0.5634915232658386
phenotype O 1 0.6217402815818787
. O 0 0.00013430381659418344

We O 0 6.511709216283634e-05
studied O 0 8.874043851392344e-05
mutations O 0 9.686697740107775e-05
in O 0 1.2759339824697236e-06
the O 0 1.1841633522635675e-06
GALNS O 0 0.004413525108247995
gene O 0 7.914718480606098e-06
from O 0 5.901773647565278e-07
23 O 0 3.161788072247873e-06
additional O 0 3.963427843700629e-06
MPS B-Disease 1 0.9544622302055359
IVA I-Disease 1 0.9999997615814209
patients O 0 0.02614348754286766
( O 0 1.0483723826837377e-06
15 O 0 4.26157640731617e-07
from O 0 1.275555234769854e-07
Australia O 0 3.1427720159626915e-07
, O 0 1.6169495609119622e-07
8 O 0 4.184960857855913e-07
from O 0 7.801180856858991e-08
Northern O 0 3.976020082063769e-07
Ireland O 0 2.1376497443270637e-06
) O 0 6.746460599060811e-07
, O 0 1.75078213260349e-07
with O 0 3.4408111559969257e-07
various O 0 4.828026249015238e-06
clinical O 0 0.11020667850971222
phenotypes O 0 0.33062466979026794
( O 0 0.00013074773596599698
severe O 0 0.22839701175689697
, O 0 4.470100520848064e-06
16 O 0 1.5221929061226547e-05
cases O 0 1.395947720084223e-06
; O 0 2.1113312413945096e-06
intermediate O 0 1.6255029549938627e-05
, O 0 1.1220354281249456e-06
4 O 0 2.253925231343601e-05
cases O 0 5.714247436117148e-06
; O 0 2.3123504433897324e-05
mild O 0 0.037907034158706665
, O 0 3.937954261346022e-06
3 O 0 3.083781848545186e-05
cases O 0 8.503046956320759e-06
) O 0 5.1547308430599514e-06
. O 0 9.4161905508372e-06

We O 0 2.0277220755815506e-05
found O 0 4.848332537221722e-06
two O 0 1.7772384808267816e-06
common O 0 1.9881465050275438e-05
mutations O 0 2.6910362066701055e-05
that O 0 1.84354703947065e-07
together O 0 3.4857851005654084e-07
accounted O 0 1.4797874428040814e-06
for O 0 1.7885473369005922e-07
32 O 0 8.451190183222934e-07
% O 0 3.0927085958865064e-07
of O 0 5.082623388830143e-08
the O 0 1.8168411486385594e-07
44 O 0 4.0224149415735155e-06
unrelated O 0 1.9089298803010024e-05
alleles O 0 1.0052578545582946e-05
in O 0 1.548840828036191e-06
these O 0 4.587443982018158e-06
patients O 0 0.0004850469122175127
. O 0 2.5603061658330262e-05

One O 0 1.931188307935372e-05
is O 0 2.3979725938261254e-06
the O 0 1.2347804840828758e-06
T312S O 0 0.00028339526033960283
mutation O 0 1.5941546735120937e-05
, O 0 5.720795570596238e-07
a O 0 9.54659753915621e-07
novel O 0 1.2337856787780765e-05
mutation O 0 1.674590203037951e-05
found O 0 8.540557132619142e-07
exclusively O 0 2.777462441372336e-06
in O 0 9.209687959810253e-06
milder O 1 0.6690627932548523
patients O 0 0.010303693823516369
. O 0 4.1000832425197586e-05

The O 0 1.976927524083294e-05
other O 0 2.0949166810169118e-06
is O 0 6.209331218087755e-07
the O 0 5.443495183499181e-07
previously O 0 3.4439831324561965e-06
described O 0 7.944512617541477e-06
I113F O 0 8.98121579666622e-05
that O 0 1.2899442936031846e-06
produces O 0 5.0787144573405385e-05
a O 0 4.7371373511850834e-05
severe O 1 0.936354398727417
phenotype O 1 0.5446833372116089
. O 0 8.002288086572662e-05

The O 0 3.6728746636072174e-05
I113F O 0 0.0002469188184477389
and O 0 7.746223673166241e-06
T312S O 0 0.000553480873350054
mutations O 0 6.926145579200238e-05
accounted O 0 3.5075881896773353e-06
for O 0 4.970788154423644e-07
8 O 0 5.581558070844039e-06
( O 0 6.8467511482595e-07
18 O 0 5.332755108611309e-07
% O 0 6.639118055318249e-07
) O 0 2.42983674070274e-07
and O 0 2.0358018559818447e-07
6 O 0 4.06428762289579e-06
( O 0 4.808873654837953e-07
14 O 0 6.679961757072306e-07
% O 0 4.3134181737514155e-07
) O 0 2.072166722655311e-07
of O 0 1.4377579304891697e-07
44 O 0 3.8285975278995465e-06
unrelated O 0 2.1203602955210954e-05
alleles O 0 1.1802458175225183e-05
, O 0 1.945892563526286e-06
respectively O 0 2.7787031285697594e-05
. O 0 1.831894405768253e-05

The O 0 3.2352807465940714e-05
relatively O 0 2.483079515513964e-05
high O 0 1.2943352885486092e-05
residual O 0 0.00011683788034133613
GALNS O 0 0.001330781844444573
activity O 0 3.2891662158363033e-06
seen O 0 9.113936698668113e-07
when O 0 1.8793109290982102e-07
the O 0 2.238683975974709e-07
T312S O 0 7.299956905626459e-06
mutant O 0 3.7663121474906802e-06
cDNA O 0 3.910723535227589e-06
is O 0 6.811926027694426e-07
overexpressed O 0 1.811051697586663e-05
in O 0 6.600928941224993e-07
mutant O 0 1.4515806469717063e-05
cells O 0 2.578010389697738e-05
provides O 0 1.5837238152016653e-06
an O 0 3.0300105891001294e-07
explanation O 0 1.3354494967643404e-06
for O 0 3.9978982613320113e-07
the O 0 4.344113676779671e-06
mild O 1 0.9848037958145142
phenotype O 1 0.9710835218429565
in O 0 4.580398672260344e-05
patients O 0 0.0002698164607863873
with O 0 2.2128206182969734e-06
this O 0 5.8683299357653596e-06
mutation O 0 0.00012457494449336082
. O 0 1.8561197066446766e-05

The O 0 1.9826558855129406e-05
distribution O 0 1.1154014828207437e-05
and O 0 1.8928744793811347e-06
relative O 0 2.229453002655646e-06
frequencies O 0 1.3469352779793553e-06
of O 0 1.4260727709825005e-07
the O 0 2.396309923824447e-07
I113F O 0 2.2552110749529675e-05
and O 0 1.299750238104025e-06
T312S O 0 0.00022178085055202246
mutations O 0 8.374813660338987e-06
in O 0 1.7360079596073774e-07
Australia O 0 2.9436154136419646e-07
corresponded O 0 7.831458788132295e-07
to O 0 1.2726501097404253e-07
those O 0 1.3560176626015163e-07
observed O 0 4.786016347679833e-07
in O 0 1.2910687985367986e-07
Northern O 0 7.834311759324919e-07
Ireland O 0 1.4842012205917854e-06
and O 0 2.7767291044256126e-07
are O 0 5.7446328582955175e-08
unique O 0 1.4850334650873265e-07
to O 0 7.258862666503774e-08
these O 0 5.260341850998884e-08
two O 0 1.4297113182237808e-07
populations O 0 1.126207735069329e-06
, O 0 2.4834031364662223e-07
suggesting O 0 8.332474408234702e-07
that O 0 8.233060100337752e-08
both O 0 2.666007787865965e-07
mutations O 0 5.089378646516707e-06
were O 0 8.61864961620995e-08
probably O 0 1.965108822332695e-07
introduced O 0 2.989097538375063e-07
to O 0 1.0222120749858732e-07
Australia O 0 1.7311012356913125e-07
by O 0 1.3880290339329804e-07
Irish O 0 1.2054051694576629e-06
migrants O 0 1.4404027979253442e-06
during O 0 3.887183765982627e-07
the O 0 3.7823770071554463e-07
19th O 0 5.526315362658352e-06
century O 0 1.258978863916127e-05
. O 0 1.4304712749435566e-05

Haplotype O 0 0.02366691827774048
analysis O 0 0.00010885891242651269
using O 0 9.473729733144864e-06
6 O 0 1.2432298717612866e-05
RFLPs O 0 5.625734047498554e-05
provides O 0 1.2927743000545888e-06
additional O 0 5.645218266181473e-07
data O 0 7.223167131087393e-07
that O 0 8.887435853921488e-08
the O 0 1.6416846904121485e-07
I113F O 0 9.175129525829107e-05
mutation O 0 6.557687356689712e-06
originated O 0 6.790606335016491e-07
from O 0 1.7383439399054623e-07
a O 0 1.020858348965703e-06
common O 0 1.1187689779035281e-05
ancestor O 0 6.04601445957087e-05
. O 0 2.6086570869665593e-05

The O 0 1.7770889826351777e-05
other O 0 3.45132843904139e-06
9 O 0 1.826448533392977e-05
novel O 0 1.59147493832279e-05
mutations O 0 4.200048715574667e-05
identified O 0 3.5543062040233053e-06
in O 0 3.29070871885051e-07
these O 0 2.7182039730178076e-07
23 O 0 2.031221447396092e-05
patients O 0 1.764474291121587e-05
were O 0 7.895216924680426e-08
each O 0 7.840831273142612e-08
limited O 0 2.908669216594717e-07
to O 0 1.477284428119674e-07
a O 0 4.597424663188576e-07
single O 0 4.974589955963893e-06
family O 0 1.7370926798321307e-05
. O 0 2.168769424315542e-05

These O 0 2.4758532163104974e-05
data O 0 1.6993215467664413e-05
provide O 0 4.755881946039153e-06
further O 0 1.5199051404124475e-06
evidence O 0 1.0948473345706589e-06
for O 0 4.40682754287991e-07
extensive O 0 1.0979520084219985e-05
allelic O 0 0.000622403109446168
heterogeneity O 0 0.00042163237230852246
in O 0 4.783606982527999e-06
MPS B-Disease 1 0.9660378694534302
IVA I-Disease 1 0.999967098236084
in O 0 4.078319307154743e-06
British O 0 1.0680994819267653e-05
- O 0 0.07927621901035309
Irish O 0 0.0007093386957421899
patients O 0 0.00026329554384574294
and O 0 6.117415409789828e-07
provide O 0 1.1920335509785218e-06
evidence O 0 7.649095437045617e-07
for O 0 1.286565378677551e-07
their O 0 2.0458973892800714e-07
transmission O 0 1.970911171156331e-06
to O 0 1.6055848561791208e-07
Australia O 0 3.484585420210351e-07
by O 0 1.3585183467057504e-07
British O 0 1.2844006960222032e-06
- O 0 9.238253551302478e-05
Irish O 0 1.32982950162841e-05
migrants O 0 8.564132258470636e-06
. O 0 2.351663169974927e-06
. O 0 9.634901289246045e-06

Identification O 0 0.00016757553385104984
of O 0 1.607682861504145e-05
constitutional O 0 6.715626659570262e-05
WT1 O 1 0.9899299740791321
mutations O 0 0.007523751351982355
, O 0 4.151960183662595e-06
in O 0 5.143564521858934e-06
patients O 0 0.00023031824093777686
with O 0 1.850287662819028e-05
isolated O 0 0.1560307741165161
diffuse B-Disease 1 0.999990701675415
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 8.625854206911754e-06
and O 0 1.2021665725114872e-06
analysis O 0 2.403162397968117e-06
of O 0 1.2268853879504604e-06
genotype O 0 0.3660913109779358
/ O 1 0.5951583981513977
phenotype O 0 0.006596330553293228
correlations O 0 1.0108980859513395e-05
by O 0 2.0114970311624347e-07
use O 0 3.101959862306103e-07
of O 0 2.0615406981505657e-07
a O 0 2.056514858850278e-06
computerized O 0 0.0007126612472347915
mutation O 0 8.418207289651036e-05
database O 0 3.719057349371724e-05
. O 0 2.0377832697704434e-05

Constitutional O 0 0.000367835076758638
mutations O 0 0.00020515081996563822
of O 0 3.5888408547180006e-06
the O 0 3.341514229759923e-06
WT1 O 0 0.0037829873617738485
gene O 0 1.1631087545538321e-05
, O 0 6.349359296109469e-07
encoding O 0 2.0261845747882035e-06
a O 0 8.273057119367877e-07
zinc O 0 0.0002093518414767459
- O 0 0.00013287457113619894
finger O 0 2.820640838763211e-05
transcription O 0 6.475209374912083e-06
factor O 0 1.2700895695161307e-06
involved O 0 6.318998657661723e-07
in O 0 3.3605513181100832e-06
renal O 1 0.9989011287689209
and O 0 3.3374253689544275e-05
gonadal O 1 0.9817690849304199
development O 0 2.3777418391546234e-05
, O 0 8.448644166492159e-07
are O 0 1.4670872872102336e-07
found O 0 3.6824252447331673e-07
in O 0 4.301644764836965e-07
most O 0 2.2591971173824277e-06
patients O 0 8.38559863041155e-05
with O 0 8.167388841684442e-06
Denys B-Disease 1 0.9964267611503601
- I-Disease 1 0.9999624490737915
Drash I-Disease 1 0.9999979734420776
syndrome I-Disease 1 0.9999988079071045
( O 0 0.00013058824697509408
DDS B-Disease 1 0.9999997615814209
) O 0 1.657423490541987e-05
, O 0 2.1886264676140854e-06
or O 0 2.666207183210645e-05
diffuse B-Disease 1 0.9991816878318787
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.0009697002242319286
DMS B-Disease 1 0.9963536262512207
) O 0 5.331531156116398e-06
associated O 0 1.4666020433651283e-06
with O 0 9.675521823737654e-07
pseudohermaphroditism B-Disease 1 0.9988151788711548
and O 0 2.7601519832387567e-05
/ O 0 0.02666224166750908
or O 0 7.324024045374244e-05
Wilms B-Disease 1 0.999944806098938
tumor I-Disease 1 0.8592344522476196
( O 0 6.422815204132348e-05
WT B-Disease 1 0.9998189806938171
) O 0 2.0711542674689554e-05
. O 0 1.411583161825547e-05

Most O 0 0.000273236189968884
mutations O 0 0.001705703791230917
in O 0 0.00015008807531557977
DDS B-Disease 1 1.0
patients O 1 0.9915561676025391
lie O 0 0.0001367313088849187
in O 0 1.918715497595258e-06
exon O 0 3.104720963165164e-05
8 O 0 2.5540575734339654e-06
or O 0 3.636737346823793e-07
exon O 0 4.36832124250941e-06
9 O 0 1.0630940323608229e-06
, O 0 1.7842646116150718e-07
encoding O 0 1.1880421197929536e-06
zinc O 0 2.6091198378708214e-05
finger O 0 9.10560538613936e-06
2 O 0 2.7657265491143335e-06
or O 0 5.849404942637193e-07
zinc O 0 8.877190703060478e-05
finger O 0 1.4162646039039828e-05
3 O 0 4.137765699852025e-06
, O 0 2.323101284673612e-07
respectively O 0 6.522819830934168e-07
, O 0 7.080858921426625e-08
with O 0 9.679327916956026e-08
a O 0 4.194022267256514e-07
hot O 0 2.898915408877656e-05
spot O 0 1.1778844964283053e-05
( O 0 1.508219497736718e-06
R394W O 0 3.4139193303417414e-05
) O 0 9.184375926452049e-07
in O 0 7.918469577816722e-07
exon O 0 4.358003207016736e-05
9 O 0 2.2240346879698336e-05
. O 0 1.4382915651367512e-05

We O 0 4.3107549572596326e-05
analyzed O 0 5.1818275096593425e-05
a O 0 2.4843366190907545e-06
series O 0 3.843256308755372e-06
of O 0 7.699168804720102e-07
24 O 0 4.5426622818922624e-05
patients O 0 0.00014171170187182724
, O 0 6.016948077558482e-07
10 O 0 8.563180813325744e-07
with O 0 2.0801492155442247e-06
isolated B-Disease 0 0.0004717518750112504
DMS I-Disease 1 0.999729573726654
( O 0 3.321609256090596e-05
IDMS B-Disease 0 0.3100353181362152
) O 0 1.1703450581990182e-06
, O 0 1.9614783752786025e-07
10 O 0 2.1531759841764142e-07
with O 0 8.159987032740901e-07
DDS B-Disease 1 0.9999995231628418
, O 0 3.0201954359654337e-06
and O 0 6.260156624193769e-07
4 O 0 8.764898666413501e-06
with O 0 1.067691027856199e-05
urogenital B-Disease 1 0.9789992570877075
abnormalities I-Disease 1 0.9683626294136047
and O 0 2.310736817889847e-05
/ O 0 0.12731018662452698
or O 0 0.00010019719047704712
WT B-Disease 1 0.999925971031189
. O 0 4.798054578714073e-05

We O 0 8.689075912116095e-05
report O 0 0.00011638996511464939
WT1 O 0 0.016369277611374855
heterozygous O 0 0.0004246353346388787
mutations O 0 0.0002042329142568633
in O 0 3.2883599487831816e-06
16 O 0 4.971979797119275e-05
patients O 0 0.00015928586071822792
, O 0 7.529128538408258e-07
4 O 0 3.342161107866559e-06
of O 0 4.816010914510116e-07
whom O 0 1.2399275874486193e-05
presented O 0 1.2139444152126089e-05
with O 0 1.567064828122966e-05
IDMS B-Disease 1 0.9836793541908264
. O 0 8.572725346311927e-05

One O 0 3.2428823033114895e-05
male O 0 3.5072353057330474e-05
and O 0 3.964036295656115e-06
two O 0 4.244522642693482e-06
female O 0 0.000387253996450454
IDMS B-Disease 1 0.9999245405197144
patients O 0 0.040430136024951935
with O 0 5.788334965473041e-05
WT1 O 1 0.9997881054878235
mutations O 0 0.02512436918914318
underwent O 0 0.011408569291234016
normal O 0 0.00013326387852430344
puberty O 0 0.0010652112541720271
. O 0 4.840224573854357e-05

Two O 0 0.00019795172556769103
mutations O 0 0.0015151174739003181
associated O 0 1.6690499251126312e-05
with O 0 5.320539457898121e-06
IDMS B-Disease 1 0.5287659168243408
are O 0 5.659821340486815e-07
different O 0 2.5567328520992305e-07
from O 0 3.9349257008325367e-07
those O 0 8.491342100569454e-07
described O 0 6.476935959653929e-05
in O 0 0.00011576159886317328
DDS B-Disease 1 1.0
patients O 1 0.8580682873725891
. O 0 6.856526306364685e-05

No O 0 0.00027155689895153046
WT1 O 1 0.925884485244751
mutations O 0 0.0019325735047459602
were O 0 2.6374775643489556e-06
detected O 0 8.569646524847485e-06
in O 0 3.5937202369495935e-07
the O 0 1.9504057036101585e-07
six O 0 1.2642623232750339e-06
other O 0 6.072998530726181e-06
IDMS B-Disease 1 0.9999189376831055
patients O 0 0.026885123923420906
, O 0 4.131917648919625e-06
suggesting O 0 3.726913928403519e-05
genetic O 0 6.2678569520358e-05
heterogeneity O 0 0.0002521963615436107
of O 0 3.3357543998135952e-06
this O 0 1.87527130037779e-05
disease O 0 0.028465919196605682
. O 0 4.468768020160496e-05

We O 0 0.00012731201422866434
analyzed O 0 0.000792496488429606
genotype O 0 0.3094009459018707
/ O 1 0.7081120610237122
phenotype O 0 0.0699969232082367
correlations O 0 7.6227770477999e-05
, O 0 6.249288730941771e-07
on O 0 1.7765746918030345e-07
the O 0 9.964054470401607e-08
basis O 0 1.6308908357132168e-07
of O 0 7.665059342798486e-08
the O 0 1.5437018419106607e-07
constitution O 0 4.724405755496264e-07
of O 0 1.745933388974663e-07
a O 0 1.4868320477035013e-06
WT1 O 0 0.03492124006152153
mutation O 0 1.1146220458613243e-05
database O 0 1.025979486257711e-06
of O 0 2.0966066927030624e-07
84 O 0 1.2046699339407496e-05
germ O 0 0.0005263880011625588
- O 0 0.00012486845662351698
line O 0 7.486664799216669e-06
mutations O 0 4.548229753709165e-06
, O 0 1.1390089582619112e-07
to O 0 9.365721354015477e-08
compare O 0 8.337673307323712e-07
the O 0 8.88235263118986e-08
distribution O 0 4.0955404756459757e-07
and O 0 3.0490059543808457e-07
type O 0 1.769702066667378e-06
of O 0 4.450145638656977e-07
mutations O 0 2.2470041585620493e-05
, O 0 4.501950172652869e-07
according O 0 3.561016796993499e-07
to O 0 1.9459206157534936e-07
the O 0 6.341625748973456e-07
different O 0 5.45203874935396e-06
symptoms O 0 0.008127321489155293
. O 0 2.496573142707348e-05

This O 0 2.0629715436371043e-05
demonstrated O 0 4.551312667899765e-05
( O 0 3.231382834201213e-06
1 O 0 2.553399781390908e-06
) O 0 5.696834364243841e-07
the O 0 1.6509211775428412e-07
association O 0 6.410140258594765e-07
between O 0 2.8388765827003226e-07
mutations O 0 3.7583538414764917e-06
in O 0 2.2325370707676484e-07
exons O 0 1.0117661076947115e-05
8 O 0 1.1213592188141774e-06
and O 0 3.4100548873539083e-07
9 O 0 4.107158929400612e-06
and O 0 2.3104862520995084e-06
DMS B-Disease 1 0.8788580894470215
; O 0 8.734608854865655e-06
( O 0 8.858908699949097e-07
2 O 0 3.7562936086033005e-06
) O 0 1.8623859432409517e-06
among O 0 1.2876594155386556e-06
patients O 0 3.082658440689556e-05
with O 0 1.6786167407190078e-06
DMS B-Disease 1 0.9861584305763245
, O 0 5.100278031022754e-07
a O 0 1.6253446233349678e-07
higher O 0 5.826789220009232e-07
frequency O 0 4.814430667465786e-07
of O 0 1.3306853929861973e-07
exon O 0 9.338950803794432e-06
8 O 0 5.306725597620243e-06
mutations O 0 4.6943873712734785e-06
among O 0 2.1366804503486492e-07
46 O 0 4.901989541394869e-06
, O 0 4.855658062297152e-06
XY O 1 0.9494606256484985
patients O 0 0.0001707823685137555
with O 0 1.2188246500954847e-06
female O 0 3.683636532514356e-05
phenotype O 0 0.001006465288810432
than O 0 2.80409580000196e-07
among O 0 4.885114890385012e-07
46 O 0 1.3066730389255099e-05
, O 0 1.1054292372136842e-05
XY O 1 0.9497655034065247
patients O 0 0.00010891362762777135
with O 0 7.517734843531798e-07
sexual O 0 1.4352142443385674e-06
ambiguity O 0 4.574809281621128e-06
or O 0 3.3639500998106087e-06
male O 0 6.977668817853555e-05
phenotype O 0 0.030791567638516426
; O 0 6.595060767722316e-06
and O 0 1.0131876706509502e-06
( O 0 1.0378279284850578e-06
3 O 0 3.7110025914444122e-06
) O 0 1.0284284144290723e-06
statistically O 0 9.754719485499663e-07
significant O 0 3.0174439302754763e-07
evidence O 0 4.269166993253748e-07
that O 0 1.6739028296797187e-07
mutations O 0 2.4779976683930727e-06
in O 0 1.901122601566385e-07
exons O 0 1.217726730828872e-05
8 O 0 1.4354085351442336e-06
and O 0 1.6656363754918857e-07
9 O 0 1.6765768577897688e-06
preferentially O 0 2.760627694442519e-06
affect O 0 7.696614261476498e-07
amino O 0 1.443161067982146e-06
acids O 0 1.261746206182579e-06
with O 0 1.6482248099691788e-07
different O 0 3.805547805768583e-07
functions O 0 1.4819468105997657e-06
. O 0 2.1350622319005197e-06
. O 0 1.550451634102501e-05

The O 0 9.014962415676564e-05
185delAG O 0 0.004759351722896099
BRCA1 O 0 0.01896100677549839
mutation O 0 0.00010668472532415763
originated O 0 6.421027592296014e-06
before O 0 1.2080647593393223e-06
the O 0 3.1816290402275627e-07
dispersion O 0 8.56955648487201e-06
of O 0 1.5245520046391903e-07
Jews O 0 1.000497718450788e-06
in O 0 1.7635731808240962e-07
the O 0 1.1825726176084572e-07
diaspora O 0 8.880073437467217e-06
and O 0 4.2688085954978305e-07
is O 0 1.7663033702319808e-07
not O 0 1.2957882233877172e-07
limited O 0 8.315185482388188e-07
to O 0 1.8186593706559506e-06
Ashkenazim O 0 0.0006576188607141376
. O 0 2.434310590615496e-05

The O 0 6.567680247826502e-05
185delAG O 0 0.00259016128256917
mutation O 0 0.00026315374998375773
in O 0 6.7203013713879045e-06
BRCA1 O 0 0.0005520882550626993
is O 0 2.9688096674362896e-06
detected O 0 2.3048562070471235e-05
in O 0 1.0354681307944702e-06
Ashkenazi O 0 0.00041073968168348074
Jews O 0 2.6866512143897125e-06
both O 0 7.857701689317764e-07
in O 0 7.825478860468138e-06
familial B-Disease 1 0.9968460202217102
breast I-Disease 1 0.9999934434890747
and I-Disease 1 0.999618649482727
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
and O 0 7.136909971450223e-06
in O 0 1.397635514877038e-06
the O 0 9.780765140021686e-07
general O 0 5.691952992492588e-06
population O 0 6.651408057223307e-06
. O 0 1.0675362318579573e-05

All O 0 3.4403459721943364e-05
tested O 0 0.00013951231085229665
Ashkenazi O 0 0.011315071024000645
mutation O 0 4.632244963431731e-05
carriers O 0 5.191850505070761e-06
share O 0 1.3376367178352666e-06
the O 0 4.4663659082289087e-07
same O 0 7.788713105583156e-07
allelic O 0 4.0656563214724883e-05
pattern O 0 1.1955859008594416e-05
at O 0 1.15758405172528e-06
the O 0 3.090681957473862e-06
BRCA1 O 0 0.0005439239321276546
locus O 0 0.0001020366107695736
. O 0 2.1673262381227687e-05

Our O 0 5.392138336901553e-05
previous O 0 5.723162030335516e-05
study O 0 1.2368426723696757e-05
showed O 0 5.778402282885509e-06
that O 0 3.8686630432493985e-07
this O 0 3.4402566484459385e-07
Ashkenazi O 0 0.023541295900940895
mutation O 0 2.295237936777994e-05
also O 0 8.025384090615262e-07
occurs O 0 7.746659207441553e-07
in O 0 1.4443229190419515e-07
Iraqi O 0 8.989622983790468e-07
Jews O 0 7.523386784669128e-07
with O 0 3.7021862908659386e-07
a O 0 2.3238292214955436e-06
similar O 0 1.8558825104264542e-05
allelic O 0 0.0012497641146183014
pattern O 0 0.0003184163651894778
. O 0 2.435745409457013e-05

We O 0 2.127216248482e-05
extended O 0 1.286742917727679e-05
our O 0 2.7083656277682167e-06
analysis O 0 1.7647470258452813e-06
to O 0 1.8224497466690082e-07
other O 0 2.208085163601936e-07
non O 0 2.190739678553655e-06
- O 0 5.348571721697226e-05
Ashkenazi O 0 8.619367145001888e-05
subsets O 0 4.905909008812159e-06
354 O 0 3.1419858714798465e-06
of O 0 1.7319433709417353e-07
Moroccan O 0 1.0223782737739384e-05
origin O 0 7.206302825579769e-07
, O 0 2.6956416832035757e-07
200 O 0 4.895146616945567e-07
Yemenites O 0 2.0387629774631932e-05
and O 0 3.350754411712842e-07
150 O 0 1.271927203561063e-06
Iranian O 0 7.077711416059174e-06
Jews O 0 8.998785233416129e-06
. O 0 9.32954117160989e-06

Heteroduplex O 0 0.008134675212204456
analysis O 0 8.401174272876233e-05
complemented O 0 3.440267391852103e-05
by O 0 1.7948574395632022e-06
direct O 0 2.5227036530850455e-06
DNA O 0 7.3239029916294385e-06
sequencing O 0 5.156584393262165e-06
of O 0 6.754772812200827e-07
abnormally O 0 0.00018173769058194011
migrating O 0 9.74607428361196e-06
bands O 0 9.260664228349924e-06
were O 0 1.8124329699276132e-06
employed O 0 1.5965204511303455e-05
. O 0 1.4461850696534384e-05

Four O 0 1.8693148376769386e-05
of O 0 3.6446124340727692e-06
Moroccan O 0 5.306020102580078e-05
origin O 0 4.090921265742509e-06
( O 0 9.540854080114514e-07
1 O 0 9.35364937504346e-07
. O 0 1.899973511854114e-07
1 O 0 8.07686546977493e-07
% O 0 1.161806721938774e-06
) O 0 2.804350174301362e-07
and O 0 1.631334072271784e-07
none O 0 1.8362950982009352e-07
of O 0 5.972025007849879e-08
the O 0 1.9721059629773663e-07
Yemenites O 0 5.9951293224003166e-05
or O 0 2.969161982946389e-07
Iranians O 0 6.90495369326527e-07
was O 0 1.517441603482439e-07
a O 0 1.8089572506596596e-07
carrier O 0 2.231631242466392e-06
of O 0 2.7608831487668795e-07
the O 0 1.552520302539051e-06
185delAG O 0 0.0011119779665023088
mutation O 0 8.509019244229421e-05
. O 0 1.2564901226141956e-05

BRCA1 O 1 0.5642297267913818
allelic O 0 0.00843010749667883
patterns O 0 0.00024552884860895574
were O 0 3.100155254287529e-06
determined O 0 2.3058964870870113e-06
for O 0 3.2036211905506207e-07
four O 0 2.6052015300592757e-07
of O 0 1.643716416310781e-07
these O 0 1.8600999851514644e-07
individuals O 0 2.397717935309629e-07
and O 0 1.6730727736558038e-07
for O 0 1.6114952927637205e-07
12 O 0 8.905369668354979e-07
additional O 0 6.886251071591687e-07
non O 0 8.25759707367979e-06
- O 0 0.0005138837732374668
Ashkenazi O 0 0.0026203563902527094
185delAG O 0 0.00016570789739489555
mutation O 0 7.88981924415566e-06
carriers O 0 2.600445441203192e-06
who O 0 2.152448132619611e-06
had O 0 8.77099228091538e-05
breast B-Disease 1 0.9998527765274048
/ I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999901056289673
. O 0 0.0001353294210275635

Six O 0 0.00012274572509340942
non O 0 0.00024298622156493366
- O 0 0.03180640563368797
Ashkenazi O 0 0.04775059223175049
individuals O 0 1.0883566119446186e-06
shared O 0 4.91710409278312e-07
the O 0 2.393482247953216e-07
common O 0 5.123667506268248e-06
Ashkenazi O 0 0.02955217845737934
haplotype O 0 0.0006513241096399724
, O 0 3.1356290719486424e-07
four O 0 1.7967586529721302e-07
had O 0 1.6912937894630886e-07
a O 0 3.8780567024332413e-07
closely O 0 9.942762517312076e-06
related O 0 1.2378622159303632e-05
pattern O 0 2.6003761377069168e-05
, O 0 6.542194341818686e-07
and O 0 2.456243066717434e-07
the O 0 1.3426706857444515e-07
rest O 0 9.98082896330743e-07
( O 0 6.641511731686478e-07
n O 0 3.2548570743529126e-05
= O 0 3.775233926717192e-05
6 O 0 3.0018579764146125e-06
) O 0 3.92219504874447e-07
displayed O 0 6.484785899374401e-07
a O 0 1.0476699117134558e-06
distinct O 0 2.6753434212878346e-05
BRCA1 O 0 0.0007186704897321761
allelic O 0 0.000864367582835257
pattern O 0 0.0002491248887963593
. O 0 3.1131352443480864e-05

We O 0 3.126893352600746e-05
conclude O 0 7.610951433889568e-05
that O 0 1.6317493418682716e-06
the O 0 1.271522023671423e-06
185delAG O 0 0.0011163385352119803
BRCA1 O 0 0.01656324602663517
mutation O 0 4.908951814286411e-05
occurs O 0 1.4119099205345265e-06
in O 0 1.55026995685148e-07
some O 0 1.0648073356378518e-07
non O 0 9.559931640978903e-06
- O 0 0.010284621268510818
Ashkenazi O 0 0.07178115099668503
populations O 0 2.789367499644868e-06
at O 0 2.679162207641639e-07
rates O 0 7.283159106918902e-07
comparable O 0 9.004750154417707e-07
with O 0 2.2261929188971408e-07
that O 0 4.0294153791364806e-07
of O 0 1.9372896531422157e-06
Ashkenazim O 0 0.0015904017491266131
. O 0 3.76241332560312e-05

The O 0 1.5877049008850008e-05
majority O 0 9.61448677117005e-06
of O 0 1.2872714023615117e-06
Jewish O 0 1.4624562027165666e-05
185delAG O 0 0.0017799038905650377
mutation O 0 3.610669227782637e-05
carriers O 0 2.5712477054185e-06
have O 0 1.6506236022451048e-07
a O 0 3.5221387406636495e-07
common O 0 4.169856765656732e-06
allelic O 0 0.00017516037041787058
pattern O 0 1.416953637090046e-05
, O 0 3.270020272339025e-07
supporting O 0 5.758552674706152e-07
the O 0 1.6417942561020027e-07
founder O 0 2.2206502762855962e-05
effect O 0 9.306428978561598e-07
notion O 0 4.540522979823436e-07
, O 0 2.758030746008444e-07
but O 0 1.4780820833948383e-07
dating O 0 6.177183990985213e-07
the O 0 3.193920292687835e-07
mutations O 0 7.756906597933266e-06
origin O 0 2.681636885881744e-07
to O 0 7.788945310949202e-08
an O 0 9.845340542824488e-08
earlier O 0 1.7352231225231662e-06
date O 0 1.2029211120534455e-06
than O 0 3.0351790769600484e-07
currently O 0 1.5179828096734127e-06
estimated O 0 8.593691745772958e-06
. O 0 1.226099266204983e-05

However O 0 4.9160262278746814e-05
, O 0 3.3100475320679834e-06
the O 0 9.995974323828705e-07
different O 0 8.561286790609302e-07
allelic O 0 2.6903950129053555e-05
pattern O 0 7.673668733332306e-06
at O 0 5.706399406335549e-07
the O 0 6.507870011773775e-07
BRCA1 O 0 9.339007374364883e-05
locus O 0 4.488781087275129e-06
even O 0 3.039747298316797e-07
in O 0 1.424448470288553e-07
some O 0 9.894738894900001e-08
Jewish O 0 4.785742930835113e-06
mutation O 0 8.037777661229484e-06
carriers O 0 2.030440100497799e-06
, O 0 3.923006488548708e-07
might O 0 5.461653813654266e-07
suggest O 0 7.162630595303199e-07
that O 0 1.3284703470617387e-07
the O 0 5.141172323419596e-07
mutation O 0 1.443422388547333e-05
arose O 0 1.0235801710223313e-05
independently O 0 7.78322009864496e-06
. O 0 3.2157286113942973e-06
. O 0 1.3350444532989059e-05

Crystal O 0 0.0026052561588585377
structure O 0 4.7599012759746984e-05
of O 0 3.2012130759540014e-06
the O 0 4.321111191529781e-06
hemochromatosis B-Disease 1 0.9998576641082764
protein O 0 9.806423622649163e-05
HFE O 0 0.0023577979300171137
and O 0 1.2007366194666247e-06
characterization O 0 3.7221570892143063e-06
of O 0 1.7895369808229589e-07
its O 0 8.991869435703848e-07
interaction O 0 1.8562595869298093e-06
with O 0 2.2678727873426396e-06
transferrin O 0 0.0011461349204182625
receptor O 0 0.00013901459169574082
. O 0 2.396337549726013e-05

HFE O 0 0.4261159598827362
is O 0 2.528138975321781e-05
an O 0 6.1339001149463e-06
MHC O 0 0.0009749978198669851
- O 0 0.0015194793231785297
related O 0 9.463075002713595e-06
protein O 0 1.5783756452947273e-06
that O 0 8.882521740360971e-08
is O 0 1.14264608441772e-07
mutated O 0 1.7654574548942037e-06
in O 0 1.7900079285482207e-07
the O 0 4.798181976184424e-07
iron B-Disease 0 0.21558444201946259
- I-Disease 1 0.9999610185623169
overload I-Disease 1 0.999854326248169
disease I-Disease 1 0.9990215301513672
hereditary B-Disease 1 0.9999988079071045
hemochromatosis I-Disease 1 1.0
. O 0 0.0006947403308004141

HFE O 0 0.018986932933330536
binds O 0 0.0001990228920476511
to O 0 1.4332870705402456e-05
transferrin O 0 0.0007788838120177388
receptor O 0 6.882743036840111e-05
( O 0 3.4634686016943306e-06
TfR O 0 3.544081482687034e-05
) O 0 4.974895091436338e-07
and O 0 1.9536543049980537e-07
reduces O 0 1.4904350109645748e-06
its O 0 2.5667443992460903e-07
affinity O 0 7.781830504427489e-07
for O 0 2.6316581624996616e-07
iron O 0 1.5464525858988054e-05
- O 0 3.236379416193813e-05
loaded O 0 6.698131528537488e-06
transferrin O 0 5.484872235683724e-05
, O 0 1.6435078578069806e-06
implicating O 0 0.0001273366651730612
HFE O 0 0.0013194700004532933
in O 0 6.144449343992164e-06
iron O 0 0.0016589983133599162
metabolism O 0 0.0011788326082751155
. O 0 4.878952677245252e-05

The O 0 0.0002312243013875559
2 O 0 0.00043228743015788496
. O 0 0.00015921461454126984

6 O 0 0.0004087589040864259
A O 0 2.2893747882335447e-05
crystal O 0 0.0002500341215636581
structure O 0 8.360848369193263e-06
of O 0 1.1300626283627935e-06
HFE O 0 0.0027559574227780104
reveals O 0 1.2413591321092099e-05
the O 0 2.708810313833965e-07
locations O 0 1.0089132729262928e-06
of O 0 1.4569023960575578e-06
hemochromatosis B-Disease 1 0.9999994039535522
mutations O 0 0.0003316236543469131
and O 0 5.52452661395364e-07
a O 0 1.045354338202742e-06
patch O 0 0.008464154787361622
of O 0 9.29137115690537e-07
histidines O 0 0.00485096825286746
that O 0 2.3053263475958374e-07
could O 0 2.788402468922868e-07
be O 0 1.3101575291329937e-07
involved O 0 4.979850700692623e-07
in O 0 8.898960004444234e-07
pH O 0 0.0028226180002093315
- O 0 0.07136605679988861
dependent O 0 0.0002572378725744784
interactions O 0 2.7471325665828772e-05
. O 0 1.8159980754717253e-05

We O 0 3.585558442864567e-05
also O 0 6.830506663391134e-06
demonstrate O 0 1.0162105354538653e-05
that O 0 1.1345319990141434e-06
soluble O 0 0.00016961763321887702
TfR O 0 0.00026683913893066347
and O 0 2.3191532818600535e-06
HFE O 0 0.0006084736669436097
bind O 0 1.0131787348655052e-05
tightly O 0 2.2632707441516686e-06
at O 0 2.5484027332822734e-07
the O 0 1.1485457207527361e-07
basic O 0 5.734735282203474e-07
pH O 0 2.387872154940851e-05
of O 0 1.0662584060128211e-07
the O 0 2.6999330771104724e-07
cell O 0 3.40738806698937e-05
surface O 0 9.577634955348913e-06
, O 0 5.35635933829326e-07
but O 0 8.595617373430287e-08
not O 0 5.926839463654687e-08
at O 0 1.0954295248666313e-07
the O 0 3.7472594272003334e-07
acidic O 0 0.002353056101128459
pH O 0 0.0002223114133812487
of O 0 2.1754001409135526e-06
intracellular O 0 9.113932173931971e-05
vesicles O 0 0.0004346156201791018
. O 0 2.504592703189701e-05

TfR O 0 0.4945841431617737
HFE O 1 0.82101970911026
stoichiometry O 0 0.005292658228427172
( O 0 3.180655403411947e-05
2 O 0 1.0751665286079515e-05
1 O 0 5.257621523924172e-06
) O 0 1.7387729940310237e-06
differs O 0 3.175588972226251e-06
from O 0 9.052977816281782e-07
TfR O 0 8.379315113415942e-05
transferrin O 0 0.00010864010982913896
stoichiometry O 0 2.300139567523729e-05
( O 0 8.340544468410371e-07
2 O 0 1.211241738019453e-06
2 O 0 2.5713777631608536e-06
) O 0 6.674631549685728e-07
, O 0 1.6273887126772024e-07
implying O 0 9.568966561346315e-07
a O 0 1.3459833780871122e-07
different O 0 1.064319974375394e-07
mode O 0 4.949699246026285e-07
of O 0 8.590962607968322e-08
binding O 0 1.319727402915305e-06
for O 0 4.6771458528382936e-07
HFE O 0 0.0004545726114884019
and O 0 1.2711511772067752e-06
transferrin O 0 6.610823038499802e-05
to O 0 5.441984853860049e-07
TfR O 0 7.131264283088967e-05
, O 0 3.41650661539461e-07
consistent O 0 6.98704639034986e-07
with O 0 1.766369024380765e-07
our O 0 4.2756371954055794e-07
demonstration O 0 1.8608183154356084e-06
that O 0 3.031314292911702e-07
HFE O 0 0.00018424936570227146
, O 0 9.489602348367043e-07
transferrin O 0 7.27935039321892e-05
, O 0 6.828421419413644e-07
and O 0 7.26896871583449e-07
TfR O 0 8.949762559495866e-05
form O 0 2.635423243191326e-06
a O 0 3.0475832772935973e-06
ternary O 0 0.00017472232866566628
complex O 0 6.444306927733123e-05
. O 0 2.9794586225762032e-05

Identification O 0 0.000110146269435063
of O 0 4.565491053654114e-06
three O 0 2.3716111172689125e-06
novel O 0 1.771155439200811e-05
mutations O 0 1.9678143871715292e-05
and O 0 3.043901131150051e-07
a O 0 4.784368456967059e-07
high O 0 1.8958047576234094e-06
frequency O 0 9.878980335997767e-07
of O 0 1.4778127876979852e-07
the O 0 4.141699605497706e-07
Arg778Leu O 0 0.002876258920878172
mutation O 0 1.3455663975037169e-05
in O 0 8.01139776740456e-07
Korean O 0 8.242514013545588e-05
patients O 0 0.00030360283562913537
with O 0 1.717724990157876e-05
Wilson B-Disease 0 0.023250997066497803
disease I-Disease 0 0.016614388674497604
. O 0 3.419650602154434e-05

Four O 0 0.00021173953427933156
mutations O 0 0.000587762042414397
- O 0 0.0001821326877688989
- O 0 0.0003213179879821837
R778L O 0 9.108137601288036e-05
, O 0 9.93122739600949e-07
A874V O 0 1.09229968074942e-05
, O 0 4.4092448092669656e-07
L1083F O 0 7.921182259451598e-06
, O 0 2.1364358815390005e-07
and O 0 2.842910760136874e-07
2304delC O 0 3.242192542529665e-05
- O 0 3.146348535665311e-05
- O 0 1.4361301509779878e-05
in O 0 1.3235599283234478e-07
the O 0 1.1563093238464717e-07
copper O 0 4.670068847190123e-06
- O 0 9.758788110048044e-06
transporting O 0 2.792598706946592e-06
enzyme O 0 3.4763611438393127e-06
, O 0 3.065300688831485e-07
P O 0 9.375876834383234e-05
- O 0 4.7273664677049965e-05
type O 0 4.47692127636401e-06
ATPase O 0 0.0001719588617561385
( O 0 9.561823617332266e-07
ATP7B O 0 0.00017526463489048183
) O 0 5.662407147610793e-07
, O 0 1.6723230089610297e-07
were O 0 1.5741801462354488e-07
identified O 0 9.79070364337531e-07
in O 0 4.040628880375152e-07
Korean O 0 0.00012637392501346767
Patients O 0 0.00019322533626109362
with O 0 3.31791234202683e-05
Wilson B-Disease 0 0.07067476212978363
disease I-Disease 0 0.01613040268421173
. O 0 4.160058597335592e-05

Arg778Leu O 0 0.03726420924067497
, O 0 1.6106645489344373e-05
the O 0 1.4290911849457189e-06
most O 0 8.230632602135302e-07
frequently O 0 4.006148174084956e-06
reported O 0 1.240815890923841e-05
mutation O 0 2.4331370696017984e-06
of O 0 1.1143472988806025e-07
this O 0 1.444277444306863e-07
enzyme O 0 1.3018719073443208e-05
, O 0 4.3764171664406604e-07
was O 0 2.074976919175242e-07
found O 0 1.9952838670178608e-07
in O 0 1.1752153739053028e-07
six O 0 3.0381761462194845e-07
of O 0 2.432834662613459e-07
eight O 0 2.00526301341597e-05
unrelated O 0 0.01845734938979149
patients O 0 0.002405876759439707
studied O 0 2.9272516712808283e-06
, O 0 4.224087319926184e-07
an O 0 3.284018248450593e-07
allele O 0 6.9315296968852635e-06
frequency O 0 2.6783193334267708e-06
of O 0 1.104630428017117e-06
37 O 0 2.6227859052596614e-05
. O 0 2.1537996872211806e-05

5 O 0 0.0004189344181213528
% O 0 2.324632805539295e-05
, O 0 1.0338035281165503e-06
which O 0 2.912755405759526e-07
is O 0 2.2652803011169453e-07
considerably O 0 2.5381384602951584e-06
higher O 0 7.591364692416391e-07
than O 0 1.6754167120325292e-07
those O 0 1.7884893566133542e-07
in O 0 2.4632899453536083e-07
other O 0 5.798247002530843e-07
Asian O 0 9.257255442207679e-06
populations O 0 2.590777148725465e-05
. O 0 1.3009087524551433e-05

The O 0 3.0084125683060847e-05
novel O 0 2.3105581931304187e-05
single O 0 9.090706953429617e-06
nucleotide O 0 4.60683113487903e-05
deletion O 0 4.94399901072029e-05
, O 0 1.8455804138284293e-06
2304delC O 0 8.11478093964979e-05
, O 0 9.373098350806686e-07
was O 0 4.473732246879081e-07
found O 0 4.336189363129961e-07
in O 0 5.523863251255534e-07
one O 0 2.9175084819144104e-06
patient O 0 0.00029332865960896015
. O 0 2.7795353162218817e-05

Since O 0 7.199977699201554e-05
a O 0 9.439872883376665e-06
mutation O 0 1.2469794455682859e-05
at O 0 1.2249844303369173e-06
cDNA O 0 2.2315962269203737e-05
nucleotide O 0 4.372427792986855e-05
2302 O 0 0.002045947825536132
( O 0 2.9226573587948224e-06
2302insC O 0 4.727487976197153e-05
) O 0 8.163730740307074e-07
had O 0 3.555977343694394e-07
been O 0 2.9192486294959963e-07
previously O 0 1.341216034234094e-06
described O 0 7.142260983528104e-06
, O 0 3.0085129765211605e-07
this O 0 1.2281620342946553e-07
region O 0 8.378452207580267e-07
of O 0 1.3797750852972968e-07
the O 0 5.885361815671786e-07
ATP7B O 0 0.08817952126264572
gene O 0 2.451563887007069e-05
may O 0 3.2193770493904594e-06
be O 0 3.122671330402227e-07
susceptible O 0 4.540773807093501e-05
to O 0 2.3393670289806323e-06
gene O 0 6.049814692232758e-05
rearrangements O 0 0.028060467913746834
causing O 0 0.024370120838284492
Wilson B-Disease 0 0.018839994445443153
disease I-Disease 0 0.012415164150297642
. O 0 7.157159416237846e-05

Disruption O 0 0.0006524426280520856
of O 0 1.307136790273944e-05
splicing O 0 0.0001376384898321703
regulated O 0 1.09403863461921e-05
by O 0 7.470586069757701e-07
a O 0 8.645088200864848e-07
CUG O 0 0.000491687620524317
- O 0 0.0003274509508628398
binding O 0 3.2294665288645774e-05
protein O 0 4.484871169552207e-05
in O 0 3.842443766188808e-05
myotonic B-Disease 1 0.9999970197677612
dystrophy I-Disease 1 0.999998927116394
. O 0 0.00018893973901867867

Myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 1.0
( O 1 0.9894943833351135
DM B-Disease 1 1.0
) O 0 0.00035662297159433365
is O 0 2.2577821710001444e-06
caused O 0 3.2438040307170013e-06
by O 0 3.4334129850321915e-07
a O 0 5.92411538491433e-07
CTG O 0 0.00032136726076714694
expansion O 0 2.6809359496837715e-06
in O 0 1.7978435096210887e-07
the O 0 1.5433514022333839e-07
3 O 0 3.0615253763244255e-06
untranslated O 0 0.0007840821635909379
region O 0 3.2105808713822626e-06
of O 0 4.524287646745506e-07
the O 0 5.255174983176403e-06
DM B-Disease 1 0.9999988079071045
gene O 0 0.00018660043133422732
. O 0 2.3562030037282966e-05

One O 0 3.505205677356571e-05
model O 0 4.42627897427883e-05
of O 0 2.0240509911673144e-05
DM B-Disease 1 0.9999998807907104
pathogenesis O 1 0.913137674331665
suggests O 0 2.308551484020427e-05
that O 0 5.210195581639709e-07
RNAs O 0 6.735700026183622e-06
from O 0 1.5397849040255096e-07
the O 0 1.1776522512718657e-07
expanded O 0 5.574178203460178e-07
allele O 0 1.2310226793488255e-06
create O 0 3.666442580652074e-07
a O 0 2.974913115849631e-07
gain O 0 2.9119185001036385e-06
- O 0 1.235232502949657e-05
of O 0 2.1596930821488058e-07
- O 0 0.00010049316188087687
function O 0 1.2910456916870316e-06
mutation O 0 1.3091537311993307e-06
by O 0 9.932082889463345e-08
the O 0 1.444156083607595e-07
inappropriate O 0 8.726222517907445e-07
binding O 0 8.219156484301493e-07
of O 0 1.1310486058846436e-07
proteins O 0 3.6550994764183997e-07
to O 0 2.5531414848956047e-07
the O 0 1.646714736125432e-06
CUG O 0 0.0031704395078122616
repeats O 0 0.0002694473078008741
. O 0 1.571084067109041e-05

Data O 0 0.00017288677918259054
presented O 0 3.431862569414079e-05
here O 0 3.7050372156954836e-06
indicate O 0 3.4746476558211725e-06
that O 0 2.890603241212375e-07
the O 0 3.059252549064695e-07
conserved O 0 2.6392010568088153e-06
heterogeneous O 0 4.0397313568973914e-05
nuclear O 0 4.6788612962700427e-05
ribonucleoprotein O 0 0.0001317074929829687
, O 0 9.230325872522371e-07
CUG O 0 4.3292897316860035e-05
- O 0 2.3994156435946934e-05
binding O 0 3.4434117424098076e-06
protein O 0 2.006662043640972e-06
( O 0 6.987465894781053e-07
CUG O 0 0.00010953574383165687
- O 0 0.000338567333528772
BP O 0 0.00983809307217598
) O 0 1.2021355360047892e-06
, O 0 1.9247950433509686e-07
may O 0 3.098896570463694e-07
mediate O 0 8.574412277084775e-06
the O 0 2.558484197834332e-07
trans O 0 3.558769458322786e-05
- O 0 0.00011444605479482561
dominant O 0 6.127825145085808e-06
effect O 0 6.6645435481405e-07
of O 0 1.724424549820469e-07
the O 0 9.283621125177888e-07
RNA O 0 2.8748676413670182e-05
. O 0 1.823752245400101e-05

CUG O 0 0.39679521322250366
- O 0 0.2509516477584839
BP O 0 0.16062277555465698
was O 0 4.863981757807778e-06
found O 0 6.383031063705857e-07
to O 0 2.910039711423451e-07
bind O 0 2.985134187838412e-06
to O 0 4.520009611042042e-07
the O 0 1.1314267567286151e-06
human O 0 2.5393892428837717e-05
cardiac O 1 0.9785635471343994
troponin O 1 0.9835662245750427
T O 1 0.957478404045105
( O 0 3.832173661066918e-06
cTNT O 0 4.884017471340485e-05
) O 0 6.772122560505522e-07
pre O 0 4.0908739720180165e-06
- O 0 1.0357967767049558e-05
messenger O 0 3.6152571283309953e-06
RNA O 0 1.5092439298314275e-06
and O 0 2.1498723867807712e-07
regulate O 0 2.8945173653482925e-06
its O 0 1.7015846651702304e-06
alternative O 0 2.296061211382039e-05
splicing O 0 0.00023335489095188677
. O 0 2.0714564016088843e-05

Splicing O 0 0.0009312272886745632
of O 0 2.190887971664779e-05
cTNT O 0 0.0007584134000353515
was O 0 6.982682862144429e-06
disrupted O 0 0.00010227331222267821
in O 0 2.6185893148067407e-05
DM B-Disease 1 0.9999998807907104
striated O 1 0.9899465441703796
muscle O 0 0.001411460223607719
and O 0 1.3871043620383716e-06
in O 0 8.762214065427543e-07
normal O 0 5.699781013390748e-06
cells O 0 3.771476986003108e-05
expressing O 0 6.812349511164939e-06
transcripts O 0 1.0085630492540076e-05
that O 0 5.785840357930283e-07
contain O 0 5.798053734906716e-06
CUG O 0 0.0025110095739364624
repeats O 0 0.00030091343796812
. O 0 2.31049216381507e-05

Altered O 0 0.0009222320513799787
expression O 0 7.300184370251372e-05
of O 0 4.715790510090301e-06
genes O 0 1.282921130041359e-05
regulated O 0 8.532874744560104e-06
posttranscriptionally O 0 0.00011911907495232299
by O 0 2.200799599449965e-06
CUG O 0 0.0015330907190218568
- O 0 0.0026054494082927704
BP O 0 0.021747242659330368
therefore O 0 2.703351810851018e-06
may O 0 1.576006752657122e-06
contribute O 0 2.55803820436995e-06
to O 0 6.844963536423165e-06
DM B-Disease 1 0.9999998807907104
pathogenesis O 1 0.5795707702636719
. O 0 8.408826033701189e-06
. O 0 1.225174855790101e-05

Identification O 0 0.00011124404409201816
of O 0 5.0134149205405265e-06
a O 0 5.136554136697669e-06
novel O 0 1.4181621736497618e-05
nonsense O 0 0.00011496887600515038
mutation O 0 1.745119152474217e-05
and O 0 3.9073208313311625e-07
a O 0 8.307370080729015e-07
missense O 0 2.714687980187591e-05
substitution O 0 1.34897936732159e-06
in O 0 3.8883257502675406e-07
the O 0 4.1896009861375205e-07
vasopressin O 0 0.0001603322452865541
- O 0 0.0003919609298463911
neurophysin O 0 0.0014646914787590504
II O 0 2.8503149223979563e-05
gene O 0 1.9056076325796312e-06
in O 0 1.6911083378090552e-07
two O 0 2.8518934414023533e-07
Spanish O 0 3.9536839722131845e-06
kindreds O 0 0.0002459227107465267
with O 0 1.2674960998992901e-05
familial B-Disease 1 0.9825328588485718
neurohypophyseal I-Disease 1 0.9999935626983643
diabetes I-Disease 1 0.9999904632568359
insipidus I-Disease 1 0.9995998740196228
. O 0 0.00019003408669959754

Familial B-Disease 1 0.99991774559021
neurohypophyseal I-Disease 1 0.9999954700469971
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999951124191284
( O 0 0.033273499459028244
FNDI B-Disease 1 0.9999951124191284
) O 0 0.00012826807505916804
is O 0 1.4752951074115117e-06
an O 0 8.607315066910814e-06
autosomal B-Disease 1 0.9597748517990112
dominant I-Disease 1 0.9711195230484009
disease I-Disease 1 0.9854885935783386
caused O 0 0.0008513582870364189
by O 0 3.838601696770638e-05
deficiency O 1 0.6092725396156311
in O 0 8.723318956072035e-07
the O 0 1.0212702363787685e-06
antidiuretic O 0 0.03381747379899025
hormone O 0 4.7794088459340855e-05
arginine O 0 3.459800791461021e-05
vasopressin O 0 7.443454524036497e-05
( O 0 7.096352305779874e-07
AVP O 0 5.299273834680207e-05
) O 0 2.3539062965483026e-07
encoded O 0 2.976643997953943e-07
by O 0 8.94484841751364e-08
the O 0 2.634633915477025e-07
AVP O 0 0.00042830395977944136
- O 0 0.00044744781916961074
neurophysin O 0 0.0006435641553252935
II O 0 3.078240843024105e-05
( O 0 2.4453822788927937e-06
AVP O 0 0.0002925890439655632
- O 0 0.00018007263133767992
NPII O 0 0.0005376861663535237
) O 0 3.4924544252135092e-06
gene O 0 5.150652668817202e-06
on O 0 2.829531922543538e-06
chromosome O 0 0.00010185210703639314
20p13 O 0 0.000398593838326633
. O 0 4.2297280742786825e-05

In O 0 4.469283521757461e-05
this O 0 3.1498582302447176e-06
study O 0 3.7342133509810083e-06
, O 0 6.992652856752102e-07
we O 0 2.0141403922480094e-07
analyzed O 0 1.0181106517848093e-06
two O 0 1.192781269310217e-07
families O 0 2.814641391069017e-07
with O 0 3.5736863424062904e-07
FNDI B-Disease 1 0.8355739116668701
using O 0 5.315967541719147e-07
direct O 0 4.838088329961465e-07
automated O 0 4.77526600661804e-06
fluorescent O 0 1.4123668734100647e-05
, O 0 3.7973759958731534e-07
solid O 0 2.1092484985274496e-06
phase O 0 5.872405381524004e-06
, O 0 2.08416125246913e-07
single O 0 4.5224931000120705e-07
- O 0 1.4626012671214994e-05
stranded O 0 4.77218827654724e-06
DNA O 0 1.980924707822851e-06
sequencing O 0 1.2364254189378698e-06
of O 0 2.440559114802454e-07
PCR O 0 1.48688650369877e-05
- O 0 3.8740818126825616e-05
amplified O 0 3.367326280567795e-05
AVP O 0 0.0004157691146247089
- O 0 0.00018341151007916778
NPII O 0 0.0008325429516844451
DNA O 0 6.91301393089816e-05
. O 0 1.745655208651442e-05

In O 0 2.0381290596560575e-05
one O 0 1.8390428522252478e-06
of O 0 6.02550414896541e-07
the O 0 6.19732247741922e-07
families O 0 3.610181920521427e-06
, O 0 2.39641553889669e-06
affected O 0 2.8066933737136424e-06
individuals O 0 4.452701318768959e-07
presented O 0 1.429307985745254e-06
a O 0 8.088165941444458e-07
novel O 0 5.579269782174379e-06
nonsense O 0 6.71508169034496e-05
mutation O 0 4.751380402012728e-06
in O 0 2.8357973747006326e-07
exon O 0 4.2597580431902315e-06
3 O 0 4.127421959765343e-07
of O 0 1.0002385408824921e-07
the O 0 2.137098249477276e-07
gene O 0 1.3758793784290901e-06
, O 0 1.2620924394468602e-07
consisting O 0 2.802425171921641e-07
in O 0 1.6800312607756496e-07
a O 0 5.205477577874262e-07
G O 0 0.0019843915943056345
to O 0 8.04092792350275e-07
T O 0 0.001399244531057775
transition O 0 3.065641976718325e-06
at O 0 4.986175667909265e-07
nucleotide O 0 7.508193448302336e-06
2101 O 0 8.25069218990393e-05
, O 0 2.782001047307858e-07
which O 0 1.3186287617372727e-07
produces O 0 7.579789667033765e-07
a O 0 1.8297657788934885e-07
stop O 0 7.573185598630516e-07
signal O 0 1.3608320159619325e-06
in O 0 2.851336091680423e-07
codon O 0 5.10606787429424e-06
82 O 0 6.15892895439174e-06
( O 0 1.7597388932699687e-06
Glu O 0 0.00680726021528244
) O 0 1.4682268556498457e-06
of O 0 1.6651265468681231e-06
NPII O 0 0.0022579277865588665
. O 0 3.0250206691562198e-05

The O 0 0.00010751059744507074
premature O 0 0.016599567607045174
termination O 0 0.0004039083141833544
eliminates O 0 3.707113501150161e-05
part O 0 8.363683150491852e-07
of O 0 1.3101725926389918e-07
the O 0 2.106593655071265e-07
C O 0 1.589139355928637e-05
- O 0 6.0297254094621167e-05
terminal O 0 6.657386620645411e-06
domain O 0 5.612874360849673e-07
of O 0 9.360327624108322e-08
NPII O 0 8.291498670587316e-05
, O 0 1.980001940182774e-07
including O 0 7.912749566685306e-08
a O 0 1.7794063467135857e-07
cysteine O 0 2.149160309272702e-06
residue O 0 3.8859298001625575e-06
in O 0 2.014822371165792e-07
position O 0 5.163524861018232e-07
85 O 0 1.4906822798366193e-06
, O 0 1.7592410017641669e-07
which O 0 1.0325369004249296e-07
could O 0 1.5943849973609758e-07
be O 0 5.1329127614963e-08
involved O 0 1.653577754723301e-07
in O 0 1.3328636327969434e-07
the O 0 2.8498735105131345e-07
correct O 0 1.2178103133919649e-05
folding O 0 1.3064674931229092e-05
of O 0 5.939264724474924e-07
the O 0 3.28787700709654e-06
prohormone O 0 0.009664240293204784
. O 0 2.4227028916357085e-05

In O 0 2.5680923499749042e-05
the O 0 3.6497146993497154e-06
second O 0 3.217658331777784e-06
family O 0 2.371247092014528e-06
, O 0 5.085552174932673e-07
a O 0 4.2959422330568486e-07
G279A O 0 1.643484392843675e-05
substitution O 0 1.456573158975516e-06
at O 0 2.3156802342327865e-07
position O 0 3.1794846222510387e-07
- O 0 9.177519132208545e-06
1 O 0 2.7893281639990164e-07
of O 0 4.406663123290855e-08
the O 0 8.253468308794254e-08
signal O 0 1.5888551843090681e-06
peptide O 0 3.5972220757685136e-06
was O 0 4.825020596399554e-07
observed O 0 9.471997941545851e-07
in O 0 2.784570369840367e-07
all O 0 3.8648573763566674e-07
affected O 0 8.177629752026405e-06
individuals O 0 6.2458070715365466e-06
. O 0 1.7500471585663036e-05

This O 0 6.29302958259359e-05
missense O 0 0.0034046811051666737
mutation O 0 0.00019937523757107556
, O 0 2.0303259589127265e-06
which O 0 1.0208924550170195e-06
replaces O 0 0.00014649552758783102
Ala O 0 0.1911802589893341
with O 0 6.967570243432419e-06
Thr O 1 0.8792563676834106
, O 0 1.2012978913844563e-06
is O 0 1.7832610410550842e-07
frequent O 0 3.075375389016699e-06
among O 0 5.842073733219877e-06
FNDI B-Disease 1 0.9999991655349731
patients O 0 0.02595178596675396
and O 0 7.71732629800681e-07
is O 0 1.579827397790723e-07
thought O 0 1.6623911847091222e-07
to O 0 1.3236028451046877e-07
reduce O 0 1.3212285239205812e-06
the O 0 1.0157845764524609e-07
efficiency O 0 1.771518896021007e-06
of O 0 1.8992670902662212e-07
cleavage O 0 2.6054844056488946e-05
by O 0 1.0968686865453492e-06
signal O 0 9.271090675611049e-06
peptidases O 0 0.00027070517535321414
. O 0 4.84058500660467e-06
. O 0 1.1872868526552338e-05

Genetic O 0 0.005063778255134821
heterogeneity O 0 0.0025066002272069454
of O 0 2.9068800358800218e-05
Saethre B-Disease 1 0.7334547638893127
- I-Disease 1 0.9998530149459839
Chotzen I-Disease 1 0.9999853372573853
syndrome I-Disease 1 0.9999942779541016
, O 0 2.895930947488523e-06
due O 0 2.5528618152748095e-06
to O 0 8.322166422658483e-07
TWIST O 0 0.00011454409104771912
and O 0 1.826061816245783e-05
FGFR O 1 0.8710940480232239
mutations O 0 0.0007246344466693699
. O 0 2.3420874640578404e-05

Thirty O 0 0.0005512690404430032
- O 0 0.0026242926251143217
two O 0 1.370740938000381e-05
unrelated O 0 0.0006320585962384939
patients O 0 0.00028546922840178013
with O 0 7.40807536203647e-07
features O 0 2.9082577839290025e-06
of O 0 1.3353909480429138e-06
Saethre B-Disease 1 0.6137120723724365
- I-Disease 1 0.9992146492004395
Chotzen I-Disease 1 0.9999535083770752
syndrome I-Disease 1 0.9999210834503174
, O 0 9.922309800458606e-07
a O 0 2.3018844785838155e-06
common O 0 0.0002661386679392308
autosomal B-Disease 0 0.47249895334243774
dominant I-Disease 0 0.0013780868612229824
condition I-Disease 0 0.002850507153198123
of O 0 4.7615685616619885e-06
craniosynostosis B-Disease 1 0.9991866946220398
and O 0 0.00020171666983515024
limb B-Disease 1 0.8877130746841431
anomalies I-Disease 1 0.5359905362129211
, O 0 1.7952015696209855e-06
were O 0 2.614183358673472e-07
screened O 0 1.0373371424066136e-06
for O 0 8.054889235609153e-07
mutations O 0 1.1251728210481815e-05
in O 0 4.819659125132603e-07
TWIST O 0 4.86419812659733e-05
, O 0 1.949492343555903e-06
FGFR2 O 0 0.0014748251996934414
, O 0 1.8320808976568514e-06
and O 0 3.223752173653338e-06
FGFR3 O 0 0.02917194552719593
. O 0 3.321058102301322e-05

Nine O 0 0.0001771487295627594
novel O 0 3.910174564225599e-05
and O 0 4.070252998644719e-06
three O 0 4.910449661110761e-06
recurrent O 0 0.003193762619048357
TWIST O 0 0.024553002789616585
mutations O 0 0.0002905168221332133
were O 0 5.030259444538387e-07
found O 0 7.524900524913392e-07
in O 0 7.536283419540268e-07
12 O 0 5.7160677897627465e-06
families O 0 1.3071143257548101e-05
. O 0 1.6754398529883474e-05

Seven O 0 5.3946270782034844e-05
families O 0 1.2225183127156924e-05
were O 0 7.819830898370128e-07
found O 0 3.8563266002711316e-07
to O 0 1.1940139188482135e-07
have O 0 1.263949798158137e-07
the O 0 3.958804768444679e-07
FGFR3 O 0 0.0064774989150464535
P250R O 0 0.0008701372426003218
mutation O 0 6.1138562159612775e-06
, O 0 2.0560469238262158e-07
and O 0 1.0021500429502339e-07
one O 0 6.80388225759998e-08
individual O 0 1.560766804686864e-07
was O 0 1.4525099345519266e-07
found O 0 1.1044128456205726e-07
to O 0 7.45509325383864e-08
have O 0 8.066414380891729e-08
an O 0 2.6293679411537596e-07
FGFR2 O 0 0.0007071440923027694
VV269 O 0 0.00013472042337525636
- O 0 0.000177098045242019
270 O 0 5.7962450227933004e-05
deletion O 0 0.00019552365120034665
. O 0 1.7057576769730076e-05

To O 0 5.137573316460475e-05
date O 0 3.342881245771423e-05
, O 0 2.051013098025578e-06
our O 0 1.652351215852832e-06
detection O 0 8.690100003150292e-06
rate O 0 1.3784062957711285e-06
for O 0 2.5403420522707165e-07
TWIST O 0 2.264281465613749e-05
or O 0 2.3902439352241345e-06
FGFR O 0 0.13924270868301392
mutations O 0 2.638563273649197e-05
is O 0 2.29419796937691e-07
68 O 0 3.4039569527521962e-06
% O 0 5.221128276389209e-07
in O 0 2.3538164839465026e-07
our O 0 1.1033976079488639e-06
Saethre B-Disease 0 0.23937048017978668
- I-Disease 1 0.9996248483657837
Chotzen I-Disease 1 0.9999973773956299
syndrome I-Disease 1 0.9999997615814209
patients O 0 0.0025183246470987797
, O 0 2.661366806933074e-07
including O 0 2.427515823910653e-07
our O 0 8.370481054953416e-07
five O 0 1.5357065421994776e-05
patients O 0 0.000676911324262619
elsewhere O 0 7.772701792418957e-06
reported O 0 4.6825157369312365e-06
with O 0 1.4956007134969695e-06
TWIST O 0 0.002970505505800247
mutations O 0 0.0005209679366089404
. O 0 2.0706071154563688e-05

More O 0 8.799798706604633e-06
than O 0 2.543988330216962e-06
35 O 0 3.1963259061740246e-06
different O 0 8.207767336898542e-07
TWIST O 0 9.047378262039274e-05
mutations O 0 5.0854654546128586e-05
are O 0 2.4395910713792546e-07
now O 0 3.494085945021652e-07
known O 0 6.988173026911682e-07
in O 0 6.122365334704227e-07
the O 0 1.4445297438214766e-06
literature O 0 1.4294483662524726e-05
. O 0 2.1599025785690174e-05

The O 0 1.4944523172744084e-05
most O 0 3.070460934395669e-06
common O 0 3.4136216982005863e-06
phenotypic O 0 8.251480721810367e-06
features O 0 2.9442908271448687e-06
, O 0 8.005364406926674e-07
present O 0 2.8519534112092515e-07
in O 0 1.2055529907684104e-07
more O 0 6.032034605141234e-08
than O 0 6.451205791790926e-08
a O 0 1.3863396475244372e-07
third O 0 6.333532951430243e-07
of O 0 1.7463263191075384e-07
our O 0 3.263411372245173e-06
patients O 0 3.712470061145723e-05
with O 0 8.768508905632189e-07
TWIST O 0 0.0013919139746576548
mutations O 0 3.325225770822726e-05
, O 0 2.9564472470156034e-07
are O 0 1.946635279637121e-07
coronal B-Disease 0 0.00025438598822802305
synostosis I-Disease 0 0.007670987397432327
, O 0 1.3196242889534915e-06
brachycephaly B-Disease 0 0.0003093975828960538
, O 0 1.1369061212462839e-06
low B-Disease 0 2.9000299036852084e-05
frontal I-Disease 0 0.14368948340415955
hairline I-Disease 1 0.9999635219573975
, O 0 0.00014191695663612336
facial B-Disease 1 0.9798966646194458
asymmetry I-Disease 0 0.00876579899340868
, O 0 4.512051600613631e-05
ptosis B-Disease 1 0.9982897639274597
, O 0 1.8970302335219458e-05
hypertelorism B-Disease 0 0.17502650618553162
, O 0 1.5490359146497212e-06
broad B-Disease 0 6.9111465563764796e-06
great I-Disease 0 3.775331379074487e-06
toes I-Disease 0 0.000598494487348944
, O 0 4.1906905607902445e-06
and O 0 6.219249826244777e-06
clinodactyly B-Disease 0 0.015613206662237644
. O 0 3.4684260754147545e-05

Significant O 0 0.00012106232316000387
intra O 0 0.00028878398006781936
- O 0 0.000880938139744103
and O 0 1.3483384464052506e-05
interfamilial O 0 0.004485134035348892
phenotypic O 0 8.57489212648943e-05
variability O 0 0.00020654591207858175
is O 0 6.075600822441629e-07
present O 0 5.721995535168389e-07
for O 0 3.5926788655160635e-07
either O 0 1.6995930991470232e-06
TWIST O 0 0.0006067799404263496
mutations O 0 0.0001817619486246258
or O 0 8.752353096497245e-06
FGFR O 0 0.4563508629798889
mutations O 0 0.0004346486821305007
. O 0 1.957587301149033e-05

The O 0 3.427045521675609e-05
overlap O 0 6.740610115230083e-05
in O 0 9.938354196492583e-06
clinical O 0 0.00011104106670245528
features O 0 2.8429535632312763e-06
and O 0 6.378430157383264e-07
the O 0 2.41707880377362e-07
presence O 0 6.082418622099794e-07
, O 0 1.7128368767771462e-07
in O 0 1.1334586957900683e-07
the O 0 6.706017074975534e-08
same O 0 2.123547346855048e-07
genes O 0 5.288308670969855e-07
, O 0 1.062196659518122e-07
of O 0 1.4503699219403643e-07
mutations O 0 3.958214620070066e-06
for O 0 7.756521824830998e-08
more O 0 6.54424141544041e-08
than O 0 1.11274793823668e-07
one O 0 3.4522690839366987e-07
craniosynostotic B-Disease 0 0.04372011125087738
condition I-Disease 0 4.7584711865056306e-05
- O 0 2.119143209711183e-05
such O 0 1.3241709950762015e-07
as O 0 2.7152918846695684e-07
Saethre B-Disease 0 9.985057840822265e-05
- I-Disease 0 0.0001207882451126352
Chotzen I-Disease 0 9.329455497208983e-05
, I-Disease 0 6.087432780077506e-07
Crouzon I-Disease 0 3.0496876206598245e-05
, I-Disease 0 5.332205432750925e-07
and I-Disease 0 3.3115220503532328e-06
Pfeiffer I-Disease 1 0.5618093609809875
syndromes I-Disease 1 0.9170199632644653
- O 0 9.14105330593884e-05
support O 0 6.535166789944924e-07
the O 0 2.2457555814980878e-07
hypothesis O 0 2.005082023970317e-06
that O 0 1.1501306573791226e-07
TWIST O 0 6.15539966020151e-06
and O 0 4.1232553371628455e-07
FGFRs O 0 4.1951167077058926e-05
are O 0 9.36979489551959e-08
components O 0 4.700451938788319e-07
of O 0 6.595693946565007e-08
the O 0 8.751151625574494e-08
same O 0 3.48111456105471e-07
molecular O 0 1.2037397027597763e-05
pathway O 0 4.03034800910973e-06
involved O 0 6.526540232698608e-07
in O 0 2.436596275856573e-07
the O 0 2.3692685147125303e-07
modulation O 0 1.7741222109179944e-05
of O 0 1.5888188045209972e-06
craniofacial O 1 0.9998527765274048
and O 0 4.744596662931144e-05
limb O 0 0.010588232427835464
development O 0 2.0054372726008296e-05
in O 0 3.639735723481863e-06
humans O 0 5.054735538578825e-06
. O 0 2.6280317797500174e-06
. O 0 1.1366090802766848e-05

Mutation O 0 0.0032729061786085367
analysis O 0 0.00030540101579390466
of O 0 6.368797039613128e-05
UBE3A O 1 0.9991638660430908
in O 1 0.9651215672492981
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9997398257255554
. O 0 0.000316902733175084

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.006423530168831348
AS B-Disease 0 0.0011622038437053561
) O 0 1.6742356820032e-05
is O 0 1.6456093590022647e-06
caused O 0 5.630165560432943e-06
by O 0 1.163335696219292e-06
chromosome O 0 1.746297857607715e-05
15q11 O 0 7.216097583295777e-05
- O 0 9.113723353948444e-05
q13 O 0 5.029030944569968e-05
deletions O 0 6.361976375046652e-06
of O 0 3.248948132750229e-07
maternal O 0 7.2220277615997475e-06
origin O 0 2.0285106074879877e-06
, O 0 4.915181648357247e-07
by O 0 8.169205898411747e-07
paternal O 0 4.167682709521614e-05
uniparental B-Disease 0 0.30824586749076843
disomy I-Disease 1 0.7499330639839172
( O 0 1.6217092706938274e-05
UPD B-Disease 1 0.9933634996414185
) O 0 2.658672883626423e-06
15 O 0 6.997262289587525e-07
, O 0 3.102013295119832e-07
by O 0 6.697222829643579e-07
imprinting O 0 0.0581623837351799
defects O 1 0.5912830233573914
, O 0 1.5423023569383076e-06
and O 0 7.030868687252223e-07
by O 0 1.3697666645384743e-06
mutations O 0 1.1522803106345236e-05
in O 0 5.903225996917172e-07
the O 0 2.2727399482391775e-06
UBE3A O 0 0.014332630671560764
gene O 0 9.204118396155536e-05
. O 0 2.9355067454162054e-05

UBE3A O 0 0.009182936511933804
encodes O 0 0.00030183859053067863
a O 0 2.077019053103868e-05
ubiquitin O 0 0.00010591424506856129
- O 0 0.00016325908654835075
protein O 0 9.763163689058274e-06
ligase O 0 1.3250493793748319e-05
and O 0 9.387160844198661e-07
shows O 0 4.8107776819961146e-06
brain O 0 9.210808639181778e-05
- O 0 0.00020696857245638967
specific O 0 1.150340358435642e-05
imprinting O 0 0.0005398790817707777
. O 0 2.4661445422680117e-05

Here O 0 8.462668483844027e-05
we O 0 1.4651197489001788e-05
describe O 0 6.770165055058897e-05
UBE3A O 0 0.002665227511897683
coding O 0 0.0015785123687237501
- O 0 0.04170430451631546
region O 0 0.00036396010546013713
mutations O 0 8.457569492748007e-05
detected O 0 4.804849140782608e-06
by O 0 4.87330510168249e-07
SSCP O 0 0.0005344243254512548
analysis O 0 3.1111731004784815e-06
in O 0 5.924873107687745e-07
13 O 0 4.100388650840614e-06
AS B-Disease 0 2.8665015634032898e-05
individuals O 0 1.5262132819771068e-06
or O 0 1.962776650543674e-06
families O 0 1.1200276276213117e-05
. O 0 1.960312874871306e-05

Two O 0 4.557975989882834e-05
identical O 0 8.906138828024268e-05
de O 0 6.507209036499262e-05
novo O 0 7.418595487251878e-05
5 O 0 8.82897620613221e-06
- O 0 9.11246461328119e-05
bp O 0 0.0001684041490079835
duplications O 0 9.400910130352713e-06
in O 0 5.429491807262821e-07
exon O 0 9.119456990447361e-06
16 O 0 1.5590559314659913e-06
were O 0 7.003531550253683e-07
found O 0 3.702843287101132e-06
. O 0 1.0977572856063489e-05

Among O 0 2.0302511984482408e-05
the O 0 2.5683655167085817e-06
other O 0 9.470110171605484e-07
11 O 0 2.72121769739897e-06
unique O 0 4.096202701475704e-06
mutations O 0 1.6684960428392515e-05
, O 0 3.0782902626924624e-07
8 O 0 5.581838422585861e-07
were O 0 9.392053357260011e-08
small O 0 3.0000325068613165e-07
deletions O 0 4.7507460294582415e-06
or O 0 4.783520353157655e-07
insertions O 0 2.6429324861965142e-05
predicted O 0 2.5813953470787965e-05
to O 0 5.348732656784705e-07
cause O 0 7.0454534579766914e-06
frameshifts O 0 0.0006308819283731282
, O 0 6.69571534217539e-07
1 O 0 7.371189667537692e-07
was O 0 1.5993053636975674e-07
a O 0 2.73944493756062e-07
mutation O 0 1.4797930134591297e-06
to O 0 7.07719962633746e-08
a O 0 2.0003902534426743e-07
stop O 0 1.2044571349179023e-06
codon O 0 2.6119930680579273e-06
, O 0 1.6377330780414923e-07
1 O 0 5.232743092165038e-07
was O 0 1.7932320872660057e-07
a O 0 6.727398158545839e-07
missense O 0 0.00014493477647192776
mutation O 0 8.760252967476845e-06
, O 0 2.8522552497634024e-07
and O 0 2.652629973454168e-07
1 O 0 1.7479904954598169e-06
was O 0 5.325142069523281e-07
predicted O 0 1.0021775779023301e-05
to O 0 2.7935180924032466e-07
cause O 0 1.5203951306830277e-06
insertion O 0 2.741441448961268e-06
of O 0 1.2579168640058924e-07
an O 0 3.517392315188772e-07
isoleucine O 0 0.00044513135799206793
in O 0 3.2265188565361314e-07
the O 0 1.4208394816250802e-07
hect O 0 2.2805672415415756e-05
domain O 0 3.928817307041754e-07
of O 0 6.264910723530193e-08
the O 0 2.019250615603596e-07
UBE3A O 0 0.00018986871873494238
protein O 0 2.679016688489355e-06
, O 0 1.486578184994869e-07
which O 0 9.014762269998755e-08
functions O 0 1.1284897283303508e-07
in O 0 2.2353751205628214e-07
E2 O 0 4.3454165279399604e-05
binding O 0 5.0253538574907e-06
and O 0 7.915193123153585e-07
ubiquitin O 0 3.888806895702146e-05
transfer O 0 1.2434657946869265e-05
. O 0 2.0929195670760237e-05

Eight O 0 3.5946657590102404e-05
of O 0 3.857385763694765e-06
the O 0 2.5628364710428286e-06
cases O 0 4.003425146947848e-06
were O 0 9.740032282934408e-07
familial O 0 0.001940141199156642
, O 0 3.159931111440528e-06
and O 0 9.81222115115088e-07
five O 0 1.6871581465238705e-06
were O 0 1.7951244899450103e-06
sporadic O 0 8.141149737639353e-05
. O 0 2.8127733457949944e-05

In O 0 5.969850462861359e-05
two O 0 1.4206475498212967e-05
familial O 0 0.4608108103275299
cases O 0 5.8672449085861444e-05
and O 0 1.6810533907118952e-06
one O 0 9.73514715951751e-07
sporadic O 0 5.149718708707951e-05
case O 0 5.2578316172002815e-06
, O 0 1.6778965346020414e-06
mosaicism O 0 0.0011803561355918646
for O 0 2.7296653115627123e-06
UBE3A O 0 0.39338910579681396
mutations O 0 7.813836418790743e-05
was O 0 1.1976796940871282e-06
detected O 0 4.684440682467539e-06
in O 0 1.6213611786497495e-07
the O 0 1.3663168374478118e-07
mother O 0 1.796288870536955e-06
of O 0 9.022382840839782e-08
three O 0 3.749894119664532e-07
AS B-Disease 0 0.00013949102140031755
sons O 0 0.0010511155705899
, O 0 9.296289817939396e-07
in O 0 1.7195259260915918e-07
the O 0 2.2603319393965648e-07
maternal O 0 6.177028353704372e-06
grandfather O 0 2.749712848526542e-06
of O 0 7.30677243154787e-08
two O 0 1.3894752726173465e-07
AS B-Disease 0 7.646770427527372e-06
first O 0 7.880673820181983e-07
cousins O 0 1.2073451216565445e-05
, O 0 1.8719484273788112e-07
and O 0 1.4014445071097725e-07
in O 0 1.7953215092347818e-07
the O 0 2.509529792860121e-07
mother O 0 3.257565367675852e-06
of O 0 2.577083080268494e-07
an O 0 9.528615123599593e-07
AS B-Disease 0 0.000760384020395577
daughter O 0 0.0032580909319221973
. O 0 4.2710064008133486e-05

The O 0 2.1260540961520746e-05
frequencies O 0 1.7066575310309418e-05
with O 0 1.6869264527485939e-06
which O 0 7.956332979119907e-07
we O 0 6.461031603066658e-07
detected O 0 7.445965366059681e-06
mutations O 0 3.4338165733061032e-06
were O 0 1.4498472467039392e-07
5 O 0 1.0813997732839198e-06
( O 0 5.459101544147416e-07
14 O 0 8.486597948831331e-07
% O 0 4.851413564210816e-07
) O 0 1.430956615422474e-07
of O 0 4.8580943712295266e-08
35 O 0 8.361920436072978e-07
in O 0 4.6947266696406587e-07
sporadic O 0 3.6506658943835646e-05
cases O 0 1.3964444178782287e-06
and O 0 4.713474197615142e-07
8 O 0 4.047967195219826e-06
( O 0 5.333578769750602e-07
80 O 0 3.778504833462648e-07
% O 0 5.087501904199598e-07
) O 0 1.0613521794766712e-07
of O 0 5.310900164090526e-08
10 O 0 1.368230073239829e-06
in O 0 3.2805166938487673e-06
familial O 0 0.12375835329294205
cases O 0 3.334075154270977e-05
. O 0 3.438059820837225e-06
. O 0 1.505284399172524e-05

The O 0 0.0003470659430604428
hemochromatosis B-Disease 1 0.999951958656311
845 O 0 0.24284739792346954
G O 1 0.7149303555488586
- O 0 0.013690559193491936
- O 0 0.0011281106853857636
> O 0 3.100345202255994e-05
A O 0 7.022163686087879e-07
and O 0 3.05119925769759e-07
187 O 0 2.8057245344825787e-06
C O 0 1.5932198948576115e-05
- O 0 0.00012429810885805637
- O 0 0.004224661272019148
> O 0 0.0011643657926470041
G O 0 0.2223079949617386
mutations O 0 5.384728137869388e-05
: O 0 1.600043674443441e-06
prevalence O 0 9.284602128900588e-06
in O 0 6.128463496679615e-07
non O 0 2.3338954633800313e-05
- O 0 0.005121519789099693
Caucasian O 0 0.0025080291088670492
populations O 0 0.00010828534868778661
. O 0 2.301783206348773e-05

Hemochromatosis B-Disease 1 0.9996492862701416
, O 0 0.0004902424989268184
the O 0 0.0002539962879382074
inherited B-Disease 1 0.9999964237213135
disorder I-Disease 1 0.9999951124191284
of I-Disease 0 8.350831194547936e-06
iron I-Disease 0 0.4039139449596405
metabolism I-Disease 0 0.008844658732414246
, O 0 5.513639734999742e-06
leads O 0 2.5330404241685756e-05
, O 0 2.756846924967249e-06
if O 0 1.678555804573989e-06
untreated O 0 0.00064125593053177
, O 0 4.720028243809793e-07
to O 0 5.879953732801368e-07
progressive O 0 0.0002755322493612766
iron B-Disease 0 0.05246131494641304
overload I-Disease 0 0.0697576180100441
and O 0 4.672833165386692e-05
premature B-Disease 0 0.05294981971383095
death I-Disease 0 0.00011102711141575128
. O 0 3.215438118786551e-05

The O 0 0.00023122540733311325
hemochromatosis B-Disease 1 0.9999821186065674
gene O 0 0.0008172258385457098
, O 0 1.5249464013322722e-05
HFE O 0 0.02392636239528656
, O 0 5.934343789704144e-06
recently O 0 6.290670171438251e-06
has O 0 4.962309390066366e-07
been O 0 3.682334011045896e-07
identified O 0 1.863055558715132e-06
, O 0 1.9648520321879914e-07
and O 0 2.413061963579821e-07
characterization O 0 4.807626737601822e-06
of O 0 1.2988465414309758e-07
this O 0 2.5872952846839326e-07
gene O 0 2.6078016617248068e-06
has O 0 2.6702318223215116e-07
shown O 0 2.379476313763007e-07
that O 0 5.239034450710278e-08
it O 0 5.820080417606732e-08
contains O 0 1.345024998045119e-07
two O 0 2.818460984599369e-07
mutations O 0 4.035875008412404e-06
that O 0 9.204142514818159e-08
result O 0 2.3832645013044385e-07
in O 0 1.6339203057214036e-07
amino O 0 1.407113700224727e-06
acid O 0 8.162515769072343e-06
substitutions O 0 1.044402779371012e-06
- O 0 3.1965514608600643e-06
cDNA O 0 3.1039626264828257e-06
nucleotides O 0 3.093338818871416e-06
845 O 0 7.501973868784262e-06
G O 0 6.407967157429084e-05
- O 0 3.6323228414403275e-05
- O 0 8.866971620591357e-05
> O 0 1.6577207134105265e-05
A O 0 4.0601821638119873e-07
( O 0 3.406755695323227e-07
C282Y O 0 4.393790277390508e-06
) O 0 1.862922687223545e-07
and O 0 1.3077632843305764e-07
187 O 0 1.988031272048829e-06
C O 0 2.3893504476291128e-05
- O 0 0.0002548843913245946
- O 0 0.006056058220565319
> O 0 0.00038894274621270597
G O 0 0.002324946690350771
( O 0 5.906159458390903e-06
H63D O 0 0.0004916801117360592
) O 0 5.958070232736645e-06
. O 0 8.408601388509851e-06

Although O 0 0.0017688920488581061
hemochromatosis B-Disease 1 0.9999918937683105
is O 0 1.4142670806904789e-05
common O 0 1.2744546438625548e-05
in O 0 3.7592285480059218e-06
Caucasians O 0 0.00037179692299105227
, O 0 3.3024459753505653e-06
affecting O 0 5.259160843706923e-06
> O 0 0.00020401923393364996
= O 0 0.0002549624477978796
1 O 0 5.369136488297954e-06
/ O 0 2.952897375507746e-05
300 O 0 3.3702073665153875e-07
individuals O 0 7.208736718666842e-08
of O 0 3.9865668099992035e-08
northern O 0 4.745470789657702e-07
European O 0 2.824360990416608e-06
origin O 0 8.462860137115058e-07
, O 0 1.9059042699609563e-07
it O 0 7.913489241673233e-08
has O 0 1.5428922495175357e-07
not O 0 1.4394454694866e-07
been O 0 1.582614146400374e-07
recognized O 0 4.518725233992882e-07
in O 0 4.106984476948128e-07
other O 0 1.86476916042011e-06
populations O 0 3.121446934528649e-05
. O 0 1.8373917555436492e-05

The O 0 1.7904836568050086e-05
present O 0 5.9003164096793626e-06
study O 0 2.798039986373624e-06
used O 0 9.417307182957302e-07
PCR O 0 1.7969083273783326e-05
and O 0 2.615726941712637e-07
restriction O 0 7.648993118891667e-07
- O 0 3.565829319995828e-05
enzyme O 0 5.805240562040126e-06
digestion O 0 4.9388636398362e-06
to O 0 2.088074353423508e-07
analyze O 0 1.1905190149263944e-06
the O 0 1.1580904413222015e-07
frequency O 0 4.4895890027873975e-07
of O 0 7.414677583028606e-08
the O 0 2.1994388532675657e-07
845 O 0 5.683822018909268e-05
G O 0 0.004802556708455086
- O 0 9.904991020448506e-05
- O 0 8.144830644596368e-05
> O 0 6.527662662847433e-06
A O 0 2.2491870765861677e-07
and O 0 1.7287864295667532e-07
187 O 0 2.1606335849355673e-06
C O 0 1.59803603310138e-05
- O 0 8.607416384620592e-05
- O 0 0.0010969771537929773
> O 0 0.0006263579707592726
G O 0 0.029477443546056747
mutations O 0 8.61034459376242e-06
in O 0 1.5455961488441972e-07
HLA O 0 0.00027417612727731466
- O 0 1.899858398246579e-05
typed O 0 2.68303074335563e-06
samples O 0 5.411249048847822e-07
from O 0 9.825456004364241e-08
non O 0 1.504071178715094e-06
- O 0 0.00012865051394328475
Caucasian O 0 0.0001487910922151059
populations O 0 1.462815248487459e-06
, O 0 1.2086530887245317e-07
comprising O 0 2.829438301432674e-07
Australian O 0 2.9575440407825226e-07
Aboriginal O 0 8.024672411011124e-07
, O 0 1.3229920625690283e-07
Chinese O 0 1.4256335134632536e-07
, O 0 2.0100340236695047e-07
and O 0 4.4587142156160553e-07
Pacific O 0 1.0165876119572204e-05
Islanders O 0 6.826820754213259e-05
. O 0 9.632613000576384e-06

Results O 0 0.001115044578909874
showed O 0 3.387546894373372e-05
that O 0 9.967607184080407e-07
the O 0 6.811451953581127e-07
845 O 0 0.00017542680143378675
G O 0 0.14026765525341034
- O 0 0.0024478211998939514
- O 0 0.002023761859163642
> O 0 8.98459111340344e-05
A O 0 1.6388155472668586e-06
mutation O 0 3.976091193180764e-06
was O 0 1.7357315584831667e-07
present O 0 1.916186818107235e-07
in O 0 1.6065143881860422e-07
these O 0 1.7946744890195987e-07
populations O 0 1.4528025076288031e-06
( O 0 3.8231905818975065e-07
allele O 0 1.3111304042467964e-06
frequency O 0 8.153001544997096e-07
0 O 0 1.1616559731919551e-06
. O 0 1.40541700943686e-07
32 O 0 5.70353222428821e-07
% O 0 5.469988764161826e-07
) O 0 2.1344098399822542e-07
, O 0 1.1730330840009628e-07
and O 0 2.6381388806839823e-07
, O 0 4.7183721108012833e-07
furthermore O 0 1.8321804873266956e-06
, O 0 2.2125517773474712e-07
it O 0 8.459675626681928e-08
was O 0 1.5463258762338228e-07
always O 0 1.6272430514163716e-07
seen O 0 3.856867465401592e-07
in O 0 2.133040197804803e-07
conjunction O 0 4.236466793372529e-06
with O 0 3.422974486966268e-06
HLA O 1 0.962642252445221
haplotypes O 0 0.0005387897253967822
common O 0 2.354068556087441e-06
in O 0 5.506889806383697e-07
Caucasians O 0 3.386028765817173e-05
, O 0 5.33389425072528e-07
suggesting O 0 1.7316770026809536e-06
that O 0 2.2242998909405287e-07
845 O 0 5.399130895966664e-05
G O 0 0.028152909129858017
- O 0 0.007478262297809124
- O 0 0.051167745143175125
> O 0 0.00015224976232275367
A O 0 1.3615511988973594e-06
may O 0 1.292219621973345e-06
have O 0 6.471996982782002e-08
been O 0 6.870744329035006e-08
introduced O 0 2.2037954749976052e-07
into O 0 2.2556461942713213e-07
these O 0 3.3689124734337383e-07
populations O 0 2.987327206938062e-06
by O 0 1.8732588387138094e-06
Caucasian O 0 0.0002864449343178421
admixture O 0 0.0011490406468510628
. O 0 5.2207193220965564e-05

187 O 0 0.0005970180500298738
C O 0 0.00043836113763973117
- O 0 0.001020411727949977
- O 0 0.004961684811860323
> O 0 0.0003705938870552927
G O 0 0.0002725636004470289
was O 0 3.9672931961831637e-07
present O 0 2.3855724862187344e-07
at O 0 1.81412616484522e-07
an O 0 2.742445701642282e-07
allele O 0 4.199860086373519e-06
frequency O 0 1.9320314095239155e-06
of O 0 8.214062745537376e-07
2 O 0 1.7892647520056926e-05
. O 0 2.4214210498030297e-05

68 O 0 0.0010572789469733834
% O 0 3.234157702536322e-05
in O 0 2.1075916265544947e-06
the O 0 5.538770437851781e-07
two O 0 7.859073889449064e-07
populations O 0 8.826551493257284e-06
analyzed O 0 7.419921530527063e-06
( O 0 6.03287560352328e-07
Australian O 0 5.962920113233849e-07
Aboriginal O 0 1.2001916047665873e-06
and O 0 5.640713425236754e-07
Chinese O 0 1.5917200926196529e-06
) O 0 6.067070899007376e-06
. O 0 9.188229341816623e-06

In O 0 3.0200053515727632e-05
the O 0 4.783096301252954e-06
Australian O 0 6.4083274082804564e-06
Aboriginal O 0 8.781531505519524e-06
samples O 0 4.868608812103048e-06
, O 0 7.165602369241242e-07
187 O 0 2.991215751535492e-06
C O 0 1.5140766663535032e-05
- O 0 0.00019507986144162714
- O 0 0.008900419808924198
> O 0 0.0006025246693752706
G O 0 0.003375930478796363
was O 0 3.0193550060175767e-07
found O 0 1.1108055275599327e-07
to O 0 7.903020815547279e-08
be O 0 8.541569940234695e-08
associated O 0 4.786207910001394e-07
with O 0 1.1039869605156127e-06
HLA O 1 0.8954999446868896
haplotypes O 0 0.002059478312730789
common O 0 3.83768929168582e-06
in O 0 9.922272283802158e-07
Caucasians O 0 7.257953257067129e-05
, O 0 7.735187637081253e-07
suggesting O 0 1.618817805137951e-06
that O 0 8.673879392517847e-08
it O 0 1.2844027708069916e-07
was O 0 3.001394759394316e-07
introduced O 0 1.5311146626117988e-06
by O 0 1.502812551734678e-06
recent O 0 1.560318560223095e-05
admixture O 0 0.0012917035492137074
. O 0 6.6862310632132e-05

In O 0 2.2496560632134788e-05
the O 0 3.061192273889901e-06
Chinese O 0 2.709791942834272e-06
samples O 0 4.937327958032256e-06
analyzed O 0 5.01101067129639e-06
, O 0 5.112121357342403e-07
187 O 0 2.7673465865518665e-06
C O 0 1.7388279957231134e-05
- O 0 0.00011685481149470434
- O 0 0.003468148410320282
> O 0 0.00016649601457174867
G O 0 0.00016278744442388415
was O 0 2.5686250637591e-07
present O 0 2.7146396064381406e-07
in O 0 1.522259509556534e-07
association O 0 4.871019427810097e-07
with O 0 1.1517024489648975e-07
a O 0 4.024277302505652e-07
wide O 0 8.28143981834728e-07
variety O 0 1.2912144029542105e-06
of O 0 7.878464316490863e-07
HLA O 1 0.9227525591850281
haplotypes O 0 0.0032154573127627373
, O 0 4.915627300761116e-07
showing O 0 8.376230766771187e-07
this O 0 1.366744299957645e-07
mutation O 0 1.2724125326712965e-06
to O 0 1.3924373831741832e-07
be O 0 6.374854422119824e-08
widespread O 0 7.192461453087162e-07
and O 0 4.268555926500994e-07
likely O 0 1.3449508742269245e-06
to O 0 2.569891819348413e-07
predate O 0 2.045931978500448e-05
the O 0 1.361506605235263e-07
more O 0 2.574746815753315e-07
genetically O 0 7.594589078507852e-06
restricted O 0 1.971309757209383e-06
845 O 0 7.918122719274834e-05
G O 0 0.003157947212457657
- O 0 0.000634805066511035
- O 0 0.0017823361558839679
> O 0 0.00014119414845481515
A O 0 1.0662381100701168e-05
mutation O 0 6.876621773699299e-05
. O 0 1.6190298993024044e-05

Genotype O 1 0.9648357629776001
- O 1 0.9658011794090271
phenotype O 1 0.868539035320282
correlations O 0 0.003654582193121314
in O 0 0.0006370946066454053
attenuated B-Disease 1 0.9938307404518127
adenomatous I-Disease 1 0.9999991655349731
polyposis I-Disease 1 0.999998927116394
coli I-Disease 1 0.9999468326568604
. O 0 0.00039712866418994963

Germ O 0 0.12199147045612335
- O 0 0.0016271189088001847
line O 0 6.603810470551252e-05
mutations O 0 2.9098588129272684e-05
of O 0 1.0636781553330366e-06
the O 0 2.456644097037497e-06
tumor B-Disease 0 0.0010190450120717287
suppressor O 0 0.00040622230153530836
APC O 0 0.00015309777518268675
are O 0 1.0194622745984816e-06
implicated O 0 0.0001085545591195114
in O 0 2.324233719264157e-05
attenuated B-Disease 1 0.9724712371826172
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999966621398926
( O 0 0.0001876839087344706
AAPC B-Disease 1 0.9999858140945435
) O 0 7.843806997698266e-06
, O 0 6.480668162112124e-07
a O 0 1.3601301134258392e-06
variant O 0 0.0002972921938635409
of O 0 5.058018723502755e-05
familial B-Disease 1 0.9999979734420776
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.001603286131285131
FAP B-Disease 1 0.5372450351715088
) O 0 4.05995269829873e-05
. O 0 3.764412394957617e-05

AAPC B-Disease 1 0.9998779296875
is O 0 6.979837780818343e-05
recognized O 0 1.4278380149335135e-05
by O 0 1.3497076452040346e-06
the O 0 9.962246849681833e-07
occurrence O 0 4.362733761809068e-06
of O 0 6.610845275645261e-07
< O 0 0.0002046061708824709
100 O 0 4.6916479732317384e-06
colonic B-Disease 0 0.036604102700948715
adenomas I-Disease 0 0.19093318283557892
and O 0 7.646673907402146e-07
a O 0 1.3625696055896697e-06
later O 0 3.093820487265475e-05
onset O 1 0.791605532169342
of O 0 0.049105510115623474
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
( O 0 3.4042212064377964e-05
age O 0 5.520373633771669e-06
> O 0 9.352489723823965e-05
40 O 0 2.861840130208293e-06
years O 0 3.831713456747821e-06
) O 0 7.1110926000983454e-06
. O 0 1.0425545951875392e-05

The O 0 2.5783103410503827e-05
aim O 0 3.780035694944672e-05
of O 0 1.6240211380136316e-06
this O 0 8.328589728989755e-07
study O 0 1.6525419823665288e-06
was O 0 6.687789095849439e-07
to O 0 1.808615479603759e-06
assess O 0 0.0004651338967960328
genotype O 0 0.1056041419506073
- O 0 0.43631207942962646
phenotype O 0 0.054203495383262634
correlations O 0 0.00016300241986755282
in O 0 2.483607386238873e-05
AAPC B-Disease 1 0.9999586343765259
families O 0 0.00016468844842165709
. O 0 4.0151699067791924e-05

By O 0 3.314281639177352e-05
protein O 0 4.276251274859533e-05
- O 0 0.00011891761823790148
truncation O 0 8.885847637429833e-05
test O 0 5.590092314378126e-06
( O 0 1.3394623010754003e-06
PTT O 0 3.655350883491337e-05
) O 0 9.652352446209989e-07
assay O 0 2.8942356493644184e-06
, O 0 7.365133569692262e-08
the O 0 6.475033842434641e-08
entire O 0 4.4129379261903523e-07
coding O 0 1.6520911231054924e-05
region O 0 1.301442125622998e-06
of O 0 1.296883596069165e-07
the O 0 2.8676956276285637e-07
APC B-Disease 0 4.9479138397146016e-05
gene O 0 2.365990440011956e-06
was O 0 3.635690291048377e-07
screened O 0 1.7347002767564845e-06
in O 0 4.780998210662801e-07
affected O 0 1.319475813943427e-06
individuals O 0 3.650536086752254e-07
from O 0 4.3844377728419204e-07
11 O 0 1.6388987205573358e-05
AAPC B-Disease 1 0.9997268319129944
kindreds O 0 0.002052866155281663
, O 0 4.491905940540164e-07
and O 0 2.0883251750092313e-07
their O 0 7.87629289789038e-07
phenotypic O 0 1.2974149285582826e-05
differences O 0 9.788241186470259e-06
were O 0 5.3961111916578375e-06
examined O 0 0.00011007497960235924
. O 0 2.8361124350340106e-05

Five O 0 8.897751831682399e-05
novel O 0 8.635541598778218e-05
germ O 0 0.001939420122653246
- O 0 0.00022050077677704394
line O 0 1.4034526429895777e-05
APC B-Disease 0 0.00023596543178427964
mutations O 0 1.0884471521421801e-05
were O 0 3.3262770671171893e-07
identified O 0 1.931537553900853e-06
in O 0 9.522319714960759e-07
seven O 0 1.1518650353536941e-05
kindreds O 0 0.0025997168850153685
. O 0 2.9385144443949685e-05

Mutations O 0 0.0026464839465916157
were O 0 7.862237907829694e-06
located O 0 2.4284406663355185e-06
in O 0 4.416318688527099e-07
three O 0 2.33540774274843e-07
different O 0 1.3643609975133586e-07
regions O 0 4.39644225025404e-07
of O 0 8.380627747328617e-08
the O 0 2.9047134830761934e-07
APC B-Disease 0 5.8343986893305555e-05
gene O 0 1.9979299850092502e-06
( O 0 2.2448540448749554e-07
1 O 0 4.2846946257668606e-07
) O 0 1.691797137937101e-07
at O 0 6.818874709324518e-08
the O 0 5.9423470588626515e-08
5 O 0 5.16472198341944e-07
end O 0 2.424954459456785e-07
spanning O 0 8.075864457168791e-07
exons O 0 1.0816300346050411e-05
4 O 0 1.0997468962159473e-06
and O 0 1.6599040009168675e-07
5 O 0 1.3480764664564049e-06
, O 0 2.598258959096711e-07
( O 0 1.7588249079381058e-07
2 O 0 4.349297455519263e-07
) O 0 1.544078713777708e-07
within O 0 6.714515876637961e-08
exon O 0 1.5666558965676813e-06
9 O 0 7.075713597259892e-07
, O 0 1.0584955845160948e-07
and O 0 1.2772972013408435e-07
( O 0 2.5060020902856195e-07
3 O 0 7.48352817936393e-07
) O 0 2.0310100978804257e-07
at O 0 6.972675237193471e-08
the O 0 7.575657434699679e-08
3 O 0 1.5816212908248417e-06
distal O 0 3.606312384363264e-05
end O 0 1.623472940082138e-06
of O 0 4.3234382474111044e-07
the O 0 2.3564764433103846e-06
gene O 0 3.869750798912719e-05
. O 0 2.1793746782350354e-05

Variability O 0 0.015525687485933304
in O 0 1.6884130673133768e-05
the O 0 2.7201022021472454e-06
number O 0 3.0846074423607206e-06
of O 0 7.213613571366295e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999996423721313
was O 0 2.0003068129881285e-05
most O 0 1.2087054983567214e-06
apparent O 0 3.0132390747894533e-05
in O 0 9.55517748479906e-07
individuals O 0 4.2261143562427606e-07
with O 0 2.3128670818550745e-06
mutations O 0 4.443949364940636e-05
in O 0 5.396880737862375e-07
region O 0 8.876872016116977e-06
1 O 0 6.045803729648469e-06
, O 0 4.2987332449229143e-07
and O 0 8.41487860725465e-07
upper O 0 0.0017760805785655975
- O 1 0.9997791647911072
gastrointestinal O 1 0.9820986986160278
manifestations O 0 0.0003006610495503992
were O 0 7.631964535903535e-07
more O 0 1.443518840460456e-06
severe O 0 0.0007358458824455738
in O 0 2.4428884444205323e-06
them O 0 4.332896878622705e-06
. O 0 2.9298878871486522e-05

In O 0 4.5504100853577256e-05
individuals O 0 7.826240107533522e-06
with O 0 6.183346613397589e-06
mutations O 0 7.080368959577754e-05
in O 0 6.822855880272982e-07
either O 0 6.534773433486407e-07
region O 0 7.9464225564152e-06
2 O 0 5.5528512348246295e-06
or O 0 4.3126536297677376e-07
region O 0 2.0827535536227515e-06
3 O 0 1.6666024293954251e-06
, O 0 1.1635680863264497e-07
the O 0 6.225744186849624e-08
average O 0 2.9656925448762195e-07
number O 0 1.298477485534022e-07
of O 0 2.423331579848309e-07
adenomas B-Disease 0 0.020578501746058464
tended O 0 3.1080294320418034e-06
to O 0 1.3089011474676226e-07
be O 0 7.770796628392418e-08
lower O 0 1.008837216431857e-06
than O 0 8.163787157400293e-08
those O 0 8.825205810580883e-08
in O 0 2.0506460884917033e-07
individuals O 0 2.1122909288351366e-07
with O 0 1.0644259873515693e-06
mutations O 0 1.834985778259579e-05
in O 0 3.929566787519434e-07
region O 0 9.031005902215838e-06
1 O 0 6.530844984808937e-06
, O 0 5.037792334405822e-07
although O 0 4.4353546968523005e-07
age O 0 1.2426563671397162e-06
at O 0 4.766552592627704e-06
diagnosis O 0 0.21127483248710632
was O 0 6.0707111515512224e-06
similar O 0 2.309496449015569e-05
. O 0 2.4764576664892957e-05

In O 0 6.356030644383281e-05
all O 0 1.4567547623300925e-05
AAPC B-Disease 1 0.9996523857116699
kindreds O 0 0.02817952260375023
, O 0 4.4675903154711705e-06
a O 0 1.7466891222284175e-06
predominance O 0 3.648250276455656e-05
of O 0 1.6835514315971523e-06
right O 0 2.6852301743929274e-05
- O 1 0.9964998960494995
sided O 1 0.9999945163726807
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999994039535522
and O 0 0.0007856180309318006
rectal B-Disease 1 0.9999661445617676
polyp I-Disease 1 0.9987288117408752
sparing O 0 0.001530350069515407
was O 0 1.784507003321778e-05
observed O 0 5.949339902144857e-05
. O 0 2.8743384973495267e-05

No O 0 0.0003608993429224938
desmoid B-Disease 1 0.9966841340065002
tumors I-Disease 1 0.9999902248382568
were O 0 5.7750421547098085e-06
found O 0 3.3049063858925365e-06
in O 0 2.4527907953597605e-06
these O 0 4.579419055517064e-06
kindreds O 0 0.0018669493729248643
. O 0 3.952617771574296e-05

Our O 0 6.186798418639228e-05
data O 0 3.239676880184561e-05
suggest O 0 1.2509686712292023e-05
that O 0 7.164201747400512e-07
, O 0 9.380770507050329e-07
in O 0 2.1862169887754135e-06
AAPC B-Disease 1 0.9999293088912964
families O 0 8.551367500331253e-06
, O 0 2.587736958048481e-07
the O 0 9.7810662680331e-08
location O 0 2.7489735998642573e-07
of O 0 1.3702837975415605e-07
the O 0 7.227997116387996e-07
APC B-Disease 0 0.0009566138032823801
mutation O 0 5.2972129196859896e-05
may O 0 5.321026492310921e-06
partially O 0 3.437686973484233e-05
predict O 0 5.218006481300108e-05
specific O 0 4.984638508176431e-06
phenotypic O 0 3.787920650211163e-05
expression O 0 2.906314330175519e-05
. O 0 2.7209811378270388e-05

This O 0 2.6621093638823368e-05
should O 0 4.907256425212836e-06
help O 0 3.5949515222455375e-06
in O 0 6.694872354273684e-07
the O 0 3.416874960748828e-07
design O 0 3.998628926638048e-06
of O 0 7.27181884485617e-07
tailored O 0 0.0406939722597599
clinical O 0 0.019975926727056503
- O 0 0.17698495090007782
management O 0 0.0006372081697918475
protocols O 0 2.727585524553433e-05
in O 0 2.414910795778269e-07
this O 0 1.7920422124007018e-07
subset O 0 4.054404143971624e-06
of O 0 4.215775334159844e-06
FAP B-Disease 1 0.9940844178199768
patients O 0 0.0137947928160429
. O 0 4.07610696129268e-06
. O 0 1.4399288374988828e-05

Wilms B-Disease 1 0.9996668100357056
' I-Disease 1 0.6002793312072754
tumor I-Disease 0 0.0441480427980423
1 O 0 8.832572348183021e-06
and O 0 1.3135196468283539e-06
Dax O 0 0.00011162837472511455
- O 0 2.6626528779161163e-05
1 O 0 1.2972685681233997e-06
modulate O 0 5.179191703064134e-06
the O 0 3.1093230745682376e-07
orphan O 0 1.5242876543197781e-05
nuclear O 0 2.7622956622508354e-05
receptor O 0 7.95116739027435e-06
SF O 0 0.0011323640355840325
- O 0 2.062159364868421e-05
1 O 0 8.4335579231265e-07
in O 0 2.5086589516831737e-07
sex O 0 8.39857989376469e-07
- O 0 3.8071073504397646e-05
specific O 0 3.817546712525655e-06
gene O 0 1.1739237379515544e-05
expression O 0 1.4436825949815102e-05
. O 0 1.3300552382133901e-05

Products O 0 0.00014293185085989535
of O 0 1.1781990906456485e-05
steroidogenic O 0 0.0054834159091115
factor O 0 2.1607327653327957e-05
1 O 0 6.283948550844798e-06
( O 0 3.2895018193812575e-06
SF O 0 0.011817536316812038
- O 0 0.00015780914691276848
1 O 0 3.3083310881920625e-06
) O 0 9.561476872477215e-07
and O 0 1.8757472162178601e-06
Wilms B-Disease 1 0.988287627696991
tumor I-Disease 0 0.001971907913684845
1 O 0 6.214637323864736e-06
( O 0 1.5051704167490243e-06
WT1 O 0 0.0002592121309135109
) O 0 7.68894778957474e-07
genes O 0 4.073088746281428e-07
are O 0 4.6961414312818306e-08
essential O 0 2.1567703356595302e-07
for O 0 3.259838479152677e-07
mammalian O 0 3.40899387083482e-05
gonadogenesis O 0 0.000668985303491354
prior O 0 3.492850737529807e-06
to O 0 9.489638159720926e-07
sexual O 0 5.863093974767253e-06
differentiation O 0 3.821227073785849e-05
. O 0 2.073820542136673e-05

In O 0 9.849289926933125e-05
males O 0 8.501119737047702e-05
, O 0 8.652810720377602e-06
SF O 1 0.5206479430198669
- O 0 0.0006508363294415176
1 O 0 6.196912636369234e-06
participates O 0 5.534137017093599e-06
in O 0 4.4351557448862877e-07
sexual O 0 7.075956887092616e-07
development O 0 9.027234568748099e-07
by O 0 3.421811811676889e-07
regulating O 0 3.3833539418992586e-06
expression O 0 1.0099404335051076e-06
of O 0 1.8322069195164659e-07
the O 0 6.168371555759222e-07
polypeptide O 0 9.022832091432065e-05
hormone O 0 5.348938793758862e-05
Mullerian O 0 0.0007500752108171582
inhibiting O 0 0.00011948538303840905
substance O 0 4.773806358571164e-05
( O 0 1.284107202081941e-05
MIS O 0 0.06211834400892258
) O 0 1.4393220226338599e-05
. O 0 1.634444015508052e-05

Here O 0 3.835019015241414e-05
, O 0 4.442896170075983e-06
we O 0 1.0344130032535759e-06
show O 0 1.257811504729034e-06
that O 0 5.863473688805243e-07
WT1 O 0 0.0007286212057806551
- O 0 0.0007459546905010939
KTS O 0 0.006206686142832041
isoforms O 0 1.3419077731668949e-05
associate O 0 3.7302413602446904e-06
and O 0 5.242072802502662e-07
synergize O 0 0.000197238041437231
with O 0 2.2068754788051592e-06
SF O 0 0.17228330671787262
- O 0 5.552438960876316e-05
1 O 0 1.225425990014628e-06
to O 0 5.983210371596215e-07
promote O 0 8.73413409863133e-06
MIS O 0 0.022025011479854584
expression O 0 5.857478754478507e-05
. O 0 2.2229112801142037e-05

In O 0 0.00010697219840949401
contrast O 0 0.00014047448348719627
, O 0 2.593441604403779e-05
WT1 O 0 0.467124342918396
missense O 0 0.09174895286560059
mutations O 0 0.00039314996683970094
, O 0 1.8367746861258638e-06
associated O 0 2.331367340957513e-06
with O 0 1.0109898767041159e-06
male B-Disease 0 6.388388283085078e-05
pseudohermaphroditism I-Disease 1 0.9995607733726501
in O 0 5.08885204908438e-05
Denys B-Disease 1 0.9649255275726318
- I-Disease 1 0.9994220733642578
Drash I-Disease 1 0.9999673366546631
syndrome I-Disease 1 0.9999644756317139
, O 0 2.5086401365115307e-06
fail O 0 2.5643528715590946e-05
to O 0 9.24756818676542e-07
synergize O 0 0.0007593680056743324
with O 0 4.890815489488887e-06
SF O 1 0.9123374223709106
- O 0 0.0009656717884354293
1 O 0 2.3739061361993663e-05
. O 0 1.787560904631391e-05

Additionally O 0 0.00014387219562195241
, O 0 6.813610070821596e-06
the O 0 1.7686154478724347e-06
X O 0 0.00024701186339370906
- O 0 0.0023453293833881617
linked O 0 4.81341194245033e-05
, O 0 9.512952487966686e-07
candidate O 0 2.3737109131616307e-06
dosage O 0 1.6194746422115713e-05
- O 0 3.8921938539715484e-05
sensitive O 0 5.208593393035699e-06
sex O 0 7.570810112156323e-07
- O 0 5.496380617842078e-05
reversal O 0 3.2029609428718686e-05
gene O 0 1.4518357147608185e-06
, O 0 1.7872312696454173e-07
Dax O 0 2.8709742764476687e-05
- O 0 2.1021955035394058e-05
1 O 0 1.5325754247896839e-06
, O 0 4.99850671076274e-07
antagonizes O 0 2.0699319065897726e-05
synergy O 0 6.876787665532902e-06
between O 0 9.035624088937766e-07
SF O 0 0.040727972984313965
- O 0 4.902313958154991e-05
1 O 0 1.369668780171196e-06
and O 0 4.334568757258239e-07
WT1 O 0 0.00022925563098397106
, O 0 2.2931260446057422e-07
most O 0 1.033910521641701e-07
likely O 0 2.608776412671432e-07
through O 0 8.755259273129923e-08
a O 0 1.4817459259575116e-07
direct O 0 5.195419134906842e-07
interaction O 0 9.302480066253338e-07
with O 0 1.7579959603608586e-06
SF O 1 0.9220410585403442
- O 0 0.0011273607378825545
1 O 0 1.760866871336475e-05
. O 0 1.3105955076753162e-05

We O 0 7.895375165389851e-05
propose O 0 0.00013072340516373515
that O 0 4.286245712137315e-06
WT1 O 0 0.0005938694230280817
and O 0 2.7182841222384013e-06
Dax O 0 0.000392553600249812
- O 0 0.0002162475575460121
1 O 0 3.598306193453027e-06
functionally O 0 6.104028216213919e-06
oppose O 0 7.970709816618182e-07
each O 0 7.8527151003982e-08
other O 0 8.40072900132327e-08
in O 0 2.8461715828598244e-07
testis O 0 0.00010728938650572672
development O 0 1.1873091807501623e-06
by O 0 5.662520834448515e-07
modulating O 0 0.0001440649211872369
SF O 0 0.2589610517024994
- O 0 0.0001289403298869729
1 O 0 4.442815679794876e-06
- O 0 0.00013438337191473693
mediated O 0 0.00023539402172900736
transactivation O 0 0.00040321817505173385
. O 0 3.258696551711182e-06
. O 0 7.573664788651513e-06

A O 0 0.00013993225002195686
mouse O 0 0.00026808815891854465
model O 0 9.45500360103324e-05
for O 0 0.00011601356527535245
Prader B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
imprinting O 0 0.4794389605522156
- O 0 0.2696530818939209
centre O 0 0.0003307538281660527
mutations O 0 0.0003696736821439117
. O 0 2.6470441298442893e-05

Imprinting O 0 0.004370899870991707
in O 0 2.064569889626e-05
the O 0 3.105357109234319e-06
15q11 O 0 0.00017335278971586376
- O 0 0.0004613960045389831
q13 O 0 0.00016625740681774914
region O 0 7.377804195130011e-06
involves O 0 2.1466632915689843e-06
an O 0 8.126166335387097e-07
imprinting O 0 6.551441038027406e-05
centre O 0 9.987436897063162e-06
( O 0 2.4849434794305125e-06
IC O 0 0.0012371164048090577
) O 0 8.908274935492955e-07
, O 0 2.4086639882625605e-07
mapping O 0 2.0576410406647483e-06
in O 0 9.366989672798809e-08
part O 0 1.398980771227798e-07
to O 0 1.1117657550130389e-07
the O 0 1.7697750820389047e-07
promoter O 0 8.851773600326851e-06
and O 0 4.736414496164798e-07
first O 0 1.0083246024805703e-06
exon O 0 1.8392500351183116e-05
of O 0 3.265908162575215e-06
SNRPN O 0 0.002200087998062372
. O 0 3.418877531657927e-05

Deletion O 0 0.0014178561978042126
of O 0 1.3629966815642547e-05
this O 0 3.979304437962128e-06
IC O 0 0.0007858606986701488
abolishes O 0 0.0002844848786480725
local O 0 5.544358373299474e-06
paternally O 0 8.811206498648971e-05
derived O 0 7.872456990298815e-06
gene O 0 4.539251676760614e-06
expression O 0 1.9674857867357787e-06
and O 0 1.4416781368709053e-06
results O 0 8.699431782588363e-05
in O 0 0.00014405572437681258
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0012244927929714322
PWS B-Disease 1 0.9999693632125854
) O 0 8.097690442809835e-05
. O 0 2.643819789227564e-05

We O 0 1.8450298739480786e-05
have O 0 2.612531034174026e-06
created O 0 2.105279236275237e-06
two O 0 1.1257889127591625e-06
deletion O 0 0.00020309750107116997
mutations O 0 5.640560993924737e-05
in O 0 1.5012082030807505e-06
mice O 0 6.232667510630563e-05
to O 0 1.0651094726199517e-06
understand O 0 6.428827418858418e-06
PWS B-Disease 1 0.9988306164741516
and O 0 6.027883614478924e-07
the O 0 1.8968920301176695e-07
mechanism O 0 8.577909511586768e-07
of O 0 3.0603467848777655e-07
this O 0 1.5128495078897686e-06
IC O 0 0.0044717793352901936
. O 0 3.534364441293292e-05

Mice O 0 0.12960182130336761
harbouring O 0 0.07557806372642517
an O 0 2.732037137320731e-05
intragenic O 0 0.019915089011192322
deletion O 0 0.0005277180462144315
in O 0 3.858629042952089e-06
Snrpn O 0 0.0008981245337054133
are O 0 1.7325575072391075e-06
phenotypically O 0 0.0002906173758674413
normal O 0 4.175921276328154e-06
, O 0 7.155803132263827e-07
suggesting O 0 4.098269528185483e-06
that O 0 2.472277742526785e-07
mutations O 0 2.03032777790213e-06
of O 0 1.2456352749268262e-07
SNRPN O 0 0.004937781020998955
are O 0 2.41146778989787e-07
not O 0 2.0329345318259584e-07
sufficient O 0 1.7193289068018203e-06
to O 0 3.360554728715215e-06
induce O 0 0.0006581104826182127
PWS B-Disease 1 0.999817430973053
. O 0 7.151346653699875e-05

Mice O 0 0.009079870767891407
with O 0 1.703179623291362e-05
a O 0 8.585540854255669e-06
larger O 0 9.478572792431805e-06
deletion O 0 6.89354128553532e-05
involving O 0 2.4304956696141744e-06
both O 0 6.002768486723653e-07
Snrpn O 0 0.00011787254334194586
and O 0 8.082984095381107e-07
the O 0 9.243442491424503e-07
putative O 0 0.0006214460590854287
PWS O 1 0.999972939491272
- O 0 0.04590896889567375
IC O 0 0.010252956300973892
lack O 0 2.394457851551124e-06
expression O 0 4.790253456121718e-07
of O 0 8.616562752195023e-08
the O 0 3.2995325227602734e-07
imprinted O 0 0.0001519206998636946
genes O 0 4.655066277337028e-06
Zfp127 O 0 8.6742322309874e-05
( O 0 8.012299304027692e-07
mouse O 0 3.461269670879119e-06
homologue O 0 1.5002353393356316e-05
of O 0 6.301306711975485e-07
ZNF127 O 0 0.00255509652197361
) O 0 1.8051347296932363e-06
, O 0 5.893292609471246e-07
Ndn O 0 0.0002578131388872862
and O 0 6.355962796078529e-07
Ipw O 0 6.170471169753e-05
, O 0 7.136842441468616e-07
and O 0 7.742272600808064e-07
manifest O 0 1.559092925162986e-05
several O 0 1.2462892300391104e-06
phenotypes O 0 0.00029176700627431273
common O 0 2.7619427783065476e-05
to O 0 4.9793627113103867e-05
PWS B-Disease 1 0.9999995231628418
infants O 1 0.8600375056266785
. O 0 7.65414151828736e-05

These O 0 3.731541073648259e-05
data O 0 1.9728484403458424e-05
demonstrate O 0 8.090349183476064e-06
that O 0 3.0843551712678163e-07
both O 0 1.5611627190992294e-07
the O 0 1.0116102089341439e-07
position O 0 3.035413271845755e-07
of O 0 1.0072916722947411e-07
the O 0 1.6012955939004314e-07
IC O 0 0.00017319466860499233
and O 0 2.3638563106942456e-07
its O 0 3.692007339850534e-07
role O 0 2.9533362067013513e-07
in O 0 6.970135757455864e-08
the O 0 7.037570526335912e-08
coordinate O 0 4.274550519767217e-06
expression O 0 4.03722395958539e-07
of O 0 8.449515576103295e-08
genes O 0 4.992289746041934e-07
is O 0 8.515153382404606e-08
conserved O 0 3.4736760312625847e-07
between O 0 1.6082083220680943e-07
mouse O 0 9.568113455316052e-06
and O 0 1.7680168866718304e-06
human O 0 6.48529294267064e-07
, O 0 2.7736720653592783e-07
and O 0 3.122576117675635e-07
indicate O 0 9.8002794857166e-07
that O 0 5.362527843999487e-08
the O 0 8.501991288767385e-08
mouse O 0 4.6967825255705975e-06
is O 0 1.6283824777474365e-07
a O 0 2.501477354144299e-07
suitable O 0 3.0921828511054628e-06
model O 0 2.5115605239989236e-06
system O 0 5.41771441930905e-07
in O 0 9.034144454744819e-08
which O 0 1.0487229928912711e-07
to O 0 1.3798251075058943e-07
investigate O 0 1.3818704474033439e-06
the O 0 1.835055485344128e-07
molecular O 0 4.187398644717177e-06
mechanisms O 0 6.924320814505336e-07
of O 0 1.480240285900436e-07
imprinting O 0 7.748355710646138e-05
in O 0 3.95867999714028e-07
this O 0 9.09460382558791e-08
region O 0 1.0289023748555337e-06
of O 0 1.2077509836672107e-07
the O 0 5.416690669335367e-07
genome O 0 8.958701982919592e-06
. O 0 1.9054332369705662e-06
. O 0 8.76275862538023e-06

Mutations O 0 0.0012002175208181143
of O 0 4.670821908803191e-06
the O 0 2.244476036139531e-06
ATM O 0 0.0002928558678831905
gene O 0 2.0874720576102845e-05
detected O 0 8.56656606629258e-06
in O 0 1.0644718031471712e-06
Japanese O 0 0.00020154728554189205
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 1.0
patients O 1 0.9021853804588318
: O 0 3.6083231407246785e-06
possible O 0 1.0501456699785194e-06
preponderance O 0 9.935558409779333e-06
of O 0 1.307470256506349e-07
the O 0 1.8324674044833955e-07
two O 0 8.72049895406235e-07
founder O 0 0.0003553169663064182
mutations O 0 4.8185283958446234e-05
4612del165 O 0 4.234469815855846e-05
and O 0 3.1720414881419856e-06
7883del5 O 0 0.00045076353126205504
. O 0 3.494315387797542e-05

The O 0 4.3272506445646286e-05
ATM O 0 0.0005910494946874678
( O 0 1.1337142495904118e-05
A O 0 5.9793368563987315e-05
- O 1 0.9020833373069763
T O 1 0.9999271631240845
, O 0 4.719875960290665e-06
mutated O 0 9.729487828735728e-06
) O 0 1.0660097586878692e-06
gene O 0 2.102466396536329e-06
on O 0 8.939815074882063e-07
human O 0 5.492940090334741e-06
chromosome O 0 0.00010743394523160532
11q22 O 0 0.00032071350142359734
. O 0 2.434496309433598e-05

3 O 0 0.0002478902169968933
has O 0 1.1874532901856583e-05
recently O 0 8.866237294569146e-06
been O 0 7.949173550514388e-07
identified O 0 1.0007554465119028e-06
as O 0 1.325524152662183e-07
the O 0 1.681748074133793e-07
gene O 0 1.7194240626849933e-06
responsible O 0 1.404798126714013e-06
for O 0 4.389081595945754e-07
the O 0 5.9818689805979375e-06
human O 0 0.0036323899403214455
recessive B-Disease 1 0.9999587535858154
disease I-Disease 1 0.9997953772544861
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999939203262329
telangiectasia I-Disease 1 0.9999998807907104
( O 0 3.9857910451246426e-05
A B-Disease 0 0.00025835324777290225
- I-Disease 1 0.9937450289726257
T I-Disease 1 0.9999806880950928
) O 0 2.665042848093435e-05
. O 0 1.3163513358449563e-05

In O 0 2.946913991763722e-05
order O 0 8.27844542072853e-06
to O 0 1.2810207863367395e-06
define O 0 4.602693934430135e-06
the O 0 6.152473019938043e-07
types O 0 2.613961669339915e-06
of O 0 2.6329914817324607e-06
disease O 0 0.0020424770191311836
- O 0 0.007776002399623394
causing O 0 9.817258251132444e-05
ATM O 0 0.0007128544966690242
mutations O 0 1.3727360055781901e-05
in O 0 2.3947700356075075e-07
Japanese O 0 2.640271077325451e-06
A B-Disease 0 0.0002879119710996747
- I-Disease 1 0.9999502897262573
T I-Disease 1 1.0
patients O 0 0.0008564129821024835
as O 0 1.875629607184237e-07
well O 0 1.3783153463009512e-07
as O 0 9.606493733826937e-08
to O 0 1.6841474348439078e-07
look O 0 8.056287583713129e-07
for O 0 3.9824030295676494e-07
possible O 0 1.7397450164935435e-06
mutational O 0 0.00014978669059928507
hotspots O 0 1.5344050552812405e-05
, O 0 6.727033223796752e-07
reverse O 0 6.46118269287399e-06
- O 0 3.268125874456018e-05
transcribed O 0 5.981988579151221e-06
RNA O 0 1.4687295788462507e-06
derived O 0 5.506894922291394e-07
from O 0 1.1742497463274049e-07
ten O 0 5.890628926863428e-07
patients O 0 7.142547474359162e-06
belonging O 0 1.024459038490022e-06
to O 0 9.677685142150949e-08
eight O 0 3.907779273504275e-07
unrelated O 0 3.1488671083934605e-06
Japanese O 0 2.8012384518660838e-06
A B-Disease 0 4.653577707358636e-05
- I-Disease 1 0.9515897631645203
T I-Disease 1 0.9999542236328125
families O 0 2.8222714263392845e-06
was O 0 5.070345991953218e-07
analyzed O 0 2.0325189780123765e-06
for O 0 3.8862421547491977e-07
mutations O 0 4.0653922042110935e-06
by O 0 1.4142922566406924e-07
the O 0 3.7550080378423445e-07
restriction O 0 3.909299266524613e-06
endonuclease O 0 7.268120680237189e-05
fingerprinting O 0 8.974751835921779e-05
method O 0 2.5251556508010253e-05
. O 0 1.917896770464722e-05

As O 0 4.351728784968145e-05
has O 0 6.594827937078662e-06
been O 0 2.12353029382939e-06
reported O 0 3.2266216294374317e-06
by O 0 5.151941309122776e-07
others O 0 2.3721268007648177e-06
, O 0 1.9414883354329504e-06
mutations O 0 4.75382330478169e-06
that O 0 8.155725339520359e-08
lead O 0 6.062184638722101e-07
to O 0 1.5630577365755016e-07
exon O 0 6.004393526382046e-06
skipping O 0 4.159755917498842e-06
or O 0 1.0997217714248109e-06
premature O 0 6.157268944662064e-05
protein O 0 2.774007953121327e-06
truncation O 0 1.4197712516761385e-05
were O 0 1.7328785872905428e-07
also O 0 2.932097231678199e-07
predominant O 0 3.8059868074924452e-06
in O 0 4.39847610778088e-07
our O 0 2.0324046090536285e-06
mutants O 0 0.00014576052490156144
. O 0 1.7052323528332636e-05

Six O 0 0.00011319302575429901
different O 0 1.8533341062720865e-05
mutations O 0 0.00011017557699233294
were O 0 1.0772711220852216e-06
identified O 0 9.597536063665757e-07
on O 0 2.4212616267504927e-07
12 O 0 5.877066087123239e-07
of O 0 2.1296294505646074e-07
the O 0 5.222119625614141e-07
16 O 0 1.2702829735644627e-05
alleles O 0 4.3775933590950444e-05
examined O 0 6.439024582505226e-05
. O 0 1.9253844584454782e-05

Four O 0 4.454582085600123e-05
were O 0 7.028319942037342e-06
deletions O 0 3.0456596505246125e-05
involving O 0 4.702515070675872e-06
a O 0 1.4758848010387737e-06
loss O 0 1.519556280982215e-05
of O 0 2.0841393677528686e-07
a O 0 4.872468934991048e-07
single O 0 1.3295353937792243e-06
exon O 0 1.2614570550795179e-05
exon O 0 6.746262442902662e-06
7 O 0 1.2823493307223544e-06
, O 0 3.133781376618572e-07
exon O 0 4.435863502294524e-06
16 O 0 8.012833632164984e-07
, O 0 4.5470662257685035e-07
exon O 0 7.085423476382857e-06
33 O 0 2.7404714728618274e-06
or O 0 2.134013811883051e-06
exon O 0 5.709130709874444e-05
35 O 0 1.9471439372864552e-05
. O 0 1.610947037988808e-05

The O 0 4.6262724936241284e-05
others O 0 1.8072507373290136e-05
were O 0 1.857180222941679e-06
minute O 0 3.488859192657401e-06
deletions O 0 1.1923249076062348e-05
, O 0 1.0992215493388358e-06
4649delA O 0 2.5013703634613194e-05
in O 0 6.819577151873091e-07
exon O 0 8.324283044203185e-06
33 O 0 2.069955826300429e-06
and O 0 7.176798249020067e-07
7883del5 O 0 4.500878640101291e-05
in O 0 1.9244073428126285e-06
exon O 0 6.477201532106847e-05
55 O 0 3.9862014091340825e-05
. O 0 2.7128480724059045e-05

The O 0 7.535873010056093e-05
mutations O 0 0.00023752609558869153
4612del165 O 0 0.0001755961711751297
and O 0 4.895948677585693e-06
7883del5 O 0 0.00014235801063477993
were O 0 7.314789627343998e-07
found O 0 3.717484560183948e-07
in O 0 1.1968400315254257e-07
more O 0 5.6741978227137224e-08
than O 0 1.1358036289266238e-07
two O 0 3.3140324262603826e-07
unrelated O 0 8.841025191941299e-06
families O 0 1.6733438314986415e-06
; O 0 1.3274296861709445e-06
44 O 0 1.1062508065151633e-06
% O 0 4.95040751502529e-07
( O 0 1.3264738640828e-07
7 O 0 3.805431845194107e-07
of O 0 6.364940219327764e-08
16 O 0 5.998922461003531e-07
) O 0 1.179475361823279e-07
of O 0 2.938092258375491e-08
the O 0 1.2871052490481816e-07
mutant O 0 5.28675309396931e-06
alleles O 0 1.9548410818970297e-06
had O 0 1.2367539170554664e-07
one O 0 6.308160749313174e-08
of O 0 8.68016840627206e-08
the O 0 3.409319901948038e-07
two O 0 4.415806870383676e-06
mutations O 0 0.00017956699593923986
. O 0 2.3500613679061644e-05

The O 0 5.880817479919642e-05
4612del165 O 0 0.0028071135748177767
mutations O 0 0.00027890445198863745
in O 0 1.420341163793637e-06
three O 0 4.342542183621845e-07
different O 0 2.2645608055427147e-07
families O 0 5.238934477347357e-07
were O 0 9.691223823438122e-08
all O 0 4.3877257382973767e-08
ascribed O 0 1.4977674709371058e-06
to O 0 1.2822781059185218e-07
the O 0 1.1328935300980447e-07
same O 0 4.5767151846121124e-07
T O 0 0.006062723230570555
- O 0 7.711065700277686e-05
- O 0 6.977155862841755e-05
> O 0 3.523355189827271e-06
A O 0 1.5155077903727943e-07
substitution O 0 2.796578257857618e-07
at O 0 1.1109263198250119e-07
the O 0 1.3949268407031923e-07
splice O 0 3.953545092372224e-05
donor O 0 1.633739702810999e-05
site O 0 2.5421065856789937e-06
in O 0 1.959677319973707e-06
intron O 0 0.00033260363852605224
33 O 0 3.348838436068036e-05
. O 0 2.4788772861938924e-05

Microsatellite O 0 0.00792331900447607
genotyping O 0 0.0022241389378905296
around O 0 1.4088959687796887e-05
the O 0 3.073777406825684e-06
ATM O 0 4.7758912842255086e-05
locus O 0 2.1951062080916017e-05
also O 0 2.0052084437338635e-06
indicated O 0 3.7497545690712286e-06
that O 0 1.7853233202913543e-07
a O 0 5.333782269190124e-07
common O 0 1.6357913409592584e-05
haplotype O 0 0.003707751166075468
was O 0 5.304203796185902e-07
shared O 0 3.6922997992405726e-07
by O 0 1.4471507370217296e-07
the O 0 2.7839624294756504e-07
mutant O 0 7.5091752478329e-06
alleles O 0 4.596136022883002e-06
in O 0 1.0883575214393204e-06
both O 0 3.377564098627772e-06
mutations O 0 0.0001327400968875736
. O 0 1.7286809452343732e-05

This O 0 2.539791057643015e-05
suggests O 0 2.1291258235578425e-05
that O 0 7.86674490882433e-07
these O 0 3.408715087971359e-07
two O 0 8.16670535641606e-07
founder O 0 0.000519725785125047
mutations O 0 0.00013128470163792372
may O 0 1.792712282622233e-06
be O 0 1.7520882522603642e-07
predominant O 0 2.8870349524368066e-06
among O 0 7.470863465641742e-07
Japanese O 0 6.1980240388948005e-06
ATM O 0 0.00018145408830605447
mutant O 0 7.05956990714185e-05
alleles O 0 4.864295260631479e-05
. O 0 1.2744120795105118e-05

W474C O 0 0.0028636190108954906
amino O 0 0.00019575850456021726
acid O 0 0.0002716589660849422
substitution O 0 7.863092832849361e-06
affects O 0 4.072178398928372e-06
early O 0 7.7733523085044e-07
processing O 0 6.81279004766111e-07
of O 0 6.077721792507873e-08
the O 0 8.270928475440087e-08
alpha O 0 1.0923672562057618e-06
- O 0 1.7047129858838161e-06
subunit O 0 7.108503723429749e-07
of O 0 7.001420954111381e-08
beta O 0 1.6067075421233312e-06
- O 0 9.308895641879644e-06
hexosaminidase O 0 1.6108057025121525e-05
A O 0 3.2890582701838866e-07
and O 0 3.068886655910319e-07
is O 0 2.765223143796902e-07
associated O 0 1.6308672456943896e-06
with O 0 4.510769485932542e-06
subacute O 1 0.998228132724762
G B-Disease 1 0.9409174919128418
( I-Disease 0 6.542508344864473e-06
M2 I-Disease 0 0.0002664898056536913
) I-Disease 0 7.775014637445565e-06
gangliosidosis I-Disease 0 0.0003803245781455189
. O 0 2.4887307517929003e-05

Mutations O 0 0.004301611799746752
in O 0 1.833983333199285e-05
the O 0 5.211519692238653e-06
HEXA O 0 0.2696112394332886
gene O 0 1.5893545423750766e-05
, O 0 4.496603480674821e-07
encoding O 0 8.693736504028493e-07
the O 0 1.0212843903900648e-07
alpha O 0 1.5832043800401152e-06
- O 0 1.4000488590681925e-06
subunit O 0 1.2436059932952048e-06
of O 0 1.1541433053707806e-07
beta O 0 2.315692427146132e-06
- O 0 7.203017048595939e-06
hexosaminidase O 0 2.0746432710438967e-05
A O 0 4.3652042336361774e-07
( O 0 3.3276569411100354e-07
Hex O 0 3.623499651439488e-06
A O 0 3.980732117270236e-07
) O 0 2.590623466858233e-07
, O 0 6.88000270088196e-08
that O 0 7.345015973214686e-08
abolish O 0 1.7467190218667383e-06
Hex O 0 6.425358606065856e-06
A O 0 1.7424514453523443e-06
enzyme O 0 2.3182390577858314e-05
activity O 0 9.059075637196656e-06
cause O 0 0.00036571407690644264
Tay B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999991655349731
Sachs I-Disease 1 1.0
disease I-Disease 1 0.811966061592102
( O 0 2.0673754988820292e-05
TSD B-Disease 0 0.45883411169052124
) O 0 3.0731471269973554e-06
, O 0 4.541571172467229e-07
the O 0 1.2427535693859681e-06
fatal O 0 0.06852161139249802
infantile B-Disease 0 0.06313428282737732
form I-Disease 0 4.403031198307872e-06
of I-Disease 0 1.018263105834194e-06
G I-Disease 0 0.13676021993160248
( I-Disease 0 4.296857696317602e-06
M2 I-Disease 0 0.00011035348143195733
) I-Disease 0 1.4609777281293646e-06
gangliosidosis I-Disease 0 4.3943779019173235e-05
, I-Disease 0 7.133127724046062e-07
Type I-Disease 0 3.282932766524027e-06
1 I-Disease 0 7.664044460398145e-06
. O 0 1.224530024046544e-05

Less O 0 0.0042520505376160145
severe O 1 0.9960054755210876
, O 0 0.00032040971564128995
subacute O 1 0.9999567270278931
( O 0 0.007606506813317537
juvenile O 1 0.8852071762084961
- O 1 0.9994907379150391
onset O 1 0.9984503984451294
) O 0 5.2930976380594075e-05
and O 0 5.7404009567108005e-05
chronic O 1 0.9998646974563599
( O 0 4.821939000976272e-05
adult O 0 4.325892587075941e-05
- O 1 0.8464181423187256
onset O 0 0.43185293674468994
) O 0 2.5018737233040156e-06
variants O 0 3.4859092465922004e-06
are O 0 1.325315679423511e-07
characterized O 0 2.5575941435818095e-06
by O 0 1.1331766813782451e-07
a O 0 4.166976452779636e-07
broad O 0 1.2910633813589811e-05
spectrum O 0 1.5026682376628742e-05
of O 0 1.6202465076275985e-06
clinical O 0 0.0006722361431457102
manifestations O 0 0.00010611938341753557
and O 0 1.252484935321263e-06
are O 0 2.308584754473486e-07
associated O 0 7.371407377831929e-07
with O 0 3.7356662119236717e-07
residual O 0 3.8959300582064316e-05
levels O 0 1.2206393193991971e-06
of O 0 2.2413092892747954e-07
Hex O 0 2.0506378859863617e-05
A O 0 3.6592748529074015e-06
enzyme O 0 4.725973849417642e-05
activity O 0 1.3190605386625975e-05
. O 0 1.2363248970359564e-05

We O 0 6.746396684320644e-05
identified O 0 3.073494735872373e-05
a O 0 7.199700121418573e-06
1422 O 0 0.003986170049756765
G O 0 0.20678211748600006
- O 0 0.005737920757383108
- O 0 0.004287955351173878
> O 0 9.104072523768991e-05
C O 0 9.370146472065244e-06
( O 0 3.1566585789732926e-07
amino O 0 7.92469450061617e-07
acid O 0 4.830550551560009e-06
W474C O 0 6.028784355294192e-06
) O 0 1.8259343903537228e-07
substitution O 0 1.9111990923192934e-07
in O 0 4.1149505136672815e-08
the O 0 4.162646050076546e-08
first O 0 1.350673102251676e-07
position O 0 2.869495574486791e-07
of O 0 1.303749854741909e-07
exon O 0 4.801550858246628e-06
13 O 0 5.710351160814753e-07
of O 0 2.4066065407168935e-07
HEXA O 0 0.0010587323922663927
of O 0 1.742832438367259e-07
a O 0 3.2186235898734594e-07
non O 0 4.84099564346252e-06
- O 0 9.919131844071671e-05
Jewish O 0 8.281493137474172e-06
proband O 0 0.0003659966168925166
who O 0 2.654214085850981e-06
manifested O 0 1.5804173017386347e-05
a O 0 3.090289965257398e-06
subacute O 0 0.2881043553352356
variant O 0 0.00015923558385111392
of O 0 1.305899218095874e-06
G B-Disease 0 0.24371710419654846
( I-Disease 0 7.342112894548336e-06
M2 I-Disease 0 0.00035930771264247596
) I-Disease 0 1.3169239537091926e-05
gangliosidosis I-Disease 0 0.0005629550432786345
. O 0 2.656258766364772e-05

On O 0 2.0784853404620662e-05
the O 0 3.871390163112665e-06
second O 0 8.249741767940577e-06
maternally O 0 0.0008218273287639022
inherited O 0 0.0011716847075149417
allele O 0 4.7225679736584425e-05
, O 0 1.5594634987792233e-06
we O 0 3.9491587244810944e-07
identified O 0 1.690680619503837e-06
the O 0 8.60010800352029e-07
common O 0 0.0004887722316198051
infantile O 1 0.9999710321426392
disease O 1 0.7553844451904297
- O 0 0.013628923334181309
causing O 0 5.654650158248842e-05
4 O 0 5.8934156186296605e-06
- O 0 0.00016321084694936872
bp O 0 0.0004379755991976708
insertion O 0 1.3234329344413709e-05
, O 0 1.2710347618849482e-06
+ O 0 5.0936003390233964e-05
TATC O 0 0.0003407257900107652
1278 O 0 0.00012610162957571447
, O 0 1.2437637906259624e-06
in O 0 1.8246563513457659e-06
exon O 0 6.759063398931175e-05
11 O 0 1.742498170642648e-05
. O 0 1.862766112026293e-05

Pulse O 0 0.004571439698338509
- O 0 0.0010218960233032703
chase O 0 0.00019294586672913283
analysis O 0 7.950447979965247e-06
using O 0 3.3431908832426416e-06
proband O 0 0.0007077184855006635
fibroblasts O 0 0.0001847960229497403
revealed O 0 3.458722176219453e-06
that O 0 8.831217712668149e-08
the O 0 9.42408391324534e-08
W474C O 0 5.6019403018581215e-06
- O 0 3.2767525226518046e-06
containing O 0 4.55394882692417e-07
alpha O 0 1.3548584547606879e-06
- O 0 2.0291276996431407e-06
subunit O 0 1.06354525541974e-06
precursor O 0 1.0005302328863763e-06
was O 0 9.354062768807125e-08
normally O 0 2.64142926198474e-07
synthesized O 0 1.704973215055361e-06
, O 0 1.2606777488599619e-07
but O 0 9.54527124008564e-08
not O 0 9.881461693339588e-08
phosphorylated O 0 2.188730832131114e-06
or O 0 2.705157555737969e-07
secreted O 0 1.1796389571827604e-06
, O 0 1.1452087278485124e-07
and O 0 1.0598026989327991e-07
the O 0 2.013034219316978e-07
mature O 0 1.1563467523956206e-05
lysosomal O 0 8.898515079636127e-05
alpha O 0 6.704650331812445e-06
- O 0 9.110764040087815e-06
subunit O 0 3.1638392101740465e-06
was O 0 7.051731927276705e-07
not O 0 1.2832583706767764e-06
detected O 0 1.818318196455948e-05
. O 0 1.0588641089270823e-05

When O 0 2.151135413441807e-05
the O 0 3.3552641980350018e-06
W474C O 0 2.4637491151224822e-05
- O 0 1.0617470252327621e-05
containing O 0 1.4336628737510182e-06
alpha O 0 3.847084826702485e-06
- O 0 4.1584034988773055e-06
subunit O 0 1.918323960126145e-06
was O 0 2.747094640653813e-07
transiently O 0 7.110224032658152e-06
co O 0 9.054031579580624e-06
- O 0 6.311028300842736e-06
expressed O 0 2.5337124043289805e-07
with O 0 3.827085848229217e-08
the O 0 7.153388281722073e-08
beta O 0 9.69904249359388e-07
- O 0 2.0287484403525013e-06
subunit O 0 4.228343470913387e-07
to O 0 9.117008659131898e-08
produce O 0 4.451767381397076e-07
Hex O 0 3.32922650159162e-06
A O 0 4.826654276257614e-07
( O 0 4.851945618611353e-07
alphabeta O 0 4.929348506266251e-05
) O 0 5.600468853117491e-07
in O 0 3.456357262621168e-07
COS O 0 0.002927436027675867
- O 0 5.64673900953494e-05
7 O 0 7.711514626862481e-06
cells O 0 3.347628535266267e-06
, O 0 1.1477824557459826e-07
the O 0 1.1193725413249922e-07
mature O 0 3.022131522811833e-06
alpha O 0 1.7280478914472042e-06
- O 0 3.3864434954011813e-06
subunit O 0 8.803927471490169e-07
was O 0 1.0940618722088402e-07
present O 0 8.090682968031615e-08
, O 0 5.651149237451136e-08
but O 0 3.221568078970449e-08
its O 0 1.0635042002604678e-07
level O 0 1.9061842237988458e-07
was O 0 9.619805041438667e-08
much O 0 8.506971482802328e-08
lower O 0 8.576633945267531e-07
than O 0 6.428187049323242e-08
that O 0 4.653929153164427e-08
from O 0 8.749282898179445e-08
normal O 0 4.6345030568772927e-07
alpha O 0 1.4061317870073253e-06
- O 0 5.188549039303325e-06
subunit O 0 2.2138676740723895e-06
transfections O 0 2.2228538000490516e-05
, O 0 1.528886457435874e-07
although O 0 1.30188112734686e-07
higher O 0 2.8024118137182086e-07
than O 0 1.053631066838534e-07
in O 0 1.1496942420308187e-07
those O 0 2.852121951946174e-07
cells O 0 8.836515917209908e-06
transfected O 0 4.224052463541739e-05
with O 0 1.3873660975605162e-07
an O 0 2.213220824387463e-07
alpha O 0 4.4362359403749e-06
- O 0 2.346079782000743e-05
subunit O 0 8.218135917559266e-06
associated O 0 4.442116733116563e-06
with O 0 6.227179255802184e-06
infantile O 0 0.06939385831356049
TSD B-Disease 1 0.8265312910079956
. O 0 7.65500299166888e-05

Furthermore O 0 0.00019090287969447672
, O 0 4.228833859087899e-06
the O 0 7.748565735710145e-07
precursor O 0 4.19514117311337e-06
level O 0 3.816626019670366e-07
of O 0 1.3270722831748571e-07
the O 0 1.614567395336053e-07
W474C O 0 8.150729627232067e-06
alpha O 0 2.8858457881142385e-06
- O 0 2.852129682651139e-06
subunit O 0 1.0004118848883081e-06
was O 0 1.5701108679877507e-07
found O 0 1.1078433459488224e-07
to O 0 1.3639889573369146e-07
accumulate O 0 1.0953143828373868e-05
in O 0 2.0171140135971655e-07
comparison O 0 4.1969832409449737e-07
to O 0 9.690170799103726e-08
the O 0 1.2693348594439158e-07
normal O 0 5.986429414406302e-07
alpha O 0 1.8242161559101078e-06
- O 0 8.004769370018039e-06
subunit O 0 8.36474009702215e-06
precursor O 0 1.3348688298719935e-05
levels O 0 7.197763807198498e-06
. O 0 7.744156391709112e-06

We O 0 5.5676351621514186e-05
conclude O 0 9.251177834812552e-05
that O 0 1.6677854546287563e-06
the O 0 1.852732907536847e-06
1422 O 0 0.0010279278503730893
G O 0 0.09818269312381744
- O 0 0.007074394728988409
- O 0 0.011085252277553082
> O 0 0.0002728844410739839
C O 0 4.610438918462023e-05
mutation O 0 1.915125039886334e-06
is O 0 9.960672997522124e-08
the O 0 1.1300448221618353e-07
cause O 0 7.973972060426604e-07
of O 0 2.422430327442271e-07
Hex B-Disease 0 0.0004778743314091116
A I-Disease 0 0.0002769562997855246
enzyme I-Disease 1 0.9998762607574463
deficiency I-Disease 1 0.9998811483383179
in O 0 2.1096004729770357e-06
the O 0 3.070739012400736e-06
proband O 0 0.0034526896197348833
. O 0 1.7829164789873175e-05

The O 0 2.277124804095365e-05
resulting O 0 3.109360841335729e-05
W474C O 0 6.76702766213566e-05
substitution O 0 1.083787083189236e-05
clearly O 0 2.9502834877348505e-06
interferes O 0 5.116557986184489e-06
with O 0 3.108629016423947e-07
alpha O 0 2.97528640658129e-06
- O 0 1.169884762930451e-05
subunit O 0 1.955062771230587e-06
processing O 0 7.141221090023464e-07
, O 0 1.0863328725463361e-07
but O 0 5.2383349213869224e-08
because O 0 5.6735160569587606e-08
the O 0 4.8082590353715204e-08
base O 0 2.4238676132881665e-07
substitution O 0 4.1750425339159847e-07
falls O 0 1.9668182176246773e-06
at O 0 7.919861388927529e-08
the O 0 4.84238604769871e-08
first O 0 1.1703210844871137e-07
position O 0 2.4761237682469073e-07
of O 0 1.5231671568471938e-07
exon O 0 6.758342806278961e-06
13 O 0 1.079380240298633e-06
, O 0 3.264888164267177e-07
aberrant O 0 6.770108939235797e-06
splicing O 0 3.318978633615188e-05
may O 0 1.243175461240753e-06
also O 0 1.4812796678143059e-07
contribute O 0 4.1011489315678773e-07
to O 0 2.0949397594449692e-07
Hex B-Disease 0 7.01787430443801e-05
A I-Disease 0 5.914359280723147e-05
deficiency I-Disease 0 0.22082048654556274
in O 0 6.688822509204329e-07
this O 0 6.882114576001186e-07
proband O 0 0.0007939371862448752
. O 0 6.201547421369469e-06
. O 0 1.4804401871515438e-05

Two O 0 0.00011753290891647339
frequent O 0 0.001266578328795731
missense O 0 0.41981256008148193
mutations O 0 0.05143488943576813
in O 0 0.0007569174049422145
Pendred B-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999998807907104
. O 0 0.00034464659984223545

Pendred B-Disease 1 0.9999996423721313
syndrome I-Disease 1 1.0
is O 0 0.01158416923135519
an O 1 0.5743321180343628
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9914421439170837
by O 0 9.636717004468665e-05
early O 0 0.013775119557976723
childhood O 1 0.9783157110214233
deafness B-Disease 1 1.0
and O 1 0.7808986902236938
goiter B-Disease 1 1.0
. O 0 0.0009178179316222668

A O 0 7.45938450563699e-05
century O 0 1.958500433829613e-05
after O 0 6.229287919268245e-06
its O 0 1.5135377680053352e-06
recognition O 0 2.105935891449917e-06
as O 0 9.546806722937617e-07
a O 0 4.099676516489126e-05
syndrome O 1 0.9997599720954895
by O 0 3.2450882372359047e-06
Vaughan O 0 0.0002791529113892466
Pendred O 0 0.0023058063816279173
, O 0 1.918614998430712e-06
the O 0 2.305667976543191e-06
disease O 0 0.000493741943500936
gene O 0 7.271046797541203e-06
( O 0 1.4520684317176347e-06
PDS O 0 0.0011852774769067764
) O 0 1.2238633644301444e-06
was O 0 4.6197030201255984e-07
mapped O 0 4.365047971077729e-06
to O 0 1.6405919041062589e-06
chromosome O 0 5.3592626500176266e-05
7q22 O 0 0.0002848735311999917
- O 0 0.0007104736287146807
q31 O 0 0.0005958183319307864
. O 0 3.438863859628327e-05

1 O 0 0.00011072282359236851
and O 0 5.299625172483502e-06
, O 0 2.209626018156996e-06
recently O 0 3.947749519284116e-06
, O 0 5.472477369039552e-07
found O 0 3.721819439306273e-07
to O 0 2.7026328552892664e-07
encode O 0 3.862613084493205e-06
a O 0 3.0511425848089857e-06
putative O 0 0.0004925731336697936
sulfate O 0 0.0024096989072859287
transporter O 0 0.0008890738245099783
. O 0 3.6398581869434565e-05

We O 0 4.3269945308566093e-05
performed O 0 3.881207521772012e-05
mutation O 0 1.40341790029197e-05
analysis O 0 2.4990788460854674e-06
of O 0 2.961679115287552e-07
the O 0 7.205629231066268e-07
PDS B-Disease 0 0.16582567989826202
gene O 0 2.9574008294730447e-05
in O 0 2.904812390625011e-06
patients O 0 3.773592470679432e-05
from O 0 3.5354520377950394e-07
14 O 0 3.2865573302842677e-06
Pendred B-Disease 0 0.00012041747686453164
families O 0 7.439297178279958e-07
originating O 0 8.962247761701292e-07
from O 0 1.2210823285840888e-07
seven O 0 3.2961486340354895e-07
countries O 0 2.7763053367380053e-07
and O 0 6.351248771352402e-07
identified O 0 3.482323791104136e-06
all O 0 1.3142488342055003e-06
mutations O 0 0.00010717956320149824
. O 0 2.459887218719814e-05

The O 0 5.739350672229193e-05
mutations O 0 0.00013237958773970604
include O 0 2.4879952889023116e-06
three O 0 4.99011434840213e-07
single O 0 1.2742971193802077e-06
base O 0 2.8723125069518574e-06
deletions O 0 7.144986284401966e-06
, O 0 3.0529832883985364e-07
one O 0 1.647680960559228e-07
splice O 0 6.255019980017096e-05
site O 0 3.2407954222435364e-06
mutation O 0 3.7205952594376868e-06
and O 0 7.097299885572284e-07
10 O 0 9.540859537082724e-06
missense O 0 0.0007326914346776903
mutations O 0 0.00022646956495009363
. O 0 3.3440737752243876e-05

One O 0 0.00010023589857155457
missense O 0 0.007275902200490236
mutation O 0 0.0004479275085031986
( O 0 1.339934897259809e-05
L236P O 0 0.00034107110695913434
) O 0 3.467904207354877e-06
was O 0 6.131006671239447e-07
found O 0 3.161997597089794e-07
in O 0 1.7093252324684727e-07
a O 0 8.077867619249446e-07
homozygous O 0 8.345863534486853e-06
state O 0 3.118127551715588e-07
in O 0 1.981286317231934e-07
two O 0 3.630181595326576e-07
consanguineous O 0 0.0008001411915756762
families O 0 2.5978033590945415e-06
and O 0 3.6811960058003024e-07
in O 0 1.4737004505605e-07
a O 0 3.2536487992729235e-07
heterozygous O 0 2.5272188395319972e-06
state O 0 2.2900620422205975e-07
in O 0 1.9073880253017705e-07
five O 0 4.165355278473726e-07
additional O 0 1.8837012021322153e-06
non O 0 1.567520848766435e-05
- O 0 0.0006125995423644781
consanguineous O 0 0.0021125839557498693
families O 0 2.220925671281293e-05
. O 0 1.6391704775742255e-05

Another O 0 0.00017501380352769047
missense O 0 0.020920587703585625
mutation O 0 0.0007887997780926526
( O 0 1.0634707905410323e-05
T416P O 0 0.0002007571019930765
) O 0 2.9348939278861508e-06
was O 0 3.443988703111245e-07
found O 0 2.5620320798225293e-07
in O 0 1.4261841840834677e-07
a O 0 4.6046602619753685e-07
homozygous O 0 7.395915872621117e-06
state O 0 2.272015251492121e-07
in O 0 1.964098998996633e-07
one O 0 1.739660717703373e-07
family O 0 1.1482657100714277e-06
and O 0 3.4842034324356064e-07
in O 0 2.740226250352862e-07
a O 0 7.432092843373539e-07
heterozygous O 0 3.3418457405787194e-06
state O 0 4.51257989197984e-07
in O 0 3.721521295574348e-07
four O 0 1.789449697753298e-06
families O 0 1.1156057553307619e-05
. O 0 1.3806789866066538e-05

Pendred B-Disease 1 0.9985685348510742
patients O 1 0.7010001540184021
in O 0 5.282010988594266e-06
three O 0 2.277730573041481e-06
non O 0 3.007035775226541e-05
- O 0 0.0010175040224567056
consanguineous O 0 0.0011968440376222134
families O 0 2.7630112526821904e-06
were O 0 2.2840204394469765e-07
shown O 0 2.7181704354006797e-07
to O 0 1.8653440747584682e-07
be O 0 1.9193326750155393e-07
compound O 0 1.4495927644020412e-05
heterozygotes O 0 0.0001112182653741911
for O 0 8.508088740200037e-07
L236P O 0 8.182829333236441e-05
and O 0 6.029997621226357e-06
T416P O 0 0.0004190047620795667
. O 0 2.5761377401067875e-05

In O 0 2.9260374503792264e-05
total O 0 7.711640137131326e-06
, O 0 1.0566141099843662e-06
one O 0 2.2308049096864124e-07
or O 0 2.2876697869378404e-07
both O 0 1.2759616652147088e-07
of O 0 1.7443024091789994e-07
these O 0 5.634326498693554e-07
mutations O 0 7.577204542030813e-06
were O 0 8.067814860623912e-08
found O 0 1.221310697019362e-07
in O 0 7.619507869094377e-08
nine O 0 2.149136406615071e-07
of O 0 1.270785929818885e-07
the O 0 3.363275311585312e-07
14 O 0 5.576258899964159e-06
families O 0 9.467733434576076e-06
analyzed O 0 4.0795875975163653e-05
. O 0 1.7734049833961762e-05

The O 0 2.7044505259254947e-05
identification O 0 1.8584649296826683e-05
of O 0 1.6741929584895843e-06
two O 0 1.9130732198391343e-06
frequent O 0 2.8529826522571966e-05
PDS B-Disease 0 0.4312935173511505
mutations O 0 4.298341809771955e-05
will O 0 3.4872351761805476e-07
facilitate O 0 1.6681893839631812e-06
the O 0 1.346634803667257e-06
molecular O 0 0.0017840262735262513
diagnosis O 1 0.924828290939331
of O 0 0.00039746498805470765
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0001775347482180223

Insertional O 0 0.17045290768146515
mutation O 0 0.0005891276523470879
by O 0 1.1025519597751554e-05
transposable O 0 0.00045727292308583856
element O 0 1.1044724487874191e-05
, O 0 2.2964775325817754e-06
L1 O 0 0.00028026895597577095
, O 0 6.965430543459661e-07
in O 0 4.5785009206156246e-07
the O 0 2.0108020635234425e-06
DMD B-Disease 1 0.999998927116394
gene O 0 6.603489600820467e-05
results O 0 1.215385509567568e-05
in O 0 1.507816818957508e-06
X B-Disease 0 0.12059241533279419
- I-Disease 1 0.9431238770484924
linked I-Disease 1 0.5535239577293396
dilated I-Disease 1 0.9994369149208069
cardiomyopathy I-Disease 1 0.9999974966049194
. O 0 0.0002044918801402673

X B-Disease 1 0.9447036981582642
- I-Disease 1 0.9851120114326477
linked I-Disease 1 0.5018088817596436
dilated I-Disease 1 0.9999244213104248
cardiomyopathy I-Disease 1 0.9999998807907104
( O 0 0.0003512788098305464
XLDCM B-Disease 1 0.705822229385376
) O 0 7.798109436407685e-06
is O 0 3.523821874296118e-07
a O 0 2.7226219572185073e-06
clinical O 0 0.0018253730377182364
phenotype O 0 0.0010681785643100739
of O 0 6.314757570180518e-07
dystrophinopathy B-Disease 0 0.02758941613137722
which O 0 1.3839687653671717e-06
is O 0 5.215962346483138e-07
characterized O 0 2.3911736207082868e-05
by O 0 2.2197111775312806e-06
preferential O 0 0.016623783856630325
myocardial B-Disease 1 0.9999668598175049
involvement I-Disease 0 0.0001469244307372719
without O 0 1.8178217260356178e-06
any O 0 1.0829622851815657e-06
overt O 0 6.393721560016274e-05
clinical O 0 0.00041652543586678803
signs O 0 0.00010768071661004797
of O 0 7.29391467757523e-05
skeletal B-Disease 1 0.9999945163726807
myopathy I-Disease 1 0.9999998807907104
. O 0 0.0005323246587067842

To O 0 5.113325096317567e-05
date O 0 3.212759111193009e-05
, O 0 2.517670964152785e-06
several O 0 1.7652789665589808e-06
mutations O 0 1.8103748516296037e-05
in O 0 9.161211664832081e-07
the O 0 1.0134841431863606e-05
Duchenne B-Disease 1 0.999995231628418
muscular I-Disease 1 0.9999814033508301
dystrophy I-Disease 1 0.9999948740005493
gene O 0 0.0003368339384905994
, O 0 2.8656595532083884e-05
DMD O 1 0.999998927116394
, O 0 9.2682439571945e-06
have O 0 3.7087278315084404e-07
been O 0 4.3299783669681347e-07
identified O 0 3.582678573366138e-06
in O 0 2.181468516937457e-06
patients O 0 4.777435606229119e-05
with O 0 1.8589487353892764e-06
XLDCM B-Disease 1 0.5062185525894165
, O 0 1.5852530168558587e-06
but O 0 1.630704105082259e-07
a O 0 3.544175228853419e-07
pathogenic O 0 3.4785566640493926e-06
correlation O 0 5.303880357132584e-07
of O 0 1.4727491759458644e-07
these O 0 5.145371346770844e-07
cardiospecific O 0 0.018350975587964058
mutations O 0 7.530067523475736e-05
in O 0 2.069073843813385e-06
DMD O 1 0.9999867677688599
with O 0 3.86224110116018e-06
the O 0 2.5033773454197217e-06
XLDCM B-Disease 1 0.8196139931678772
phenotype O 0 0.01514109130948782
has O 0 9.18514729164599e-07
remained O 0 1.6577982933085877e-06
to O 0 1.0072529903482064e-06
be O 0 2.342164179935935e-06
elucidated O 0 0.0002652937837410718
. O 0 2.3554322979180142e-05

We O 0 6.501638563349843e-05
report O 0 1.5824882211745717e-05
here O 0 7.571120477223303e-07
the O 0 2.4816037580421835e-07
identification O 0 1.0438382105348865e-06
of O 0 1.526971828980095e-07
a O 0 5.46300782389153e-07
unique O 0 2.6886170871875947e-06
de O 0 7.870009540056344e-06
novo O 0 2.2302496290649287e-05
L1 O 0 0.0001055079119396396
insertion O 0 9.27490236790618e-06
in O 0 3.977931442022964e-07
the O 0 4.512945679380209e-07
muscle O 0 1.4526857739838306e-05
exon O 0 2.3665776097914204e-05
1 O 0 4.039471605210565e-06
in O 0 1.921300963658723e-06
DMD O 1 0.999988317489624
in O 0 2.838007048922009e-06
three O 0 2.888610424633953e-06
XLDCM B-Disease 1 0.9909921884536743
patients O 0 0.00037805590545758605
from O 0 2.2615954264892935e-07
two O 0 4.355619296347868e-07
unrelated O 0 1.1177867236256134e-05
Japanese O 0 1.309231356572127e-05
families O 0 1.371262624161318e-05
. O 0 2.2493430151371285e-05

The O 0 2.8189309887238778e-05
insertion O 0 5.807874913443811e-05
was O 0 2.3688985493208747e-06
a O 0 1.1654443596853525e-06
5 O 0 1.8019700291915797e-06
- O 0 2.0779303667950444e-05
truncated O 0 6.814403150201542e-06
form O 0 5.393504807216232e-07
of O 0 2.1292437679676368e-07
human O 0 5.98919939420739e-07
L1 O 0 8.268239616882056e-05
inversely O 0 7.56456302042352e-06
integrated O 0 2.3970692382135894e-06
in O 0 1.442390242800684e-07
the O 0 1.3349932714845636e-07
5 O 0 2.6356897251389455e-06
- O 0 0.00027115357806906104
untranslated O 0 0.12956349551677704
region O 0 6.9634320425393526e-06
in O 0 2.388921416240919e-07
the O 0 2.447178246711701e-07
muscle O 0 1.1325039849907625e-05
exon O 0 8.260819413408171e-06
1 O 0 8.365270787180634e-07
, O 0 1.3301639967266965e-07
which O 0 9.813675205805339e-08
affected O 0 1.9299085352031398e-07
the O 0 5.4490744361146426e-08
transcription O 0 1.2869571719420492e-06
or O 0 1.2946406968694646e-07
the O 0 9.910397125167947e-08
stability O 0 1.0431963346491102e-06
of O 0 8.982974719629055e-08
the O 0 2.552781097620027e-07
muscle O 0 2.0863435565843247e-05
form O 0 9.494988262304105e-07
of O 0 3.147460461150331e-07
dystrophin O 0 0.00018332741456106305
transcripts O 0 1.4118604667601176e-05
but O 0 1.678765926271808e-07
not O 0 6.64989698861973e-08
that O 0 3.935728187798304e-08
of O 0 8.681659124931684e-08
the O 0 8.877480581759301e-07
brain O 0 0.00020557826792355627
or O 0 3.0709936709172325e-06
Purkinje O 0 0.19306986033916473
cell O 0 0.00011596112744882703
form O 0 1.3875674085284118e-06
, O 0 4.0387104149886e-07
probably O 0 4.180170094514324e-07
due O 0 3.4092906275873247e-07
to O 0 8.715039001572222e-08
its O 0 2.3838396145947627e-07
unique O 0 7.555007641713019e-07
site O 0 1.5027852668936248e-06
of O 0 7.119080578377179e-07
integration O 0 4.318918945500627e-05
. O 0 1.7312382624368183e-05

We O 0 4.1123748815152794e-05
speculate O 0 4.993771290173754e-05
that O 0 5.279228503241029e-07
this O 0 2.762724307103781e-07
insertion O 0 1.8084757584801991e-06
of O 0 1.2308424857110367e-07
an O 0 3.662078142951941e-07
L1 O 0 0.00017731702246237546
sequence O 0 2.1280043256410863e-06
in O 0 3.121586587440106e-06
DMD O 1 0.9999985694885254
is O 0 1.5165359172897297e-06
responsible O 0 1.7633036577535677e-06
for O 0 8.921471561507133e-08
some O 0 4.249445595405632e-08
of O 0 5.1309942961097477e-08
the O 0 1.1773333596920565e-07
population O 0 2.0737107320201176e-07
of O 0 1.4231461875624518e-07
Japanese O 0 3.15736724587623e-05
patients O 0 5.05992429680191e-05
with O 0 1.7472154922870686e-06
XLDCM B-Disease 0 0.10861299932003021
. O 0 7.261254722834565e-06
. O 0 1.898014852486085e-05

Severe O 1 0.998234748840332
early O 0 0.009770682081580162
- O 1 0.9999710321426392
onset O 1 0.9999969005584717
obesity B-Disease 1 0.9999955892562866
, O 0 0.01264255028218031
adrenal B-Disease 1 0.9999994039535522
insufficiency I-Disease 1 0.9999994039535522
and O 0 6.958749872865155e-05
red O 0 0.19930201768875122
hair O 1 0.9994701743125916
pigmentation O 1 0.9995428323745728
caused O 0 0.0002529447665438056
by O 0 7.297040610865224e-06
POMC O 1 0.9881248474121094
mutations O 0 0.0002064935106318444
in O 0 3.528768957039574e-06
humans O 0 1.9539631466614082e-05
. O 0 3.5066699638264254e-05

Sequential O 0 0.00032099185045808554
cleavage O 0 0.00022486165107693523
of O 0 2.725412059589871e-06
the O 0 9.264941240871849e-07
precursor O 0 6.043567282176809e-06
protein O 0 2.4017328996706055e-06
pre O 0 5.549129582504975e-06
- O 0 3.315223511890508e-05
pro O 0 9.973759006243199e-06
- O 0 0.000153138636960648
opiomelanocortin O 0 0.0003877667768392712
( O 0 2.062289013338159e-06
POMC O 0 0.00021526504133362323
) O 0 6.759862571925623e-07
generates O 0 1.4916096233719145e-06
the O 0 4.929377155349357e-07
melanocortin O 0 0.00021016024402342737
peptides O 0 2.8414377084118314e-05
adrenocorticotrophin O 0 0.00020693661645054817
( O 0 2.671253469088697e-06
ACTH O 0 7.544587424490601e-05
) O 0 5.996708978273091e-07
, O 0 5.088317038826062e-07
melanocyte O 0 0.000277371727861464
- O 0 0.00024071101506706327
stimulating O 0 0.00010526692494750023
hormones O 0 1.0706479770306032e-05
( O 0 8.006990128706093e-07
MSH O 0 0.00015142583288252354
) O 0 3.7059308510833944e-07
alpha O 0 8.634623895886762e-07
, O 0 1.0318576926238165e-07
beta O 0 6.256563551687577e-07
and O 0 8.045179811233538e-08
gamma O 0 8.954789336712565e-07
as O 0 3.774578516413385e-08
well O 0 4.0849059246284014e-08
as O 0 6.898004301092442e-08
the O 0 1.889886078743075e-07
opioid O 0 4.491128493100405e-05
- O 0 4.7897112381178886e-05
receptor O 0 9.233106538886204e-06
ligand O 0 2.0188539565424435e-05
beta O 0 1.9004184650839306e-05
- O 0 0.00011514025391079485
endorphin O 0 0.0006584102520719171
. O 0 1.4478686352958903e-05

While O 0 3.5585897421697155e-05
a O 0 7.489821200579172e-06
few O 0 5.045455054641934e-06
cases O 0 3.2871496387087973e-06
of O 0 3.4084882827301044e-06
isolated O 0 0.17991210520267487
ACTH B-Disease 1 0.9999970197677612
deficiency I-Disease 1 0.9980510473251343
have O 0 1.5389055079140235e-06
been O 0 1.6732305994082708e-06
reported O 0 2.5293737053289078e-05
( O 0 5.943065843894146e-06
OMIM O 0 0.36549296975135803
201400 O 0 0.0006621376960538328
) O 0 1.7716946558721247e-06
, O 0 5.587622808889137e-07
an O 0 1.6736981933718198e-06
inherited O 0 0.028752382844686508
POMC O 1 0.9997418522834778
defect O 0 0.06737487763166428
has O 0 1.2925918326800456e-06
not O 0 2.842658375357132e-07
been O 0 4.5217601041258604e-07
described O 0 6.970880349399522e-06
so O 0 2.017904080275912e-06
far O 0 6.336877049761824e-06
. O 0 1.7692564142635092e-05

Recent O 0 0.0006916027050465345
studies O 0 0.00014143413864076138
in O 0 5.727603820560034e-06
animal O 0 9.995078471547458e-06
models O 0 2.746676909737289e-05
elucidated O 0 3.426490002311766e-05
a O 0 5.087725298835721e-07
central O 0 7.220074849101366e-07
role O 0 3.842864089165232e-07
of O 0 2.668589900167717e-07
alpha O 0 9.285939086112194e-06
- O 0 0.0001025838209898211
MSH O 0 0.0007462546927854419
in O 0 1.1269109734257654e-07
the O 0 6.565106502876006e-08
regulation O 0 3.395691408059065e-07
of O 0 7.236357646434044e-08
food O 0 4.2984669335055514e-07
intake O 0 8.902253512133029e-07
by O 0 1.492121697310722e-07
activation O 0 1.2470989076973638e-06
of O 0 1.4833209149855975e-07
the O 0 5.051927587373939e-07
brain O 0 7.422316411975771e-05
melanocortin O 0 0.0004153155896347016
- O 0 5.0312326493440196e-05
4 O 0 2.786169034152408e-06
- O 0 3.878965799231082e-05
receptor O 0 4.5678029891860206e-06
( O 0 9.729041039463482e-07
MC4 O 0 0.00019882811466231942
- O 0 3.398117405595258e-05
R O 0 8.621710730949417e-05
; O 0 6.535609031743661e-07
refs O 0 3.4643110211618477e-06
3 O 0 1.1807577493527788e-06
- O 0 1.9517208784236573e-05
5 O 0 1.3379825531956158e-06
) O 0 1.15073405027033e-07
and O 0 4.308287770982133e-08
the O 0 8.711050725196401e-08
linkage O 0 4.264639756001998e-06
of O 0 9.301876957579225e-07
human O 0 1.3434379070531577e-05
obesity B-Disease 0 0.17693331837654114
to O 0 1.0621080264172633e-06
chromosome O 0 9.341336408397183e-06
2 O 0 1.3040449857726344e-06
in O 0 1.5795259855622135e-07
close O 0 5.012105930291e-07
proximity O 0 1.0254062772219186e-06
to O 0 2.9243230414977006e-07
the O 0 4.401636033435352e-07
POMC O 0 0.005131167359650135
locus O 0 5.8249165704182815e-06
, O 0 2.530754272811464e-07
led O 0 2.1717507081575604e-07
to O 0 6.809049324374428e-08
the O 0 8.576636645329927e-08
proposal O 0 1.0589454859655234e-06
of O 0 1.2974525986919616e-07
an O 0 2.8427697884580994e-07
association O 0 2.608622480693157e-06
of O 0 9.98353243630845e-07
POMC O 0 0.49913856387138367
with O 0 2.1213150830590166e-05
human O 0 0.00014093858771957457
obesity B-Disease 1 0.6530030965805054
. O 0 3.950074460590258e-05

The O 0 1.9219449313823134e-05
dual O 0 2.500134905858431e-05
role O 0 3.964595634897705e-06
of O 0 9.376880711897684e-07
alpha O 0 2.028890412475448e-05
- O 0 0.00020438797946553677
MSH O 0 0.002804930554702878
in O 0 7.274357471942494e-07
regulating O 0 4.112552687729476e-06
food O 0 1.1740049785657902e-06
intake O 0 3.386866637811181e-06
and O 0 1.241843733623682e-06
influencing O 0 5.777222759206779e-05
hair O 1 0.9124148488044739
pigmentation O 1 0.9793680906295776
predicts O 0 0.05043430253863335
that O 0 4.775283741764724e-07
the O 0 6.702231871713593e-07
phenotype O 0 0.00501131359487772
associated O 0 3.3297505979135167e-06
with O 0 3.4486427580304735e-07
a O 0 5.391723334469134e-06
defect O 0 0.002165069803595543
in O 0 3.1839617804507725e-06
POMC O 0 0.08082512021064758
function O 0 2.4189682790165534e-06
would O 0 8.086145157903957e-07
include O 0 9.917637726175599e-06
obesity B-Disease 0 0.38143444061279297
, O 0 5.809959475300275e-06
alteration O 0 0.0002085531159536913
in O 0 2.071624476229772e-05
pigmentation O 1 0.993733823299408
and O 0 0.006827940233051777
ACTH B-Disease 1 0.9999126195907593
deficiency I-Disease 1 0.9751395583152771
. O 0 4.116656054975465e-05

The O 0 3.409715282032266e-05
observation O 0 3.698875298141502e-05
of O 0 2.6904176593234297e-06
these O 0 3.7446231999638258e-06
symptoms O 0 0.0008118365076370537
in O 0 4.178101562501979e-07
two O 0 6.456073720073618e-07
probands O 0 0.0010895893210545182
prompted O 0 8.393076313950587e-06
us O 0 6.593442094526836e-07
to O 0 1.3565245637892076e-07
search O 0 6.222093702490383e-07
for O 0 4.781563234246278e-07
mutations O 0 5.131986199558014e-06
within O 0 7.439992373292625e-07
their O 0 5.057305770606035e-06
POMC O 0 0.22055912017822266
genes O 0 6.049884177627973e-05
. O 0 1.4920799003448337e-05

Patient O 0 0.08614997565746307
1 O 0 8.834814798319712e-05
was O 0 5.086923465569271e-06
found O 0 9.563264029566199e-07
to O 0 2.1558078344696696e-07
be O 0 7.907635080073305e-08
a O 0 2.8832769771725e-07
compound O 0 7.972405910550151e-06
heterozygote O 0 3.220210055587813e-05
for O 0 2.672073833309696e-07
two O 0 4.606487209457555e-07
mutations O 0 6.033443241904024e-06
in O 0 2.495630155863182e-07
exon O 0 6.466421837103553e-06
3 O 0 3.2372556688642362e-06
( O 0 6.08264485890686e-07
G7013T O 0 1.123620222642785e-05
, O 0 4.868158498538833e-07
C7133delta O 0 4.743438330478966e-05
) O 0 4.915716544928728e-07
which O 0 1.2939631233166438e-07
interfere O 0 7.547432119281439e-07
with O 0 1.288269544374998e-07
appropriate O 0 5.670843279403925e-07
synthesis O 0 3.909023234882625e-06
of O 0 7.76978708927345e-07
ACTH O 0 0.00045519202831201255
and O 0 2.1889352410653373e-06
alpha O 0 4.5742261136183515e-05
- O 0 0.0006921240128576756
MSH O 0 0.017905786633491516
. O 0 2.5945597371901385e-05

Patient O 0 0.10971149057149887
2 O 0 0.00011743915092665702
was O 0 7.939634997455869e-06
homozygous O 0 1.0296130312781315e-05
for O 0 5.53695372218499e-07
a O 0 1.5564279465252184e-06
mutation O 0 8.646557944302913e-06
in O 0 6.034774173713231e-07
exon O 0 1.8010774510912597e-05
2 O 0 6.148986358311959e-06
( O 0 1.4703228998769191e-06
C3804A O 0 2.4894619855331257e-05
) O 0 1.3949123740530922e-06
which O 0 1.416534587406204e-06
abolishes O 0 0.0004326987254898995
POMC O 0 0.02480783686041832
translation O 0 5.7375778851564974e-05
. O 0 1.9587130736908875e-05

These O 0 5.950344348093495e-05
findings O 0 5.665698699885979e-05
represent O 0 2.349145916014095e-06
the O 0 3.8164657212291786e-07
first O 0 5.524600510398159e-07
examples O 0 6.565707622030459e-07
of O 0 3.178738836595585e-07
a O 0 2.8100008421461098e-05
genetic B-Disease 1 0.9415585994720459
defect I-Disease 1 0.9132261872291565
within O 0 7.863324640311475e-07
the O 0 1.0575899977993686e-06
POMC O 0 0.2406194657087326
gene O 0 4.539389919955283e-06
and O 0 4.088898037934996e-07
define O 0 3.3265987440245226e-06
a O 0 2.235832198493881e-06
new O 0 0.000509897421579808
monogenic B-Disease 1 0.9999897480010986
endocrine I-Disease 1 0.9999984502792358
disorder I-Disease 1 0.9925730228424072
resulting O 0 4.560358138405718e-05
in O 0 3.5412901979725575e-06
early O 0 0.0002565591421443969
- O 1 0.9999616146087646
onset O 1 0.9999942779541016
obesity B-Disease 1 0.9999608993530273
, O 0 0.0013797191204503179
adrenal B-Disease 1 0.9999983310699463
insufficiency I-Disease 1 0.9999980926513672
and O 0 4.932489537168294e-05
red O 0 0.1612807810306549
hair O 1 0.9981434345245361
pigmentation O 1 0.9957228899002075
. O 0 1.691341276455205e-05
. O 0 1.748284194036387e-05

A O 0 0.00017473765183240175
European O 0 0.0005205701454542577
multicenter O 1 0.8134310245513916
study O 0 8.358685590792447e-05
of O 0 3.4887481888290495e-05
phenylalanine B-Disease 1 0.9999982118606567
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
: O 0 2.4809585738694295e-05
classification O 0 2.8520767955342308e-05
of O 0 5.392543016569107e-07
105 O 0 3.026001650141552e-05
mutations O 0 1.8594735593069345e-05
and O 0 2.0288652535782603e-07
a O 0 2.8929613904438156e-07
general O 0 5.376383569455356e-07
system O 0 6.290115379670169e-07
for O 0 5.816906423206092e-07
genotype O 0 0.0008025480201467872
- O 0 0.004283769987523556
based O 0 3.165018279105425e-05
prediction O 0 0.0001108988726628013
of O 0 6.7239743657410145e-06
metabolic O 0 0.35743507742881775
phenotype O 0 0.14038315415382385
. O 0 8.398714271606877e-05

Phenylketonuria B-Disease 1 0.9999480247497559
( O 0 0.012226938270032406
PKU B-Disease 1 0.998989999294281
) O 0 0.0001339768641628325
and O 0 5.085126031190157e-05
mild B-Disease 1 0.9915724992752075
hyperphenylalaninemia I-Disease 1 0.9999997615814209
( O 0 0.011172408238053322
MHP B-Disease 1 0.999998927116394
) O 0 2.02365372388158e-05
are O 0 1.6277347185678082e-06
allelic B-Disease 0 0.3636195957660675
disorders I-Disease 1 0.9939191341400146
caused O 0 4.7086905397009104e-05
by O 0 2.0071177004865604e-06
mutations O 0 1.2176582458778284e-05
in O 0 2.650301098583441e-07
the O 0 3.83059926889473e-07
gene O 0 4.1674634303490166e-06
encoding O 0 1.1416321285651065e-05
phenylalanine O 0 0.0008846462587825954
hydroxylase O 1 0.908420979976654
( O 0 5.338695700629614e-05
PAH O 1 0.9987356066703796
) O 0 2.05976321012713e-05
. O 0 1.961232555913739e-05

Previous O 0 0.0006808313191868365
studies O 0 0.00010874956205952913
have O 0 3.7770062135678018e-06
suggested O 0 4.738456937047886e-06
that O 0 4.2594513161020586e-07
the O 0 6.536599812534405e-07
highly O 0 9.085203600989189e-06
variable O 0 0.0004664153093472123
metabolic O 0 0.2001945823431015
phenotypes O 0 0.016025982797145844
of O 0 0.00013339966244529933
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9997698664665222
correlate O 0 0.0004314990364946425
with O 0 7.449702388839796e-05
PAH O 1 0.9999973773956299
genotypes O 0 0.18096721172332764
. O 0 4.295293183531612e-05

We O 0 8.413552131969482e-05
identified O 0 4.828049713978544e-05
both O 0 8.100972081592772e-06
causative O 0 0.0010163843398913741
mutations O 0 0.0003507451037876308
in O 0 7.2285602072952315e-06
686 O 0 0.4857814908027649
patients O 0 0.0027044909074902534
from O 0 1.1422923762438586e-06
seven O 0 4.013364105048822e-06
European O 0 4.249048652127385e-05
centers O 0 2.0258394215488806e-05
. O 0 2.262811358377803e-05

On O 0 1.8891932995757088e-05
the O 0 2.2320953121379716e-06
basis O 0 1.411212565471942e-06
of O 0 4.769408405991271e-07
the O 0 1.0683862683436018e-06
phenotypic O 0 1.1216630809940398e-05
characteristics O 0 4.765975518239429e-06
of O 0 8.55503515140299e-07
297 O 0 0.0003191908181179315
functionally O 0 0.004227442666888237
hemizygous O 1 0.9229904413223267
patients O 0 0.0014047921868041158
, O 0 2.557623020038591e-07
105 O 0 7.064844567139517e-07
of O 0 8.904777359930449e-08
the O 0 2.974666131194681e-07
mutations O 0 3.6805540730711073e-06
were O 0 9.190073768650109e-08
assigned O 0 2.0348235807432502e-07
to O 0 7.741697771734835e-08
one O 0 6.988639711380529e-08
of O 0 1.1770661245691372e-07
four O 0 7.353706337198673e-07
arbitrary O 0 4.529792568064295e-05
phenotype O 0 0.0028083710931241512
categories O 0 2.4296066840179265e-05
. O 0 2.085090454784222e-05

We O 0 3.969752651755698e-05
proposed O 0 2.8904380087624304e-05
and O 0 3.5076118365395814e-06
tested O 0 4.753909706778359e-06
a O 0 7.010012836872193e-07
simple O 0 1.5043308394524502e-06
model O 0 2.4946216399257537e-06
for O 0 5.250828962743981e-07
correlation O 0 3.1628799206373515e-06
between O 0 1.838116986618843e-06
genotype O 0 0.000754734268411994
and O 0 7.420806014124537e-06
phenotypic O 0 0.00010409156675450504
outcome O 0 6.325585854938254e-05
. O 0 3.160261985613033e-05

The O 0 5.9950205468339846e-05
observed O 0 0.00011949620238738135
phenotype O 0 0.001929541933350265
matched O 0 5.084461736259982e-05
the O 0 2.3464747300749877e-06
predicted O 0 0.00035242183366790414
phenotype O 0 0.0018074387917295098
in O 0 1.02809121926839e-06
79 O 0 1.662313297856599e-05
% O 0 4.997010023544135e-07
of O 0 7.147032476950699e-08
the O 0 2.2575076741304656e-07
cases O 0 1.2547840242405073e-06
, O 0 2.9683465641028306e-07
and O 0 2.0299083303143561e-07
in O 0 1.4049453511688625e-07
only O 0 3.390429270666573e-08
5 O 0 5.658520763063279e-07
of O 0 1.523238353229317e-07
184 O 0 0.0001264595048269257
patients O 0 8.137687109410763e-05
was O 0 2.339085369840177e-07
the O 0 2.728691868014721e-07
observed O 0 7.442117748723831e-06
phenotype O 0 6.056205165805295e-05
more O 0 9.576052661941503e-08
than O 0 6.459442403183857e-08
one O 0 7.407270175008307e-08
category O 0 5.344403462004266e-07
away O 0 2.7825024062622106e-07
from O 0 2.256222728647117e-07
that O 0 5.5027680900821e-07
expected O 0 1.3179087545722723e-05
. O 0 1.3699973351322114e-05

Among O 0 2.244504685222637e-05
the O 0 3.210158411093289e-06
seven O 0 2.3056877580529545e-06
contributing O 0 4.883847850578604e-06
centers O 0 1.547323222439445e-06
, O 0 3.398620265215868e-07
the O 0 1.433796654737307e-07
proportion O 0 1.4330983049148927e-06
of O 0 1.0083466577270883e-06
patients O 0 0.00011517924576764926
for O 0 8.100432182800432e-07
whom O 0 8.924549547373317e-06
the O 0 7.762802738398022e-07
observed O 0 1.533983595436439e-05
phenotype O 0 0.00024617768940515816
did O 0 5.430739520306815e-07
not O 0 1.0182967713490143e-07
match O 0 3.891701680913684e-07
the O 0 4.7191417706926586e-07
predicted O 0 0.00012256526679266244
phenotype O 0 7.561621896456927e-05
was O 0 2.8796003448405827e-07
4 O 0 1.4157552641336224e-06
% O 0 7.723179464846908e-07
- O 0 3.937531801057048e-05
23 O 0 4.498989255807828e-06
% O 0 1.0079198773382814e-06
( O 0 9.592987453288515e-07
P O 0 0.0015932710375636816
< O 0 0.0001422105124220252
. O 0 9.475666047364939e-07
0001 O 0 0.00014891925093252212
) O 0 5.075779085927934e-07
, O 0 2.067462929744579e-07
suggesting O 0 9.100084525925922e-07
that O 0 1.0567264752125993e-07
differences O 0 9.068514259524818e-07
in O 0 3.3632690588092373e-07
methods O 0 1.5420627050843905e-06
used O 0 6.6617093352761e-07
for O 0 1.0110380799233099e-06
mutation O 0 1.006695947580738e-05
detection O 0 3.941491013392806e-05
or O 0 8.665156201459467e-06
phenotype O 0 0.11579140275716782
classification O 0 0.010077415965497494
may O 0 7.704289600951597e-06
account O 0 4.144655179061374e-07
for O 0 1.2367222268494515e-07
a O 0 4.04201614401245e-07
considerable O 0 1.7231175206688931e-06
proportion O 0 4.7081739467103034e-06
of O 0 3.211086323062773e-06
genotype O 0 0.20424309372901917
- O 1 0.6191442608833313
phenotype O 0 0.19116386771202087
inconsistencies O 0 0.0007350140367634594
. O 0 4.797419023816474e-05

Our O 0 3.5187396861147135e-05
data O 0 2.4142338588717394e-05
indicate O 0 7.029117568890797e-06
that O 0 6.361378268593398e-07
the O 0 1.8042346709989943e-06
PAH O 1 0.9999815225601196
- O 1 0.5232304334640503
mutation O 0 5.035913272877224e-05
genotype O 0 4.2893821955658495e-05
is O 0 8.06547575393779e-08
the O 0 6.419610798502617e-08
main O 0 3.225638920412166e-07
determinant O 0 5.61557999390061e-06
of O 0 1.1545124607437174e-06
metabolic O 0 0.4519025385379791
phenotype O 0 0.30470770597457886
in O 0 6.58300223221886e-06
most O 0 1.767322282830719e-05
patients O 0 0.013951314613223076
with O 0 0.002840308705344796
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999339580535889
. O 0 8.301832713186741e-05

In O 0 5.336924732546322e-05
the O 0 6.165246304590255e-06
present O 0 5.771226824435871e-06
study O 0 2.850416422006674e-06
, O 0 3.511527211230714e-07
the O 0 1.9730032363440841e-07
classification O 0 1.4333635590446647e-05
of O 0 7.63623802413349e-07
105 O 0 0.0006189162959344685
PAH O 1 0.9999998807907104
mutations O 0 0.0003176092868670821
may O 0 6.81407641422993e-07
allow O 0 1.7761426818196924e-07
the O 0 1.7194882673265965e-07
prediction O 0 3.5623047551780473e-06
of O 0 1.8304203308616707e-07
the O 0 6.666800231869274e-07
biochemical O 0 0.00017991814820561558
phenotype O 0 0.004798540845513344
in O 0 2.0670206595241325e-06
> O 0 0.00024246599059551954
10 O 0 1.0332121291867224e-06
, O 0 4.5747646026939037e-07
000 O 0 3.925913915736601e-06
genotypes O 0 4.401490878080949e-05
, O 0 3.384301692221925e-07
which O 0 2.616470737848431e-07
may O 0 8.464563734378316e-07
be O 0 3.807042858738896e-08
useful O 0 1.3895986228362744e-07
for O 0 1.0921520754436642e-07
the O 0 3.2536300409446994e-07
management O 0 3.774060314754024e-05
of O 0 2.763019210760831e-06
hyperphenylalaninemia B-Disease 1 0.9998375177383423
in O 0 7.398241723421961e-05
newborns O 0 0.01847057044506073
. O 0 3.676239066408016e-05

Somatic O 0 0.010929422453045845
instability O 0 0.0006907201022841036
of O 0 1.0707613000704441e-05
the O 0 5.767105449194787e-06
CTG O 0 0.009128712117671967
repeat O 0 0.00035737938014790416
in O 0 3.5144896628480637e-06
mice O 0 5.226766734267585e-05
transgenic O 0 4.1135557694360614e-05
for O 0 1.5959016081978916e-06
the O 0 1.9680826881085522e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
region O 0 0.0017149134073406458
is O 0 1.6003274367903941e-06
age O 0 1.102822125176317e-06
dependent O 0 5.285663974063937e-06
but O 0 2.6342118530919834e-07
not O 0 1.904715958289671e-07
correlated O 0 1.7744694105203962e-06
to O 0 7.50833493157188e-08
the O 0 1.8556174552486482e-07
relative O 0 1.7346191043543513e-06
intertissue O 0 0.0002058797690551728
transcription O 0 1.95949414774077e-05
levels O 0 4.415751845954219e-06
and O 0 4.417731361172628e-06
proliferative O 0 0.26769745349884033
capacities O 0 0.00021709600696340203
. O 0 3.209078931831755e-05

A O 0 0.00019131343287881464
( O 0 5.372546365833841e-05
CTG O 0 0.0016683253925293684
) O 0 7.1130189098767005e-06
nexpansion O 0 9.80217955657281e-05
in O 0 3.542438378190127e-07
the O 0 1.916316705319332e-07
3 O 0 3.3513499602122465e-06
- O 0 0.0005353968590497971
untranslated O 0 0.30500122904777527
region O 0 2.219331327069085e-05
( O 0 1.3231980346972705e-06
UTR O 0 0.0006182768847793341
) O 0 3.710493103881163e-07
of O 0 1.0621177182201791e-07
the O 0 6.499496976175578e-07
DM O 1 0.999997615814209
protein O 0 5.099111149320379e-05
kinase O 0 0.00013379355368670076
gene O 0 4.959327725373441e-06
( O 0 8.503003527948749e-07
DMPK O 0 0.00018010819621849805
) O 0 9.176680464406672e-07
is O 0 2.6299372279936506e-07
responsible O 0 4.1770726966205984e-06
for O 0 1.579254421812948e-05
causing O 1 0.86161208152771
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00564454635605216
DM B-Disease 1 0.9999996423721313
) O 0 6.620816566282883e-05
. O 0 3.725897477124818e-05

Major O 0 0.00037761323619633913
instability O 0 0.0005509533802978694
, O 0 4.439287749846699e-06
with O 0 8.971414899860974e-07
very O 0 4.6464253955491586e-07
large O 0 8.141059879562818e-07
expansions O 0 3.798596480919514e-06
between O 0 3.2281408834933245e-07
generations O 0 1.1642501931419247e-06
and O 0 2.481201306636649e-07
high O 0 1.291869693886838e-06
levels O 0 6.851702210042276e-07
of O 0 3.216804032035725e-07
somatic O 0 0.00020546303130686283
mosaicism O 0 0.02391877956688404
, O 0 1.6972104504020535e-06
is O 0 6.026285177540558e-07
observed O 0 5.79793777433224e-06
in O 0 8.275525033241138e-06
patients O 0 0.0004984316183254123
. O 0 2.5278301109210588e-05

There O 0 1.311723463004455e-05
is O 0 2.180975570809096e-06
a O 0 9.72577481661574e-07
good O 0 1.977485680981772e-06
correlation O 0 3.159006610076176e-06
between O 0 1.178941602120176e-06
repeat O 0 8.742159843677655e-05
size O 0 2.696631099752267e-06
( O 0 6.430425401049433e-07
at O 0 1.626136736376793e-07
least O 0 1.6102755751035147e-07
in O 0 5.57618250240921e-07
leucocytes O 0 0.015090014785528183
) O 0 1.12735742732184e-05
, O 0 1.2450143003661651e-05
clinical O 0 0.0009419422131031752
severity O 0 0.0019210082245990634
and O 0 4.479424205783289e-06
age O 0 5.699172106687911e-06
of O 0 9.589680303179193e-06
onset O 0 0.3722515404224396
. O 0 6.481643504230306e-05

The O 0 0.00020983145805075765
trinucleotide O 0 0.08241164684295654
repeat O 0 0.0028724006842821836
instability O 0 0.00039274615119211376
mechanisms O 0 3.985327566624619e-05
involved O 0 1.2043471542710904e-05
in O 0 1.870234882517252e-05
DM B-Disease 1 1.0
and O 0 3.3791191526688635e-05
other O 0 1.35705386128393e-05
human O 0 0.0005665888311341405
genetic B-Disease 1 0.9996898174285889
diseases I-Disease 1 0.9999035596847534
are O 0 5.8325545069237705e-06
unknown O 0 3.513273986754939e-05
. O 0 2.63916499534389e-05

We O 0 4.414956129039638e-05
studied O 0 4.8065870942082256e-05
somatic O 0 0.00043058948358520865
instability O 0 8.944643923314288e-05
by O 0 2.0457914615690242e-06
measuring O 0 1.4427259884541854e-05
the O 0 1.3370067790674511e-06
CTG O 0 0.0009199239430017769
repeat O 0 3.665865369839594e-05
length O 0 1.1687088772305287e-06
at O 0 2.588223253496835e-07
several O 0 2.315163669663889e-07
ages O 0 1.911778326757485e-06
in O 0 1.925336761132712e-07
various O 0 2.457081791362725e-07
tissues O 0 5.876467184862122e-06
of O 0 4.777041908710089e-07
transgenic O 0 0.00026101930416189134
mice O 0 4.8579815484117717e-05
carrying O 0 1.446885903533257e-06
a O 0 6.7078400434184e-07
( O 0 2.263313945150003e-06
CTG O 0 0.00033893840736709535
) O 0 6.498591460513126e-07
55expansion O 0 1.2467013220884837e-05
surrounded O 0 9.993839285016293e-07
by O 0 1.4461670616583433e-07
45 O 0 3.536922292823874e-07
kb O 0 1.6730211427784525e-05
of O 0 1.639695881294756e-07
the O 0 3.863210054078081e-07
human O 0 7.014278708084021e-06
DM B-Disease 1 0.9999991655349731
region O 0 3.107926022494212e-05
, O 0 2.8018797593176714e-07
using O 0 4.1914631765394006e-07
small O 0 1.2456215472411714e-06
- O 0 0.00013317748380359262
pool O 0 5.104589945403859e-05
PCR O 0 0.00017959131218958646
. O 0 1.8766704670269974e-05

These O 0 8.275148866232485e-05
mice O 0 0.0005912044434808195
have O 0 1.1194231319677783e-06
been O 0 5.733297143706295e-07
shown O 0 5.872163910680683e-07
to O 0 3.8934837220949703e-07
reproduce O 0 9.756917279446498e-06
the O 0 3.147820564208814e-07
intergenerational O 0 2.6387471734778956e-05
and O 0 8.665063546686724e-07
somatic O 0 5.153648817213252e-05
instability O 0 4.766939127875958e-06
of O 0 1.844018271413006e-07
the O 0 2.771662650502549e-07
55 O 0 8.372050615435e-06
CTG O 0 0.0006735277129337192
repeat O 0 3.834726521745324e-05
suggesting O 0 2.1822424969286658e-06
that O 0 1.0738569500290396e-07
surrounding O 0 5.118336048326455e-07
sequences O 0 3.9607607504876796e-07
and O 0 1.19954478350337e-07
the O 0 2.0017336055389023e-07
chromatin O 0 1.9009876268683e-05
environment O 0 1.1336018360452726e-05
are O 0 3.9887430602902896e-07
involved O 0 1.3465499932863167e-06
in O 0 2.6117115794477286e-06
instability O 0 0.0002672449918463826
mechanisms O 0 0.00010271587234456092
. O 0 3.495008422760293e-05

As O 0 3.9592268876731396e-05
observed O 0 1.530963163531851e-05
in O 0 8.609347901256115e-07
some O 0 1.5898966410077264e-07
of O 0 1.8678041158182168e-07
the O 0 5.90900526731275e-07
tissues O 0 4.4128260924480855e-05
of O 0 1.3428859347186517e-05
DM B-Disease 1 1.0
patients O 1 0.9342314600944519
, O 0 1.4766802678423119e-06
there O 0 8.691085895407014e-08
is O 0 1.0256179905354657e-07
a O 0 3.010820819326909e-07
tendency O 0 3.513303227009601e-06
for O 0 3.1855941529101983e-07
repeat O 0 1.8195794837083668e-05
length O 0 1.4286511031968985e-06
and O 0 6.002041459396423e-07
somatic O 0 6.529536767629907e-05
mosaicism O 0 0.0004954580217599869
to O 0 2.7631378429759934e-07
increase O 0 3.841585112240864e-07
with O 0 1.1799163246450917e-07
the O 0 3.040941862764157e-07
age O 0 7.399602282021078e-07
of O 0 3.38878777483842e-07
the O 0 2.0371994651213754e-06
mouse O 0 0.00012733873154502362
. O 0 2.8971910069230944e-05

Furthermore O 0 0.0011038149241358042
, O 0 1.8942177121061832e-05
we O 0 1.9109982076770393e-06
observed O 0 1.8353372297497117e-06
no O 0 4.526894770151557e-07
correlation O 0 9.838580581345013e-07
between O 0 3.9978104382498714e-07
the O 0 5.870181780665007e-07
somatic O 0 0.00013326361658982933
mutation O 0 1.5122757758945227e-05
rate O 0 2.3856207462813472e-06
and O 0 2.8595238745765528e-06
tissue O 0 0.0005309880361892283
proliferation O 0 0.00025404352345503867
capacity O 0 1.0550610568316188e-05
. O 0 1.3696146197617054e-05

The O 0 4.4477990741143e-05
somatic O 0 0.0021402419079095125
mutation O 0 0.0001942440721904859
rates O 0 8.8002943812171e-06
in O 0 9.944685643858975e-07
different O 0 6.448289582294819e-07
tissues O 0 7.63677144277608e-06
were O 0 2.1676021333405515e-07
also O 0 2.6110961925951415e-07
not O 0 1.3571768420206354e-07
correlated O 0 1.5309248055928038e-06
to O 0 1.2788257208740106e-07
the O 0 1.3227827366790734e-07
relative O 0 1.0052665402326966e-06
inter O 0 2.5908118914230727e-05
- O 0 0.05302902311086655
tissue O 0 6.618139741476625e-05
difference O 0 6.464989041887748e-07
in O 0 1.2472590071865852e-07
transcriptional O 0 1.6035601220210083e-06
levels O 0 1.8690799663545477e-07
of O 0 2.6979813938510233e-08
the O 0 7.355306053113964e-08
three O 0 3.246984192628588e-07
genes O 0 1.4472061593551189e-06
( O 0 6.811296202613448e-07
DMAHP O 0 0.00013367697829380631
, O 0 6.035476758370351e-07
DMPK O 0 0.0001147375805885531
and O 0 5.866992296432727e-07
59 O 0 6.930254130566027e-06
) O 0 6.722127068314876e-07
surrounding O 0 1.2797801218766836e-06
the O 0 9.978867865356733e-07
repeat O 0 0.00014797245967201889
. O 0 4.798767804459203e-06
. O 0 1.1392796295695007e-05

A O 0 0.00014184959582053125
novel O 0 0.00018317399371881038
missense O 0 0.014629912562668324
mutation O 0 0.00060371431754902
in O 0 2.705213955778163e-05
patients O 0 0.0005463121924549341
from O 0 1.1434094631113112e-06
a O 0 8.992574294097722e-06
retinoblastoma B-Disease 1 0.8343767523765564
pedigree O 0 0.005208871327340603
showing O 0 3.364402073202655e-05
only O 0 9.38127243443887e-07
mild O 0 0.00043808770715259016
expression O 0 3.705828476086026e-06
of O 0 1.2414362799972878e-06
the O 0 2.6919808078673668e-05
tumor B-Disease 0 0.3978848159313202
phenotype O 0 0.07255690544843674
. O 0 4.663786603487097e-05

We O 0 2.107068576151505e-05
have O 0 1.762027750373818e-06
used O 0 1.1607590977291693e-06
single O 0 1.7079154304155963e-06
strand O 0 2.5116056349361315e-05
conformation O 0 9.057719580596313e-06
polymorphism O 0 1.0740965080913156e-05
analysis O 0 1.5140444702410605e-06
to O 0 2.8672363328041683e-07
study O 0 6.04499234668765e-07
the O 0 2.6439471412231796e-07
27 O 0 2.416100414848188e-06
exons O 0 6.8103490775683895e-06
of O 0 2.1082438195207942e-07
the O 0 6.610756599911838e-07
RB1 O 0 0.08253113925457001
gene O 0 4.742561941384338e-06
in O 0 3.604972675930185e-07
individuals O 0 2.820929694280494e-07
from O 0 1.9219812941173586e-07
a O 0 1.223663844029943e-06
family O 0 1.9841445464408025e-05
showing O 0 0.00010306652256986126
mild O 0 0.029301093891263008
expression O 0 6.426657364499988e-06
of O 0 8.404148275076295e-07
the O 0 1.0914708582276944e-05
retinoblastoma B-Disease 1 0.9716676473617554
phenotype O 1 0.6178950071334839
. O 0 6.7108754592482e-05

In O 0 5.377303023124114e-05
this O 0 6.275427040236536e-06
family O 0 1.8761245883069932e-05
affected O 0 2.075965494441334e-05
individuals O 0 3.831636604445521e-06
developed O 0 9.449937351746485e-05
unilateral B-Disease 1 0.8447459936141968
tumors I-Disease 1 0.9999990463256836
and O 0 7.548751909780549e-06
, O 0 9.618335070626927e-07
as O 0 1.6734956886921282e-07
a O 0 3.6894167010359524e-07
result O 0 9.305994694841502e-07
of O 0 1.8356419673182245e-07
linkage O 0 6.265747651923448e-05
analysis O 0 1.3635622963192873e-05
, O 0 2.064579575744574e-06
unaffected O 0 8.688653178978711e-05
mutation O 0 7.449062195519218e-06
carriers O 0 1.4134781167740584e-06
were O 0 1.1162277502307916e-07
also O 0 3.296355828297237e-07
identified O 0 1.0925307378784055e-06
within O 0 4.615801003637898e-07
the O 0 1.50233393014787e-06
pedigree O 0 0.0002318399929208681
. O 0 3.0212642741389573e-05

A O 0 5.640673771267757e-05
single O 0 1.8972927136928774e-05
band O 0 1.8683293092180975e-05
shift O 0 1.0097544873133302e-05
using O 0 2.8410129289113684e-06
SSCP O 0 0.0005729899276047945
was O 0 1.5451128092536237e-06
identified O 0 1.3829212548444048e-06
in O 0 2.717356437642593e-07
exon O 0 9.563433195580728e-06
21 O 0 2.046138661171426e-06
which O 0 2.2094731377819699e-07
resulted O 0 9.277903245674679e-07
in O 0 2.9287045322234917e-07
a O 0 9.629193300497718e-07
missense O 0 5.649136073770933e-05
mutation O 0 3.2239765914710006e-06
converting O 0 1.56945225171512e-06
a O 0 1.6211166666835197e-06
cys O 1 0.7795175313949585
- O 0 0.0012521024327725172
- O 0 0.0004836989101022482
> O 0 6.572416896233335e-05
arg O 0 7.181101682363078e-05
at O 0 3.411694251553854e-07
nucleotide O 0 2.0815741663682275e-06
position O 0 6.26414589532942e-07
28 O 0 1.1987228845100617e-06
in O 0 4.873923558079696e-07
the O 0 1.5575742509099655e-06
exon O 0 0.00013511793804354966
. O 0 2.3719216187600978e-05

The O 0 6.871869118185714e-05
mutation O 0 0.0001014579611364752
destroyed O 0 1.6956404579104856e-05
an O 0 2.0244096958776936e-06
NdeI O 0 0.00023862540547270328
restriction O 0 1.0218713214271702e-05
enzyme O 0 3.4223390684928745e-05
site O 0 1.6370147932320833e-05
. O 0 1.6876643712748773e-05

Analysis O 0 8.428256114711985e-05
of O 0 2.5557387743901927e-06
all O 0 8.070097692325362e-07
family O 0 1.686876544226834e-06
members O 0 1.2900795809400734e-06
demonstrated O 0 1.9159799649060005e-06
that O 0 1.0197467048556064e-07
the O 0 3.0300395792437484e-07
missense O 0 0.00011504324356792495
mutation O 0 1.5573972632410005e-05
co O 0 4.2440471588633955e-05
- O 0 7.784891204209998e-05
segregated O 0 5.041909844294423e-06
with O 0 4.606048150890274e-06
patients O 0 0.0015432114014402032
with O 0 7.14725538273342e-05
tumors B-Disease 1 0.9999970197677612
or O 0 5.936110028414987e-06
who O 0 9.48264471389848e-07
, O 0 2.0028639369229495e-07
as O 0 7.258308443169881e-08
a O 0 2.2817627609583724e-07
result O 0 5.560183353736647e-07
of O 0 1.4950303750538296e-07
linkage O 0 4.818877641810104e-05
analysis O 0 5.5483569667558186e-06
had O 0 4.951559731125599e-07
been O 0 3.7280858578014886e-07
predicted O 0 4.289455773687223e-06
to O 0 2.5017206439770234e-07
carry O 0 1.6911693592192023e-06
the O 0 3.5777652556134854e-06
predisposing O 0 0.0008797076297923923
mutation O 0 0.0001776201097527519
. O 0 2.4295835828525014e-05

These O 0 2.4141047106240876e-05
observations O 0 2.3539729227195494e-05
point O 0 2.5045524125744123e-06
to O 0 6.074581051507266e-07
another O 0 4.484210478494788e-07
region O 0 1.3387802937359083e-06
of O 0 2.1853300324892189e-07
the O 0 5.637481308440329e-07
RB1 O 0 0.007625238504260778
gene O 0 3.43741089636751e-06
where O 0 3.7310022094061424e-07
mutations O 0 1.5172200846791384e-06
only O 0 7.185222017369597e-08
modify O 0 3.1084859983820934e-06
the O 0 6.169500466057798e-08
function O 0 8.813330509838124e-08
of O 0 4.708769907324495e-08
the O 0 1.58334785282932e-07
gene O 0 1.1120398539787857e-06
and O 0 2.3280495042854454e-07
raise O 0 1.4569941413355991e-06
important O 0 2.2144030253912206e-07
questions O 0 6.057180144125596e-07
for O 0 9.531323712508311e-07
genetic O 0 3.391729114810005e-05
counseling O 0 3.264107363065705e-05
in O 0 1.085833105207712e-06
families O 0 1.4840300082141766e-06
with O 0 8.294655913232418e-07
these O 0 9.672578471509041e-07
distinctive O 0 0.0002872632467187941
phenotypes O 0 0.005811972543597221
. O 0 5.3157564252614975e-06
. O 0 1.3363272046262864e-05

Maternal B-Disease 0 0.027530165389180183
disomy I-Disease 1 0.8174518942832947
and O 0 0.016423562541604042
Prader B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
consistent O 0 9.649524872656912e-05
with O 0 5.011799203202827e-06
gamete O 0 0.0013125576078891754
complementation O 0 0.34786203503608704
in O 0 1.0597242408039165e-06
a O 0 7.072718517520116e-07
case O 0 1.4540111124006216e-06
of O 0 3.919626010429056e-07
familial O 0 0.0020498887170106173
translocation O 0 0.0022707602474838495
( O 0 4.577261734084459e-06
3 O 0 5.107236574986018e-06
; O 0 1.5340085610660026e-06
15 O 0 9.965401659428608e-07
) O 0 9.596820973456488e-07
( O 0 8.407988048020343e-07
p25 O 0 2.9046133931842633e-05
; O 0 1.7983321640713257e-06
q11 O 0 2.3840881112846546e-05
. O 0 6.257691893551964e-07
2 O 0 3.5172586194676114e-06
) O 0 6.8659751377708744e-06
. O 0 1.3870600014342926e-05

Maternal B-Disease 0 0.08007750660181046
uniparental I-Disease 1 0.9863161444664001
disomy I-Disease 1 0.9857937693595886
( I-Disease 0 0.0006111797993071377
UPD I-Disease 1 0.9998096823692322
) I-Disease 0 2.867479997803457e-05
for I-Disease 0 1.9225949472456705e-06
chromosome I-Disease 0 4.1285838960902765e-05
15 I-Disease 0 1.84041493866971e-06
is O 0 2.416929021364922e-07
responsible O 0 1.1690643759720842e-06
for O 0 1.4237463119570748e-07
an O 0 2.502524978353904e-07
estimated O 0 1.2635813391170814e-06
30 O 0 6.343548761833517e-07
% O 0 4.638102382159559e-07
of O 0 2.6909850703304983e-07
cases O 0 2.748210818026564e-06
of O 0 2.32768761634361e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.0006836599786765873
PWS B-Disease 1 0.9999830722808838
) O 0 6.73005633871071e-05
. O 0 2.2576770788873546e-05

We O 0 6.224209937499836e-05
report O 0 2.1470794308697805e-05
on O 0 8.636625352664851e-07
an O 0 5.817727242174442e-07
unusual O 0 2.672231858014129e-06
case O 0 1.647173348828801e-06
of O 0 4.670887676638813e-07
maternal B-Disease 0 3.3591284591238946e-05
disomy I-Disease 0 0.0189067292958498
15 I-Disease 0 1.1187390555278398e-05
in O 0 3.836503765342059e-06
PWS B-Disease 1 0.9999631643295288
that O 0 7.380685929092579e-07
is O 0 1.6137791192250006e-07
most O 0 8.952665808692473e-08
consistent O 0 4.994213895770372e-07
with O 0 1.7526262752198818e-07
adjacent O 0 1.484359813730407e-06
- O 0 7.657354581169784e-05
1 O 0 1.7977355355469626e-06
segregation O 0 1.049781189976784e-06
of O 0 9.604808326457714e-08
a O 0 7.474398557860695e-07
paternal O 0 4.637438905774616e-05
t O 0 0.12954141199588776
( O 0 9.80636514213984e-07
3 O 0 3.006269935212913e-06
; O 0 1.372571546198742e-06
15 O 0 9.220877359439328e-07
) O 0 3.9155500530796417e-07
( O 0 3.4652421732062066e-07
p25 O 0 1.8355704014538787e-05
; O 0 8.473270440845226e-07
q11 O 0 9.172619684250094e-06
. O 0 2.541192429816874e-07
2 O 0 6.604026907552907e-07
) O 0 3.0021331554053177e-07
with O 0 3.172793583416933e-07
simultaneous O 0 7.156565970944939e-06
maternal O 0 2.9736624128418043e-05
meiotic O 0 0.0007414653082378209
nondisjunction O 0 0.002135287504643202
for O 0 3.2287027806887636e-06
chromosome O 0 6.467232742579654e-05
15 O 0 1.1174445717188064e-05
. O 0 1.5816793165868148e-05

The O 0 9.334741480415687e-05
patient O 0 0.003192335832864046
( O 0 4.2131421650992706e-05
J O 0 0.24471844732761383
. O 0 3.3525041089887964e-06
B O 0 3.0034045266802423e-05
. O 0 3.065941029944952e-07
) O 0 3.4061156384268543e-07
, O 0 1.1073173311615392e-07
a O 0 1.9542841300790315e-07
17 O 0 1.7399507896698196e-06
- O 0 3.9594346162630245e-05
year O 0 1.878561420198821e-06
- O 0 2.519335066608619e-05
old O 0 4.50686957265134e-06
white O 0 1.9977902411483228e-05
male O 0 4.331640866439557e-06
with O 0 3.1589916034135967e-06
PWS B-Disease 1 0.999984622001648
, O 0 2.5485464902885724e-06
was O 0 2.712142190830491e-07
found O 0 1.5991375335033808e-07
to O 0 8.756644831464655e-08
have O 0 1.080688818433373e-07
47 O 0 3.248454049753491e-06
chromosomes O 0 1.2953277064298163e-06
with O 0 1.9116075122838083e-07
a O 0 9.333760999652441e-07
supernumerary O 0 0.00041065042023546994
, O 0 3.803345407504821e-06
paternal O 0 3.836152973235585e-05
der O 0 0.0029723970219492912
( O 0 6.783402000110073e-07
15 O 0 3.094233704814542e-07
) O 0 1.334248622697487e-07
consisting O 0 1.2137830651681725e-07
of O 0 5.698068861192951e-08
the O 0 1.231655062383652e-07
short O 0 1.9701651581272017e-06
arm O 0 1.83676111191744e-05
and O 0 4.5009966243014787e-07
the O 0 3.0308314080684795e-07
proximal O 0 0.0001613558124518022
long O 0 8.639354746264871e-06
arm O 0 3.3101056033046916e-05
of O 0 4.76881666600093e-07
chromosome O 0 1.243966198671842e-05
15 O 0 1.186924237117637e-06
, O 0 5.050954428043042e-07
and O 0 2.2424412691179896e-06
distal O 0 0.008110487833619118
chromosome O 0 0.0006646093679592013
arm O 0 0.0007426334777846932
3p O 0 0.3073253035545349
. O 0 5.900112955714576e-05

The O 0 6.762023258488625e-05
t O 0 0.06457236409187317
( O 0 6.529206530103693e-06
3 O 0 5.0020917115034536e-06
; O 0 1.6951448742474895e-06
15 O 0 1.0404600061519886e-06
) O 0 3.4788777725225373e-07
was O 0 1.6669841329530755e-07
present O 0 1.4810846948876133e-07
in O 0 8.649164584539903e-08
the O 0 7.807268787018984e-08
balanced O 0 5.3869589464738965e-06
state O 0 4.842861471843207e-07
in O 0 3.862241442220693e-07
the O 0 1.495130049988802e-06
patients O 0 0.00011375711619621143
father O 0 3.1092715744307498e-06
and O 0 1.7349963172819116e-06
a O 0 5.759938630944816e-06
sister O 0 0.0002590554649941623
. O 0 3.486606146907434e-05

Fluorescent O 0 0.0013838867889717221
in O 0 6.04396263952367e-05
situ O 0 0.0006173447472974658
hybridization O 0 8.552964573027566e-05
analysis O 0 2.023507113335654e-05
demonstrated O 0 7.487957191187888e-06
that O 0 4.3283355921630573e-07
the O 0 1.1284633956165635e-06
PWS B-Disease 1 0.9998120665550232
critical O 0 2.39580749621382e-05
region O 0 1.5213629012578167e-05
resided O 0 4.605850790539989e-06
on O 0 2.958974505418155e-07
the O 0 2.6719871470959333e-07
derivative O 0 3.375376763870008e-05
chromosome O 0 1.5142441952775698e-05
3 O 0 2.8340311928332085e-06
and O 0 2.3906738988443976e-07
that O 0 7.959431513882009e-08
there O 0 5.3476764350079975e-08
was O 0 1.9392088290715037e-07
no O 0 2.1378708936481416e-07
deletion O 0 3.919632490578806e-06
of O 0 1.4538362336224964e-07
the O 0 1.1582798151721363e-06
PWS B-Disease 1 0.9999315738677979
region O 0 2.215184758824762e-05
on O 0 3.375450319254014e-07
the O 0 1.8561642889380892e-07
normal O 0 6.061866884010669e-07
pair O 0 9.243671570402512e-07
of O 0 4.118865888358414e-07
15s O 0 2.7276610126136802e-05
present O 0 2.238725301140221e-06
in O 0 4.0388167690252885e-06
J O 0 0.03556649386882782
. O 0 4.249234916642308e-05

B O 0 0.01046031154692173
. O 0 0.0007414736319333315

Methylation O 0 0.0009762434638105333
analysis O 0 6.413035589503124e-05
at O 0 4.201150204607984e-06
exon O 0 2.4430246412521228e-05
alpha O 0 5.5620675993850455e-06
of O 0 1.471043731271493e-07
the O 0 1.8849398486509017e-07
small O 0 7.476024279640114e-07
nuclear O 0 3.771678530029021e-05
ribonucleoprotein O 0 0.00023538032837677747
- O 0 0.0001719429565127939
associated O 0 4.998443728254642e-06
polypeptide O 0 8.265878932434134e-06
N O 0 4.4503620301838964e-05
( O 0 5.973432735117967e-07
SNRPN O 0 0.0001006562088150531
) O 0 9.33287083171308e-07
gene O 0 1.0356468465033686e-06
showed O 0 4.87087106648687e-07
a O 0 2.5423875626984227e-07
pattern O 0 7.12267819835688e-06
characteristic O 0 3.0494352358800825e-06
of O 0 1.0743998046791603e-07
only O 0 1.0206495204556632e-07
the O 0 4.2861657334469783e-07
maternal O 0 1.9674371287692338e-05
chromosome O 0 2.728735125856474e-05
15 O 0 3.5644727631733986e-06
in O 0 3.4496963507990586e-06
J O 0 0.07052026689052582
. O 0 3.136743180220947e-05

B O 0 0.014906098134815693
. O 0 0.0011678192531690001

Maternal B-Disease 0 0.007753672543913126
disomy I-Disease 0 0.04664956405758858
was O 0 3.1106246751733124e-05
confirmed O 0 1.5634019291610457e-05
by O 0 1.6257489505733247e-06
polymerase O 0 3.076641587540507e-05
chain O 0 1.3496687643055338e-05
reaction O 0 4.168548457528232e-06
analysis O 0 1.5385268170575728e-06
of O 0 5.333100716597983e-07
microsatellite O 0 5.6012169807218015e-05
repeats O 0 1.09315633380902e-05
at O 0 3.4572045137792884e-07
the O 0 3.671302408747579e-07
gamma O 0 1.2545934623631183e-05
- O 0 4.089594222023152e-05
aminobutyric O 0 0.00017035528435371816
acid O 0 3.271330933785066e-05
receptor O 0 8.7292455646093e-06
beta3 O 0 4.152294422965497e-05
subunit O 0 8.905997674446553e-06
( O 0 2.412637286397512e-06
GABRB3 O 0 0.00012001979484921321
) O 0 6.212344032974215e-06
locus O 0 6.989869871176779e-05
. O 0 2.7055184546043165e-05

A O 0 0.00022040054318495095
niece O 0 0.02171959914267063
( O 0 5.3601623221766204e-05
B O 0 0.00010927721450570971
. O 0 1.300734766118694e-06
B O 0 1.4930021279724315e-05
. O 0 2.559479810315679e-07
) O 0 1.488995735599019e-07
with O 0 9.271874290561755e-08
45 O 0 4.4862721892968693e-07
chromosomes O 0 7.984960461726587e-07
and O 0 9.780804788306341e-08
the O 0 1.2360217738205392e-07
derivative O 0 5.188549039303325e-06
3 O 0 2.012501909121056e-06
but O 0 1.4605220144403575e-07
without O 0 1.9229695169542538e-07
the O 0 4.2015926737803966e-07
der O 0 0.003047514706850052
( O 0 5.547386763282702e-07
15 O 0 3.165708619690122e-07
) O 0 3.3377705221937504e-07
demonstrated O 0 1.0167212849410134e-06
a O 0 1.3014991964155342e-06
phenotype O 0 0.0011669552186504006
consistent O 0 3.0408828024519607e-06
with O 0 6.724588956785738e-07
that O 0 4.135171707275731e-07
reported O 0 2.1461228243424557e-06
for O 0 2.969937895613839e-07
haploinsufficiency O 0 0.00016233051428571343
of O 0 1.2657800425586174e-06
distal O 0 0.0010272666113451123
3 O 0 9.184041118714958e-05
p O 0 0.00683240732178092
. O 0 2.2939424525247887e-05

Uniparental B-Disease 1 0.9999071359634399
disomy I-Disease 1 0.999956488609314
associated O 0 0.0021077492274343967
with O 0 1.1742248716473114e-05
unbalanced O 0 0.0007728733471594751
segregation O 0 2.1463729353854433e-05
of O 0 8.659808941047231e-07
non O 0 2.0561328710755333e-05
- O 0 0.0007243547588586807
Robertsonian O 0 0.000916913675609976
translocations O 0 0.00017808389384299517
has O 0 5.304441970110929e-07
been O 0 2.977575093154883e-07
reported O 0 3.2790840123197995e-06
previously O 0 8.38201628994284e-07
but O 0 1.0618644097348806e-07
has O 0 1.3437198731480748e-07
not O 0 5.4820159078872166e-08
, O 0 7.633850884758431e-08
to O 0 6.216002645942353e-08
our O 0 1.6969582361525681e-07
knowledge O 0 5.206053401707322e-07
, O 0 3.3344042549288133e-07
been O 0 1.8534137780079618e-07
observed O 0 6.286276743594499e-07
in O 0 1.9173550924733718e-07
a O 0 8.47886383326113e-07
case O 0 6.883697096782271e-06
of O 0 7.99217559688259e-06
PWS B-Disease 1 0.9999806880950928
. O 0 0.00011605548206716776

Furthermore O 0 0.0004295760300010443
, O 0 1.800105565052945e-05
our O 0 5.974708074063528e-06
findings O 0 1.0493143236089963e-05
are O 0 3.076476389196614e-07
best O 0 6.769856213395542e-07
interpreted O 0 1.758621465342003e-06
as O 0 5.266159632810741e-07
true O 0 4.303423338569701e-06
gamete O 0 0.00021901080617681146
complementation O 0 0.07357293367385864
resulting O 0 4.717877527582459e-05
in O 0 5.874219823454041e-06
maternal B-Disease 0 0.0002627102949190885
UPD I-Disease 1 0.9997366070747375
15 I-Disease 0 0.00014432067109737545
and O 0 0.00010234551155008376
PWS B-Disease 1 0.9996223449707031

Schwartz B-Disease 1 0.996599018573761
- I-Disease 1 0.9997016787528992
Jampel I-Disease 1 0.9999570846557617
syndrome I-Disease 1 0.9999961853027344
type I-Disease 0 8.088027243502438e-05
2 I-Disease 0 2.5621624445193447e-05
and O 0 1.4825991456746124e-05
Stuve B-Disease 1 0.974513828754425
- I-Disease 1 0.9999942779541016
Wiedemann I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999924898147583
: O 0 4.7299463403760456e-06
a O 0 1.1259714938205434e-06
case O 0 2.1388448203651933e-06
for O 0 9.073860951502866e-07
" O 0 7.3953660830738954e-06
lumping O 0 0.00012817919196095318
" O 0 2.1248135453788564e-05
. O 0 1.7544003640068695e-05

Recent O 0 0.0007707759505137801
studies O 0 8.472171612083912e-05
demonstrated O 0 1.9877181330230087e-05
the O 0 6.526478273372049e-07
existence O 0 1.8745045053947251e-06
of O 0 1.8692973924316902e-07
a O 0 9.009036148199812e-07
genetically O 0 6.341639527818188e-05
distinct O 0 6.457209565269295e-06
, O 0 1.0749671446319553e-06
usually O 0 1.0599213737805258e-06
lethal O 0 6.753266006853664e-06
form O 0 4.4513174657367927e-07
of O 0 1.6379750888972922e-07
the O 0 2.0133984435233288e-06
Schwartz B-Disease 0 0.2789853811264038
- I-Disease 1 0.9979331493377686
Jampel I-Disease 1 0.9999672174453735
syndrome I-Disease 1 0.9999880790710449
( O 0 3.513545379973948e-05
SJS B-Disease 1 0.99885094165802
) O 0 1.5631754877176718e-06
of O 0 1.1232773431402165e-06
myotonia B-Disease 1 0.9955981373786926
and O 0 4.3763702706201e-05
skeletal B-Disease 1 0.9871006011962891
dysplasia I-Disease 1 0.9999932050704956
, O 0 4.417950549395755e-06
which O 0 4.929871124659257e-07
we O 0 3.858758361729997e-07
called O 0 1.7717518858262338e-05
SJS B-Disease 1 0.9973067045211792
type I-Disease 0 1.394893024553312e-05
2 I-Disease 0 1.4569632185157388e-05
. O 0 1.4941146218916401e-05

This O 0 0.00043501515756361187
disorder O 1 0.8685192465782166
is O 0 4.1458588384557515e-06
reminiscent O 0 5.898193921893835e-05
of O 0 1.7926198552231654e-06
another O 0 7.73085866967449e-06
rare O 0 0.0003546856460161507
condition O 0 0.000678279553540051
, O 0 1.569046730764967e-06
the O 0 1.7120086113209254e-06
Stuve B-Disease 1 0.9480828642845154
- I-Disease 1 0.999985933303833
Wiedemann I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999960660934448
( O 0 3.8622485590167344e-05
SWS B-Disease 1 0.8559146523475647
) O 0 1.689061036813655e-06
, O 0 2.3070242605172098e-07
which O 0 1.3131810305822e-07
comprises O 0 8.141812486428535e-07
campomelia B-Disease 0 0.00010382965410826728
at O 0 6.652205684076762e-07
birth O 0 7.123717750801006e-06
with O 0 8.637888640805613e-06
skeletal B-Disease 1 0.9794484972953796
dysplasia I-Disease 1 0.9999992847442627
, O 0 5.675432475982234e-05
contractures B-Disease 1 0.9898716807365417
, O 0 2.4315272639796603e-06
and O 0 1.6954422790149692e-06
early B-Disease 0 2.464541103108786e-05
death I-Disease 0 4.599916792358272e-05
. O 0 2.0012608729302883e-05

To O 0 4.0093505958793685e-05
test O 0 1.4273805390985217e-05
for O 0 1.5311218248825753e-06
possible O 0 3.2215946248470573e-06
nosologic O 0 0.0006670778966508806
identity O 0 1.6119629435706884e-05
between O 0 1.4131492207525298e-06
these O 0 4.54315340903122e-06
disorders O 1 0.7055203914642334
, O 0 2.347248937439872e-06
we O 0 2.606975897379016e-07
reviewed O 0 1.4749574575034785e-06
the O 0 9.160952174624981e-08
literature O 0 2.21443897885365e-07
and O 0 1.3995013148360158e-07
obtained O 0 4.975117917638272e-07
a O 0 1.1817159162319513e-07
follow O 0 4.240280588874157e-07
- O 0 4.8664037421985995e-06
up O 0 9.894456098891169e-08
of O 0 4.3670112859217625e-08
the O 0 6.424117771075544e-08
only O 0 6.406950348036844e-08
two O 0 4.906831350126595e-07
surviving O 0 0.0004415924777276814
patients O 0 7.235749217215925e-05
, O 0 1.667235238755893e-07
one O 0 1.0417294049602788e-07
with O 0 2.2928513772058068e-06
SJS B-Disease 1 0.9988993406295776
type I-Disease 0 4.359223567007575e-06
2 I-Disease 0 3.5004238725377945e-06
at O 0 4.278332994545053e-07
age O 0 3.549292557636363e-07
10 O 0 2.399804372998915e-07
years O 0 2.2379367692337837e-07
and O 0 1.0931523775070673e-07
another O 0 2.991889687109506e-07
with O 0 2.045375822490314e-06
SWS B-Disease 1 0.9040905833244324
at O 0 1.9816145595541457e-06
age O 0 1.961204816325335e-06
7 O 0 9.983960808312986e-06
years O 0 8.833237188810017e-06
. O 0 1.588083614478819e-05

Patients O 1 0.9963020086288452
reported O 0 0.00021200395713094622
as O 0 3.8301277527352795e-06
having O 0 8.503249773639254e-06
either O 0 4.421216362970881e-05
neonatal O 1 0.9999957084655762
SJS B-Disease 1 0.9999986886978149
or O 0 9.239354403689504e-05
SWS B-Disease 1 0.8183776140213013
presented O 0 7.014145467110211e-06
a O 0 8.202774779419997e-07
combination O 0 4.657686076825485e-06
of O 0 7.62389674946462e-07
a O 0 3.0953196983318776e-05
severe O 1 0.9745228886604309
, O 0 0.0014321402413770556
prenatal O 1 0.9998283386230469
- O 1 0.9999992847442627
onset O 1 0.9999996423721313
neuromuscular B-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9998975992202759
( O 0 7.092059968272224e-05
with O 0 0.0014870463637635112
congenital B-Disease 1 0.9999998807907104
joint I-Disease 1 0.9996671676635742
contractures I-Disease 1 0.9999998807907104
, O 0 0.05405635014176369
respiratory O 1 0.9631775617599487
and O 0 6.554398623848101e-06
feeding O 0 2.267858144477941e-05
difficulties O 0 8.542205614503473e-05
, O 0 2.4720848159631714e-06
tendency O 0 9.59357748797629e-06
to O 0 1.9329841052240226e-06
hyperthermia B-Disease 1 0.8383219242095947
, O 0 1.8838843516277848e-06
and O 0 1.0606291880321805e-06
frequent O 0 3.106885924353264e-05
death O 0 4.448028266779147e-05
in O 0 4.33806508226553e-06
infancy O 0 0.00015584289212711155
) O 0 4.633654668850795e-07
with O 0 1.827371391982524e-07
a O 0 1.0722906154114753e-06
distinct O 0 2.960324491141364e-05
campomelic B-Disease 0 0.1958252191543579
- I-Disease 1 0.6052459478378296
metaphyseal I-Disease 1 0.9421233534812927
skeletal I-Disease 1 0.953599214553833
dysplasia I-Disease 1 0.99994957447052
. O 0 0.00012877865810878575

The O 0 1.957335371116642e-05
similarity O 0 2.278621650475543e-05
of O 0 1.7021721987475757e-06
the O 0 2.551304078224348e-06
clinical O 0 0.0005674121784977615
and O 0 2.411919012956787e-05
radiographic O 1 0.9710178971290588
findings O 0 0.00023108920140657574
is O 0 6.024636149959406e-07
so O 0 4.277594314316957e-07
extensive O 0 1.0472758731339127e-05
that O 0 2.5683311832835898e-06
these O 0 8.080185580183752e-06
disorders O 0 0.2682167589664459
appear O 0 3.710118107846938e-06
to O 0 2.5997039188041526e-07
be O 0 1.7004055052893818e-07
a O 0 6.929116693754622e-07
single O 0 6.398855475708842e-06
entity O 0 5.119375782669522e-05
. O 0 2.162742748623714e-05

The O 0 1.8631215425557457e-05
follow O 0 1.3874807336833328e-05
- O 0 2.7071031581726857e-05
up O 0 1.0375052852396038e-06
observation O 0 1.2113780485378811e-06
of O 0 1.276864907140407e-07
an O 0 2.3080056621438416e-07
identical O 0 2.5698750505398493e-06
and O 0 7.238006105581007e-07
unique O 0 2.3370280359813478e-06
pattern O 0 2.0915091226925142e-05
of O 0 3.652890427474631e-06
progressive O 1 0.9577877521514893
bone B-Disease 1 0.9998964071273804
dysplasia I-Disease 1 0.9999995231628418
in O 0 8.173248716047965e-06
the O 0 1.007474907055439e-06
two O 0 5.961139777355129e-06
patients O 0 0.0003189033595845103
( O 0 7.471946901205229e-07
one O 0 1.4049426511064667e-07
with O 0 2.179202056140639e-06
SJS B-Disease 1 0.9999262094497681
type I-Disease 0 5.151389359525638e-06
2 I-Disease 0 2.1085363641759614e-06
, O 0 1.856920306408938e-07
one O 0 9.307026971328014e-08
with O 0 9.820712421060307e-07
SWS B-Disease 1 0.9174020886421204
) O 0 1.6888386653590715e-06
surviving O 0 4.478210939851124e-06
beyond O 0 2.3882432742539095e-06
infancy O 0 6.59748402540572e-05
adds O 0 1.0432009730720893e-05
to O 0 1.1109580810853004e-07
the O 0 1.3266725318317185e-07
evidence O 0 3.6403014291863656e-07
in O 0 1.7360345339056948e-07
favor O 0 1.554895447952731e-06
of O 0 1.1680804163916036e-06
identity O 0 6.186095561133698e-05
. O 0 2.4266753825941123e-05

The O 0 4.501530565903522e-05
hypothesis O 0 0.00011677894508466125
that O 0 5.210585641179932e-06
SWS B-Disease 0 0.3077961802482605
and O 0 2.289416443090886e-05
SJS B-Disease 1 0.9989921450614929
type I-Disease 0 1.4470459063886665e-05
2 I-Disease 0 3.0989106107881526e-06
are O 0 1.2226648493651737e-07
the O 0 3.0801226102994406e-07
same O 0 4.9483487600809895e-06
disorder O 0 0.022495271638035774
should O 0 3.722877295331273e-07
be O 0 1.863695757720052e-07
testable O 0 6.623241006309399e-06
by O 0 5.328078032107442e-07
molecular O 0 2.393640170339495e-05
methods O 0 1.2514877198555041e-05
. O 0 5.2439609135035425e-06
. O 0 1.6311616491293535e-05

A O 0 0.00018349668243899941
mouse O 0 0.0007329428917728364
model O 0 0.00024250596470665187
of O 0 0.0001595203939359635
severe O 1 0.9999877214431763
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
: O 0 0.05514641851186752
defects O 1 0.995071291923523
in O 0 5.8649959100876004e-05
hemostasis O 1 0.9978783130645752
and O 0 0.0022094333544373512
thrombosis B-Disease 1 0.9999270439147949
. O 0 0.00020293604757171124

von B-Disease 1 0.9994951486587524
Willebrand I-Disease 1 0.9995692372322083
factor I-Disease 0 0.0035492898896336555
( I-Disease 0 0.0005828341818414629
vWf I-Disease 1 0.9352089166641235
) I-Disease 0 0.16171398758888245
deficiency I-Disease 1 0.9999147653579712
causes O 1 0.9098246693611145
severe O 1 0.9999972581863403
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 0.9999985694885254
in O 0 7.927686237962916e-05
humans O 0 5.8953377447323874e-05
. O 0 3.1852570828050375e-05

We O 0 2.2018821255187504e-05
generated O 0 1.3172867511457298e-05
a O 0 2.9389520932454616e-06
mouse O 0 1.6205005522351712e-05
model O 0 7.564995939901564e-06
for O 0 1.6238244597843732e-06
this O 0 2.94400433631381e-06
disease O 0 6.263585237320513e-05
by O 0 4.783652229889412e-07
using O 0 3.4856532238336513e-06
gene O 0 1.547807187307626e-05
targeting O 0 3.0353050533449277e-05
. O 0 2.181331001338549e-05

vWf B-Disease 1 0.9842002987861633
- I-Disease 1 0.9973453879356384
deficient I-Disease 1 0.996051013469696
mice O 0 0.005609195679426193
appeared O 0 2.7670861527440138e-05
normal O 0 8.026639989111573e-06
at O 0 2.0379050056362757e-06
birth O 0 1.3453714018396568e-05
; O 0 2.2814306248619687e-06
they O 0 3.157245771490125e-07
were O 0 3.133075949790509e-07
viable O 0 1.5387735402327962e-05
and O 0 4.666529548558174e-06
fertile O 0 0.0005169337964616716
. O 0 3.870913860737346e-05

Neither O 0 0.002094608498737216
vWf O 0 0.02492373436689377
nor O 0 0.0017224630573764443
vWf O 0 0.017541559413075447
propolypeptide O 0 0.3662993609905243
( O 0 0.00021510481019504368
von B-Disease 1 0.9217969179153442
Willebrand I-Disease 1 0.9838115572929382
antigen O 0 0.0679805725812912
II O 0 0.0002113903610734269
) O 0 1.7672430203674594e-06
were O 0 2.912860850301513e-07
detectable O 0 2.831427082128357e-06
in O 0 3.1926288102113176e-07
plasma O 0 2.1425445083878003e-05
, O 0 1.5325024378398666e-06
platelets O 0 0.00021045339235570282
, O 0 6.863925818834105e-07
or O 0 1.2315568937992794e-06
endothelial O 0 0.0018521458841860294
cells O 0 1.2146404515078757e-05
of O 0 2.0838093917063816e-07
the O 0 1.3491722938852035e-06
homozygous O 0 6.48232307867147e-05
mutant O 0 0.00010208595631411299
mice O 0 0.0002848602016456425
. O 0 2.1064455722807907e-05

The O 0 8.640334999654442e-05
mutant O 0 0.002971427980810404
mice O 0 0.20224425196647644
exhibited O 0 0.009233666583895683
defects O 1 0.9714098572731018
in O 0 1.4630337318521924e-05
hemostasis O 0 0.46611034870147705
with O 0 3.357040895934915e-06
a O 0 7.285414994839812e-06
highly O 0 0.00035802548518404365
prolonged O 1 0.9349168539047241
bleeding O 1 0.7728883028030396
time O 0 1.5367729702120414e-06
and O 0 2.8120787192165153e-06
spontaneous O 0 7.713308150414377e-05
bleeding O 0 0.019209055230021477
events O 0 4.379840845558647e-07
in O 0 2.2856154657802108e-07
approximately O 0 4.0948646073957207e-07
10 O 0 6.688931080134353e-07
% O 0 2.254599849038641e-06
of O 0 2.2498657017422374e-06
neonates O 0 0.021418554708361626
. O 0 3.407810800126754e-05

As O 0 2.8275248041609302e-05
in O 0 8.570676982344594e-06
the O 0 3.5718637718673563e-06
human O 0 3.9651287806918845e-05
disease O 0 0.0003423229500185698
, O 0 6.551035198754107e-07
the O 0 3.5818678156829264e-07
factor O 0 1.985804829018889e-06
VIII O 0 0.000265915208728984
level O 0 1.7125704516729456e-06
in O 0 5.536562639463227e-07
these O 0 2.6540064368418825e-07
mice O 0 1.787044311640784e-05
was O 0 4.805518187822599e-07
reduced O 0 1.974353835976217e-06
strongly O 0 6.979048521316145e-07
as O 0 1.0987881182700221e-07
a O 0 2.2797725307555083e-07
result O 0 5.530214934879041e-07
of O 0 7.375620469929345e-08
the O 0 1.7998748091940797e-07
lack O 0 1.0055972552436288e-06
of O 0 2.6323434099140286e-07
protection O 0 1.0035643754235934e-05
provided O 0 3.45929265677114e-06
by O 0 3.781298573812819e-06
vWf O 0 0.0007017091265879571
. O 0 2.460096038703341e-05

Defective O 1 0.9991077780723572
thrombosis B-Disease 1 0.9999773502349854
in O 0 0.0003563178179319948
mutant O 0 0.0032731920946389437
mice O 0 0.004118618089705706
was O 0 2.589501946204109e-06
also O 0 1.0558646863501053e-06
evident O 0 3.1135057270148536e-06
in O 0 3.1323978078035e-07
an O 0 2.942849164355721e-07
in O 0 1.4793471336815855e-06
vivo O 0 0.01939237117767334
model O 0 1.820001307351049e-05
of O 0 2.0742516426253133e-05
vascular B-Disease 1 0.9999361038208008
injury I-Disease 0 0.15519867837429047
. O 0 0.00010089376155519858

In O 0 3.106598524027504e-05
this O 0 2.3822196908440674e-06
model O 0 4.975890078640077e-06
, O 0 7.054194384181756e-07
the O 0 5.781719778497063e-07
exteriorized O 0 0.0004114548792131245
mesentery O 0 0.0005469871684908867
was O 0 1.2348617701718467e-06
superfused O 0 6.892917008372024e-05
with O 0 1.2852743793700938e-06
ferric O 0 0.020548051223158836
chloride O 0 0.00018684523820411414
and O 0 4.0466719042342447e-07
the O 0 3.006107078817877e-07
accumulation O 0 4.0361173887504265e-06
of O 0 5.162471552466741e-07
fluorescently O 0 0.001208082539960742
labeled O 0 0.00010071323777083308
platelets O 0 0.0006268483120948076
was O 0 1.4416988278753706e-06
observed O 0 3.466740054136608e-06
by O 0 1.7234297047252767e-06
intravital O 0 0.0006579492473974824
microscopy O 0 0.0002370717702433467
. O 0 3.129428660031408e-05

We O 0 5.917863018112257e-05
conclude O 0 0.00021891645155847073
that O 0 1.7951296058527078e-06
these O 0 9.813156793825328e-07
mice O 0 7.769123476464301e-05
very O 0 2.758403979896684e-06
closely O 0 8.379666542168707e-05
mimic O 1 0.9163972735404968
severe O 1 0.9947783946990967
human O 0 0.01763174869120121
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999439716339111
and O 0 3.909716724592727e-06
will O 0 7.693296879551781e-07
be O 0 8.17227743254989e-08
very O 0 1.4312023211004998e-07
useful O 0 4.0353839381168655e-07
for O 0 2.1922768667081982e-07
investigating O 0 2.6827005967788864e-06
the O 0 1.471525052920697e-07
role O 0 6.110016670390905e-07
of O 0 3.338512328809884e-07
vWf O 0 0.00017362491053063422
in O 0 1.0722640126914484e-06
normal O 0 5.590726686932612e-06
physiology O 0 5.100745693198405e-05
and O 0 4.800415808858816e-06
in O 0 3.422903682803735e-05
disease O 0 0.003629752667620778
models O 0 9.197467443300411e-05
. O 0 7.118807843653485e-06
. O 0 2.0799685444217175e-05

Oral O 0 0.029944440349936485
contraceptives O 0 0.07260753214359283
and O 0 3.3143951441161335e-05
the O 0 1.3025226508034393e-05
risk O 0 0.000574605364818126
of O 0 0.00025233608903363347
hereditary B-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 0.00018371554324403405

Hereditary B-Disease 1 0.9999982118606567
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999988079071045
Clinical O 1 0.9578077793121338
Study O 0 0.00038562441477552056
Group O 0 0.0006756621296517551
. O 0 7.426947558997199e-05

BACKGROUND O 0 0.001545528182759881
Women O 0 6.796848902013153e-05
with O 0 1.2162445273133926e-05
mutations O 0 6.921681051608175e-05
in O 0 7.95028768152406e-07
either O 0 7.785184834574466e-07
the O 0 4.817342755814025e-07
BRCA1 O 0 9.475257684243843e-05
or O 0 5.238854896560952e-07
the O 0 5.975558110549173e-07
BRCA2 O 0 0.0005297536263242364
gene O 0 2.2995084236754337e-06
have O 0 1.3054082614871731e-07
a O 0 5.214837983658072e-07
high O 0 2.6649717256077565e-05
lifetime O 0 0.0009681889205239713
risk O 0 0.0015809716423973441
of O 0 0.004344060085713863
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999901056289673
. O 0 0.0001013861910905689

Oral O 0 0.05630612000823021
contraceptives O 1 0.7706806659698486
protect O 0 0.028785767033696175
against O 1 0.9590886831283569
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
in O 0 1.6166230125236325e-05
general O 0 9.169233635475393e-06
, O 0 8.302609444399423e-07
but O 0 1.513718217438509e-07
it O 0 9.287732893881184e-08
is O 0 1.1184527437535507e-07
not O 0 1.1995173565537698e-07
known O 0 7.213143931039667e-07
whether O 0 2.2464152493739675e-07
they O 0 9.76950644826502e-08
also O 0 4.350164886091079e-07
protect O 0 3.2758464385551633e-06
against O 0 3.6030517094332026e-06
hereditary B-Disease 0 0.014962279237806797
forms I-Disease 0 0.0003478556463960558
of I-Disease 0 0.02286595292389393
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999897480010986
. O 0 0.0001100400259019807

METHODS O 0 0.0003524124331306666
We O 0 9.474867511016782e-06
enrolled O 0 2.772638799797278e-05
207 O 0 6.575274164788425e-05
women O 0 2.381733611400705e-05
with O 0 0.0003107295779045671
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
and O 0 4.143084424867993e-06
161 O 0 1.0939656021946575e-05
of O 0 1.482900842120216e-07
their O 0 5.137707148605841e-07
sisters O 0 8.959138540376443e-06
as O 0 1.4667892855868558e-07
controls O 0 1.1998872651020065e-06
in O 0 1.7619392167489423e-07
a O 0 6.481397463176108e-07
case O 0 6.269635832722997e-06
- O 0 0.003009234322234988
control O 0 3.685386400320567e-05
study O 0 1.6523825252079405e-05
. O 0 1.759299084369559e-05

All O 0 2.022393891820684e-05
the O 0 8.459201126242988e-06
patients O 0 0.00012995349243283272
carried O 0 2.3893230718385894e-06
a O 0 2.6381844691059086e-06
pathogenic O 0 0.00012194913870189339
mutation O 0 1.3190706340537872e-05
in O 0 6.617884196202795e-07
either O 0 1.634139835005044e-06
BRCA1 O 0 0.0003763667482417077
( O 0 2.31447802434559e-06
179 O 0 1.4690400348627008e-05
women O 0 2.9487023311958183e-06
) O 0 1.3726553333981428e-06
or O 0 1.9815672658296535e-06
BRCA2 O 0 0.0009293234325014055
( O 0 3.6310650557425106e-06
28 O 0 7.927597835077904e-06
women O 0 4.059255388710881e-06
) O 0 4.064926997671137e-06
. O 0 1.0096293408423662e-05

The O 0 2.6280062229488976e-05
control O 0 2.7517156922840513e-05
women O 0 5.945798420725623e-06
were O 0 6.562239605045761e-07
enrolled O 0 3.539588306011865e-06
regardless O 0 7.806597182025143e-07
of O 0 1.55171051119396e-07
whether O 0 3.2072955491457833e-07
or O 0 3.104031520706485e-07
not O 0 1.48497690588556e-07
they O 0 2.5933425717994396e-07
had O 0 7.985942147570313e-07
either O 0 4.787171292264247e-06
mutation O 0 6.384764128597453e-05
. O 0 1.3906625099480152e-05

Lifetime O 0 0.0015468511264771223
histories O 0 0.0004775756096933037
of O 0 1.1095779882452916e-05
oral O 0 0.00028624458354897797
- O 0 0.08000276982784271
contraceptive O 0 0.053721487522125244
use O 0 1.4034162632015068e-06
were O 0 1.9057134181821311e-07
obtained O 0 9.076509286387591e-07
by O 0 3.287659353645722e-07
interview O 0 3.940147962566698e-06
or O 0 2.1710488340431766e-07
by O 0 2.10000436595692e-07
written O 0 5.462632657327049e-07
questionnaire O 0 1.3213229976827279e-06
and O 0 1.7684388353700342e-07
were O 0 1.2201755339447118e-07
compared O 0 2.4178013973141788e-06
between O 0 1.6780037412900128e-06
patients O 0 7.828409434296191e-05
and O 0 8.088158551800007e-07
control O 0 4.598236046149395e-06
women O 0 2.2479785002360586e-06
, O 0 3.3617072858760366e-07
after O 0 5.415735699898505e-07
adjustment O 0 1.4055405017643352e-06
for O 0 1.687076292000711e-07
year O 0 8.350827442882292e-07
of O 0 3.976687423801195e-07
birth O 0 1.737894672260154e-05
and O 0 2.7936962396779563e-06
parity O 0 4.3590713175944984e-05
. O 0 2.515810410841368e-05

RESULTS O 0 0.0007557426579296589
The O 0 1.1315086339891423e-05
adjusted O 0 0.00011992140935035422
odds O 0 0.000324939755955711
ratio O 0 0.00021692512382287532
for O 0 0.25699669122695923
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
associated O 0 1.2531861102615949e-05
with O 0 3.957317176173092e-07
any O 0 1.9408999207826128e-07
past O 0 3.1590889193466865e-07
use O 0 5.961589408798318e-07
of O 0 6.239408776309574e-07
oral O 0 0.00010015068255597726
contraceptives O 0 0.0011697085574269295
was O 0 4.756711859954521e-06
0 O 0 5.961749411653727e-05
. O 0 2.5915531296050176e-05

5 O 0 0.0002369926660321653
( O 0 1.726751543174032e-05
95 O 0 7.1705503614794e-06
percent O 0 9.993133971875068e-06
confidence O 0 7.177652150858194e-06
interval O 0 3.3495607567601837e-06
, O 0 4.912238864562823e-07
0 O 0 2.2964663912716787e-06
. O 0 2.135996055585565e-07
3 O 0 7.020148018455075e-07
to O 0 2.4108217644425167e-07
0 O 0 3.381844408067991e-06
. O 0 6.917634891578928e-07
8 O 0 5.352842435968341e-06
) O 0 5.421619334811112e-06
. O 0 1.2165867701696698e-05

The O 0 0.00013731115905102342
risk O 0 0.0007429775432683527
decreased O 0 3.790847767959349e-05
with O 0 1.4799397831666283e-06
increasing O 0 4.065892426297069e-06
duration O 0 6.54995028526173e-06
of O 0 2.620853365442599e-07
use O 0 1.3551273241318995e-06
( O 0 1.5544239886366995e-06
P O 0 0.0003895041299983859
for O 0 4.2389547161292285e-07
trend O 0 4.325815552874701e-06
, O 0 5.110230176796904e-07
< O 0 1.4819701391388662e-05
0 O 0 3.135669658149709e-06
. O 0 2.3162193940606812e-07
001 O 0 2.9185908715589903e-05
) O 0 2.752349814727495e-07
; O 0 1.1375683328651576e-07
use O 0 1.0070726830235799e-07
for O 0 7.153333569931419e-08
six O 0 2.8320945943960396e-07
or O 0 1.9660141958866006e-07
more O 0 1.0515190496107607e-07
years O 0 5.044599902248592e-07
was O 0 2.0626535501833132e-07
associated O 0 3.074669621128123e-07
with O 0 9.20061467013511e-08
a O 0 5.299122562973935e-07
60 O 0 3.2257971724902745e-06
percent O 0 2.5810753868427128e-05
reduction O 0 6.289693556027487e-05
in O 0 5.980089099466568e-06
risk O 0 9.94832516880706e-05
. O 0 2.402841164439451e-05

Oral O 0 0.0050271544605493546
- O 0 0.038324981927871704
contraceptive O 0 0.04701429605484009
use O 0 1.8893177184509113e-05
protected O 0 0.000134027490275912
against O 0 0.01391065027564764
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9996726512908936
both O 0 7.166149202930683e-07
for O 0 4.287899457722233e-07
carriers O 0 1.8696090364755946e-06
of O 0 1.340232387292417e-07
the O 0 5.920518333368818e-07
BRCA1 O 0 0.0034481759648770094
mutation O 0 1.7670728993834928e-05
( O 0 8.385182468373387e-07
odds O 0 7.177987754403148e-06
ratio O 0 1.7504777360954904e-06
, O 0 3.1692158586338337e-07
0 O 0 1.8255753957419074e-06
. O 0 1.78448075871529e-07
5 O 0 4.814495468963287e-07
; O 0 3.2521970183552185e-07
95 O 0 6.260037253014161e-07
percent O 0 2.018150325966417e-06
confidence O 0 1.385161112921196e-06
interval O 0 9.236006235369132e-07
, O 0 2.4639498974465823e-07
0 O 0 1.5418552266055485e-06
. O 0 1.1359357898754752e-07
3 O 0 4.4461327775024984e-07
to O 0 9.669842881976365e-08
0 O 0 1.9116071143798763e-06
. O 0 1.3972687895602576e-07
9 O 0 1.0358621693740133e-06
) O 0 1.1338707395225356e-07
and O 0 5.391818902467094e-08
for O 0 8.645734084211654e-08
carriers O 0 7.40423274692148e-07
of O 0 1.458659539821383e-07
the O 0 9.86521627055481e-07
BRCA2 O 0 0.009906619787216187
mutation O 0 2.3933618649607524e-05
( O 0 1.050933178703417e-06
odds O 0 7.673259460716508e-06
ratio O 0 1.545886561871157e-06
, O 0 3.73178522750095e-07
0 O 0 1.4538642290062853e-06
. O 0 1.4819747207184264e-07
4 O 0 6.408538979485456e-07
; O 0 3.9735255086270627e-07
95 O 0 6.724525292156613e-07
percent O 0 1.8222131075162906e-06
confidence O 0 1.161205204880389e-06
interval O 0 7.379848625532759e-07
, O 0 1.5206039449822129e-07
0 O 0 8.331743401868152e-07
. O 0 9.342918616539464e-08
2 O 0 3.330257243305823e-07
to O 0 8.374939142186122e-08
1 O 0 6.625872970289493e-07
. O 0 3.2219188028648205e-07
1 O 0 2.490191036486067e-06
) O 0 4.223505584377563e-06
. O 0 1.183462609333219e-05

CONCLUSIONS O 0 0.0032678113784641027
Oral O 0 0.0012975895078852773
- O 0 0.14722833037376404
contraceptive O 0 0.029827846214175224
use O 0 6.752918125130236e-06
may O 0 4.446617822395638e-06
reduce O 0 9.05895467440132e-06
the O 0 1.2181320698800846e-06
risk O 0 0.00011933110363315791
of O 0 0.0007732717785984278
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999963045120239
in O 0 4.986426574760117e-06
women O 0 3.5697728435479803e-06
with O 0 2.3755451366014313e-06
pathogenic O 0 0.00011014322808478028
mutations O 0 1.3406199286691844e-05
in O 0 2.936403973308188e-07
the O 0 1.4068816653889371e-06
BRCA1 O 0 0.0006237772759050131
or O 0 4.15012109442614e-05
BRCA2 O 0 0.010528896003961563
gene O 0 0.0002971703070215881

A O 0 7.063872908474877e-05
Japanese O 0 5.709756806027144e-05
family O 0 2.072922870866023e-05
with O 0 1.5838424587855116e-05
adrenoleukodystrophy B-Disease 1 0.999996542930603
with O 0 4.573190835799323e-06
a O 0 3.3029780297511024e-06
codon O 0 2.5120894861174747e-05
291 O 0 5.983289884170517e-05
deletion O 0 6.819617556175217e-05
: O 0 1.7921616972671472e-06
a O 0 3.3047078886738745e-06
clinical O 0 0.000247688964009285
, O 0 6.9039133450132795e-06
biochemical O 0 0.00023374773445539176
, O 0 1.5870085917413235e-05
pathological O 0 0.0028282231651246548
, O 0 5.794112439616583e-06
and O 0 2.1940973965683952e-05
genetic O 0 0.0005503985448740423
report O 0 0.0001084503746824339
. O 0 2.4119419322232716e-05

We O 0 6.707861757604405e-05
report O 0 2.7693462470779195e-05
a O 0 3.086149263253901e-06
Japanese O 0 1.7973883586819284e-05
family O 0 3.353709325892851e-05
with O 0 0.00023146960302256048
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.12054583430290222
ALD B-Disease 1 1.0
) O 0 7.366014415310929e-06
with O 0 3.1586944260197924e-07
a O 0 4.190743823073717e-07
three O 0 4.939004725201812e-07
base O 0 1.6266483271465404e-06
pair O 0 8.439531484327745e-06
deletion O 0 3.752226984943263e-05
( O 0 1.0284707059327047e-06
delGAG O 0 6.261960515985265e-05
291 O 0 1.1281317711109295e-05
) O 0 7.469232059520436e-07
in O 0 7.998053774826985e-07
the O 0 6.304423550318461e-06
ALD B-Disease 1 0.9999992847442627
gene O 0 0.00033426994923502207
. O 0 2.6209954739897512e-05

A O 0 0.00010369232040829957
variety O 0 3.464039400569163e-05
of O 0 6.510391813208116e-06
phenotypes O 0 0.0013327396009117365
were O 0 1.5025316315586679e-06
observed O 0 3.9095452848414425e-06
within O 0 8.467503107567609e-07
this O 0 1.274073611057247e-06
family O 0 2.0248851797077805e-05
. O 0 3.2335592550225556e-05

While O 0 5.059393879491836e-05
the O 0 8.186229024431668e-06
proband O 0 0.048850707709789276
( O 0 3.089333768002689e-05
patient O 0 8.895801147446036e-05
1 O 0 9.189518095809035e-06
) O 0 1.9623892058007186e-06
was O 0 4.000163755790709e-07
classified O 0 2.37589847529307e-06
as O 0 1.5305525380426843e-07
having O 0 3.2168222219297604e-07
a O 0 7.767090437482693e-07
rare O 0 1.0432984709041193e-05
intermediate O 0 4.4253927626414225e-05
type O 0 3.8132750432851026e-06
of O 0 5.954623247816926e-07
adult O 0 1.5532014003838412e-05
cerebral O 0 0.0005066480371169746
and O 0 7.610800821566954e-06
cerebello O 1 0.8780457973480225
- O 1 0.9917095303535461
brain O 0 0.17386414110660553
stem O 0 0.00017220270819962025
forms O 0 3.2439525057270657e-06
, O 0 5.768908977188403e-07
his O 0 1.334369926553336e-06
younger O 0 2.8739192202920094e-05
brother O 0 8.071547199506313e-05
( O 0 9.003625564218964e-06
patient O 0 1.9750788851524703e-05
2 O 0 9.867645530903246e-06
) O 0 1.6944434264587471e-06
and O 0 8.752426765568089e-07
nephew O 0 0.0002895821526180953
( O 0 1.3339778888621368e-05
patient O 0 3.5912671592086554e-05
3 O 0 1.0072923942061607e-05
) O 0 1.7860022580862278e-06
had O 0 1.2228366585986805e-06
a O 0 1.3189599485485815e-05
childhood O 0 0.13784827291965485
ALD B-Disease 1 0.9999998807907104
type O 0 0.002774165477603674
. O 0 5.784119639429264e-05

Another O 0 0.0001776602293830365
nephew O 0 0.016276255249977112
( O 0 0.00014111542259342968
patient O 0 0.00044057980994693935
4 O 0 3.887868660967797e-05
) O 0 2.2064082259021234e-06
of O 0 3.944025195323775e-07
patient O 0 5.8277815696783364e-05
1 O 0 6.457024483097484e-06
was O 0 1.1866458180520567e-06
classified O 0 5.112904545967467e-06
as O 0 3.766050156173151e-07
having O 0 8.791174650468747e-07
an O 0 2.021706450250349e-06
adolescent O 0 0.0004378962912596762
form O 0 3.751096301130019e-05
. O 0 3.695113264257088e-05

The O 0 2.9647739211213775e-05
tau O 0 0.00016319123096764088
level O 0 8.37772950035287e-06
in O 0 2.0815264178963844e-06
the O 0 2.282952209498035e-06
cerebrospinal O 0 0.0025124673265963793
fluid O 0 0.001270422711968422
( O 0 7.357744470937178e-05
CSF O 1 0.9554588794708252
) O 0 7.926547368697356e-06
in O 0 9.908314950735075e-07
patient O 0 1.1073443602072075e-05
1 O 0 2.144993459296529e-06
was O 0 1.778039120381436e-07
as O 0 9.408942958089028e-08
high O 0 3.957407841426175e-07
as O 0 1.7304607524692983e-07
that O 0 1.6803515734409302e-07
of O 0 1.4188181012286805e-06
patients O 0 0.014495953917503357
with O 0 0.004852148704230785
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9889290928840637
( O 0 1.734579745971132e-05
AD B-Disease 0 0.00012963813787791878
) O 0 1.6711985153960995e-05
. O 0 1.7410164218745194e-05

His O 0 0.0005925063160248101
brain O 0 0.009608427062630653
magnetic O 0 0.0002832834143191576
resonance O 0 0.00046130301780067384
image O 0 0.00049056694842875
( O 0 5.282200800138526e-05
MRI O 0 0.037088070064783096
) O 0 2.5265238946303725e-05
showed O 0 7.76940505602397e-05
abnormalities B-Disease 0 0.007186353672295809
in I-Disease 0 7.660987648705486e-07
the I-Disease 0 8.110960152407642e-07
bilateral I-Disease 0 8.932974742492661e-05
cerebellar I-Disease 1 0.9616970419883728
hemispheres I-Disease 0 0.002878862665966153
and O 0 5.708199751097709e-05
brain O 0 0.03468699753284454
stem O 0 0.0033156934659928083
, O 0 1.7674047967375373e-06
but O 0 2.6513046691434283e-07
not O 0 1.2138755778323684e-07
in O 0 2.689319842374971e-07
the O 0 1.1823814247691189e-06
cerebral O 0 0.004866389557719231
white O 0 0.0001340509916190058
matter O 0 1.689009536676167e-06
, O 0 2.7981067773907853e-07
where O 0 1.7990630851727474e-07
marked O 0 1.3187058129915386e-06
reductions O 0 1.62585038196994e-05
of O 0 2.5946241066776565e-07
the O 0 1.696079493740399e-06
cerebral O 0 0.027553221210837364
blood O 0 4.413907663547434e-05
flow O 0 5.4739625738875475e-06
and O 0 1.4601810107706115e-06
oxygen O 0 5.9710859204642475e-05
metabolism O 0 1.4645372175436933e-05
were O 0 3.029583126590296e-07
clearly O 0 8.654665748508705e-07
demonstrated O 0 1.456752443118603e-06
by O 0 4.727903331058769e-07
positron O 0 0.0013542770175263286
emission O 0 0.0010191731853410602
tomography O 0 0.0012781261466443539
( O 0 8.674913260620087e-06
PET O 0 0.00016058303299359977
) O 0 1.6337036868208088e-05
. O 0 1.4918607121217065e-05

In O 0 0.001006383798085153
patients O 0 0.02924690768122673
2 O 0 2.5321007342427038e-05
and O 0 2.267600166305783e-06
3 O 0 1.0615667633828707e-05
, O 0 7.823165333320503e-07
the O 0 7.902597189968219e-07
autopsy O 0 0.0037473069969564676
findings O 0 6.487283098977059e-05
showed O 0 1.2155592230556067e-05
massive O 0 0.00016356122796423733
demyelination B-Disease 1 0.9999051094055176
of I-Disease 0 2.691395593501511e-06
the I-Disease 0 5.1425786296022125e-06
cerebral I-Disease 0 0.06488974392414093
white I-Disease 0 0.00013362805475480855
matter I-Disease 0 1.115492977987742e-06
with O 0 3.030496316114295e-07
sparing O 0 4.237735538481502e-06
of O 0 1.4281768301316333e-07
the O 0 3.8953405123720586e-07
U O 0 0.0009943039622157812
- O 0 0.010117629542946815
fibers O 0 0.0006772748893126845
, O 0 3.077154246966529e-07
compatible O 0 1.2822881672036601e-06
with O 0 2.6979822109751694e-07
the O 0 6.93619085723185e-07
findings O 0 1.745891677273903e-05
of O 0 7.915746209619101e-06
childhood O 0 0.011283678002655506
ALD B-Disease 1 0.9999995231628418
. O 0 0.00037729067844338715

Oleic O 0 0.03784038871526718
and O 0 0.00015389322652481496
erucic O 1 0.8758592009544373
acids O 0 0.0004420749319251627
( O 0 8.491896551277023e-06
Lorenzos O 0 0.00013224083522800356
Oil O 0 1.1335715498717036e-05
) O 0 7.438942475346266e-07
were O 0 1.818520729557349e-07
administered O 0 6.579434739251155e-07
to O 0 7.296924877664424e-07
patients O 0 1.808433444239199e-05
1 O 0 1.8772882413031766e-06
and O 0 5.67168683573982e-07
4 O 0 3.869758529617684e-06
, O 0 5.381246523938898e-07
but O 0 3.021065992925287e-07
sufficient O 0 1.8325177961742156e-06
effectiveness O 0 6.411781214410439e-06
was O 0 8.502152013534214e-07
not O 0 1.127813447965309e-06
obtained O 0 1.1459134839242324e-05
. O 0 1.615374640095979e-05

The O 0 3.099608875345439e-05
findings O 0 0.00010954618483083323
in O 0 1.842380015659728e-06
this O 0 4.6283460619633843e-07
family O 0 2.9023701699770754e-06
suggest O 0 3.0586563752876827e-06
that O 0 3.6104810874348914e-07
delGAG291 O 0 7.114656182238832e-05
is O 0 2.620038799250324e-07
part O 0 2.2867622817557276e-07
of O 0 2.0093477814953076e-07
the O 0 5.666486231348244e-07
cause O 0 3.7054855965834577e-06
of O 0 6.827893912486616e-07
Japanese O 0 0.0001050187784130685
ALD B-Disease 1 0.9999994039535522
with O 0 2.9360329790506512e-05
phenotypic O 0 0.00016154581680893898
variations O 0 0.0001869664411060512
. O 0 3.899617149727419e-05

Moreover O 0 0.0008382608648389578
, O 0 8.018575499590952e-06
although O 0 1.3673848116013687e-06
the O 0 4.524831638264004e-07
scale O 0 4.29755436925916e-06
of O 0 2.7737303298636107e-07
the O 0 5.602937562798616e-07
study O 0 2.1587613900919678e-06
is O 0 2.50394776912799e-07
limited O 0 1.4285175211625756e-06
, O 0 3.393127485651348e-07
there O 0 5.338484143635469e-08
is O 0 8.000802154128905e-08
a O 0 3.2231358204626304e-07
possibility O 0 1.364814352200483e-06
that O 0 2.0221816043886065e-07
PET O 0 4.114638431929052e-05
can O 0 1.0935095815511886e-06
detect O 0 5.275167859508656e-05
an O 0 2.081351794913644e-06
insidious B-Disease 0 0.006354224402457476
lesion I-Disease 0 0.23047150671482086
which O 0 7.162678343775042e-07
is O 0 3.219486188754672e-07
undetectable O 0 9.526603207632434e-06
by O 0 3.478642156551359e-07
computed O 0 5.746940132667078e-06
tomogram O 0 0.0006821961724199355
( O 0 5.591681201622123e-06
CT O 1 0.7382619976997375
) O 0 1.9236019852542086e-06
or O 0 6.653436912529287e-07
MRI O 0 0.000284438458038494
analysis O 0 1.7382920987074613e-06
, O 0 1.570245728998998e-07
and O 0 1.0789752735718139e-07
that O 0 3.056641872944965e-08
the O 0 4.837954747927142e-08
higher O 0 2.7446120043350675e-07
level O 0 1.561252105375388e-07
of O 0 7.221039055593792e-08
tau O 0 6.520899205497699e-06
reflects O 0 8.755757789913332e-07
the O 0 1.2972299145985744e-07
process O 0 6.363259217323503e-07
of O 0 1.2935647646372672e-06
neuronal B-Disease 0 0.020603233948349953
degeneration I-Disease 1 0.9978931546211243
in O 0 0.00020252607646398246
ALD B-Disease 1 0.9999994039535522
. O 0 0.00021373567869886756

Lorenzos O 0 0.01160360500216484
Oil O 0 0.00028187441057525575
should O 0 5.004830654797843e-06
be O 0 4.353505573817529e-07
given O 0 2.749715690697485e-07
in O 0 2.386020696576452e-07
the O 0 3.779477992793545e-07
early O 0 4.96661641591345e-06
stage O 0 3.481469684629701e-05
. O 0 3.499132390061277e-06
. O 0 1.3302657862368505e-05

Nonsense O 0 0.003983713686466217
mutation O 0 0.00031788740307092667
in O 0 7.329492746066535e-06
exon O 0 4.660745617002249e-05
4 O 0 4.22645916842157e-06
of O 0 6.448449880736007e-07
human O 0 1.135105549110449e-06
complement O 0 4.580877885018708e-06
C9 O 0 0.07568562030792236
gene O 0 5.272625003271969e-06
is O 0 1.7615947456306458e-07
the O 0 1.8208167773536843e-07
major O 0 1.2568332294904394e-06
cause O 0 1.652472519708681e-06
of O 0 3.9648989513807464e-07
Japanese O 0 2.8650147214648314e-05
complement B-Disease 0 0.00018310730229131877
C9 I-Disease 1 0.9995575547218323
deficiency I-Disease 1 0.9626837968826294
. O 0 3.135286897304468e-05

Deficiency B-Disease 1 0.9989078044891357
of I-Disease 0 8.189009349734988e-06
the I-Disease 0 1.8469819451638614e-06
ninth I-Disease 0 1.1283018466201611e-05
component I-Disease 0 3.853856014757184e-06
of I-Disease 0 3.819280607331166e-07
human I-Disease 0 9.48563013025705e-07
complement I-Disease 0 3.844062575808493e-06
( O 0 2.865412170649506e-06
C9 O 0 0.0231525506824255
) O 0 7.640914532203169e-07
is O 0 5.209390252502999e-08
the O 0 5.3495128327085695e-08
most O 0 2.4753117600084806e-07
common O 0 3.204742097295821e-05
complement B-Disease 1 0.990830659866333
deficiency I-Disease 1 0.9999821186065674
in O 0 9.37728259486903e-07
Japan O 0 5.434342256194213e-06
but O 0 3.441388400915457e-07
is O 0 2.5108107593041495e-07
rare O 0 1.6193305327760754e-06
in O 0 4.771814587911649e-07
other O 0 7.160738277889322e-07
countries O 0 3.758246293728007e-06
. O 0 1.313696429861011e-05

We O 0 3.1841362215345725e-05
studied O 0 1.600514406163711e-05
the O 0 1.80489553258667e-06
molecular O 0 1.250769491889514e-05
basis O 0 1.5227792573568877e-06
of O 0 3.4079132547049085e-06
C9 B-Disease 1 0.9999666213989258
deficiency I-Disease 1 0.9619869589805603
in O 0 7.312613661270007e-07
four O 0 8.703093499207171e-07
Japanese O 0 2.1243637092993595e-05
C9 B-Disease 1 0.9729507565498352
- I-Disease 1 0.9974933862686157
deficient I-Disease 1 0.9949369430541992
patients O 0 0.002519560046494007
who O 0 5.984196832287125e-06
had O 0 2.9519964300561696e-05
suffered O 1 0.8811362385749817
from O 0 0.0007925685495138168
meningococcal B-Disease 1 0.9999912977218628
meningitis I-Disease 1 0.9998806715011597
. O 0 0.00016773476090747863

Direct O 0 8.677574805915356e-05
sequencing O 0 7.813904085196555e-05
of O 0 3.512887815304566e-06
amplified O 0 3.7937988963676617e-05
C9 O 0 0.0009867994813248515
cDNA O 0 3.0244378649513237e-05
and O 0 2.6310685825592373e-06
DNA O 0 1.3174362720747013e-05
revealed O 0 5.264218998490833e-06
a O 0 6.843363280495396e-07
nonsense O 0 6.798396043450339e-06
substitution O 0 2.018244686041726e-06
( O 0 9.518769275018713e-07
CGA O 0 2.7967325877398252e-05
- O 0 8.019766391953453e-05
- O 0 0.0002627769426908344
> O 0 6.188273255247623e-05
TGA O 0 7.162649126257747e-05
) O 0 3.4915277069558215e-07
at O 0 1.2453774900222925e-07
codon O 0 8.781345854913525e-07
95 O 0 3.277307030202792e-07
in O 0 1.624125047783309e-07
exon O 0 2.464653334754985e-06
4 O 0 5.838865604346211e-07
in O 0 1.437988288444103e-07
the O 0 2.3534417437076627e-07
four O 0 1.931706947289058e-06
C9 B-Disease 1 0.7801660895347595
- I-Disease 1 0.901479959487915
deficient I-Disease 0 0.33944249153137207
individuals O 0 1.4828126950305887e-05
. O 0 1.5809375327080488e-05

An O 0 5.6583230616524816e-05
allele O 0 0.0001564092090120539
- O 0 0.00021811641636304557
specific O 0 6.952250714675756e-06
polymerase O 0 2.0946707081748173e-05
chain O 0 5.989403689454775e-06
reaction O 0 1.68239091635769e-06
system O 0 5.968244636278541e-07
designed O 0 1.0608821412461111e-06
to O 0 2.2567327562228456e-07
detect O 0 4.8980177780322265e-06
exclusively O 0 3.8232599308685167e-07
only O 0 3.658195879552295e-08
one O 0 3.9010206620559984e-08
of O 0 4.4566775159182725e-08
the O 0 1.418261916796837e-07
normal O 0 7.036308602437202e-07
and O 0 5.852038498233014e-07
mutant O 0 1.4058868146094028e-05
alleles O 0 5.653877906297566e-06
indicated O 0 1.7723333485264448e-06
that O 0 3.031721362845019e-08
all O 0 2.441834290323186e-08
the O 0 8.407429419321488e-08
four O 0 2.500399659766117e-06
patients O 0 4.306946357246488e-05
were O 0 1.540993963544679e-07
homozygous O 0 7.602057507938298e-07
for O 0 8.184304789438102e-08
the O 0 1.821283888148173e-07
mutation O 0 1.9286439965071622e-06
in O 0 1.7994233303397777e-07
exon O 0 3.4505715120758396e-06
4 O 0 6.12221299434168e-07
and O 0 1.2584280284499982e-07
that O 0 6.034244393049448e-08
the O 0 1.20674357617645e-07
parents O 0 5.971057248643774e-07
of O 0 5.484201324179594e-07
patient O 0 6.464791658800095e-05
2 O 0 1.9929741029045545e-05
were O 0 3.0825781323073898e-06
heterozygous O 0 4.41610136476811e-05
. O 0 2.022658009082079e-05

The O 0 3.859954449580982e-05
common O 0 5.04269810335245e-05
mutation O 0 1.7193999156006612e-05
at O 0 1.8915029613708612e-06
codon O 0 7.5569346336124e-06
95 O 0 1.7220792187799816e-06
in O 0 5.573237444878032e-07
exon O 0 6.188449788169237e-06
4 O 0 1.983609308808809e-06
might O 0 3.766075451494544e-07
be O 0 1.0770794744985324e-07
responsible O 0 5.318944431564887e-07
for O 0 1.8634680998275144e-07
most O 0 8.776154913903156e-07
Japanese O 0 0.000223822527914308
C9 B-Disease 1 0.9999597072601318
deficiency I-Disease 1 0.9773355722427368
. O 0 7.048121460684342e-06
. O 0 2.6593308575684205e-05

BRCA1 O 0 0.03332541137933731
required O 0 4.07768166041933e-05
for O 0 4.072159299539635e-06
transcription O 0 3.8870639400556684e-05
- O 0 0.0005627790815196931
coupled O 0 0.0003981037298217416
repair O 0 0.001270978944376111
of O 0 7.245289452839643e-06
oxidative O 0 0.027879318222403526
DNA O 0 0.001381315989419818
damage O 0 0.0021245151292532682
. O 0 5.696465086657554e-05

The O 0 0.00075822341023013
breast B-Disease 1 0.9995647072792053
and I-Disease 1 0.9881107807159424
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
susceptibility O 1 0.8909956216812134
gene O 0 9.78180396487005e-05
BRCA1 O 0 0.00015908533532638103
encodes O 0 7.465966973541072e-06
a O 0 1.4547850923918304e-06
zinc O 0 0.00016470886475872248
finger O 0 3.887575803673826e-05
protein O 0 4.9277932703262195e-06
of O 0 5.04046397509228e-07
unknown O 0 6.645353096246254e-06
function O 0 9.003032573673408e-06
. O 0 1.3959976058686152e-05

Association O 0 0.00011916826042579487
of O 0 3.914044555131113e-06
the O 0 2.3799943846825045e-06
BRCA1 O 0 0.00011779917258536443
protein O 0 3.520742211549077e-06
with O 0 3.4423010220052674e-07
the O 0 4.6040366896704654e-07
DNA O 0 1.1969663319177926e-05
repair O 0 0.0003508370427880436
protein O 0 1.5802470443304628e-05
Rad51 O 0 0.000561091466806829
and O 0 5.785911980638048e-07
changes O 0 3.4781544400175335e-07
in O 0 8.927089112376052e-08
the O 0 6.247858408414686e-08
phosphorylation O 0 6.349723093990178e-07
and O 0 2.2302134539131657e-07
cellular O 0 4.154035650572041e-06
localization O 0 2.054946662610746e-06
of O 0 6.928754459067932e-08
the O 0 1.1860310422662224e-07
protein O 0 2.6942357180814724e-06
after O 0 1.3950919992566924e-06
exposure O 0 1.924668686115183e-05
to O 0 2.5383781121490756e-07
DNA O 0 9.189044249069411e-06
- O 0 0.0005456390208564699
damaging O 0 7.670297782169655e-05
agents O 0 3.0392827738978667e-06
are O 0 9.351511209843011e-08
consistent O 0 4.5934362447042076e-07
with O 0 1.3324468284281465e-07
a O 0 4.860717695009953e-07
role O 0 1.5148605143622262e-06
for O 0 1.5903619896562304e-06
BRCA1 O 0 0.00035193347139284015
in O 0 5.8390992307977285e-06
DNA O 0 0.00022257439559325576
repair O 0 0.05458904057741165
. O 0 4.86245407955721e-05

Here O 0 5.43245259905234e-05
, O 0 6.527699952130206e-06
it O 0 8.19520607819868e-07
is O 0 3.6133536696070223e-07
shown O 0 6.128177005848556e-07
that O 0 3.8151230796756863e-07
mouse O 0 3.4785356547217816e-05
embryonic O 0 0.0007436992600560188
stem O 0 0.03422631323337555
cells O 0 0.018309883773326874
deficient B-Disease 0 0.05139465257525444
in I-Disease 0 3.094637122558197e-06
BRCA1 I-Disease 0 0.00020798876357730478
are O 0 3.2061274168881937e-07
defective O 0 2.41495235968614e-05
in O 0 2.0573945391788584e-07
the O 0 1.0882428824743329e-07
ability O 0 3.9887430602902896e-07
to O 0 8.407974405599816e-08
carry O 0 2.0249605370281643e-07
out O 0 1.33877222197043e-07
transcription O 0 1.8804039427777752e-06
- O 0 4.4427626562537625e-05
coupled O 0 4.413389615365304e-05
repair O 0 0.00029320537578314543
of O 0 1.19438334422739e-06
oxidative O 0 0.0028021337930113077
DNA O 0 0.000579118903260678
damage O 0 0.0006572410347871482
, O 0 5.377434604270093e-07
and O 0 4.4187498815517756e-07
are O 0 3.231257892366557e-07
hypersensitive O 0 9.658676572144032e-05
to O 0 3.199525053787511e-06
ionizing O 0 0.0020871078595519066
radiation O 0 0.00043556932359933853
and O 0 2.4397545530518983e-06
hydrogen O 0 0.000123659148812294
peroxide O 0 0.11343162506818771
. O 0 3.440998989390209e-05

These O 0 6.506154022645205e-05
results O 0 0.00012714556942228228
suggest O 0 1.7890786693897098e-05
that O 0 2.280329908899148e-06
BRCA1 O 0 0.00023616707767359912
participates O 0 2.1003337678848766e-05
, O 0 5.969047833787045e-07
directly O 0 4.2760896690197114e-07
or O 0 5.22893174093042e-07
indirectly O 0 3.5052141811320325e-06
, O 0 2.2387457931927202e-07
in O 0 2.8257977646717336e-07
transcription O 0 6.131343980086967e-06
- O 0 0.00015055850963108242
coupled O 0 0.00017737400776240975
repair O 0 0.0014073208440095186
of O 0 3.4487554785300745e-06
oxidative O 0 0.02362133376300335
DNA O 0 0.003030732274055481
damage O 0 0.001893271692097187
. O 0 8.603359674452804e-06
. O 0 2.1641353669110686e-05

Truncation O 0 0.016432631760835648
mutations O 0 0.0017748989630490541
in O 0 7.71581835579127e-06
the O 0 2.8225299502082635e-06
transactivation O 0 0.0004232060455251485
region O 0 2.0702616893686354e-05
of O 0 1.7659120885582524e-06
PAX6 O 0 0.07415886968374252
result O 0 6.965391548874322e-06
in O 0 1.0887956705118995e-06
dominant O 0 2.190348823205568e-05
- O 0 0.001019825809635222
negative O 0 2.222773400717415e-05
mutants O 0 0.00018464629829395562
. O 0 2.392711212451104e-05

PAX6 O 0 0.2957291901111603
is O 0 2.176690941269044e-05
a O 0 6.257874701987021e-06
transcription O 0 1.4209143955667969e-05
factor O 0 1.5462950386790908e-06
with O 0 2.0875765471828345e-07
two O 0 3.2961233387140965e-07
DNA O 0 4.4582775444723666e-06
- O 0 4.0217346395365894e-05
binding O 0 4.48082528237137e-06
domains O 0 1.4134700450085802e-06
( O 0 3.2420985007775016e-07
paired O 0 1.6861285985214636e-06
box O 0 1.1828833521576598e-06
and O 0 8.075541018115473e-07
homeobox O 0 0.00043400246067903936
) O 0 4.868372229793749e-07
and O 0 1.4155985184061137e-07
a O 0 3.7978472278155095e-07
proline O 0 5.788886846858077e-05
- O 0 9.460242290515453e-05
serine O 0 2.2761563741369173e-05
- O 0 0.0001002239587251097
threonine O 0 0.00012952963879797608
( O 0 3.6729941257362952e-06
PST O 0 0.00025103261577896774
) O 0 1.6748462030591327e-06
- O 0 2.6740450266515836e-05
rich O 0 1.663605507928878e-05
transactivation O 0 0.00032166586606763303
domain O 0 3.249795190640725e-05
. O 0 1.7300993931712583e-05

PAX6 O 1 0.9757550358772278
regulates O 0 0.009502816013991833
eye O 0 0.3038477301597595
development O 0 5.691567275789566e-05
in O 0 4.15543036069721e-06
animals O 0 1.8399672399027622e-06
ranging O 0 5.770819370809477e-06
from O 0 1.0068956726172473e-06
jellyfish O 0 2.251849764434155e-05
to O 0 7.082492174959043e-07
Drosophila O 0 1.0434338037157431e-05
to O 0 3.0584494652430294e-06
humans O 0 1.0267399375152308e-05
. O 0 1.7147902326541953e-05

Heterozygous O 0 0.00884223822504282
mutations O 0 0.0018408088944852352
in O 0 4.893414370599203e-06
the O 0 1.7805806464821217e-06
human O 0 5.79687593926792e-06
PAX6 O 0 0.1360238790512085
gene O 0 6.056268830434419e-05
result O 0 2.792468421830563e-06
in O 0 5.396721007855376e-07
various O 0 9.025676490637125e-07
phenotypes O 0 0.00025626676506362855
, O 0 1.6247010989900446e-06
including O 0 4.563254151435103e-06
aniridia B-Disease 1 0.9999724626541138
, O 0 0.0001625659642741084
Peters B-Disease 1 0.9997530579566956
anomaly I-Disease 1 0.9992555975914001
, O 0 7.099021604517475e-05
autosomal B-Disease 0 0.1839195042848587
dominant I-Disease 0 0.008806183934211731
keratitis I-Disease 1 0.999626636505127
, O 0 1.811544098018203e-05
and O 0 6.832246435806155e-05
familial B-Disease 1 0.9842653274536133
foveal I-Disease 1 0.9999523162841797
dysplasia I-Disease 1 0.9999973773956299
. O 0 0.00034496741136536

It O 0 1.9443401470198296e-05
is O 0 2.443899347781553e-06
believed O 0 2.495107082722825e-06
that O 0 3.444225171733706e-07
the O 0 3.734626261575613e-07
mutated O 0 8.327181603817735e-06
allele O 0 5.049604169471422e-06
of O 0 6.161304781926447e-07
PAX6 O 0 0.0013149945298209786
produces O 0 9.953805601981003e-06
an O 0 3.984762315667467e-07
inactive O 0 3.4412187233101577e-06
protein O 0 2.6563714072835864e-06
and O 0 9.813991255214205e-07
aniridia B-Disease 1 0.9804784655570984
is O 0 1.5715401104898774e-06
caused O 0 9.877531738311518e-06
due O 0 8.584640454500914e-06
to O 0 4.5025567487755325e-06
genetic O 0 0.00013825103815179318
haploinsufficiency O 0 0.0097584817558527
. O 0 5.0033428124152124e-05

However O 0 5.493178832693957e-05
, O 0 7.503776942030527e-06
several O 0 2.369000185353798e-06
truncation O 0 0.00020958173263352364
mutations O 0 7.453817670466378e-05
have O 0 3.491834092983481e-07
been O 0 1.8212021757335606e-07
found O 0 2.2292906010079605e-07
to O 0 1.8590839090393274e-07
occur O 0 6.544740358549461e-07
in O 0 1.1354688922438072e-07
the O 0 2.3635271872990415e-07
C O 0 3.797302269958891e-05
- O 0 7.370561070274562e-05
terminal O 0 7.92251194070559e-06
half O 0 3.0178870247254963e-07
of O 0 3.516074400522484e-07
PAX6 O 0 0.00804272759705782
in O 0 6.173930614750134e-06
patients O 0 2.8559714337461628e-05
with O 0 1.0802082215377595e-06
Aniridia B-Disease 1 0.9937124848365784
resulting O 0 1.2700854313152377e-05
in O 0 3.982649730005505e-07
mutant O 0 2.576749011495849e-06
proteins O 0 2.7750849085350637e-07
that O 0 6.021597442895654e-08
retain O 0 9.451424602957559e-07
the O 0 1.126094559822377e-07
DNA O 0 1.9125716335111065e-06
- O 0 2.6719189918367192e-05
binding O 0 2.2884953523316653e-06
domains O 0 8.129522939270828e-07
but O 0 8.158743725061868e-08
have O 0 7.013785108256343e-08
lost O 0 3.28581023723018e-07
most O 0 1.7004040842039103e-07
of O 0 1.839507746126401e-07
the O 0 1.6230720802923315e-06
transactivation O 0 0.00046130435657687485
domain O 0 3.882107193931006e-05
. O 0 2.2853348127682693e-05

It O 0 1.9938923287554644e-05
is O 0 2.143786787200952e-06
not O 0 5.857650080542953e-07
clear O 0 1.2172030210422236e-06
whether O 0 4.5908308266007225e-07
such O 0 2.401425263087731e-07
mutants O 0 7.262294093379751e-05
really O 0 3.2926782296271995e-06
behave O 0 4.595737209456274e-06
as O 0 3.6173565831632004e-07
loss O 0 4.693643859354779e-06
- O 0 1.6513145965291187e-05
of O 0 2.0921326893130754e-07
- O 0 8.067992166616023e-05
function O 0 1.1500443406475824e-06
mutants O 0 9.024634891829919e-06
as O 0 3.937665837838722e-07
predicted O 0 1.00537863545469e-05
by O 0 2.571296818132396e-06
haploinsufficiency O 0 0.0006930583040229976
. O 0 3.074339110753499e-05

Contrary O 0 0.0001479851343901828
to O 0 6.807699719502125e-06
this O 0 1.0787330211314838e-06
theory O 0 2.19421281144605e-06
, O 0 5.969844778519473e-07
our O 0 5.495913910635863e-07
data O 0 1.4432037005462917e-06
showed O 0 7.047953545225027e-07
that O 0 6.379099914965991e-08
these O 0 1.1015832512839552e-07
mutants O 0 6.538154593727086e-06
are O 0 1.1644606701111115e-07
dominant O 0 1.839742708398262e-06
- O 0 6.152515561552718e-05
negative O 0 1.9398335098230746e-06
in O 0 6.273580197557749e-07
transient O 0 6.613332516280934e-05
transfection O 0 0.01509387232363224
assays O 0 1.3510775715985801e-05
when O 0 2.29149748065538e-07
they O 0 1.0030086627921264e-07
are O 0 1.0307600462056143e-07
coexpressed O 0 1.8330792954657227e-05
with O 0 4.703169054209866e-07
wild O 0 1.70998591784155e-05
- O 0 0.005710472818464041
type O 0 8.613647514721379e-05
PAX6 O 0 0.007976492866873741
. O 0 1.595562935108319e-05

We O 0 1.6248766769422218e-05
found O 0 4.175320100330282e-06
that O 0 4.927431405121752e-07
the O 0 2.9722045269409136e-07
dominant O 0 1.1785406968556345e-05
- O 0 0.003151996759697795
negative O 0 9.832851901592221e-06
effects O 0 9.35327261686325e-06
result O 0 6.920195119164418e-07
from O 0 1.5631560756901308e-07
the O 0 1.831354552450648e-07
enhanced O 0 1.1349215128575452e-05
DNA O 0 8.900852662918624e-06
binding O 0 3.982345333497506e-06
ability O 0 9.948480510502122e-07
of O 0 4.532735431439505e-07
these O 0 1.4426340158024686e-06
mutants O 0 0.00020372435392346233
. O 0 1.804240673664026e-05

Kinetic O 0 0.0007277472177520394
studies O 0 6.175086309667677e-05
of O 0 3.056107971133315e-06
binding O 0 2.007984403462615e-05
and O 0 5.801045517728198e-06
dissociation O 0 0.0011419005459174514
revealed O 0 2.1133877453394234e-05
that O 0 2.620166128508572e-07
various O 0 2.40965647435587e-07
truncation O 0 1.7338057659799233e-05
mutants O 0 1.5847248505451716e-05
have O 0 1.6635806332487846e-07
3 O 0 5.62739387532929e-07
- O 0 1.3554421457229182e-05
5 O 0 8.734956509215408e-07
- O 0 6.071215011616005e-06
fold O 0 2.460006271576276e-06
higher O 0 2.804350174301362e-07
affinity O 0 3.183070589329873e-07
to O 0 5.411260062260226e-08
various O 0 1.091954189291755e-07
DNA O 0 1.3140044075043988e-06
- O 0 6.685444532195106e-06
binding O 0 1.0502027407710557e-06
sites O 0 1.7397204032931768e-07
when O 0 1.0681290518732567e-07
compared O 0 3.996034081410471e-07
with O 0 1.374580733681796e-07
the O 0 4.6888558813407144e-07
wild O 0 1.8586420992505737e-05
- O 0 0.0032511220779269934
type O 0 5.9331359807401896e-05
PAX6 O 0 0.004846716299653053
. O 0 2.633392250572797e-05

These O 0 5.2920830057701096e-05
results O 0 4.360896855359897e-05
provide O 0 3.512911234793137e-06
a O 0 1.1961649306613253e-06
new O 0 2.3048455659591127e-06
insight O 0 1.3407106962404214e-05
into O 0 4.011915279988898e-07
the O 0 3.233838015148649e-07
role O 0 6.879844249851885e-07
of O 0 6.870704396533256e-07
mutant O 0 4.6087072405498475e-05
PAX6 O 0 0.020702090114355087
in O 0 1.34701977003715e-05
causing O 0 0.00032560183899477124
aniridia B-Disease 1 0.9960648417472839
. O 0 1.4129473129287362e-05
. O 0 2.2151214579935186e-05

Reversal O 0 0.03875214233994484
of O 0 0.0005457944935187697
severe O 1 0.9999700784683228
hypertrophic B-Disease 1 0.9999996423721313
cardiomyopathy I-Disease 1 1.0
and O 0 0.0002175415284000337
excellent O 0 0.00043623766396194696
neuropsychologic O 1 0.6025925874710083
outcome O 0 4.130111847189255e-05
in O 0 7.412138529616641e-07
very B-Disease 0 6.131386953711626e-07
- I-Disease 0 8.499206887790933e-05
long I-Disease 0 8.499212526658084e-06
- I-Disease 0 0.00017224637849722058
chain I-Disease 0 1.4940775145078078e-05
acyl I-Disease 0 5.4016643844079226e-05
- I-Disease 0 0.00026468842406757176
coenzyme I-Disease 0 0.00015251434524543583
A I-Disease 0 3.3685751986922696e-05
dehydrogenase I-Disease 1 0.9276776909828186
deficiency I-Disease 0 0.3404204845428467
. O 0 2.9764623832306825e-05

Very B-Disease 0 9.420714195584878e-05
- I-Disease 0 0.00043177074985578656
long I-Disease 0 2.9687122150789946e-05
- I-Disease 0 0.0001998769585043192
chain I-Disease 0 2.324397792108357e-05
acyl I-Disease 0 4.193944550934248e-05
- I-Disease 0 8.156909461831674e-05
coenzyme I-Disease 0 2.5874931452563033e-05
A I-Disease 0 2.4725707135075936e-06
dehydrogenase I-Disease 0 0.0011076312512159348
( I-Disease 0 1.015926682157442e-05
VLCAD I-Disease 0 0.3952302932739258
) I-Disease 0 0.00019144297402817756
deficiency I-Disease 0 0.038564637303352356
is O 0 6.250152750908455e-07
a O 0 6.588089490833227e-06
disorder O 0 0.021967194974422455
of O 0 1.0929915106316912e-06
fatty O 0 0.00014518265379592776
acid O 0 0.0002628047368489206
beta O 0 1.612896448932588e-05
oxidation O 0 1.099852943298174e-05
that O 0 1.9166584763752326e-07
reportedly O 0 2.2961598915571813e-06
has O 0 2.00010006778939e-07
high O 0 1.1902477581315907e-06
rates O 0 2.70146506409219e-06
of O 0 1.7133398841906455e-06
morbidity O 0 0.20336292684078217
and O 0 3.1575869797961786e-05
mortality O 0 0.0006717085489071906
. O 0 3.912185275112279e-05

We O 0 4.7685010940767825e-05
describe O 0 4.801354953087866e-05
the O 0 1.798373318706581e-06
outcome O 0 3.796376404352486e-06
of O 0 2.230562330396424e-07
a O 0 7.41276778626343e-07
5 O 0 6.070369636290707e-06
- O 0 0.00021892438235227019
year O 0 3.5611972180049634e-06
- O 0 7.907309918664396e-05
old O 0 9.186906027025543e-06
girl O 0 5.5637712648604065e-05
with O 0 5.9886671806452796e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.999997615814209
who O 0 1.9512592643877724e-06
was O 0 3.2751231060501595e-07
first O 0 1.8289684078354185e-07
seen O 0 5.715647262150014e-07
at O 0 2.639970944073866e-07
5 O 0 1.7808556549425703e-06
months O 0 1.3103228866384597e-06
of O 0 2.4925046204771206e-07
age O 0 4.099305897398153e-06
with O 0 9.878203127300367e-05
severe O 1 0.9999865293502808
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
, O 0 0.38717177510261536
hepatomegaly B-Disease 1 1.0
, O 0 0.02296590805053711
encephalopathy B-Disease 1 0.9963898062705994
, O 0 1.5066186279000249e-05
and O 0 3.957678927690722e-05
hypotonia B-Disease 1 0.9647528529167175
. O 0 0.00010495779861230403

Biochemical O 1 0.7656763195991516
studies O 0 0.018992416560649872
indicated O 1 0.8553212881088257
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.00039147393545135856
by O 0 1.8948232991533587e-06
a O 0 2.499455604265677e-06
stable O 0 0.00011306346277706325
yet O 0 9.679290997155476e-06
inactive O 0 3.943551564589143e-05
enzyme O 0 9.025164763443172e-05
. O 0 2.027615664701443e-05

Molecular O 0 0.00975798349827528
genetic O 0 0.0007657722453586757
analysis O 0 2.0528646928141825e-05
of O 0 1.8956438907480333e-06
her O 0 1.7166228644782677e-05
VLCAD O 1 0.784750759601593
gene O 0 4.3436313717393205e-05
revealed O 0 8.495136171404738e-06
a O 0 8.972544378593739e-07
T1372C O 0 0.00016061072528827935
( O 0 2.0857867184531642e-06
F458L O 0 8.337629697052762e-05
) O 0 3.281048520875629e-06
missense O 0 6.384289736161008e-05
mutation O 0 6.6918996708409395e-06
and O 0 6.484080472546339e-07
a O 0 4.505365723161958e-06
1668 O 0 0.034754615277051926
ACAG O 0 0.21183183789253235
1669 O 0 0.00615094555541873
splice O 0 0.002501782262697816
site O 0 3.247849963372573e-05
mutation O 0 8.210521627916023e-05
. O 0 2.00084105017595e-05

After O 0 0.0002317308244528249
initial O 0 0.0002458228264003992
treatment O 0 0.0001342929172096774
with O 0 3.179213308612816e-06
intravenous O 0 0.00017841430963017046
glucose O 0 0.0002954693918582052
and O 0 6.700380254187621e-06
carnitine O 0 0.0014633357059210539
, O 0 8.168660770024871e-07
the O 0 2.326606818314758e-07
patient O 0 8.188727406377438e-06
has O 0 2.806410179800878e-07
thrived O 0 2.0978436623408925e-06
on O 0 1.76629143311402e-07
a O 0 2.0940987610629236e-07
low O 0 2.851411636584089e-06
- O 0 0.00020502058032434434
fat O 0 4.454208101378754e-05
diet O 0 2.2518900095747085e-06
supplemented O 0 5.658202439917659e-07
with O 0 1.2948568439696828e-07
medium O 0 3.4787622098519932e-06
- O 0 3.3485670428490266e-05
chain O 0 4.529971192823723e-06
triglyceride O 0 1.073408293450484e-05
oil O 0 3.4716367736109532e-06
and O 0 6.683651463390561e-07
carnitine O 0 0.00010400920291431248
and O 0 9.576890533935511e-07
avoidance O 0 8.222839096561074e-05
of O 0 3.4258971481904155e-06
fasting O 0 0.00019109630375169218
. O 0 2.743721051956527e-05

Her O 0 0.0035742400214076042
ventricular O 1 0.9991340041160583
hypertrophy O 1 0.9933344125747681
resolved O 0 0.0005727392854169011
significantly O 0 3.8701902667526156e-05
over O 0 1.3704657249036245e-06
1 O 0 5.475763373397058e-06
year O 0 2.357209268666338e-06
, O 0 4.3289918494338053e-07
and O 0 1.2149484973633662e-06
cognitively O 0 0.0018458411796018481
, O 0 1.2749937923217658e-06
she O 0 4.0683292468202126e-07
is O 0 1.0890858703760387e-07
in O 0 1.5415039911204076e-07
the O 0 3.45920284416934e-07
superior O 0 1.4659066437161528e-05
range O 0 2.145713551726658e-06
for O 0 2.1175583242438734e-06
age O 0 9.502429747954011e-06
. O 0 1.8555885617388412e-05

Clinical O 0 0.02833855152130127
recognition O 0 0.00015412071661558002
of O 0 0.00018644197552930564
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 5.362954652810004e-06
important O 0 5.484781695486163e-07
because O 0 3.182506134180585e-07
it O 0 8.201776324767707e-08
is O 0 7.329817464096777e-08
one O 0 5.3094215246574095e-08
of O 0 7.311749072869134e-08
the O 0 2.368030465049742e-07
few O 0 1.8019613889919128e-06
directly O 0 3.053121690754779e-05
treatable O 1 0.9971990585327148
causes O 0 0.00011689681559801102
of O 0 1.4433577234740369e-05
cardiomyopathy B-Disease 1 0.9999998807907104
in O 0 3.9728918636683375e-05
children O 0 1.8326456483919173e-05
. O 0 5.0080916480510496e-06
. O 0 1.5177617569861468e-05

Cloning O 0 0.0004700380959548056
of O 0 8.728447028261144e-06
a O 0 4.554306542559061e-06
novel O 0 6.372110419761157e-06
member O 0 1.3346041214390425e-06
of O 0 2.164871091281384e-07
the O 0 3.428397121751914e-07
low O 0 6.263737304834649e-06
- O 0 0.0002188116923207417
density O 0 1.6878511814866215e-05
lipoprotein O 0 0.0011122268624603748
receptor O 0 4.9012716772267595e-05
family O 0 1.3379160009208135e-05
. O 0 1.7135771486209705e-05

A O 0 5.300178600009531e-05
gene O 0 3.5472628951538354e-05
encoding O 0 1.3100182513881009e-05
a O 0 1.5769854826430674e-06
novel O 0 3.7014415283920243e-06
transmembrane O 0 4.347244612290524e-05
protein O 0 4.30778845839086e-06
was O 0 3.740172189736768e-07
identified O 0 5.835308343193901e-07
by O 0 1.1584339887349415e-07
DNA O 0 1.3513562180378358e-06
sequence O 0 4.1427898622714565e-07
analysis O 0 5.3224715657052e-07
within O 0 2.3826281392302917e-07
the O 0 6.602377311537566e-07
insulin B-Disease 0 0.30819961428642273
- I-Disease 1 0.9954356551170349
dependent I-Disease 1 0.9853144884109497
diabetes I-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999997615814209
( O 0 4.674553929362446e-05
IDDM B-Disease 0 0.009967238642275333
) O 0 3.3480052934464766e-06
locus O 0 1.4210811059456319e-05
IDDM4 O 0 0.0004343438777141273
on O 0 9.7243946584058e-06
chromosome O 0 0.00021402197307907045
11q13 O 0 0.0006083472399041057
. O 0 4.8343521484639496e-05

Based O 0 0.00012399021943565458
on O 0 1.2497511306719389e-05
its O 0 1.0192260560870636e-05
chromosomal O 0 0.0002594066900201142
position O 0 5.354256700229598e-06
, O 0 1.0339651907997904e-06
this O 0 3.133826282919472e-07
gene O 0 1.4152815310808364e-06
is O 0 1.4643754298049316e-07
a O 0 3.3367106766490906e-07
candidate O 0 2.5603103495086543e-06
for O 0 9.525299446977442e-07
conferring O 0 0.0004674563533626497
susceptibility O 0 0.0992821753025055
to O 0 0.00010145534906769171
diabetes B-Disease 1 0.9945420622825623
. O 0 7.516307232435793e-05

The O 0 4.243298462824896e-05
gene O 0 6.506674981210381e-05
, O 0 3.6711310258397134e-06
termed O 0 2.3900614905869588e-05
low O 0 1.2595312909979839e-05
- O 0 0.0001918817579280585
density O 0 1.2154549949627835e-05
lipoprotein O 0 0.0006093952688388526
receptor O 0 2.1258756532915868e-05
related O 0 2.809724946928327e-06
protein O 0 1.7282388853345765e-06
5 O 0 1.1329187827868736e-06
( O 0 3.932971139875008e-07
LRP5 O 0 4.68396428914275e-05
) O 0 3.989587469277467e-07
, O 0 8.563935693928215e-08
encodes O 0 3.6506233414002054e-07
a O 0 1.3605020399154455e-07
protein O 0 5.150884589966154e-07
of O 0 1.3276938659601e-07
1615 O 0 4.5333366870181635e-05
amino O 0 2.381465492362622e-06
acids O 0 1.0093809805766796e-06
that O 0 4.418740928713305e-08
contains O 0 9.492419650314332e-08
conserved O 0 3.137477619929996e-07
modules O 0 7.27344854567491e-07
which O 0 6.985507639001298e-08
are O 0 3.753936894668186e-08
characteristic O 0 3.5085710692328576e-07
of O 0 8.470525614256985e-08
the O 0 1.2938495785874693e-07
low O 0 7.177631687227404e-06
- O 0 0.0004419976321514696
density O 0 1.4882669347571209e-05
lipoprotein O 0 0.005254906602203846
( O 0 7.990087397047319e-06
LDL O 0 0.0006764366407878697
) O 0 5.514837994269328e-06
receptor O 0 2.2727641407982446e-05
family O 0 7.3903952397813555e-06
. O 0 1.3214830687502399e-05

These O 0 1.9706407329067588e-05
modules O 0 3.8319853047141805e-05
include O 0 2.8020504032610916e-06
a O 0 2.381420245001209e-06
putative O 0 2.3730142856948078e-05
signal O 0 4.882432222075295e-06
peptide O 0 3.1227718864101917e-06
for O 0 2.2192760695816105e-07
protein O 0 7.301748610188952e-07
export O 0 5.479966489474464e-07
, O 0 1.8267390089476976e-07
four O 0 3.78438670622927e-07
epidermal O 0 0.0003415836254134774
growth O 0 1.090376463253051e-05
factor O 0 1.666646994635812e-06
( O 0 8.744407864469395e-07
EGF O 0 6.014759492245503e-05
) O 0 6.852172873550444e-07
repeats O 0 1.969101958820829e-06
with O 0 2.2581384939712734e-07
associated O 0 1.312559106736444e-06
spacer O 0 2.3841153961257078e-05
domains O 0 1.603355258339434e-06
, O 0 2.2816345790488413e-07
three O 0 3.876566552207805e-07
LDL O 0 0.001828499836847186
- O 0 0.0018807202577590942
receptor O 0 1.802978295017965e-05
( O 0 9.222873700309719e-07
LDLR O 0 0.00011997253022855148
) O 0 5.855365543538937e-07
repeats O 0 1.7889788068714552e-06
, O 0 8.842898324701309e-08
a O 0 1.1937416388718702e-07
single O 0 4.6916025553400686e-07
transmembrane O 0 7.50546632843907e-06
spanning O 0 1.0491565944903414e-06
domain O 0 7.1111207944341e-07
, O 0 1.7251615247459995e-07
and O 0 1.5748798887216253e-07
a O 0 1.1572805078685633e-06
cytoplasmic O 0 0.00019831160898320377
domain O 0 3.454245597822592e-05
. O 0 1.756033998390194e-05

The O 0 1.6931810023379512e-05
encoded O 0 1.8869966879719868e-05
protein O 0 8.500598596583586e-06
has O 0 3.565771180547017e-07
a O 0 3.0104936854513653e-07
unique O 0 7.368490742010181e-07
organization O 0 8.63520028815401e-07
of O 0 2.9870003004361934e-07
EGF O 0 0.00010135923366760835
and O 0 2.0712611785711488e-06
LDLR O 0 0.02608044445514679
repeats O 0 7.042457582429051e-05
; O 0 1.044087071022659e-06
therefore O 0 2.7237624067311117e-07
, O 0 2.9898131970185204e-07
LRP5 O 0 0.00047295293188653886
likely O 0 1.4500424185825977e-06
represents O 0 5.850531579199014e-07
a O 0 2.475916005550971e-07
new O 0 6.602603548344632e-07
category O 0 1.1872854202010785e-06
of O 0 2.897804733947851e-07
the O 0 1.1056833955080947e-06
LDLR O 0 0.021473940461874008
family O 0 4.852744677918963e-05
. O 0 2.6695146516431123e-05

Both O 0 4.8714766307966784e-05
human O 0 1.9302380678709596e-05
and O 0 4.410676410770975e-06
mouse O 0 6.4369487517979e-05
LRP5 O 0 0.038637083023786545
cDNAs O 0 0.001756857382133603
have O 0 8.293572477668931e-07
been O 0 3.0316783750095055e-07
isolated O 0 1.04794264643715e-06
and O 0 1.4066090159303712e-07
the O 0 1.1358057605548311e-07
encoded O 0 5.387952910496097e-07
mature O 0 4.759929652209394e-06
proteins O 0 2.006473636129158e-07
are O 0 3.5697546252322354e-08
95 O 0 5.172007035980641e-07
% O 0 3.5943818943451333e-07
identical O 0 1.0313397069694474e-06
, O 0 2.70498986765233e-07
indicating O 0 1.559179395371757e-06
a O 0 2.4939694753811636e-07
high O 0 3.4323561521887314e-06
degree O 0 7.3675528255989775e-06
of O 0 8.043750199249189e-07
evolutionary O 0 1.6246784070972353e-05
conservation O 0 3.5800101613858715e-05
. O 0 5.905325906496728e-06
. O 0 2.1243940864223987e-05

The O 0 5.149129356141202e-05
APC B-Disease 0 0.00030345760751515627
variants O 0 3.849382483167574e-05
I1307K O 0 9.461334411753342e-05
and O 0 2.8805859528802102e-06
E1317Q O 0 0.00011384175013517961
are O 0 1.5085676068338216e-06
associated O 0 4.2205614590784535e-05
with O 0 0.2796306908130646
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.187294689472765e-05
but O 0 4.5551607286142826e-07
not O 0 1.5823394505787292e-07
always O 0 2.515145922643569e-07
with O 0 2.505113343431731e-07
a O 0 1.7677402865956537e-06
family O 0 1.5797226296854205e-05
history O 0 1.0007286618929356e-05
. O 0 2.7616159059107304e-05

Classical O 1 0.5399410724639893
familial B-Disease 1 0.9999963045120239
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 1.0
( O 0 0.10160582512617111
FAP B-Disease 1 0.954950749874115
) O 0 2.2540220015798695e-05
is O 0 7.804364372532291e-07
a O 0 8.127848332151189e-07
high O 0 4.569765951600857e-05
- O 1 0.9922089576721191
penetrance O 1 0.9997640252113342
autosomal B-Disease 1 0.9809049367904663
dominant I-Disease 0 0.06630906462669373
disease I-Disease 0 0.004357143770903349
that O 0 5.025344762543682e-07
predisposes O 0 4.2763575038407e-05
to O 0 3.746884260635852e-07
hundreds O 0 7.348322696998366e-07
or O 0 5.046591695645475e-07
thousands O 0 2.046489953499986e-06
of O 0 1.856859671534039e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.3020538091659546
carcinoma I-Disease 1 1.0
and O 0 6.738854608556721e-06
that O 0 4.63873504941148e-07
results O 0 4.3306163206580095e-06
from O 0 5.893101047149685e-07
truncating O 0 0.0003727650619111955
mutations O 0 3.067550642299466e-05
in O 0 4.623885843102471e-07
the O 0 1.0356567372582504e-06
APC B-Disease 0 0.00024124221818055958
gene O 0 5.0408420065650716e-05
. O 0 1.588269878993742e-05

A O 0 0.00014270115934778005
variant O 0 0.0004557709617074579
of O 0 1.3848974958818872e-05
FAP B-Disease 0 0.27011358737945557
is O 0 6.499618757516146e-05
attenuated B-Disease 1 0.7804351449012756
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999097585678101
, O 0 3.445750735409092e-06
which O 0 4.3242712877145095e-07
results O 0 2.8755603125318885e-06
from O 0 4.315755575134972e-07
germ O 0 0.0035132525954395533
- O 0 0.00037616529152728617
line O 0 5.929083272349089e-06
mutations O 0 2.716809603953152e-06
in O 0 5.07938615612602e-08
the O 0 4.224877159231255e-08
5 O 0 4.30983277510677e-07
and O 0 1.0599805477795599e-07
3 O 0 9.494119126429723e-07
regions O 0 5.941298582001764e-07
of O 0 1.5998224967006536e-07
the O 0 1.0394146556791384e-06
APC B-Disease 0 0.0002539914275985211
gene O 0 3.347488018334843e-05
. O 0 1.2644248272408731e-05

Attenuated B-Disease 1 0.9997901320457458
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999997615814209
patients O 1 0.9992724061012268
have O 0 2.5809669750742614e-05
" O 0 4.400655598146841e-05
multiple O 0 0.0003565563529264182
" O 0 0.24174976348876953
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
( O 0 6.108319939812645e-05
typically O 0 4.5837923607905395e-06
fewer O 0 1.2792187362720142e-06
than O 0 1.6637171995625977e-07
100 O 0 3.870183320486831e-07
) O 0 4.4294833401181677e-07
without O 0 3.770132650515734e-07
the O 0 5.955588449069182e-07
florid O 0 0.05644991621375084
phenotype O 0 0.0012324308045208454
of O 0 1.6883074067663983e-06
classical O 0 6.66541454847902e-05
FAP B-Disease 0 0.021277476102113724
. O 0 4.82833493151702e-05

Another O 0 8.467536099487916e-05
group O 0 0.00016840046737343073
of O 0 8.513018656230997e-06
patients O 0 0.000434779649367556
with O 0 4.10752727475483e-06
multiple O 0 0.0003780597180593759
adenomas B-Disease 1 0.9932401180267334
has O 0 4.04191087000072e-06
no O 0 1.7150628082163166e-06
mutations O 0 7.351585736614652e-06
in O 0 1.2090981726942118e-07
the O 0 1.9671993811698485e-07
APC B-Disease 0 6.583394133485854e-05
gene O 0 2.1313148863555398e-06
, O 0 1.8197958695509442e-07
and O 0 1.9392957995023608e-07
their O 0 2.043373569904361e-06
phenotype O 0 0.0073200794868171215
probably O 0 2.625193701533135e-06
results O 0 2.3327663711825153e-06
from O 0 1.3737511039835226e-07
variation O 0 1.062753426595009e-06
at O 0 3.0567329645236896e-07
a O 0 3.7724484514001233e-07
locus O 0 6.888562893436756e-06
, O 0 4.4995033476880053e-07
or O 0 4.770827786160226e-07
loci O 0 4.56180077890167e-06
, O 0 4.1205669276678236e-07
elsewhere O 0 1.14981742171949e-06
in O 0 3.916819650839898e-07
the O 0 1.4584608152290457e-06
genome O 0 2.5767913029994816e-05
. O 0 1.3886548913433217e-05

Recently O 0 0.00048323487862944603
, O 0 1.3309333553479519e-05
however O 0 2.921261284427601e-06
, O 0 7.057450943648291e-07
a O 0 1.136715354732587e-06
missense O 0 7.104325050022453e-05
variant O 0 2.208188561780844e-05
of O 0 6.598499453502882e-07
APC B-Disease 0 0.00013514963211491704
( O 0 2.5169413220282877e-06
I1307K O 0 6.212071457412094e-05
) O 0 1.024861717269232e-06
was O 0 3.090709412845172e-07
described O 0 1.8291478909304715e-06
that O 0 1.9474059342883265e-07
confers O 0 1.9668030290631577e-05
an O 0 7.102648851287086e-07
increased O 0 3.1261482945410535e-05
risk O 0 0.0003994388389401138
of O 0 0.0042881122790277
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.2585383703699335e-05
including O 0 4.7989419726945926e-06
multiple O 0 0.00013213443162385374
adenomas B-Disease 1 0.9642270803451538
, O 0 6.389160262187943e-06
in O 0 5.268543191050412e-06
Ashkenazim O 0 0.0017546009039506316
. O 0 4.078953497810289e-05

We O 0 1.914592576213181e-05
have O 0 1.5526771903751069e-06
studied O 0 1.5581181287416257e-06
a O 0 4.945632099406794e-07
set O 0 5.325629786057107e-07
of O 0 4.853500286117196e-07
164 O 0 0.0015578202437609434
patients O 0 0.001030247425660491
with O 0 2.500034861441236e-05
multiple O 1 0.9741902351379395
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 0 0.0002463488490320742
/ I-Disease 1 0.7493867874145508
or I-Disease 0 0.0001859590847743675
carcinoma I-Disease 1 1.0
and O 0 1.3941190445621032e-05
analyzed O 0 2.5986186301452108e-05
codons O 0 4.996587085770443e-05
1263 O 0 0.0003008996427524835
- O 0 0.00046860604197718203
1377 O 0 0.0008225877536460757
( O 0 1.835538455452479e-06
exon O 0 1.0631543773342855e-05
15G O 0 2.4785202185739763e-05
) O 0 3.402388415452151e-07
of O 0 9.430755198991392e-08
the O 0 2.0085546736936521e-07
APC B-Disease 0 3.190489223925397e-05
gene O 0 2.2672975319437683e-06
for O 0 6.780873604839144e-07
germ O 0 0.000409294618293643
- O 0 0.00011419020302128047
line O 0 1.4983480468799826e-05
variants O 0 3.8324094930430874e-05
. O 0 1.2374443940643687e-05

Three O 0 0.00013197401131037623
patients O 0 0.000995902344584465
with O 0 1.538142441859236e-06
the O 0 1.1377478585927747e-06
I1307K O 0 0.00027293883613310754
allele O 0 1.7337941244477406e-05
were O 0 4.658582781758014e-07
detected O 0 2.2325934878608678e-06
, O 0 1.5964420185810013e-07
each O 0 1.8842406745989138e-07
of O 0 1.2907096333947266e-06
Ashkenazi O 0 0.005062519107013941
descent O 0 0.0002457450027577579
. O 0 3.3877793612191454e-05

Four O 0 0.000684903294313699
patients O 0 0.01402151957154274
had O 0 4.559190983854933e-06
a O 0 4.049156814289745e-06
germ O 0 0.0035728388465940952
- O 0 0.0001397133310092613
line O 0 6.001719611958833e-06
E1317Q O 0 6.114882125984877e-05
missense O 0 3.922944233636372e-05
variant O 0 7.93629624240566e-06
of O 0 4.3048461861872056e-07
APC O 0 3.596287569962442e-05
that O 0 2.3424763639923185e-07
was O 0 2.0757130414494895e-07
not O 0 7.732489137879384e-08
present O 0 1.393153326034735e-07
in O 0 8.024384356986047e-08
controls O 0 4.06409753850312e-06
; O 0 1.120472006732598e-06
one O 0 5.271239444937237e-08
of O 0 6.20830107322945e-08
these O 0 1.4169640394356975e-07
individuals O 0 2.0359028951588698e-07
had O 0 1.8478684182809957e-07
an O 0 1.9446554233581992e-07
unusually O 0 1.921316288644448e-05
large O 0 5.354311269911705e-07
number O 0 2.8209646529830934e-07
of O 0 4.770622581418138e-07
metaplastic B-Disease 0 0.014736967161297798
polyps I-Disease 0 0.0005065517034381628
of I-Disease 0 7.085640731929743e-07
the I-Disease 0 2.7164210223418195e-06
colorectum I-Disease 0 0.002178211696445942
. O 0 3.190626375726424e-05

There O 0 3.273465335951187e-05
is O 0 4.125436589674791e-06
increasing O 0 3.915055913239485e-06
evidence O 0 2.1074026790302014e-06
that O 0 2.461092094563355e-07
there O 0 2.6931465413326805e-07
exist O 0 1.1463683904366917e-06
germ O 0 0.0002324537927052006
- O 0 2.544688686612062e-05
line O 0 6.042790801075171e-07
variants O 0 4.775388333655428e-07
of O 0 5.4893405376787996e-08
the O 0 1.3680927679615706e-07
APC B-Disease 0 1.7113788999267854e-05
gene O 0 1.17052809400775e-06
that O 0 1.4126949565707037e-07
predispose O 0 3.371999127921299e-06
to O 0 1.318349518442119e-07
the O 0 1.1869928329133472e-07
development O 0 9.546852197672706e-07
of O 0 2.7200087515666382e-06
multiple O 1 0.7008806467056274
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.4894435703754425
carcinoma I-Disease 1 1.0
, O 0 2.1763213226222433e-05
but O 0 4.04832775302566e-07
without O 0 3.0081287150096614e-07
the O 0 4.7504741473858303e-07
florid O 0 0.059729259461164474
phenotype O 0 0.0007392727420665324
of O 0 2.6787739670908195e-07
classical O 0 9.841904102358967e-06
FAP B-Disease 0 0.0032001659274101257
, O 0 6.221079615897906e-07
and O 0 2.5153116212095483e-07
possibly O 0 8.937138318287907e-07
with O 0 5.841221764057991e-07
importance O 0 2.5463972633588128e-05
for O 1 0.8971313834190369
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0018340921960771084
in O 0 6.152062610453868e-07
the O 0 3.3246561770283733e-07
general O 0 2.4398850655416027e-06
population O 0 1.3857345493306639e-06
. O 0 1.8029652437689947e-06
. O 0 9.474181752011646e-06

Genomic O 0 0.0017872796161100268
structure O 0 7.539824582636356e-05
of O 0 6.208932518347865e-06
the O 0 2.095873605867382e-05
human O 0 0.0059084524400532246
congenital B-Disease 1 0.9999998807907104
chloride I-Disease 1 0.9999978542327881
diarrhea I-Disease 1 1.0
( O 0 0.0022524516098201275
CLD B-Disease 1 0.9992172718048096
) O 0 4.404963328852318e-05
gene O 0 4.6426292101386935e-05
. O 0 1.6917349057621323e-05

Congenital B-Disease 1 0.9999998807907104
chloride I-Disease 1 0.9999980926513672
diarrhea I-Disease 1 1.0
( O 0 0.20140130817890167
CLD B-Disease 1 0.9999743700027466
) O 0 9.926227357937023e-05
is O 0 2.0331217456259765e-06
caused O 0 1.0519906936679035e-05
by O 0 1.4944273516448447e-06
mutations O 0 1.4516388546326198e-05
in O 0 2.404269139333337e-07
a O 0 6.497166396002285e-07
gene O 0 2.5099179765675217e-06
which O 0 4.7073334030756087e-07
encodes O 0 7.3504220381437335e-06
an O 0 4.491915660764789e-06
intestinal O 0 0.18712693452835083
anion O 0 0.0021621377673000097
transporter O 0 0.001149146119132638
. O 0 2.7574162231758237e-05

We O 0 4.418227763380855e-05
report O 0 2.1199437469476834e-05
here O 0 1.3733492778555956e-06
the O 0 4.860504532189225e-07
complete O 0 3.769215481952415e-06
genomic O 0 1.15801876745536e-05
organization O 0 8.79081426319317e-07
of O 0 1.752679850142158e-07
the O 0 4.827244310945389e-07
human O 0 2.007508328460972e-06
CLD B-Disease 0 0.39398193359375
gene O 0 5.029808107792633e-06
which O 0 2.3392259151933104e-07
spans O 0 1.8492200979380868e-06
approximately O 0 6.290067062764138e-07
39kb O 0 3.699492663145065e-05
, O 0 3.264072461206524e-07
and O 0 2.9111723165442527e-07
comprises O 0 2.3305915419769008e-06
21 O 0 1.1604764040384907e-05
exons O 0 0.0002841674431692809
. O 0 1.6025504010031e-05

All O 0 5.261443220661022e-05
exon O 0 0.00040193312452174723
/ O 0 0.000284771405858919
intron O 0 0.0001546105631859973
boundaries O 0 4.052648819197202e-06
conform O 0 1.2082792636647355e-05
to O 0 5.592127649833856e-07
the O 0 9.129926752393658e-07
GT O 0 0.19897517561912537
/ O 0 0.14993810653686523
AG O 1 0.9997225403785706
rule O 0 3.718422522069886e-05
. O 0 1.4415845726034604e-05

An O 0 2.698028583836276e-05
analysis O 0 1.1152844308526255e-05
of O 0 5.3213238970784e-07
the O 0 5.828850930811313e-07
putative O 0 4.121731035411358e-05
promoter O 0 2.8500107873696834e-05
region O 0 3.108047167188488e-06
sequence O 0 5.511481617759273e-07
shows O 0 2.2438993596551882e-07
a O 0 2.4936269937825273e-07
putative O 0 2.618572034407407e-05
TATA O 0 0.01777796633541584
box O 0 3.632526841101935e-06
and O 0 1.0010284086092724e-06
predicts O 0 7.428527896991e-05
multiple O 0 3.0396247439057333e-06
transcription O 0 7.366070349235088e-06
factor O 0 3.1493298138229875e-06
binding O 0 1.0115702025359496e-05
sites O 0 9.67024880083045e-06
. O 0 1.5595538570778444e-05

The O 0 4.256575630279258e-05
genomic O 0 0.00018228752014692873
structure O 0 1.4732222552993335e-05
was O 0 1.590685201335873e-06
determined O 0 1.9979070202680305e-06
using O 0 8.443859087492456e-07
DNA O 0 2.8202646262798226e-06
from O 0 1.48497690588556e-07
several O 0 2.0785340382190043e-07
sources O 0 7.168849265326571e-07
including O 0 2.6058873459078313e-07
multiple O 0 6.476528255916492e-07
large O 0 6.256677238525299e-07
- O 0 5.250471440376714e-05
insert O 0 1.97470417333534e-05
libaries O 0 5.775531826657243e-05
and O 0 5.207950266594708e-07
genomic O 0 4.275088485883316e-06
DNA O 0 4.421963694767328e-06
from O 0 1.2350219549261965e-06
Finnish O 0 0.2012956589460373
CLD B-Disease 1 0.999977707862854
patients O 0 0.01090196892619133
and O 0 3.133284280920634e-06
controls O 0 0.00010578546789474785
. O 0 4.2038267565658316e-05

Exon O 0 0.0015551599208265543
- O 0 0.0009322136174887419
specific O 0 1.9104489183519036e-05
primers O 0 0.0001282886223634705
developed O 0 1.067694029188715e-05
in O 0 5.928557698098302e-07
this O 0 2.432134351693094e-07
study O 0 5.939275524724508e-07
will O 0 4.6554697519241017e-07
facilitate O 0 6.685278549412033e-06
mutation O 0 1.8696267943596467e-05
screening O 0 8.216349669964984e-06
studies O 0 1.7752023495631875e-06
of O 0 1.1130573511763941e-06
patients O 0 0.00026040407828986645
with O 0 4.493582764553139e-06
the O 0 7.726361218374223e-05
disease O 0 0.02730419673025608
. O 0 3.308423765702173e-05

Genomic O 0 0.0013940432108938694
sequencing O 0 0.000165215038578026
of O 0 5.5650070862611756e-06
a O 0 1.1203032045159489e-05
BAC O 0 0.0019213513005524874
clone O 0 0.005595950875431299
H O 1 0.9942505359649658
_ O 0 1.3949275853519794e-05
RG364P16 O 0 0.0001124450282077305
revealed O 0 5.3386947911349125e-06
the O 0 1.783383396514182e-07
presence O 0 3.1925435450830264e-07
of O 0 8.438853171810479e-08
another O 0 2.8693096965071163e-07
, O 0 3.585244883197447e-07
highly O 0 8.072946116044477e-07
homologous O 0 3.565234237612458e-06
gene O 0 1.2939287898916518e-06
3 O 0 3.983462875112309e-07
of O 0 1.0650185799931933e-07
the O 0 7.077036912050971e-07
CLD B-Disease 1 0.79432213306427
gene O 0 4.5027327360003255e-06
, O 0 1.6212095488299383e-07
with O 0 1.1124741661205917e-07
a O 0 4.1131070815936255e-07
similar O 0 2.3586528641317273e-06
genomic O 0 1.7474940250394866e-05
structure O 0 4.083997737325262e-06
, O 0 1.0828548511199187e-06
recently O 0 4.703340437117731e-06
identified O 0 1.2754011322613223e-06
as O 0 3.237893224650179e-07
the O 0 1.027105281536933e-05
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
gene O 0 0.0001416271406924352
( O 0 7.396452019747812e-06
PDS B-Disease 0 0.02178475819528103
) O 0 3.1029530873638578e-06
. O 0 1.8611501673149178e-06
. O 0 7.631762855453417e-06

The O 0 7.332074164878577e-05
APCI1307K O 0 0.041271474212408066
allele O 0 0.00117046432569623
and O 0 0.0007087690755724907
cancer B-Disease 1 0.9682281017303467
risk O 0 0.00012067967327311635
in O 0 1.0193912203249056e-06
a O 0 1.238318191099097e-06
community O 0 2.830940729836584e-06
- O 0 0.005630123429000378
based O 0 1.4485258361673914e-05
study O 0 1.0300323083356488e-06
of O 0 7.147059477574658e-07
Ashkenazi O 0 0.0013397028669714928
Jews O 0 2.880520696635358e-05
. O 0 1.854735819506459e-05

Mutations O 0 0.017272302880883217
in O 0 3.315166395623237e-05
APC O 0 0.0013581500388681889
are O 0 9.83918198471656e-06
classically O 0 0.22330009937286377
associated O 0 0.0001957556960405782
with O 0 0.00022367511701304466
familial B-Disease 1 0.9999995231628418
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.010898527689278126
FAP B-Disease 1 0.6021408438682556
) O 0 6.824496722401818e-06
, O 0 8.595401368438615e-07
a O 0 3.7193572097748984e-06
highly O 0 0.000519393477588892
penetrant O 1 0.9999570846557617
autosomal B-Disease 1 0.999998927116394
dominant I-Disease 1 0.9994022846221924
disorder I-Disease 1 0.9999997615814209
characterized O 0 0.10572391748428345
by O 0 5.50524600839708e-05
multiple O 0 0.2598424553871155
intestinal O 1 0.9999808073043823
polyps B-Disease 1 0.9190680384635925
and O 0 5.803878593724221e-06
, O 0 2.367085244259215e-06
without O 0 3.032131871805177e-06
surgical O 0 0.07091423869132996
intervention O 0 8.72754753800109e-06
, O 0 6.309508648882911e-07
the O 0 5.688300461770268e-07
development O 0 3.356262095621787e-05
of O 0 0.01001992542296648
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
( O 0 0.00026725823408924043
CRC B-Disease 0 0.10493268072605133
) O 0 2.200152630393859e-05
. O 0 1.9902276108041406e-05

APC B-Disease 0 0.010842232964932919
is O 0 2.654146919667255e-05
a O 0 2.5377285055583343e-05
tumour O 1 0.9999592304229736
- O 0 0.3018839657306671
suppressor O 0 0.004486197140067816
gene O 0 1.2049823453708086e-05
, O 0 5.721645948142395e-07
and O 0 1.557057430545683e-06
somatic O 0 0.00288276094943285
loss O 0 0.0016403712797909975
occurs O 0 5.749452247982845e-05
in O 0 5.034847345086746e-05
tumours B-Disease 1 0.9999921321868896
. O 0 0.00011426198034314439

The O 0 0.00010704106534831226
germline O 0 0.12751834094524384
T O 0 0.10296989232301712
- O 0 0.00017907048459164798
to O 0 1.2290636277612066e-06
- O 0 2.644772939675022e-05
A O 0 1.5055436506372644e-06
transversion O 0 0.00016713127843104303
responsible O 0 2.305072030139854e-06
for O 0 2.8618873670893663e-07
the O 0 3.5541771126190724e-07
APC O 0 1.737109232635703e-05
I1307K O 0 1.3579212463810109e-05
allele O 0 2.2794733922637533e-06
converts O 0 1.2521959433797747e-06
the O 0 1.448491531164109e-07
wild O 0 1.100505414797226e-06
- O 0 2.6232610252918676e-05
type O 0 9.811847121454775e-07
sequence O 0 3.8048040096327895e-07
to O 0 1.4103540024734684e-07
a O 0 1.0414696589577943e-06
homopolymer O 1 0.7200955748558044
tract O 0 0.0018637246685102582
( O 0 4.9897994358616415e-06
A8 O 0 0.17069701850414276
) O 0 1.9397523374209413e-06
that O 0 2.1692461871225532e-07
is O 0 5.06668186517345e-07
genetically O 0 7.259815174620599e-05
unstable O 0 0.0005180175066925585
and O 0 5.705338935513282e-06
prone O 0 0.00019016438454855233
to O 0 4.4536118366522714e-06
somatic O 0 0.0016419260064139962
mutation O 0 0.00011063754936913028
. O 0 1.9000270185642876e-05

The O 0 4.9919432058231905e-05
I1307K O 0 0.000786660413723439
allele O 0 0.00015295330376829952
was O 0 5.86319492867915e-06
found O 0 3.3142489428428235e-06
in O 0 2.4534808744647307e-06
6 O 0 3.277085488662124e-05
. O 0 2.351823241042439e-05

1 O 0 0.00013144852709956467
% O 0 1.789044836186804e-05
of O 0 3.2798504889797186e-06
unselected O 0 0.0012569340178743005
Ashkenazi O 0 0.0034137587063014507
Jews O 0 6.831568043708103e-06
and O 0 9.058591103894287e-07
higher O 0 1.93970799955423e-06
proportions O 0 5.7322372413182165e-06
of O 0 4.283166674667882e-07
Ashkenazim O 0 0.00015168591926340014
with O 0 1.7727475096762646e-06
family O 0 5.272237558529014e-06
or O 0 9.4600000011269e-07
personal O 0 3.625919362093555e-06
histories O 0 1.066230015567271e-05
of O 0 1.2115098115828005e-06
CRC B-Disease 0 0.012522706761956215
( O 0 6.106951332185417e-06
ref O 0 0.0004430034605320543
. O 0 1.3267361964608426e-06
2 O 0 6.3238912844099104e-06
) O 0 5.910503659833921e-06
. O 0 1.4254502275434788e-05

To O 0 4.811778126168065e-05
evaluate O 0 8.257483568741009e-05
the O 0 1.6555436559428927e-06
role O 0 2.1244904928607866e-06
of O 0 8.427222155660274e-07
I1307K O 0 0.0005649054073728621
in O 0 3.3661512134131044e-05
cancer B-Disease 0 0.010348975658416748
, O 0 8.897975476429565e-07
we O 0 4.5652808466911665e-07
genotyped O 0 0.00018509173241909593
5 O 0 5.366157438402297e-06
, O 0 1.3830517673341092e-06
081 O 0 0.0004732613742817193
Ashkenazi O 0 0.00033804416307248175
volunteers O 0 3.227932893423713e-06
in O 0 5.265532081466517e-07
a O 0 1.8134945776182576e-06
community O 0 1.3114119610690977e-05
survey O 0 5.441474786493927e-05
. O 0 2.3931541363708675e-05

Risk O 0 0.006505665369331837
of O 0 6.812455103499815e-05
developing O 1 0.8425847887992859
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 0.002980947494506836
breast I-Disease 1 0.8766987919807434
and I-Disease 0 2.1932899471721612e-05
other I-Disease 0 1.5844256267882884e-05
cancers I-Disease 0 0.08895676583051682
were O 0 3.501818639506382e-07
compared O 0 8.484227009830647e-07
between O 0 4.807250775229477e-07
genotyped O 0 0.00019548318232409656
I1307K O 0 8.57562044984661e-05
carriers O 0 1.7629740796110127e-06
and O 0 1.670990315005838e-07
non O 0 1.673128394941159e-06
- O 0 2.7515136025613174e-05
carriers O 0 1.2472761454773718e-06
and O 0 8.915313998159036e-08
their O 0 1.826172990604391e-07
first O 0 1.2338482520135585e-06
- O 0 0.00036146046477369964
degree O 0 6.76609852234833e-05
relatives O 0 0.00010555329208727926
. O 0 2.9432207156787626e-05

Sperm O 0 0.007519461680203676
DNA O 0 0.0004966280539520085
analysis O 0 2.349512215005234e-05
in O 0 3.8104903978819493e-06
a O 0 1.2359254469629377e-05
Friedreich B-Disease 1 0.9983454942703247
ataxia I-Disease 1 0.9998761415481567
premutation O 1 0.6213406920433044
carrier O 0 0.00011062510020565242
suggests O 0 4.857723524764879e-06
both O 0 4.855222641708679e-07
meiotic O 0 5.128312113811262e-05
and O 0 6.70895929033577e-07
mitotic O 0 2.5662780899438076e-05
expansion O 0 4.26939641329227e-06
in O 0 6.824951128692192e-07
the O 0 1.3550200037570903e-06
FRDA B-Disease 0 0.016027402132749557
gene O 0 5.849897570442408e-05
. O 0 1.7988390027312562e-05

Friedreich B-Disease 1 0.9999186992645264
ataxia I-Disease 1 0.9999905824661255
is O 0 0.00017843507521320134
usually O 0 2.6702022296376526e-05
caused O 0 2.1181451302254573e-05
by O 0 4.813530836145219e-07
an O 0 3.7430555721584824e-07
expansion O 0 1.5660733652111958e-06
of O 0 2.120924307291716e-07
a O 0 1.0928017672995338e-06
GAA O 0 0.0002536052488721907
trinucleotide O 0 0.005332946311682463
repeat O 0 2.871732613130007e-05
in O 0 4.839653229282703e-07
intron O 0 2.9182094294810668e-05
1 O 0 1.173033524537459e-06
of O 0 3.744840739727806e-07
the O 0 1.0842478559425217e-06
FRDA B-Disease 0 0.0034168907441198826
gene O 0 4.5864562707720324e-05
. O 0 1.547225474496372e-05

Occasionally O 0 0.00019000491010956466
, O 0 7.860251571401022e-06
a O 0 1.8736948277364718e-06
fully O 0 4.212640760670183e-06
expanded O 0 1.681375692896836e-06
allele O 0 4.350643393991049e-06
has O 0 2.314212110832159e-07
been O 0 1.6024517890400602e-07
found O 0 2.1683051443233126e-07
to O 0 2.400793448487093e-07
arise O 0 3.0534190500475233e-06
from O 0 1.4819563887158438e-07
a O 0 5.194681307330029e-07
premutation O 0 0.00017160901916213334
of O 0 1.7405419328042626e-07
100 O 0 4.400406510285393e-07
or O 0 1.0066096365335397e-06
less O 0 3.345053301018197e-06
triplet O 0 0.005965896882116795
repeats O 0 0.0003647856065072119
. O 0 2.4802726329653524e-05

We O 0 2.924168438767083e-05
have O 0 5.991511898173485e-06
examined O 0 1.679979141044896e-05
the O 0 1.0296867003489751e-06
sperm O 0 1.891105785034597e-05
DNA O 0 5.029501153330784e-06
of O 0 4.1871444977914507e-07
a O 0 3.7454944958881242e-06
premutation O 0 0.00743893114849925
carrier O 0 0.00019457735470496118
. O 0 3.066114732064307e-05

This O 0 3.4158569178543985e-05
mans O 0 0.00025893052225001156
leucocyte O 0 0.004244240466505289
DNA O 0 0.00012818200048059225
showed O 0 8.408304893237073e-06
one O 0 6.572786901415384e-07
normal O 0 1.5064197214087471e-06
allele O 0 3.836722953565186e-06
and O 0 2.1001608274673345e-07
one O 0 2.289374378960929e-07
allele O 0 2.1223579551588045e-06
of O 0 2.4580310764577007e-07
approximately O 0 1.291173816753144e-06
100 O 0 2.899069841078017e-06
repeats O 0 7.828888192307204e-05
. O 0 1.8125150745618157e-05

His O 0 0.0001532151800347492
sperm O 0 0.0006917818100191653
showed O 0 1.4661751265521161e-05
an O 0 9.445684554520994e-07
expanded O 0 1.965264118553023e-06
allele O 0 3.3943035759875784e-06
in O 0 2.0792477073428017e-07
a O 0 2.913569403517613e-07
tight O 0 4.2547276279947255e-06
range O 0 1.2713524029095424e-06
centering O 0 1.9072330132985371e-06
on O 0 3.2608832611913385e-07
a O 0 2.843924846729351e-07
size O 0 8.636073403067712e-07
of O 0 4.7105490352805646e-07
approximately O 0 3.562990968930535e-06
320 O 0 4.442500357981771e-05
trinucleotide O 0 0.003009177278727293
repeats O 0 0.0002691663976293057
. O 0 2.8037482479703613e-05

His O 0 0.00037545966915786266
affected O 0 0.0003905254998244345
son O 0 0.0003131380944978446
has O 0 4.30137606599601e-06
repeat O 0 4.645631634048186e-05
sizes O 0 9.253847565560136e-06
of O 0 1.1517631719470955e-06
1040 O 0 0.00045926676830276847
and O 0 7.1084205046645366e-06
540 O 0 0.0001819091703509912
. O 0 2.4876628231140785e-05

These O 0 2.849635529855732e-05
data O 0 1.323364722338738e-05
suggest O 0 4.25368853029795e-06
that O 0 2.288913520942515e-07
expansion O 0 2.4039418349275365e-06
occurs O 0 8.617447520009591e-07
in O 0 1.4393616254437802e-07
two O 0 1.4147740046155377e-07
stages O 0 6.279114131757524e-06
, O 0 2.309401736511063e-07
the O 0 7.88809728646811e-08
first O 0 2.02489289335972e-07
during O 0 5.198700137043488e-07
meiosis O 0 3.3669125514279585e-06
followed O 0 3.6935850289410155e-07
by O 0 1.3449775337903702e-07
a O 0 3.7477849446077016e-07
second O 0 2.659048050190904e-06
mitotic O 0 0.00015082907339092344
expansion O 0 3.518162338878028e-05
. O 0 1.9100518329651095e-05

We O 0 3.6667013773694634e-05
also O 0 5.76948195885052e-06
show O 0 2.0917584606650053e-06
that O 0 2.606195437238057e-07
in O 0 2.444705557991256e-07
all O 0 1.3322561187578685e-07
informative O 0 2.207229272244149e-06
carrier O 0 1.220571812154958e-05
father O 0 2.760835513981874e-06
to O 0 7.716089953646588e-07
affected O 0 5.285815859679133e-06
child O 0 5.493641765497159e-06
transmissions O 0 2.4505683541065082e-05
, O 0 2.2032239144209598e-07
with O 0 9.203457551620886e-08
the O 0 1.7428740761715744e-07
notable O 0 8.39267102037411e-07
exception O 0 3.9974179344426375e-07
of O 0 8.307799248541414e-08
the O 0 2.580159446097241e-07
premutation O 0 0.00013416275032795966
carrier O 0 3.4231932204420445e-06
, O 0 1.446859556608615e-07
the O 0 1.0462714783443516e-07
expansion O 0 1.8693345964493346e-06
size O 0 2.012396180361975e-06
decreases O 0 1.6166506611625664e-05
. O 0 2.4604846657894086e-06
. O 0 1.0844032658496872e-05

The O 0 8.609871292719617e-05
R496H O 0 0.0011913655325770378
mutation O 0 0.00011026860011043027
of O 0 3.6944024941476528e-06
arylsulfatase O 0 0.0011570475762709975
A O 0 9.16499448067043e-06
does O 0 8.121455721266102e-06
not O 0 4.102125330973649e-06
cause O 0 0.00037352985236793756
metachromatic B-Disease 1 0.999962568283081
leukodystrophy I-Disease 1 0.9999908208847046
. O 0 0.00013328573550097644

Deficiency B-Disease 1 0.999113142490387
of I-Disease 0 3.123043279629201e-05
arylsulfatase I-Disease 0 0.007143552880734205
A I-Disease 0 4.113743852940388e-05
( O 0 3.005662620125804e-05
ARSA O 1 0.5176407098770142
) O 0 1.0427654160594102e-05
enzyme O 0 4.1860053897835314e-05
activity O 0 1.348040132143069e-05
causes O 0 0.00023639015853405
metachromatic B-Disease 1 0.9999555349349976
leukodystrophy I-Disease 1 0.9999986886978149
( O 0 0.00032969884341582656
MLD B-Disease 1 0.9998500347137451
) O 0 3.543422280927189e-05
. O 0 2.0160643543931656e-05

A O 0 5.2505118219414726e-05
number O 0 1.0857422239496373e-05
of O 0 6.698705874441657e-06
ARSA O 1 0.9818679094314575
gene O 0 0.00044732671813108027
mutations O 0 0.00012614612933248281
responsible O 0 1.1607165106397588e-05
for O 0 7.35782759875292e-06
MLD B-Disease 1 0.99998939037323
have O 0 6.505538294732105e-06
been O 0 4.114395778742619e-06
identified O 0 2.4427588869002648e-05
. O 0 2.0244024199200794e-05

Recently O 0 0.0003270332235842943
, O 0 1.3206440598878544e-05
the O 0 3.49373726749036e-06
R496H O 0 0.00023585611779708415
mutation O 0 2.187628524552565e-05
of O 0 1.3435472965284134e-06
ARSA O 0 0.10537732392549515
was O 0 2.1331654806999722e-06
proposed O 0 1.6026061757656862e-06
to O 0 2.847849316367501e-07
be O 0 1.277805239396912e-07
a O 0 6.771618927814416e-07
cause O 0 9.069258339877706e-06
of O 0 3.0385378977371147e-06
MLD B-Disease 1 0.999997615814209
( O 0 3.5522665712051094e-05
Draghia O 0 0.0045950827188789845
et O 0 0.0062227193266153336
al O 0 8.33457670523785e-05
. O 0 9.494861501480045e-07
, O 0 1.0032695172412787e-06
1997 O 0 8.7980370153673e-06
) O 0 4.449765583558474e-06
. O 0 8.32868227007566e-06

We O 0 4.781492680194788e-05
have O 0 4.4251696635910776e-06
investigated O 0 1.425306163582718e-05
the O 0 1.1586774917304865e-06
R496H O 0 0.0002531290811020881
mutation O 0 1.3266248970467132e-05
and O 0 3.8408563796110684e-07
found O 0 5.030797183280811e-07
this O 0 3.112319291176391e-07
mutation O 0 2.8196247967571253e-06
at O 0 1.8846576210762578e-07
a O 0 2.420384248580376e-07
relatively O 0 1.6050656768129556e-06
high O 0 2.2386184355127625e-06
frequency O 0 1.347638203696988e-06
in O 0 1.5095966432454588e-07
an O 0 1.2259492621069512e-07
African O 0 4.895164806839603e-07
American O 0 5.95991821228381e-07
population O 0 3.5886480986846436e-07
( O 0 4.725572750885476e-07
f O 0 1.849338696047198e-05
= O 0 1.3200081411923748e-05
0 O 0 1.1758818345697364e-06
. O 0 1.9062497358390829e-07
09 O 0 3.509197767925798e-06
, O 0 4.3824607587339415e-07
n O 0 2.0436216800590046e-05
= O 0 7.269181514857337e-05
61 O 0 1.8617163732415065e-05
subjects O 0 5.207570211496204e-06
) O 0 7.091913175827358e-06
. O 0 1.2922213500132784e-05

The O 0 8.570068894186988e-05
ARSA O 1 0.6059063076972961
enzyme O 0 0.00037164465175010264
activity O 0 8.244959644798655e-06
in O 0 9.286445674661081e-07
subjects O 0 1.1110126933999709e-06
with O 0 3.8671691982017364e-07
and O 0 7.329439881686994e-07
without O 0 3.385386264653789e-07
the O 0 3.3057941095648857e-07
R496H O 0 0.00016342854360118508
mutation O 0 5.017117018724093e-06
was O 0 2.570115213984536e-07
determined O 0 5.068195036983525e-07
and O 0 1.8843897464648762e-07
found O 0 2.7841588234878145e-07
to O 0 3.42018410037781e-07
be O 0 6.10214954122057e-07
normal O 0 7.972109415277373e-06
. O 0 1.4140917301119771e-05

It O 0 2.182286152674351e-05
is O 0 3.407328222237993e-06
therefore O 0 2.8133019895904e-06
concluded O 0 3.684821422211826e-06
that O 0 1.4291224204043829e-07
the O 0 2.5919777613125916e-07
R496H O 0 6.92821922712028e-05
mutation O 0 5.2971595323469955e-06
of O 0 5.199905217523337e-07
ARSA O 0 0.1138584315776825
does O 0 1.2302245977480197e-06
not O 0 1.9528103223365179e-07
negatively O 0 9.69410507423163e-07
influence O 0 3.8938176771807775e-07
the O 0 1.6734669827656035e-07
activity O 0 4.754607800805388e-07
of O 0 3.424910346438992e-07
ARSA O 0 0.25492820143699646
and O 0 1.4059802424526424e-06
is O 0 4.710710470590129e-07
not O 0 4.397918189624761e-07
a O 0 3.6114663544140058e-06
cause O 0 7.42188494768925e-05
of O 0 4.1709230572450906e-05
MLD B-Disease 1 0.9999336004257202

Down O 0 9.497492283117026e-05
- O 0 0.00015177794557530433
regulation O 0 2.417899486317765e-05
of O 0 4.3219929466431495e-06
transmembrane O 0 0.0003388996119610965
carbonic O 0 0.05234619230031967
anhydrases O 0 0.04317847639322281
in O 0 0.00012967101065441966
renal B-Disease 1 0.9999984502792358
cell I-Disease 1 0.999955415725708
carcinoma I-Disease 1 1.0
cell O 0 0.2188829928636551
lines O 0 1.1663955774565693e-05
by O 0 8.600829914939823e-07
wild O 0 7.527688467234839e-06
- O 0 0.004911698866635561
type O 0 0.0001570738386362791
von B-Disease 1 0.8419743180274963
Hippel I-Disease 1 0.9816185832023621
- I-Disease 0 0.30413374304771423
Lindau I-Disease 1 0.5454933047294617
transgenes O 0 0.0019033916760236025
. O 0 3.3400487154722214e-05

To O 0 9.04389307834208e-05
discover O 0 0.00033863959833979607
genes O 0 4.768755752593279e-05
involved O 0 7.307075520657236e-06
in O 0 6.7235255301056895e-06
von B-Disease 1 0.9384940266609192
Hippel I-Disease 1 0.999600350856781
- I-Disease 1 0.9606199264526367
Lindau I-Disease 1 0.9742240905761719
( O 0 1.2375423466437496e-05
VHL B-Disease 0 0.0016453962307423353
) O 0 3.506574785205885e-06
- O 0 0.00018380051187705249
mediated O 0 0.0005603315075859427
carcinogenesis O 0 0.015182808972895145
, O 0 7.708146654294978e-07
we O 0 2.919691439728922e-07
used O 0 1.2357309060462285e-05
renal B-Disease 1 0.9999955892562866
cell I-Disease 1 0.9980379939079285
carcinoma I-Disease 1 1.0
cell O 0 0.034547220915555954
lines O 0 3.3572323445696384e-05
stably O 0 0.00013787229545414448
transfected O 0 0.00021867988107260317
with O 0 7.305656595235632e-07
wild O 0 1.0008307981479447e-05
- O 0 0.004597632680088282
type O 0 8.281574991997331e-05
VHL O 0 0.06370017677545547
- O 0 0.0012395608937367797
expressing O 0 0.00011390993313398212
transgenes O 0 0.0007814658456481993
. O 0 2.9181537684053183e-05

Large O 0 0.00010067346738651395
- O 0 0.00034381519071757793
scale O 0 4.315048863645643e-05
RNA O 0 1.0610252502374351e-05
differential O 0 5.75331796426326e-06
display O 0 7.637170256202808e-07
technology O 0 2.2227952740649926e-06
applied O 0 6.766067031094281e-07
to O 0 1.1762346474597507e-07
these O 0 1.21853247492254e-07
cell O 0 5.352480002329685e-06
lines O 0 1.8547076479080715e-06
identified O 0 1.0476558145455783e-06
several O 0 3.084699642386113e-07
differentially O 0 7.138597538869362e-06
expressed O 0 1.0968906281050295e-06
genes O 0 8.809025757727795e-07
, O 0 1.3185419334149628e-07
including O 0 1.269449967367109e-07
an O 0 3.2699020380277943e-07
alpha O 0 2.5724626539158635e-05
carbonic O 0 0.005548680201172829
anhydrase O 0 0.0018872907385230064
gene O 0 9.865989341051318e-06
, O 0 2.053387106570881e-06
termed O 0 7.630187610629946e-05
CA12 O 0 0.003890309249982238
. O 0 4.7951227315934375e-05

The O 0 2.426886021567043e-05
deduced O 0 7.50778999645263e-05
protein O 0 1.320404771831818e-05
sequence O 0 2.7595931442192523e-06
was O 0 6.194592856445524e-07
classified O 0 1.1652043667709222e-06
as O 0 1.3034278367740626e-07
a O 0 1.7697395549021167e-07
one O 0 1.325968099763486e-07
- O 0 4.7549150622216985e-05
pass O 0 1.5700900348747382e-06
transmembrane O 0 5.694982246495783e-05
CA O 0 6.971552011236781e-06
possessing O 0 1.6432601341875852e-06
an O 0 3.3034999091796635e-07
apparently O 0 1.978774207600509e-06
intact O 0 3.1174099603958894e-06
catalytic O 0 2.840373554136022e-06
domain O 0 1.2742121953124297e-06
in O 0 2.6355161253377446e-07
the O 0 4.89657054458803e-07
extracellular O 0 2.0663819668698125e-05
CA O 0 4.597583392751403e-05
module O 0 0.00018881923460867256
. O 0 1.726898153719958e-05

Reintroduced O 0 0.00110818597022444
wild O 0 0.00020394823513925076
- O 0 0.003914693836122751
type O 0 0.00010613323684083298
VHL B-Disease 0 0.01163359172642231
strongly O 0 1.6657535525155254e-05
inhibited O 0 2.385502557444852e-05
the O 0 1.1612684147621621e-06
overexpression O 0 2.037952253886033e-05
of O 0 3.43241111977477e-07
the O 0 6.155196956569853e-07
CA12 O 0 0.0006870701909065247
gene O 0 4.3062236727564596e-06
in O 0 5.782723633274145e-07
the O 0 3.0591379527322715e-06
parental O 0 0.058642398566007614
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999871253967285
carcinoma I-Disease 1 1.0
cell O 1 0.8288047313690186
lines O 0 0.00026006493135355413
. O 0 5.4750162234995514e-05

Similar O 0 0.0002074047806672752
results O 0 0.00012564024655148387
were O 0 3.1345516617875546e-06
obtained O 0 4.505885499384021e-06
with O 0 2.4890632630558684e-06
CA9 O 0 0.38422325253486633
, O 0 1.0489685564607498e-06
encoding O 0 2.670448566277628e-06
another O 0 9.053884468812612e-07
transmembrane O 0 3.669013676699251e-05
CA O 0 5.172937108000042e-06
with O 0 2.684330979718652e-07
an O 0 9.809723451326136e-07
intact O 0 3.000318247359246e-05
catalytic O 0 5.156568659003824e-05
domain O 0 3.938034933526069e-05
. O 0 2.2930698833079077e-05

Although O 0 3.501370156300254e-05
both O 0 2.9514285415643826e-06
domains O 0 6.755958565918263e-06
of O 0 9.083124723474612e-07
the O 0 1.276834723284992e-06
VHL B-Disease 0 0.0021170759573578835
protein O 0 8.551342943974305e-06
contribute O 0 1.1791834140240098e-06
to O 0 2.5017806137839216e-07
regulation O 0 1.6416531707363902e-06
of O 0 3.0359402103385946e-07
CA12 O 0 0.0005011596949771047
expression O 0 1.8111096551365335e-06
, O 0 2.1967890972973692e-07
the O 0 2.1667298710781324e-07
elongin O 0 3.084705531364307e-05
binding O 0 3.555218199835508e-06
domain O 0 1.839700644268305e-06
alone O 0 1.6473335335831507e-06
could O 0 1.064806724571099e-06
effectively O 0 7.389288839476649e-06
regulate O 0 8.774983143666759e-05
CA9 O 0 0.0948934331536293
expression O 0 7.202574488474056e-05
. O 0 2.9094315323163755e-05

We O 0 9.050640073837712e-05
mapped O 0 0.0002969019114971161
CA12 O 0 0.004300747998058796
and O 0 3.322420525364578e-05
CA9 O 0 0.23793235421180725
loci O 0 8.8349828729406e-05
to O 0 4.9690802370605525e-06
chromosome O 0 3.179891427862458e-05
bands O 0 1.3019886864640284e-05
15q22 O 0 0.0001029091072268784
and O 0 6.914231562404893e-06
17q21 O 0 0.0005179449217393994
. O 0 4.314612669986673e-05

2 O 0 0.00022356743284035474
respectively O 0 4.0809107304085046e-05
, O 0 4.000478838861454e-06
regions O 0 1.1711439583450556e-05
prone O 0 4.538496432360262e-05
to O 0 1.576827571625472e-06
amplification O 0 6.607564864680171e-05
in O 0 1.5352613900176948e-06
some O 0 2.587890094218892e-06
human O 0 0.00010680452396627516
cancers B-Disease 1 0.57084721326828
. O 0 4.193124550511129e-05

Additional O 0 0.00011128636833745986
experiments O 0 9.53294220380485e-05
are O 0 1.2969791214345605e-06
needed O 0 1.5483594779652776e-06
to O 0 2.868237061193213e-07
define O 0 1.8687891270019463e-06
the O 0 2.8218229886078916e-07
role O 0 6.889705446155858e-07
of O 0 4.1917593307516654e-07
CA O 0 5.328335828380659e-05
IX O 0 0.0005232066032476723
and O 0 4.0506242839910556e-06
CA O 0 5.368961865315214e-05
XII O 0 0.00026218683342449367
enzymes O 0 4.439546046342002e-06
in O 0 1.3540250165533507e-07
the O 0 1.0417672058338212e-07
regulation O 0 9.090048820326047e-07
of O 0 2.0248197074579366e-07
pH O 0 3.793404539464973e-05
in O 0 2.1397842431269964e-07
the O 0 1.6654902879054134e-07
extracellular O 0 2.9347486361075426e-06
microenvironment O 0 2.44293605646817e-05
and O 0 2.1926763338342425e-07
its O 0 5.662677153850382e-07
potential O 0 1.851913339123712e-06
impact O 0 4.1096668610407505e-06
on O 0 2.701488665479701e-05
cancer B-Disease 0 0.19110678136348724
cell O 0 0.0006796919042244554
growth O 0 0.0001322741009062156
. O 0 2.6999770852853544e-05

A O 0 9.43206759984605e-05
gene O 0 4.606132642948069e-05
encoding O 0 1.727804192341864e-05
a O 0 3.3511967103549978e-06
transmembrane O 0 8.635748235974461e-05
protein O 0 8.161891855706926e-06
is O 0 9.097333872887248e-07
mutated O 0 3.277638825238682e-05
in O 0 7.470916898455471e-06
patients O 0 0.014935498125851154
with O 0 0.05679943785071373
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.8832616806030273
optic B-Disease 1 0.9999998807907104
atrophy I-Disease 1 0.9999810457229614
( O 0 0.10683941096067429
Wolfram B-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999998807907104
) O 0 7.7750526543241e-05
. O 0 3.135576844215393e-05

Wolfram B-Disease 1 0.9999980926513672
syndrome I-Disease 1 1.0
( O 0 0.0383368618786335
WFS B-Disease 1 0.9999158382415771
; O 0 0.005132945254445076
OMIM O 1 0.9966520667076111
222300 O 0 0.06938083469867706
) O 0 2.769198181340471e-05
is O 0 1.9571186840039445e-06
an O 0 4.0462746255798265e-05
autosomal B-Disease 1 0.9999723434448242
recessive I-Disease 1 0.9999983310699463
neurodegenerative I-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999191761016846
defined O 0 2.0617757400032133e-05
by O 0 1.35742709517217e-06
young O 0 2.378941462666262e-05
- O 1 0.554618775844574
onset O 1 0.7736753821372986
non O 0 0.0004922279040329158
- O 1 0.951270341873169
immune O 0 0.08708096295595169
insulin B-Disease 0 0.4648051857948303
- I-Disease 1 0.9909259080886841
dependent I-Disease 1 0.9882823824882507
diabetes I-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999996423721313
and O 0 0.0004641851410269737
progressive O 1 0.6775842308998108
optic B-Disease 1 0.9998264908790588
atrophy I-Disease 1 0.5593680143356323
. O 0 8.208533108700067e-05

Linkage O 0 0.0006921147578395903
to O 0 2.0070445316378027e-05
markers O 0 3.275595008744858e-05
on O 0 8.744143087824341e-06
chromosome O 0 0.00018538000585976988
4p O 1 0.7380480170249939
was O 0 4.506624463829212e-06
confirmed O 0 4.7128319238254335e-06
in O 0 6.49665821583767e-07
five O 0 2.8240890515007777e-06
families O 0 2.0733321434818208e-05
. O 0 2.7961059458903037e-05

On O 0 1.7291757103521377e-05
the O 0 2.899650553445099e-06
basis O 0 2.0986240087950137e-06
of O 0 1.0900205325015122e-06
meiotic O 0 0.005693592596799135
recombinants O 1 0.8176738023757935
and O 0 0.0003335381334181875
disease O 0 0.034257855266332626
- O 0 0.0526118241250515
associated O 0 3.045403900614474e-05
haplotypes O 0 9.287550346925855e-05
, O 0 5.546185661842173e-07
the O 0 6.242188419491868e-07
WFS B-Disease 1 0.8941575884819031
gene O 0 5.003098067390965e-06
was O 0 4.418488401825016e-07
localized O 0 3.5838950225297594e-06
to O 0 2.4176895863092795e-07
a O 0 9.01610178516421e-07
BAC O 0 0.0003917048452422023
/ O 0 0.00016225561557803303
P1 O 0 0.0006680296501144767
contig O 0 7.760719017824158e-05
of O 0 2.688591678179364e-07
less O 0 8.119705512399378e-07
than O 0 9.513324243926036e-07
250 O 0 8.294012332044076e-06
kb O 0 0.0007939658244140446
. O 0 3.098695742664859e-05

Mutations O 0 0.009021651931107044
in O 0 1.697993320703972e-05
a O 0 9.00150462257443e-06
novel O 0 2.961490463349037e-05
gene O 0 2.3723445337964222e-05
( O 0 3.609789473557612e-06
WFS1 O 0 0.00031380789005197585
) O 0 7.861134463382768e-07
encoding O 0 8.241306659328984e-07
a O 0 3.1207039796754543e-07
putative O 0 1.1624845683400054e-05
transmembrane O 0 2.6514098863117397e-05
protein O 0 2.1071837181807496e-06
were O 0 1.532533104864342e-07
found O 0 1.657695634094125e-07
in O 0 1.1178725856098026e-07
all O 0 1.1272269517803579e-07
affected O 0 1.5136287174755125e-06
individuals O 0 1.9099400105915265e-07
in O 0 1.9203359613584325e-07
six O 0 2.6513323518884135e-06
WFS B-Disease 1 0.9657317996025085
families O 0 3.2230602755589643e-06
, O 0 2.9713882554460724e-07
and O 0 2.149657092331836e-07
these O 0 3.577013671929308e-07
mutations O 0 1.082981179933995e-05
were O 0 1.8888050590248895e-07
associated O 0 1.5348089164035628e-06
with O 0 2.035410943790339e-06
the O 0 0.00010794739500852302
disease O 0 0.4615258574485779
phenotype O 0 0.12701061367988586
. O 0 5.997736661811359e-05

WFS1 O 0 0.29978272318840027
appears O 0 0.00011771450226660818
to O 0 4.622189408109989e-06
function O 0 3.730629032361321e-06
in O 0 1.1005557780663366e-06
survival O 0 7.053076114971191e-05
of O 0 1.3037440567131853e-06
islet O 0 0.0008512357599101961
beta O 0 0.00033483575680293143
- O 0 0.007282869424670935
cells O 0 5.992282603983767e-05
and O 0 1.454904463571438e-06
neurons O 0 7.682140858378261e-05
. O 0 2.863846930267755e-06
. O 0 1.3558301361626945e-05

Stable O 0 0.0004219079564791173
interaction O 0 1.8625991287990473e-05
between O 0 1.699029212431924e-06
the O 0 5.812225936097093e-07
products O 0 1.641603034840955e-06
of O 0 2.701854668885062e-07
the O 0 7.651196369806712e-07
BRCA1 O 0 0.00014737485616933554
and O 0 1.4855911103950348e-05
BRCA2 O 0 0.05489358305931091
tumor B-Disease 0 0.006566749885678291
suppressor O 0 0.0002772440202534199
genes O 0 5.272112048260169e-06
in O 0 1.0703862471928005e-06
mitotic O 0 0.00012955928104929626
and O 0 1.6676593077136204e-05
meiotic O 0 0.05652224272489548
cells O 0 0.0010206763399764895
. O 0 3.0892893846612424e-05

BRCA1 O 1 0.5452697277069092
and O 0 0.00027211414999328554
BRCA2 O 0 0.05138207599520683
account O 0 1.6478819816256873e-05
for O 0 1.9940714537369786e-06
most O 0 8.527153454451764e-07
cases O 0 1.2664513633353636e-06
of O 0 5.704766294911678e-07
familial O 0 0.056162621825933456
, O 0 2.9199549317127094e-05
early O 0 0.0010981288505718112
onset O 1 0.9980009198188782
breast B-Disease 1 0.7677509188652039
and I-Disease 0 9.353453788207844e-05
/ I-Disease 1 0.997307300567627
or I-Disease 1 0.7017849683761597
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9996336698532104
and O 0 1.3126943940733327e-06
encode O 0 3.1163162930170074e-06
products O 0 1.4050996242076508e-06
that O 0 9.007973744701303e-08
each O 0 1.681945178688693e-07
interact O 0 1.5108712432265747e-06
with O 0 2.2553460894414457e-06
hRAD51 O 0 0.000994015601463616
. O 0 3.519357051118277e-05

Results O 0 0.001164445886388421
presented O 0 4.4446191168390214e-05
here O 0 3.7646029795723734e-06
show O 0 2.359082600378315e-06
that O 0 4.465096878902841e-07
BRCA1 O 0 8.211273234337568e-05
and O 0 7.047146482364042e-06
BRCA2 O 0 0.008431020192801952
coexist O 0 4.174094647169113e-05
in O 0 3.188059167769097e-07
a O 0 7.361459779531287e-07
biochemical O 0 3.0370394597412087e-05
complex O 0 6.150282843009336e-06
and O 0 1.5866837657085853e-06
colocalize O 0 0.0011459175730124116
in O 0 1.5184664334810805e-06
subnuclear O 0 0.0009859162382781506
foci O 0 9.584999497747049e-05
in O 0 6.830302936577937e-07
somatic O 0 6.0526770539581776e-05
cells O 0 1.6868179955054075e-05
and O 0 1.4578945695120638e-07
on O 0 1.3722257108383928e-07
the O 0 1.575136678866329e-07
axial O 0 5.062599484517705e-06
elements O 0 8.456672730972059e-07
of O 0 7.500175911445695e-07
developing O 0 2.803911229420919e-05
synaptonemal O 0 0.003087378107011318
complexes O 0 0.00016280545969493687
. O 0 2.034823592111934e-05

Like O 0 0.00031898877932690084
BRCA1 O 0 0.005880154203623533
and O 0 4.1467621485935524e-05
RAD51 O 0 0.2531644403934479
, O 0 3.832774382317439e-05
BRCA2 O 0 0.0006588452961295843
relocates O 0 0.00011395143519621342
to O 0 2.198731181124458e-06
PCNA O 0 0.0013816297287121415
+ O 0 8.449749293504283e-05
replication O 0 6.192547061800724e-06
sites O 0 7.385544336102612e-07
following O 0 8.579791597185249e-07
exposure O 0 8.01635815150803e-06
of O 0 3.7982817957527004e-07
S O 0 0.018477950245141983
phase O 0 9.830512863118201e-05
cells O 0 2.8953762011951767e-05
to O 0 1.69628651747189e-06
hydroxyurea O 0 0.0010880620684474707
or O 0 1.6603646145085804e-05
UV O 0 0.008294280618429184
irradiation O 0 0.00018474721582606435
. O 0 2.06970489671221e-05

Thus O 0 0.00017724705685395747
, O 0 2.7698137273546308e-05
BRCA1 O 0 0.0004875751619692892
and O 0 1.1451607861090451e-05
BRCA2 O 0 0.0006057889549992979
participate O 0 2.5241620278393384e-06
, O 0 4.2413159917487064e-07
together O 0 4.744877912798984e-07
, O 0 2.98052668767923e-07
in O 0 1.501175148632683e-07
a O 0 5.792824708805711e-07
pathway O 0 1.9211458493373357e-05
( O 0 9.791210686671548e-06
s O 0 0.06044987961649895
) O 0 2.362493432883639e-06
associated O 0 4.5678635274271073e-07
with O 0 9.898477060232835e-08
the O 0 1.6698210458798712e-07
activation O 0 2.154721642000368e-06
of O 0 1.1118399356746522e-07
double O 0 2.1815496893395903e-06
- O 0 0.00014076479419600219
strand O 0 7.437962631229311e-05
break O 0 1.1809337593149394e-05
repair O 0 0.000624489679466933
and O 0 2.8348692922008922e-06
/ O 0 0.0001339814771199599
or O 0 3.803613708441844e-06
homologous O 0 5.2959145250497386e-05
recombination O 0 8.528002945240587e-05
. O 0 2.3442098608938977e-05

Dysfunction O 1 0.6209551095962524
of O 0 1.3826449503540061e-05
this O 0 4.49331673735287e-06
pathway O 0 1.8575079593574628e-05
may O 0 7.009891760390019e-06
be O 0 1.3096878603846562e-07
a O 0 2.864451005279989e-07
general O 0 1.2726236491289455e-06
phenomenon O 0 2.340040964554646e-06
in O 0 1.67972686426765e-07
the O 0 1.5006612841261813e-07
majority O 0 8.761704179960361e-07
of O 0 3.1067000350049057e-07
cases O 0 2.8939375624759123e-06
of O 0 3.487046342343092e-06
hereditary B-Disease 1 0.9981186985969543
breast I-Disease 1 0.9901931285858154
and I-Disease 0 0.0006524171913042665
/ I-Disease 1 0.9997847676277161
or I-Disease 1 0.9770466685295105
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999898672103882
. O 0 1.2020992471661884e-05
. O 0 2.201821371272672e-05

A O 0 0.00015035722753964365
novel O 0 0.00014869689766783267
Arg362Ser O 0 0.007479480002075434
mutation O 0 6.127268716227263e-05
in O 0 1.1348934094712604e-06
the O 0 6.847338909210521e-07
sterol O 0 0.0005955994711257517
27 O 0 3.163186920573935e-05
- O 0 0.00322354887612164
hydroxylase O 0 0.10538249462842941
gene O 0 6.477569058915833e-06
( O 0 7.373671451205155e-07
CYP27 O 0 8.075396908679977e-05
) O 0 5.059893055658904e-07
: O 0 2.0017432689201087e-07
its O 0 2.5174691131724103e-07
effects O 0 1.3314081570570124e-06
on O 0 2.0836763781062473e-07
pre O 0 3.5580130770540563e-06
- O 0 9.585145562596153e-06
mRNA O 0 2.241930133095593e-06
splicing O 0 7.175332029873971e-06
and O 0 7.309601528504572e-07
enzyme O 0 1.7668588043306954e-05
activity O 0 7.356803507718723e-06
. O 0 9.1529236669885e-06

A O 0 8.926740702008829e-05
novel O 0 4.614006320480257e-05
C O 0 4.838595486944541e-05
to O 0 8.22699064428889e-07
A O 0 2.1975781692162855e-06
mutation O 0 4.69808173875208e-06
in O 0 2.891869144150405e-07
the O 0 4.859771820520109e-07
sterol O 0 0.0004974481416866183
27 O 0 2.8149603167548776e-05
- O 0 0.002121051773428917
hydroxylase O 0 0.1291854977607727
gene O 0 7.4810473051911686e-06
( O 0 6.859273753434536e-07
CYP27 O 0 0.00026200589491054416
) O 0 6.313445055639022e-07
was O 0 1.6973903882444574e-07
identified O 0 4.99473742365808e-07
by O 0 1.6029044047627394e-07
sequencing O 0 2.9071959488646826e-06
amplified O 0 1.1470616300357506e-05
CYP27 O 0 0.00031571940053254366
gene O 0 3.377418806849164e-06
products O 0 1.2750058431265643e-06
from O 0 3.6693703009405e-07
a O 0 1.5497969343414297e-06
patient O 0 8.305886149173602e-05
with O 0 2.926308116002474e-05
cerebrotendinous B-Disease 1 0.9999908208847046
xanthomatosis I-Disease 1 0.9999678134918213
( O 0 5.6159839004976675e-05
CTX B-Disease 0 0.2430778592824936
) O 0 1.4617952729167882e-05
. O 0 1.6736817997298203e-05

The O 0 7.573499897262082e-05
mutation O 0 0.00013615703210234642
changed O 0 1.5271702068275772e-05
the O 0 2.107143473040196e-06
adrenodoxin O 0 6.316772487480193e-05
cofactor O 0 3.0323975806823e-05
binding O 0 1.1044355233025271e-05
residue O 0 1.3288230547914281e-05
362Arg O 0 4.031837670481764e-05
to O 0 1.0168755579798017e-06
362Ser O 0 5.632460306514986e-05
( O 0 2.2335475478030276e-06
CGT O 0 0.00012608274118974805
362Arg O 0 5.064249489805661e-05
to O 0 1.4264197716329363e-06
AGT O 0 0.05126752331852913
362Ser O 0 0.00038994834176264703
) O 0 1.5222826732497197e-06
, O 0 3.0038631848583464e-07
and O 0 3.135264137199556e-07
was O 0 6.842716970822948e-07
responsible O 0 1.1917780284420587e-05
for O 0 4.03424164687749e-05
deficiency O 1 0.6422845125198364
in O 0 6.550153557327576e-07
the O 0 5.694205356121529e-07
sterol O 0 0.001394262770190835
27 O 0 1.869571497081779e-05
- O 0 0.0006862858426757157
hydroxylase O 0 0.012915796600282192
activity O 0 8.548200298719166e-07
, O 0 1.211459732530784e-07
as O 0 8.658077632617278e-08
confirmed O 0 3.885082549004437e-07
by O 0 7.011885827523656e-08
expression O 0 2.3930621750878345e-07
of O 0 1.3375917262692383e-07
mutant O 0 1.6748589359849575e-06
cDNA O 0 3.539669478413998e-06
into O 0 5.941043355051079e-07
COS O 0 0.00034802535083144903
- O 0 0.00010188260057475418
1 O 0 1.7177953850477934e-05
cells O 0 7.231507333926857e-05
. O 0 9.100110219151247e-06

Quantitative O 0 0.0016858322778716683
analysis O 0 9.937364666257054e-05
showed O 0 1.061911098076962e-05
that O 0 4.844062573283736e-07
the O 0 2.3779472257956513e-07
expression O 0 7.878997507759777e-07
of O 0 2.0818946211420553e-07
CYP27 O 0 0.00020663374743890017
gene O 0 3.2098707833938533e-06
mRNA O 0 3.4346483062108746e-06
in O 0 3.9976617927095504e-07
the O 0 6.129492362560995e-07
patient O 0 1.662923750700429e-05
represented O 0 5.2817390496784355e-06
52 O 0 3.822451617452316e-05
. O 0 2.0591938664438203e-05

5 O 0 0.00013885337102692574
% O 0 1.725538277241867e-05
of O 0 1.5401636801470886e-06
the O 0 2.1266043859213823e-06
normal O 0 1.3646772458741907e-05
level O 0 1.2789364518539514e-05
. O 0 2.757421498245094e-05

As O 0 3.127853779005818e-05
the O 0 1.1481824003567453e-05
mutation O 0 2.761305404419545e-05
occurred O 0 4.428272859513527e-06
at O 0 6.505549094981689e-07
the O 0 4.1315846033285197e-07
penultimate O 0 1.0193192792939954e-05
nucleotide O 0 3.881629709212575e-06
of O 0 3.0884172019796097e-07
exon O 0 7.293012458831072e-06
6 O 0 2.007177045015851e-06
( O 0 3.5941110354542616e-07
- O 0 4.2413257688167505e-06
2 O 0 5.92011758726585e-07
position O 0 2.038000843640475e-07
of O 0 1.0593317512075373e-07
exon O 0 3.717495474120369e-06
6 O 0 1.829015332077688e-06
- O 0 1.6281714124488644e-05
intron O 0 2.6940124371321872e-05
6 O 0 9.375834224556456e-07
splice O 0 1.3215915714681614e-05
site O 0 4.7603609232282906e-07
) O 0 1.1098293128952719e-07
of O 0 3.167608042531356e-08
the O 0 1.0612509271368253e-07
gene O 0 1.0196946504947846e-06
, O 0 2.2038628344489553e-07
we O 0 1.7537115581944818e-07
hypothesized O 0 2.599994104457437e-06
that O 0 1.6645408607018908e-07
the O 0 3.701060222738306e-07
mutation O 0 9.789828254724853e-06
may O 0 2.4518412828911096e-06
partially O 0 5.2486634558590595e-06
affect O 0 6.895253932270862e-07
the O 0 1.3029792000907037e-07
normal O 0 5.143869543644541e-07
splicing O 0 5.959701411484275e-06
efficiency O 0 3.788199364862521e-06
in O 0 3.248842688208242e-07
exon O 0 6.065201887395233e-06
6 O 0 1.6088157508420409e-06
and O 0 4.070564898484008e-07
cause O 0 1.5402621329485555e-06
alternative O 0 2.1313251181709347e-06
splicing O 0 3.3848082239273936e-05
elsewhere O 0 1.7341460534225916e-06
, O 0 1.993427645174961e-07
which O 0 2.3112434632821532e-07
resulted O 0 1.1720338761733728e-06
in O 0 5.129429041517142e-07
decreased O 0 1.1477280168037396e-05
transcript O 0 3.4104730730177835e-05
in O 0 7.812511171323422e-07
the O 0 2.6138918656215537e-06
patient O 0 0.0002089332847390324
. O 0 2.5462928533670492e-05

Transfection O 0 0.06276123225688934
of O 0 2.4142405891325325e-05
constructed O 0 4.698866905528121e-05
minigenes O 0 0.004640466533601284
, O 0 1.3317993534656125e-06
with O 0 2.7410231950852904e-07
or O 0 3.440105729168863e-07
without O 0 2.7349602760295966e-07
the O 0 1.763056900472293e-07
mutation O 0 1.2125454986744444e-06
, O 0 1.3148388688932755e-07
into O 0 2.5577938345122675e-07
COS O 0 0.005037527997046709
- O 0 0.00016407229122705758
1 O 0 6.846334144938737e-06
cells O 0 1.712972516543232e-05
confirmed O 0 7.92789990100573e-07
that O 0 4.8680377062737534e-08
the O 0 1.1092748053442847e-07
mutant O 0 2.9434540920192376e-06
minigene O 0 9.966015204554424e-05
was O 0 3.008473186127958e-07
responsible O 0 5.848278306075372e-07
for O 0 1.5320027557663707e-07
a O 0 4.0647964283380134e-07
mRNA O 0 4.012556473753648e-06
species O 0 8.51768447773793e-07
alternatively O 0 3.2725054097682005e-06
spliced O 0 2.4874636437743902e-05
at O 0 3.134738051357999e-07
an O 0 4.012979104572878e-07
activated O 0 1.0658009159669746e-05
cryptic O 0 1.6673460777383298e-05
5 O 0 1.3801372915622778e-06
splice O 0 2.022307126026135e-05
site O 0 1.7510453744762344e-06
88 O 0 2.8236283924343297e-06
bp O 0 3.466230191406794e-05
upstream O 0 1.7275831396545982e-06
from O 0 1.9996595312932186e-07
the O 0 1.0778973802416658e-07
3 O 0 7.086897539920756e-07
end O 0 6.99840370543825e-07
of O 0 7.781273438922653e-07
exon O 0 5.397658605943434e-05
6 O 0 2.2690217519993894e-05
. O 0 1.2286614946788177e-05

Our O 0 7.05436832504347e-05
data O 0 3.467308124527335e-05
suggest O 0 6.6252873693883885e-06
that O 0 3.163731889799237e-07
the O 0 1.663850355271279e-07
C O 0 7.404752068396192e-06
to O 0 1.697382430165817e-07
A O 0 6.310056051006541e-07
mutation O 0 2.0549659893731587e-06
at O 0 1.3208979510181962e-07
the O 0 9.938506195794616e-08
penultimate O 0 7.0506557676708326e-06
nucleotide O 0 1.525395646240213e-06
of O 0 8.982598842521838e-08
exon O 0 2.886057927753427e-06
6 O 0 5.515430530067533e-07
of O 0 6.332983559786953e-08
the O 0 1.869859005410035e-07
CYP27 O 0 0.0004056940379086882
gene O 0 2.6535710730968276e-06
not O 0 1.0103818937068354e-07
only O 0 1.3906112883432797e-07
causes O 0 5.541002337849932e-06
the O 0 4.143538717471529e-06
deficiency B-Disease 0 0.08153528720140457
in I-Disease 0 2.8398756057868013e-07
the I-Disease 0 4.3205656652389735e-07
sterol I-Disease 0 0.003309043124318123
27 I-Disease 0 2.150171530956868e-05
- I-Disease 0 0.00020179802959319204
hydroxylase I-Disease 0 0.003593889530748129
activity I-Disease 0 6.375706220751454e-07
, O 0 1.37003283384729e-07
but O 0 8.502073001181998e-08
also O 0 2.637358988977212e-07
partially O 0 3.790118398683262e-06
leads O 0 1.6098944115583436e-06
to O 0 1.808527656521619e-07
alternative O 0 1.6854630757734412e-06
pre O 0 4.314325451559853e-06
- O 0 5.6606922953506e-06
mRNA O 0 2.1859168555238284e-06
splicing O 0 4.998701115255244e-06
of O 0 2.8953516562069126e-07
the O 0 1.2410635008563986e-06
gene O 0 2.3970713300514035e-05
. O 0 1.3614209819934331e-05

To O 0 1.7095962903113104e-05
our O 0 3.869064585160231e-06
knowledge O 0 1.786496341082966e-06
, O 0 3.891107951403683e-07
this O 0 7.819951974852302e-08
is O 0 5.3323375936997763e-08
the O 0 6.644014405310372e-08
first O 0 5.867557320016203e-07
report O 0 2.93430616693513e-06
regarding O 0 8.393118946514733e-07
effects O 0 1.6370067896787077e-06
on O 0 1.9479705315461615e-07
pre O 0 6.950368060643086e-06
- O 0 9.574348041496705e-06
mRNA O 0 8.970610565484094e-07
splicing O 0 1.618015289750474e-06
of O 0 8.952631702641156e-08
a O 0 2.251403827813192e-07
mutation O 0 1.1111028470622841e-06
at O 0 8.308781218602235e-08
the O 0 7.221355957653941e-08
- O 0 6.146963642095216e-06
2 O 0 8.251278131865547e-07
position O 0 3.179551129051106e-07
of O 0 1.1491439266819725e-07
a O 0 6.578719649041886e-07
5 O 0 5.9892950048379134e-06
splice O 0 0.0004446952079888433
site O 0 1.805693500500638e-05
. O 0 1.4005501725478098e-05

ATM O 0 0.17009252309799194
germline O 1 0.995674192905426
mutations O 0 0.004934143740683794
in O 0 1.6481979400850832e-05
classical O 0 0.0018159307073801756
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
patients O 1 0.9509381055831909
in O 0 1.6740157207095763e-06
the O 0 1.8593636923469603e-06
Dutch O 0 7.780407759128138e-05
population O 0 9.101186151383445e-06
. O 0 1.1953954526688904e-05

Germline O 1 0.9942264556884766
mutations O 0 0.003829169785603881
in O 0 9.236321602656972e-06
the O 0 3.0731000606465386e-06
ATM O 0 0.0002751791325863451
gene O 0 1.1072766938013956e-05
are O 0 5.692479021490726e-07
responsible O 0 3.3736880595824914e-06
for O 0 7.06023729435401e-06
the O 0 0.02285465970635414
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0001305317273363471
A B-Disease 0 0.0007421732880175114
- I-Disease 1 0.9975025057792664
T I-Disease 1 0.9999916553497314
) O 0 3.719277083291672e-05
. O 0 1.5036861441330984e-05

In O 0 4.017046740045771e-05
our O 0 1.2047687960148323e-05
study O 0 7.247210760397138e-06
, O 0 1.09648692614428e-06
we O 0 2.0350273643998662e-07
have O 0 1.053717539889476e-07
determined O 0 3.94930964375817e-07
the O 0 1.691932709491084e-07
ATM O 0 8.790946594672278e-05
mutation O 0 5.234707259660354e-06
spectrum O 0 1.5879736565693747e-06
in O 0 2.2937210530926677e-07
19 O 0 1.0719297733885469e-06
classical O 0 4.0269133023684844e-06
A B-Disease 0 0.0024045587051659822
- I-Disease 1 0.999987006187439
T I-Disease 1 1.0
patients O 0 0.02429436892271042
, O 0 2.484909771283128e-07
including O 0 1.2317349273871514e-07
some O 0 1.269630445221992e-07
immigrant O 0 1.932944360305555e-05
populations O 0 1.8374159935774514e-06
, O 0 1.1731851401464155e-07
as O 0 6.487482551165158e-08
well O 0 1.0176676568107723e-07
as O 0 9.847894943959545e-08
12 O 0 3.2973022712212696e-07
of O 0 2.1580501652351813e-07
Dutch O 0 1.2514542504504789e-05
ethnic O 0 5.226924713497283e-06
origin O 0 1.1413904758228455e-05
. O 0 1.5504043403780088e-05

Both O 0 3.123403439531103e-05
the O 0 5.0044391173287295e-06
protein O 0 9.470641089137644e-06
truncation O 0 3.3239382901228964e-05
test O 0 4.466363407118479e-06
( O 0 1.202011844725348e-06
PTT O 0 2.8059497708454728e-05
) O 0 3.583860177513998e-07
and O 0 1.2257540049631643e-07
the O 0 1.7911743555032444e-07
restriction O 0 1.035834543472447e-06
endonuclease O 0 1.9835939383483492e-05
fingerprinting O 0 7.495364843634889e-05
( O 0 1.3949244248578907e-06
REF O 0 0.0003148999821860343
) O 0 5.422583626568667e-07
method O 0 4.25253489311217e-07
were O 0 5.76281706798909e-08
used O 0 1.0924750171170672e-07
and O 0 1.374087901240273e-07
compared O 0 5.26098972386535e-07
for O 0 8.323247158159575e-08
their O 0 2.3113845770694752e-07
detection O 0 5.685833457391709e-06
efficiency O 0 7.484908110200195e-06
, O 0 5.878383717572433e-07
identifying O 0 3.5067489534412744e-06
76 O 0 3.7471095311047975e-06
% O 0 4.461751075268694e-07
and O 0 1.231439057391981e-07
60 O 0 3.758099751394184e-07
% O 0 2.6398200247967907e-07
of O 0 1.1540849698121747e-07
the O 0 1.1849901966343168e-06
mutations O 0 4.4939220970263705e-05
, O 0 1.9140568383591017e-06
respectively O 0 1.9162183889420703e-05
. O 0 1.4405277397600003e-05

Most O 0 0.00026244192849844694
patients O 0 0.006561009678989649
were O 0 2.3545264866697835e-06
found O 0 2.0294585283409106e-06
to O 0 9.03638181171118e-07
be O 0 1.6229729453698383e-06
compound O 0 8.909723692340776e-05
heterozygote O 0 0.0013756661210209131
. O 0 3.742163971764967e-05

Seventeen O 0 0.0010645275469869375
mutations O 0 0.000487859477289021
were O 0 3.006189899679157e-06
distinct O 0 3.883621957356809e-06
, O 0 5.227425958764798e-07
of O 0 1.895635222126657e-07
which O 0 2.9277217095113883e-07
10 O 0 7.060372695377737e-07
were O 0 2.909151817220845e-07
not O 0 9.095182349483366e-07
reported O 0 1.2129849892517086e-05
previously O 0 1.7534001017338596e-05
. O 0 1.7044079868355766e-05

Mutations O 0 0.0045885853469371796
are O 0 6.741953257005662e-06
small O 0 4.179622465017019e-06
deletions O 0 3.791390190599486e-05
or O 0 2.3590398541273316e-06
point O 0 5.522648280020803e-06
mutations O 0 3.808581823250279e-05
frequently O 0 6.72426949677174e-06
affecting O 0 1.433296529285144e-05
splice O 0 0.0009731283062137663
sites O 0 3.2715368433855474e-05
. O 0 1.7962829588213935e-05

Moreover O 0 0.0006002482841722667
, O 0 1.837803574744612e-05
a O 0 1.211678591062082e-05
16 O 0 5.444827547762543e-05
. O 0 4.806032302440144e-05

7 O 0 0.00032335479045286775
- O 0 0.0010942687513306737
kb O 0 0.005659156944602728
genomic O 0 7.946282858029008e-05
deletion O 0 1.80584847839782e-05
of O 0 2.6165855615545297e-07
the O 0 2.0239971831870207e-07
3 O 0 7.928497325337958e-07
end O 0 2.9340216656237317e-07
of O 0 6.761333537497194e-08
the O 0 1.372268911836727e-07
gene O 0 1.2885807336715516e-06
, O 0 1.718838973374659e-07
most O 0 9.934640843312081e-08
likely O 0 2.574786037712329e-07
a O 0 1.7586856415618968e-07
result O 0 3.375724020315829e-07
of O 0 8.379861071716732e-08
recombination O 0 1.446520400349982e-06
between O 0 1.288038617985876e-07
two O 0 1.41687209520569e-07
LINE O 0 1.5305394072129275e-06
elements O 0 1.6706809446986881e-06
, O 0 1.0267781362927053e-06
was O 0 2.136659304596833e-06
identified O 0 2.258990571135655e-05
. O 0 1.759924998623319e-05

The O 0 2.618572034407407e-05
most O 0 4.822297796636121e-06
frequently O 0 7.730851393716875e-06
found O 0 4.087426987098297e-06
mutation O 0 1.0011897757067345e-05
, O 0 8.149386303557549e-07
identified O 0 1.8418493255012436e-06
in O 0 3.1747822504257783e-07
three O 0 6.661817906206124e-07
unrelated O 0 1.1442775758041535e-05
Turkish O 0 6.409237812476931e-06
A B-Disease 0 0.0003221535007469356
- I-Disease 1 0.999396800994873
T I-Disease 1 0.9999973773956299
individuals O 0 1.5822608929738635e-06
, O 0 3.457797959072195e-07
was O 0 3.3674123756100016e-07
previously O 0 1.2089452638974763e-06
described O 0 1.4683948847959982e-06
to O 0 1.1609987637939412e-07
be O 0 8.730911105203631e-08
a O 0 3.0951576945881243e-07
Turkish O 0 5.5924597290868405e-06
A B-Disease 0 0.00019624250126071274
- I-Disease 1 0.9912910461425781
T I-Disease 1 0.9999852180480957
founder O 0 0.009420031681656837
mutation O 0 0.00011635212285909802
. O 0 1.9494793377816677e-05

The O 0 1.8546652427176014e-05
presence O 0 7.207304861367447e-06
of O 0 7.668056127840828e-07
a O 0 1.7383370050083613e-06
founder O 0 0.00022091891150921583
mutation O 0 1.0270054190186784e-05
among O 0 3.168007367548853e-07
relatively O 0 6.279638000705745e-07
small O 0 3.6451578466767387e-07
ethnic O 0 1.2441113312888774e-06
population O 0 3.611035310768784e-07
groups O 0 1.6639583577671146e-07
in O 0 1.1592595683396212e-07
Western O 0 6.621331181122514e-07
Europe O 0 1.717116788313433e-06
could O 0 3.9259671780200733e-07
indicate O 0 7.139068429751205e-07
a O 0 2.77208272336793e-07
high O 0 2.529656512706424e-06
carrier O 0 8.412716852035373e-06
frequency O 0 2.2113272279966623e-06
in O 0 3.607324856602645e-07
such O 0 8.047095434449147e-07
communities O 0 1.5364566934295e-05
. O 0 2.500766822777223e-05

In O 0 0.0005904560093767941
patients O 0 0.0023706238716840744
of O 0 1.7246875358978286e-06
Dutch O 0 4.026193346362561e-05
ethnic O 0 5.81460972171044e-06
origin O 0 2.704607595660491e-06
, O 0 6.292538614616205e-07
however O 0 3.7334049807213887e-07
, O 0 2.711012143663538e-07
no O 0 2.8592410217243014e-07
significant O 0 8.283319630209007e-07
founder O 0 4.481699215830304e-05
effect O 0 4.0477125367033295e-06
could O 0 1.0738052651504404e-06
be O 0 7.232465577544644e-07
identified O 0 1.3223882888269145e-05
. O 0 1.2424417036527302e-05

The O 0 6.758129165973514e-05
observed O 0 0.00010708966146921739
genetic O 0 0.00011683932825690135
heterogeneity O 0 0.00014989670307841152
including O 0 2.371326218053582e-06
the O 0 5.81807114485855e-07
relative O 0 2.423549631203059e-06
high O 0 1.5933725308059365e-06
percentage O 0 1.8055978898701142e-06
of O 0 2.8668316076618794e-07
splice O 0 0.000288495299173519
- O 0 0.0034765731543302536
site O 0 1.4422294952964876e-05
mutations O 0 1.0898119398916606e-05
had O 0 2.1694074803235708e-07
no O 0 2.729576920046384e-07
reflection O 0 3.126645651718718e-06
on O 0 1.3431808838504367e-06
the O 0 5.007346317142947e-06
phenotype O 0 0.005991099402308464
. O 0 3.82278703909833e-05

All O 0 0.00017223652685061097
patients O 0 0.024914128705859184
manifested O 0 0.0003409480268601328
classical O 0 5.075997978565283e-05
A B-Disease 0 0.0003784899599850178
- I-Disease 1 0.9756215810775757
T I-Disease 1 0.9997076392173767
and O 0 1.5713274024165003e-06
increased O 0 3.4374861570540816e-06
cellular O 0 4.650148548535071e-05
radioresistant O 0 0.00038484507240355015
DNA O 0 5.510656410478987e-05
synthesis O 0 8.581313886679709e-05
. O 0 2.4410868718405254e-05

Determination O 0 0.000318526872433722
of O 0 4.923992946714861e-06
the O 0 1.8262162484461442e-06
genomic O 0 1.2126531146350317e-05
structure O 0 1.6061667338362895e-06
of O 0 2.9349283181545616e-07
the O 0 4.804386435353081e-07
COL4A4 O 0 0.0023291625548154116
gene O 0 3.987589934695279e-06
and O 0 3.267292640884989e-07
of O 0 1.029157488119381e-06
novel O 0 0.00021524842304643244
mutations O 0 0.09024125337600708
causing O 1 0.7285776138305664
autosomal B-Disease 1 0.999969482421875
recessive I-Disease 1 0.9999821186065674
Alport I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999985694885254
. O 0 0.0003802526625804603

Autosomal B-Disease 1 0.9999927282333374
recessive I-Disease 1 0.9999971389770508
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
is O 0 0.00010142352402908728
a O 0 4.4153603084851056e-05
progressive O 0 0.4803783595561981
hematuric B-Disease 1 0.9997965693473816
glomerulonephritis I-Disease 1 0.9999997615814209
characterized O 0 0.10456109046936035
by O 0 1.344096745015122e-05
glomerular B-Disease 0 0.049597784876823425
basement I-Disease 0 0.0965631902217865
membrane I-Disease 0 0.003422118490561843
abnormalities I-Disease 1 0.7037171125411987
and O 0 5.4198103498492856e-06
associated O 0 1.226316817337647e-05
with O 0 2.9361453925957903e-06
mutations O 0 3.0375666028703563e-05
in O 0 2.5527543812131626e-07
either O 0 2.933230121016095e-07
the O 0 2.1576651931809465e-07
COL4A3 O 0 0.00020301793119870126
or O 0 4.5762047307107423e-07
the O 0 2.0329693484200106e-07
COL4A4 O 0 0.0020683528855443
gene O 0 2.3730408429400995e-06
, O 0 1.1618572415272865e-07
which O 0 8.13413194578061e-08
encode O 0 4.059795060129545e-07
the O 0 1.0748055956355529e-07
alpha3 O 0 4.461691059987061e-05
and O 0 1.112246764023439e-06
alpha4 O 0 0.0009669343708083034
type O 0 3.306118378532119e-05
IV O 0 0.11384296417236328
collagen O 0 0.0012361753033474088
chains O 0 2.530603887862526e-05
, O 0 3.4966835755767534e-06
respectively O 0 1.8135577192879282e-05
. O 0 1.0953101991617586e-05

To O 0 2.9920496672275476e-05
date O 0 3.349244434502907e-05
, O 0 3.559547167242272e-06
mutation O 0 5.813162715639919e-06
screening O 0 2.080559852402075e-06
in O 0 1.9355599079062813e-07
the O 0 1.0658374804961568e-07
two O 0 2.5215777554876695e-07
genes O 0 1.8621461777001969e-06
has O 0 3.2944922168098856e-07
been O 0 2.5426032834729995e-07
hampered O 0 4.583758709486574e-05
by O 0 2.8381970196278417e-07
the O 0 2.220279640141598e-07
lack O 0 1.2261648407729808e-06
of O 0 5.571361612055625e-07
genomic O 0 2.732818938966375e-05
structure O 0 9.606366802472621e-06
information O 0 5.947726549493382e-06
. O 0 1.084057930711424e-05

We O 0 6.389820191543549e-05
report O 0 2.072424831567332e-05
here O 0 1.660719362917007e-06
the O 0 5.812037784380664e-07
complete O 0 2.0936704459018074e-06
characterization O 0 8.985570275399368e-06
of O 0 2.9943302592982945e-07
the O 0 3.044859511192044e-07
48 O 0 1.610872686796938e-06
exons O 0 4.620047548087314e-06
of O 0 1.9293860020752618e-07
the O 0 2.430142558296211e-07
COL4A4 O 0 0.001576866488903761
gene O 0 2.9255352274049073e-06
, O 0 1.671044458362303e-07
a O 0 3.2053964105216437e-07
comprehensive O 0 9.084407793125138e-06
gene O 0 3.1550384846923407e-06
screen O 0 1.3431488241621992e-06
, O 0 2.1794191695789777e-07
and O 0 1.7920098116519512e-07
the O 0 1.721833058354605e-07
subsequent O 0 2.0298787148931297e-06
detection O 0 6.608603598579066e-06
of O 0 2.75209259825715e-07
10 O 0 2.4442442736472003e-06
novel O 0 1.0830091014213394e-05
mutations O 0 3.555530201992951e-05
in O 0 1.6569779290875886e-06
eight O 0 0.0008674633572809398
patients O 1 0.9829574227333069
diagnosed O 1 0.9996353387832642
with O 0 0.1535620242357254
autosomal B-Disease 1 0.9999978542327881
recessive I-Disease 1 0.9999978542327881
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999994039535522
. O 0 0.00020171263895463198

Furthermore O 0 0.00042373445467092097
, O 0 8.909310963645112e-06
we O 0 1.1940894637518795e-06
identified O 0 1.466458002141735e-06
a O 0 4.663872914534295e-07
glycine O 0 9.196030987368431e-06
to O 0 3.0148493124215747e-07
alanine O 0 9.26073425944196e-06
substitution O 0 9.719525451146183e-07
in O 0 2.2348292816332105e-07
the O 0 2.2634726803971716e-07
collagenous O 0 0.0022443656343966722
domain O 0 1.9282726952951634e-06
that O 0 1.315365665277568e-07
is O 0 1.5301584710414318e-07
apparently O 0 1.4958918654883746e-06
silent O 0 1.3575163393397816e-06
in O 0 2.5002276515806443e-07
the O 0 2.7677455705088505e-07
heterozygous O 0 3.021094244104461e-06
carriers O 0 3.073656898777699e-06
, O 0 5.894416403862124e-07
in O 0 8.958436410466675e-07
11 O 0 8.055487342062406e-06
. O 0 1.4457437828241382e-05

5 O 0 0.00017176878463942558
% O 0 7.5682432907342445e-06
of O 0 5.027617362429737e-07
all O 0 2.135949159765005e-07
control O 0 1.9149370018567424e-06
individuals O 0 5.2021624696863e-07
, O 0 3.26932195093832e-07
and O 0 2.7087017429039406e-07
in O 0 1.8284784175648383e-07
one O 0 1.6075672704118915e-07
control O 0 1.5070174868014874e-06
individual O 0 1.0447853355799452e-06
homozygous O 0 3.5229991226515267e-06
for O 0 3.868028670694912e-07
this O 0 6.321005798781698e-07
glycine O 0 5.556936594075523e-05
substitution O 0 2.631707684486173e-05
. O 0 1.7046972061507404e-05

There O 0 2.4111279344651848e-05
has O 0 3.268207819928648e-06
been O 0 9.274479566556693e-07
no O 0 4.2781127262969676e-07
previous O 0 1.1898368939000648e-06
finding O 0 6.670908874184533e-07
of O 0 8.938538087477355e-08
a O 0 3.5960860600425804e-07
glycine O 0 2.4070151994237676e-05
substitution O 0 1.0009749757955433e-06
that O 0 1.078115374752997e-07
is O 0 1.011205128520487e-07
not O 0 1.0884753720574736e-07
associated O 0 5.130187332724745e-07
with O 0 2.114090733584817e-07
any O 0 5.323714731275686e-07
obvious O 0 5.395774860517122e-05
phenotype O 0 0.05920395627617836
in O 0 7.75488751969533e-06
homozygous O 0 0.00017209140060003847
individuals O 0 1.2514328773249872e-05
. O 0 1.986749703064561e-05

Founder O 0 0.029390832409262657
BRCA1 O 0 0.24284136295318604
and O 0 0.00013462922652252018
BRCA2 O 0 0.437838613986969
mutations O 0 0.000632800511084497
in O 0 4.343591626820853e-06
French O 0 0.00011099874245701358
Canadian O 0 0.0013937923358753324
breast B-Disease 1 0.9989205598831177
and I-Disease 1 0.9743154048919678
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
families O 0 0.0004073338641319424
. O 0 7.547767017967999e-05

We O 0 2.6031375455204397e-05
have O 0 2.7454234441393055e-06
identified O 0 3.8425964703492355e-06
four O 0 1.0924850357696414e-06
mutations O 0 7.516712230426492e-06
in O 0 1.5498470418151555e-07
each O 0 1.1150255119218855e-07
of O 0 3.011705587141478e-07
the O 0 2.3545788280898705e-05
breast B-Disease 1 0.9997392296791077
cancer I-Disease 1 0.9816670417785645
- O 1 0.7672701478004456
susceptibility O 0 0.026988869532942772
genes O 0 5.425006747827865e-06
, O 0 1.0014178997153067e-06
BRCA1 O 0 8.023247210076079e-05
and O 0 2.5226124762411928e-06
BRCA2 O 0 0.0004234767984598875
, O 0 4.910581310468842e-07
in O 0 3.956694740736566e-07
French O 0 2.609453076729551e-05
Canadian O 0 0.0008434472256340086
breast B-Disease 1 0.9983983635902405
cancer I-Disease 1 0.9854190349578857
and O 0 0.03365626558661461
breast B-Disease 1 0.9999986886978149
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
families O 0 2.3947977751959115e-05
from O 0 4.431939942151075e-06
Quebec O 0 0.00014367343101184815
. O 0 2.960476922453381e-05

To O 0 6.029248106642626e-05
identify O 0 0.00014958401152398437
founder O 0 0.000411717570386827
effects O 0 0.00015111741959117353
, O 0 2.5889687549351947e-06
we O 0 7.579225780318666e-07
examined O 0 8.742776117287576e-06
independently O 0 3.1191136713459855e-06
ascertained O 0 1.5104510566743556e-05
French O 0 8.973178410087712e-06
Canadian O 0 7.245595043059438e-05
cancer B-Disease 0 0.0005258000455796719
families O 0 6.42970803710341e-07
for O 0 2.2725028259173996e-07
the O 0 1.7381069028488128e-07
distribution O 0 6.121290994087758e-07
of O 0 2.2435527569086844e-07
these O 0 6.077269745219382e-07
eight O 0 1.175839588540839e-05
mutations O 0 0.00019136612536385655
. O 0 2.1396086594904773e-05

Mutations O 0 0.005636753514409065
were O 0 1.15583861770574e-05
found O 0 4.306913524487754e-06
in O 0 9.814383474804345e-07
41 O 0 4.960074875270948e-06
of O 0 9.617252771931817e-07
97 O 0 4.4277057895669714e-05
families O 0 2.707002204260789e-05
. O 0 2.2994794562691823e-05

Six O 0 6.309986929409206e-05
of O 0 8.062643246375956e-06
eight O 0 1.8580165487946942e-05
mutations O 0 0.00010129902511835098
were O 0 1.428786049473274e-06
observed O 0 3.254267767260899e-06
at O 0 9.21546131849027e-07
least O 0 2.253711954836035e-06
twice O 0 1.191220053442521e-05
. O 0 2.2365131371770985e-05

The O 0 7.369268132606521e-05
BRCA1 O 0 0.0027898731641471386
C4446T O 0 0.004925090353935957
mutation O 0 0.00013990142906550318
was O 0 2.0206616682116874e-06
the O 0 4.728331362002791e-07
most O 0 4.13788171726992e-07
common O 0 6.439590379159199e-06
mutation O 0 1.3710167877434287e-05
found O 0 6.027210588399612e-07
, O 0 2.963306542369537e-07
followed O 0 5.360472528082028e-07
by O 0 4.1132443584501743e-07
the O 0 3.1051972655404825e-06
BRCA2 O 0 0.00475917337462306
8765delAG O 0 0.003584617283195257
mutation O 0 0.00015449413331225514
. O 0 2.7341222448740155e-05

Together O 0 8.652736141812056e-05
, O 0 1.5282788808690384e-05
these O 0 1.6967168221526663e-06
mutations O 0 6.396390745067038e-06
were O 0 1.9843194820623467e-07
found O 0 1.8587860495244968e-07
in O 0 1.8659808631582564e-07
28 O 0 8.937207098824729e-07
of O 0 1.4159104466671124e-07
41 O 0 5.859108568984084e-06
families O 0 1.388421196679701e-06
identified O 0 2.1235182430245914e-06
to O 0 3.055278625652136e-07
have O 0 5.426308007372427e-07
a O 0 4.282670488464646e-06
mutation O 0 0.00013279377890285105
. O 0 1.702728150121402e-05

The O 0 3.8570808101212606e-05
odds O 0 0.0001390306424582377
of O 0 2.6265811357006896e-06
detection O 0 1.8834511138265952e-05
of O 0 3.2630455848448037e-07
any O 0 1.7398613749719516e-07
of O 0 1.9455755762010085e-07
the O 0 4.401052535740746e-07
four O 0 6.283331458689645e-06
BRCA1 O 0 0.06418981403112411
mutations O 0 0.0001330267114099115
was O 0 1.9661806618387345e-06
18 O 0 8.835799235384911e-06
. O 0 1.5526002243859693e-05

7x O 1 0.6498277187347412
greater O 0 0.00015995264402590692
if O 0 5.101857823319733e-06
one O 0 9.064649475476472e-07
or O 0 1.1472905043774517e-06
more O 0 8.270611147054296e-07
cases O 0 9.376170964969788e-06
of O 0 0.0016580793308094144
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999945163726807
were O 0 9.697174618850113e-07
also O 0 7.587434538436355e-07
present O 0 5.764311481470941e-07
in O 0 4.224248755235749e-07
the O 0 1.3459016372507904e-06
family O 0 2.2561318473890424e-05
. O 0 2.7585732823354192e-05

The O 0 2.9129325412213802e-05
odds O 0 0.000115282426122576
of O 0 1.7086127854781807e-06
detection O 0 1.2651122233364731e-05
of O 0 3.69815296608067e-07
any O 0 1.752081573158648e-07
of O 0 1.2221634904108214e-07
the O 0 4.4979759650232154e-07
four O 0 9.573371244187001e-06
BRCA2 O 0 0.181878000497818
mutations O 0 7.322264718823135e-05
was O 0 1.7294638610110269e-06
5 O 0 1.2111367141187657e-05
. O 0 2.0791079805349e-05

3x O 0 0.035462770611047745
greater O 0 6.744775600964203e-05
if O 0 3.754761110030813e-06
there O 0 3.944679747291957e-07
were O 0 2.550829094616347e-07
at O 0 2.596628974060877e-07
least O 0 3.1190879212772415e-07
five O 0 8.083400757641357e-07
cases O 0 2.1068701698823133e-06
of O 0 1.3261353160487488e-05
breast B-Disease 1 0.9998893737792969
cancer I-Disease 1 0.6269928812980652
in O 0 1.918715497595258e-06
the O 0 1.946413931364077e-06
family O 0 2.3758675524732098e-05
. O 0 2.4937295165727846e-05

Interestingly O 0 0.000999626936390996
, O 0 9.605578270566184e-06
the O 0 1.1624273383858963e-06
presence O 0 1.3010152315473533e-06
of O 0 6.709375384161831e-07
a O 0 0.0001905853278003633
breast B-Disease 1 0.9999879598617554
cancer I-Disease 1 0.9848824143409729
case O 0 2.2948437617742456e-05
< O 0 0.0003100111207459122
36 O 0 5.0285752877243795e-06
years O 0 4.9199792329091e-07
of O 0 1.0663011096312403e-07
age O 0 4.3031056407016877e-07
was O 0 2.712977789087745e-07
strongly O 0 1.0642251027093153e-06
predictive O 0 3.050462055398384e-06
of O 0 8.255514671873243e-08
the O 0 1.3153167799373477e-07
presence O 0 2.743576033026329e-07
of O 0 7.140791780102518e-08
any O 0 1.0782819259702592e-07
of O 0 1.3888659111671586e-07
the O 0 5.037148866904317e-07
eight O 0 9.007524568005465e-06
mutations O 0 0.00012249351129867136
screened O 0 3.340192051837221e-05
. O 0 1.3340237273951061e-05

Carriers O 0 0.0001810382673284039
of O 0 5.166335540707223e-06
the O 0 2.3454433630831772e-06
same O 0 2.1616021967929555e-06
mutation O 0 8.07734249974601e-06
, O 0 3.1676898970545153e-07
from O 0 1.222185659344177e-07
different O 0 1.174135420001221e-07
families O 0 4.5059618969389703e-07
, O 0 3.010476348208613e-07
shared O 0 5.56937493456644e-07
similar O 0 2.0060481347172754e-06
haplotypes O 0 0.0005683756899088621
, O 0 1.0382783557361108e-06
indicating O 0 2.365625277889194e-06
that O 0 7.159462711570086e-08
the O 0 1.1536613442331145e-07
mutant O 0 3.3219921533600427e-06
alleles O 0 1.5428819324370124e-06
were O 0 1.1653071396722225e-07
likely O 0 2.917459198670258e-07
to O 0 7.3115536736168e-08
be O 0 6.44707256469701e-08
identical O 0 6.674930546068936e-07
by O 0 2.1624711621370807e-07
descent O 0 4.00897670260747e-06
for O 0 2.0223377816819266e-07
a O 0 1.1023311117241974e-06
mutation O 0 5.802771738672163e-06
in O 0 3.3134921295641107e-07
the O 0 7.845579261811508e-07
founder O 0 0.0001641245762584731
population O 0 8.778760275163222e-06
. O 0 1.2027757293253671e-05

The O 0 2.844953996827826e-05
identification O 0 2.5526556783006527e-05
of O 0 3.069116928600124e-06
common O 0 2.4793549528112635e-05
BRCA1 O 0 0.0017818451160565019
and O 0 4.37849921581801e-05
BRCA2 O 0 0.16439974308013916
mutations O 0 5.321587377693504e-05
will O 0 4.833615321331308e-07
facilitate O 0 1.8879113667935599e-06
carrier O 0 1.3509719792637043e-05
detection O 0 1.5183075447566807e-05
in O 0 1.5238819059959496e-06
French O 0 6.120535545051098e-05
Canadian O 0 0.0011731788981705904
breast B-Disease 1 0.998530387878418
cancer I-Disease 1 0.9929266571998596
and O 0 0.09173931181430817
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999959468841553
families O 0 0.0001851168053690344
. O 0 4.926758992951363e-05

Are O 0 4.913195516564883e-05
Dp71 O 0 0.0016019265167415142
and O 0 3.9001231925794855e-05
Dp140 O 0 0.008717875927686691
brain O 0 0.0032549547031521797
dystrophin O 0 0.0014783722581341863
isoforms O 0 7.593900227220729e-05
related O 0 1.836305636970792e-05
to O 0 5.374598003982101e-06
cognitive B-Disease 0 0.018606657162308693
impairment I-Disease 1 0.9734816551208496
in O 0 0.0007850066758692265
Duchenne B-Disease 1 0.9999986886978149
muscular I-Disease 1 0.9999939203262329
dystrophy I-Disease 1 0.9999940395355225
? O 0 0.0014915696810930967

Molecular O 0 0.00688434112817049
study O 0 0.00013089268759358674
and O 0 1.444189365429338e-05
neuropsychological O 0 0.002049354137852788
analysis O 0 9.75197872321587e-06
were O 0 6.622474302275805e-07
performed O 0 1.2378907285892637e-06
concurrently O 0 1.1434400448706583e-06
on O 0 1.3035128176852595e-06
49 O 0 0.0002868368464987725
patients O 0 0.0008544566808268428
with O 0 0.00010850189573829994
Duchenne B-Disease 1 0.9999997615814209
muscular I-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.019147031009197235
DMD B-Disease 1 0.9999997615814209
) O 0 5.7246111282438505e-06
in O 0 1.759935770451193e-07
order O 0 2.0785695653557923e-07
to O 0 1.96571434685211e-07
find O 0 4.5551215066552686e-07
a O 0 6.083567427594971e-07
molecular O 0 2.8819604267482646e-05
explanation O 0 2.8516374186438043e-06
for O 0 5.370505959945149e-07
the O 0 3.7583538414764917e-06
cognitive B-Disease 0 0.004284973721951246
impairment I-Disease 0 0.32103750109672546
observed O 0 2.245151154056657e-05
in O 0 8.058599632931873e-06
most O 0 0.00011661581083899364
DMD B-Disease 1 0.9999998807907104
patients O 1 0.8571907877922058
. O 0 6.06317407800816e-05

Complete O 0 0.00019786095072049648
analysis O 0 2.8422262403182685e-05
of O 0 1.571552161294676e-06
the O 0 1.3090376569380169e-06
dystrophin O 0 0.0006128641543909907
gene O 0 5.962742761767004e-06
was O 0 3.617556956214685e-07
performed O 0 4.074200035120157e-07
to O 0 1.260299171690349e-07
define O 0 8.352173495040915e-07
the O 0 9.885231833095531e-08
localization O 0 2.5489159725111676e-06
of O 0 1.673693645898311e-07
deletions O 0 8.258850357378833e-06
and O 0 5.744226427850663e-07
duplications O 0 1.01200639619492e-05
in O 0 3.809251438724459e-07
relation O 0 1.169532879430335e-06
to O 0 3.9042666344357713e-07
the O 0 9.46253635447647e-07
different O 0 7.691544851695653e-06
DMD B-Disease 1 0.9999934434890747
promoters O 0 0.00888686440885067
. O 0 4.510081635089591e-05

Qualitative O 0 0.0006996791344136
analysis O 0 3.2867912523215637e-05
of O 0 1.9309059098304715e-06
the O 0 1.1277124940534122e-06
Dp71 O 0 0.00016892474377527833
transcript O 0 3.274908158346079e-05
and O 0 7.431568178617454e-07
testing O 0 9.372168392474123e-07
for O 0 1.262501712062658e-07
the O 0 1.2175486574506067e-07
specific O 0 2.0172045367417013e-07
first O 0 2.2908267283128225e-07
exon O 0 2.61834793491289e-06
of O 0 1.337594284223087e-07
Dp140 O 0 1.646873352001421e-05
were O 0 2.191919463712111e-07
also O 0 4.507311359702726e-07
carried O 0 1.3174337709642714e-06
out O 0 2.629122263897443e-06
. O 0 1.7086313164327294e-05

Neuropsychological O 1 0.7756156921386719
analysis O 0 0.0010170344030484557
assessed O 0 0.00025301158893853426
verbal O 0 7.86146119935438e-05
and O 0 7.72561088524526e-06
visuospatial O 0 0.009559662081301212
intelligence O 0 6.90815068082884e-05
, O 0 1.9257181520515587e-06
verbal O 0 9.654850146034732e-06
memory O 0 2.9366938179009594e-05
, O 0 1.5103698842722224e-06
and O 0 7.452774752891855e-07
reading O 0 8.855235137161799e-06
skills O 0 4.601676118909381e-05
. O 0 2.6856781914830208e-05

Comparison O 0 0.00011258428276050836
of O 0 7.663182259420864e-06
molecular O 0 6.637771002715454e-05
and O 0 5.140965186001267e-06
psychometric O 0 0.0030360938981175423
findings O 0 0.0001448708208044991
demonstrated O 0 7.829704372852575e-06
that O 0 3.9618487335246755e-07
deletions O 0 4.271098987373989e-06
and O 0 5.65717698464141e-07
duplications O 0 8.179362339433283e-06
that O 0 1.102941382669087e-07
were O 0 1.356765295668083e-07
localized O 0 5.153620350029087e-06
in O 0 2.4546835675209877e-07
the O 0 2.9645781296494533e-07
distal O 0 8.224791963584721e-05
part O 0 3.662214282940113e-07
of O 0 9.326644345719615e-08
the O 0 2.376414727223164e-07
gene O 0 1.1383556284272345e-06
seemed O 0 5.575943760049995e-07
to O 0 1.2703037555183982e-07
be O 0 2.015029849644634e-07
preferentially O 0 8.919623724068515e-06
associated O 0 4.445006652531447e-06
with O 0 8.996828910312615e-06
cognitive B-Disease 0 0.009669037535786629
impairment I-Disease 0 0.32438164949417114
. O 0 6.021841909387149e-05

Two O 0 4.287971023586579e-05
altered O 0 0.00011725317017408088
Dp71 O 0 0.00034592184238135815
transcripts O 0 2.2013195120962337e-05
and O 0 6.336765068226669e-07
two O 0 3.190111783624161e-07
deleted O 0 3.7544282349699643e-06
Dp140 O 0 1.4472887414740399e-05
DNA O 0 3.3652754609647673e-06
sequences O 0 6.587961252080277e-07
were O 0 1.3307172253007593e-07
found O 0 2.817367033003393e-07
in O 0 4.851760309065867e-07
four O 0 2.628364563861396e-05
patients O 0 0.04542141407728195
with O 0 0.001844481797888875
severe O 1 0.9999897480010986
cerebral B-Disease 1 0.9999847412109375
dysfunction I-Disease 1 0.9989281296730042
. O 0 0.00015073848771862686

These O 0 5.16634427185636e-05
findings O 0 0.0001039723283611238
suggest O 0 7.667013051104732e-06
that O 0 2.8868484491795243e-07
some O 0 1.5127238839340862e-07
sequences O 0 4.4217850359018485e-07
located O 0 1.6752441922562866e-07
in O 0 8.572172305321146e-08
the O 0 1.199210828417563e-07
distal O 0 2.907104317273479e-05
part O 0 3.174334040068061e-07
of O 0 9.030182468450221e-08
the O 0 1.4309881635199417e-07
gene O 0 1.3710185839954647e-06
and O 0 3.2872017641238926e-07
, O 0 3.508052657252847e-07
in O 0 1.686880040097094e-07
particular O 0 3.3873271831907914e-07
, O 0 5.373534008867864e-07
some O 0 4.3121187331962574e-07
DMD B-Disease 1 0.9999572038650513
isoforms O 0 2.5678571546450257e-05
expressed O 0 1.3862752439308679e-06
in O 0 4.364887900010217e-07
the O 0 1.4156040606394527e-06
brain O 0 0.012522765435278416
may O 0 1.3771547855867539e-05
be O 0 1.8510820609662915e-07
related O 0 1.4114466466708109e-06
to O 0 4.120503831472888e-07
the O 0 2.327415131730959e-06
cognitive B-Disease 0 0.01186902541667223
impairment I-Disease 1 0.9128778576850891
associated O 0 5.403849354479462e-05
with O 0 3.737235238077119e-05
DMD B-Disease 1 0.9999997615814209
. O 0 5.5176704336190596e-05
. O 0 2.8143402232672088e-05

I1307K O 0 0.006122026592493057
APC O 0 0.003551796544343233
and O 0 3.230526272091083e-05
hMLH1 O 0 0.0032327533699572086
mutations O 0 0.00011000897211488336
in O 0 7.107812507456401e-07
a O 0 7.628966613992816e-07
non O 0 1.580955540703144e-05
- O 0 0.00047929902211762965
Jewish O 0 1.0903910151682794e-05
family O 0 2.738013563430286e-06
with O 0 6.455288712459151e-06
hereditary B-Disease 1 0.950366735458374
non I-Disease 1 0.9584271907806396
- I-Disease 1 0.9999995231628418
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999953508377075
. O 0 0.00016720076382625848

We O 0 2.831377787515521e-05
describe O 0 3.373149593244307e-05
a O 0 3.4647305255930405e-06
French O 0 3.697746433317661e-05
Canadian O 0 6.669934373348951e-05
hereditary B-Disease 0 0.3013308644294739
non I-Disease 1 0.6617766618728638
- I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0012702220119535923
HNPCC B-Disease 1 0.9992901086807251
) O 0 1.1361030374246184e-05
kindred O 0 0.00010001954797189683
which O 0 5.034949026594404e-07
carries O 0 1.130984514929878e-06
a O 0 1.0646868986441405e-06
novel O 0 7.051381544442847e-06
truncating O 0 0.0005837645730935037
mutation O 0 5.353020969778299e-05
in O 0 3.6364674542710418e-06
hMLH1 O 0 0.0007552673923783004
. O 0 3.860944707412273e-05

Interestingly O 0 0.0011167252669110894
, O 0 1.2233253983140457e-05
the O 0 1.8545359807831119e-06
I1307K O 0 0.00016854456043802202
APC O 0 0.0003054447297472507
polymorphism O 0 3.952319821109995e-05
, O 0 1.1200959306734148e-06
associated O 0 6.951381692488212e-07
with O 0 2.0121589727750688e-07
an O 0 8.140376053233922e-07
increased O 0 3.28519927279558e-05
risk O 0 0.0006713551701977849
of O 0 0.009096385911107063
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
, O 0 6.39691506876261e-06
is O 0 4.7311144157902163e-07
also O 0 5.464784749165119e-07
present O 0 6.249735520214017e-07
in O 0 5.417688271336374e-07
this O 0 1.0463209036970511e-06
family O 0 2.652345210663043e-05
. O 0 3.309240855742246e-05

The O 0 4.842302223551087e-05
I1307K O 0 0.0006576113519258797
polymorphism O 0 0.00018013393855653703
has O 0 3.006926590387593e-06
previously O 0 2.8634399313887116e-06
only O 0 2.1182238185701863e-07
been O 0 3.6805363379244227e-07
identified O 0 1.0710621154430555e-06
in O 0 2.8921974148943264e-07
individuals O 0 2.3504003365815151e-07
of O 0 2.895879163133941e-07
self O 0 0.00010613647464197129
- O 0 0.4852558374404907
reported O 0 0.00018935398838948458
Ashkenazi O 0 0.0003931621613446623
Jewish O 0 1.6033971405704506e-05
origins O 0 4.260185960447416e-05
. O 0 1.8975568309542723e-05

In O 0 4.9587219109525904e-05
addition O 0 1.2384196452330798e-05
, O 0 2.090258931275457e-06
in O 0 5.427731366580701e-07
this O 0 2.2757191686650913e-07
family O 0 2.430739186820574e-06
, O 0 9.817370028031291e-07
there O 0 1.1389622756041717e-07
appears O 0 6.720197234244552e-07
to O 0 1.2084191780559195e-07
be O 0 6.69299637934273e-08
no O 0 1.194043477426021e-07
relationship O 0 3.881619932144531e-07
between O 0 1.5518141083248338e-07
the O 0 2.3748765443087905e-07
I1307K O 0 5.85213492740877e-05
polymorphism O 0 5.046296791988425e-06
and O 0 1.6378689338125696e-07
the O 0 1.249516259349548e-07
presence O 0 5.8184429008179e-07
or O 0 5.941978429291339e-07
absence O 0 5.434824743133504e-06
of O 0 5.328282895789016e-06
cancer B-Disease 0 0.06527214497327805
. O 0 6.011985988152446e-06
. O 0 1.5936286217765883e-05

Identification O 0 9.532078547636047e-05
of O 0 3.746108859559172e-06
a O 0 2.6475752292753896e-06
novel O 0 6.865032446512487e-06
mutation O 0 3.64824995813251e-06
of O 0 2.3130868953558092e-07
the O 0 3.9738591794957756e-07
CPO O 0 0.00013718970876652747
gene O 0 1.870470555331849e-06
in O 0 1.727883187641055e-07
a O 0 7.537031478932477e-07
Japanese O 0 5.641750249196775e-05
hereditary B-Disease 0 0.03388110175728798
coproporphyria I-Disease 0 0.2036287486553192
family O 0 9.192566358251497e-05
. O 0 3.8276535633485764e-05

Hereditary B-Disease 1 0.9948638081550598
coproporphyria I-Disease 1 0.9925122261047363
( O 0 0.0029518536757677794
HCP B-Disease 1 0.9934607744216919
) O 0 3.7785117456223816e-05
is O 0 2.6095754037669394e-06
an O 0 8.279898793261964e-06
autosomal B-Disease 1 0.9747636318206787
dominant I-Disease 1 0.9701085090637207
disease I-Disease 1 0.9518609642982483
characterized O 0 0.006740460637956858
by O 0 4.727583018393489e-06
a O 0 4.974260809831321e-05
deficiency B-Disease 1 0.5884992480278015
of I-Disease 0 9.586384521753644e-07
coproporphyrinogen I-Disease 0 0.10245654731988907
oxidase I-Disease 0 0.00014532447676174343
( O 0 4.134602022531908e-06
CPO O 0 0.0001969800068764016
) O 0 8.865154086379334e-07
caused O 0 1.0578855835774448e-06
by O 0 1.4931538316886872e-07
a O 0 6.739786044818175e-07
mutation O 0 5.40633618584252e-06
in O 0 4.315368755669624e-07
the O 0 1.7983562656809227e-06
CPO O 0 0.0008119178237393498
gene O 0 4.7907531552482396e-05
. O 0 1.694352067715954e-05

Only O 0 2.7201253033126704e-05
11 O 0 4.199964314466342e-05
mutations O 0 2.201187271566596e-05
of O 0 7.578748864034424e-07
the O 0 7.190452038230433e-07
gene O 0 4.522123617789475e-06
have O 0 3.978963434292382e-07
been O 0 7.421263035212178e-07
reported O 0 1.8495466065360233e-05
in O 0 1.585975223861169e-05
HCP B-Disease 1 0.9998053908348083
patients O 0 0.04699033126235008
. O 0 3.150719930999912e-05

We O 0 6.294091872405261e-05
report O 0 2.2942882424104027e-05
another O 0 3.723718918990926e-06
mutation O 0 1.277031515201088e-05
in O 0 1.0154645906368387e-06
a O 0 2.6002744561992586e-06
Japanese O 0 4.0947685192804784e-05
family O 0 4.363106199889444e-05
. O 0 3.233358802390285e-05

Polymerase O 0 0.0018729281146079302
chain O 0 0.000271466065896675
reaction O 0 2.767669502645731e-05
- O 0 3.054298213100992e-05
single O 0 2.8598783501365688e-06
strand O 0 3.818433469859883e-05
conformational O 0 1.772907853592187e-05
polymorphism O 0 6.440044671762735e-06
and O 0 3.293282873073622e-07
direct O 0 6.20263165274082e-07
sequence O 0 1.5375881048385054e-06
analyses O 0 3.1032227525429334e-06
demonstrated O 0 1.1558587402760168e-06
a O 0 3.2655515269652824e-07
C O 0 1.2788096682925243e-05
to O 0 3.7984847267580335e-07
T O 0 0.00014305251534096897
substitution O 0 5.753370828642801e-07
in O 0 1.4156647409890866e-07
exon O 0 1.2647857374759042e-06
1 O 0 1.8700249881931086e-07
of O 0 4.532812880597703e-08
the O 0 1.0581523923747227e-07
CPO O 0 2.7942856831941754e-05
gene O 0 6.978702344895282e-07
at O 0 1.2393986992265127e-07
nucleotide O 0 1.2957058288520784e-06
position O 0 3.5034557299695734e-07
85 O 0 1.0747826308943331e-06
, O 0 1.3613339433504734e-07
which O 0 8.768611792220327e-08
lies O 0 5.807527827528247e-07
in O 0 1.501609006027138e-07
the O 0 2.4845212465152144e-07
putative O 0 1.947296186699532e-05
presequence O 0 5.9404737839940935e-05
for O 0 4.0076474761008285e-07
targeting O 0 6.283996754063992e-06
to O 0 2.2831459318695124e-06
mitochondria O 0 0.00010737372213043272
. O 0 2.1547979486058466e-05

This O 0 4.506908589974046e-05
mutation O 0 6.975293945288286e-05
changes O 0 4.48021455667913e-06
the O 0 6.172213602440024e-07
codon O 0 3.8006585327821085e-06
for O 0 3.257377443333098e-07
glutamine O 0 1.1129650374641642e-05
to O 0 1.9743151824513916e-07
a O 0 4.1319077581647434e-07
termination O 0 8.525473276677076e-06
codon O 0 3.615974037529668e-06
at O 0 3.60051302550346e-07
amino O 0 2.685247409317526e-06
acid O 0 2.660081554495264e-05
position O 0 5.254703864920884e-06
29 O 0 2.400743142061401e-05
. O 0 1.667605283728335e-05

MaeI O 0 0.007133168168365955
restriction O 0 8.307961979880929e-05
analysis O 0 2.163660610676743e-05
showed O 0 4.869300482823746e-06
two O 0 3.9736355006425583e-07
other O 0 3.1716891157884675e-07
carriers O 0 2.4550233774789376e-06
in O 0 5.477411946230859e-07
the O 0 1.4146390867608716e-06
family O 0 1.8274833564646542e-05
. O 0 2.9722306862822734e-05

The O 0 5.972219514660537e-05
C O 0 0.0009463030728511512
- O 0 0.2022051066160202
T O 1 0.8673034906387329
mutation O 0 1.6870046238182113e-05
is O 0 1.9203433510028844e-07
located O 0 1.8187965622473712e-07
within O 0 8.416012065026734e-08
a O 0 2.43571122382491e-07
recently O 0 1.9193230400560424e-06
proposed O 0 2.253653974548797e-06
putative O 0 1.073434941645246e-05
alternative O 0 2.702194478843012e-06
translation O 0 1.8027038777290727e-06
initiation O 0 2.852107627404621e-06
codon O 0 6.781669981137384e-06
( O 0 1.0131519729839056e-06
TIC O 0 4.272077785572037e-05
- O 0 2.8286469387239777e-05
1 O 0 1.2162028042439488e-06
) O 0 2.468891864282341e-07
, O 0 1.1458160997790401e-07
supporting O 0 3.321601127481699e-07
that O 0 1.9902553560768865e-07
TIC O 0 9.018280252348632e-05
- O 0 2.2914675355423242e-05
1 O 0 7.811885325281764e-07
is O 0 9.919814658587711e-08
the O 0 1.3627577288843895e-07
real O 0 2.567261162766954e-06
TIC O 0 8.429389708908275e-05
rather O 0 4.3912254454880895e-07
than O 0 3.8916161315682984e-07
TIC O 0 7.446861127391458e-05
- O 0 4.533470200840384e-05
2 O 0 5.700096153304912e-06
. O 0 2.9867744615330594e-06
. O 0 1.132272882387042e-05

Human B-Disease 0 0.0005374308093450963
complement I-Disease 0 0.0005509670590981841
factor I-Disease 0 0.002662303391844034
H I-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999866485595703
associated O 0 0.011610141955316067
with O 0 0.2736879885196686
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0014332571299746633

This O 0 3.767745874938555e-05
study O 0 1.9120274373563007e-05
reports O 0 5.193063771002926e-06
on O 0 7.981541330082109e-07
six O 0 4.589566287904745e-06
cases O 0 7.3485994107613806e-06
of O 0 9.88479678198928e-06
deficiency B-Disease 1 0.9402622580528259
in I-Disease 0 5.657916517520789e-07
the I-Disease 0 2.2378451092208707e-07
human I-Disease 0 5.506065008376027e-07
complement I-Disease 0 1.786721327334817e-06
regulatory I-Disease 0 8.573309060011525e-06
protein I-Disease 0 7.427837317663943e-06
Factor I-Disease 0 4.105659172637388e-06
H I-Disease 1 0.9982775449752808
( O 0 1.2209804481244646e-05
FH O 0 0.14221106469631195
) O 0 4.6912535367482633e-07
in O 0 1.0145667062033681e-07
the O 0 1.1956889522934944e-07
context O 0 1.0055005077447277e-06
of O 0 2.0972956917830743e-06
an O 0 0.010048164054751396
acute B-Disease 1 0.9999998807907104
renal I-Disease 1 1.0
disease I-Disease 1 0.9999991655349731
. O 0 0.0003187744878232479

Five O 0 3.3201016776729375e-05
of O 0 2.5891959012369625e-06
the O 0 1.4213601389201358e-06
cases O 0 2.0787251742149238e-06
were O 0 3.5331834169483045e-07
observed O 0 2.191053226852091e-06
in O 0 9.82535880211799e-07
children O 0 7.908200132078491e-06
presenting O 0 0.0008388194255530834
with O 1 0.6293861269950867
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.2118436098098755
HUS B-Disease 1 0.9999985694885254
) O 0 0.00024391632177866995
. O 0 4.377113145892508e-05

Two O 0 1.3908018445363268e-05
of O 0 3.2588984595349757e-06
the O 0 1.7823474536271533e-06
children O 0 6.4923870013444684e-06
exhibited O 0 4.545747651718557e-05
a O 0 7.569932495243847e-05
homozygous O 1 0.9048557281494141
deficiency O 1 0.9993489384651184
characterized O 0 0.0007164095295593143
by O 0 5.551906951950514e-07
the O 0 2.0869813965873618e-07
absence O 0 6.32503997621825e-07
of O 0 7.8644660561622e-08
the O 0 1.2220749567859457e-07
150 O 0 9.708816151032806e-07
- O 0 7.75399457779713e-05
kD O 0 0.00025243283016607165
form O 0 2.48354496079628e-07
of O 0 9.605064121842588e-08
Factor O 0 8.630079832983029e-07
H O 0 0.36666035652160645
and O 0 3.261349945660186e-07
the O 0 1.272030090149201e-07
presence O 0 2.8277037245061365e-07
, O 0 1.8738650453542505e-07
upon O 0 2.7564922788769763e-07
immunoblotting O 0 2.959342054964509e-05
, O 0 1.1663022547736546e-07
of O 0 4.010568233070444e-08
the O 0 9.282668145260686e-08
42 O 0 1.20083166166296e-06
- O 0 4.339942097431049e-05
kD O 0 0.0003351643681526184
Factor O 0 1.6107406963783433e-06
H O 0 0.009174437262117863
- O 0 1.5036817785585299e-05
like O 0 3.3374649888173735e-07
protein O 0 9.283957069783355e-07
1 O 0 6.914007144587231e-07
( O 0 5.619676812784746e-07
FHL O 0 0.00010084440873470157
- O 0 1.438915751350578e-05
1 O 0 7.067688443385123e-07
) O 0 1.9535964668193628e-07
and O 0 1.1105704089686697e-07
other O 0 3.604810956403526e-07
FH O 0 0.4828759431838989
- O 0 0.0017800183268263936
related O 0 1.3964955542178359e-05
protein O 0 5.72478529647924e-06
( O 0 1.8767403844321962e-06
FHR O 0 0.00031445472268387675
) O 0 3.441999751885305e-06
bands O 0 1.9361339582246728e-05
. O 0 1.2853262887801975e-05

Southern O 0 0.0004564988485071808
blot O 0 0.004135692026466131
and O 0 1.0254971130052581e-05
PCR O 0 9.065635094884783e-05
analysis O 0 3.8582247725571506e-06
of O 0 4.059090201735671e-07
DNA O 0 4.706741492555011e-06
of O 0 2.1180539988563396e-07
one O 0 1.006011643767124e-06
patient O 0 0.00013034266885370016
with O 0 3.3397082006558776e-05
homozygous O 0 0.49775296449661255
deficiency O 1 0.9564837217330933
ruled O 0 5.725320988858584e-06
out O 0 2.0460301186631114e-07
the O 0 1.1678336875320383e-07
presence O 0 1.9968410924775526e-07
of O 0 6.648907913131552e-08
a O 0 2.3550785499537596e-07
large O 0 9.829886948864441e-07
deletion O 0 7.739814464002848e-06
of O 0 1.5534872943590017e-07
the O 0 7.216673907350923e-07
FH O 0 0.14848659932613373
gene O 0 2.4706541807972826e-06
as O 0 1.9339637447046698e-07
the O 0 3.5666249686983065e-07
underlying O 0 8.683055057190359e-05
defect O 0 0.00026195222744718194
for O 0 2.814396793837659e-06
the O 0 3.5208613553550094e-05
deficiency O 1 0.935766339302063
. O 0 5.5918291764101014e-05

The O 0 1.5875702956691384e-05
other O 0 3.4565523492346983e-06
four O 0 1.8439092173139215e-06
children O 0 2.710298304009484e-06
presented O 0 1.1705767064995598e-05
with O 0 2.4810862669255584e-05
heterozygous O 0 0.01847270503640175
deficiency O 1 0.9770984649658203
and O 0 4.880923825112404e-06
exhibited O 0 1.4154140444588847e-05
a O 0 7.779597126500448e-07
normal O 0 4.376335709821433e-06
immunoblotting O 0 0.0003578189935069531
pattern O 0 4.8425245040562e-06
of O 0 2.0748046836160938e-07
proteins O 0 5.382709673540376e-07
of O 0 2.811213164477522e-07
the O 0 1.9749224975385005e-06
FH O 1 0.6146025657653809
family O 0 4.7852830903138965e-05
. O 0 1.7377355106873438e-05

Factor B-Disease 0 0.14053399860858917
H I-Disease 1 0.9999984502792358
deficiency I-Disease 1 0.9996722936630249
is O 0 3.235631993447896e-06
the O 0 1.5250609521899605e-06
only O 0 2.2505932975036558e-06
complement B-Disease 0 0.44187498092651367
deficiency I-Disease 1 0.9999927282333374
associated O 0 9.938577568391338e-05
with O 0 5.501876148628071e-05
HUS B-Disease 1 0.9999912977218628
. O 0 0.00012976786820217967

These O 0 3.590130290831439e-05
observations O 0 5.9870511904591694e-05
suggest O 0 1.499462996434886e-05
a O 0 2.4892221972550033e-06
role O 0 2.954196816062904e-06
for O 0 2.4387147732340964e-06
FH O 1 0.9161338210105896
and O 0 1.1677145266730804e-05
/ O 0 0.001964885974302888
or O 0 6.779012437618803e-06
FH O 1 0.7092731595039368
receptors O 0 6.187193503137678e-05
in O 0 7.996574140634038e-07
the O 0 2.0190129816910485e-06
pathogenesis O 0 0.011048195883631706
of O 0 3.8004251109668985e-05
idiopathic O 1 0.9999986886978149
HUS B-Disease 1 0.9999990463256836
. O 0 6.785826553823426e-05
. O 0 3.7497047742363065e-05

Further O 0 7.676582754356787e-05
evidence O 0 1.6029140169848688e-05
for O 0 1.5879766124271555e-06
a O 0 2.2050874122214736e-06
major O 0 6.4833229771465994e-06
ancient O 0 3.9774677134118974e-05
mutation O 0 0.0015320429811254144
underlying O 0 0.08856827020645142
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999997615814209
from O 0 2.8426386052160524e-05
linkage O 0 0.0006198522169142962
disequilibrium O 0 0.02884061448276043
studies O 0 1.0765833394543733e-05
in O 0 7.247559210554755e-07
the O 0 8.909531743483967e-07
Japanese O 0 2.8350714273983613e-05
population O 0 1.3486175703292247e-05
. O 0 1.8341004761168733e-05

The O 0 0.0036485602613538504
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 1.0
( O 1 0.7424203753471375
DM B-Disease 1 1.0
) O 0 0.0007648438913747668
mutation O 0 5.417724241851829e-05
is O 0 7.820382847967267e-07
an O 0 1.1323529633955332e-06
unstable O 0 0.001476457342505455
( O 0 8.776759386819322e-06
CTG O 0 0.0035481094382703304
) O 0 2.471545030857669e-06
n O 0 3.4900258469861e-05
repeat O 0 1.6199041056097485e-05
, O 0 2.1794897975269123e-07
present O 0 1.2073972754933493e-07
at O 0 6.765009885612017e-08
a O 0 1.0187162757802071e-07
copy O 0 7.088830784596212e-07
number O 0 7.233625609615046e-08
of O 0 4.823967358902337e-08
5 O 0 1.5566001820843667e-06
- O 0 4.4952466851100326e-05
37 O 0 2.3891682303656125e-06
repeats O 0 2.117986468874733e-06
on O 0 1.844433370479237e-07
normal O 0 5.429445195659355e-07
chromosomes O 0 9.173171520160395e-07
but O 0 9.229245989672563e-08
amplified O 0 9.071948738892388e-07
to O 0 8.874342682929637e-08
50 O 0 2.856264984529844e-07
- O 0 1.1361820725142024e-05
3000 O 0 6.0019033298885915e-06
copies O 0 2.160884832846932e-06
on O 0 4.131366040383e-06
DM B-Disease 1 0.999985933303833
chromosomes O 0 0.00026766827795654535
. O 0 2.0863235477008857e-05

Previous O 0 0.00045694419532082975
findings O 0 0.00021214128355495632
in O 0 6.1809291764802765e-06
Caucasian O 0 0.0008026180439628661
populations O 0 1.0715224561863579e-05
of O 0 7.46120178973797e-07
a O 0 1.371529378957348e-05
DM B-Disease 1 1.0
founder O 0 0.05442247912287712
chromosome O 0 3.857959382003173e-05
raise O 0 1.256061523235985e-06
a O 0 2.859538028587849e-07
question O 0 2.2346139871842752e-07
about O 0 8.364641956859487e-08
the O 0 1.8466985807208403e-07
molecular O 0 8.91421404958237e-06
events O 0 4.421519292918674e-07
involved O 0 4.6899384642529185e-07
in O 0 2.9050181638012873e-07
the O 0 1.1237788157814066e-06
expansion O 0 5.624452023766935e-05
mutation O 0 0.00011832355812657624
. O 0 2.2992206140770577e-05

To O 0 7.486186223104596e-05
investigate O 0 0.0001289086212636903
whether O 0 7.48785032556043e-06
a O 0 3.559696551747038e-06
founder O 0 0.0002170918887713924
chromosome O 0 3.692108657560311e-05
for O 0 9.508490279586113e-07
the O 0 6.475264854088891e-06
DM B-Disease 1 1.0
mutation O 0 0.0002047260059043765
exists O 0 1.054532276612008e-06
in O 0 7.78364324105496e-08
the O 0 7.266287838092467e-08
Japanese O 0 1.3875925333195482e-06
population O 0 2.7069225438935973e-07
, O 0 1.538403608947192e-07
we O 0 1.2428313311829697e-07
genotyped O 0 2.458273957017809e-05
families O 0 5.142564987181686e-07
using O 0 6.787491884097108e-07
polymorphic O 0 2.4229388145613484e-05
markers O 0 3.1672686873207567e-06
near O 0 1.1356913773852284e-06
the O 0 4.5986391228325374e-07
( O 0 2.959255425594165e-06
CTG O 0 0.0004945181426592171
) O 0 1.8046820287054288e-06
n O 0 3.8484795368276536e-05
repeat O 0 2.0359299014671706e-05
region O 0 5.178391347726574e-06
and O 0 1.7255546254091314e-06
constructed O 0 3.928398291463964e-05
haplotypes O 0 0.0014102335553616285
. O 0 3.0450295525952242e-05

Six O 0 7.45079669286497e-05
different O 0 1.0948288036161102e-05
haplotypes O 0 0.0004126397252548486
were O 0 2.330526967853075e-06
found O 0 2.0324821434769547e-06
and O 0 1.5601637642248534e-05
DM B-Disease 1 0.9999998807907104
alleles O 0 0.00015903438907116652
were O 0 1.1768566992031992e-06
always O 0 4.089228241355158e-06
haplotype O 0 0.0007185123395174742
A O 0 1.8653792722034268e-05
. O 0 3.547648520907387e-05

To O 0 2.6421790607855655e-05
find O 0 1.099042401619954e-05
an O 0 9.076959486264968e-07
origin O 0 6.954876994313963e-07
of O 0 2.4514341134818096e-07
the O 0 4.926848760078428e-07
( O 0 2.9104912755428813e-06
CTG O 0 0.0013497561449185014
) O 0 1.4084818076298689e-06
n O 0 3.565540100680664e-05
repeat O 0 2.5786892365431413e-05
mutation O 0 1.106757281377213e-06
and O 0 9.834061387437032e-08
to O 0 9.347053975261588e-08
investigate O 0 8.887332683116256e-07
the O 0 7.061611739800355e-08
mechanism O 0 2.0981788395602052e-07
of O 0 4.946669562855277e-08
the O 0 1.0021595642228931e-07
expansion O 0 3.7658094242942752e-06
mutation O 0 1.6563380995648913e-06
in O 0 5.590907292685188e-08
the O 0 7.220585018785641e-08
Japanese O 0 8.376694609069091e-07
population O 0 2.0965487124158244e-07
we O 0 7.75808999264882e-08
have O 0 8.244688842751202e-08
studied O 0 5.004378067496873e-07
90 O 0 7.12347457465512e-07
Japanese O 0 1.6808446162031032e-05
DM B-Disease 1 0.9999971389770508
families O 0 4.050516054121545e-06
comprising O 0 1.6649216831865488e-06
190 O 0 2.9882817216275726e-06
affected O 0 1.6077527789093438e-06
and O 0 8.537234634786728e-07
130 O 0 1.0912407560681459e-05
unaffected O 0 7.778627332299948e-05
members O 0 1.1621342309808824e-05
. O 0 2.7810758183477446e-05

The O 0 5.2743842388736084e-05
results O 0 9.623888036003336e-05
suggest O 0 7.44020871934481e-06
that O 0 2.8921365924361453e-07
a O 0 4.153558279540448e-07
few O 0 6.521364070977143e-07
common O 0 5.065917321189772e-06
ancestral O 0 0.00010805655620060861
mutations O 0 3.691830352181569e-05
in O 0 2.4664421971465345e-07
both O 0 2.593844783405075e-07
Caucasian O 0 4.7171753976726905e-05
and O 0 6.088500867917901e-07
Japanese O 0 3.821815880655777e-06
populations O 0 1.0210287655354477e-06
have O 0 1.1043770342666903e-07
originated O 0 2.8616332770070585e-07
by O 0 6.52820872915072e-08
expansion O 0 4.6091324179542426e-07
of O 0 8.418179220370803e-08
an O 0 1.4933146985640633e-07
ancestral O 0 7.217256552394247e-06
n O 0 7.79648034949787e-05
= O 0 2.0546960513456725e-05
5 O 0 1.0214270105279866e-06
repeat O 0 1.8982689198310254e-06
to O 0 2.4052641833804955e-07
n O 0 1.8584029021440074e-05
= O 0 2.081515958707314e-05
19 O 0 1.5667873185520875e-06
- O 0 2.1034184101154096e-05
37 O 0 7.558001016150229e-06
copies O 0 8.806372534309048e-06
. O 0 8.064742360147648e-06

These O 0 1.487090685259318e-05
data O 0 5.918631813983666e-06
support O 0 2.4520049919374287e-06
multistep O 0 3.680862209876068e-05
models O 0 6.3795528149057645e-06
of O 0 6.58595070035517e-07
triplet O 0 0.0005420224624685943
repeat O 0 8.373708260478452e-05
expansion O 0 2.877776751120109e-06
that O 0 1.1399228583286458e-07
have O 0 8.482101065965253e-08
been O 0 8.199022971666636e-08
proposed O 0 7.257498282342567e-07
for O 0 3.115740696557623e-07
both O 0 2.582067054390791e-06
DM B-Disease 1 0.9999998807907104
and O 0 9.155822772299871e-05
Friedreichs B-Disease 1 0.8949809670448303
ataxia I-Disease 1 0.9961960315704346
. O 0 8.801922376733273e-06
. O 0 1.745810004649684e-05

The O 0 4.465048550628126e-05
molecular O 0 0.00012684936518780887
basis O 0 9.498969120613765e-06
of O 0 3.144233414786868e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
in O 0 1.166412857855903e-06
the O 0 4.2732767724373844e-07
western O 0 3.314264631626429e-06
Cape O 0 2.600410698505584e-05
, O 0 1.2591425502250786e-06
South O 0 2.8057993404217996e-06
Africa O 0 7.169476702983957e-06
. O 0 1.4894325431669131e-05

Deficiency B-Disease 1 0.9983870983123779
of I-Disease 0 9.225898793374654e-06
the I-Disease 0 1.8128203009837307e-06
sixth I-Disease 0 8.30959379527485e-06
component I-Disease 0 3.1312708870245842e-06
of I-Disease 0 4.6204209525058104e-07
human I-Disease 0 7.186222319433e-07
complement I-Disease 0 3.7872098346269922e-06
( O 0 3.959494733862812e-06
C6 O 0 0.24065370857715607
) O 0 2.6581608381093247e-06
has O 0 1.9676573970173195e-07
been O 0 1.5665527541841584e-07
reported O 0 1.1070380878663855e-06
in O 0 8.238856707976083e-08
a O 0 9.581734872199377e-08
number O 0 1.1123554344294462e-07
of O 0 7.567281556930538e-08
families O 0 3.3950115607694897e-07
from O 0 1.4726789743235713e-07
the O 0 1.533945521714486e-07
western O 0 1.3679717767445254e-06
Cape O 0 1.7520478650112636e-05
, O 0 7.186551442828204e-07
South O 0 1.9002286535396706e-06
Africa O 0 5.946575129200937e-06
. O 0 9.776300430530682e-06

Meningococcal B-Disease 1 0.9999861717224121
disease I-Disease 1 0.9998642206192017
is O 0 5.953131403657608e-05
endemic O 0 0.0003379236732143909
in O 0 2.0450852389330976e-06
the O 0 8.439270118287823e-07
Cape O 0 2.7286103431833908e-05
and O 0 5.229425710240321e-07
almost O 0 2.3181594599464006e-07
all O 0 1.218345317965941e-07
pedigrees O 0 3.838344127871096e-06
of O 0 7.072354719639407e-07
total O 0 8.682293264428154e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
( O 0 1.7505662981420755e-05
C6Q0 O 0 0.016568094491958618
) O 0 1.2829976867578807e-06
have O 0 1.8799777024014475e-07
been O 0 4.6969478262326447e-07
ascertained O 0 1.1375742360542063e-05
because O 0 1.922972842294257e-06
of O 0 8.623945177532732e-06
recurrent O 1 0.9965278506278992
disease O 1 0.7233830690383911
. O 0 0.00011264291970292106

We O 0 2.1905994799453765e-05
have O 0 3.4802956179191824e-06
sequenced O 0 1.5853069271543063e-05
the O 0 7.53647043438832e-07
expressed O 0 1.5618716133758426e-06
exons O 0 7.87905173638137e-06
of O 0 2.5012531068568933e-07
the O 0 3.116525135737902e-07
C6 O 0 0.06094209849834442
gene O 0 2.9758339223917574e-06
from O 0 1.4488009014712588e-07
selected O 0 2.632381210787571e-07
cases O 0 1.9793959893377178e-07
and O 0 1.4234055356610043e-07
have O 0 1.820089323700813e-07
found O 0 2.681974251572683e-07
three O 0 8.229446848417865e-07
molecular O 0 0.0006521166069433093
defects O 0 0.0751800686120987
leading O 0 6.2260810409497935e-06
to O 0 1.221633738168748e-06
total O 0 3.203153028152883e-05
deficiency O 1 0.7445576786994934
879delG O 0 0.0011024908162653446
, O 0 6.928449352017196e-07
which O 0 1.4841670292753406e-07
is O 0 8.894389225133637e-08
the O 0 1.265665048322262e-07
common O 0 6.876118277432397e-06
defect O 0 9.659100032877177e-05
in O 0 3.4442416563251754e-07
the O 0 2.590811334357568e-07
Cape O 0 1.734771649353206e-05
and O 0 1.4546033071383135e-06
hitherto O 0 3.0515291655319743e-05
unreported O 0 1.3256573765829671e-05
, O 0 3.6487995203060564e-07
and O 0 4.2065883576469787e-07
1195delC O 0 6.564561044797301e-05
and O 0 9.204824777953036e-07
1936delG O 0 0.00012670586875174195
, O 0 4.0984082261275034e-07
which O 0 1.3926060660196526e-07
have O 0 1.2066307419900113e-07
been O 0 1.867704355618116e-07
previously O 0 3.566686473277514e-06
reported O 0 3.786671641137218e-06
in O 0 4.791940000359318e-07
African O 0 3.333881295475294e-06
- O 0 0.0008446170249953866
Americans O 0 3.537743032211438e-05
. O 0 2.1360121536417864e-05

We O 0 2.9080139938741922e-05
also O 0 5.012038400309393e-06
show O 0 1.8302158650840283e-06
that O 0 2.3536908599908202e-07
the O 0 2.8995103207307693e-07
879delG O 0 0.00010965863475576043
and O 0 4.721369805338327e-06
1195delC O 0 0.3303601145744324
defects O 0 0.4057099223136902
are O 0 3.909967745130416e-07
associated O 0 1.7413385648978874e-06
with O 0 8.693271524862212e-07
characteristic O 0 0.00024395351647399366
C6 O 1 0.9988779425621033
/ O 0 0.019946981221437454
C7 O 0 0.009069206193089485
region O 0 1.2335727660683915e-05
DNA O 0 1.1596345757425297e-05
marker O 0 5.255310497886967e-06
haplotypes O 0 0.00012415855599101633
, O 0 3.702945718941919e-07
although O 0 2.9973730875099136e-07
small O 0 6.805803423048928e-07
variations O 0 1.925437754835002e-05
were O 0 1.7160461993626086e-06
observed O 0 1.744407018122729e-05
. O 0 1.7259300875593908e-05

The O 0 6.683980609523132e-05
1936delG O 0 0.005246264394372702
defect O 0 0.005069095175713301
was O 0 5.764097750216024e-06
observed O 0 3.0028486435185187e-06
only O 0 1.8822166225618275e-07
once O 0 5.353652454687108e-07
in O 0 2.0815649293126626e-07
the O 0 2.025217469281415e-07
Cape O 0 1.715765210974496e-05
, O 0 3.721730479355756e-07
but O 0 1.8425100734020816e-07
its O 0 1.0760851409941097e-06
associated O 0 1.0214445865130983e-05
haplotype O 0 0.0003575700684450567
could O 0 1.382379196002148e-06
be O 0 1.03644913451717e-06
deduced O 0 2.693673195608426e-05
. O 0 1.4304630894912407e-05

The O 0 1.6893231077119708e-05
data O 0 9.941491043718997e-06
from O 0 1.2782602425431833e-06
the O 0 8.373771152037079e-07
haplotypes O 0 0.0001931527367560193
indicate O 0 3.3497458389319945e-06
that O 0 1.5229754524170858e-07
these O 0 9.353260566058452e-08
three O 0 7.685993068662356e-07
molecular O 0 0.002087219385430217
defects O 0 0.18379683792591095
account O 0 2.254795390399522e-06
for O 0 5.204901185607014e-07
the O 0 3.070349521294702e-06
defects O 0 0.1793309897184372
in O 0 4.3070306787740265e-07
all O 0 9.91192834476351e-08
the O 0 1.9381458571388066e-07
38 O 0 5.646802492265124e-06
unrelated O 0 1.7012285752571188e-05
C6Q0 O 0 0.008648076094686985
individuals O 0 4.992794515601418e-07
we O 0 1.272119760642454e-07
have O 0 1.3600363502064283e-07
studied O 0 1.1283106005066657e-06
from O 0 5.094377115710813e-07
the O 0 1.918920588650508e-06
Cape O 0 0.00017295735597144812
. O 0 3.218192796339281e-05

We O 0 2.4394694264628924e-05
have O 0 2.6936832000501454e-06
also O 0 1.6783478713477962e-06
observed O 0 2.893763621614198e-06
the O 0 6.25583538749197e-07
879delG O 0 0.00030671025160700083
defect O 0 9.974009299185127e-05
in O 0 4.6363950900740747e-07
two O 0 5.475202442539739e-07
Dutch O 0 0.00047337825526483357
C6 B-Disease 1 0.9999946355819702
- I-Disease 1 0.9986067414283752
deficient I-Disease 1 0.9992592930793762
kindreds O 0 0.0011847080895677209
, O 0 5.289801947583328e-07
but O 0 1.6075244957391988e-07
the O 0 2.0667098965532205e-07
879delG O 0 0.00019114968017674983
defect O 0 9.087030775845051e-05
in O 0 3.6127815405961883e-07
the O 0 3.5316710977895127e-07
Cape O 0 4.271112265996635e-05
probably O 0 1.7369399074596004e-06
did O 0 3.6800096836486773e-07
not O 0 1.0241362957685851e-07
come O 0 2.5586305696378986e-07
from O 0 1.440184149714696e-07
The O 0 4.4367888563101587e-07
Netherlands O 0 1.4629221368522849e-05
. O 0 2.1608952920360025e-06
. O 0 1.0635671969794203e-05

Complement B-Disease 0 0.12821412086486816
C7 I-Disease 1 0.9999985694885254
deficiency I-Disease 1 0.999998927116394
: O 0 3.7058056477690116e-05
seven O 0 1.0320685760234483e-05
further O 0 7.02391753293341e-06
molecular O 0 0.0022577892523258924
defects O 0 0.20733632147312164
and O 0 2.3445040824299213e-06
their O 0 6.1768400883011054e-06
associated O 0 4.8695161240175366e-05
marker O 0 0.00010327786731068045
haplotypes O 0 0.004227037541568279
. O 0 3.7036505091236904e-05

Seven O 0 8.7737113062758e-05
further O 0 2.979066630359739e-05
molecular O 0 6.724353443132713e-05
bases O 0 2.080127342196647e-05
of O 0 4.0781989810056984e-05
C7 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999991655349731
are O 0 1.085604617401259e-05
described O 0 0.0001347296783933416
. O 0 3.531103357090615e-05

All O 0 1.1181182344444096e-05
these O 0 2.70670784630056e-06
new O 0 7.789428309479263e-06
molecular O 0 0.00026965237339027226
defects O 0 0.011950383894145489
involve O 0 3.6704766444017878e-06
single O 0 2.8761801331711467e-06
- O 0 0.0001375031133648008
nucleotide O 0 8.749399057705887e-06
events O 0 3.3805696375566185e-07
, O 0 2.1525002580347063e-07
deletions O 0 1.963222075573867e-06
and O 0 2.4336699766536185e-07
substitutions O 0 1.2261812116776127e-06
, O 0 1.4531154590713413e-07
some O 0 3.573985551952319e-08
of O 0 4.1279761830992356e-08
which O 0 1.7508888561224012e-07
alter O 0 1.513891857030103e-05
splice O 0 5.883066842216067e-05
sites O 0 8.653939289615664e-07
, O 0 4.025547752917191e-07
and O 0 7.128326728889078e-07
others O 0 1.0279470188834239e-05
codons O 0 0.0001230507914442569
. O 0 1.8836595700122416e-05

They O 0 1.7868502254714258e-05
are O 0 1.1950406815230963e-06
distributed O 0 1.4857632777420804e-06
along O 0 7.685370064791641e-07
the O 0 5.873082500329474e-07
C7 O 0 0.0012669636635109782
gene O 0 6.081970695959171e-06
, O 0 2.9456569450303505e-07
but O 0 1.6031764005219884e-07
predominantly O 0 4.281794474536582e-07
towards O 0 4.5058413888909854e-07
the O 0 5.501792657014448e-07
3 O 0 6.340075287880609e-06
end O 0 1.3127796592016239e-05
. O 0 1.3960135220258962e-05

All O 0 1.2783865713572595e-05
were O 0 3.869898591801757e-06
found O 0 2.6811458155862056e-06
in O 0 1.8026006500804215e-06
compound O 0 0.0001312710519414395
heterozygous O 0 5.90118725085631e-05
individuals O 0 1.09695247374475e-05
. O 0 1.8358801753493026e-05

The O 0 0.00019929501286242157
C6 O 1 0.9119244813919067
/ O 0 0.06237487122416496
C7 O 0 0.05792791768908501
marker O 0 0.0001785777130862698
haplotypes O 0 0.003485387656837702
associated O 0 1.1029178494936787e-05
with O 0 1.7177096651721513e-06
most O 0 8.009534212760627e-06
C7 B-Disease 1 0.9996427297592163
defects I-Disease 1 0.9416933059692383
are O 0 1.6237470390478848e-06
tabulated O 0 4.359188096714206e-05
. O 0 2.31498597713653e-06
. O 0 1.088176213670522e-05

A O 0 0.00010637275408953428
genome O 0 9.072173270396888e-05
- O 0 6.475107511505485e-05
wide O 0 3.0837984468234936e-06
search O 0 2.6135978714592056e-06
for O 0 1.1940849162783707e-06
chromosomal O 0 0.00048678641906008124
loci O 0 0.00010362640023231506
linked O 0 0.00014516660303343087
to O 0 1.0151296010008082e-05
mental O 0 0.23288075625896454
health O 0 0.0019633343908935785
wellness O 0 0.0023350424598902464
in O 0 3.844535513053415e-06
relatives O 0 1.7305284927715547e-05
at O 0 3.628544845923898e-06
high O 0 0.00016688797040842474
risk O 0 0.0010561811504885554
for O 0 0.0011068953899666667
bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.995923638343811
among O 0 9.761251931195147e-07
the O 0 3.6799184499614057e-07
Old O 0 2.631989673318458e-06
Order O 0 4.380085101729492e-06
Amish O 0 0.000213991166674532
. O 0 2.733848668867722e-05

Bipolar B-Disease 1 0.9999991655349731
affective I-Disease 1 0.9999985694885254
disorder I-Disease 1 0.999997615814209
( O 0 0.08574125915765762
BPAD B-Disease 1 0.9999992847442627
; O 1 0.9462471604347229
manic B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
depressive I-Disease 1 1.0
illness I-Disease 1 0.9994376301765442
) O 0 2.5448925953241996e-05
is O 0 7.372384516202146e-07
characterized O 0 2.223898991360329e-05
by O 0 4.6499496875185287e-07
episodes O 0 1.74963497556746e-06
of O 0 4.934410071655293e-07
mania B-Disease 0 0.10098043829202652
and O 0 9.299285920860711e-06
/ O 0 0.0035203879233449697
or O 0 3.025597834493965e-06
hypomania B-Disease 0 0.17800909280776978
interspersed O 0 2.4492275770171545e-05
with O 0 1.6545239986953675e-06
periods O 0 2.02533119590953e-05
of O 0 5.942170901107602e-06
depression B-Disease 0 0.006037930492311716
. O 0 4.897309190710075e-05

Compelling O 0 0.00045885800500400364
evidence O 0 5.466950096888468e-05
supports O 0 2.73299592663534e-05
a O 0 4.4709950088872574e-06
significant O 0 6.638620106969029e-06
genetic O 0 1.2426987268554512e-05
component O 0 2.7332937406754354e-06
in O 0 4.635807329123054e-07
the O 0 9.019438493851339e-07
susceptibility O 0 0.0001668453187448904
to O 0 4.551041456579696e-06
develop O 0 0.0005287461681291461
BPAD B-Disease 1 0.9996204376220703
. O 0 8.447977597825229e-05

To O 0 3.989182732766494e-05
date O 0 4.377430377644487e-05
, O 0 3.5379346172703663e-06
however O 0 1.2115028766856994e-06
, O 0 6.695242973364657e-07
linkage O 0 2.5838633519015275e-05
studies O 0 2.1954288058623206e-06
have O 0 1.4324272967769502e-07
attempted O 0 1.8349521724303486e-06
only O 0 1.047793247721529e-07
to O 0 3.657721947547543e-07
identify O 0 1.1906023246410768e-05
chromosomal O 0 0.00028180962544865906
loci O 0 2.5730931156431325e-05
that O 0 4.902589125777013e-07
cause O 0 4.36610525866854e-06
or O 0 4.923936671730189e-07
increase O 0 1.470637016609544e-06
the O 0 5.391160016188223e-07
risk O 0 7.767751412757207e-06
of O 0 9.483567282586591e-07
developing O 0 0.0003275999042671174
BPAD B-Disease 1 0.9997075200080872
. O 0 5.8586072555044666e-05

To O 0 4.69968217657879e-05
determine O 0 2.446491453156341e-05
whether O 0 3.109787712674006e-06
there O 0 4.4585740965885634e-07
could O 0 5.554427957576991e-07
be O 0 2.649576060775871e-07
protective O 0 2.6460445951670408e-05
alleles O 0 5.148805485077901e-06
that O 0 2.7203304853173904e-07
prevent O 0 1.8795021787809674e-06
or O 0 7.023871830824646e-07
reduce O 0 1.2033448911097366e-05
the O 0 3.7151031051507744e-07
risk O 0 2.62467301581637e-06
of O 0 2.930967752945435e-07
developing O 0 6.185753591125831e-05
BPAD B-Disease 1 0.9994581341743469
, O 0 1.6504566247022012e-06
similar O 0 3.5346462823326874e-07
to O 0 1.8483443398054078e-07
what O 0 1.7719148104333726e-07
is O 0 2.3447672958809562e-07
observed O 0 1.6580037254243507e-06
in O 0 1.4441674238696578e-06
other O 0 3.5238470445619896e-05
genetic B-Disease 1 0.9999639987945557
disorders I-Disease 1 0.9999995231628418
, O 0 7.883530997787602e-06
we O 0 6.198150117597834e-07
used O 0 3.541773548931815e-05
mental O 1 0.6356281042098999
health O 0 0.012058498337864876
wellness O 0 0.05615746229887009
( O 0 6.204747933225008e-06
absence O 0 2.8515230496850563e-06
of O 0 1.0710060678320588e-06
any O 0 3.656117769423872e-05
psychiatric B-Disease 1 0.9999814033508301
disorder I-Disease 1 0.9750242233276367
) O 0 4.12208601119346e-06
as O 0 3.308900602405629e-07
the O 0 3.8938810575928073e-07
phenotype O 0 0.00020804051018785685
in O 0 3.37482930490296e-07
our O 0 6.342472715914482e-07
genome O 0 2.650940587045625e-06
- O 0 1.2567717021738645e-05
wide O 0 1.2589540574481362e-06
linkage O 0 1.6405092537752353e-05
scan O 0 1.1311741218378302e-05
of O 0 9.906050024710567e-08
several O 0 1.620738174779035e-07
large O 0 5.96931499785569e-07
multigeneration O 0 0.00015124038327485323
Old O 0 1.6628476942059933e-06
Order O 0 7.650116913282545e-07
Amish O 0 2.6573738068691455e-05
pedigrees O 0 0.00012228041305206716
exhibiting O 0 2.188843245676253e-05
an O 0 7.699514412706776e-07
extremely O 0 1.6220930774579756e-05
high O 0 3.7223890103632584e-05
incidence O 0 0.0007265370222739875
of O 0 9.498779036221094e-06
BPAD B-Disease 1 0.9998941421508789
. O 0 9.288268483942375e-05

We O 0 2.1878498955629766e-05
have O 0 3.194820465068915e-06
found O 0 1.5763690726089408e-06
strong O 0 2.630092694744235e-06
evidence O 0 1.06070206129516e-06
for O 0 2.3254621339674486e-07
a O 0 5.511512881639646e-07
locus O 0 8.321013410750311e-06
on O 0 2.131093424395658e-06
chromosome O 0 3.602002834668383e-05
4p O 0 0.04549335688352585
at O 0 1.2334317034401465e-06
D4S2949 O 0 3.415351966395974e-05
( O 0 7.386840366052638e-07
maximum O 0 1.1641491255431902e-06
GENEHUNTER O 0 0.00014878598449286073
- O 0 4.037297185277566e-05
PLUS O 0 6.695768206554931e-06
nonparametric O 0 1.5107607396203093e-05
linkage O 0 5.672018232871778e-06
score O 0 1.2042572734571877e-06
= O 0 1.3718250556848943e-05
4 O 0 8.510702400599257e-07
. O 0 2.6022391352853447e-07
05 O 0 1.856192284321878e-05
, O 0 3.9377187022182625e-07
P O 0 0.00011957645619986579
= O 0 1.2865748431067914e-05
5 O 0 5.194577283873514e-07
. O 0 1.1307498226642565e-07
22 O 0 4.610297708040889e-07
x O 0 5.7586807997722644e-06
10 O 0 4.3530985749384854e-07
( O 0 2.778347720777674e-07
- O 0 1.3038127690379042e-05
4 O 0 3.925820237782318e-06
) O 0 5.977336172691139e-07
; O 0 6.101148528614431e-07
SIBPAL O 0 4.413558417581953e-05
Pempirical O 0 1.9973938833572902e-05
value O 0 3.353848967435624e-07
< O 0 3.6900223676639143e-06
3 O 0 6.517061592603568e-07
x O 0 9.168394171865657e-06
10 O 0 4.4359128992255137e-07
( O 0 2.8183455924590817e-07
- O 0 1.9217011868022382e-05
5 O 0 3.3037563298421446e-06
) O 0 5.327142957867181e-07
) O 0 2.4293547085108003e-07
and O 0 2.1149334372694284e-07
suggestive O 0 8.849376172292978e-06
evidence O 0 4.157350872446841e-07
for O 0 1.3195042924962763e-07
a O 0 4.911499331683444e-07
locus O 0 7.759451364108827e-06
on O 0 4.17662204199587e-06
chromosome O 0 0.0001455670571886003
4q O 1 0.9929535984992981
at O 0 1.5762773273308994e-06
D4S397 O 0 5.434401464299299e-05
( O 0 8.807882636574504e-07
maximum O 0 1.0465922741786926e-06
GENEHUNTER O 0 0.00011638485739240423
- O 0 3.6023735447088256e-05
PLUS O 0 5.239826350589283e-06
nonparametric O 0 2.245739960926585e-05
linkage O 0 6.354257493512705e-06
score O 0 8.963572213360749e-07
= O 0 1.8016580725088716e-05
3 O 0 1.4546726561093237e-06
. O 0 2.466075272877788e-07
29 O 0 1.138008315137995e-06
, O 0 3.2163990226763417e-07
P O 0 0.00022191664902493358
= O 0 1.5572191841783933e-05
2 O 0 9.077184586203657e-07
. O 0 1.7095763382712903e-07
57 O 0 1.0961010730170528e-06
x O 0 5.11514281242853e-06
10 O 0 4.725397104721196e-07
( O 0 2.4938265141827287e-07
- O 0 8.243308911914937e-06
3 O 0 2.5376157282153144e-06
) O 0 3.9340289959000074e-07
; O 0 3.5915141438636056e-07
SIBPAL O 0 3.0705883546033874e-05
Pempirical O 0 1.4575830391549971e-05
value O 0 3.144631079976534e-07
< O 0 4.048237769893603e-06
1 O 0 6.220610657692305e-07
x O 0 7.473375262634363e-06
10 O 0 3.941396755635651e-07
( O 0 4.186014734841592e-07
- O 0 2.22516137000639e-05
3 O 0 4.527923465502681e-06
) O 0 4.975786396244075e-07
) O 0 1.556404214397844e-07
that O 0 4.974211265107442e-08
are O 0 1.3475735727297433e-07
linked O 0 2.054372635029722e-05
to O 0 1.7206681150128134e-05
mental O 0 0.10594942420721054
health O 0 0.002361300168558955
wellness O 0 0.011761581525206566
. O 0 5.968433106318116e-05

These O 0 6.627631955780089e-05
findings O 0 9.698288340587169e-05
are O 0 1.0167824484597077e-06
consistent O 0 2.1778287191409618e-06
with O 0 5.446413524623495e-07
the O 0 5.677542276316672e-07
hypothesis O 0 5.918117949477164e-06
that O 0 2.2864418269818998e-07
certain O 0 3.311012619633402e-07
alleles O 0 3.634020004028571e-06
could O 0 3.370943488789635e-07
prevent O 0 1.1639848480626824e-06
or O 0 6.672970016552426e-07
modify O 0 2.847635914804414e-05
the O 0 1.2571375691550202e-06
clinical O 0 8.932939817896113e-05
manifestations O 0 3.195674798917025e-05
of O 0 7.376632424893614e-07
BPAD B-Disease 1 0.9999127388000488
and O 0 8.808086022327188e-06
perhaps O 0 4.299563443055376e-06
other O 0 5.668313860951457e-06
related O 0 0.01133760530501604
affective B-Disease 1 0.9999741315841675
disorders I-Disease 1 0.9990001320838928
. O 0 8.866439020493999e-05

Segregation O 0 0.012825898826122284
distortion O 0 0.4624197483062744
in O 0 0.004327891860157251
myotonic B-Disease 1 0.9999982118606567
dystrophy I-Disease 1 0.999998927116394
. O 0 0.003633396467193961

Myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 1.0
( O 1 0.9912744164466858
DM B-Disease 1 1.0
) O 0 0.0015830970369279385
is O 0 3.893092980433721e-06
an O 0 8.84272867551772e-06
autosomal B-Disease 1 0.9163463115692139
dominant I-Disease 1 0.5162973999977112
disease I-Disease 0 0.09588741511106491
which O 0 6.790748443563643e-07
, O 0 2.5267968339903746e-07
in O 0 1.1184740600356236e-07
the O 0 1.264789091237617e-07
typical O 0 5.204690751270391e-06
pedigree O 0 4.6806864702375606e-05
, O 0 3.7164531363487185e-07
shows O 0 2.78565948974574e-07
a O 0 2.6395457553007873e-07
three O 0 8.094841064121283e-07
generation O 0 2.3662169041926973e-05
anticipation O 0 3.206071414751932e-05
cascade O 0 0.000338442885549739
. O 0 2.142319681297522e-05

This O 0 6.27153494860977e-05
results O 0 0.00039215671131387353
in O 0 0.00012546606012620032
infertility B-Disease 1 0.9999535083770752
and O 1 0.9609283804893494
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0007945180404931307
CDM B-Disease 0 0.19435235857963562
) O 0 1.532122496428201e-06
with O 0 2.0834913527778554e-07
the O 0 3.006643112257734e-07
disappearance O 0 2.096649222949054e-05
of O 0 2.10660687116615e-06
DM B-Disease 1 0.9999997615814209
in O 0 1.1799374988186173e-05
that O 0 3.0522137421939988e-06
pedigree O 0 0.0003354674845468253
. O 0 3.105691939708777e-05

The O 0 1.0197296433034353e-05
concept O 0 7.447641564795049e-06
of O 0 1.0480575838300865e-06
segregation O 0 1.0868559002119582e-05
distortion O 0 9.943374607246369e-05
, O 0 8.916757678889553e-07
where O 0 1.5788212692768866e-07
there O 0 7.224166154173872e-08
is O 0 1.4047282093088143e-07
preferential O 0 7.249464488268131e-06
transmission O 0 1.6486080767208477e-06
of O 0 7.828488435279723e-08
the O 0 1.1475055572418569e-07
larger O 0 7.533969892392633e-07
allele O 0 2.9870309390389593e-06
at O 0 2.8409266406015377e-07
the O 0 6.031236239323334e-07
DM B-Disease 1 0.9999994039535522
locus O 0 6.0031328757759184e-05
, O 0 4.5985689212102443e-07
has O 0 1.1445776237906102e-07
been O 0 8.005365970120693e-08
put O 0 1.7095908333430998e-07
forward O 0 2.1960099161333346e-07
to O 0 1.758766217108132e-07
explain O 0 1.2910826399092912e-06
partially O 0 2.181909621867817e-06
the O 0 2.6933494723380136e-07
maintenance O 0 1.002569479169324e-05
of O 0 1.3735065067521646e-06
DM B-Disease 1 0.9999994039535522
in O 0 3.5174530239601154e-06
the O 0 1.942010385391768e-06
population O 0 7.894380360085052e-06
. O 0 1.1234359590162057e-05

In O 0 3.7878373404964805e-05
a O 0 8.911384611565154e-06
survey O 0 2.3003085516393185e-05
of O 0 2.722871158766793e-06
DM B-Disease 1 0.9999998807907104
in O 0 7.609291969856713e-06
Northern O 0 2.9881364298489643e-06
Ireland O 0 3.2026848657551454e-06
, O 0 9.154042004411167e-07
59 O 0 1.268716459890129e-05
pedigrees O 0 6.23736486886628e-05
were O 0 3.6401208944880636e-06
ascertained O 0 9.286372369388118e-05
. O 0 2.3978967874427326e-05

Sibships O 0 0.007117653731256723
where O 0 9.553151357977185e-06
the O 0 8.873883530213789e-07
status O 0 8.260963113571052e-07
of O 0 1.155764621785238e-07
all O 0 5.110502598881794e-08
the O 0 1.0598915878290427e-07
members O 0 4.005072469226434e-07
had O 0 3.119712914667616e-07
been O 0 2.2533993160323007e-07
identified O 0 8.916119895729935e-07
were O 0 1.812962295844045e-07
examined O 0 2.2360113689501304e-06
to O 0 1.8674656132589007e-07
determine O 0 4.1339492895531293e-07
the O 0 1.2432604989953688e-07
transmission O 0 1.1883944353030529e-06
of O 0 1.1833284929707588e-07
the O 0 6.617732992708625e-07
DM B-Disease 1 0.9999963045120239
expansion O 0 2.2512014766107313e-05
from O 0 6.397413585546019e-07
affected O 0 1.1148302974106628e-06
parents O 0 5.156247198101482e-07
to O 0 3.1881864970273455e-07
their O 0 2.259742132082465e-06
offspring O 0 0.00012629464617930353
. O 0 2.432463224977255e-05

Where O 0 3.980730616603978e-05
the O 0 8.027359399420675e-06
transmitting O 0 0.00013329322973731905
parent O 0 7.129944424377754e-05
was O 0 2.7389639853936387e-06
male O 0 1.4194951290846802e-05
, O 0 4.043306489620591e-06
58 O 0 6.680871592834592e-05
. O 0 2.6934087145491503e-05

3 O 0 0.00018624865333549678
% O 0 1.2841745046898723e-05
of O 0 9.697063205749146e-07
the O 0 8.661874630888633e-07
offspring O 0 2.5881890906021e-05
were O 0 4.558780801744433e-07
affected O 0 1.4092704532231437e-06
, O 0 3.046305607767863e-07
and O 0 1.7125053375366406e-07
in O 0 1.4134603532056644e-07
the O 0 1.599620986780792e-07
case O 0 4.2425864421602455e-07
of O 0 1.1345900219339455e-07
a O 0 1.0254219660055242e-06
female O 0 2.28498629439855e-05
transmitting O 0 0.0002754644665401429
parent O 0 5.1495218940544873e-05
, O 0 3.253883051002049e-06
68 O 0 5.861272074980661e-05
. O 0 1.7746029698173515e-05

7 O 0 0.0008193458779715002
% O 0 0.0001152533950516954
were O 0 2.22624385060044e-05
affected O 0 7.734492101008072e-05
. O 0 4.632302443496883e-05

Studies O 0 0.00020604589371941984
on O 0 1.4855230801913422e-05
meiotic O 0 0.0006397097022272646
drive O 0 5.646852150675841e-05
in O 0 2.0050756575074047e-05
DM B-Disease 1 0.9999996423721313
have O 0 2.508530087652616e-06
shown O 0 1.0243613814964192e-06
increased O 0 5.659184694195574e-07
transmission O 0 6.825042078162369e-07
of O 0 8.544812857280704e-08
the O 0 1.2054989895204926e-07
larger O 0 7.246867994581407e-07
allele O 0 3.5946738989878213e-06
at O 0 3.2397801419392636e-07
the O 0 7.442496894327633e-07
DM B-Disease 1 0.9999946355819702
locus O 0 3.380711132194847e-05
in O 0 2.8627628125832416e-06
non O 0 7.84221847425215e-05
- O 1 0.7727382183074951
DM O 1 0.9999992847442627
heterozygotes O 0 0.0016980721848085523
for O 0 9.272444003727287e-06
CTGn O 0 0.0012437541736289859
. O 0 3.311036925879307e-05

This O 0 2.8029300665366463e-05
study O 0 1.5204054761852603e-05
provides O 0 6.14677628618665e-06
further O 0 2.1391342670540325e-06
evidence O 0 1.2065173677910934e-06
that O 0 3.2141971928467683e-07
the O 0 7.793066743033705e-07
DM B-Disease 1 0.9999974966049194
expansion O 0 3.258732976973988e-05
tends O 0 5.915832389291609e-06
to O 0 4.671787792176474e-07
be O 0 5.910324034630321e-07
transmitted O 0 1.2195908311696257e-05
preferentially O 0 5.22617920069024e-05
. O 0 1.8232549336971715e-05

Diagnosis O 1 0.9994387030601501
of O 0 0.0010125349508598447
hemochromatosis B-Disease 1 0.9999884366989136
. O 0 0.0010969593422487378

If O 0 0.0007304869941435754
untreated O 1 0.991378903388977
, O 0 0.0006492657703347504
hemochromatosis B-Disease 1 0.9999997615814209
can O 0 0.0016148814465850592
cause O 0 0.3141798973083496
serious O 1 0.6751799583435059
illness O 1 0.8032131791114807
and O 0 1.5105951206351165e-05
early B-Disease 0 0.00010631485201884061
death I-Disease 0 5.344544115359895e-05
, O 0 2.3543223051092355e-06
but O 0 8.143366017066e-07
the O 0 3.2518789794266922e-06
disease O 0 0.00016701468848623335
is O 0 4.631176580005558e-07
still O 0 1.6563997178309364e-06
substantially O 0 2.2222329789656214e-05
under O 0 1.2444492313079536e-05
- O 1 0.9924997687339783
diagnosed O 1 0.9763703346252441
. O 0 3.298465526313521e-05

The O 0 2.6383948352304287e-05
cornerstone O 0 0.00011635723058134317
of O 0 3.305855216240161e-06
screening O 0 1.3116546142555308e-05
and O 0 2.4851187845342793e-06
case O 0 4.2090669012395665e-06
detection O 0 1.230141151609132e-05
is O 0 1.881915068224771e-07
the O 0 1.2562540518956666e-07
measurement O 0 3.2839286632224685e-06
of O 0 2.8787354722226155e-07
serum O 0 1.9543080270523205e-05
transferrin O 0 7.796763384249061e-05
saturation O 0 4.10306438425323e-06
and O 0 4.071426644713938e-07
the O 0 7.990193466866913e-07
serum O 0 2.4296368792420253e-05
ferritin O 0 0.00014696746075060219
level O 0 1.3710049643123057e-05
. O 0 1.5639014236512594e-05

Once O 0 0.0001802475017029792
the O 0 3.860252763843164e-05
diagnosis O 0 0.3398008942604065
is O 0 4.845480816584313e-06
suspected O 0 0.0002546092146076262
, O 0 7.82298684498528e-06
physicians O 0 5.321998105500825e-05
must O 0 8.379450946449651e-07
use O 0 1.1140491551486775e-06
serum O 0 1.4239381016523112e-05
ferritin O 0 9.529697854304686e-05
levels O 0 2.396424633843708e-06
and O 0 9.666492815085803e-07
hepatic O 0 0.019174542278051376
iron O 0 0.00013815720740240067
stores O 0 1.8328903024666943e-05
on O 0 1.8909813661593944e-05
liver O 1 0.8342612385749817
biopsy O 1 0.9186837673187256
specimens O 0 7.149335579015315e-05
to O 0 4.139159045735141e-06
assess O 0 0.024251621216535568
patients O 0 7.722633745288476e-05
for O 0 2.2534015897690551e-07
the O 0 2.2041129454919428e-07
presence O 0 1.0718101748352638e-06
of O 0 9.512408496448188e-07
iron B-Disease 0 0.011116843670606613
overload I-Disease 0 0.0155487060546875
. O 0 3.580792326829396e-05

Liver O 1 0.9999867677688599
biopsy O 1 0.9980997443199158
is O 0 9.152661732514389e-06
also O 0 1.0754880577223958e-06
used O 0 3.6533782576952945e-07
to O 0 1.66430737635892e-07
establish O 0 5.453773610497592e-07
the O 0 1.5411040976687218e-07
presence O 0 4.0134003143066366e-07
or O 0 2.978026998334826e-07
absence O 0 1.716003566798463e-06
of O 0 1.89735305866634e-06
cirrhosis B-Disease 1 0.9885278940200806
, O 0 2.0192401279928163e-06
which O 0 1.0387685733803664e-06
can O 0 3.5324426335137105e-06
affect O 0 9.064580081030726e-05
prognosis O 1 0.966049313545227
and O 0 3.300601747469045e-05
management O 0 0.0027195943985134363
. O 0 5.29557655681856e-05

A O 0 9.365216101286933e-05
DNA O 0 0.00024134897103067487
- O 0 0.0005690223770216107
based O 0 6.000122994009871e-06
test O 0 1.0719635383793502e-06
for O 0 2.270778480806257e-07
the O 0 4.132211017804366e-07
HFE O 0 0.002321326406672597
gene O 0 3.877692961395951e-06
is O 0 2.0783316756478598e-07
commercially O 0 1.3606282891487353e-06
available O 0 2.0614619700154435e-07
, O 0 1.1741802552478475e-07
but O 0 8.315520005908184e-08
its O 0 1.6788956713753578e-07
place O 0 2.9435227588692214e-07
in O 0 3.902155754076375e-07
the O 0 1.1464876479294617e-06
diagnosis O 0 0.15074984729290009
of O 0 9.63144611887401e-06
hemochromatosis B-Disease 1 0.9999995231628418
is O 0 6.009463049849728e-06
still O 0 3.6858825751551194e-06
being O 0 2.1708035546907922e-06
evaluated O 0 4.339163933764212e-05
. O 0 1.577630428073462e-05

Currently O 0 6.381825369317085e-05
, O 0 5.030004558648216e-06
the O 0 5.357610461942386e-07
most O 0 2.767597493402718e-07
useful O 0 5.817272494823555e-07
role O 0 4.387842977848777e-07
for O 0 2.0546590917547292e-07
this O 0 1.6992449047847913e-07
test O 0 6.752447347935231e-07
is O 0 1.0064524502695349e-07
in O 0 1.2069391175373312e-07
the O 0 1.7862123513623374e-07
detection O 0 8.388090463995468e-06
of O 0 7.399729611279326e-07
hemochromatosis B-Disease 1 0.999985933303833
in O 0 1.6831082803037134e-06
the O 0 2.8125057838224166e-07
family O 0 1.5401152495542192e-06
members O 0 6.931039706614683e-07
of O 0 5.099334430269664e-07
patients O 0 3.200887294951826e-05
with O 0 3.912735451194749e-07
a O 0 3.6750616345671006e-06
proven O 0 9.641578799346462e-05
case O 0 2.218013833044097e-06
of O 0 7.50220749523578e-07
the O 0 2.3658560166950338e-05
disease O 0 0.005358213558793068
. O 0 2.8612221285584383e-05

It O 0 2.4167815354303457e-05
is O 0 6.195743026182754e-06
crucial O 0 2.757237416517455e-05
to O 0 6.507562648039311e-05
diagnose O 1 0.9999899864196777
hemochromatosis B-Disease 1 1.0
before O 1 0.7732552886009216
hepatic B-Disease 1 0.9999994039535522
cirrhosis I-Disease 1 0.9999992847442627
develops O 1 0.9144198894500732
because O 0 8.528011676389724e-05
phlebotomy O 1 0.998923122882843
therapy O 0 0.16284243762493134
can O 0 3.310803367639892e-05
avert O 1 0.998364269733429
serious O 1 0.9998652935028076
chronic O 1 1.0
disease O 1 0.9666689038276672
and O 0 7.883125363150612e-06
can O 0 7.026665684861655e-07
even O 0 5.157731948202127e-07
lead O 0 4.7731759877933655e-06
to O 0 4.887920681539981e-07
normal O 0 4.511449333222117e-06
life O 0 5.532004706765292e-06
expectancy O 0 4.7464251110795885e-05
. O 0 3.632446805568179e-06
. O 0 1.3707985090150032e-05

Prevalence O 0 0.007295063231140375
of O 0 1.1343416190356947e-05
the O 0 5.621774107567035e-06
I1307K O 0 0.0002888935850933194
APC B-Disease 0 0.0003318150120321661
gene O 0 1.0713302799558733e-05
variant O 0 1.0798005860124249e-05
in O 0 5.170280701349839e-07
Israeli O 0 3.382128170414944e-06
Jews O 0 1.0144694897462614e-06
of O 0 1.9198525080810214e-07
differing O 0 1.6876199424586957e-06
ethnic O 0 2.0365741875139065e-06
origin O 0 3.312327635285328e-06
and O 0 9.296226380683947e-06
risk O 0 0.002847774652764201
for O 0 0.12984253466129303
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999972581863403
. O 0 0.00014096492668613791

BACKGROUND O 0 0.0022371760569512844
& O 0 0.011013269424438477
AIMS O 0 0.0002717905445024371
Israeli O 0 3.4336171665927395e-05
Jews O 0 2.949149575215415e-06
of O 0 5.151499067324039e-07
European O 0 1.031795000017155e-05
birth O 0 1.568332481838297e-05
, O 0 6.852368983345514e-07
i O 0 2.604170674658235e-07
. O 0 1.9942871176681365e-07
e O 0 2.248799546578084e-06
. O 0 1.1032148705680811e-07
, O 0 2.6122694407604286e-07
Ashkenazim O 0 3.674346226034686e-05
, O 0 2.864983912331809e-07
have O 0 2.2052188342058798e-07
the O 0 2.8070494408893865e-06
highest O 1 0.9809694290161133
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.006891660857945681
of O 0 6.925370712451695e-07
any O 0 6.733072268616525e-07
Israeli O 0 2.9030068617430516e-05
ethnic O 0 1.627811070648022e-05
group O 0 0.00010425029176985845
. O 0 2.2820444428361952e-05

The O 0 3.27537018165458e-05
I1307K O 0 0.0006157374009490013
APC B-Disease 0 0.000684465398080647
gene O 0 3.57104217982851e-05
variant O 0 2.2905827790964395e-05
was O 0 1.2812797649530694e-06
found O 0 1.520525643172732e-06
in O 0 1.980573415494291e-06
6 O 0 3.7189191061770543e-05
. O 0 2.7059699277742766e-05

1 O 0 0.00010970727453241125
% O 0 9.653103006712627e-06
of O 0 1.0936107628367608e-06
American O 0 1.944782979990123e-06
Jews O 0 2.0785546439583413e-06
, O 0 5.349145908439823e-07
28 O 0 1.443799760636466e-06
% O 0 5.530478688342555e-07
of O 0 2.541076185025304e-07
their O 0 0.00034933851566165686
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 8.359323692275211e-05
, O 0 8.091035965662741e-07
but O 0 2.095339510788108e-07
not O 0 1.233085384910737e-07
in O 0 3.0773978210163477e-07
non O 0 1.3098507224640343e-05
- O 0 0.0002309636474819854
Jews O 0 2.756007233983837e-05
. O 0 1.7715692592901178e-05

We O 0 4.0263777918880805e-05
assessed O 0 6.64819817757234e-05
the O 0 5.1141287258360535e-06
I1307K O 0 0.0015328199369832873
prevalence O 0 0.00030227232491597533
in O 0 7.746954793219629e-07
Israeli O 0 5.571166639128933e-06
Jews O 0 1.91529488802189e-06
of O 0 2.4965251554931456e-07
differing O 0 2.16922239815176e-06
ethnic O 0 2.006367594731273e-06
origin O 0 3.669367060865625e-06
and O 0 9.723198672872968e-06
risk O 0 0.0026692559476941824
for O 0 0.2840874195098877
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 0.000226916978135705

METHODS O 0 0.0006303626578301191
DNA O 0 0.0002297479659318924
samples O 0 2.8698819733108394e-05
from O 0 1.351436139884754e-06
500 O 0 2.0259644770703744e-06
unrelated O 0 2.868988758564228e-06
Jews O 0 5.501236159943801e-07
of O 0 1.0489670643210047e-07
European O 0 1.0610976914904313e-06
or O 0 3.7917382655905385e-07
non O 0 3.6191204344504513e-06
- O 0 1.9073067960562184e-05
European O 0 2.025479489020654e-06
origin O 0 5.559812166211486e-07
, O 0 1.392035215985743e-07
with O 0 1.2560407469663915e-07
or O 0 2.7665024049383646e-07
without O 0 2.3296330198263604e-07
a O 0 2.8929227369189903e-07
personal O 0 2.6187324237980647e-06
and O 0 2.780390559564694e-06
/ O 0 0.001616195891983807
or O 0 7.566977160422539e-07
family O 0 1.028869974106783e-06
history O 0 3.6523817925626645e-07
of O 0 4.942369287164183e-07
neoplasia B-Disease 1 0.61358243227005
, O 0 1.285705934606085e-06
were O 0 1.8497955522889242e-07
examined O 0 1.5593429907312384e-06
for O 0 1.1083336914907704e-07
the O 0 2.0977367398700153e-07
I1307K O 0 3.8902646338101476e-05
variant O 0 7.920139978523366e-06
by O 0 2.0690981727966573e-07
the O 0 2.7579778816289036e-07
allele O 0 6.554535957548069e-06
- O 0 4.383274063002318e-05
specific O 0 2.930039045168087e-06
oligonucleotide O 0 0.00047138036461547017
( O 0 4.295612598070875e-06
ASO O 0 0.002824225230142474
) O 0 5.9383069128671195e-06
method O 0 2.051336196018383e-05
. O 0 1.572738983668387e-05

RESULTS O 0 0.002037846017628908
In O 0 1.285974940401502e-05
persons O 0 8.647440154163633e-06
at O 0 2.6277461984136607e-06
average O 0 6.273831240832806e-05
risk O 0 0.0026255957782268524
for O 0 0.1625427007675171
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
, O 0 1.406142928317422e-05
I1307K O 0 0.0002156958798877895
was O 0 1.5061611975397682e-06
found O 0 7.379039175248181e-07
in O 0 9.801232181416708e-07
5 O 0 2.071037670248188e-05
. O 0 2.95251993520651e-05

0 O 0 0.0001745162153383717
% O 0 1.218810666614445e-05
of O 0 1.1428764992160723e-06
120 O 0 3.774143351620296e-06
European O 0 5.7373240451852325e-06
and O 0 2.3635775505681522e-06
1 O 0 1.6812822650535963e-05
. O 0 2.504454278096091e-05

6 O 0 0.00018351610924582928
% O 0 1.324071672570426e-05
of O 0 1.3720807601202978e-06
188 O 0 1.640343361941632e-05
non O 0 9.579572179063689e-06
- O 0 4.534564504865557e-05
European O 0 4.72698366138502e-06
Jews O 0 2.956400749098975e-06
( O 0 1.217016233567847e-06
P O 0 0.00018631828424986452
= O 0 2.8685713914455846e-05
0 O 0 2.9520620046241675e-06
. O 0 7.343166430473502e-07
08 O 0 1.768490437825676e-05
) O 0 5.258674264041474e-06
. O 0 7.673405889363494e-06

It O 0 4.083577005076222e-05
occurred O 0 3.752509655896574e-05
in O 0 7.701071808696724e-06
15 O 0 1.846432678576093e-05
. O 0 3.5329423553775996e-05

4 O 0 0.00020849767315667123
% O 0 1.5549117961199954e-05
of O 0 1.5637898513887194e-06
52 O 0 4.3135059968335554e-05
Ashkenazi O 0 0.0027810679748654366
Israelis O 0 0.00017939877579919994
with O 0 3.84867780667264e-05
familial O 1 0.9994951486587524
cancer B-Disease 1 0.9955099821090698
( O 0 1.7881542589748278e-05
P O 0 0.28357869386672974
= O 0 0.00031036543077789247
0 O 0 6.53196002531331e-06
. O 0 5.347197884475463e-07
02 O 0 3.529352761688642e-05
) O 0 2.8993608225391654e-07
and O 0 1.4358710132000851e-07
was O 0 2.758909261046938e-07
not O 0 2.5557895355632354e-07
detected O 0 1.998259676838643e-06
in O 0 2.1805044525535777e-07
51 O 0 3.449334371907753e-06
non O 0 3.387628794371267e-06
- O 0 2.120825411111582e-05
European O 0 4.380899554234929e-06
Jews O 0 3.878994903061539e-06
at O 0 2.51089954872441e-06
increased O 0 0.0001268093183171004
cancer B-Disease 0 0.3650260865688324
risk O 0 0.00018896513211075217
. O 0 2.206927638326306e-05

Colorectal B-Disease 1 0.9999716281890869
neoplasia I-Disease 1 0.999679684638977
occurred O 0 0.001289195497520268
personally O 0 0.00024164942442439497
or O 0 3.4729680464806734e-06
in O 0 5.551790422941849e-07
the O 0 2.640600769154844e-07
families O 0 4.124895554014074e-07
of O 0 1.0155385155030672e-07
13 O 0 9.053305802808609e-07
of O 0 1.8228425346933363e-07
20 O 0 1.8744258341030218e-06
Ashkenazi O 0 0.00013096659677103162
I1307K O 0 3.944040508940816e-05
carriers O 0 2.02131718651799e-06
, O 0 2.308082684976398e-07
8 O 0 4.4242230501367885e-07
of O 0 1.3299471390837425e-07
whom O 0 2.0231491362210363e-06
also O 0 4.798781105819216e-07
had O 0 3.103688186456566e-07
a O 0 4.845657031182782e-07
personal O 0 3.5592177027865546e-06
or O 0 2.1701578134525334e-06
family O 0 3.811951273746672e-06
history O 0 2.953385319415247e-06
of O 0 6.8874592216161545e-06
noncolonic O 1 0.791818380355835
neoplasia B-Disease 1 0.9653317928314209
. O 0 6.122851482359692e-05

CONCLUSIONS O 0 0.0009751772158779204
The O 0 2.5278279281337745e-05
I1307K O 0 0.000765398726798594
APC O 0 0.0013623804552480578
variant O 0 0.00022021986660547554
may O 0 5.437328582047485e-06
represent O 0 6.122172635514289e-07
a O 0 1.3603688557850546e-06
susceptibility O 0 0.0020424393005669117
gene O 0 3.087795994360931e-05
for O 0 3.166914393659681e-05
colorectal B-Disease 1 0.9999991655349731
, I-Disease 0 4.27287932325271e-06
or I-Disease 0 8.057962759266957e-07
other I-Disease 0 6.46937394321867e-07
, I-Disease 0 1.5599749531247653e-05
cancers I-Disease 0 0.14241409301757812
in O 0 1.9219974092266057e-06
Ashkenazi O 0 0.00851934589445591
Jews O 0 4.416139290697174e-06
, O 0 4.6563798150600633e-07
and O 0 4.779876690008678e-07
partially O 0 1.7487560398876667e-05
explains O 0 5.592342404270312e-06
the O 0 4.2094094965250406e-07
higher O 0 2.38811790040927e-05
incidence O 0 0.01722603477537632
of O 0 0.026749422773718834
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
in O 0 6.126165772002423e-06
European O 0 6.220987415872514e-05
Israelis O 0 0.0004886199021711946
. O 0 3.060111339436844e-05

Systematic O 0 0.0017779411282390356
analysis O 0 9.820179548114538e-05
of O 0 1.0024223229265772e-05
coproporphyrinogen O 0 0.027203457430005074
oxidase O 0 0.0022761791478842497
gene O 0 0.0006366776651702821
defects O 0 0.12611041963100433
in O 0 1.3509952623280697e-05
hereditary B-Disease 0 0.21240516006946564
coproporphyria I-Disease 1 0.7622697353363037
and O 0 6.29355781711638e-05
mutation O 0 0.00025397862191312015
update O 0 0.0006162619101814926
. O 0 2.410787419648841e-05

Hereditary B-Disease 1 0.9974055886268616
coproporphyria I-Disease 1 0.9973102807998657
( O 0 0.0013816850259900093
HC B-Disease 1 0.9999032020568848
) O 0 0.00013930784189142287
is O 0 4.642369276552927e-06
an O 0 3.562253186828457e-05
acute O 1 0.9998101592063904
hepatic B-Disease 1 0.9999997615814209
porphyria I-Disease 1 0.9999997615814209
with O 0 0.006104827858507633
autosomal O 1 0.9774786233901978
dominant O 0 0.003857189556583762
inheritance O 0 0.0010718180565163493
caused O 0 8.161841105902568e-05
by O 0 2.7808414415630978e-06
deficient B-Disease 0 0.0028524918016046286
activity I-Disease 0 1.7026203522618744e-06
of I-Disease 0 6.612200422750902e-07
coproporphyrinogen I-Disease 0 0.002368723275139928
III I-Disease 0 0.003178555751219392
oxidase I-Disease 0 8.299498585984111e-05
( O 0 5.270372639643028e-06
CPO O 0 0.00018622913921717554
) O 0 6.941557785467012e-06
. O 0 1.1177578926435672e-05

Clinical O 1 0.7825962901115417
manifestations O 0 0.0025920786429196596
of O 0 1.4506257684843149e-05
the O 0 6.0598271375056356e-05
disease O 0 0.15855219960212708
are O 0 2.4084854430839187e-06
characterized O 0 0.0014845399418845773
by O 0 2.5906487280735746e-05
acute O 1 0.956809937953949
attacks O 0 0.0035732805263251066
of O 0 0.0001836971496231854
neurological B-Disease 1 0.9999947547912598
dysfunction I-Disease 1 0.9976465106010437
often O 0 2.0256982679711655e-05
precipitated O 0 0.0015598285244777799
by O 0 1.742308654684166e-06
drugs O 0 5.482049800775712e-06
, O 0 6.34802745480556e-07
fasting O 0 1.9671182599267922e-05
, O 0 4.825071755476529e-06
cyclical O 0 0.04597919434309006
hormonal O 0 0.0004154632624704391
changes O 0 5.485004294314422e-06
, O 0 6.109380592533853e-06
or O 0 0.00021892230142839253
infectious B-Disease 1 0.9442704916000366
diseases I-Disease 0 0.46230459213256836
. O 0 8.300399349536747e-05

Skin O 1 0.9999853372573853
photosensitivity O 1 0.9999508857727051
may O 0 0.0009952684631571174
also O 0 9.89488762570545e-06
be O 0 3.3067758522520307e-06
present O 0 1.1707698831742164e-05
. O 0 2.476549707353115e-05

The O 0 1.628933932806831e-05
seven O 0 1.004514160740655e-05
exons O 0 5.965037053101696e-05
, O 0 1.3929715123595088e-06
the O 0 5.882567393200588e-07
exon O 0 1.4153275515127461e-05
/ O 0 2.7759484510170296e-05
intron O 0 2.040630170085933e-05
boundaries O 0 6.580118565580051e-07
and O 0 1.77594969841266e-07
part O 0 1.5638838135600963e-07
of O 0 1.1022684276440486e-07
3 O 0 2.0096920252399286e-06
noncoding O 0 2.213719199062325e-05
sequence O 0 3.7053337109682616e-07
of O 0 5.91025646201615e-08
the O 0 1.41004605325179e-07
CPO O 0 5.303237776388414e-05
gene O 0 1.0329342785553308e-06
were O 0 7.855561534597655e-08
systematically O 0 1.6923777366173454e-06
analyzed O 0 8.964316862147825e-07
by O 0 1.0545156925445553e-07
an O 0 1.3788213948373595e-07
exon O 0 4.355118107923772e-06
- O 0 8.163426173268817e-06
by O 0 5.930423867539503e-07
- O 0 4.349803566583432e-05
exon O 0 4.975584670319222e-05
denaturing O 0 0.00041926398989744484
gradient O 0 0.00012448232155293226
gel O 0 0.000584110151976347
electrophoresis O 0 9.614934242563322e-05
( O 0 1.7181077964778524e-06
DGGE O 0 7.392212137347087e-05
) O 0 5.733816692554683e-07
strategy O 0 1.2933675179738202e-06
followed O 0 2.816754829382262e-07
by O 0 1.3785742680738622e-07
direct O 0 4.4151104816592124e-07
sequencing O 0 2.000162339754752e-06
in O 0 3.1062467087394907e-07
seven O 0 1.0373529448770569e-06
unrelated O 0 3.5669720091391355e-05
heterozygous O 0 6.740603566868231e-05
HC B-Disease 1 0.9999760389328003
patients O 0 0.01734323427081108
from O 0 8.008617555788078e-07
France O 0 1.1446039934526198e-05
, O 0 1.2333752010817989e-06
Holland O 0 4.481750511331484e-05
, O 0 1.0490045951883076e-06
and O 0 1.4997085600043647e-06
Czech O 0 9.214525198331103e-05
Republic O 0 2.2896369046065956e-05
. O 0 2.3481075913878158e-05

Seven O 0 0.00023374080774374306
novel O 0 0.00019924086518585682
mutations O 0 0.00010809325613081455
and O 0 9.475341471443244e-07
two O 0 1.0969889672196587e-06
new O 0 1.1699840797518846e-05
polymorphisms O 0 0.0003740875981748104
were O 0 3.5977020615973743e-06
detected O 0 6.0221515013836324e-05
. O 0 1.318621616519522e-05

Among O 0 7.100389484548941e-05
these O 0 7.614053629367845e-06
mutations O 0 1.8962380636367016e-05
two O 0 5.853489710716531e-07
are O 0 6.811049502175592e-07
missense O 0 8.022841939236969e-05
( O 0 2.104207624142873e-06
G197W O 0 3.702746471390128e-05
, O 0 5.424455480351753e-07
W427R O 0 2.323338412679732e-05
) O 0 5.675626084666874e-07
, O 0 1.3025926648424502e-07
two O 0 8.888656566341524e-08
are O 0 1.376495930571764e-07
nonsense O 0 1.025330857373774e-05
( O 0 8.674174978295923e-07
Q306X O 0 1.6218826203839853e-05
, O 0 3.4668818216232467e-07
Q385X O 0 1.974329279619269e-05
) O 0 3.2649347758706426e-07
, O 0 6.308004429911307e-08
two O 0 4.425876909408544e-08
are O 0 5.399764546609731e-08
small O 0 2.9763828024442773e-07
deletions O 0 1.6108826457639225e-05
( O 0 8.145276524373912e-07
662de14bp O 0 2.0575174858095124e-05
; O 0 9.672883152234135e-07
1168del3bp O 0 2.0182957086944953e-05
removing O 0 8.68766903749929e-07
a O 0 2.401457379619387e-07
glycine O 0 9.64482023846358e-06
at O 0 2.063472237523456e-07
position O 0 3.0269117701209325e-07
390 O 0 3.7462127693288494e-06
) O 0 3.0464278211184137e-07
, O 0 8.762559389197122e-08
and O 0 5.543061831758678e-08
one O 0 5.4597169452108574e-08
is O 0 9.563166969428494e-08
a O 0 3.711030842623586e-07
splicing O 0 0.0002130916400346905
mutation O 0 1.2458835954021197e-05
( O 0 6.069427627153345e-07
IVS1 O 0 9.029484499478713e-05
- O 0 6.699481309624389e-05
15c O 0 4.2904091969830915e-05
- O 0 7.187006849562749e-05
- O 0 0.00014389140415005386
> O 0 7.40026735002175e-05
g O 0 7.206909504020587e-05
) O 0 3.589408379411907e-07
which O 0 9.980869464243369e-08
creates O 0 6.578995339623361e-07
a O 0 3.8443488392658764e-07
new O 0 1.6175170003407402e-06
acceptor O 0 7.652156637050211e-05
splice O 0 0.00046186885447241366
site O 0 2.4382366973441094e-05
. O 0 2.1918953279964626e-05

The O 0 6.845445750514045e-05
pathological O 0 0.0008443099795840681
significance O 0 1.13646810859791e-05
of O 0 1.0890428256971063e-06
the O 0 6.260669920266082e-07
point O 0 2.599570279926411e-06
mutations O 0 2.5780153009691276e-05
G197W O 0 5.3503776143770665e-05
, O 0 8.30664134809922e-07
W427R O 0 2.0917404981446452e-05
, O 0 1.8396130485598405e-07
and O 0 8.13883431760587e-08
the O 0 8.13248774989006e-08
in O 0 1.4541814152835286e-07
- O 0 2.463352029735688e-05
frame O 0 2.2681220798403956e-05
deletion O 0 3.806486347457394e-05
390delGly O 0 3.744738205568865e-05
were O 0 1.3355548844629084e-07
assessed O 0 4.203736807539826e-07
by O 0 6.088175297236376e-08
their O 0 1.043766033603788e-07
respective O 0 5.599272867584659e-07
expression O 0 7.08678953742492e-07
in O 0 1.644450264848274e-07
a O 0 3.820114784502948e-07
prokaryotic O 0 4.55117151432205e-06
system O 0 1.2251992984602111e-06
using O 0 1.361843374070304e-06
site O 0 2.918112159022712e-06
- O 0 0.0001000993070192635
directed O 0 2.0228664652677253e-05
mutagenesis O 0 0.0003873643872793764
. O 0 3.9097940316423774e-05

These O 0 9.490195225225762e-05
mutations O 0 0.0006126377847976983
resulted O 0 1.9721655917237513e-05
in O 0 1.3802925877826056e-06
the O 0 6.559261009897455e-07
absence O 0 3.1305482934840256e-06
or O 0 6.197038828759105e-07
a O 0 9.267061500395357e-07
dramatic O 0 4.155237184022553e-05
decrease O 0 4.678201730712317e-05
of O 0 1.4686637541672098e-06
CPO O 0 0.0006436457042582333
activity O 0 1.5459247151738964e-05
. O 0 1.7025671695591882e-05

The O 0 1.994447666220367e-05
two O 0 6.08506343269255e-06
polymorphisms O 0 0.0001407850650139153
were O 0 1.2598368357430445e-06
localized O 0 1.1815815923910122e-05
in O 0 8.417190429099719e-07
noncoding O 0 4.4172043999424204e-05
part O 0 3.53675034148182e-07
of O 0 1.1314823211705516e-07
the O 0 2.2729646786956437e-07
gene O 0 1.5173430938375532e-06
1 O 0 7.568781370537181e-07
) O 0 3.369175942680158e-07
a O 0 5.102691602587583e-07
C O 0 0.00012737272481899709
/ O 0 0.00048023773706518114
G O 0 0.0007073223823681474
polymorphism O 0 3.5391865367273567e-06
in O 0 1.3826307565523166e-07
the O 0 1.6800471769329306e-07
promotor O 0 0.00019005798094440252
region O 0 3.7242409689497435e-06
, O 0 2.7270996838524297e-07
142 O 0 1.8377734249952482e-06
bp O 0 5.30195829924196e-05
upstream O 0 1.0456734571562265e-06
from O 0 1.2535934956758865e-07
the O 0 1.1530145371807521e-07
transcriptional O 0 1.78897357727692e-06
initiation O 0 1.357785663458344e-06
site O 0 1.1694547765728203e-06
( O 0 4.642209034955158e-07
- O 0 2.4771756216068752e-05
142C O 0 0.00010207417653873563
/ O 0 0.00021208343969192356
G O 0 0.0003714243939612061
) O 0 4.683546706019115e-07
, O 0 8.932642003856017e-08
and O 0 1.3740105941906222e-07
2 O 0 1.643714767851634e-06
) O 0 3.1479973472414713e-07
a O 0 2.4878144699869154e-07
6 O 0 6.391067927324912e-06
bp O 0 0.0010321784066036344
deletion O 0 1.9036158846574835e-05
polymorphism O 0 2.048079295491334e-06
in O 0 9.826280233937723e-08
the O 0 7.657095579816087e-08
3 O 0 1.3494476434061653e-06
noncoding O 0 2.2550562789547257e-05
part O 0 1.2697017837126623e-07
of O 0 6.771606564370813e-08
the O 0 1.5067647041178134e-07
CPO O 0 8.825796248856932e-05
gene O 0 1.662560748627584e-06
, O 0 2.710637261316151e-07
574 O 0 6.5082681430794764e-06
bp O 0 9.682949166744947e-05
downstream O 0 1.0718326848291326e-06
of O 0 6.299011090504791e-08
the O 0 9.719027360688415e-08
last O 0 3.261872620896611e-07
base O 0 2.868289357138565e-07
of O 0 7.241825272785718e-08
the O 0 2.0677568102200894e-07
normal O 0 3.3676994917186676e-06
termination O 0 3.21461666317191e-05
codon O 0 1.405688362865476e-05
( O 0 1.8787495719152503e-06
+ O 0 6.336035585263744e-05
574 O 0 7.459762127837166e-05
delATTCTT O 0 0.0002680789621081203
) O 0 1.0374171324656345e-05
. O 0 1.1529234143381473e-05

Five O 0 8.379874634556472e-05
intragenic O 0 0.0038620203267782927
dimorphisms O 0 0.007207159884274006
are O 0 2.275101451232331e-06
now O 0 8.955241810326697e-07
well O 0 5.261084652374848e-07
characterized O 0 2.6426150725455955e-05
and O 0 4.6920587237764266e-07
the O 0 2.5248263568755647e-07
high O 0 2.879083695006557e-06
degree O 0 5.512430107046384e-06
of O 0 9.660392379373661e-07
allelic O 0 0.00032895946060307324
heterogeneity O 0 0.000503977935295552
in O 0 4.551110578177031e-06
HC B-Disease 1 0.9911571741104126
is O 0 2.191341536672553e-06
demonstrated O 0 1.5007658475951757e-06
with O 0 1.7538702934416506e-07
seven O 0 4.905404580313188e-07
new O 0 8.262538813141873e-07
different O 0 2.2436555013882753e-07
mutations O 0 2.331736595806433e-06
making O 0 1.3257201203487057e-07
a O 0 1.0177821252455033e-07
total O 0 1.675929723887748e-07
of O 0 2.2203452942903823e-07
nineteen O 0 3.158638355671428e-05
CPO O 0 0.23576796054840088
gene B-Disease 0 0.0003401557041797787
defects I-Disease 0 0.20455589890480042
reported O 0 1.0135952834389172e-05
so O 0 3.9644109506298264e-07
far O 0 1.0614367056405172e-06
. O 0 1.8688265299715567e-06
. O 0 7.403869858535472e-06

Coincidence O 0 0.00014015512715559453
of O 0 3.335350584166008e-06
two O 0 1.8102807644027052e-06
novel O 0 7.24731444279314e-06
arylsulfatase O 0 0.00024894921807572246
A O 0 4.7402963900822215e-06
alleles O 0 1.3832332115271129e-05
and O 0 2.137551973646623e-06
mutation O 0 1.3418015441857278e-05
459 O 0 7.085421384545043e-05
+ O 0 0.0002474453649483621
1G O 0 0.000337352481437847
> O 0 2.8785520044039004e-05
A O 0 6.353720891638659e-07
within O 0 2.682091917449725e-07
a O 0 4.799848056791234e-07
family O 0 4.349249593360582e-06
with O 0 2.0687715732492507e-05
metachromatic B-Disease 1 0.9999933242797852
leukodystrophy I-Disease 1 0.9999967813491821
: O 0 1.0005062904383522e-05
molecular O 0 1.1021355931006838e-05
basis O 0 1.6763883650128264e-06
of O 0 2.7712026167137083e-06
phenotypic O 0 0.00015982608601916581
heterogeneity O 0 0.002016050973907113
. O 0 7.226550224004313e-05

In O 0 3.411488069104962e-05
a O 0 8.33966532809427e-06
family O 0 9.921923265210353e-06
with O 0 2.149158262909623e-06
three O 0 2.3536667868029326e-06
siblings O 0 4.362598338047974e-05
, O 0 6.055597623344511e-07
one O 0 3.2561848684053984e-07
developed O 0 4.6305103751365095e-06
classical O 0 2.6513338525546715e-05
late O 0 0.00027300597866997123
infantile O 1 0.9787020683288574
metachromatic B-Disease 1 0.9999985694885254
leukodystrophy I-Disease 1 0.9999997615814209
( O 0 0.0001517396158305928
MLD B-Disease 1 0.9999818801879883
) O 0 2.082117680402007e-05
, O 0 1.946566271726624e-06
fatal O 0 9.949786181095988e-05
at O 0 1.1207456509509939e-06
age O 0 1.507963474978169e-06
5 O 0 3.5254527119832346e-06
years O 0 9.195980510412483e-07
, O 0 3.101741015143489e-07
with O 0 2.461848453094717e-06
deficient O 0 0.048938412219285965
arylsulfatase O 0 0.011036669835448265
A O 0 4.83617350255372e-06
( O 0 6.676766133750789e-06
ARSA O 0 0.17353889346122742
) O 0 1.3712892723560799e-06
activity O 0 4.2622957607818535e-07
and O 0 2.8294732601352734e-07
increased O 0 2.0572288121911697e-06
galactosylsulfatide O 0 0.005146274343132973
( O 0 1.3191209291107953e-05
GS O 1 0.9498444199562073
) O 0 1.2743075785692781e-05
excretion O 0 7.554694457212463e-05
. O 0 1.8445687601342797e-05

The O 0 1.393391994497506e-05
two O 0 1.7258968227906735e-06
other O 0 1.026830091177544e-06
siblings O 0 3.350707265781239e-05
, O 0 2.621456133056199e-06
apparently O 0 7.705714779149275e-06
healthy O 0 3.900034243997652e-06
at O 0 4.877406354353298e-07
12 O 0 1.2266350495337974e-06
( O 0 5.506485081241408e-07
1 O 0 1.6347694327123463e-06
/ O 0 3.081620889133774e-05
2 O 0 2.0174402379780076e-06
) O 0 2.3396924575536104e-07
and O 0 1.085235226128134e-07
15 O 0 6.200407938194985e-07
years O 0 3.211767420907563e-07
, O 0 2.589173675460188e-07
respectively O 0 1.4345793033498921e-06
, O 0 9.605120254718713e-08
and O 0 1.0974894593118734e-07
their O 0 4.995899871573783e-07
father O 0 5.3601115723722614e-06
, O 0 1.2054408671247074e-06
apparently O 0 5.894017249374883e-06
healthy O 0 1.6441975958514377e-06
as O 0 1.6711815931103047e-07
well O 0 2.057309984593303e-07
, O 0 4.903949388790352e-07
presented O 0 4.470258318178821e-06
ARSA O 0 0.024168195202946663
and O 0 2.0871755168627715e-06
GS O 1 0.9844301342964172
values O 0 9.979457900044508e-07
within O 0 2.0086427809928864e-07
the O 0 2.3311085328714398e-07
range O 0 2.512224000383867e-06
of O 0 7.720102075836621e-06
MLD B-Disease 1 0.999998927116394
patients O 0 0.08324844390153885
. O 0 3.542510239640251e-05

Mutation O 0 0.002198921050876379
screening O 0 0.0001186855006380938
and O 0 5.103327112010447e-06
sequence O 0 6.623158242291538e-06
analysis O 0 8.509057806804776e-06
disclosed O 0 2.3735912691336125e-05
the O 0 4.922443963550904e-07
involvement O 0 2.8157658107375028e-06
of O 0 1.8552812264260865e-07
three O 0 4.24429373424573e-07
different O 0 1.1230802101636073e-06
ARSA O 1 0.9014472961425781
mutations O 0 3.35167242155876e-05
being O 0 2.537838099669898e-07
the O 0 1.602905825848211e-07
molecular O 0 2.8185706923977705e-06
basis O 0 7.87401006618893e-07
of O 0 7.649095437045617e-07
intrafamilial O 0 0.00713255675509572
phenotypic O 0 0.00014333266881294549
heterogeneity O 0 0.0007933997549116611
. O 0 4.268962220521644e-05

The O 0 6.312719051493332e-05
late O 0 0.0006626060931012034
infantile O 1 0.9976943135261536
patient O 1 0.7059937715530396
inherited O 0 0.017750777304172516
from O 0 3.227597517252434e-06
his O 0 7.999023182492238e-06
mother O 0 2.402905374765396e-05
the O 0 7.668304533581249e-07
frequent O 0 1.2054535545757972e-05
0 O 0 4.641965279006399e-05
- O 0 0.003423149697482586
type O 0 2.8887461667181924e-05
mutation O 0 6.835211024736054e-06
459 O 0 1.063096624420723e-05
+ O 0 8.742310456000268e-05
1G O 0 0.0001323407341260463
> O 0 1.5664525562897325e-05
A O 0 4.012083536508726e-07
, O 0 2.3342454369412735e-07
and O 0 1.4978775197960204e-07
from O 0 1.8030409876246267e-07
his O 0 9.251035066881741e-07
father O 0 5.776799298473634e-06
a O 0 7.678366387153801e-07
novel O 0 2.152696424673195e-06
, O 0 2.1880703116039513e-07
single O 0 4.934094590680616e-07
basepair O 0 5.3299365390557796e-05
microdeletion O 0 1.6757516277721152e-05
of O 0 1.7567361965120654e-07
guanine O 0 1.9847104795189807e-06
at O 0 1.9051483945986547e-07
nucleotide O 0 2.0161248812655685e-06
7 O 0 9.047039952747582e-07
in O 0 2.4234955731117225e-07
exon O 0 7.422257112921216e-06
1 O 0 2.3076411252986873e-06
( O 0 2.547773647165741e-06
7delG O 0 0.00012095731653971598
) O 0 7.003623977652751e-06
. O 0 1.490100385126425e-05

The O 0 2.3169151972979307e-05
two O 0 1.5096878087206278e-05
clinically O 0 0.0020749103277921677
unaffected O 0 0.0002126572944689542
siblings O 0 5.859880184289068e-05
carried O 0 2.8224437755852705e-06
the O 0 1.416104964846454e-06
maternal O 0 3.57790086127352e-05
mutation O 0 1.36675453177304e-05
459 O 0 5.012445762986317e-05
+ O 0 0.00027442979626357555
1G O 0 0.00023788600810803473
> O 0 3.723581903614104e-05
A O 0 5.906182423132122e-07
and O 0 2.4710425350349396e-07
, O 0 1.6982777140128746e-07
on O 0 2.2367846952420223e-07
their O 0 5.516198484656343e-07
paternal O 0 1.1557415746210609e-05
allele O 0 6.470838798122713e-06
, O 0 2.1249817905300006e-07
a O 0 3.0435239750659093e-07
novel O 0 1.6243418485828442e-06
cytosine O 0 4.788226306118304e-06
to O 0 3.7910839978394506e-07
thymidine O 0 4.976988930138759e-05
transition O 0 2.3419029275828507e-06
at O 0 4.420254526849021e-07
nucleotide O 0 4.58833255834179e-06
2435 O 0 6.633961311308667e-05
in O 0 3.4844393326238787e-07
exon O 0 5.070363386039389e-06
8 O 0 1.0238584309263388e-06
, O 0 1.9159055852924212e-07
resulting O 0 4.2977330849680584e-07
in O 0 1.2636847657176986e-07
substitution O 0 5.212779683461122e-07
of O 0 2.2117248477115936e-07
alanine O 0 5.709218021365814e-05
464 O 0 4.935087054036558e-05
by O 0 1.9130150121782208e-06
valine O 0 0.0023151682689785957
( O 0 6.5898484535864554e-06
A464V O 0 0.00020785414380952716
) O 0 9.73010992311174e-06
. O 0 1.2704706932709087e-05

The O 0 8.420809172093868e-05
fathers O 0 0.0004938487545587122
genotype O 0 0.0034311506897211075
thus O 0 2.6314617571188137e-05
was O 0 9.862998012977187e-06
7delG O 0 0.001463412307202816
/ O 0 0.0019902789499610662
A464V O 0 0.0011280473554506898
. O 0 5.63714602321852e-05

Mutation O 0 0.0031082620844244957
A464V O 0 0.002021991880610585
was O 0 1.6201451217057183e-05
not O 0 1.022961555463553e-06
found O 0 8.61688022268936e-07
in O 0 1.054103904607473e-06
18 O 0 3.0322296879603527e-05
unrelated O 0 0.036390699446201324
MLD B-Disease 1 0.9999998807907104
patients O 0 0.02182180806994438
and O 0 1.7519106449981336e-06
50 O 0 6.05039531365037e-06
controls O 0 6.418683187803254e-05
. O 0 2.1262121663312428e-05

A464V O 0 0.00591115839779377
, O 0 3.069850572501309e-05
although O 0 9.103617230721284e-06
clearly O 0 6.144970939203631e-06
modifying O 0 4.978365541319363e-05
ARSA O 0 0.3726346492767334
and O 0 2.00757658603834e-05
GS O 1 0.9999561309814453
levels O 0 1.9126035113004036e-05
, O 0 1.1065716307712137e-06
apparently O 0 2.879978865166777e-06
bears O 0 5.6088897508743685e-06
little O 0 1.0314793144061696e-06
significance O 0 1.7762997686077142e-06
for O 0 2.848788653864176e-06
clinical O 0 0.00015282048843801022
manifestation O 0 4.8014786443673074e-05
of O 0 3.7106240142747993e-06
MLD B-Disease 1 0.999975323677063
, O 0 9.66988955042325e-06
mimicking O 0 9.666619007475674e-05
the O 0 1.9267727111582644e-06
frequent O 0 8.403272659052163e-05
ARSA O 1 0.8829541802406311
pseudodeficiency O 0 0.024820322170853615
allele O 0 0.00028973404550924897
. O 0 4.26211190642789e-05

Our O 0 0.0001306958874920383
results O 0 0.00011798735795309767
demonstrate O 0 1.9290566342533566e-05
that O 0 7.798516321599891e-07
in O 0 8.906898187888146e-07
certain O 0 3.090384325332707e-06
genetic O 0 0.00023819418856874108
conditions O 0 0.021333375945687294
MLD B-Disease 1 0.9999948740005493
- O 0 0.023316366598010063
like O 0 4.0252507460536435e-06
ARSA O 0 0.1345009207725525
and O 0 3.1120364383241395e-06
GS O 1 0.9790468811988831
values O 0 1.319076886829862e-06
need O 0 3.8876655139574723e-07
not O 0 9.484981688956395e-08
be O 0 1.2236272084464872e-07
paralleled O 0 1.593683373357635e-05
by O 0 2.2438713131123222e-05
clinical O 1 0.6536964178085327
disease O 0 0.031401995569467545
, O 0 8.046895914048946e-07
a O 0 6.771657581339241e-07
finding O 0 3.490886001600302e-06
with O 0 7.3987380346807186e-06
serious O 0 0.0016553814057260752
diagnostic O 0 0.10416083037853241
and O 0 5.665731441695243e-05
prognostic O 1 0.7110989093780518
implications O 0 0.00033191402326337993
. O 0 3.4222866815980524e-05

Moreover O 0 0.0006598905893042684
, O 0 2.46632316702744e-05
further O 0 1.147222428699024e-05
ARSA O 0 0.17799538373947144
alleles O 0 8.94193144631572e-05
functionally O 0 5.4493888455908746e-05
similar O 0 2.4224611934187124e-06
to O 0 8.769913506512239e-07
A464V O 0 0.00013396255963016301
might O 0 2.2158108095027274e-06
exist O 0 5.877296302969626e-07
which O 0 1.4116470481440047e-07
, O 0 1.2076921507286897e-07
together O 0 1.8300536908100185e-07
with O 0 7.528159358116682e-07
0 O 0 0.00019695448281709105
- O 0 0.2045390009880066
type O 0 0.00028327692416496575
mutations O 0 6.558524182764813e-05
, O 0 1.5808205944267684e-06
may O 0 1.164914920082083e-05
cause O 0 2.8410500817699358e-05
pathological O 0 0.0017463329713791609
ARSA O 1 0.946358859539032
and O 0 1.1717471352312714e-05
GS O 1 0.9999629259109497
levels O 0 1.366961714666104e-05
, O 0 6.187779035826679e-07
but O 0 4.800589294973179e-07
not O 0 1.2360269465716556e-06
clinical O 0 0.00027684622909873724
outbreak O 0 1.6469221009174362e-05
of O 0 6.770379172849061e-07
the O 0 1.6200076061068103e-05
disease O 0 0.008194820955395699
. O 0 7.595204806420952e-06
. O 0 2.1410065528471023e-05

Human O 0 0.01174996979534626
MLH1 O 1 0.9999289512634277
deficiency O 1 0.9999682903289795
predisposes O 0 0.2519138753414154
to O 0 0.00037319152033887804
hematological B-Disease 1 0.9999903440475464
malignancy I-Disease 1 0.9999736547470093
and O 0 0.0005484730354510248
neurofibromatosis B-Disease 1 0.999985933303833
type I-Disease 0 0.0002864615817088634
1 I-Disease 0 6.792294152546674e-05
. O 0 4.855494626099244e-05

Heterozygous O 0 0.0029425788670778275
germ O 0 0.07059568166732788
- O 0 0.0013991384766995907
line O 0 4.622880442184396e-05
mutations O 0 4.7440447815461084e-05
in O 0 6.751507157787273e-07
the O 0 8.668187660987314e-07
DNA O 0 2.8953319997526705e-05
mismatch O 0 0.0005888435989618301
repair O 0 0.024273579940199852
genes O 0 1.5706749763921835e-05
lead O 0 2.435341230011545e-05
to O 0 2.7286416298011318e-05
hereditary B-Disease 1 0.9994435906410217
nonpolyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.999997615814209
. O 0 0.00022088039258960634

The O 0 0.0011444296687841415
disease O 1 0.9023582935333252
susceptibility O 0 0.00565924821421504
of O 0 4.039055511384504e-06
individuals O 0 6.098320227465592e-06
who O 0 6.276336534938309e-06
constitutionally O 0 1.6077365216915496e-05
lack O 0 4.7793801059015095e-06
both O 0 7.249688565025281e-07
wild O 0 1.2044999493809883e-05
- O 0 0.0034796076361089945
type O 0 3.361615017638542e-05
alleles O 0 1.56252699525794e-05
is O 0 1.5722057469247375e-06
unknown O 0 1.0858044333872385e-05
. O 0 1.4845033547317144e-05

We O 0 2.6772342607728206e-05
have O 0 3.0163698738761013e-06
identified O 0 3.950307018385502e-06
three O 0 8.201320156331349e-07
offspring O 0 2.3182725271908566e-05
in O 0 1.501534711678687e-06
a O 0 2.6381581847090274e-05
hereditary B-Disease 1 0.9998986721038818
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 0.00030139347654767334
who O 0 8.067706949077547e-05
developed O 0 0.004139279946684837
hematological B-Disease 1 0.9998438358306885
malignancy I-Disease 1 0.990835428237915
at O 0 2.7108801532449434e-06
a O 0 1.1029325150957447e-06
very O 0 9.798260407478665e-07
early O 0 3.910432496923022e-06
age O 0 9.235653237738006e-07
, O 0 3.5122738495374506e-07
and O 0 1.765833417266549e-07
at O 0 1.3575677826338506e-07
least O 0 6.503117333522823e-08
two O 0 4.674158304851517e-08
of O 0 4.824160271255096e-08
them O 0 9.551791180228975e-08
displayed O 0 5.906244382458681e-07
signs O 0 3.2129148621606873e-06
of O 0 1.3724536529480247e-06
neurofibromatosis B-Disease 1 0.9981080293655396
type I-Disease 0 5.36746192665305e-05
1 I-Disease 0 2.9876757253077812e-05
( O 0 1.755913399392739e-05
NF1 B-Disease 0 0.004728012252599001
) O 0 1.2190559573355131e-05
. O 0 1.517282726126723e-05

DNA O 0 0.0005519536207430065
sequence O 0 3.1231324101099744e-05
analysis O 0 8.273709681816399e-06
and O 0 1.875854650279507e-06
allele O 0 1.4228264262783341e-05
- O 0 3.958222805522382e-05
specific O 0 1.3571603858508752e-06
amplification O 0 1.6904254152905196e-05
in O 0 3.3773986274354684e-07
two O 0 5.173723138796049e-07
siblings O 0 3.027317870873958e-05
revealed O 0 1.4570493476639967e-05
a O 0 2.3662298644921975e-06
homozygous O 0 6.0738799220416695e-05
MLH1 O 0 0.22431716322898865
mutation O 0 1.9954655726905912e-05
( O 0 8.653535132907564e-07
C676T O 0 2.714985930651892e-05
- O 0 0.00018265651306137443
- O 0 0.002146173035725951
> O 0 0.0002981275029014796
Arg226Stop O 0 0.00042932876385748386
) O 0 6.5543613345653284e-06
. O 0 1.263870217371732e-05

Thus O 0 0.00010550499428063631
, O 0 8.554189662390854e-06
a O 0 7.414178071485367e-06
homozygous O 0 5.7014378398889676e-05
germ O 0 0.0010161943500861526
- O 0 0.0003318763629067689
line O 0 2.2194732082425617e-05
MLH1 O 0 0.016239190474152565
mutation O 0 3.9813079638406634e-05
and O 0 4.035001438751351e-06
consequent O 0 0.030910588800907135
mismatch O 1 0.9744559526443481
repair O 1 0.9999939203262329
deficiency O 1 0.9999847412109375
results O 0 0.00012399967818055302
in O 0 2.7810510800918564e-06
a O 0 2.335968747502193e-05
mutator O 1 0.9998371601104736
phenotype O 1 0.9948535561561584
characterized O 0 0.09048382192850113
by O 0 0.00010454995936015621
leukemia B-Disease 1 0.9999854564666748
and O 0 0.00029333229758776724
/ O 1 0.9971888661384583
or O 0 0.12467197328805923
lymphoma B-Disease 1 1.0
associated O 0 0.0009369669132865965
with O 0 4.549941513687372e-05
neurofibromatosis B-Disease 1 0.9999711513519287
type I-Disease 0 7.52190753701143e-05
1 I-Disease 0 1.7565031157573685e-05
. O 0 5.54515145267942e-06
. O 0 2.020822648773901e-05

Missense O 1 0.9018369913101196
mutations O 0 0.010706942528486252
in O 0 5.286914529278874e-06
the O 0 6.390912403730908e-07
most O 0 3.694839278978179e-07
ancient O 0 9.275965453525714e-07
residues O 0 3.419056156417355e-06
of O 0 2.5497152478237695e-07
the O 0 7.926138323455234e-07
PAX6 O 0 0.001533133676275611
paired O 0 3.567825478967279e-05
domain O 0 6.0354923334671184e-06
underlie O 0 3.690316589199938e-05
a O 0 1.8811914515026729e-06
spectrum O 0 3.369523255969398e-05
of O 0 1.7241154637304135e-05
human O 0 0.0532204806804657
congenital B-Disease 1 0.9999998807907104
eye I-Disease 1 0.9999984502792358
malformations I-Disease 1 0.9999867677688599
. O 0 0.00044984149280935526

Mutations O 0 0.003333378816023469
of O 0 1.436478032701416e-05
the O 0 9.955655514204409e-06
human O 0 2.333637348783668e-05
PAX6 O 1 0.6927477121353149
gene O 0 0.0007432355778291821
underlie O 0 0.3437694013118744
aniridia B-Disease 1 0.999998927116394
( O 0 0.03704165667295456
congenital B-Disease 1 0.9999927282333374
absence I-Disease 0 4.760786032420583e-05
of I-Disease 0 1.113101916416781e-06
the I-Disease 0 4.197461748844944e-06
iris I-Disease 1 0.9865971207618713
) O 0 7.624437330377987e-06
, O 0 4.977324579158449e-07
a O 0 1.4325489701150218e-06
rare O 0 0.00012510073429439217
dominant O 0 0.007599454373121262
malformation B-Disease 1 0.9426273107528687
of I-Disease 0 3.0313799470604863e-06
the I-Disease 0 1.5897245248197578e-05
eye I-Disease 0 0.15746231377124786
. O 0 8.697133307578042e-05

The O 0 4.0299968532053754e-05
spectrum O 0 6.003550879540853e-05
of O 0 1.1834908946184441e-05
PAX6 O 1 0.9229552149772644
mutations O 0 0.0023781326599419117
in O 0 2.152350134565495e-05
aniridia B-Disease 1 0.9999988079071045
patients O 0 0.1093398779630661
is O 0 1.0902441545113106e-06
highly O 0 3.2936861771304393e-06
biased O 0 6.757079518138198e-06
, O 0 2.7363793719814566e-07
with O 0 1.522960815236729e-07
92 O 0 6.376645615091547e-06
% O 0 3.574292861685535e-07
of O 0 7.923336653448132e-08
all O 0 1.599410666131007e-07
reported O 0 1.9165601770509966e-05
mutations O 0 7.767381248413585e-06
leading O 0 1.4185299050950562e-06
to O 0 7.907240728854958e-07
premature O 0 7.798278966220096e-05
truncation O 0 1.0446903615957126e-05
of O 0 1.2684286332387273e-07
the O 0 2.57320522223381e-07
protein O 0 3.866217411996331e-06
( O 0 5.631855515275674e-07
nonsense O 0 2.4107537228701403e-06
, O 0 2.0919530641094752e-07
splicing O 0 5.138455890119076e-06
, O 0 3.171078333252808e-07
insertions O 0 2.6132936454814626e-06
and O 0 3.5145387755619595e-07
deletions O 0 5.87194654144696e-06
) O 0 3.455170940469543e-07
and O 0 1.0583885767800894e-07
just O 0 1.3094967243887368e-07
2 O 0 1.401308509230148e-06
% O 0 5.051879270467907e-07
leading O 0 1.8502331045056053e-07
to O 0 5.763542532122301e-08
substitution O 0 1.73500836808671e-07
of O 0 4.1984321796917357e-08
one O 0 1.351759379986106e-07
amino O 0 2.0311354091973044e-06
acid O 0 3.108572127530351e-05
by O 0 3.2441644748359977e-07
another O 0 5.70204178984568e-07
( O 0 4.133072252443526e-06
missense O 0 0.00010220391413895413
) O 0 5.083382802695269e-06
. O 0 1.4739852304046508e-05

The O 0 4.8788504500407726e-05
extraordinary O 0 5.685225551133044e-05
conservation O 0 1.3059244338364806e-05
of O 0 7.882086947574862e-07
the O 0 8.727695899324317e-07
PAX6 O 0 0.000496698310598731
protein O 0 4.14975147577934e-06
at O 0 2.7960476245425525e-07
the O 0 1.8067416363010125e-07
amino O 0 1.7452222209612955e-06
acid O 0 1.3750288417213596e-05
level O 0 7.619884172527236e-07
amongst O 0 1.0837122772500152e-06
vertebrates O 0 8.098871148831677e-06
predicts O 0 0.00034539905027486384
that O 0 7.192694511104492e-07
pathological O 0 0.0001951228332472965
missense O 0 0.006267065182328224
mutations O 0 6.839253182988614e-05
should O 0 2.9285789082678093e-07
in O 0 1.8545736679698166e-07
fact O 0 2.8891042802570155e-07
be O 0 1.0737688427298053e-07
common O 0 6.000329904054524e-07
even O 0 3.8710805938535486e-07
though O 0 3.0724302746421017e-07
they O 0 1.1018836687526345e-07
are O 0 1.553943747012454e-07
hardly O 0 1.6497909882673412e-06
ever O 0 1.035009972838452e-06
seen O 0 4.236899258103222e-06
in O 0 1.7346690583508462e-05
aniridia B-Disease 1 0.9999972581863403
patients O 0 0.1387537270784378
. O 0 3.4743588912533596e-05

This O 0 4.9108060920843855e-05
indicates O 0 5.079261973151006e-05
that O 0 7.63492721489456e-07
there O 0 2.2388312004295585e-07
is O 0 2.7781621270150936e-07
a O 0 7.458676236637984e-07
heavy O 0 0.0011328775435686111
ascertainment O 0 0.1533534973859787
bias O 0 3.6163826734991744e-05
in O 0 3.332665414745861e-07
the O 0 1.6393035195960692e-07
selection O 0 7.29009400401992e-07
of O 0 8.707128245077911e-07
patients O 0 0.00011632627865765244
for O 0 3.142447212667321e-06
PAX6 O 1 0.7812821269035339
mutation O 0 5.4035710491007194e-05
analysis O 0 1.7070198055080255e-06
and O 0 2.213377001680783e-07
that O 0 1.7342208025183936e-07
the O 0 6.550860121024016e-07
missing O 0 2.2399819499696605e-05
PAX6 O 1 0.6126263737678528
missense O 0 0.03730388358235359
mutations O 0 0.0004601589171215892
frequently O 0 1.7796601241570897e-05
may O 0 4.302171873860061e-05
underlie O 0 0.0014636003179475665
phenotypes O 0 0.0013267138274386525
distinct O 0 2.1744919649790972e-05
from O 0 7.620635642524576e-06
textbook O 0 0.000366453779861331
aniridia B-Disease 1 0.999221920967102
. O 0 0.00010103006934514269

Here O 0 6.50723377475515e-05
we O 0 6.1442442529369146e-06
present O 0 2.785223614409915e-06
four O 0 2.049591557806707e-06
novel O 0 1.877869726740755e-05
PAX6 O 0 0.2548511028289795
missense O 0 0.032988112419843674
mutations O 0 0.0001531425805296749
, O 0 5.652215691043239e-07
two O 0 2.330226180902173e-07
in O 0 9.067840096577129e-07
association O 0 4.103737410332542e-06
with O 0 3.954735802835785e-06
atypical O 0 0.02887718938291073
phenotypes O 0 0.0060985335148870945
ectopia B-Disease 0 0.0433453693985939
pupillae I-Disease 0 0.013823911547660828
( O 0 3.51825815414486e-06
displaced B-Disease 0 1.0651953743945342e-05
pupils I-Disease 0 1.667318974796217e-05
) O 0 1.3127584679750726e-05
and O 0 0.00012190971756353974
congenital B-Disease 1 0.9999955892562866
nystagmus I-Disease 1 0.9983003735542297
( O 0 5.244115982350195e-06
searching B-Disease 0 5.545701242226642e-06
gaze I-Disease 0 4.557979991659522e-05
) O 0 7.667872523597907e-07
, O 0 1.4775366707908688e-07
and O 0 6.909644412189664e-08
two O 0 1.47959539731346e-07
in O 0 4.909167046207585e-07
association O 0 1.1627289495663717e-06
with O 0 3.3319281556032365e-07
more O 0 1.3955257145426003e-06
recognizable O 0 0.0006635322351939976
aniridia B-Disease 1 0.9994262456893921
phenotypes O 0 0.003954033832997084
. O 0 3.417991320020519e-05

Strikingly O 0 0.0034623160026967525
, O 0 1.782109211490024e-05
all O 0 1.1654844911390683e-06
four O 0 1.64988534834265e-06
mutations O 0 1.0452583410369698e-05
are O 0 1.4796898994973162e-07
located O 0 2.1877301037420693e-07
within O 0 1.3181445979171258e-07
the O 0 1.7971578358810802e-07
PAX6 O 0 0.00013708131154999137
paired O 0 5.070934093964752e-06
domain O 0 7.427628361256211e-07
and O 0 1.395897015754599e-07
affect O 0 9.095051609619986e-07
amino O 0 7.629431593159097e-07
acids O 0 8.208855319935537e-07
which O 0 6.503489657916361e-08
are O 0 4.692130417538465e-08
highly O 0 2.6277209030922677e-07
conserved O 0 3.365819907230616e-07
in O 0 1.0944042116989294e-07
all O 0 7.717931538309131e-08
known O 0 5.650642265209171e-07
paired O 0 7.480712156393565e-06
domain O 0 6.171634595375508e-06
proteins O 0 7.677724170207512e-06
. O 0 9.598261385690421e-06

Our O 0 6.343193672364578e-05
results O 0 3.436785482335836e-05
support O 0 2.2251410882745404e-06
the O 0 5.793421564703749e-07
hypothesis O 0 2.8316590032773092e-06
that O 0 1.0200695754747358e-07
the O 0 7.668246837511106e-08
under O 0 2.2378792152721871e-07
- O 0 8.053298188315239e-06
representation O 0 1.3858006013833801e-06
of O 0 8.368909334421915e-07
missense O 0 0.0008548939949832857
mutations O 0 5.47929375898093e-05
is O 0 5.949548267381033e-07
caused O 0 4.853611244470812e-06
by O 0 1.030713406180439e-06
ascertainment O 0 0.023017439991235733
bias O 0 7.376375288004056e-05
and O 0 1.1510890089994064e-06
suggest O 0 1.8739252709565335e-06
that O 0 1.0311926956774187e-07
a O 0 3.4733082543425553e-07
substantial O 0 4.38661436419352e-06
burden O 0 1.709154457785189e-05
of O 0 1.7199275816892623e-06
PAX6 B-Disease 1 0.988064706325531
- I-Disease 1 0.9983975291252136
related I-Disease 0 0.1333453208208084
disease I-Disease 0 0.003222651081159711
remains O 0 4.8863539632293396e-06
to O 0 5.971695600237581e-07
be O 0 7.934404493425973e-07
uncovered O 0 4.847564559895545e-05
. O 0 4.495121174841188e-06
. O 0 1.801940015866421e-05

The O 0 7.257925608428195e-05
chromosomal O 0 0.0010122254025191069
order O 0 7.085491233738139e-06
of O 0 2.4575790575909195e-06
genes O 0 7.878285032347776e-06
controlling O 0 9.358822353533469e-06
the O 0 9.104494438361144e-07
major O 0 6.400155598385027e-06
histocompatibility O 0 0.001399230444803834
complex O 0 1.006576894724276e-05
, O 0 1.698637106528622e-06
properdin O 0 0.0003898838476743549
factor O 0 4.008158612123225e-06
B O 0 3.105114956269972e-05
, O 0 1.777975853656244e-06
and O 0 8.528206308255903e-06
deficiency B-Disease 0 0.008946930058300495
of I-Disease 0 1.1854384496245984e-07
the I-Disease 0 2.4151916022674413e-07
second I-Disease 0 6.730979862368258e-07
component I-Disease 0 1.8932192915599444e-06
of I-Disease 0 6.467208777394262e-07
complement I-Disease 0 1.8813130736816674e-05
. O 0 2.2348078346112743e-05

The O 0 2.2879561583977193e-05
relationship O 0 2.3787057216395624e-05
of O 0 1.425423079126631e-06
the O 0 1.181200332212029e-06
genes O 0 3.3452765819674823e-06
coding O 0 1.581775904924143e-05
for O 0 5.699290568372817e-07
HLA O 0 0.004586677998304367
to O 0 4.315788544317911e-07
those O 0 2.039844275714131e-07
coding O 0 7.732031008345075e-06
for O 0 3.780728832225577e-07
properdin O 0 0.0002850172168109566
Factor O 0 1.5482412436540471e-06
B O 0 1.0745226973085664e-05
allotypes O 0 0.00010524794925004244
and O 0 1.3553495818996453e-06
for O 0 8.000433808774687e-06
deficiency B-Disease 0 0.026059160009026527
of I-Disease 0 1.1053717230424809e-07
the I-Disease 0 1.0543708839350074e-07
second I-Disease 0 5.58308443032729e-07
component I-Disease 0 8.749689186515752e-07
of I-Disease 0 1.3404778087533487e-07
complement I-Disease 0 1.701623659755569e-06
( O 0 1.281727122659504e-06
C2 O 0 0.000574530684389174
) O 0 8.600205774200731e-07
was O 0 2.5789071855797374e-07
studied O 0 7.05683874002716e-07
in O 0 2.5690366101116524e-07
families O 0 1.797742356757226e-06
of O 0 5.8781429288501386e-06
patients O 0 0.005885452497750521
with O 0 0.0002736924507189542
connective O 1 0.9999737739562988
tissue O 1 0.9999754428863525
disorders O 1 0.9994176626205444
. O 0 0.00010969911090796813

Patients O 0 0.35996484756469727
were O 0 1.1365699720045086e-05
selected O 0 4.0065260691335425e-06
because O 0 1.0311252935935045e-06
they O 0 3.440312354996422e-07
were O 0 4.0822277469487744e-07
heterozygous O 0 4.3978693611279596e-06
or O 0 2.3919587874843273e-06
homozygous O 0 6.90234883222729e-05
for O 0 7.727997581241652e-05
C2 B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999984502792358
. O 0 0.00010540473886067048

12 O 0 0.00011003258259734139
families O 0 1.603042437636759e-05
with O 0 3.097784883721033e-06
15 O 0 7.91336060501635e-06
matings O 0 0.0004326920898165554
informative O 0 4.142971374676563e-05
for O 0 0.00011190195800736547
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999991655349731
were O 0 9.172785212285817e-06
found O 0 1.3205659342929721e-05
. O 0 2.4576831492595375e-05

Of O 0 2.0778432372026145e-05
57 O 0 8.750750566832721e-05
informative O 0 2.4730830773478374e-05
meioses O 0 0.00047379109309986234
, O 0 1.212074835166277e-06
two O 0 3.905703920281667e-07
crossovers O 0 4.645487024390604e-06
were O 0 2.773613800854946e-07
noted O 0 5.340195343706e-07
between O 0 4.104952324723854e-07
the O 0 9.906738341669552e-06
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999992847442627
gene O 0 4.3700129026547074e-06
and O 0 1.6346341169537482e-07
the O 0 2.3716467012491194e-07
HLA O 0 0.010487379506230354
- O 0 0.0003651998413261026
B O 0 2.2368034478859045e-05
gene O 0 1.0258327165502124e-06
, O 0 7.260523915419981e-08
with O 0 7.317761685499136e-08
a O 0 4.297725126889418e-07
recombinant O 0 1.2063357644365169e-05
fraction O 0 1.901655423353077e-06
of O 0 7.00465989211807e-07
0 O 0 3.6372763133840635e-05
. O 0 3.4176980989286676e-05

035 O 1 0.8834249973297119
. O 0 0.003443547058850527

A O 0 0.00014956931408960372
lod O 0 0.03870551660656929
score O 0 9.795599908102304e-06
of O 0 1.2764293160216766e-06
13 O 0 2.657602863109787e-06
was O 0 6.500389417851693e-07
calculated O 0 1.3468428505802876e-06
for O 0 5.609845175058581e-07
linkage O 0 5.1669754611793905e-05
between O 0 5.1046092266915366e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999990463256836
and O 0 1.1617608834058046e-05
HLA O 1 0.5736569166183472
- O 0 0.0005009810556657612
B O 0 1.5938749129418284e-05
at O 0 2.0823989643758978e-07
a O 0 1.9469435130758939e-07
maximum O 0 1.0611289553708048e-06
likelihood O 0 1.18625894174329e-06
value O 0 1.026533951176134e-07
of O 0 5.915365264286265e-08
the O 0 1.8985716110364592e-07
recombinant O 0 4.864946731686359e-06
fraction O 0 1.5802145298948744e-06
of O 0 8.051210329540481e-07
0 O 0 2.1387191736721434e-05
. O 0 1.5985910067684017e-05

04 O 0 0.08436058461666107
. O 0 0.0016819004667922854

18 O 0 0.00011286107474006712
families O 0 1.540980883873999e-05
with O 0 2.178875774916378e-06
21 O 0 5.068130121799186e-06
informative O 0 3.802877472480759e-06
matings O 0 3.8060104998294264e-05
for O 0 3.4617076494214416e-07
both O 0 5.11117093537905e-07
properdin O 0 0.00019965656974818558
Factor O 0 1.6686651633790461e-06
B O 0 6.215769190021092e-06
allotype O 0 7.938723865663633e-05
and O 0 1.5386442555609392e-06
HLA O 0 0.023817017674446106
- O 0 0.00025424876366741955
B O 0 2.0959854737157002e-05
were O 0 9.170740327135718e-07
found O 0 3.959506102546584e-06
. O 0 1.037008496496128e-05

Of O 0 3.265047780587338e-05
72 O 0 0.0001073801759048365
informative O 0 2.6485642592888325e-05
meioses O 0 0.0005776951438747346
, O 0 2.029584493357106e-06
three O 0 6.040336302248761e-07
recombinants O 0 0.00022985665418673307
were O 0 3.394638952158857e-07
found O 0 3.8023480897209083e-07
, O 0 2.1761128721209388e-07
giving O 0 4.187480158179824e-07
a O 0 6.272066457313485e-07
recombinant O 0 1.3621131074614823e-05
fraction O 0 3.2512773486814694e-06
of O 0 8.604226309216756e-07
0 O 0 3.691622623591684e-05
. O 0 2.221004069724586e-05

042 O 0 0.08522702753543854
. O 0 0.002265373943373561

A O 0 7.088165148161352e-05
lod O 0 0.012959090992808342
score O 0 5.181557753530797e-06
of O 0 6.079449690332694e-07
16 O 0 1.5700869653301197e-06
between O 0 8.070629178291711e-07
HLA O 0 0.21721547842025757
- O 0 0.0007998152868822217
B O 0 1.2701823834504467e-05
and O 0 2.7843552174999786e-07
Factor O 0 5.636949254039791e-07
B O 0 3.840757472062251e-06
allotypes O 0 2.3142432837630622e-05
was O 0 2.3364012236015697e-07
calculated O 0 3.761236939681112e-07
at O 0 8.628452974335232e-08
a O 0 1.1950209000133327e-07
maximum O 0 6.222277875167492e-07
likelihood O 0 1.0292860679328442e-06
value O 0 9.849228632674567e-08
of O 0 5.6269385595442145e-08
the O 0 2.445099482883961e-07
recombinant O 0 6.776091140636709e-06
fraction O 0 2.514369271011674e-06
of O 0 7.041423373266298e-07
0 O 0 3.699975786730647e-05
. O 0 2.107960608555004e-05

04 O 0 0.07752052694559097
. O 0 0.0015657665207982063

A O 0 5.4105057643027976e-05
crossover O 0 0.00011361466022208333
was O 0 5.79929201194318e-06
shown O 0 1.3885761518395157e-06
to O 0 2.044783684596041e-07
have O 0 1.7089145387672033e-07
occurred O 0 5.330288672666939e-07
between O 0 1.560875375616888e-07
genes O 0 6.826636536061415e-07
for O 0 1.7635008475735958e-07
Factor O 0 9.658760973252356e-07
B O 0 7.43590999263688e-06
and O 0 7.743985293018341e-07
HLA O 0 0.05655314773321152
- O 0 0.0016129446448758245
D O 0 0.0034826493356376886
, O 0 2.2851774872378883e-07
in O 0 1.701711482837709e-07
which O 0 2.7710044037121406e-07
HLA O 0 0.009070700965821743
- O 0 0.000542955007404089
D O 0 0.0016115690814331174
segregared O 0 4.240042107994668e-05
with O 0 6.987799565649766e-07
HLA O 0 0.00130096182692796
- O 0 2.460757787048351e-05
A O 0 1.572990072418179e-06
and O 0 2.0454831428651232e-06
B O 0 5.5593216529814526e-05
. O 0 1.5782923583174124e-05

These O 0 4.5691562263527885e-05
studies O 0 4.2241652408847585e-05
suggest O 0 6.418021712306654e-06
that O 0 3.6735579556079756e-07
the O 0 4.1305918330181157e-07
genes O 0 1.5220504110402544e-06
for O 0 3.808303574714955e-07
Factor O 0 1.6887534002307802e-06
B O 0 0.00011073918722104281
and O 0 0.0001765492488630116
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999953508377075
are O 0 1.7830431886523002e-07
located O 0 1.8963096692914405e-07
outside O 0 1.2585012143517815e-07
those O 0 7.902885812427485e-08
for O 0 2.8753768788192247e-07
HLA O 0 0.08212017267942429
, O 0 1.873209214409144e-07
that O 0 2.9267770429441953e-08
the O 0 4.2297632063537094e-08
order O 0 1.0293808117012304e-07
of O 0 9.534353750950686e-08
genese O 0 0.00016011438856367022
is O 0 4.968659368387307e-07
HLA O 0 0.00025304852169938385
- O 0 1.0370748896093573e-05
A O 0 5.066025323685608e-07
, O 0 3.60478679795051e-07
- O 0 5.4190208174986765e-05
B O 0 1.4512082998408005e-05
, O 0 4.925721555082418e-07
- O 0 9.625576058169827e-05
D O 0 0.0004893703735433519
, O 0 5.178842457098654e-07
Factor O 0 1.1992843838015688e-06
B O 0 2.0923427655361593e-05
allotype O 0 0.005192870274186134
, O 0 9.613129805075005e-05
C2 B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999752044677734
, O 0 8.718320145817415e-07
that O 0 8.714274457588544e-08
the O 0 1.9958396535457723e-07
genes O 0 1.9840670120174764e-06
coding O 0 0.00012617005268111825
for O 0 3.3212800190085545e-05
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999971389770508
and O 0 3.0300159323815024e-06
Factor O 0 1.1352907449690974e-06
B O 0 6.428649612644222e-06
allotypes O 0 3.7904756027273834e-05
are O 0 7.784088751350282e-08
approximately O 0 9.28095147401109e-08
3 O 0 3.809393263054517e-07
- O 0 9.692287676443812e-06
- O 0 2.2319834897643887e-05
5 O 0 1.0692945124901598e-06
centimorgans O 0 1.1269909009570256e-05
from O 0 1.1052220116880562e-07
the O 0 1.211415678881167e-07
HLA O 0 0.000171673993463628
- O 0 7.280059890035773e-06
A O 0 3.915206434612628e-07
and O 0 1.1556570598258986e-06
HLA O 0 0.05893093720078468
- O 0 0.0007802087347954512
B O 0 2.0735376892844215e-05
loci O 0 2.4062539978331188e-06
, O 0 9.665804157066304e-08
and O 0 8.217779168262496e-08
that O 0 7.561279602441573e-08
the O 0 1.1048447134953676e-07
apparent O 0 9.247142770618666e-06
lack O 0 1.1408226328057935e-06
of O 0 2.0653445176321839e-07
recombinants O 0 0.0001470166607759893
between O 0 2.5437699946451175e-07
the O 0 1.9972905818121944e-07
Factor O 0 1.1709869340847945e-06
B O 0 2.7064008463639766e-05
gene O 0 6.25182610747288e-06
and O 0 3.6782308598048985e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
gene O 0 2.7597177904681303e-05
suggests O 0 1.7479571852163645e-06
that O 0 7.62794201136785e-08
these O 0 5.1694716063366286e-08
two O 0 1.681545995779743e-07
genes O 0 1.0480265473233885e-06
lie O 0 2.6056786737171933e-06
in O 0 1.8788234967814788e-07
close O 0 4.962886919201992e-07
proximity O 0 1.7405779999535298e-06
to O 0 4.793288326254697e-07
one O 0 7.607947054566466e-07
another O 0 4.881370841758326e-06
. O 0 1.5950547094689682e-05

Distribution O 0 0.0001155789359472692
of O 0 1.1367792467353866e-05
emerin O 0 0.0014450206654146314
and O 0 1.0137364370166324e-05
lamins O 0 0.007079836912453175
in O 0 2.3249638161360053e-06
the O 0 1.57695990310458e-06
heart O 0 8.290488040074706e-05
and O 0 5.360510385798989e-06
implications O 0 2.806865086313337e-05
for O 0 7.728263881290331e-06
Emery B-Disease 1 0.9392458200454712
- I-Disease 1 0.9997454285621643
Dreifuss I-Disease 1 0.9999874830245972
muscular I-Disease 1 0.9996967315673828
dystrophy I-Disease 1 0.9997901320457458
. O 0 0.00012365489965304732

Emerin O 0 0.008222756907343864
is O 0 1.0593650586088188e-05
a O 0 3.74159617422265e-06
nuclear O 0 4.511226143222302e-05
membrane O 0 5.302547378960298e-06
protein O 0 2.771007075352827e-06
which O 0 1.5351353965797898e-07
is O 0 1.392758832707841e-07
missing O 0 7.15881981250277e-07
or O 0 7.556729428870312e-07
defective O 0 0.00010345824557589367
in O 0 3.858121544908499e-06
Emery B-Disease 0 0.3280917704105377
- I-Disease 1 0.9992235898971558
Dreifuss I-Disease 1 0.999980092048645
muscular I-Disease 1 0.999915361404419
dystrophy I-Disease 1 0.9999775886535645
( O 0 0.00011088532482972369
EDMD B-Disease 1 0.9979060888290405
) O 0 3.880733856931329e-05
. O 0 3.1009425583761185e-05

It O 0 1.5079410331964027e-05
is O 0 2.053435991911101e-06
one O 0 4.4974527213526017e-07
member O 0 8.922661436372437e-07
of O 0 2.1238633962639142e-07
a O 0 5.231145792095049e-07
family O 0 2.063937927232473e-06
of O 0 1.3246992693893844e-06
lamina O 1 0.9635549187660217
- O 0 0.011836734600365162
associated O 0 4.2683136598498095e-06
proteins O 0 3.4005071825049527e-07
which O 0 1.56549234020531e-07
includes O 0 5.22139714576042e-07
LAP1 O 0 0.000137354654725641
, O 0 8.536038649253896e-07
LAP2 O 0 0.00012899655848741531
and O 0 3.2626830943627283e-06
lamin O 0 0.03658866509795189
B O 0 0.0001813356066122651
receptor O 0 6.883642345201224e-05
( O 0 1.4767487300559878e-05
LBR O 0 0.0017664049519225955
) O 0 1.2148188034188934e-05
. O 0 1.3504903108696453e-05

A O 0 9.563872299622744e-05
panel O 0 6.437685806304216e-05
of O 0 3.901883701473707e-06
16 O 0 1.2014447747787926e-05
monoclonal O 0 9.195091115543619e-05
antibodies O 0 3.0741983209736645e-05
( O 0 3.7062668525322806e-06
mAbs O 0 0.0001473324082326144
) O 0 6.956415177228337e-07
has O 0 1.9402706641358236e-07
been O 0 1.5217122495414515e-07
mapped O 0 1.0171373787670746e-06
to O 0 1.1463658466936977e-07
six O 0 1.978310848471665e-07
specific O 0 1.6708452221791958e-07
sites O 0 2.2901605234437739e-07
throughout O 0 1.7935057883278205e-07
the O 0 1.217847085399626e-07
emerin O 0 2.094714727718383e-05
molecule O 0 1.3948684909337317e-06
using O 0 5.946071155449317e-07
phage O 0 4.201622687105555e-06
- O 0 3.410104454815155e-06
displayed O 0 3.2446533282382006e-07
peptide O 0 7.807728934494662e-07
libraries O 0 1.997216259042034e-07
and O 0 9.37651662979988e-08
has O 0 8.002999862810611e-08
been O 0 6.279386610685833e-08
used O 0 1.3554758027112257e-07
to O 0 2.852298734978831e-07
localize O 0 7.20602911314927e-05
emerin O 0 0.00037609844002872705
in O 0 8.355662544090592e-07
human O 0 1.5161251667450415e-06
and O 0 4.765180165122729e-06
rabbit O 0 0.04578268527984619
heart O 0 0.00801951251924038
. O 0 6.820268754381686e-05

Several O 0 8.372973388759419e-05
mAbs O 0 0.0011192592792212963
against O 0 1.3158868569007609e-05
different O 0 4.067820100317476e-06
emerin O 0 0.0008810363942757249
epitopes O 0 0.0007387427613139153
did O 0 1.7183683667099103e-06
not O 0 3.698417572195467e-07
recognize O 0 2.012258164540981e-06
intercalated O 0 4.604174318956211e-05
discs O 0 5.2211871661711484e-05
in O 0 7.256647336362221e-07
the O 0 6.226658797459095e-07
heart O 0 2.916303856181912e-05
, O 0 9.91470415101503e-07
though O 0 3.9742687363286677e-07
they O 0 1.3549988864269835e-07
recognized O 0 5.31149851212831e-07
cardiomyocyte O 0 0.00013165561540517956
nuclei O 0 3.954427666030824e-05
strongly O 0 1.314291466769646e-06
, O 0 1.4103028433964937e-07
both O 0 6.602893165563728e-08
at O 0 8.944063267790625e-08
the O 0 1.4824129834778432e-07
rim O 0 1.396703373757191e-05
and O 0 4.912112672172952e-07
in O 0 6.258711664486327e-07
intranuclear O 0 0.00020609090279322118
spots O 0 8.028292540984694e-06
or O 0 2.026594302151352e-06
channels O 0 1.757205063768197e-05
. O 0 1.4532844033965375e-05

A O 0 0.00023239415895659477
polyclonal O 0 0.007808167953044176
rabbit O 0 0.004715743009001017
antiserum O 0 0.0058726049028337
against O 0 1.9780760339926928e-05
emerin O 0 0.00098020292352885
did O 0 5.156343831913546e-06
recognize O 0 3.5507318898453377e-06
both O 0 4.5754450184176676e-07
nuclear O 0 8.211092790588737e-06
membrane O 0 2.8991337330808165e-06
and O 0 5.003972773920395e-07
intercalated O 0 2.668534762051422e-05
discs O 0 1.8804035789798945e-05
but O 0 2.0560332814056892e-07
, O 0 1.3397990983321506e-07
after O 0 2.3383850589198119e-07
affinity O 0 8.208322697100812e-07
purification O 0 3.843490958388429e-06
against O 0 1.78313001697461e-07
a O 0 2.1124601801147946e-07
pure O 0 2.632461701068678e-06
- O 0 0.00014410835865419358
emerin O 0 0.00020593826775439084
band O 0 2.680769966900698e-06
on O 0 2.699158017094305e-07
a O 0 3.51627221562012e-07
western O 0 3.204793074473855e-06
blot O 0 0.00035684535396285355
, O 0 7.075524877109274e-07
it O 0 1.702666025948929e-07
stained O 0 4.424257349455729e-05
only O 0 2.5933030656233313e-07
the O 0 8.091992640402168e-07
nuclear O 0 7.710477075306699e-05
membrane O 0 5.8582270867191255e-05
. O 0 1.6718489860068075e-05

These O 0 2.9741868274868466e-05
results O 0 2.725167178141419e-05
would O 0 1.096645746656577e-06
not O 0 1.844567094622107e-07
be O 0 1.2299648233238258e-07
expected O 0 5.166130563338811e-07
if O 0 2.436601107547176e-07
immunostaining O 0 3.1014955311547965e-05
at O 0 4.4687607214655145e-07
intercalated O 0 2.6883737518801354e-05
discs O 0 1.3952257177152205e-05
were O 0 1.544542556075612e-07
due O 0 3.2898424251470715e-07
to O 0 6.688963338774556e-08
a O 0 1.4244321278056304e-07
product O 0 5.28683642642136e-07
of O 0 6.02345835432061e-08
the O 0 2.3547167415927106e-07
emerin O 0 0.0006595149752683938
gene O 0 2.0367449451441644e-06
and O 0 2.6013134402091964e-07
, O 0 2.431099801469827e-07
therefore O 0 1.6595051022250118e-07
, O 0 1.0267238792494027e-07
cast O 0 2.997369961121876e-07
some O 0 9.135617062838719e-08
doubt O 0 6.098228482187551e-07
upon O 0 3.0173114851095306e-07
the O 0 4.651559493140667e-07
hypothesis O 0 3.9510498027084395e-05
that O 0 1.1140024980704766e-05
cardiac B-Disease 1 0.9997416138648987
defects I-Disease 1 0.9861899018287659
in O 0 1.6026664525270462e-05
EDMD B-Disease 1 0.9999910593032837
are O 0 2.1887808543397114e-06
caused O 0 5.377884463086957e-06
by O 0 2.51340992463156e-07
absence O 0 1.0872682878471096e-06
of O 0 4.471467605071666e-07
emerin O 0 0.0003068249498028308
from O 0 2.1565081169683253e-06
intercalated O 0 0.00016013743879739195
discs O 0 0.0002133459784090519
. O 0 1.8393218851997517e-05

Although O 0 0.00012126012006774545
emerin O 0 0.0019948608241975307
was O 0 8.011909812921658e-06
abundant O 0 5.355564098863397e-06
in O 0 4.816116074835008e-07
the O 0 3.306288931526069e-07
membranes O 0 2.5161850771837635e-06
of O 0 3.283507794549223e-07
cardiomyocyte O 0 0.0005672908737324178
nuclei O 0 7.497480692109093e-05
, O 0 4.337765631134971e-07
it O 0 9.388811150756737e-08
was O 0 1.717195630135393e-07
absent O 0 1.2417145853760303e-06
from O 0 1.2520594339093805e-07
many O 0 1.1479850314799478e-07
non O 0 7.46667910789256e-06
- O 0 0.008019322529435158
myocyte O 0 0.3961048424243927
cells O 0 5.288793545332737e-05
in O 0 5.703950591851026e-07
the O 0 2.050567218248034e-06
heart O 0 0.0002306760143255815
. O 0 2.505414522602223e-05

This O 0 1.7048096196958795e-05
distribution O 0 8.77109505381668e-06
of O 0 1.2640525710594375e-06
emerin O 0 0.0003938657173421234
was O 0 1.1179552075191168e-06
similar O 0 3.9189421841001604e-07
to O 0 1.435602712263062e-07
that O 0 1.0040422893098366e-07
of O 0 1.7819756692460942e-07
lamin O 0 0.004335478879511356
A O 0 1.0999335700034862e-06
, O 0 3.488282800390152e-07
a O 0 4.2786632548086345e-07
candidate O 0 3.093769691986381e-06
gene O 0 1.7895589508043486e-06
for O 0 2.973066557387938e-07
an O 0 2.4737616968195653e-06
autosomal O 0 0.0043447017669677734
form O 0 1.0311713595001493e-05
of O 0 9.276272976421751e-06
EDMD B-Disease 1 0.9999483823776245
. O 0 9.205558308167383e-05

In O 0 7.295430987142026e-05
contrast O 0 0.00012453099770937115
, O 0 1.3888613466406241e-05
lamin O 1 0.5666899681091309
B1 O 0 0.33272573351860046
was O 0 1.9741542018891778e-06
absent O 0 4.163395260547986e-06
from O 0 4.973462068846857e-07
cardiomyocyte O 0 0.00018466584151610732
nuclei O 0 4.1664348827907816e-05
, O 0 5.543187739931454e-07
showing O 0 1.4779059256397886e-06
that O 0 4.67144019467014e-07
lamin O 0 0.041440438479185104
B1 O 0 0.06718301773071289
is O 0 3.372126968770317e-07
not O 0 1.1924707621346897e-07
essential O 0 2.559143013058929e-07
for O 0 1.7692991605144925e-07
localization O 0 4.4827661440649536e-06
of O 0 3.3094656259891053e-07
emerin O 0 0.00013000392937101424
to O 0 1.1612373782554641e-06
the O 0 3.238113777115359e-06
nuclear O 0 0.00029721198370680213
lamina O 0 0.18005536496639252
. O 0 5.366197365219705e-05

Lamin O 1 0.9928763508796692
B1 O 1 0.98259037733078
is O 0 3.2983462006086484e-05
also O 0 6.127515462139854e-06
almost O 0 3.5356006264919415e-06
completely O 0 9.333902198704891e-06
absent O 0 1.6500711353728548e-05
from O 0 4.9296118049824145e-06
skeletal O 0 0.012207592837512493
muscle O 0 0.00224610255099833
nuclei O 0 0.0011074286885559559
. O 0 3.688621291075833e-05

In O 0 0.00015347133739851415
EDMD B-Disease 1 0.9964724779129028
, O 0 6.73089743941091e-06
the O 0 6.062716693122638e-07
additional O 0 1.0344613201596076e-06
absence O 0 1.4787124200665858e-06
of O 0 7.743239507362887e-07
lamin O 1 0.6608092784881592
B1 O 1 0.7144500613212585
from O 0 5.737673745898064e-06
heart O 0 0.00012010805221507326
and O 0 8.789843377599027e-06
skeletal O 0 0.036261726170778275
muscle O 0 0.0014417243655771017
nuclei O 0 9.637184848543257e-05
which O 0 4.3649296799230797e-07
already O 0 1.2257182788744103e-06
lack O 0 3.120711426163325e-06
emerin O 0 0.00870188232511282
may O 0 2.7678138394549023e-06
offer O 0 5.326127165972139e-07
an O 0 1.5112979667719628e-07
alternative O 0 1.3858085594620206e-06
explanation O 0 1.3355361261346843e-06
of O 0 1.2240496971571702e-07
why O 0 7.776384904900624e-07
these O 0 3.138830209081789e-07
tissues O 0 1.3590820344688836e-05
are O 0 5.695384288628702e-07
particularly O 0 8.59236388350837e-06
affected O 0 1.0116310477314983e-05
. O 0 4.653250925912289e-06
. O 0 1.5463936506421305e-05

Genetic O 0 0.0011476026847958565
mapping O 0 0.0001060846698237583
of O 0 4.314782017900143e-06
the O 0 2.9228328912722645e-06
copper B-Disease 0 0.00018857525719795376
toxicosis I-Disease 0 0.02255307137966156
locus O 0 2.0286155631765723e-05
in O 0 1.3546698482969077e-06
Bedlington O 0 0.0002936924574896693
terriers O 0 0.0005435183411464095
to O 0 1.7652823771641124e-06
dog O 0 4.3756732338806614e-05
chromosome O 0 2.9512812034226954e-05
10 O 0 7.177626457632869e-07
, O 0 2.2892149331710243e-07
in O 0 1.0728271604421025e-07
a O 0 4.905058403892326e-07
region O 0 1.797468758013565e-05
syntenic O 0 0.0008830970618873835
to O 0 1.3190001482143998e-06
human O 0 3.624519422373851e-06
chromosome O 0 4.688563058152795e-05
region O 0 3.337915404699743e-05
2p13 O 0 0.0004136071656830609
- O 0 0.0020468293223530054
p16 O 0 0.0006207171245478094
. O 0 3.482744796201587e-05

Abnormal O 1 0.9981474876403809
hepatic B-Disease 1 0.9999504089355469
copper I-Disease 0 0.3100244402885437
accumulation I-Disease 0 0.004079673904925585
is O 0 5.72460567127564e-06
recognized O 0 3.0945604976295726e-06
as O 0 1.8895937046181643e-06
an O 0 5.21437032148242e-05
inherited B-Disease 1 0.9999988079071045
disorder I-Disease 1 0.9999997615814209
in O 0 1.1317826647427864e-05
man O 0 5.0609614845598117e-05
, O 0 4.167646238784073e-06
mouse O 0 2.8132051738793962e-05
, O 0 3.28921328218712e-06
rat O 0 0.0027876771055161953
and O 0 5.657647761836415e-06
dog O 0 0.00019081789650954306
. O 0 5.380637594498694e-05

The O 0 5.922232230659574e-05
major O 0 6.51705777272582e-05
cause O 0 6.40385114820674e-05
of O 0 7.608965006511426e-06
hepatic B-Disease 1 0.9988523721694946
copper I-Disease 0 0.3238355219364166
accumulation I-Disease 0 0.0011686149518936872
in O 0 1.7343445506412536e-06
man O 0 6.624775778618641e-06
is O 0 4.5040542318020016e-07
a O 0 1.2506397979450412e-06
dysfunctional O 0 0.00253017689101398
ATP7B O 1 0.6838486790657043
gene O 0 4.384365092846565e-05
, O 0 4.134310074732639e-06
causing O 0 0.00032844144152477384
Wilson B-Disease 0 0.07383354008197784
disease I-Disease 0 0.18971945345401764
( O 0 5.874102862435393e-05
WD B-Disease 1 0.9986139535903931
) O 0 1.9796481865341775e-05
. O 0 1.735082514642272e-05

Mutations O 0 0.003098727436736226
in O 0 9.759589374880306e-06
the O 0 2.3820539354346693e-06
ATP7B O 0 0.010537076741456985
genes O 0 1.182379673991818e-05
have O 0 3.5704294987226604e-07
also O 0 3.976766720370506e-07
been O 0 3.3350119110764354e-07
demonstrated O 0 2.6958880425809184e-06
in O 0 9.673426575318445e-07
mouse O 0 3.4523782233009115e-05
and O 0 1.0727083463279996e-05
rat O 0 0.045803505927324295
. O 0 5.6944605603348464e-05

The O 0 9.466162737226114e-05
ATP7B O 0 0.0344269722700119
gene O 0 9.929191583069041e-05
has O 0 2.053056277873111e-06
been O 0 9.267591849493328e-07
excluded O 0 2.6034133497887524e-06
in O 0 3.6316393448032613e-07
the O 0 2.511699221940944e-07
much O 0 9.370345424031257e-07
rarer O 0 0.00020696385763585567
human O 0 1.4650861885456834e-05
copper B-Disease 0 0.4513038396835327
overload I-Disease 1 0.963640034198761
disease O 0 0.012525076977908611
non B-Disease 0 2.9520046155084856e-05
- I-Disease 0 0.002652809489518404
Indian I-Disease 0 6.200714415172115e-05
childhood I-Disease 0 0.0048666601069271564
cirrhosis I-Disease 1 0.9976121187210083
, O 0 2.0697523723356426e-05
indicating O 0 0.0003960106405429542
genetic O 0 0.0004423084610607475
heterogeneity O 0 0.004222196526825428
. O 0 6.656223558820784e-05

By O 0 7.496515172533691e-05
investigating O 0 0.00020515786309260875
the O 0 1.4431470845011063e-05
common O 0 0.0006159859476611018
autosomal O 1 0.9949575066566467
recessive O 1 0.9775559306144714
copper B-Disease 1 0.9556653499603271
toxicosis I-Disease 1 0.9999585151672363
( O 0 0.0001214562653331086
CT B-Disease 1 0.9529472589492798
) O 0 3.2493212529516313e-06
in O 0 8.394527526434103e-07
Bedlington O 0 0.0018757997313514352
terriers O 0 0.006371097639203072
, O 0 1.1585990478124586e-06
we O 0 1.452861937423222e-07
have O 0 1.1969507340836572e-07
identified O 0 4.4348388428261387e-07
a O 0 2.6904663741333934e-07
new O 0 3.3405392514396226e-06
locus O 0 2.8015967473038472e-05
involved O 0 6.394639967766125e-06
in O 0 7.698207627981901e-05
progressive O 1 0.9999517202377319
liver B-Disease 1 1.0
disease I-Disease 1 0.9999874830245972
. O 0 0.0001739457220537588

We O 0 6.737158400937915e-05
examined O 0 0.00010920648492174223
whether O 0 6.304675480350852e-06
the O 0 2.297110313520534e-06
WD B-Disease 1 0.9506075978279114
gene O 0 2.7696869437932037e-05
ATP7B O 0 0.0004190918116364628
was O 0 1.6102599147416186e-06
also O 0 1.0455747769810841e-06
causative O 0 1.2572776540764607e-05
for O 0 1.3772709053228027e-06
CT B-Disease 1 0.7068989872932434
by O 0 1.0351334367442178e-06
investigating O 0 5.614037945633754e-06
the O 0 6.000558983032533e-07
chromosomal O 0 0.0001434066507499665
co O 0 0.00010300562280463055
- O 0 7.107815326889977e-05
localization O 0 7.87134649726795e-06
of O 0 2.2692456980166753e-07
ATP7B O 0 0.0002899905084632337
and O 0 9.15459224870574e-07
C04107 O 0 2.9298571462277323e-05
, O 0 2.615629739466385e-07
using O 0 3.6845119666395476e-07
fluorescence O 0 1.02770391094964e-05
in O 0 6.328967856461531e-07
situ O 0 5.399357542046346e-05
hybridization O 0 1.9234577848692425e-05
( O 0 1.8110682731276029e-06
FISH O 0 5.473226337926462e-06
) O 0 7.221463420137297e-06
. O 0 1.3474785191647243e-05

C04107 O 0 0.005780644249171019
is O 0 2.3103113562683575e-05
an O 0 4.4722401071339846e-06
anonymous O 0 2.0425110051291995e-05
microsatellite O 0 0.000172216328792274
marker O 0 2.3112061171559617e-05
closely O 0 1.746447742334567e-05
linked O 0 5.7538505643606186e-05
to O 0 9.64842638495611e-06
CT B-Disease 1 0.9415385127067566
. O 0 6.640620267717168e-05

However O 0 7.282349542947486e-05
, O 0 1.1369755156920291e-05
BAC O 0 0.00021954206749796867
clones O 0 5.362023148336448e-05
containing O 0 3.917072717740666e-06
ATP7B O 0 0.00026291501126252115
and O 0 1.2874384083261248e-06
C04107 O 0 5.361010698834434e-05
mapped O 0 5.397094355430454e-06
to O 0 2.89271866904528e-07
the O 0 3.665956569420814e-07
canine O 0 5.101562783238478e-05
chromosome O 0 2.8847376597695984e-05
regions O 0 5.962140221527079e-06
CFA22q11 O 0 0.0001095338593586348
and O 0 8.185871820387547e-07
CFA10q26 O 0 0.00011096867820015177
, O 0 5.926601716055302e-07
respectively O 0 1.6253706007773872e-06
, O 0 2.6522303642195766e-07
demonstrating O 0 1.9645856355055002e-06
that O 0 8.14011968941486e-07
WD B-Disease 1 0.8595717549324036
cannot O 0 2.457534719724208e-06
be O 0 3.107375334820972e-07
homologous O 0 7.40705445423373e-06
to O 0 4.7305552470788825e-06
CT B-Disease 1 0.5298308730125427
. O 0 3.573130743461661e-05

The O 0 2.692900125111919e-05
copper O 0 0.00010884459334192798
transport O 0 3.533279232215136e-05
genes O 0 9.884693099593278e-06
CTR1 O 0 0.0002650685200933367
and O 0 1.6396159026044188e-06
CTR2 O 0 0.00044133912888355553
were O 0 6.078660703678906e-07
also O 0 3.0913963655621046e-07
excluded O 0 1.5295879620680353e-06
as O 0 3.3577791214156605e-07
candidate O 0 1.6061605947470525e-06
genes O 0 1.1830040875793202e-06
for O 0 1.0777067700473708e-06
CT B-Disease 1 0.9326041340827942
since O 0 1.8076206060868572e-06
they O 0 1.2498476564815064e-07
both O 0 2.9956211733406235e-07
mapped O 0 5.646554654958891e-06
to O 0 1.982171852432657e-06
canine O 0 0.0003872844681609422
chromosome O 0 0.0002539260603953153
region O 0 0.00010329115320928395
CFA11q22 O 0 0.001808827742934227
. O 0 3.999238833785057e-05

2 O 0 0.0005303394282236695
- O 0 0.0021517283748835325
22 O 0 0.00017418639617972076
. O 0 7.331067172344774e-05

5 O 0 0.0026501475367695093
. O 0 0.000786378572229296

A O 0 6.504875636892393e-05
transcribed O 0 0.0001515621697762981
sequence O 0 1.0771759662020486e-05
identified O 0 4.014443675259827e-06
from O 0 4.18959302805888e-07
the O 0 2.8638609705922136e-07
C04107 O 0 2.3804575903341174e-05
- O 0 4.145065395277925e-05
containing O 0 1.0036858384410152e-06
BAC O 0 1.9889394025085494e-05
was O 0 2.3730585496650747e-07
found O 0 1.0805590022755496e-07
to O 0 6.231874749573763e-08
be O 0 5.205288289289456e-08
homologous O 0 4.906742105958983e-07
to O 0 1.28413589095544e-07
a O 0 3.4234471968375146e-07
gene O 0 2.0081977254449157e-06
expressed O 0 5.959668101240823e-07
from O 0 2.5334057340842264e-07
human O 0 1.026090103550814e-06
chromosome O 0 2.134313945134636e-05
2p13 O 0 6.126187508925796e-05
- O 0 0.0001876801543403417
p16 O 0 1.883567892946303e-05
, O 0 2.355711785639869e-07
a O 0 3.16782887921363e-07
region O 0 3.0750320547667798e-06
devoid O 0 3.963786639360478e-06
of O 0 2.6587588308757404e-07
any O 0 5.305544732436829e-07
positional O 0 3.244336403440684e-05
candidate O 0 3.413606827962212e-05
genes O 0 3.0625724320998415e-05
. O 0 1.760754457791336e-05

Molecular O 0 0.0012934767873957753
analysis O 0 4.3732452468248084e-05
of O 0 1.5012225276223035e-06
the O 0 1.029674876917852e-06
APC B-Disease 0 6.493124965345487e-05
gene O 0 3.4647007396415574e-06
in O 0 3.079893247104337e-07
205 O 0 2.521890792195336e-06
families O 0 1.3976234640722396e-06
: O 0 1.2031323421979323e-06
extended O 0 9.720186426420696e-06
genotype O 0 0.0026602535508573055
- O 0 0.01629173755645752
phenotype O 0 0.0023023602552711964
correlations O 0 2.0371575374156237e-05
in O 0 1.6941186231633765e-06
FAP B-Disease 0 0.0019854733254760504
and O 0 8.645138223073445e-07
evidence O 0 3.6958192595193395e-07
for O 0 8.032147746916962e-08
the O 0 1.0912733472423497e-07
role O 0 3.6360543731461803e-07
of O 0 2.5143188508991443e-07
APC B-Disease 0 5.0521226512501016e-05
amino O 0 8.336596692970488e-06
acid O 0 0.00023278291337192059
changes O 0 3.2992142223520204e-05
in O 0 0.002846803981810808
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
predisposition O 0 0.2596755623817444
. O 0 9.611204586690292e-05

BACKGROUND O 0 0.0020071924664080143
/ O 0 0.00323334033600986
AIMS O 0 6.217167538125068e-05
The O 0 1.8701780390983913e-06
development O 0 1.8654112864169292e-05
of O 0 0.0010112469317391515
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999969005584717
and O 0 4.196504960418679e-06
a O 0 2.8014922008878784e-06
variable O 0 4.790616367245093e-05
range O 0 3.3398862342437496e-06
of O 0 1.3057858723186655e-06
extracolonic O 0 0.055367037653923035
manifestations O 0 0.001929615973494947
in O 0 7.366780482698232e-05
familial B-Disease 1 0.9999973773956299
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.0003811125934589654
FAP B-Disease 0 0.09855370223522186
) O 0 2.081407274090452e-06
is O 0 1.3253927022560674e-07
the O 0 1.2489491041378642e-07
result O 0 3.1185913940134924e-07
of O 0 1.3349969663067895e-07
the O 0 4.265683060111769e-07
dominant O 0 5.607250568573363e-05
inheritance O 0 0.00024407730961684138
of O 0 0.00010488687257748097
adenomatous B-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.999882698059082
( O 0 2.9681092200917192e-05
APC B-Disease 0 0.0004117205098737031
) O 0 2.1957948774797842e-05
gene O 0 7.739494321867824e-05
mutations O 0 0.00017632803064770997
. O 0 2.279978070873767e-05

In O 0 5.995255196467042e-05
this O 0 6.150118679215666e-06
study O 0 4.746511422126787e-06
, O 0 7.31173429358023e-07
direct O 0 1.509333173999039e-06
mutation O 0 5.324082394508878e-06
analysis O 0 6.293493015618878e-07
of O 0 1.4697829442411603e-07
the O 0 3.9668921658631007e-07
APC B-Disease 0 9.6628769824747e-05
gene O 0 2.776006112981122e-06
was O 0 4.0320833250007126e-07
performed O 0 9.24435028082371e-07
to O 0 4.4368184148879664e-07
determine O 0 6.969670266698813e-06
genotype O 0 0.00489597674459219
- O 0 0.18209294974803925
phenotype O 0 0.006639092694967985
correlations O 0 1.1028967492165975e-05
for O 0 4.7339216280306573e-07
nine O 0 3.817124252236681e-06
extracolonic O 0 0.0031043814960867167
manifestations O 0 3.305815698695369e-05
and O 0 5.514619942914578e-07
to O 0 4.636519008727191e-07
investigate O 0 6.128468157839961e-06
the O 0 4.3587067466432927e-07
incidence O 0 2.0032599422847852e-05
of O 0 7.110978685886948e-07
APC B-Disease 0 0.001194725395180285
mutations O 0 4.270187855581753e-05
in O 0 1.617176053514413e-06
non O 0 0.0006668913410976529
- O 1 0.9999557733535767
FAP O 1 0.9999988079071045
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999959468841553
. O 0 0.0001269321219297126

METHODS O 0 0.00026565269217826426
The O 0 1.6248055544565432e-05
APC B-Disease 0 0.00035289922379888594
gene O 0 1.7578922779648565e-05
was O 0 1.7189829577546334e-06
analysed O 0 7.865013685659505e-06
in O 0 6.386586619555601e-07
190 O 0 5.5408595471817534e-06
unrelated O 0 2.1627281967084855e-05
FAP B-Disease 0 0.0003080269380006939
and O 0 1.4683095059808693e-06
15 O 0 5.662446255882969e-06
non O 0 0.0005149752832949162
- O 1 0.999895453453064
FAP O 1 0.9999994039535522
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
patients O 0 0.0012100551975890994
using O 0 8.230810635723174e-06
denaturing O 0 0.01276957243680954
gradient O 0 0.0005653152475133538
gel O 0 0.0012755842180922627
electrophoresis O 0 3.776418816414662e-05
, O 0 4.474240142826602e-07
the O 0 1.8282831604210514e-07
protein O 0 1.5207214119072887e-06
truncation O 0 1.3052621397946496e-05
test O 0 1.5570515188301215e-06
, O 0 5.302019303599081e-07
and O 0 5.901363238081103e-07
direct O 0 5.3597027545038145e-06
sequencing O 0 4.6435321564786136e-05
. O 0 1.853616959124338e-05

RESULTS O 0 0.0015049614012241364
Chain O 0 0.0001230071356985718
terminating O 0 5.584837344940752e-05
signals O 0 1.3186015166866127e-05
were O 0 5.500533575286681e-07
only O 0 2.3683173822064418e-07
identified O 0 2.330847109988099e-06
in O 0 1.4125940879239351e-06
patients O 0 3.769010800169781e-05
belonging O 0 2.8942577046109363e-06
to O 0 2.7477969410938385e-07
the O 0 5.762618116023077e-07
FAP B-Disease 0 0.00649016909301281
group O 0 4.0303195419255644e-05
( O 0 2.42349869949976e-06
105 O 0 4.636408630176447e-05
patients O 0 0.00014099921099841595
) O 0 6.850311820016941e-06
. O 0 1.281348795600934e-05

Amino O 0 0.0005984143353998661
acid O 0 0.0007936800247989595
changes O 0 8.161783625837415e-06
were O 0 8.029740001802566e-07
identified O 0 2.3155023427534616e-06
in O 0 4.5687173155783967e-07
four O 0 3.3389339932909934e-06
patients O 0 7.996772910701111e-05
, O 0 2.960902349968819e-07
three O 0 1.3765051676273288e-07
of O 0 1.7648871164510638e-07
whom O 0 1.5861210158618633e-06
belonged O 0 9.986046052290476e-07
to O 0 1.2538876603684912e-07
the O 0 2.0582207582720002e-07
non O 0 7.805891982570756e-06
- O 0 0.010098830796778202
FAP O 0 0.15740609169006348
group O 0 0.0016058932524174452
of O 0 0.0016546264523640275
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 0.32933974266052246
. O 0 9.09021109691821e-05

Genotype O 1 0.9717379808425903
- O 1 0.981956958770752
phenotype O 1 0.9403632283210754
correlations O 0 0.0010559794027358294
identified O 0 7.220708357635885e-05
significant O 0 3.756551450351253e-06
differences O 0 4.904192337562563e-06
in O 0 7.709676310696523e-07
the O 0 3.4734804899017035e-07
nature O 0 1.383086100759101e-06
of O 0 4.3819633788189094e-07
certain O 0 1.7332565676042577e-06
extracolonic O 0 0.08713670074939728
manifestations O 0 0.0004351623938418925
in O 0 5.9872681958950125e-06
FAP B-Disease 1 0.7399646639823914
patients O 0 0.00014298458700068295
belonging O 0 3.04966488329228e-06
to O 0 4.2884065010184713e-07
three O 0 2.1533578546950594e-06
mutation O 0 5.46471965208184e-05
subgroups O 0 0.00010976816702168435
. O 0 1.9447386875981465e-05

CONCLUSIONS O 0 0.0014983888249844313
Extended O 0 0.0002633314288686961
genotype O 0 0.1667196899652481
- O 1 0.5024691820144653
phenotype O 0 0.07835133373737335
correlations O 0 6.66940031806007e-05
made O 0 1.5895205933702528e-06
in O 0 6.102632710280886e-07
this O 0 3.3129106213891646e-07
study O 0 2.7930198029935127e-06
may O 0 1.7018962807924254e-06
have O 0 6.056486512306947e-08
the O 0 6.827242771123565e-08
potential O 0 4.455768305433594e-07
to O 0 1.1025712609580296e-07
determine O 0 2.863853012513573e-07
the O 0 8.415579344500657e-08
most O 0 1.49089132150948e-07
appropriate O 0 3.740482554803748e-07
surveillance O 0 2.067164587060688e-06
and O 0 2.607383748909342e-06
prophylactic O 0 0.0035455478355288506
treatment O 0 0.001346245058812201
regimens O 0 0.00026003443053923547
for O 0 2.407977717666654e-06
those O 0 5.35195931661292e-06
patients O 0 0.00021898849809076637
with O 0 7.648433893336914e-06
mutations O 0 0.0004161196411587298
associated O 0 5.311687345965765e-06
with O 0 2.37049403040146e-06
life O 0 7.01976241543889e-05
threatening O 0 0.07218668609857559
conditions O 0 0.02143949083983898
. O 0 7.05290149198845e-05

This O 0 2.4544109692214988e-05
study O 0 1.2678128769039176e-05
also O 0 1.7462909909227164e-06
provided O 0 1.6136187923621037e-06
evidence O 0 1.1584896810745704e-06
for O 0 3.20314768487151e-07
the O 0 7.146070970520668e-07
pathological O 0 0.00010767989442683756
nature O 0 9.399111036145769e-07
of O 0 2.2064180882352957e-07
amino O 0 7.451761121046729e-06
acid O 0 0.0001276460534427315
changes O 0 1.2463059420042555e-06
in O 0 4.06680101150414e-07
APC O 0 6.2089144194033e-05
associated O 0 8.043842854021932e-07
with O 0 1.6496022681167233e-07
both O 0 5.892753165426257e-07
FAP B-Disease 0 0.0007629042956978083
and O 0 4.7372282097057905e-06
non O 0 0.005231027491390705
- O 1 0.9999872446060181
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.48226410150527954
. O 0 8.342537512362469e-06
. O 0 2.141555887646973e-05

Inherited B-Disease 1 0.9999911785125732
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999994039535522
and O 1 0.9546714425086975
cancer B-Disease 1 0.9999552965164185
risk O 0 0.00028197115170769393
of O 0 1.7904859532791306e-06
the O 0 4.4990238166064955e-06
APC O 0 0.000966625870205462
I1307K O 0 0.0017207216005772352
polymorphism O 0 0.000287600007141009
. O 0 4.093660390935838e-05

Germ O 0 0.02720046602189541
- O 0 0.000442140648374334
line O 0 1.6466017768834718e-05
and O 0 3.1979786854208214e-06
somatic O 0 8.959479600889608e-05
truncating O 0 0.000246259180130437
mutations O 0 1.552301000629086e-05
of O 0 1.8916334454388561e-07
the O 0 2.61228933595703e-07
APC B-Disease 0 5.90862036915496e-05
gene O 0 1.8919323565569357e-06
are O 0 9.937976130913739e-08
thought O 0 3.139955992992327e-07
to O 0 1.3704121784030576e-06
initiate O 0 0.02401190809905529
colorectal B-Disease 1 0.9999998807907104
tumor I-Disease 1 0.9822407364845276
formation O 0 0.05839329957962036
in O 0 0.004142225254327059
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0013363256584852934
sporadic O 1 0.9782967567443848
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.9990018010139465
, O 0 2.7527026759344153e-05
respectively O 0 6.484178447863087e-05
. O 0 2.088826113322284e-05

Recently O 0 0.00022651359904557467
, O 0 9.177939318760764e-06
an O 0 2.569272055552574e-06
isoleucine O 0 0.004357316996902227
- O 0 0.004356853663921356
- O 0 0.0035933684557676315
> O 0 0.00014801349607296288
lysine O 0 0.00010167121945414692
polymorphism O 0 1.0541850315348711e-05
at O 0 6.594938781745441e-07
codon O 0 9.627846338844392e-06
1307 O 0 5.9162488469155505e-05
( O 0 7.655984290977358e-07
I1307K O 0 7.051328339002794e-06
) O 0 2.291174041602062e-07
of O 0 7.754776021329235e-08
the O 0 2.0560803193347965e-07
APC B-Disease 0 4.503840682446025e-05
gene O 0 1.4107927199802361e-06
has O 0 1.7170073363104166e-07
been O 0 1.62602361797326e-07
identified O 0 6.673187158412475e-07
in O 0 1.2352758460565383e-07
6 O 0 1.5458115285582608e-06
% O 0 4.877704213868128e-07
- O 0 1.6495801901328377e-05
7 O 0 2.4326429866050603e-06
% O 0 1.7989619038871751e-07
of O 0 9.394472044732538e-08
the O 0 6.246547741284303e-07
Ashkenazi O 0 0.0011100550182163715
Jewish O 0 3.148839823552407e-05
population O 0 1.1163654562551528e-05
. O 0 1.6283001968986355e-05

To O 0 7.990522863110527e-05
assess O 0 0.0005755980964750051
the O 0 4.779106802743627e-06
risk O 0 1.4892422768753022e-05
of O 0 5.800498001917731e-07
this O 0 4.6294715616568283e-07
common O 0 6.392475825123256e-06
APC B-Disease 0 0.00030969089129939675
allelic O 0 0.00034511348349042237
variant O 0 0.000379038043320179
in O 0 7.872159039834514e-05
colorectal O 1 0.9999991655349731
carcinogenesis O 1 0.9323525428771973
, O 0 2.5599565560696647e-06
we O 0 2.2847655145596946e-07
have O 0 1.6542780656436662e-07
analyzed O 0 1.299918835684366e-06
a O 0 3.265809880304005e-07
large O 0 1.2721746998067829e-06
cohort O 0 3.554143768269569e-05
of O 0 6.471107667493925e-07
unselected O 0 0.0006705258274450898
Ashkenazi O 0 0.0010372487595304847
Jewish O 0 7.503176220780006e-06
subjects O 0 4.640554379875539e-06
with O 0 8.338424777321052e-06
adenomatous B-Disease 1 0.9996243715286255
polyps I-Disease 1 0.9308385252952576
and O 0 1.2886451258964371e-05
. O 0 2.8849412046838552e-05
or O 0 0.39682015776634216
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999911785125732
, I-Disease 0 2.239916966573219e-06
for O 0 9.58938358053274e-07
the O 0 1.7069319255824666e-06
APC O 0 0.0003473255783319473
I1307K O 0 0.0005805962136946619
polymorphism O 0 0.00012528708612080663
. O 0 2.3406941181747243e-05

The O 0 4.976391574018635e-05
APC O 0 0.0004645839799195528
I1307K O 0 0.00037841161247342825
allele O 0 4.8893019993556663e-05
was O 0 1.4134659522824222e-06
identified O 0 1.5071238976815948e-06
in O 0 2.505964005194983e-07
48 O 0 2.6659063223632984e-06
( O 0 3.3918627195816953e-07
10 O 0 1.7977252753098583e-07
. O 0 1.0830164853814495e-07
1 O 0 5.319350862009742e-07
% O 0 8.307702614729351e-07
) O 0 5.840057610839722e-07
of O 0 1.0601620488159824e-06
476 O 0 0.0008811866864562035
patients O 0 0.0007562051177956164
. O 0 2.5811295927269384e-05

Compared O 0 0.00015657932090107352
with O 0 2.6344682737544645e-06
the O 0 6.867821866762824e-07
frequency O 0 1.8381817881163443e-06
in O 0 2.1637544023178634e-07
two O 0 1.8970656867622893e-07
separate O 0 8.631084256194299e-07
population O 0 3.1785506848791556e-07
control O 0 5.251104653325456e-07
groups O 0 2.405796521998127e-07
, O 0 1.3484142868946947e-07
the O 0 1.3622184269479476e-07
APC O 0 1.8177168385591358e-05
I1307K O 0 3.8360030885087326e-05
allele O 0 5.806602530356031e-06
is O 0 2.403844803211541e-07
associated O 0 5.385245458455756e-07
with O 0 1.6547562609048327e-07
an O 0 3.880701910929929e-07
estimated O 0 2.94412211587769e-06
relative O 0 8.686361979926005e-06
risk O 0 7.788135917508043e-06
of O 0 9.314766771240102e-07
1 O 0 2.099754783557728e-05
. O 0 2.0846469851676375e-05

5 O 0 0.00038879187195561826
- O 0 0.0012167542008683085
1 O 0 0.00011544180597411469
. O 0 6.760965334251523e-05

7 O 0 0.00349929416552186
for O 0 0.0011507438030093908
colorectal B-Disease 1 0.9999988079071045
neoplasia I-Disease 1 0.9993805885314941
( O 0 3.458480932749808e-05
both O 0 5.263028924673563e-06
P O 0 0.08215586096048355
= O 0 0.00047531822929158807
. O 0 3.952930001105415e-06
01 O 0 0.00019559505744837224
) O 0 7.944709977891762e-06
. O 0 1.906037505250424e-05

Furthermore O 0 0.001035957015119493
, O 0 2.2088353944127448e-05
compared O 0 1.459648774471134e-05
with O 0 3.2636603464197833e-06
noncarriers O 0 0.0032490240409970284
, O 0 4.152245310251601e-06
APC O 0 6.674987525912002e-05
I1307K O 0 5.6109627621481195e-05
carriers O 0 2.3441552912117913e-06
had O 0 2.7163278559783066e-07
increased O 0 5.162874572306464e-07
numbers O 0 5.86041608130472e-07
of O 0 7.496964826714247e-07
adenomas B-Disease 1 0.9888533353805542
and O 0 0.12050426006317139
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9998016953468323
per O 0 4.870315387961455e-05
patient O 0 0.00017465371638536453
( O 0 3.648257006716449e-06
P O 0 0.03519798442721367
= O 0 0.00020014205074403435
. O 0 6.617928534069506e-07
03 O 0 4.921964500681497e-05
) O 0 2.7895461585103476e-07
, O 0 7.183810879496377e-08
as O 0 4.89566467365421e-08
well O 0 8.166855991476041e-08
as O 0 1.3423877476270718e-07
a O 0 6.929903406671656e-07
younger O 0 1.8599044778966345e-05
age O 0 5.65350546821719e-06
at O 0 1.3136249435774516e-05
diagnosis O 0 0.07859992980957031
. O 0 5.147017873241566e-05

We O 0 4.8498484829906374e-05
conclude O 0 0.00010476631723577157
that O 0 1.84164741767745e-06
the O 0 1.2176918744444265e-06
APC O 0 6.60852892906405e-05
I1307K O 0 7.882923819124699e-05
variant O 0 1.8969181837746873e-05
leads O 0 4.948009063809877e-06
to O 0 8.580904591326544e-07
increased O 0 7.866123269195668e-06
adenoma B-Disease 1 0.9999891519546509
formation O 0 6.363793363561854e-05
and O 0 9.38445793963183e-07
directly O 0 5.385620625020238e-07
contributes O 0 8.825776376397698e-07
to O 0 1.8246096544771717e-07
3 O 0 7.911857551334833e-07
% O 0 4.4365603457663383e-07
- O 0 6.945054337847978e-06
4 O 0 1.217451540469483e-06
% O 0 3.0851643373353e-07
of O 0 1.786888788046781e-07
all O 0 1.3409090797722456e-06
Ashkenazi O 1 0.8970341086387634
Jewish O 1 0.9699535965919495
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999881982803345
. O 0 8.338058250956237e-05

The O 0 5.74805962969549e-05
estimated O 0 3.2298055884893984e-05
relative O 0 4.1316987335449085e-05
risk O 0 3.7816767871845514e-05
for O 0 3.281411636635312e-06
carriers O 0 3.8355126889655367e-05
may O 0 1.0624316928442568e-05
justify O 0 2.33482842304511e-05
specific O 0 3.9207839108712506e-06
clinical O 0 4.731353692477569e-05
screening O 0 3.0294409043563064e-06
for O 0 2.3661004888708703e-07
the O 0 1.3790095465537888e-07
360 O 0 3.823820861725835e-06
, O 0 3.661589005332644e-07
000 O 0 1.3255131534606335e-06
Americans O 0 2.940492436209752e-07
expected O 0 3.3328910831187386e-07
to O 0 1.3216880745403614e-07
harbor O 0 1.1770580385928042e-05
this O 0 1.9727305300420994e-07
allele O 0 3.2688467399566434e-06
, O 0 2.224686141971688e-07
and O 0 5.795764650429192e-07
genetic O 0 6.478137493104441e-06
testing O 0 1.6105916529340902e-06
in O 0 1.1980024794411293e-07
the O 0 6.565870336316948e-08
setting O 0 4.1925906657525047e-07
of O 0 1.45289646980018e-07
long O 0 2.7251860501564806e-06
- O 0 0.0003668403660412878
term O 0 3.330573963467032e-05
- O 0 0.0009618110489100218
outcome O 0 3.5418815969023854e-05
studies O 0 3.4257473089382984e-06
may O 0 3.4675765618885634e-06
impact O 0 5.8760524552781135e-06
significantly O 0 0.00017508490418549627
on O 1 0.5485808849334717
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
prevention O 0 0.00656595965847373
in O 0 2.9842321964679286e-06
this O 0 1.1762799658754375e-06
population O 0 5.874130692973267e-06
. O 0 1.4051201105758082e-05

Localization O 0 0.0009925893973559141
of O 0 2.6439382054377347e-05
human O 0 2.622961073939223e-05
BRCA1 O 0 0.0004938031197525561
and O 0 1.7959121123567456e-06
its O 0 3.1955030408425955e-06
loss O 0 2.4165050490410067e-05
in O 0 5.027727070228138e-07
high O 0 3.867920895572752e-06
- O 0 0.000455817295005545
grade O 0 1.833568785514217e-05
, O 0 2.0126553863519803e-06
non B-Disease 0 0.00011464177077868953
- I-Disease 1 0.9563238620758057
inherited I-Disease 1 0.9622937440872192
breast I-Disease 1 0.9957465529441833
carcinomas I-Disease 1 0.9999959468841553
. O 0 0.00010834918066393584

Although O 0 4.442470526555553e-05
the O 0 3.4501240406825673e-06
link O 0 6.30501290288521e-06
between O 0 1.3948246078143711e-06
the O 0 3.705351446114946e-06
BRCA1 O 0 0.08669218420982361
tumour B-Disease 1 0.9999700784683228
- O 0 0.36638426780700684
suppressor O 0 0.005123908631503582
gene O 0 1.8232289221487008e-05
and O 0 1.0159305020351894e-05
hereditary B-Disease 1 0.9987851977348328
breast I-Disease 1 0.9999850988388062
and I-Disease 1 0.9980165958404541
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
is O 0 2.2136650841275696e-06
established O 0 1.2470133015085594e-06
, O 0 2.37863687857498e-07
the O 0 1.0843083231293349e-07
role O 0 4.600196348292229e-07
, O 0 2.3269129201253236e-07
if O 0 7.133998991548651e-08
any O 0 6.732507529250142e-08
, O 0 1.4721987895427446e-07
of O 0 2.1191249288676772e-07
BRCA1 O 0 0.00021027908951509744
in O 0 2.9854875265300507e-06
non B-Disease 0 0.0007542456733062863
- I-Disease 1 0.9960728883743286
familial I-Disease 1 0.9989743232727051
cancers I-Disease 1 0.9888727068901062
is O 0 4.52574795417604e-06
unclear O 0 3.621496944106184e-05
. O 0 1.6120782674988732e-05

BRCA1 O 1 0.9966307282447815
mutations O 0 0.02511717565357685
are O 0 9.53201833908679e-06
rare O 0 3.284415652160533e-05
in O 0 1.6394285921705887e-05
sporadic B-Disease 0 0.2574335038661957
cancers I-Disease 1 0.9972919821739197
, O 0 9.471516023040749e-06
but O 0 1.3894635912947706e-06
loss O 0 2.195118577219546e-05
of O 0 1.1643166999419918e-06
BRCA1 O 0 0.0027624834328889847
resulting O 0 1.6291747670038603e-05
from O 0 5.361126795833115e-07
reduced O 0 3.949010988435475e-06
expression O 0 1.7147472135548014e-06
or O 0 5.821512445436383e-07
incorrect O 0 4.698955763160484e-06
subcellular O 0 1.5878791600698605e-05
localization O 0 1.583076846145559e-05
is O 0 4.0116856325767003e-07
postulated O 0 2.2389708647096995e-06
to O 0 1.3721327718485554e-07
be O 0 5.1162182046482485e-08
important O 0 1.278395274084687e-07
in O 0 5.903862074774224e-07
non B-Disease 0 0.00031449910602532327
- I-Disease 1 0.986393392086029
familial I-Disease 1 0.9997803568840027
breast I-Disease 1 0.9999716281890869
and I-Disease 1 0.9853577613830566
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.999998927116394
. O 0 0.00012258630886208266

Epigenetic O 0 0.32509592175483704
loss O 0 0.04885285720229149
, O 0 2.2463804270955734e-05
however O 0 2.236171212643967e-06
, O 0 6.582548053302162e-07
has O 0 3.1362631602860347e-07
not O 0 1.4658662905731035e-07
received O 0 4.2539059563750925e-07
general O 0 5.695004006156523e-07
acceptance O 0 7.042416655167472e-06
due O 0 1.373472400700848e-06
to O 0 2.985624689699762e-07
controversy O 0 1.0458279575686902e-06
regarding O 0 5.032049443798314e-07
the O 0 2.73361735025901e-07
subcellular O 0 8.777655239100568e-06
localization O 0 9.025444342114497e-06
of O 0 5.668075004905404e-07
BRCA1 O 0 0.0001335691922577098
proteins O 0 3.288905872977921e-06
, O 0 5.088472221359552e-07
reports O 0 6.106399723648792e-07
of O 0 9.657530597451114e-08
which O 0 2.0383119192501908e-07
have O 0 1.3760759998149297e-07
ranged O 0 1.8976498949996312e-06
from O 0 1.4527427083521616e-07
exclusively O 0 5.60267039872997e-07
nuclear O 0 1.0240205483569298e-05
, O 0 2.085039909616171e-07
to O 0 1.4578139939658286e-07
conditionally O 0 4.900224303128198e-05
nuclear O 0 1.8285329133505e-05
, O 0 1.5242976303397882e-07
to O 0 9.106424414540015e-08
the O 0 2.73224117108839e-07
ER O 0 0.013677519746124744
/ O 0 0.00010162682156078517
golgi O 0 0.00010959216160699725
, O 0 2.9565035220002756e-07
to O 0 2.0541790490824496e-07
cytoplasmic O 0 7.589774213556666e-06
invaginations O 0 2.839113585650921e-05
into O 0 1.043741576722823e-06
the O 0 1.7682680208963575e-06
nucleus O 0 5.687600787496194e-05
. O 0 2.3713470000075176e-05

In O 0 4.096964039490558e-05
an O 0 2.890134055633098e-06
attempt O 0 6.546284566866234e-06
to O 0 1.4810890434091561e-06
resolve O 0 2.3427573978551663e-05
this O 0 4.5995778918950236e-07
issue O 0 8.665625728099258e-07
, O 0 3.3432661439292133e-07
we O 0 1.7908001836985932e-07
have O 0 3.478114649624331e-07
comprehensively O 0 0.00010737382399383932
characterized O 0 7.516350888181478e-05
19 O 0 1.5511172023252584e-05
anti O 0 8.41128930915147e-05
- O 0 0.1650177389383316
BRCA1 O 0 0.005407822784036398
antibodies O 0 0.00011882659600814804
. O 0 2.288750692969188e-05

These O 0 5.7076773373410106e-05
reagents O 0 0.0005488186725415289
detect O 0 0.00012172479910077527
a O 0 3.3657890980975935e-06
220 O 0 7.123799150576815e-06
- O 0 0.00018298826762475073
kD O 0 0.0009189427946694195
protein O 0 6.236307854123879e-06
localized O 0 3.23653944178659e-06
in O 0 3.0105854875728255e-07
discrete O 0 2.9898637876613066e-06
nuclear O 0 2.663152918103151e-05
foci O 0 3.640156865003519e-05
in O 0 4.186457829291612e-07
all O 0 2.8490310910456174e-07
epithelial O 0 0.0005735461018048227
cell O 0 6.07915899308864e-05
lines O 0 2.423533260298427e-06
, O 0 3.479574672837771e-07
including O 0 4.1688764440550585e-07
those O 0 7.900712830632983e-07
derived O 0 1.3480222150974441e-05
from O 0 2.0784396838280372e-05
breast B-Disease 1 0.6280503273010254
malignancies I-Disease 1 0.6912720799446106
. O 0 8.211743261199445e-05

Immunohistochemical O 0 0.31286802887916565
staining O 0 0.21166913211345673
of O 0 6.778084934921935e-05
human O 0 0.0004016167367808521
breast O 1 0.8464424014091492
specimens O 0 0.0003360604459885508
also O 0 1.2552169209811836e-05
revealed O 0 0.00017237717111129314
BRCA1 O 0 0.0010361780878156424
nuclear O 0 0.00037611890002153814
foci O 0 0.0036620518658310175
in O 0 2.708373540372122e-05
benign O 1 0.9959081411361694
breast O 1 0.9943547248840332
, O 0 0.0005760476342402399
invasive B-Disease 1 0.9981416463851929
lobular I-Disease 1 0.9999997615814209
cancers I-Disease 1 0.9961690306663513
and O 0 7.5823663792107254e-06
low B-Disease 0 0.00013117406342644244
- I-Disease 1 0.7040672898292542
grade I-Disease 0 0.10005888342857361
ductal I-Disease 1 0.9999805688858032
carcinomas I-Disease 1 0.9999980926513672
. O 0 0.00017677243158686906

Conversely O 0 0.004051689524203539
, O 0 5.155929102329537e-05
BRCA1 O 0 0.0008761524222791195
expression O 0 1.4986424503149465e-05
was O 0 1.41557575261686e-06
reduced O 0 4.8214283197012264e-06
or O 0 8.921469998313114e-07
undetectable O 0 2.478735586919356e-05
in O 0 2.2485670569949434e-07
the O 0 1.1301892755000154e-07
majority O 0 3.5675637377607927e-07
of O 0 1.381158796220916e-07
high O 0 3.51237167706131e-06
- O 0 0.0035142074339091778
grade O 0 0.0001435118610970676
, O 0 3.2244202884612605e-05
ductal B-Disease 1 0.9999325275421143
carcinomas I-Disease 1 0.9999994039535522
, O 0 5.39084931006073e-06
suggesting O 0 6.056866823200835e-06
that O 0 3.015113918536372e-07
absence O 0 1.3006405197302229e-06
of O 0 8.108864903988433e-07
BRCA1 O 0 0.004863783251494169
may O 0 1.3352736459637526e-05
contribute O 0 1.0191142791882157e-06
to O 0 2.1645675474246673e-07
the O 0 3.12081397169095e-07
pathogenesis O 0 7.663504948141053e-05
of O 0 1.7126212981111166e-07
a O 0 6.001577617098519e-07
significant O 0 1.3718700984099996e-06
percentage O 0 1.2087379218428396e-05
of O 0 5.153138317837147e-06
sporadic B-Disease 1 0.9018889665603638
breast I-Disease 1 0.9999762773513794
cancers I-Disease 1 0.9981067180633545
. O 0 1.4755717529624235e-05
. O 0 2.634120755828917e-05

